

**Studie 008**  
**(FCE 20124/702 i)**

**Studienbericht**

FCE 20124/702 i



1

Product (s): REBOXETINE

Report title: PHASE II CONTROLLED STUDY OF THE ACTIVITY AND TOLERABILITY OF REBOXETINE IN COMPARISON WITH PLACEBO AND DESIPRAMINE IN PATIENTS HOSPITALIZED FROM MAJOR DEPRESSIVE DISORDERS

Line/Service: C.N.S

Author (s): A. DUBINI - T. BAN - L.C. MOREY

Date: 28.2.1991

"Some or all information reported in the text may be unpublished material and therefore is to be considered as strictly confidential; any form of divulgation of this document may be considered as a breach of confidentiality unless written express consent of Farnitalia Carlo Erba R&D."

FCF 20124/702 i

Farmitalia Carlo Erba  
R&D Direction

Line/Service: S.N.C.

Project: ANTIDEPRESSIVE

Product (s): REBOXETINE

Line/Service Report internal code:

Author (s): A. DUBINI, T. BAN, L.C. MOREY

Receivers { Full report:  
Abstract:

Author Editor Planning QC&DC  R&D Direction

Date:

Name: A. DUBINI R. FARIELLO W. GROPPi A. NAVA

Signature  

- Chem. Coord.
- Med. Coord. F. B. NICOLIS
- Biotech. & Safety

Running title: reboxetine vs desipramine and placebo in major depressive disorders. A. Dubini, T. Ban, L. Morey  
N. of pages: 114

Mod. 9010/b

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

#### SUMMARY

The present study examined the effectiveness and therapeutic usefulness of reboxetine (RBX) in double blind conditions in comparison with placebo (P) and a standard reference drug (desipramine, DMI). The study was carried out in ten centers in Hungary, Italy, France and Latin America; 258 patients, hospitalized due to a Major Depressive Episode (DSM III-R), received either RBX (n=84) at doses increased from 4 to 8 mg/ day, or DMI (n=89) at doses increased from 100 to 200 mg/day or P (n=85) for 4 weeks. Efficacy (Clinical Global Impression, Hamilton Depression Rating Scale [HAM-D], Montgomery-Asberg Depression Scale, Zung Depression Self-rating Scale) and tolerability (vital signs, lab tests, ECG, Adverse Events) were evaluated.

The experimental treatment was discontinued in 18 cases (5,6 and 7 of the RBX, DMI and P group respectively) due to inefficacy; in 3 cases (2 of the RBX and 1 of the P group) due to increase of the ventricular extrasystoles present in basal conditions and hypertension in the RBX, skin rash in the P group; in 5 cases (2,1 and 2 in the RBX, DMI and P group) for self-discharge and/or patient refusal.

Among the evaluable patients, 60% of the RBX (n = 80), 44% of the DMI (n = 82) and 36% of the P group (n = 81) showed at least 50% reduction of the HAM-D total score at end of treatment (study end-point; RBX vs P, p< 0.05). An earlier efficacy of RBX was demonstrated by the average values of the applied rating scales: in comparison with P a statistically significant difference was present in the RBX group from day 10-14 and in the DMI group from day 14-21 on, the improvement of most outcome measures being apparent on average one week sooner in the RBX group.

As to signs/symptoms, dry mouth was reported with significantly greater frequency in the DMI group (45.5%) than in the RBX (25.3%) and P (21.7%) groups. Blurred vision was also reported with greater frequency in the DMI (17.0%) than in the RBX (3.6%) and P (3.6%) groups. On the other hand urinary hesitancy was significantly more frequent in the RBX (10.8%) than in the P (1.2%) group. Noteworthy trends (p<0.10) included greater frequency of headaches in the RBX patients, of constipation in both DMI and RBX patients and of tachycardia in the DMI patients. The therapeutic index (Efficacy Index) was found to be significantly (p<0.05) more favourable in the RBX than in the DMI and P group. Neither differences in average values of laboratory tests and vital signs nor in frequencies of abnormal laboratory tests results of clinical relevance were observed. ECG abnormalities were reported rarely; signs compatible with an ischemic episode were apparent in one patient under RBX, with partial resolution while continuing treatment.

In conclusion, the results of this study clearly indicate the superiority of RBX over P in the treatment of Major Depressive Disorder. By comparison to DMI, RBX was found to be at least as effective in the treatment of depressive symptomatology with a 28 days trial, the improvement being apparent on the average one week sooner. With respect to tolerability, RBX appeared to be well-tolerated in the dose used.

reboxetine vs desipramine and placebo in major depressive disorders.

Running title:  
Author (s):

A. Dubini - T. Ban - L. Morey

Med 9010c

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

2

Farmitalia Carlo Erba R. & S.

Research Line/Service: R&D/CNS Department

**Report**

**Title** PHASE II CONTROLLED STUDY OF THE ACTIVITY AND TOLERABILITY OF REBOXETINE IN COMPARISON WITH PLACEBO AND DESIPRAMINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSIVE DISORDERS.

**Date** February, 28, 1991

**Products (s)** REBOXETINE

Author (s)	Name and Signature	Institution
Dr. A. Dubini	<i>A. Dubini</i>	Farmitalia Carlo Erba R&D/CNS Department
Prof. T. Ban	<i>Thomas A. Ban</i>	Department of Psychiatry Vanderbilt University
L.C. Morey Ph.D.	<i>L. Morey</i>	Department of Psychology Vanderbilt University

**Head of the Reserch Line/Service:** **Name and Signature**  
Prof. R. Fariello *R. Fariello*

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

2 bis

---

PHASE II CONTROLLED STUDY OF THE ACTIVITY AND TOLERABILITY  
OF REBOXETINE IN COMPARISON WITH PLACEBO AND  
DESIPRAMINE IN PATIENTS HOSPITALIZED  
FOR MAJOR DEPRESSIVE DISORDERS

DATA PROCESSING Leslie C. Morey, Ph.D.  
Department of Psychology  
Vanderbilt University

STUDY COORDINATION Prof. Thomas Ban  
Department of Psychiatry  
Vanderbilt University

STUDY DIRECTOR Dr. Adriana Dubini  
Farmitalia Carlo Erba R&D  
CNS Department

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702.i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

3

---

TABLE OF CONTENTS

1.	SUMMARY	Page	1-2
2.	IDENTITY OF THE TEST MATERIAL		3
3.	INTRODUCTION		3
4.	STUDY OBJECTIVE		4
5.	THE INVESTIGATIONAL PLAN		4
5.1	Experimental Design		5
5.2	Patients Population		5-6
5.3	Population and Treatment Groups		7
5.4	Experimental Treatment		7
5.5	Screening and Assessment of Change		7
5.6	Analysis of Data		8
5.7	Disposition of patient entered and data set analyzed		9-11
6.	RESULTS		11
6.1	Efficacy		11-15
6.2	Follow-up Assessment		11
6.3	Tolerability		15-18
7.	DISCUSSION		18-19
8.	REFERENCES		20-21
9.	TABLES		22-36
10.	FIGURES		37-48
ENCLOSURE 1:	Study Protocol		1-12
	Enclosure 1		1-4
	Enclosure 2		1-5
	Enclosure 3		1-3
	Enclosure 4		1-2
	Enclosure 4a		1
	Enclosure 5		1
	Enclosure 6		1
	Enclosure 7		1
	Enclosure 8		1
	Enclosure 9		1-2
	Attachment A		1-4
	Attachment B		1-6
	Consent Form		1-3

FCE 20124/702 i  
 FARMUTALIA CARLO ERBA  
 ERBAMONT GROUP  
 CNS DEPT

4

---

		2
ENCLOSURE 2:	List of Centers	1-2
ENCLOSURE 3:	Randomization List	1-11
INDIVIDUAL DATA APPENDIX		
Table 0	Not evaluable patients and reason for it	1-3
Table 1	Demographic Data	1-6
Table 2a	Patient Diagnosis and History of the Mental Disorder	1-6
Table 2b	Patient Diagnosis and History of the Mental Disorder	1-6
Table 3	Previous Antidepressant Treatment	1-18
Table 4a	Experimental Treatment	1-33
Table 4b	Concomitant Medications	1-3
Table 5a	Hamilton Depression Rating Scale	1-72
Table 5b	Clinical Global Impressions	1-62
Table 5c	Montgomery Asberg Depression Rating Scale	1-63
Table 5d	Zung Self-rating Depression Scale	1-63
Table 5e	Vital Signs	1-57
Table 5f	Laboratory Data	1-150
Table 6	List of Signs and Symptoms	1-22
Table 7	Summary by Sign/Symptom	
	Total No. Reported (First Episode)	1-3
Table 7a	Summary by Sign/Symptom	
	Total No. Onset Week (First Episode)	1-12
Table 7b	Summary by Sign/Symptom	
	Total No. Present at End of Treatment	1-3
Table 7c	Summary by Sign/Symptom	
	Total No. by each Severity Degree for all Reports	1-3
Table 7d	Summary by Sign/Symptom	
	Total No. by each Treatment Relationship - All Reports	1-3
Table 7e	Summary by Sign/Symptom	
	Total No. Requiring Treatment - All Reports	1
Table 7f	Summary by Sign/Symptom	1-3

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

5

## 1. SUMMARY

The present study examined the effectiveness and therapeutic usefulness of reboxetine (RBX) in double blind conditions in comparison with placebo (P) and a standard reference drug (desipramine, DMI). The study was carried out in ten centers in Hungary, Italy, France and Latin America; 258 patients, hospitalized due to a Major Depressive Episode (DSM III-R), received either RBX (n=84) at doses increased from 4 to 8 mg/day, or DMI (n=89) at doses increased from 100 to 200 mg/day or P (n=85), for 4 weeks. Efficacy (Clinical Global Impression, Hamilton Depression Rating Scale [HAM-D], Montgomery-Asberg Depression Scale, Zung Depression Self-rating Scale) and tolerability (vital signs, lab tests, ECG, Adverse Events) were evaluated.

The experimental treatment was discontinued in 18 cases (5,6 and 7 of the RBX, DMI and P group respectively) due to inefficacy; in 3 cases (2 of the RBX and 1 of the P group) due to increase of the ventricular extrasystoles present in basal conditions and hypertension in the RBX, skin rash in the P group; in 5 cases (2,1 and 2 in the RBX, DMI and P group) for self-discharge and/or patient refusal.

Among the evaluable patients, 60% of the RBX (n=80), 44% of the DMI (n=82) and 36% of the P group (n=81) showed at least 50% reduction of the HAM-D total score at end of treatment (study end-point; RBX vs P,  $p < 0.05$ ). An earlier efficacy of RBX was demonstrated by the average values of the applied rating scales: in comparison with P a statistically significant difference was present in the RBX group from day 10-14 and in the DMI group from day 14-21 on, the improvement of most outcome measures being apparent on average one week sooner in the RBX group.

As to signs/symptoms, dry mouth was reported with significantly greater frequency in the DMI group (45.5%) than in the RBX (25.3%) and P (21.7%) groups. Blurred vision was also reported with greater frequency in the DMI (17.0%) than in the RBX (3.6%) and P (3.6%) groups. On the other hand urinary hesitancy was significantly more frequent in the RBX (10.8%) than in the P (1.2%) group. Noteworthy trends ( $p < 0.10$ ) included greater frequency of headaches in the RBX patients, of constipation in both DMI and RBX patients and of tachycardia in the DMI patients. The therapeutic index (Efficacy Index) was found to be significantly ( $p < 0.05$ ) more favourable in the RBX than in the DMI and P group. Neither differences in average values of laboratory tests and vital signs nor in frequencies of abnormal laboratory tests results of clinical relevance were observed. ECG abnormalities were reported rarely; signs compatible with an ischemic episode were apparent in one patient under RBX, with partial resolution while continuing treatment.

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

6

---

In conclusion, the results of this study clearly indicate the superiority of RBX over P in the treatment of Major Depressive Disorder. By comparison to DMI, RBX was found to be at least as effective in the treatment of depressive symptomatology with a 28 days trial, the improvement being apparent on the average one week sooner. With respect to tolerability, RBX appeared to be well-tolerated in the dose used.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

7

## 2. IDENTITY OF THE TEST MATERIAL

Treatments consisted of indistinguishable capsules, containing either 2 mg of RBX plus excipients (batch no 893) or excipients only (placebo, batch no 892), manufactured on May 1987 by Farmitalia Carlo Erba Galenic Dpt., or DMI 50 mg. The latter were prepared at the School of Pharmacy, University of London, putting in each capsule, together with the same excipients, 2 tablets of Pertofran 25 mg from the U.K. market (Geigy Pharmaceuticals, product licence number 0001/5019). Analytical certificates are enclosed to the study protocol.

## 3. INTRODUCTION

RBX [FCE 20124 or RS, RS 2-[alpha-(2-ethoxy-phenoxy) benzyl] morpholine methane sulphonate) is a new chemical entity with highly potent activity on pharmacological and biochemical tests such as reserpine antagonism, norepinephrine reuptake inhibition, and REM sleep latency increase that are predictive of antidepressant effectiveness. In addition, RBX was found to prevent clonidine effects in rodents after the administration of a single oral dose. In this respect it differs from tricyclic monoamine uptake inhibitors that are active only after repeated doses. These results indicate that RBX is highly potent in decreasing the sensitivity of alpha2-noradrenergic receptors after a single oral dose. If desensitization of alpha2-noradrenergic receptors correlates with antidepressant efficacy, RBX should exert antidepressant effectiveness with a faster onset than tricyclic antidepressants (1).

In Phase I studies in healthy volunteers, orally administered single doses of the compound were well tolerated in doses lower than 5 mg. Oral administration of 5 mg resulted in orthostatic hypotension, accompanied by tachycardia and by manifestations consistent with the disturbance of circulatory regulation. In a subsequent pharmacodynamic study in healthy volunteers vs placebo and imipramine dose-related activity on the CNS (EEG activation, performance tests improvement) was apparent after RBX 1-3 mg; imipramine 75 mg was associated with modifications indicative of sedative activity and deterioration of performance tests (2,3).

Additional information on RBX pharmacodynamics in healthy volunteers derives from a single dose study vs DMI and P. One to 4 mg RBX was found to possess a profile of activity on the autonomic nervous system, with weak anticholinergic properties, similar to DMI 25 to 100 mg (4).

PCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

8

Pharmacokinetic studies showed that unchanged RBX represents the vast majority of circulating products following oral administration and that its half-life is of about 13 h, i.e. compatible with both a o.a.d. and a b.i.d. administration schedule (5). The latter was selected for repeated dose studies.

An open, dose-range finding multicenter study was also carried out in patients hospitalized for Major Depressive Disorders (6). A total of 98 patients participated in the study. RBX was administered for four weeks according to five different fixed changing dose schedules, with maximum daily doses of 4 mg (29 pts), 6 mg (27 pts), 8 mg (18 pts), 10 mg (12 pts) and 12 mg (12 pts). At the latter dose hypotension accompanied by dizziness and tachycardia was apparent in 7 patients and required dose reduction to 10 mg/day up to the end of the study in 5 patients.

When administered up to 10 mg/day the compound was well tolerated: no patient dropped from the study due to adverse events; the side-effects reported were mainly mild and transient; no clinically relevant average modifications of vital signs were apparent; laboratory tests did not show individual modifications of clinical significance; no ECG modifications were observed with the exception of slight prolongation of PR interval in one patient who received 6 mg/day. Improvement of depressive symptomatology was observed with all dose levels of the compound. Frequency of relevant modifications (50% decrease of the Hamilton Depression Rating Scale) and the average improvement of the rating scales at the end of treatment were dose-related up to the 10 mg dosage.

#### 4. STUDY OBJECTIVE

On the basis of the information provided by previous studies on the tolerability of repeated doses of RBX and the indications about the possibly active dosages of the compound, the present study was designed, aimed at evaluating the effectiveness and therapeutic usefulness of RBX in Major Depressive Disorders in double blind conditions in comparison with placebo and a standard reference drug.

#### 5. THE INVESTIGATIONAL PLAN

The study protocol is enclosed (enclosure 1).



FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

9

---

### 5.1 Experimental Design

The study was carried out according to a double-blind, parallel group design, controlled vs P and reference drug, on a multicenter, multinational basis. The 10 centers involved are listed in enclosure 2.

Among the possible positive controls/reference antidepressant drugs, DMI was selected in view of the similar activity profile to RBX both in animal (1) and human (4) studies. On the basis of the pharmacodynamic study in healthy volunteers (4) doses were chosen assuming a 1 to 25 potency ratio. On the other hand, the DMI dose regimen adopted corresponds to the indications of the manufacturer (7).

The experimental treatments were prepared in indistinguishable capsules, as described, and packaged in individual bottles. A random number list was prepared, treatments were allocated to patient numbers on the basis of it, and the study medication labelled accordingly. Each center was expected to recruit 8 patients per arm, and treatments were balanced in blocks of four. The randomization list is enclosed (enclosure 3).

At each center acceptable patients on the basis of inclusion/exclusion criteria received their progressive number and the corresponding medication according to their temporal entry into the study.

### 5.2 Patient Population

Consenting patients (documented by signed written consent form) with a DSM-III-R diagnosis of Major Depressive Episode, with the presence of illness for at least one month prior to the clinical trial were included.

All patients except those treated with an MAOI antidepressant had to undergo a seven day pre-treatment drug-free washout period (from Day -6 to Day 0). For patients treated with an MAOI, the pretreatment washout period had to be of 14 days in duration. Patients had to be hospitalized for the entire duration of the clinical investigation.

For safety reasons, patients with a history of gastrointestinal, liver, thyroid, or kidney disease, known hypersensitivity to psychotropic drugs, and seizures or brain injury were excluded. Also excluded were patients with evidence at time of screening of urinary retention, hematopoietic or cardiovascular disease, or glaucoma. Patients who, during the four weeks prior to the study, had been treated with an investigational drug or any drug with well-defined

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

10

potential for toxicity, or displayed symptoms of any important clinical illness were excluded. The same applied to pregnant women and/or patients treated with ECT in the preceding six months. Finally, any patients presenting with clinically relevant abnormal findings on the physical examination, laboratory tests, or ECG were excluded from participation.

By employing the above criteria a total of 258 patients were admitted to the clinical trial within a period of 18 months. As shown in Figure 1, they were recruited from 10 centers with each center contributing different numbers of patients. The greatest number, i.e. 48 (18.6%), were contributed by the center in Panama (Vergara), the smallest number, i.e. 4 (1.6%) by the center in Acapulco, with the centers in Budapest-Lipcsey (36, 14.0%), Panama-Batista (33, 12.8%), Catania (25, 9.7%), Budapest-Gaszner (24, 9.3%), Trieste (24, 9.3%), Lima (24, 9.3%), Mexico City (22, 8.5%), and Rouffach (18, 7.0%) being in between.

In Table I the demographic distribution of the sample is presented by centers and in total. All of the 258 patients admitted to the study were 18 years old or older. The population ranged in age from 19 to 68 with a mean of 46.7 years (s.d.= 11.5) and a median of 48 years. The mean age of patients at the time of onset of their depression was 34.1 (s.d.= 11.1). Average duration of the current depressive episode was 2.6 months (s.d.= 3.1), and the mean number of their previous episodes was 3.9 (s.d. = 3.1). Patients were admitted to the study irrespective of gender. As a result of the total sample 150 (58.1%) were female and 108 (41.9%) were male.

With respect to the form of onset the greatest number, i.e. 121 (46.9%) of patients had an insidious onset, while 97 (37.6%) had subacute and 40 (15.5%) had an acute onset of the present episode. Precipitating stressors were definitely present in 27 (10.5%) cases, probably present in 64 (24.8%) cases, and absent in 167 (64.7%) of cases.

At the time of inclusion to the clinical trial, all patients fulfilled DSM-III-R criteria of Major Depressive Episode.

Chi-square analyses indicated differences across centers with respect to sex ( $X^2 = 22.91$ ,  $p < .006$ ), type of onset ( $X^2 = 242.17$ ,  $p < .001$ ), and precipitating stressors ( $X^2 = 136.96$ ,  $p < .001$ ). Analyses of variance indicated differences across centers with respect to age ( $F = 6.30$ ,  $p < .001$ ), age at onset ( $F = 6.95$ ,  $p < .001$ ), number of previous episodes ( $F = 11.58$ ,  $p < .001$ ), and duration of present episode ( $F = 6.31$ ,  $p < .001$ ).

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

11

### 5.3 Population and Treatment Groups

Patients included in the clinical trial were randomly assigned to one of three treatment regimes, i.e., RBX (Drug Group C), DMI (Drug Group B), or an inactive P (Drug Group A). As a results, 84 (32.6%) of the 258 patients were assigned to treatment with RBX, 89 (34.5%) were assigned to treatment with DMI, and 85 (32.9%) were assigned to treatment with P.

Table II presents the comparative demography of the three treatment groups. Chi-square and analysis of variance tests indicated no significant differences across treatment groups with respect to age, sex, duration of episode, number of previous episodes, age at onset, type of onset, or precipitating stressors.

### 5.4 Experimental Treatment

As already mentioned, all medication was supplied in indistinguishable capsules containing either 2 mg RBX, 50 mg DMI with excipients, or excipients only, i.e., P. For each patient, the medication was supplied in one bottle containing 105 capsules (i.e., two more than needed).

All patients received 1 capsule b.i.d. from Day 1 to Day 3. If well tolerated the dosage was increased to 2 capsules in the morning (10:10 am) and 1 in the evening (8:00 pm) from Day 4 to Day 6, and to 2 capsules b.i.d. from Day 7 to Day 28.

No concomitant medication had to be used for the duration of the study, with the exception of the hypnotic chloral hydrate 500-1000 mg at bedtime. Medications required due to events arising during the course of the study were allowed.

### 5.5 Screening and Assessment of Change

Efficacy measurements included the Clinical Global Impression (CGI)(8), the 17-items Hamilton Depression Rating Scale (HAM-D)(9), the Montgomery Asberg Depression Rating Scale (MADRS)(10), the Zung self-rating scale for Depression (11).

Patients were also classified at admission according to the CODE-DD system (12), in order to possibly identify diagnostic sub-populations of patients particularly responsive to active treatments. The results obtained will be reported elsewhere.

FCE 20124/702.i  
FARMITALIA CARLO ERBA  
ERRAMONT GROUP  
CNS DEPT

12

Operating procedures for training on assessment instruments, study monitoring and coordination were defined (see protocol, Attachment B). Inter-rater agreement for the CGI, HAM-D, MADRS was tested during the initial Investigator meetings in May/June 1987, based upon videotaped interviews with 4 depressed patients. Reliability was calculated by assessing product-moment correlations between raters on total scores. A median inter-rater correlation of .891 for the HAM-D, of .925 for the MADRS, and of .945 for the CGI was found. These figures are judged to be excellent, given the limited number of videotapes and the restricted nature of the patient sample.

All adverse effects were recorded on a specially devised form (Newly Observed Signs and Symptoms) with information on the nature, onset, duration, severity, and resolution of the treatment emergent symptom. Relationship of adverse effects to the medications was judged on the basis of the Karch and Lasagna criteria. Tolerability assessments included, in addition, vital signs, laboratory tests, ECG.

The assessment schedule is reported in Table III.

#### 5.6 Analysis of Data

Data analyses were based upon descriptive statistics, repeated measure analysis of variance (ANOVA), and chi-square comparisons, with the primary purpose of testing differences between treatments and placebo (i.e., RBX and DMI vs P) over time. In addition differences between RBX and DMI were also tested. The main comparison between treatments was done on the basis of the response rate, defined as the % of randomized patients presenting 50% decrease of the HAMD at the end of treatment.

A total sample size of 80 patients per group was expected to provide to the test of the null hypothesis of no difference between active compound and placebo a power of 0.8, i.e. 80% probability of rejecting it in presence of a between treatment difference of 20%, assuming 50% response rate under P and a one-sided 0.05 alpha level.

Repeated measure analyses of variance utilized multivariate tests of significance if the Mauchly sphericity test indicated that the assumption of constant variance on the diagonal of the covariance matrix had been violated. Significant repeated measures ANOVAs were followed up with univariate one-way ANOVAs and Duncan multiple tests.

Statistical analysis was carried out in blind conditions, treatments being identified as A (P), B (DMI), and C (RBX).

FCE 20124/702.i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

### 5.7 Disposition of patients entered and data set analyzed

Of the 258 patients entered 14 were considered (under blind conditions) not evaluable. Treatment period and reason for exclusion from the analysis is reported in the Individual Data Appendix, Table 0. Protocol violation as far as associated treatments in 12 cases (continuous treatment with anxiolytics, hypnotics and/or antipsychotics) or self-discharge from the hospital and consequent lack of assessments after day 4 in 2 cases were the reason for exclusion. Distribution of non evaluable cases across treatments is similar: 4 cases belong to the RBX group, 4 to the P group, 6 to the DMI group. With the exception of pat. no. 7, non evaluable patients were substituted, as foreseen by the study protocol.

Individual Data Appendix groups by treatment demography of evaluable patients in Table 1; diagnosis and history of the mental disorder in Table 2; previous antidepressant treatment in Table 3; experimental treatment dates and duration in Table 4a; concomitant medications in Table 4b.

Study course is described in Table IV. A total of 233 (90.3%) of the 258 patients completed the entire 28 days of the clinical trial. Of the 25 patients who were discontinued, 4 (1.6%) refused treatment, 18 (7.0%) were discontinued because of ineffectiveness, and 3 patients (1.2%) were discontinued because of adverse effects.

Of the three patients discontinued because of adverse effects, two were treated with RBX and one was treated with P. One of the three patients, patient number 74, was a 63 year old woman treated with RBX which was discontinued on Day 18 because of frequent ventricular extrasystoles. It was noted that this patient had an abnormal electrocardiogram with ventricular extrasystoles at pretreatment and also at Day 14 of treatment. The only treatment emergent symptom in this patient was "constipation", recorded for three days.

Another of the three patients, patient number 138, was a 61 year old woman treated with RBX which was discontinued on Day 20 because of hypertension. The Day 0 blood pressure recordings for this patient were 130/90 (lying) and 120/100 (standing). On Day 20 the blood pressure of the patient increased to 180/130 for a period of three hours. The administration of nifedipine and Clorthalidone Plus KCl resulted in a decrease of blood pressure to normal. Other treatment emergent symptoms encountered in this patient included blurred vision (present throughout treatment), constipation (11 days in duration), and drowsiness (7 days in duration).

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

14

The third patient, patient number 222, was a 29 year old female treated with P who was discontinued on Day 20 because a skin rash with generalized pruritus. She was treated prior to and throughout the trial period with chlorpheniramine 10 mg/day. Additional information indicated that she received some capsules specially prepared for her by a pharmacist which contained small doses of various psychotropic agents such as benzodiazepines, tricyclic antidepressants, neuroleptics, and vitamins. Other treatment emergent symptoms included headache (a days duration) and vomiting (10 minutes duration).

Chi-square and analysis of variance tests indicated no significant differences between groups with respect to treatment discontinuation, non-pharmacological treatments, pattern of drug intake, duration of trial, or final disposition.

As indicated in the above mentioned Table 4b of the Individual Data Appendix, the expected treatment regime was complied with in the majority of patients completing the study, with a few exceptions. In the P group patient no. 1 had the dose reduced from 4 to 3 capsules per day from Day 7 to the end of treatment due to tachycardia.

In the DMI group, patient no. 2 had the dose reduced from 3 to 2 capsules per day for 3 days due to tachycardia; patient no. 78 had the dose reduced from 4 to 3 capsules per day from Day 11 to the end of treatment due to dry mouth; patient no. 90 had the dose reduced from 4 to 3 and then 2 capsules per day from Day 21 to the end of treatment due to blurred vision; patient no. 179 had the dose reduced from 4 to 3 capsules per day from Day 16 to the end of treatment due to hypotension and tachycardia; patient no. 238 had the dose reduced from 4 to 3 capsules per day for 2 days due to tremor and hypotension.

In the RBX group, patient no. 3 had the dose reduced from 3 to 2 capsules per day for 6 days due to tachycardia; patient no. 81 had the dose reduced from 4 to 3 capsules per day from Day 19 to the end of treatment due to hypotension; patient no. 86 had the dose reduced from 4 to 3 capsules per day from Day 18 to the end of treatment due to insomnia; patient no. 111 had the dose reduced from 4 to 2 capsules per day from Day 19 to the end of treatment due to urinary hesitancy/retention; patient no. 221 had the dose reduced from 4 to 3 capsules per day for 3 days due to feeling of suffocation and chest oppression (accompanied by ECG changes possibly suggestive of an ischemic condition), which disappeared after dose reduction.

FCE 20124/702 i

PARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

15

As to associated medications, protocol criteria were complied with in the majority of cases, with the exception of protocol violations (not evaluable cases) already described (Appendix, Table 0). As indicated in the Table 4b of the Appendix, 12 patients of the P group, 18 patients of the DMI group and 17 patients of the RBX group received concomitant medications. Most frequent was the use of hypnotics (mainly chloral hydrate, nitrazepam, triazolam), applied to 5 patients of the P group, 15 patients of the DMI group and 10 patients of the RBX group. A few cases required treatment for newly emerged signs/symptoms, with no indication of differences between the three treatment groups.

## 6. RESULTS

Assessments of efficacy and tolerability were based upon a series of psychiatric, psychometric, physical, and laboratory measures.

### 6.1 Efficacy

#### Hamilton Rating Scale for Depression

The HAM-D represented the primary efficacy criterion of interest. It was completed eight times, i.e., at Screening, Days 0, 4, 7, 10, 14, 21, and 28, in the course of the clinical trial. Individual data are reported in the Appendix, Table 5.

The pattern of HAM-D Total Scores by group over the clinical trial is presented in Figure 2. The repeated measures ANOVA indicated significant differences between treatment groups over time ( $F= 2.24, p < .006$ ). Univariate ANOVAs indicated that no differences between groups existed at Days 0. By Day 14 the RBX group (mean= 16.35, s.d.= 6.62) was significantly less depressed than the P group (mean= 19.54, s.d.= 7.91). By Day 21, both RBX (mean= 13.92, s.d.= 7.24) and DMI (mean= 14.84, s.d.= 6.87) groups were less depressed than the P group (mean= 17.51, s.d.= 8.43), a pattern that persisted to Day 28.

Utilizing a 50% reduction in HAM-D Total Score as an index of clinical improvement, no differences between groups were noted until Day 28, when improvement rate in the RBX group (60.0% improved) was significantly greater than that in the P group (35.0%). The pattern of improvement over the course of the clinical trial is presented in Figure 3.

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

16

To examine the specific nature of changes observed on the HAM-D, improvements upon factor scores derived from HAM-D items were analyzed. Previous studies have generally concluded that there are two primary factors and the 17 -item HAM-D, although there is controversy surrounding the specific composition of these factors (13). Rather than selecting a factor solution from these equivocal previous results, a factor analysis was conducted utilizing the HAM-D item scores at screening to derive factor scores directly pertinent to the study population. A principal components extraction followed by an orthogonal (varimax) rotation was utilized (14,15); two factors were extracted in keeping with the results of previous studies. The rotated factor loadings are presented in Table V.

Interpretation of these factors suggests one factor comprised primarily of vegetative signs (insomnia, somatic signs, weight loss) and a second factor reflecting vital disturbance (guilt, suicidality, hypochondriasis, poor insight). Factor scores representing these dimensions were calculated by summing item scores from HAM-D items loading above .50 on the respective factors.

The pattern of HAM-D factor scores by group over the trial are presented in Figure 4 for the vegetative symptom factor and in Figure 5 for the vital depression factor. Repeated measures ANOVAs indicated significant differences between treatment groups over time for both the vegetative symptom factor ( $F= 2.09$ ,  $p < .011$ ) as well as the vital depression factor ( $F= 3.16$ ,  $p < .001$ ). For the vegetative symptom factor, univariate ANOVAs indicated a trend for the RBX group (mean= 7.47, s.d.= 2.15) to display more vegetative signs at Day 0 than was true for the other two groups. This trend was no longer observable by Day 4. At Day 28 both RBX (mean= 3.01, s.d.= 2.42) and DMI (mean= 3.24, s.d.= 2.30) groups showed fewer vegetative signs than P patients (mean= 4.04, s.d.= 2.50).

For the vital depression factor, no differences were observed between groups at Day 0. By Day 21, both RBX (mean = 2.87, s.d.= 2.27) and DMI (mean= 3.11, s.d.= 2.26) groups were less depressed than P patients (mean= 3.90, s.d.= 2.58), a pattern also observed at Day 28.

To examine the possible influence of study site upon the results obtained in the study, repeated measures analyses of variance were carried out to determine the interaction of site with efficacy (i.e., pre-post analyses) and of site with onset pattern (i.e., using all seven observation points). These analyses were conducted twice: once with all ten sites included, and once with the two sites excluded (Rouffach and Acapulco) which contributed a relatively small number of patients.



FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

17

With respect to efficacy, the analysis of all ten sites demonstrated a trend toward a significant site by group by time interaction ( $F= 1.54, p < .078$ ). Removing the two smaller centers from the analyses eliminated this trend ( $F= 1.28, p < .220$ ), suggesting that site effect observed in the total sample may have been an artifact of small sample sizes at two of the sites.

With respect to pattern of onset, significant site by group by time interactions were noted for both the total sample ( $F= 1.49, p < .001$ ) and for the eight largest sites ( $F= 1.42, p < .005$ ). To investigate the specific nature of these interactions, follow-up univariate ANOVAs were conducted examining the pattern of efficacy onset at each site. Because there were relatively few subjects studied at each site, alpha levels below .20 were identified as trends in order to explore possible pattern of onset differences. A summary of the results of these analyses is presented in Table VI. Because of small sample sizes, it is difficult to draw definitive conclusions based upon the results. However, the pattern of onset of efficacy of RBX seemed to be most rapid at the Panama (Batista) site and slowest at the Rouffach center.

#### Clinical Global Impression

Individual data are reported in the Appendix, Table 5b.

#### Severity of Illness

Severity of Illness (SI) ratings were completed seven times, i.e., on Days 0, 4, 7, 10, 14, 21, and 28, in the course of the clinical trial. The pattern of scores by group over the clinical trial is presented in Figure 6. The repeated measures ANOVA indicated significant differences between treatment groups over time ( $F= 2.73, p < .001$ ). Univariate ANOVAs indicated that the RBX group (mean= 5.03, s.d.= 0.68) was significantly more ill than the P group (mean= 4.77, s.d.= 0.71) at Day 0, but by Day 14 the RBX group (mean= 3.65, s.d.= 1.07) was less ill than the P group (mean= 4.12, s.d.= 1.28). By Day 28, the RBX group (mean= 2.72, s.d.= 1.19) was significantly less ill than both the DMI group (mean= 3.17, s.d.= 1.34) and the P group (mean= 3.60, s.d.= 1.42).

Utilizing a 50% reduction on Severity of Illness as an index of clinical improvement, no significant difference between groups were noted until Day 28, when improvement rate in the RBX group (51.2% improved) was significantly greater than that with DMI (32.9%) or P (22.5%). The pattern of improvement over the course of the clinical trial is presented in Figure 7.

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

18

Global Improvement.

Global Improvement(GI) ratings were completed six times, i.e., on Days 4, 7, 10, 14, 21, and 28, in the course of the clinical trial. The pattern of scores by group over the clinical trial is presented in Figure 8. The repeated measures ANOVA indicated a main effect for treatment group ( $F= 5.76, p < .004$ ) as well as significant differences between treatment groups over time ( $F= 2.80, p < .001$ ). Univariate ANOVAs indicated that the RBX group (mean= 3.08, s.d.= 0.94) was significantly more improved than the P group (mean= 3.46, s.d.= 0.94) by Day 10. By Day 14, both RBX (mean= 2.75, s.d.= 0.95) and DMI (mean= 2.91, s.d.= 1.02) groups were more improved than P (mean= 3.37, s.d.= 1.06), a pattern that persisted to Day 28.

Montgomery-Asberg Depression Rating Scale

The MADRS was completed seven times, i.e., at Days 0, 4, 7, 10, 14, 21, and 28, in the course of the clinical trial. Individual data are reported in the Appendix, Table 5c.

The pattern of MADRS Total Scores by group over the trial is presented in Figure 9. The repeated measures ANOVA indicated significant differences between treatment groups over time ( $F= 3.03, p < .001$ ). Univariate ANOVAs indicated no differences between groups at Day 0. By Day 14 the RBX group (mean= 10.42, s.d.= 4.41) was significantly less depressed than the P group (mean= 12.53, s.d.= 5.29). By Day 21, both RBX (mean = 8.57, s.d.= 5.28) and DMI (mean= 9.23, s.d.= 4.64) groups were less depressed than P patients (mean= 11.01, s.d.= 6.00), a pattern that persisted to Day 28.

Utilizing a 50% reduction in MADRS Total Score as an index of clinical improvement, no differences between groups were noted until Day 14, when improvement rate in both the RBX group (35.0% improved) and the DMI group (32.9%) was significantly greater than that in P patients (18.5%). At Day 21, the RBX improvement rate (56.2%) was significantly greater than P (32.1%), although this was no longer true for the DMI group (43.9% improved). At Day 28, improvement rate in both the RBX group (66.2% improved) and the DMI group (54.9%) was once again significantly greater than that in P group (35.8%). The pattern of improvement over the course of the clinical trial is presented in Figure 10.

FCE 20124/702 i

19

FARMITALIA CARLO ERBA  
ERRAMONT GROUP  
CNS DEPT

---

### Zung Self-Rating Scale for Depression

The (Zung) was completed seven times, i.e., at Days 0, 4, 7, 10, 14, 21, and 28, in the course of the clinical trial. The individual data are reported in the Appendix, Table 5d. The pattern of Zung Total Scores by group over the trial is presented in Figure 11. The repeated measures ANOVA indicated significant differences between treatment groups over time ( $F= 1.85, p < .038$ ). Univariate ANOVAs indicated that no differences between groups at Day 0, with the average Zung score for the total sample being 63.47 (s.d.= 6.63). By Day 14 the RBX group (mean= 48.32, s.d.= 10.75) was significantly less depressed than the P group (mean= 53.28, s.d.= 13.53). By Day 28, both RBX (mean= 40.58, s.d.= 11.64) and DMI (mean= 43.57, s.d.= 12.92) groups were less depressed than P patients (mean= 48.03, s.d.= 15.36).

#### 6.2 Follow-up Assessment

Patients were recontacted one month following completion of the clinical trial to determine their subsequent experience and status. The results of this contact, grouped by treatment, are presented in Table VII. No differences between groups were observed with respect to the emergence of signs symptoms following treatment discontinuation ( $X^2 = 2.58, p > .10$ ). Trends were observed with respect to the use of antidepressant medication ( $X^2 = 4.82, p < .09$ ) and hospitalization status ( $X^2 = 4.73, p < .10$ ).

At follow-up, patients who had received RBX were less likely to be hospitalized, and fewer RBX patients required antidepressant treatment as compared to DMI and P patients.

#### 6.3 Tolerability

##### Vital Signs

Oral body temperature, arterial blood pressure (lying and standing) and heart rate were monitored eight times during the course of the study: Days 0, 1, 3, 6, 12, 14, 21, and 28. Body weight was measured on day 0 and at weekly intervals thereafter. Individual data are reported in the Appendix, Table 5e. The results of ANOVA analyses on blood pressure and heart rate are presented in Table VIII. These results indicated no differences over time across the three groups on the variables of lying diastolic blood pressure, standing diastolic blood pressure, lying heart rate, and standing heart rate. Differences were observed between groups on lying systolic and standing systolic blood pressure. Subsequent univariate ANOVAs revealed elevated values at Day 12 for the RBX group on both values. No other differences across the course of the trial were observed. No differential effects between RBX, DMI and P were apparent from ANOVA, carried out on body temperature ( $F= 1.06, p < 0.39$ ) or body weight ( $F= 1.07, p < 0.39$ ).

FCE 20124/702 i

FRANCESCO CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

20

---

### Laboratory Tests

A total of 38 parameters obtained from blood and urine samples were examined at Days 0, 7, 14, and 28. Individual data together with normal ranges of the laboratory tests at each site are reported in the Appendix, Table 5f. To determine the tolerability of RBX, these values were analyzed to determine time-related changes with respect to both the actual recorded value for all parameters as well as the normality of the recorded values (i.e., normal vs. abnormal) as delimited by the laboratory used at the site.

Analyses of recorded values involved repeated measures analyses of variance, where time by drug group interactions would be observed if either RBX or DMI differed from P in its effect upon laboratory values. Analysis of abnormal values consisted of chi-square comparison of percentage of abnormal readings obtained pre-treatment (i.e., Day 0) and post-treatment (i.e., Day 28). These chi-square analyses were conducted independently for the three treatment groups.

Results of the repeated measures analyses of the recorded values indicated no significant time by drug group interactions (or trends) for any of the 38 laboratory parameters. These results indicate that neither RBX nor DMI differed significantly from placebo in their effect upon these values.

Results of the chi-square analyses of abnormal values are presented in Table IX. A total of 114 pre-post analyses (38 parameters by 3 drug groups) yielded no differences pre-post that were significant at the .05 level. Four trends towards significance were noted ( $p < .10$ ). There was an increase in the percentage of abnormal CA++ values between pre-treatment (12.7%) and post-treatment (25.0%) for the RBX group (chi square = 3.11,  $p < .08$ ). The DMI group demonstrated increased abnormalities in platelets (chi square = 3.78,  $p < .06$ ) and in NA+ (chi square = 3.61,  $p < .06$ ) over the course of the trial. Finally, the placebo group demonstrated increased abnormalities in CL- (chi square = 3.40,  $p < .07$ ) over the clinical trial. Given the large number of analyses performed, the interpretative significance of these trends is doubtful when the likelihood of experiment-wise error is considered.

### Newly Observed Signs and Symptoms

Newly observed signs and symptoms representing possible adverse effects of medication were recorded on a specially devised scale on Days 4, 7, 10, 14, 21, and 28, as well as at the time of any treatment emergent symptom. A total of 58 signs and symptoms were monitored during the study.

FCE 20124/702 i

21

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

---

Signs/symptoms reported during the course of the study are listed by treatment group in the Appendix, Table 6 (individual data) and Tables 7 (frequencies of reporting), 7a (frequencies by week of treatment onset), 7b (frequencies at the end of treatment), 7c (frequencies by severity degree), 7d (frequencies by treatment relationship), 7e (frequencies by requiring treatment), 7f (frequencies by course).

The percentage of patients manifesting each sign and symptom at any time during the trial, presented by drug group, is listed in Table X. Chi-square analyses identified significant differences between medication groups on three symptoms and trends were observed on three additional symptoms. Dry mouth was reported with greater frequency in the DMI group (45.5%) than in the RBX (25.3%) or P (21.7%) groups. Blurred vision was also reported with greater frequency in DMI patients (17.0%) than in the RBX (3.6%) or P (3.6%) groups. The RBX patients manifested urinary hesitancy (10.8%) more frequently than P patients (1.2%), although RBX and DMI (4.5%) patients did not differ significantly on this symptom. Noteworthy trends included greater frequency of headaches in the RBX group, increased constipation in both DMI and RBX patients, and more frequent tachycardia in DMI patients.

Newly appeared abnormalities in the ECG examinations were reported in one patient (no 235), under P (ST flattening), in 3 patients under DMI (incomplete RBBB in patient no 44, ST flattening in patient no 218, and T and ST flattening in patient no 219) and in one patient (no 221) under RBX (inverted T wave in V1, V2 and V3). The latter was reported on day 14 and was accompanied by feeling of suffocation and chest oppression; the modifications were interpreted as possibly indicative of an ischemic, antero-septal episode; no modifications of laboratory tests were apparent; the dose was reduced for three days to 3 cps per day and the subjective symptoms disappeared; no re-emergence was observed after re-introduction of treatment at the dose of 4 cps per day up to end of 4th weeks. ECG examination on Day 28 revealed presence of inverted T wave only in V1 and was therefore indicative of partial resolution of the episode.

Previous experience has suggested that most side effects reported by P patients are mild in severity and that inclusion of these mild symptoms may obscure differences between placebo and active medication groups. Thus, chi-square analyses were conducted to identify significant differences between medication groups on any symptoms that were of at least moderate severity. The results of these analyses are presented in Table XI. Only two symptoms were observed with differential frequency between groups. Dry mouth was observed more frequently in both DMI (20.7%) and

FCE 20124/702 i  
FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

22

RBX (13.3%) patients than in P patients (3.7%). Constipation was also more frequent in both DMI (18.4%) and RBX (16.9%) groups than in P patients (1.2%). No other significant differences between groups were observed among symptoms of at least moderate severity.

#### Clinical Global Impression, Efficacy Index

Clinical Investigators were asked to weight at each assessment interval efficacy against side-effects of treatment in each patient. Individual data are reported in the Appendix, table 5b. The pattern of scores by group over the clinical trial is presented in Fig 12. Repeated measure ANOVA indicated significant differences between treatment groups over time ( $F = 1.96$ ,  $P < 0.04$ ). Univariate ANOVAs indicated that on day 28 the RBX group (mean = 2.44, s.d. = 1.10) was superior to both the DMI (mean = 2.09, s.d. = 1.09) and the P (mean = 1.84, s.d. = 1.03) group.

#### 7. DISCUSSION

The study was carried out according to a multicenter, randomized, double blind, parallel group design, in agreement with the methodology suggested by available guidelines (16,17). In order to minimize the increased error variance deriving from the multicenter condition, recognized to be unavoidable to achieve adequate number of patients (17), training sessions on diagnostic instruments and on the instruments used in the assessment of change were carried out both before and during the course of the trial.

The inclusion of both the negative and a positive control group allowed the estimate of the differences between RBX and P in sensitive experimental conditions, though the positive control was found statistically different from P mainly when continuous variables were analysed.

The frequency of response to P observed in the study is compatible with data reported in the literature for the relevant pathology (18). The 4-week treatment period corresponds to the minimal duration to detect clinically relevant differences between treatment groups (17); on the other hand, the maximal response rate might have been better estimated in a 6-week trial (19).

The results of this study clearly indicate the superiority of RBX over P in the treatment of Major Depressive Disorder.

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

23

This superiority could be observed in every outcome measure in the study, including clinical observation measures such as the HAM-D and MADRS as well as patient-rated measures such as the Zung. These differences could also be observed whether a continuous or a dichotomized (i.e., improvement vs. no improvement) measurement of outcome was examined. When the more sensitive continuous measures of outcome were examined, the efficacy of RBX could be observed as early as Day 10 on some measures, while RBX patients were invariably less symptomatic than those on P by Day 14.

By comparison to DMI, RBX was found to be at least equally effective and often more effective on all outcome measures. On the CGI severity score, RBX patients displayed a more rapid onset of action than DMI (Day 14 as compared to Day 21), and were more improved than DMI patients upon completion of the study. The finding of the more rapid onset of action of RBX as compared to DMI was also replicated with the other outcome measures: CGI Global Improvement, CGI Efficacy Index, HAM-D total score, MADRS total score, and Zung self-rating scale. The overall pattern of results consistently indicated that RBX was at least as effective in the treatment of depressive symptomatology as DMI with a 28 day trial, and that improvement in RBX patients could be observed an average of one week sooner than for DMI patients.

With respect to tolerability, RBX appeared to be well-tolerated in the dose used in this trial. The only significant side effects of at least moderate severity that RBX patients reported were dry mouth and constipation. However, both of these side effects were reported more frequently with both RBX and DMI than with P; and more frequently with DMI than with RBX. The efficacy/tolerability comparison (CGI-Efficacy Index) showed more favourable therapeutic index for RBX compared to both DMI and P.

No reliable differences in laboratory test values were observed between RBX and P patients. The increased blood pressure in RBX patients at Day 12 was due to one patient experiencing marked hypertension that was evident at pretreatment. No other significant effects upon vital signs were observed. ECG abnormalities were reported in one patient of the P group (ST flattening), in 3 patients of the DMI group (incomplete RBBB, T flattening, T & ST flattening) and in one patient of the RBX group (inverted T wave). The latter was accompanied by subjective symptomatology and was compatible with an ischemic episode. Partial resolution while continuing treatment was apparent.

In conclusion, the results of this study support the therapeutic usefulness of the compound. The latter should be confirmed in extended Phase 3 trials.

FCE 20124/702 i

FARMITALIA CARLO ERBA  
ERBAMONT GROUP  
CNS DEPT

24

---

## 8. REFERENCES

- 1) FCE 20124 - Antidepressant Agent: Basic Information (Farmitalia Carlo Erba Investigator's Brochure). July 88.
- 2) Herrmann, W.M.: Safety and Tolerance of FCE 20124 in Healthy Male Volunteers. A Single Rising Dose Tolerance Study. Internal Report N. 602, June 1984.
- 3) Herrmann, W.M.: FCE 20124 Quantitative Pharmacology-EEG and Pharmacopsychological Study. Internal Report N. 603, January 1985.
- 4) Szabadi, E. et al.: Autonomic Effects of Single Oral Doses of Reboxetine vs Desipramine and Placebo in Healthy Volunteers. Internal Report (In preparation).
- 5) Disposition and Fate of 14C-FCE 20124 Administered Orally to Healthy Volunteers; Dubini, A., Goldaniga G. C., et al; Internal Report N. 604, March 1985.
- 6) Dubini, A., Ban, T.: Reboxetine: Open Dose-Range Finding Study in Patients Hospitalized for Major Depressive Disorders. Internal Report n. 701, April 1989.
- 7) ABPI Data Sheet compendium, Datapharm Publications Limited, London, 1989-1990.
- 8) ECDEU Assessment Manual for Psychopharmacology, National Institute of Mental Health Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville. Revision 1976.
- 9) Hamilton, M.: A Rating Scale For Depression. J. Neurol. Neurosurg. Psychiat. 23: 56-62, 1960.
- 10) Montgomery, S.A., Montgomery, D.B.: Measurement of Change in Psychiatric Illness: New Obsessional, Schizophrenia and Depression Scales. Postgraduate Medical Journal, 56: 50-52, 1980.
- 11) Zung, W.W.K.: A Self-rating Depression Scale. Arch. Gen. Psychiat., 12: 65-70, 1965.
- 12) Ban, T.A.: Composite Diagnostic Evaluation of Depressive Disorders. J.M. Production, Inc., Brentwood, 1989.
- 13) Rabkin, J.G., Klein, B.F.: The Clinical Measurement of Depressive Disorders; in A.J. Marsella, R.M.A. Hirschfeld, M.M. Katz, Eds.; J. Wiley and Sons Ltd, 1987, page 30.



FCE 20124/702.i  
FARMIVALIA CARLO ERBA  
VERMONT GROUP  
CNS DEPT

25

- 
- 14) Maxwell, A. E. : Multivariate Analysis in Behavioural Research. Chapman & Hall, London, 1977.
  - 15) Wilkinson, J. H. : The calculation of eigenvectors of codiagonal matrices. Computer J., 1958, 1, pp. 90-96.
  - 16) Guidelines for the Clinical Evaluation of Antidepressant Drugs U. S., HEW (FDA) 77-3042 Rockville, 1977.
  - 17) Angst, J., Bech, P., Boyer, P., Brunivels, J., Engel, R., Helmchen, H., Lingjaerde, O., Racagni, G., Saletu, B., Sedvall, G., Silverstone, J.T., Stefanis, C.N., Stoll, K., Woggon, B.: Consensus Conference on the Methodology of Clinical Trials of Antidepressants, Zurich, March 1988: Report of the Consensus Committee. Pharmacopsychiatry, 22: 3-7 March, 1988
  - 18) Edwards, J.G.: Ethics of Placebo-controlled Trials in Depression. Human psychopharmacology, 4: 235-236, 1989.
  - 19) Quitkin, F.M., Rabkin J.G., Ross-D, McGrath-P.J., Duration of Antidepressant Drug Treatment. What is an Adequate Trial?. Arch. Gen. Psychiatry, 41: 238-45, 1984.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

22

26

**Table 1**  
**Demographic distribution and characteristics of the Depressive Disorder by Center.**

Center	Age		Sex		Age at Onset		Duration of Present Episode		Number of Previous Episodes			
	Range	Mean $\pm$ SD	M	F	Mean $\pm$ SD	Mean $\pm$ SD	Mean $\pm$ SD	Mean $\pm$ SD	Mean $\pm$ SD	Mean $\pm$ SD		
Macher	20-60	40.5 10.8	80	44.4	10	55.6	33.7	14.2	1.3	2.1	2.5	1.8
Lipcey	23-64	47.4 11.4	11	30.6	25	69.4	36.5	9.2	0.1	0.4	5.9	3.0
Gaszner	25-64	42.9 10.9	6	25.0	18	75.0	35.0	12.3	2.2	1.8	3.6	2.0
Agullia	36-65	55.7 8.1	11	45.8	13	54.2	41.9	12.2	2.1	2.0	4.3	3.6
Rapiscarde	32-65	50.4 10.2	10	40.0	15	60.0	39.5	12.8	3.4	2.2	5.6	5.0
Torres	19-62	37.9 11.8	5	22.7	17	77.3	31.7	10.3	3.0	5.1	0.5	0.9
Comas	29-46	37.5 9.8	2	50.0	2	50.0	14.0	0.0	3.5	5.1	2.0	0.0
Vergara	21-61	50.3 10.7	18	37.5	30	62.5	29.8	4.2	3.5	1.1	4.9	1.5
Battista	32-60	47.0 7.0	19	57.6	14	42.4	26.3	4.8	2.8	0.8	4.2	1.4
Castillo	22-68	43.0 13.7	6	25.0	18	75.0	39.0	13.7	5.0	6.6	1.1	3.1
<b>Total</b>	<b>19-68</b>	<b>46.7 11.5</b>	<b>108</b>	<b>41.9</b>	<b>150</b>	<b>58.1</b>	<b>34.1</b>	<b>11.1</b>	<b>2.6</b>	<b>3.1</b>	<b>3.9</b>	<b>3.1</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Table I (continued)

Centers	Insidious		Type of Onset		Acute		Definite		Probable		Present	
	N	%	N	%	N	%	N	%	N	%	N	%
Macher	7	38.8	11	61.1	0	0.0	2	11.1	4	22.2	12	66.7
Lipsey	0	00.0	34	74.4	2	5.6	0	0.0	0	0.0	36	100.0
Gaszner	3	12.5	21	87.5	0	0.0	5	20.8	13	54.2	6	25.0
Aguglia	0	0.0	8	33.3	16	66.7	0	0.0	1	4.2	23	95.8
Rapisarda	14	56.0	8	32.0	3	12.0	4	16.0	11	44.0	10	40.0
Torres	8	36.4	4	18.2	10	45.5	2	9.1	10	45.5	10	45.5
Comas	0	0.0	1	25.0	3	75.0	0	0.0	1	25.0	3	75.0
Vergara	46	95.8	2	4.24	0	0.0	0	0.0	11	22.9	37	77.1
Battista	32	97.0	1	3.0	0	0.0	0	0.0	5	15.2	28	84.8
Castillo	11	45.8	7	27.2	6	25.0	14	58.3	8	33.3	2	8.3
Row Total	121	46.9	97	37.6	40	15.5	27	10.5	64	24.8	167	64.7

FCE 20124/702 i

28 24

Table II  
Comparative demography of the three treatment groups

Feature	P	DMI	RBX	Test
Percent of females	63.5	60.7	50.0	$\chi^2 = 3.54$
Average age (in years)	46.7	45.8	47.6	$F = 0.51$
Average duration of episode (in months)	2.9	2.4	2.7	$F = 0.46$
Average number of previous episodes (in months)	4.2	4.1	3.5	$F = 1.05$
Average age at onset (in years)	34.2	33.7	34.5	$F = 0.12$
Type of onset (in % of pts)				
Acute	15.3	15.7	15.5	$\chi^2 = 3.16$
Subacute	31.8	43.8	36.9	
Insidious	52.9	40.4	47.6	
Precipitating stress (in % of pts)				
Absent	68.2	60.7	65.5	$\chi^2 = 1.59$
Probable	21.2	29.2	23.8	
Definite	10.6	10.1	10.7	

FCE 20124/702 i

25

29

Table III  
Assessment schedule over the 28 days of treatment.

		Study Day													
STUDY DAY	SCREEN	0	1	3	4	6	7	9	10	12	14	21	28		
DATE															
		D	M	D	M	D	M	D	M	D	M	D	M	D	
PHYSICAL EXAMINATION	•														
CHEST X-RAY	•														
EKG	•										•		•		
LABORATORY TESTS	•						•				•		•		
T <sub>3</sub> & T <sub>4</sub>	•														
VITAL SIGNS		•	•	•		•		•		•	•	•	•		
BODY WEIGHT		•					•				•	•	•		
HAMD	•	•			•		•		•		•	•	•		
CSI		•			•		•		•		•	•	•		
HADS		•			•		•		•		•	•	•		
ZUNG		•			•		•		•		•	•	•		
HOSS		•			•		•		•		•	•	•		

Note: Circle indicates day on which measures were recorded.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

26  
30

Table IV  
Treatment Course and Discharge  
in three Treatment Groups

	P	DMI	RBX	Test
<b>Discontinuations</b>				
Patient refusal	2 (2.4%)	1 (1.1%)	1 (1.2%)	
Ineffectiveness	7 (8.2%)	6 (6.7%)	5 (6.0%)	
Adverse exper.	1 (1.2%)	0 (0.0%)	2 (2.4%)	
Completed trial	75 (88.2%)	82 (92.1%)	76 (90.5%)	$\chi^2 = 3.03$
<b>Non-pharmacological treatment</b>				
No	78 (91.8%)	81 (91.0%)	77 (91.7%)	$\chi^2 = 0.38$
Yes	7 (8.2%)	8 (9.0%)	7 (8.3%)	
<b>Drug Intake</b>				
As prescribed	85 (100.0%)	89 (100.0%)	82 (97.6%)	$\chi^2 = 4.18$
Susp. irregular.	0 (0.0%)	0 (0.0%)	2 (2.5%)	
<b>Disposition</b>				
Remains hosp.	40 (47.1%)	33 (37.9%)	26 (31.3%)	$\chi^2 = 5.12$
Discharged	43 (50.6%)	53 (59.8%)	56 (67.5%)	
Other	2 (2.4%)	2 (2.2%)	1 (1.2%)	
Duration of trial, average days	26.5	26.5	26.9	$F = 0.26$

Table V  
Factor Analysis of Screening HAM-D Scores  
Rotated Factor Matrix

	Vegetative	Vital
Depressed Mood	.48096	.24145
Guilt	-.23273	.72396
Suicide	.04686	.51266
Early Insomnia	.50044	-.04061
Middle Insomnia	.57180	-.06421
Late Insomnia	.51236	-.09652
Work activity	.37135	.00074
Retardation	-.14147	-.05754
Agitation	.01485	.40235
Anxiety-Psychic	.09169	.29850
Anxiety-Somatic	.29052	.33021
Somatic-GI	.61609	.16799
Somatic-General	.62612	-.07132
Genital Symptoms	.34331	-.11455
Hypochondriasis	.02311	.62476
Weight Loss	.58034	.23730
Lack of Insight	-.09381	.59095
Eigenvalue	2.64	2.04
Percent variance	15.5%	12.0%

Table VI

Pattern of Onset by Center Interaction  
(Trends reported if  $p < .20$ )

Center	Screen	Day 0	Day 4	Day 7	Day 10	Day 14	Day 21	Day 28
Rouffach	-	-	-	-	-	-	-	B<A, C
Budapest-L	-	-	-	-	-	-	C<B<A	C<B<A
Budapest-G	-	-	-	-	-	-	-	C<A, B
Trieste	-	B<C	-	-	C, B<A	-	C, B<A	-
Catania	B<C	-	-	-	-	-	-	-
Mexico	A<B, C	A<B, C	-	-	-	-	B, C<A	-
Acapulco	-	-	-	-	-	-	-	-
Panama-V	-	A<B, C	A<B, C	-	-	-	-	-
Panama-B	-	-	-	-	-	C<A	C<A	C<B<A
Lima	-	A<B, C	-	-	-	-	-	-

Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine



Table VII  
Follow-Up Observations

	P	DMI	RBX
<b>New symptoms at discontinuation<sup>1</sup></b>			
No	62 (76.5%)	64 (75.3%)	67 (84.8%)
Yes	19 (23.5%)	21 (24.7%)	12 (15.2%)
<b>On Antidepressant at follow-up<sup>2</sup></b>			
No	20 (24.7%)	25 (29.8%)	32 (40.5%)
Yes	61 (75.3%)	59 (70.2%)	47 (59.5%)
<b>Hospital Status at Follow-up<sup>3</sup></b>			
Outpatient	69 (84.1%)	71 (83.5%)	75 (93.9%)
Inpatient	13 (15.9%)	14 (16.5%)	5 (6.3%)

- <sup>1</sup> 13 observations missing; not significant  
<sup>2</sup> 14 observations missing; p < .10  
<sup>3</sup> 11 observations missing; p < .10

Table VIII  
Analysis of Treatment by Time Interactions  
for Vital Signs

Vital Sign	Treatment by Time Interaction	Effect
Lying Systolic BP	F=1.81, p<.034	C > A,B: Day 12 <sup>1</sup>
Lying Diastolic BP	F=1.42, n.s.	none
Lying Heart Rate	F=0.65, n.s.	none
Standing Systolic BP	F=1.81, p<.035	C > A,B: Day 12 <sup>2</sup>
Standing Diastolic BP	F=0.99, n.s.	none
Standing Heart Rate	F=1.21, n.s.	none

Notes: <sup>1</sup> Group A mean = 122.5, s.d. = 12.9  
 Group B mean = 123.1, s.d. = 13.6  
 Group C mean = 127.6, s.d. = 13.9

<sup>2</sup> Group A mean = 120.4, s.d. = 12.5  
 Group B mean = 118.9, s.d. = 14.8  
 Group C mean = 124.7, s.d. = 13.1

Table IX

Abnormal laboratory tests values: % frequencies in baseline conditions and at the end of treatment in the three treatment groups.

Laboratory Tests	RBX		DMI		P	
	Pre %	Post %	Pre %	Post %	Pre %	Post %
HGB	12.3	15.6	9.2	14.1	14.0	15.1
HCT	24.7	14.7	20.7	20.5	21.0	19.2
RBC	23.5	16.9	19.5	17.9	31.6	30.1
WBC	18.5	14.3	12.6	10.3	4.9	8.2
Neutrophils	26.3	20.8	26.7	24.7	13.8	12.3
Lymphocytes	36.3	35.1	31.4	33.8	25.0	24.7
Eosinophils	23.8	28.6	24.4	24.7	22.5	26.0
Monocytes	8.8	7.8	3.5	3.9	5.0	6.8
Basophils	16.3	16.9	12.8	9.1	12.5	9.6
Platelets	7.5	5.3	0.0*	6.5+	5.1	2.7
NA+	11.1	15.6	5.9*	17.7*	7.4	12.3
K+	9.9	5.2	5.7	2.6	4.9	6.9
CL-	15.8	11.8	2.4	8.9	4.9*	15.1*
CA++	12.7*	25.0*	10.5	12.7	6.2	11.0
PO <sub>4</sub>	10.1	3.9	8.8	8.8	2.5	5.5
SGOT	1.3	5.2	1.1	1.3	3.7	2.7
SGPT	2.5	3.9	6.7	8.9	9.9	8.2
Υ	13.8	17.1	18.4	22.8	28.4	21.9
Blood Sugar	0.8	1.3	6.9	5.1	4.9	2.7
Alkaline Phosphate	2.5	6.6	9.2	5.1	3.7	2.7
BUN	7.5	6.5	6.9	8.9	14.8	6.9
Creatinine	2.5	5.2	6.9	6.3	7.4	5.5
Uric Acid	8.6	7.9	9.2	11.4	7.4	9.6

Table IX (continued)

Laboratory tests	RBX		DMI		P	
	Pre %	Post %	Pre %	Post %	Pre %	Post %
Total Bilirubin	6.2	5.2	5.7	1.3	3.7	1.4
Direct Bilirubin	8.7	15.2	9.6	5.9	11.4	6.3
Total Protein	9.9	11.7	8.0	12.7	12.3	8.2
Blood Albumin	18.5	14.3	14.9	13.9	13.6	16.4
Cholesterol	8.6	11.8	10.3	10.1	6.2	12.3
Triglycerides	7.5	11.8	5.9	3.8	15.0	11.0
Globulins $\alpha^1$	25.6	33.8	22.9	35.9	35.5	29.2
Globulins $\alpha^2$	28.2	18.2	18.1	19.2	26.3	25.0
Globulins $\beta$	19.2	14.3	14.5	11.5	15.8	16.7
Globulins $\gamma$	28.2	22.1	18.1	9.0	23.7	19.4
T3	2.5	--	2.3	--	0.0	--
T4	9.9	--	10.5	--	10.1	--
Specific Gravity	13.3	17.1	12.8	20.8	17.8	16.1
Ural	0.0	0.0	2.5	1.4	1.4	0.0
URSugar	1.3	0.0	0.0	0.0	0.0	0.0
URRBC	2.7	2.9	3.8	0.0	1.4	0.0
URWBC	6.7	2.9	2.5	5.6	1.4	1.6

\*Trend of significance at .10 level.

Table X  
Treatment Emergent Symptoms  
Percent Manifesting, Any Severity

Side Effect	Percentage of Patients			Chi-square
	Drug A	Drug B	Drug C	
Hypotension	8.4	13.6	6.0	3.04
Dry mouth <sup>1</sup>	21.7	45.5	25.3	13.20**
Drowsiness	12.0	15.9	10.8	1.07
Insomnia	8.4	13.6	13.3	1.35
Hypertension	0.0	4.5	3.6	3.63
Skin rash	3.6	2.3	1.2	1.05
Sweating <sup>2</sup>	21.7	29.5	18.1	3.32
Headache <sup>2</sup>	21.7	20.5	33.7	4.80+
Urticaria	0.0	0.0	1.2	2.07
Constipation <sup>3</sup>	16.9	30.7	27.7	4.74+
Increased motor activ.	6.0	2.3	6.0	1.80
Dizziness	10.8	15.9	14.5	0.97
Nausea	2.4	3.4	2.4	0.21
Dull mind	1.2	0.0	0.0	2.07
Excitement	4.8	1.1	1.2	3.23
Anxiety	0.0	0.0	0.0	--
Urinary hesitancy <sup>4</sup>	1.2	4.5	10.8	7.65*
Decreased motor activ.	4.8	3.4	3.6	0.26
Diarrhea	15.7	15.9	15.7	0.00
Taste disturbances	2.4	2.3	1.2	0.38
Vomiting	6.0	5.7	2.4	1.48
Blurred vision <sup>5</sup>	3.6	17.0	3.6	13.68**
Palpitations	1.2	1.1	1.2	0.00
Paresthesias	2.4	3.4	1.2	0.90
Facial hotness	1.2	1.1	1.2	0.00
Pruritis	0.0	1.1	0.0	1.89
Fever	0.0	1.1	0.0	1.89
Lassitude	12.0	15.9	14.5	0.53
Tachycardia <sup>6</sup>	8.4	20.5	12.0	5.51+
Confusional reaction	0.0	1.1	0.0	1.89
Nervousness	0.0	1.1	0.0	1.89
Agitation	0.0	1.1	2.4	2.07
Tinnitus	0.0	0.0	1.2	2.07
Tremor	1.2	4.5	2.4	1.83
Throat pain	1.2	0.0	0.0	2.07
Cough	1.2	0.0	0.0	2.07
Depersonalization	1.2	0.0	0.0	2.07
Decreased appetite	9.6	6.8	8.4	0.45
Nasal congestion	12.0	17.0	18.1	1.30
Increased salivation	6.0	5.7	4.8	0.12

(continued)

**Table X (continued)**  
**Treatment Emergent Symptoms**  
**Percent Manifesting, Any Severity**

Side Effect	Percentage of Patients			Chi-square
	Drug A	Drug B	Drug C	
Akathisia	1.2	0.0	0.0	2.07
Gastric acidity	0.0	1.1	0.0	1.89
Urinary retention	0.0	0.0	2.4	4.15
Increased appetite	1.2	0.0	0.0	2.07
Sexual disturbance	1.2	1.1	0.0	0.98
Irritability	0.0	0.0	0.0	--
Weight loss	0.0	0.0	0.0	--
Elevated SGOT/SGPT	1.2	0.0	1.2	1.07
Vision trouble	0.0	0.0	0.0	--
Artralgia	1.2	0.0	0.0	2.07
Feeling of Coldness	0.0	1.1	0.0	1.89
Increased dreaming	0.0	1.1	0.0	1.89
Coldness in feet	0.0	0.0	1.2	2.07
Peeling hands	0.0	1.1	0.0	1.89
Freq. vent. extrasys.	0.0	0.0	1.2	2.07
Chest oppression	0.0	0.0	1.2	2.07
Suffocation	0.0	0.0	1.2	2.07
ECG abnormalities	1.2	3.4	1.2	1.45

Notes: + p < .10  
 \* p < .05  
 \*\* p < .01

1 Group B > Group C ( $\chi^2 = 6.71, p < .01$ )  
 Group C = Group A ( $\chi^2 = 0.13, n.s.$ )

2 Group C > Group B ( $\chi^2 = 3.18, p < .08$ )  
 Group C = Group A ( $\chi^2 = 2.43, n.s.$ )

3 Group C = Group B ( $\chi^2 = 0.07, n.s.$ )  
 Group C = Group A ( $\chi^2 = 2.22, n.s.$ )

4 Group C = Group B ( $\chi^2 = 1.60, n.s.$ )  
 Group C > Group A ( $\chi^2 = 5.21, p < .03$ )

5 Group B > Group C ( $\chi^2 = 6.82, p < .01$ )  
 Group C = Group A ( $\chi^2 = 0.00, n.s.$ )

6 Group C = Group B ( $\chi^2 = 1.63, n.s.$ )  
 Group C = Group A ( $\chi^2 = 0.26, n.s.$ )

Treatment Emergent Symptoms  
Percent Manifesting, At Least Moderate Severity

Side Effect	Percentage of Patients			Chi-square
	Drug A	Drug B	Drug C	
Hypotension	4.9	8.0	1.2	4.39
Dry mouth <sup>1</sup>	3.7	20.7	13.3	11.08**
Drowsiness	0.0	2.3	3.6	2.84
Insomnia	1.2	6.9	7.2	3.86
Hypertension	0.0	4.5	3.6	3.63
Skin rash	1.2	1.1	0.0	0.99
Sweating	2.4	4.6	3.6	0.57
Headache	4.9	3.4	9.6	3.16
Urticaria	0.0	0.0	1.2	2.07
Constipation <sup>2</sup>	1.2	18.4	16.9	13.93***
Increased motor activ.	0.0	0.0	0.0	--
Dizziness	0.0	4.6	2.4	3.84
Nausea	0.0	0.0	0.0	--
Dull mind	1.2	0.0	0.0	2.07
Excitement	1.2	1.1	1.2	0.00
Anxiety	0.0	0.0	0.0	--
Urinary hesitancy	1.2	1.1	2.4	0.54
Decreased motor activ.	0.0	1.1	1.2	0.97
Diarrhea	1.2	4.6	6.0	2.64
Taste disturbances	1.2	1.1	0.0	0.99
Vomiting	0.0	1.1	1.2	0.97
Blurred vision	0.0	3.4	2.4	2.69
Palpitations	0.0	0.0	0.0	--
Paresthesias	1.2	1.1	0.0	0.99
Facial hotness	0.0	0.0	1.2	2.04
Pruritis	0.0	0.0	0.0	--
Fever	0.0	0.0	0.0	--
Lassitude	1.2	1.1	1.2	0.00
Tachycardia	2.4	4.6	7.2	2.09
Confusional reaction	0.0	0.0	0.0	--
Nervousness	0.0	1.1	0.0	1.89
Agitation	0.0	1.1	2.4	2.07
Tinnitus	0.0	0.0	0.0	--
Tremor	0.0	1.1	0.0	1.90
Sore throat	0.0	0.0	0.0	--
Cough	0.0	0.0	0.0	--
Depersonalization	1.2	0.0	0.0	2.07
Decreased appetite	2.4	1.1	2.4	0.48
Nasal congestion	0.0	1.1	0.0	1.90
Increased salivation	0.0	0.0	0.0	--

(continued)

Table XI (continued)  
Treatment Emergent Symptoms  
Percent Manifesting, At Least Moderate Severity

Side Effect	Percentage of Patients			Chi-square
	Drug A	Drug B	Drug C	
Akathisia	1.2	0.0	0.0	2.07
Gastric hyperacidity	0.0	0.0	0.0	--
Urinary retention	0.0	0.0	2.4	4.15
Increased appetite	0.0	0.0	0.0	--
Sexual disturbance	0.0	0.0	0.0	--
Irritability	0.0	0.0	0.0	--
Weight loss	0.0	0.0	1.2	2.04
Elevated SGOT/SGPT	1.2	0.0	0.0	2.08
Vision trouble	0.0	0.0	0.0	--
Artralgia	0.0	0.0	0.0	--
"Feeling of Coldness"	0.0	1.1	0.0	1.89
"Increased dreaming"	0.0	0.0	0.0	--
"Coldness in feet"	0.0	0.0	1.2	2.07
"Peeling hands"	0.0	1.1	0.0	1.89
"Freq. vent. extrasys."	0.0	0.0	0.0	--
"Chest oppression"	0.0	0.0	0.0	--
"Suffocation"	0.0	0.0	0.0	--
"ECG abnormalities"	0.0	1.1	1.2	0.97


Notes: + p < .10  
\* p < .05  
\*\* p < .01  
\*\*\* p < .001

<sup>1</sup> Group B = Group C ( $X^2 = 1.18$ , n.s.)  
Group C > Group A ( $X^2 = 3.73$ , p < .06)

<sup>2</sup> Group C = Group B ( $X^2 = 0.00$ , n.s.)  
Group C > Group A ( $X^2 = 10.40$ , p < .002)




Figure 1




Contributions to the total sample by the ten centers.

Figure 2




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 3




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Placebo

Figure 4




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 5




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 6



Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 7




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

FCE 20124/702 i

Figure 8


44



Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine




Figure 9




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 10




Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 11



Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

Figure 12



Note: Drug Group A = Placebo  
Drug Group B = Desipramine  
Drug Group C = Reboxetine

ENCLOSURE 1

FCE 20124/702 1

053



COMPOUND: R E B O X E T I N E (FCE 20124)

PROTOCOL: A D E 0 0 8

TITLE: PHASE II CONTROLLED STUDY OF THE ACTIVITY AND  
TOLERABILITY OF REBOXETINE IN COMPARISON WITH  
PLACEBO AND DESIPRAMINE IN PATIENTS HOSPITALIZ-  
ED FOR MAJOR DEPRESSIVE DISORDERS.

DATE: July 1987

FCE 20124/702 i

54

TABLE OF CONTENTS

	Page
INTRODUCTION	1
AIM OF THE STUDY	3
CLINICAL CENTERS	3
STUDY POPULATION	4
Inclusion criteria	4
Exclusion criteria	4
EXPERIMENTAL DESIGN	5
STUDY MEDICATION	5
INSTITUTIONAL REVIEW	6
INFORMED CONSENT	6
STUDY PROCEDURE	6
Pre-treatment period	6
Experimental treatment	6
Concomitant medication	7
Dropouts	7
ASSESSMENTS	7
Tolerability	7
Efficacy	8
Pharmacokinetics	9
Follow-up	9
CASE REPORT FORMS	9
DOCUMENTATION AND ANALYSIS	9
STUDY MONITORING	10
INVESTIGATORS MEETINGS	10
PUBLICATIONS	11
ETHICAL ASPECTS	11
INSURANCE COVERAGE	11
REFERENCES	12

FCE 20124/702 i

55

	<b>Page</b>
<b>ENCLOSURE 1</b>	
Statement of Investigator	1 - 4
<b>ENCLOSURE 2</b>	
DSM III R	1 - 5
<b>ENCLOSURE 3</b>	
Analysis Certificates	1 - 3
<b>ENCLOSURE 4</b>	
Newly Observed Signs and Symptoms	1 - 2
<b>ENCLOSURE 4a</b>	
Relationship of Newly Observed Signs and Symptoms to Experimental Treatment	1
<b>ENCLOSURE 5</b>	
Hamilton Depression Rating Scale	1
<b>ENCLOSURE 6</b>	
Clinical Global Impression	1
<b>ENCLOSURE 7</b>	
Montgomery Asberg Depression Rating Scale	1
<b>ENCLOSURE 8</b>	
Zung SDS	1
<b>ENCLOSURE 9</b>	
Declaration of Helsinki	1 - 2
<b>ATTACHMENT A</b>	
Data Processing and Analysis	1 - 4
<b>ATTACHMENT B</b>	
Operating Procedures for Training on Assessment Instruments, Study Monitoring and Coordination.	1 - 6
<b>PROPOSED CONSENT FORM</b>	1 - 3

FCE 20124/702 i

1

56

PHASE II CONTROLLED STUDY OF THE ACTIVITY AND TOLERABILITY  
OF REBOXETINE IN COMPARISON WITH PLACEBO AND DESIPRAMINE  
IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSIVE DISORDERS.

INTRODUCTION

Reboxetine (FCE 20124 or RS, RS 2-[ $\alpha$ -(2-ethoxy-phenoxy)benzyl]morpholine methanesulphonate is a chemically new compound highly potent in pharmacological and biochemical tests predictive of antidepressant effectiveness: reserpine antagonism, norepinephrine reuptake inhibition, REM sleep latency increase. In addition reboxetine has been found to be able to prevent clonidine effects in rodents after single oral administration, in contrast with what observed following tricyclic monoamine uptake inhibitors, which were found to be active only upon repeated doses: these results indicate that reboxetine is highly potent in decreasing the sensitivity of  $\alpha_2$ -noradrenergic receptors after single oral dose; would desensitization of  $\alpha_2$ -noradrenergic receptors correlate with antidepressant effects (1), reboxetine should exert antidepressant effectiveness of faster onset with respect to available antidepressants in patients (Investigator's Brochure: 2).

Phase I studies in healthy volunteers (3,4), orally administered single doses of 0.5 - 5 mg of the compound, indicate good tolerability of doses  $<5$  mg: the latter dose was in fact associated to orthostatic hypotension, accompanied by tachycardia and by subjective symptomatology consistent with the disturbed circulatory regulation.

In these studies single doses of 1 and 3 mg of the compound showed dose-dependent CNS effects with EEG modifications (decrease of power of theta and fast- $\beta$  waves in the fronto-central derivative), performance improvement (peg-board test) and growth hormone increase, the latter reportedly sensitive to hypothalamic noradrenergic stimulation by norepinephrine reuptake inhibitors. The comparison with the positive control, imipramine 75 mg, associated to similar EEG modifications in the fronto-central derivative, to modifications indicative of sedative activity in the occipito-temporal derivative and to deterioration of the Pauli performance test (in the absence of growth hormone modifications) indicate that reboxetine does not possess the marked sedative activity of imipramine, but rather psychostimulating properties. After all active treatments standing heart rate increase and salivation

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

2

57

decrease were apparent. No other modifications of tolerability parameters were observed.

The pharmacokinetics of the compound was evaluated in the above mentioned studies as well as after administration of 2 mg <sup>14</sup>C-FCE 20124 to 3 healthy volunteers (5). Most of the radioactivity circulating in plasma (73% in terms of AUC) was accounted for by unchanged reboxetine; its plasma half-life was estimated as 13.2 h, slightly lower than that of total radioactivity. The overall results obtained suggest for the compound linear pharmacokinetics in the dose range tested. Upon repeated administration steady-state levels are expected to be reached within 3 days.

An open, dose-range finding multicenter study is being carried out in patients hospitalized for Major Depressive Disorders. A total of 82 patients participated in the study. Reboxetine was administered for 4 weeks according to 5 different fixed changing dose schedules, with maximum daily doses of 4 mg (28 pts), 6 mg (24 pts), 8 mg (12 pts), 10 mg (6 pts) and 12 mg (12 pts). At the latter dose hypotension accompanied by dizziness and tachycardia was apparent in five patients; as a consequence the daily dose was decreased to 10 mg/day; on this dosage all 5 patients completed the study. On the average in the 12 mg dose group a maximum drop of standing systolic-diastolic blood pressure of 30-20 mm Hg and increase of standing heart rate of 14 beats/min was observed on day 15-16 of treatment. When administered up to 10 mg/day the compound was well tolerated; no patient dropped from the study due to adverse events; the side-effects reported were mainly mild and transient; no clinically relevant average modifications of vital signs were apparent; laboratory tests didn't show individual modifications of clinical significance; no ECG modifications were observed with the exception of slight prolongation of PQ interval in one patient receiving 4 mg/day. Improvement of psychopathology indicative of antidepressant activity of the compound was present at all dose levels. Frequency of relevant modifications as well as average decrease of the rating scales at the end of treatment were dose-related up to the 10 mg dosage (6).

The study provides therefore information on the tolerability of repeated doses and indications about the possibly active doses of reboxetine; the effectiveness and therapeutic usefulness of the compound need now to be tested in double blind conditions in comparison with placebo and a standard reference drug.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3  
58

AIM OF THE STUDY

The purpose of this study is to evaluate the antidepressant activity and the tolerability of reboxetine in comparison with placebo and desipramine in Major Depressive Disorders.

CLINICAL CENTERS

- FRANCE - 1) Rouffach Psychiatric Hospital, Rouffach  
Principal Investigator: Dr. J.P. Macher.
- HUNGARY - 2) Janos Korhaz, Budapest  
Principal Investigator: Dr. A. Lipcsey
- 3) Orszagos Ideg es Elmegyogyiretezet  
Budapest  
Principal Investigator: Dr. P. Gaszner
- ITALY - 4) Psychiatric Clinic, University of Trieste,  
Trieste  
Principal Investigator: Prof. E. Aguglia
- 5) Psychiatric Clinic, University of Catania,  
Catania  
Principal Investigator: Prof. Rapisarda
- MEXICO - 6) National Institute of Neurology, Mexico City  
Principal Investigator: Dr. A. Torres-Ruiz
- 7) Universidad Autonoma de Guadalajara, Guadalajara  
Principal Investigator: Dr. Galvan.
- PANAMA - 8) National Psychiatric Hospital, Panama City  
Principal Investigator: Dr. L. Vergara
- 9) National Psychiatric Hospital, Panama City  
Principal Investigator: Dr. R. Batista
- PERU - 10) Biological Psychiatric Laboratory, National  
Institute of Mental Health, Lima  
Principal Investigator: Dr. A. Castillo

The curricula-vitae of principal investigators will be summarized in enclosure 1.

• dropped; substituted by:

National Psychiatric Hospital, Acapulco  
Principal Investigator: Dr. C. Vinas

FCE 20124/702 i

4

59

#### STUDY POPULATION

The study population will consist of 240 hospitalized patients from 10 centers, each center contributing 24 patients within a period of 12 months.

#### Inclusion criteria

The patients admitted to the study will meet the following criteria:

1. Males or females from 18 through 65 years.
2. DSM-IIIr diagnosis of Major Depression (296.2-296.3, Enclosure 2) with presence of illness for at least one month. The correspondence with ICD-10 and 6 other diagnostic classifications will also be reported for each patient.
3. Written informed consent.
4. A total score of 16 or above in the 17-HAMD.

#### Exclusion criteria

1. Pregnancy (tested by pregnancy test at the end of wash-out) or breast feeding.
2. Past history of hypersensitivity to psychotropic drugs.
3. Participation in a clinical trial with an investigational drug within the four weeks preceding the study.
4. Evidence of Substance Use Disorders within past six months or currently.
5. Treatment within previous four weeks with any drug known to have a well-defined potential for toxicity to a major organ (e.g., chloramphenicol).
6. History or presence of gastrointestinal, liver, or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism and excretion of drugs.
7. History of seizures or brain injury; current evidence of clinically important hematopoietic or cardiovascular disease; current evidence of urinary retention, thyroid disease, or glaucoma.

PCE 20124/702 i

5

60

8. Symptoms of any other important clinical illness in the four weeks preceding the study.

9. Clinically relevant abnormal findings in the physical examination, laboratory tests and ECG at admission visit.

10. ECT in the previous 6 months.

#### EXPERIMENTAL DESIGN

The study will be carried out according to a multicenter double-blind, parallel group design. In each of the 10 centers 24 patients will be randomly allocated to treatment with either reboxetine (8 patients) or desipramine (8 patients) or placebo (8 patients), balanced within groups of 6 pts.

A total sample size of 80 patients per group is expected to provide to the test of the null hypothesis of no difference in treatment response (defined as  $\geq$  50% decrease of the Hamilton Depression Rating Scale at the end of treatment) between active compound and placebo a power of 0.8, i.e. a 80% probability of rejecting it in presence of a between treatments difference in response rate of 20% (assuming a 50% response rate under placebo and a 0.05 one-sided alpha level).

#### STUDY MEDICATION

Study medication will be supplied in indistinguishable capsules containing either reboxetine 2 mg or desipramine 50 mg (2 tablets of Pertofran 25 mg) with excipients or excipients only, i.e. placebo (analytical certificates, enclosure 3).

One bottle containing 105 capsules (maximum needed + 2 capsules) of one of the treatments will be prepared for each patient and labelled with the progressive number of the patient according to the treatment code. Sealed individual codes will be provided for each patient in duplicate.

Study medication needs to be stored at room temperature.

At the conclusion of the study all unused medication will be returned to Farnitalia Carlo Erba.

FCE 20124/702 i

6

61

#### INSTITUTIONAL REVIEW

The appropriate Institutional Review Board (IRB) must review and approve the protocol and the Informed Consent Form according to institutional and national regulations and requirements of individual countries. No drug will be shipped by Farmitalia Carlo Erba until the IRB has given its approval.

#### INFORMED CONSENT

The Investigator, or one of his associates must explain the nature, duration, and purpose of the study, and the action of the drug in such a manner that all patients are aware of the potential risks, inconveniences or adverse effects that may occur. They will be informed that they may withdraw from the study at any time. The IRB approved informed consent forms will be signed according to the regulations and requirements of each country.

#### STUDY PROCEDURE

##### Pre-treatment period

For all but those patients treated with a MAOI antidepressant, the study will begin with a 7 days, drug-free washout period (from Day -6 to Day 0). For patients treated with a MAOI the pre-treatment drug-free washout period will need to be 14 days. Screening for inclusion and exclusion criteria will take place prior to admission. However only those patients who fulfill inclusion/exclusion criteria on Day 0, will commence with active treatment on Day 1.

##### Experimental treatment

Patients will receive 1 capsule b.i.d. from Day 1 to Day 3. Depending upon tolerability of each dose level this dosage will be increased to 2 capsules in the morning and 1 in the evening from Day 4 to Day 6 and to 2 capsules b.i.d. from Day 7 to Day 28.

The treatments will be administered in the morning (10 a.m.) and in the evening (8 p.m.); in case of modification of clinical relevance of tolerability parameters with dosage

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

7

6:

increase, the dose will be decreased to the previously well tolerated level for 4 days. Subsequently an attempt will be made to resume regular drug schedule.

The patient will remain hospitalized for the whole study period.

#### **Concomitant medication**

-----

No concomitant medication should be used by patients for the duration of the study, with the exception of a sleep inducer (Chloral hydrate 500-1000 mg) at bed-time. If any concomitant medication is taken, the details must be entered on the appropriate forms.

#### **Dropouts**

-----

All patients who discontinue this study due to (a) refusal or withdrawal of consent, (b) administrative reasons, or (c) intercurrent medical illness without completing at least 14 days of drug administration will be replaced. To this purpose request for the material needed will be immediately addressed to the Study Monitor; the material will be provided with a label carrying the patient number with "bis" indication. Patients discontinued for inefficacy or for intolerable adverse reactions will not be replaced.

If the study medication is discontinued for any reason a complete final battery of all evaluations will be done immediately prior to or after discontinuation.

#### **ASSESSMENTS**

##### **Tolerability**

-----

1. Newly Observed Signs and Symptoms (Enclosure 4), on Days 0,4,7,10,14,21,28. Relationship to trial medication will be estimated according to Karch and Lasagna criteria (Enclosure 4a). In addition it will also be completed at times when adverse reaction(s) occur. Any serious or alarming adverse reaction, whether or not related to the experimental treatment, must be reported immediatly to the Study Monitor. At the time of the reaction 5 ml blood will be taken, put into heparinized tubes, centrifuged and the plasma stored at -20°C up to the reboxetine assay.

FCE 20124/702 i

8

63

2. Vital Signs.

They include oral body temperature, supine and standing radial pulse rates, supine and standing systolic and diastolic blood pressure. Supine recordings will be made after the patient has been recumbent for 15 minutes. Standing recordings will be made 2 minutes after the patient had been erect. All recordings will be made before the morning dose on Day 0, 1, 3, 6, 9, 12, 14, 21 and 28.

3. Weight.

On Days 0, 7, 14, 21 and 28 prior to breakfast.

4. ECG.

The standard 12-lead ECG will be done at pretreatment and repeated on Days 14 and 28.

5. Laboratory Tests.

Hematology and blood chemistry (including gamma-globulins) and urinalysis will be done at admission and on Days 7, 14 and 28. Samples for laboratory tests will be taken before the morning dose, after an overnight fast. Tests with clinically significant abnormal results must be repeated. Persistent abnormal values must be checked until the cause is determined, they return to baseline, or no further change is anticipated. The same for ECG results.

6.  $T_3$  and  $T_4$  assays at pretreatment.

**Efficacy**  
-----

All psychiatric evaluations and ratings (both observer and self-ratings) should be made, as much as possible, in the morning and in the same setting on the days they are scheduled to occur. The same rater should carry out all clinical evaluations for a given patient.

On Days 0, 4, 7, 10, 14, 21, 28:

1. Hamilton Depression Rating Scale (17 items HAMD, Enclosure 5).
2. Clinical Global Impression (CGI, Enclosure 6),
3. Montgomery-Asberg Depression Rating Scale (MADRS, Enclosure 7).
4. Zung self rating scale for Depression (Enclosure 8).

FCE 20124/702 i

9

64

#### Pharmacokinetics

In each patient a 5 ml blood sample will be collected before the morning dose on Day 28. The sample will be put in heparinized tubes, centrifuged and the plasma separated and stored at -20°C up to determination of reboxetine levels.

#### Follow-up

A follow-up visit will be carried out in all patients 4 weeks after completion of the study to collect information on the clinical conditions of the patient and on the interval events.

#### CASE REPORT FORMS

All data, including patient identification, present diagnosis and history, treatment specifications and information on study termination and follow-up in each patient will be recorded on specially designed forms, supplied by Farmitalia Carlo Erba. Forms on each completed patient will be picked up by Study Monitor without delay with copy of each form retained by Investigator.

#### DOCUMENTATION AND ANALYSIS

Data documentation and analyses will be carried out at Vanderbilt University (242 Medical Arts Building, 1211 21st Avenue South, Nashville, Tennessee 37212, USA) utilizing a SPSS-X statistical analysis system.

Documentation and analyses appropriate to non-parametric and parametric data will be provided for each assessment instrument. In addition the results of laboratory tests will be classified as normal or abnormal by comparison with the normal ranges of the performing laboratory and the frequencies of abnormal results after treatment documented and analyzed, if appropriate.

The main comparison between treatments will be done on the basis of response rate defined as % of randomized patients presenting  $\geq$  50% of decrease of HAMD at the end of treatment.

In addition the onset of activity of the treatments will be compared on the basis of the % of randomized patients

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

10

65

presenting  $\geq$  50% decrease of HAMD by day 14.

Statistical analysis is fully described in Attachment A.

#### STUDY MONITORING

Monitoring will be carried out by:

- T.A. Ban (USA)  
Home: 2304 Valley Brook Rd., Nashville, Tennessee 37215  
Phone: (615) 297-3811.  
Off.: (615) 322-6245.
- A. Dubini (Italy)  
Off.: Farmitalia Carlo Erba, CNS Line, Via Imbonati 24,  
20159 Milan. Phone: 39.2.6995.2749.  
Home: Via Mora 16, 20123 Milan.
- A. Fiorentino (Panama)  
Off.: Farmitalia Carlo Erba, Apdo. Postal N. 835, Zona Libre  
de Colon, Republica del Panama. Phone: 642133 or 694610.
- F. Hetenyi (Hungary)  
Off.: Montedison Reg. Office, Vaci u. 16/a, 1052 Budapest.  
Phone: 384-119 or 384-136.  
Home: Andor u. B. VIII.36, 1119 Budapest. Phone: 266-866.
- P. Hurteloup (France)  
Off.: Farmitalia Carlo Erba S.A., Tour Franklin Cedex  
11, Paris la Defense. Phone: 00331-47764252.
- C. Ramos (Peru)  
Off.: Farmitalia Carlo Erba S.A., Av. Arequipa 2450 9° y  
10° Piso, Edif. El Dorado Lince, Lima. Phone:  
005114-407119.
- J. Yoma (Mexico)  
Off.: Farmitalia Carlo Erba S.A. de C.U., M.A. de  
Quevedo 555, Apdo. Postal 21-909, 04310 Mexico D.F. Phone:  
00525-5541211.

Operating procedures for training on Assessment Instruments, study monitoring and coordination are described in Attachment B.

#### INVESTIGATORS MEETINGS

There will be 2 Investigators meetings, one prior to commencement of the clinical study and one with all results in hand.

FCE 20124/702 i

11

66

**PUBLICATIONS**

Final results of collaborative study will be published in single publication. Any proposed publication by the Investigators will need to be discussed with the Monitors prior to publication.

**ETHICAL ASPECTS**

The study will be carried out according to the Tokyo revision of the Helsinki declaration (Enclosure 9) and after approval of the protocol by the local IRB. Other than modifications required for patient safety, no protocol changes will be made once the study has started without the specific written agreement between the Investigator, the Ethical Committee and the study Monitor.

**INSURANCE COVERAGE**

Patients participating in the study are covered by worldwide effective insurance with Italia Assicurazioni.

Monitor  
Signature:.....

Principal Investigator's  
Signature:.....

Date:.....

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

12

67

REFERENCES  
-----

- 1) SIEVER L. J., UHDE T. W.  
New studies and perspectives on the noradrenergic receptor system in depression: effects of the  $\alpha$ -adrenergic agonist clonidine.  
Biological Psychiatry, 19:131-156 (1984).
- 2) DUBINI A., RIVA F.  
FCE 20124 - Basic Information (Summary of preclinical studies up to June 1985).  
(Farmitalia Carlo Erba Investigator's Brochure).
- 3) HERRMANN W. M. et al.  
Safety and tolerance of FCE 20124 in healthy male volunteers. A single rising dose tolerance study.  
Internal report N° 602 (June 1984).
- 4) HERRMANN W. M.  
FCE 20124 - Quantitative pharmaco EEG and pharmacopsychological study.  
Internal report N° 603 (January 1985).
- 5) Disposition and fate of  $^{14}$ C-FCE 20124 administered orally to healthy volunteers.  
Internal report N° 604 (March 1985).
- 6) Open, dose-range finding study of the activity and tolerability of reboxetine in Major Depressive Disorders.  
(Report in preparation).

FCE 20124/702 i



FARMITALIA CARLO ERBA

FOGLIO N. 1

ENCLOSURE 1

68

STATEMENT OF INVESTIGATOR

NAME OF INVESTIGATOR

INSTITUTION

HOME ADDRESS (AND PHONE)

NAME OF THE DRUG UNDER INVESTIGATION AND PROTOCOL NUMBER

FCE 20124/702 i



69

STATEMENT OF EDUCATION AND EXPERIENCE

COLLEGES, UNIVERSITIES, AND MEDICAL OR OTHER PROFESSIONAL SCHOOLS  
ATTENDED, WITH DATES OF ATTENDANCE, DEGREES, AND DATES DEGREES  
WERE AWARDED.

POSTGRADUATE MEDICAL OR OTHER PROFESSIONAL TRAINING (INDICATE DATES,  
NAMES OF INSTITUTIONS, AND NATURE OF TRAINING)

FCE 20124/702 i



70

TEACHING OR RESEARCH EXPERIENCE (INDICATE DATES, INSTITUTIONS, AND BRIEF DESCRIPTION OF EXPERIENCE)

EXPERIENCE IN MEDICAL PRACTICE OR OTHER PROFESSIONAL EXPERIENCE (INDICATE DATES, INSTITUTIONAL APPLICATIONS, NATURE OF PRACTICE, OR OTHER PROFESSIONAL EXPERIENCE)

FCE 20124/702 1



Foglio N. 4,

71

REPRESENTATIVE LIST OF PERTINENT MEDICAL OR OTHER SCIENTIFIC PUBLICATION  
(INDICATE TITLES OF ARTICLES, NAMES OF PUBLICATIONS AND VOLUME, PAGE  
NUMBER, AND DATE)

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

DATE: \_\_\_\_\_

SIGNATURE: \_\_\_\_\_

FCE 20124/702 1

72 ENCL. 2

Paq. 1

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

DSM-III-r (Revised Edition)

8/1/86 Draft Mood (Affective) Disorders G:1

MOOD (AFFECTIVE) DISORDERS

In the following section criteria are provided for manic and major depressive episodes. These are followed by criteria for the specific mood disorders.

Manic Episode

Note: A "manic syndrome" is defined as criteria A and B below.

A. One or more distinct periods lasting at least one week (or any duration if marked impairment in occupational functioning or in usual social activities or relationships with others) when mood was abnormally and persistently elevated, expansive, or irritable.

B. During the period of mood disturbance, at least three of the following symptoms have persisted (four if the mood is only irritable) and have been present to a significant degree:

- (1) inflated self-esteem (grandiosity, which may be delusional)
- (2) decreased need for sleep, e.g., feels rested after only three hours of sleep
- (3) more talkative than usual or pressure to keep talking
- (4) flight of ideas or subjective experience that thoughts are racing
- (5) distractibility, i.e., attention too easily drawn to unimportant or irrelevant external stimuli
- (6) increase in activity (either socially, at work, or sexually) or physical restlessness
- (7) excessive involvement in activities that have a high potential for painful consequences, which is not recognized, e.g., buying sprees, sexual indiscretions, foolish business investments, reckless driving

C. The episode of mood disturbance was sufficiently severe to cause marked impairment in occupational functioning or in usual social activities or relationships with others, or hospitalization was necessary to prevent harm to self or others.

D. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted).

E. Not superimposed on Schizophrenia, Schizophreniform Disorder, or a Delusional Disorder.

9/1/86 Draft Mood (Affective) Disorders G:2

F. An organic etiology has been ruled out; i.e., either there was no new organic factor (or change in a pre-existing organic factor) that precipitated the disturbance, or the disturbance was persisted for at least one month beyond the cessation of the precipitating organic factor.

Note: Manic or hypomanic episodes that are apparently precipitated by somatic antidepressant treatment (e.g., drugs, ECT) are an exception to this exclusion criterion and should be diagnosed as Mood Disorders.

Major Depressive Episode

Note: A "major depressive syndrome" is defined as criterion A below.

A. At least five of the following symptoms have been present during the same two-week period; at least one of the symptoms was either (1) depressed mood, or (2) loss of interest or pleasure. (Do not include symptoms that are clearly due to a physical condition, mood-incongruent delusions or hallucinations, incoherence, or marked loosening of associations.)

- (1) depressed mood most of the day, nearly every day (either by subjective account, e.g., feels "down" or "low," or is observed by others to look sad or depressed)
- (2) loss of interest or pleasure in all or almost all activities nearly every day (either by subjective account or is observed by others to be apathetic)
- (3) weight loss or weight gain when not dieting or binge eating (e.g., more than 5% of body weight in a month) or decrease or increase in appetite nearly every day (in children, consider failure to make expected weight gains)
- (4) insomnia or hypersomnia nearly every day
- (5) psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down) (in children under six, hypoactivity)
- (6) fatigue or loss of energy nearly every day
- (7) inappropriate or excessive or inappropriate (e.g., delusional) guilt about being sick) nearly every day (not merely self-reproach or guilt about being sick)
- (8) diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or observed by others)
- (9) thoughts that he or she would be better off dead, or suicidal ideation, nearly every day; a suicide attempt



FCE 20124/702 i

73 pag. 2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

- 8/1/86 Draft Mood (Affective) Disorders G:4
- 296.5x Bipolar Disorder, Depressed**  
For fifth digit, use the major depressive episode codes (p. xx) to describe current state.  
A. Has had one or more manic episodes (p. xx).  
B. Currently (or most recently) in a major depressive episode (p. xx). (If there has been a previous major depressive episode, the current episode need not meet the full criteria for a major depressive episode.)  
Manic episode codes: fifth-digit code numbers and criteria for current state of Bipolar Disorder, Manic or Mixed:  
1-Mild: Meets minimum symptom criteria for a manic episode.  
2-Moderate: Extreme increase in activity or impairment in judgment.  
3-Severe, without Psychotic Features: Almost continual supervision is required in order to prevent physical harm to self or others.  
4-With Psychotic Features: Delusions, or hallucinations (with delusional interpretation). When possible, specify whether the psychotic features are mood-congruent or mood-incongruent.  
Mood-congruent psychotic features: Delusions or hallucinations whose content is entirely consistent with the typical manic themes of inflated worth, power, knowledge, identity, or special relationship to a deity or famous person.  
Mood-incongruent psychotic features: Either (a) or (b):  
(a) Delusions or hallucinations whose content does not involve the typical manic themes of inflated worth, power, knowledge, identity, or special relationship to a deity or famous person. Included are such symptoms as persecutory delusions, thought insertion, and delusions of being controlled.  
(b) Any of the following catatonic symptoms: stupor, mutism, negativism, posturing.  
5-In Partial Remission: Full criteria were previously met but are not currently met, and some signs or symptoms of the disturbance have persisted.
- 8/1/86 Draft Mood (Affective) Disorders G:3
- B. (1) An organic etiology has been ruled out, i.e., either there was no new organic factor (or change in a pre-existing organic factor) that precipitated the disturbance, or the disturbance has persisted for at least one month beyond the cessation of the precipitating organic factor  
(2) Not a normal reaction to the loss of a loved one (Uncomplicated Bereavement)  
Note: Morbid preoccupation with worthlessness, suicidal ideation, marked functional impairment, prolonged duration, or marked bereavement complicated by Major Depression.  
C. At no time during the disturbance have there been delusions or hallucinations for as long as two weeks in the absence of prominent mood symptoms (i.e., before the mood symptoms developed or after they have remitted).  
D. Not superimposed on Schizophrenia, Schizophreniform Disorder, or a Delusional Disorder.
- BIPOLAR DISORDERS**
- 296.6x Bipolar Disorder, Mixed**  
For fifth digit, use the manic episode codes (p. xx) to describe current state.  
A. Current (or most recent) episode involves the full symptomatic picture of both manic and major depressive episodes (p. xx and p. xx), intermixed or rapidly alternating every few days.  
B. Depressive symptoms are prominent and last at least a full day.
- 296.4x Bipolar Disorder, Manic**  
For fifth digit, use the manic episode codes (p. xx) to describe current state.  
Currently (or most recently) in a manic episode (p. xx). (If there has been a previous manic episode, the current episode need not meet the full criteria for a manic episode.)

FCE.20124/702 i

74 pag. 3

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

<p>8/1/86 Draft      Mood (Affective) Disorders      G:5</p> <p>6-In Full Remission: Full criteria were previously met, but no significant signs or symptoms of the disturbance have existed for a period of at least two months.</p> <p>0-Unspecified.</p> <p>301.13 Cyclothymia</p> <p>A. At least two years (one year for children and adolescents) during which there have been numerous periods with abnormally elevated, expansive, or irritable mood that did not meet criteria A, B, and C of manic episode, and numerous periods with depressed mood or loss of interest or pleasure that did not meet criterion A of major depressive episode.</p> <p>B. During the two-year period (or one year in children and adolescents) never without hypomanic or depressive symptoms for more than three months at a time.</p> <p>C. During hypomanic periods there are at least three of the following:</p> <ol style="list-style-type: none"> <li>(1) decreased need for sleep</li> <li>(2) increased energy, then usual</li> <li>(3) inflated self-esteem</li> <li>(4) increased productivity, often associated with unusual self-imposed working hours</li> <li>(5) sharpened and unusually creative thinking</li> <li>(6) uninhibited people-seeking (extreme gregariousness)</li> <li>(7) hypersexuality without recognition of the possibility of painful consequences</li> <li>(8) excessive involvement in pleasurable activities with lack of concern for the high potential for painful consequences, e.g., buying spree, physical risks, sexual indiscretions</li> <li>(9) more talkative than usual</li> <li>(10) overoptimism</li> <li>(11) more talkative than usual</li> <li>(12) inappropriate laughing, joking, punning</li> </ol> <p>D. Absence of psychotic features such as delusions, hallucinations, incoherence, or loosening of associations.</p> <p>E. Not sustained by a specific organic factor or substance, e.g., repeated intoxication from drugs or alcohol.</p>	<p>8/1/86 Draft      Mood (Affective) Disorders      G:6</p> <p>296.70 Bipolar Disorder NOS</p> <p>This is a residual category for hypomanic episodes that are not part of Bipolar Disorder, Mixed, Manic or Depressed, or Cyclothymia. (A hypomanic episode is less severe than a manic episode in that criterion C of manic episode (p. xx) has had at least one hypomanic episode and at least one major depressive episode but has never had either a manic episode or Cyclothymia. Such cases have been referred to as "Bipolar II." Another example is an individual who has had one or more hypomanic episodes but does not have Cyclothymia and has never had either a manic or a major depressive episode. The hypomanic episode may have been precipitated by ECT or administration of a tricyclic antidepressant.</p> <p><b>DEPRESSIVE DISORDERS</b></p> <p>296.2x Major Depression, Single Episode</p> <p>For fifth digit, use the major depressive episode codes (p. xx) to describe current state.</p> <p>A. A single major depressive episode (p. xx).</p> <p>B. Has never had a manic episode (p. xx) or an unequivocal hypomanic episode (see p. xx).</p> <p>296.3x Major Depression, Recurrent</p> <p>For fifth digit, use the major depressive episode codes (p. xx) to describe current state.</p> <p>A. Two or more major depressive episodes (p. xx), each separated by at least two months of return to more or less usual functioning.</p> <p>B. Has never had a manic episode (p. xx) or an unequivocal hypomanic episode (see p. xx).</p>
--	---

FCE 20124/702 1

75 pag. 4

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

<p>8/1/86 Draft      Mood (Affective) Disorders      G:7</p> <p>Major depressive episode codes: fifth-digit code numbers and criteria for current state of Bipolar Disorder, Depressed, or Major Depression:</p> <p>1-Mild: Few, if any, symptoms in excess of those required to make the diagnosis AND symptoms result in only minor impairment in occupational functioning or usual social activities or relationships with others.</p> <p>2-Moderate: Symptoms or functional impairment intermediate between "mild" and "severe."</p> <p>3-Severe, without Psychotic Features: Several symptoms in excess of those required to make the diagnosis AND symptoms markedly interfere with occupational functioning or with usual social activities or relationships with others.</p> <p>4-With Psychotic Features: Delusions or hallucinations (with delusional interpretation). When possible, specify whether the psychotic features are mood-congruent or mood-incongruent.</p> <p>Mood-congruent psychotic features: Delusions or hallucinations whose content is entirely consistent with the typical depressive themes of personal inadequacy, guilt, disease, death, nihilism, or deserved punishment.</p> <p>Mood-incongruent psychotic features: Delusions or hallucinations whose content does not involve typical depressive themes of personal inadequacy, guilt, disease, death, nihilism, or deserved punishment. Included here are such symptoms as persecutory delusions, thought insertion, thought broadcasting, and delusions of control.</p> <p>5-In Partial Remission: Intermediate between "In Full Remission" and "Mild," and no prior Dysthymia. If major depressive episode was superimposed on Dysthymia, the diagnosis of Dysthymia alone is given once the full criteria for a major depressive episode are no longer met.)</p> <p>6-In Full Remission: During the past six months no significant signs or symptoms of the disturbance.</p> <p>0-Unspecified.</p> <p>Specify chronic if two consecutive years without a period of full remission for longer than two months.</p>	<p>8/1/86 Draft      Mood (Affective) Disorders      G:8</p> <p>Specify if melancholic type: i.e.:</p> <p>At least five of the following:</p> <ol style="list-style-type: none"> <li>(1) loss of interest or pleasure in all or almost all activities</li> <li>(2) lack of reactivity to usually pleasurable stimuli (loss of reactivity to something good happens)</li> <li>(3) the depression is regularly worse in the morning</li> <li>(4) early morning awakening (at least two hours before usual time of awakening)</li> <li>(5) psychomotor retardation or agitation (not mere subjective complaints)</li> <li>(6) significant anorexia or weight loss (e.g., more than 5% of body weight in a month)</li> <li>(7) no significant personality disturbance prior to first major depressive episode</li> <li>(8) episode of complete or nearly complete recovery followed by complete or nearly complete relapse</li> <li>(9) prior good response to specific and adequate somatic antidepressant therapy, e.g., tricyclics, ECT, MAOI, lithium</li> </ol> <p>300.40 Dysthymia</p> <p>A. At least two years (one year for children and adolescents) during which there has been depressed mood that is more days than not (either by subjective account e.g. feels "down" or "low," or is observed by others to look sad or depressed) and at least two of the following:</p> <ol style="list-style-type: none"> <li>(1) poor appetite or overeating</li> <li>(2) insomnia or hypersomnia</li> <li>(3) low energy or fatigue</li> <li>(4) low self-esteem</li> <li>(5) poor concentration or difficulty making decisions</li> <li>(6) pessimism</li> </ol> <p>B. During that two-year period (or one year in children and adolescents) never without the symptoms in A for more than two months at a time.</p> <p>C. No clear evidence of a major depressive episode during the first two years (or one year for children and adolescents) of the disturbance.</p>
--	--

FCE 20124/702 i

pag. 5

76

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

1/1/86 Draft Mood (Affective) Disorders G:9

Note: There may have been a prior major depressive episode provided that there was a full remission (not a partial remission) of the episode prior to the development of the dysthymia. In addition, after two years of dysthymia, major depressive episodes may be superimposed, in which case both diagnoses are given.

D. Has never had a manic episode (p. xx) or an unequivocal hypomanic episode (see p. xx).

E. No psychotic symptoms, and not the residual phase of Schizophrenia.

F. Not sustained by a specific organic factor or substance, e.g., prolonged administration of an antihypertensive medication.

Specify primary or secondary type.

Primary type: not occurring only during the course of another chronic non-mood Axis I or Axis III disorder, e.g., Anorexia Nervosa, Schizophrenia, Personality Disorder, Substance Dependence Disorder, an Anxiety Disorder, or rheumatoid arthritis.

Secondary type: occurring only during the course of another chronic non-mood Axis I or Axis III disorder.

Specify early onset or late onset.

Early onset: onset of disturbance before age 21.

Late onset: onset of disturbance age 21 or later.

296.82 Depressive Disorder NOS

This is a residual category for disorders with depressive features that do not meet the criteria for any specific Mood Disorder or Adjustment Disorder with Depressed Mood.

Examples include:

- (1) major depressive episode superimposed on residual Schizophrenia
- (2) intermittent dysthymic episodes
- (3) Non-stress-related depressive episodes that do not meet the criteria for a major depressive episode



Enclosure 3

77

VIA CARLO MIGNATI, 24  
20159 MILANO - ITALIA  
TELEFONO (02) 6995.1 (CENTRALINO)  
TELEGRAMMI ERBACAR - MILANO  
CASELLA POSTALE 10519  
C.C. POSTALE 619205  
TELEX 330314 ERBAMI

pag. 1

ANALYSIS CERTIFICATE

FCE 20124 hard-gelatin capsules .  
Capsules mg : 2      Batch : 893

MANUFACTURING DATE : MAY, 1987 .  
EXPIRATION DATE : MAY, 1989 ( stored at room temperature ) .  
APPEARANCE : aubergine cap, pink body, opaque hard gelatin capsule, self-locking, size No.2 containing a white granular powder .  
IDENTIFICATION : positive ( HPLC method ) .  
AVERAGE WEIGHT : mg 179.47 .  
UNIFORMITY OF WEIGHT : within the limits, according to European Pharm. 1980, section V.5.2 .  
CONTENT UNIFORMITY : complies, according to USP XXI page 1277 .  
ASSAY : mg 1.967 of FCE 20124/capsule .  
DISINTEGRATION TIME : 5 minutes .  
ANALYZED BY : Silvio Gambini . *Silvio Gambini*  
APPROVED BY : Virginio Busnelli . *Busnelli Virginio*  
DATE : JUNE 22, 1987 .

MOD. 5133

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



VIA CARLO IMBONATI, 24  
20159 MILANO - ITALIA  
TELEFONO (02) 6995.1 (CENTRALINO)  
TELEGRAMMI ERBACAR - MILANO  
CASSELLA POSTALE 10519  
C.C. POSTALE 618205  
TELEX 330314 ERBAMI

78 pag. 2

-----  
ANALYSIS CERTIFICATE  
-----

PLACEBO for FCE 20124 capsules .  
Batch SF : 892 .

MANUFACTURING DATE : MAY 1987 .

APPEARANCE : aubergine cap, pink body, opaque hard  
gelatin capsule, self locking, size No.2  
containing a white powder .

IDENTIFICATION : absence of FCE 20124 ( HPLC method ) .

AVERAGE WEIGHT : mg 183.31 .

WEIGHT VARIATION : according to Europ. Pharm. Section V.5.2 .

DISINTEGRATION TIME : 1 minute and 50 seconds .

ANALYZED BY : Silvio Gambini . *Silvio Gambini*

APPROVED BY : Virginio Busnelli . *Busnelli Virginio*

DATE : JUNE 22, 1987 .

MOD. 5103

FCE 20124/702 i

Quality Assmt 14 OCT 14 16:25 CIBA-GEIGY MACCLESFIELD 81 0025 25566

Date : 14-10-87

CIBA-GEIGY PHARMACEUTICALS  
MACCLESFIELD

79

pag. 3

CERTIFICATE OF ANALYSIS

Product : PERTOPRAN TABLETS 25mg

Analytical Control No. : 8600829

Batch No : J521

Formulation No. : Q-284

Product Specification : P-157/1

<u>TEST</u>	<u>RESULT</u>	<u>REQUIREMENT</u>
1. Description :	Satisfactory	Text
2. Diameter (mm) :	5.50	Approximately 5.5 mm
3. Thickness (mm) :	3.43	Approximately 3.3 mm
4. Weight		
a) Mean (mg) :	70.1	Approximately 70mg
b) Relative standard deviation (%) :	3.3	Not > 6.5%
5. Disintegration time (mins) :	8	Not > 30 minutes
6. Identity (Desipramine HCl)		
(T.L.C.) :	Positive	Confirmed
7. Related substances (%) :	<0.1	Not > 0.3% of the desipramine hydrochloride content
8. Assay (U.V.)		
Desipramine (mg/tab) :	25.3	23.25 to 26.75 mg/tab (92.5 to 107.5% theory)

Expiry date : 05.91

Analyst : M. Whitmore.

Checked by : I.B. HEGGS

CONCLUSION : COMPLIES WITH CIBA-GEIGY QUALITY STANDARD

Authorisation : Passed



FCE 20124/702 i

ENCL. 4

pag. 1

PROTOCOL [A|D|E| ]

PATIENT NO. [ ] [ ] [ ]

DAY [ 0 | 4 | 7 | 10 | 14 | 21 | 28 ]

PAGE NO. [ ] [ ]

NEWLY OBSERVED SIGNS AND SYMPTOMS: CHECK-LIST

80

1. AUTONOMIC

- DRY MOUTH
- NASAL CONGESTION
- BLURRED VISION
- CONSTIPATION
- URINARY HESITANCY
- URINARY RETENTION
- INCREASED SALIVATION
- SWEATING
- VOMITING
- DIARRHOEA
- SEXUAL DISTURBANCES

2. BEHAVIORAL TOXICITY

- CONFUSIONAL REACTION
- EXCITEMENT/AGITATION
- INCREASED MOTOR ACTIVITY
- DECREASED MOTOR ACTIVITY
- INSOMNIA
- DROWSINESS
- LASSITUDE

3. CARDIOVASCULAR

- HYPOTENSION
- DIZZINESS
- CIRCULATORY COLLAPSE
- TACHYCARDIA
- HYPERTENSION

4. NEUROLOGICAL

- RIGIDITY
- TREMOR
- AKATHISIA
- DYSTONIA
- PARESTHESIAS
- SEIZURES
- MYOCLONUS

5. OTHER

- SKIN-RASH
- URTICARIA
- DECREASED APPETITE
- HEADACHE



FCR 20124/702 i

81 pag . 2

PROTOCOL [A,D,E] [0,8] PATIENT NO. [ ] [ ] [ ] DATE [ ] [ ] [ ] [ ] [ ] [ ] [ ] ASSESSMENT DAY [ ] PAGE NO. [ ] [ ]

D M Y

ALL NEWLY OBSERVED SIGNS AND SYMPTOMS

SIGN OR SYMPTOM			
<b>REPORTED</b> ● SPONTANEOUSLY ● UPON ENQUIRY	[ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ]
<b>PRESENT BEFORE START OF STUDY</b> ● YES ● NO ● UNKNOWN	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]
<b>DATE OF ONSET</b>	[ ] [ ] [ ] [ ] [ ] [ ] D M Y	[ ] [ ] [ ] [ ] [ ] [ ] D M Y	[ ] [ ] [ ] [ ] [ ] [ ] D M Y
<b>DURATION</b>	[ ] [ ] [ ] [ ] [ ] [ ] DAYS HRS MINS	[ ] [ ] [ ] [ ] [ ] [ ] DAYS HRS MINS	[ ] [ ] [ ] [ ] [ ] [ ] DAYS HRS MINS
<b>SEVERITY</b> ● MILD ● MODERATE ● SEVERE ● VERY SEVERE	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]
<b>RELATIONSHIP TO TRIAL MEDICATION</b> ● UNKNOWN ● POSSIBLE, DOUBTFUL ● PROBABLE ● CERTAIN	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ] [ ] [ ]
<b>DID SIGN OR SYMPTOM REQUIRE TREATMENT</b> ● YES ● NO IF YES SPECIFY ● DRUG(S)  ● DAILY DOSE AND ADMIN, ROUTE ● DURATION OF TREATMENT (DAYS)	[ ] [ ] [ ] [ ] [ ] [ ]  _____ _____ _____ _____	[ ] [ ] [ ] [ ] [ ] [ ]  _____ _____ _____ _____	[ ] [ ] [ ] [ ] [ ] [ ]  _____ _____ _____ _____
<b>COURSE</b> ● DISAPPEARED, TRIAL DRUG CONTINUED ● PERSISTED, TRIAL DRUG CONTINUED ● DISAPPEARED, AFTER REDUC. DOSE ● PERSISTED, AFTER REDUCTION DOSE ● NOT TOLERATED, TRIAL DRUG DISCONTINUED: ● TEMPORARILY ● DEFINITELY ● FOLLOW-UP: DURATION AFTER DISCONTINUATION OF TRIAL DRUG	[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]   [ ] [ ] [ ] [ ] DAYS	[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]   [ ] [ ] [ ] [ ] DAYS	[ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]   [ ] [ ] [ ] [ ] DAYS
<b>OUTCOME</b> ● FULLY RECOVERED ● RECOVERED WITH SEQUELAE	[ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ]	[ ] [ ] [ ] [ ]

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

enclosure 4a

82

pag. 1

RELATIONSHIP OF NEWLY OBSERVED SIGNS AND SYMPTOMS TO EXPERIMENTAL TREATMENT

Adapted from Karch and Lasagna (1975) Journal of the American Medical Association 234: 1236-41.

1. Definite. A reaction that follows a reasonable temporal sequence from administration of the drug or in which the drug level has been established in body fluids or tissues; that follows a known or expected response pattern to the suspected drug; and that is confirmed by improvement on stopping or reducing the dosage of the drug, and reappearance of the reaction on repeated exposure (rechallenge).
2. Probable. A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to the suspected drug; that is confirmed by stopping or reducing the dosage of the drug; and that could not be reasonably explained by the known characteristics of the patient's clinical state.
3. Possible. A reaction that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to the suspected drug; but that could readily have been produced by a number of other factors.
4. Unknown. Relationship for which no evaluation can be made.
5. Not related. A reaction for which sufficient information exists to indicate that the aetiology is unrelated to the study drug.

FCE 20124/702 1

83 pag. ENCL. 5

PROTOCOL [A.i.D.E.] PATIENT NO. [ ] DATE [ ] [ ] [ ] [ ] [ ] [ ] [ ] ASSESSMENT DAY [ ] [ ] [ ] [ ] PAGE NO. [ ] [ ] [ ] [ ]

HAMD: HAMILTON DEPRESSION RATING SCALE

1	<b>DEPRESSED MOOD</b> (SADNESS, HOPELESS, HELPLESS, WORTHLESS) ABSENT <input type="checkbox"/> THESE FEELING STATES INDICATED ONLY ON QUESTIONING <input type="checkbox"/> THESE FEELING STATES SPONTANEOUSLY REPORTED VERBALLY <input type="checkbox"/> COMMUNICATES FEELING STATES NON-VERBALLY - I.E., THROUGH FACIAL EXPRESSION, POSTURE, VOICE, AND TENDENCY TO WEEP <input type="checkbox"/> PATIENT REPORTS VIRTUALLY ONLY THESE FEELING STATES IN HIS SPONTANEOUS VERBAL AND NON-VERBAL COMMUNICATION <input type="checkbox"/>
2	<b>FEELINGS OF GUILT</b> ABSENT <input type="checkbox"/> SELF REPROACH, FEELS HE HAS LET PEOPLE DOWN <input type="checkbox"/> IDEAS OF GUILT OR RUMINATION OVER PAST ERRORS OR SINFUL DEEDS <input type="checkbox"/> PRESENT ILLNESS IS A PUNISHMENT, DELUSION OF GUILT <input type="checkbox"/> HEARS ACCUSATORY OR DENUNCIATORY VOICES AND/OR EXPERIENCES THREATENING VISUAL HALLUCINATIONS <input type="checkbox"/>
3	<b>SUICIDE</b> ABSENT <input type="checkbox"/> FEELS LIFE IS NOT WORTH LIVING <input type="checkbox"/> WISHES HE WERE DEAD OR ANY THOUGHTS OF POSSIBLE DEATH TO SELF <input type="checkbox"/> SUICIDE IDEAS OR GESTURE <input type="checkbox"/> ATTEMPTS AT SUICIDE (ANY SERIOUS ATTEMPT RATES 4) <input type="checkbox"/>
4	<b>INSOMNIA EARLY</b> NO DIFFICULTY FALLING ASLEEP <input type="checkbox"/> COMPLAINS OF OCCASIONAL DIFFICULTY FALLING ASLEEP - I.E., MORE THAN 1/2 HOUR <input type="checkbox"/> COMPLAINS OF NIGHTLY DIFFICULTY FALLING ASLEEP <input type="checkbox"/>
5	<b>INSOMNIA MIDDLE</b> NO DIFFICULTY <input type="checkbox"/> PATIENT COMPLAINS OF BEING RESTLESS AND DISTURBED DURING THE NIGHT <input type="checkbox"/> WAKING DURING THE NIGHT - ANY GETTING OUT OF BED RATES 2 (EXCEPT FOR PURPOSES OF VOIDING) <input type="checkbox"/>
6	<b>INSOMNIA LATE</b> NO DIFFICULTY <input type="checkbox"/> WAKING IN EARLY HOURS OF THE MORNING BUT GOES BACK TO SLEEP <input type="checkbox"/> UNABLE TO FALL ASLEEP AGAIN IF HE GETS OUT OF BED <input type="checkbox"/>
7	<b>WORK AND ACTIVITIES</b> NO DIFFICULTY <input type="checkbox"/> THOUGHTS AND FEELINGS OF INCAPACITY, FATIGUE OR WEAKNESS RELATED TO ACTIVITIES; WORK OR HOBBIES <input type="checkbox"/> LOSS OF INTEREST IN ACTIVITY; HOBBIES OR WORK - EITHER DIRECTLY REPORTED BY PATIENT, OR INDIRECT IN LISTLESSNESS, INDECISION AND VACILLATION (FEELS HE HAS TO PUSH SELF TO WORK OR ACTIVITIES) <input type="checkbox"/> DECREASE IN ACTUAL TIME SPENT IN ACTIVITIES OR DECREASE IN PRODUCTIVITY. IN HOSPITAL, RATE 3 IF PATIENT DOES NOT SPEND AT LEAST THREE HOURS A DAY IN ACTIVITIES (HOSPITAL JOB OR HOBBIES) EXCLUSIVE OF WARD CHORES <input type="checkbox"/> STOPPED WORKING BECAUSE OF PRESENT ILLNESS. IN HOSPITAL, RATE 4 IF PATIENT ENGAGES IN NO ACTIVITIES EXCEPT WARD CHORES, OR IF PATIENT FAILS TO PERFORM WARD CHORES UNASSISTED <input type="checkbox"/>
8	<b>RETARDATION</b> (SLOWNESS OF THOUGHT AND SPEECH, IMPAIRED ABILITY TO CONCENTRATE; DECREASED MOTOR ACTIVITY) NORMAL SPEECH AND THOUGHT <input type="checkbox"/> SLIGHT RETARDATION AT INTERVIEW <input type="checkbox"/> OBVIOUS RETARDATION AT INTERVIEW <input type="checkbox"/> INTERVIEW DIFFICULT <input type="checkbox"/> COMPLETE STUPOR <input type="checkbox"/>
9	<b>AGITATION</b> NONE <input type="checkbox"/> FIDGETINESS <input type="checkbox"/> PLAYING WITH HANDS, HAIR, ETC. <input type="checkbox"/> MOVING ABOUT, CAN'T SIT STILL <input type="checkbox"/> HAND WRINGING, NAIL BITING, HAIR-PULLING, BITING OF LIPS <input type="checkbox"/>
10	<b>ANXIETY PSYCHIC</b> NO DIFFICULTY <input type="checkbox"/> SUBJECTIVE TENSION AND IRRITABILITY <input type="checkbox"/> WORRYING ABOUT MINOR MATTERS <input type="checkbox"/> APPREHENSIVE ATTITUDE APPARENT IN FACE OR SPEECH <input type="checkbox"/> FEARS EXPRESSED WITHOUT QUESTIONING <input type="checkbox"/>
11	<b>ANXIETY SOMATIC</b> ABSENT <input type="checkbox"/> MILD <input type="checkbox"/> MODERATE <input type="checkbox"/> SEVERE <input type="checkbox"/> INCAPACITATING <input type="checkbox"/> PHYSIOLOGICAL CONCOMITANTS OF ANXIETY, SUCH AS: GASTRO-INTESTINAL (DRY MOUTH, WIND, INDIGESTION, DIARRHEA, CRAMPS, BELCHING); CARDIO-VASCULAR (PALPITATIONS, HEADACHES); RESPIRATORY (HYPERVENTILATION, SIGHING); URINARY FREQUENCY; SWEATING
12	<b>SOMATIC SYMPTOMS GASTROINTESTINAL</b> NONE <input type="checkbox"/> LOSS OF APPETITE BUT EATING WITHOUT STAFF ENCOURAGEMENT, HEAVY FEELINGS IN ABDOMEN <input type="checkbox"/> DIFFICULTY EATING WITHOUT STAFF URGING. REQUESTS OR REQUIRES LAXATIVES OR MEDICATION FOR BOWELS OR MEDICATION FOR G.I. SYMPTOMS <input type="checkbox"/>
13	<b>SOMATIC SYMPTOMS GENERAL</b> NONE <input type="checkbox"/> HEAVINESS IN LIMBS, BACK OR HEAD, BACKACHES, HEADACHE, MUSCLE ACHES, LOSS OF ENERGY AND FATIGABILITY <input type="checkbox"/> ANY CLEAR-CUT SYMPTOM RATES 2 <input type="checkbox"/>
14	<b>GENITAL SYMPTOMS</b> SYMPTOMS SUCH AS: LOSS OF LIBIDO, MENSTRUAL DISTURBANCES: ABSENT <input type="checkbox"/> MILD <input type="checkbox"/> SEVERE <input type="checkbox"/>
15	<b>HYPOCHONDRIASIS</b> NOT PRESENT <input type="checkbox"/> SELF-ABSORPTION (BODILY) <input type="checkbox"/> PREOCCUPATION WITH HEALTH <input type="checkbox"/> FREQUENT COMPLAINTS, REQUESTS FOR HELP, ETC. <input type="checkbox"/> HYPOCHONDRICAL DELUSIONS <input type="checkbox"/>
16	<b>LOSS OF WEIGHT</b> (RATE EITHER A OR B) A. WHEN RATING BY HISTORY: NO WEIGHT LOSS <input type="checkbox"/> PROBABLE WEIGHT LOSS ASSOCIATED WITH PRESENT ILLNESS <input type="checkbox"/> DEFINITE (ACCORDING TO PATIENT) WEIGHT LOSS <input type="checkbox"/> NOT ASSESSED <input type="checkbox"/> B. ON WEEKLY RATINGS BY WARD PSYCHIATRISTS, WHEN ACTUAL WEIGHT CHANGES ARE MEASURED: LESS THAN 1 LB. WEIGHT LOSS IN WEEK <input type="checkbox"/> GREATER THAN 1 LB. WEIGHT LOSS IN WEEK <input type="checkbox"/> GREATER THAN 2 LB. WEIGHT LOSS IN WEEK <input type="checkbox"/> NOT ASSESSED <input type="checkbox"/>
17	<b>INSIGHT</b> ACKNOWLEDGES BEING DEPRESSED AND ILL <input type="checkbox"/> ACKNOWLEDGES ILLNESS BUT ATTRIBUTES CAUSE TO BAD FOOD, CLIMATE, OVERWORK, VIRUS, NEED FOR REST, ETC. <input type="checkbox"/> DENIES BEING ILL AT ALL <input type="checkbox"/>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i  
 PROTOCOL \_\_\_\_\_ PATIENT NO. \_\_\_\_\_

ENCL. 6

ASSESSMENT DAY 0 3 7 14 21 26 DATE           
 DAY DAY MONTH YEAR

84

CLINICAL GLOBAL IMPRESSION (CGI)

**A. SEVERITY OF ILLNESS**

CONSIDERING YOUR TOTAL CLINICAL EXPERIENCE WITH THIS PARTICULAR POPULATION, HOW MENTALLY ILL IS THE PATIENT AT THIS TIME?

- 1 NORMAL, NOT AT ALL ILL
- 2 BORDERLINE MENTALLY ILL
- 3 MILDLY ILL
- 4 MODERATELY ILL
- 5 MARKEDLY ILL
- 6 SEVERELY ILL
- 7 AMONG THE MOST EXTREMELY ILL PATIENTS

**B. GLOBAL IMPROVEMENT** (RATE TOTAL IMPROVEMENT WHETHER OR NOT, IN YOUR JUDGEMENT, IT IS DUE ENTIRELY TO DRUG TREATMENT)

COMPARED TO HIS CONDITION AT ADMISSION TO THE STUDY, HOW MUCH HAS HE CHANGED?

- 1 VERY MUCH IMPROVED
- 2 MUCH IMPROVED
- 3 MINIMALLY IMPROVED
- 4 NO CHANGE
- 5 MINIMALLY WORSE
- 6 MUCH WORSE
- 7 VERY MUCH WORSE

**C. EFFICACY INDEX** (RATE THIS ITEM ON THE BASIS OF DRUG EFFECT ONLY)

ACTIVITY	TOLERABILITY: SIDE EFFECTS			
	NONE	DO NOT SIGNIFICANTLY INTERFERE WITH PATIENT'S FUNCTIONING	SIGNIFICANTLY INTERFERE WITH PATIENT'S FUNCTIONING	OUTWEIGH THERAPEUTIC EFFECT
<b>MARKED</b> - VAST IMPROVEMENT. COMPLETE OR NEARLY COMPLETE REMISSION OF ALL SYMPTOMS	1	2	3	4
<b>MODERATE</b> - DECIDED IMPROVEMENT. PARTIAL REMISSION OF SYMPTOMS	5	6	7	8
<b>MINIMAL</b> - SLIGHT IMPROVEMENT WHICH DOES NOT ALTER STATUS OF CARE OF PATIENT	9	10	11	12
<b>UNCHANGED OR WORSE</b>	13	14	15	16

85 ENCL. 7

PROTOCOL   A.D.E.I.   PATIENT NO.    DATE                ASSESSMENT DAY    PAGE NO.     
D M Y

MADRS: MONTGOMERY ASBERG DEPRESSION RATING SCALE

<p>① <b>REPORTED SADNESS</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING SUBJECTIVELY EXPERIENCED MOOD, REGARDLESS OF WHETHER IT IS REFLECTED IN APPEARANCE OR NOT. INCLUDES DEPRESSED MOOD, LOW SPIRITS, DESPONDENCY, AND THE FEELING OF BEING BEYOND HELP AND WITHOUT HOPE.</li> <li>• RATE ACCORDING TO INTENSITY, DURATION AND THE EXTENT TO WHICH THE MOOD IS INFLUENCED BY EVENTS.</li> <li>• ELATED MOOD IS SCORED ZERO ON THIS ITEM.</li> </ul> <p>OCCASIONAL SADNESS MAY OCCUR IN THE CIRCUMSTANCES 0 PREDOMINANT FEELINGS OF SADNESS, BUT BRIGHTER MOMENTS OCCUR 1 PERSISTENT FEELINGS OF SADNESS OR GLOOMINESS. THE MOOD IS HARDLY INFLUENCED BY EXTERNAL CIRCUMSTANCES 2 CONTINUOUS EXPERIENCE OF MISERY OR EXTREME DESPONDENCY 3</p>
<p>② <b>INNER TENSION</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING FEELINGS OF ILL-DEFINED DISCOMFORT, EDGINESS, INNER TURMOIL, MENTAL TENSION MOUNTING TO PANIC, DREAD AND ANGUISH.</li> <li>• RATE ACCORDING TO INTENSITY, FREQUENCY, DURATION AND THE EXTENT OF REASSURANCE CALLED FOR.</li> <li>• DISTINGUISH FROM SADNESS, WORRYING AND MUSCULAR TENSION.</li> </ul> <p>PLACID. ONLY FLEETING INNER TENSION 0 OCCASIONAL FEELINGS OF EDGINESS AND ILL-DEFINED DISCOMFORT 1 CONTINUOUS FEELINGS OF INNER TENSION, OR INTERMITTENT PANIC WHICH THE PATIENT CAN ONLY MASTER WITH SOME DIFFICULTY 2 UNRELENTING DREAD OR ANGUISH. OVERWHELMING PANIC 3</p>
<p>③ <b>APPARENT SADNESS</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING DESPONDENCY, GLOOM AND DESPAIR (MORE THAN JUST ORDINARY TRANSIENT LOW SPIRITS) REFLECTED IN SPEECH, FACIAL EXPRESSION, AND POSTURE. RATE BY DEPTH AND INABILITY TO BRIGHTEN UP.</li> <li>• NO SADNESS 0 LOOKS DISPIRITED BUT BRIGHTENS UP OCCASIONALLY 1 APPEARS SAD AND UNHAPPY ALL OF THE TIME 2 EXTREME AND CONTINUOUS GLOOM AND DESPONDENCY 3</li> </ul>
<p>④ <b>SUICIDAL THOUGHTS</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING THE FEELING THAT LIFE IS NOT WORTH LIVING, THAT A NATURAL DEATH WOULD BE WELCOME, SUICIDAL THOUGHTS, AND PREPARATIONS FOR SUICIDE.</li> <li>• SUICIDAL ATTEMPTS SHOULD NOT IN THEMSELVES INFLUENCE THE RATING.</li> </ul> <p>ENJOYS LIFE OR TAKES IT AS IT COMES 0 NEARY OF LIFE. ONLY FLEETING SUICIDAL THOUGHTS 1 MUCH BETTER OFF DEAD. SUICIDAL THOUGHTS ARE COMMON, AND SUICIDE IS CONSIDERED AS A POSSIBLE SOLUTION, BUT WITHOUT SPECIFIC PLANS OR INTENTION 2 EXPLICIT PLANS FOR SUICIDE WHEN THERE IS AN OPPORTUNITY. ACTIVE PREPARATION FOR SUICIDE 3</p>
<p>⑤ <b>INERTIA</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING A DIFFICULTY GETTING STARTED OR SLOWNESS INITIATING AND PERFORMING EVERYDAY ACTIVITIES.</li> <li>• DISTINGUISH FROM INDECISION AND FATIGUABILITY.</li> </ul> <p>NO DIFFICULTY IN GETTING STARTED. NO SLUGGISHNESS 0 DIFFICULTIES IN STARTING NEW ACTIVITIES 1 DIFFICULTIES IN STARTING VERY SIMPLE ROUTINE ACTIVITIES, WHICH ARE CARRIED OUT ONLY WITH EFFORT 2 COMPLETE INERTIA. UNABLE TO START ANY ACTIVITY WITHOUT HELP 3</p>
<p>⑥ <b>INABILITY TO FEEL</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING THE SUBJECTIVE EXPERIENCE OF REDUCED INTEREST IN THE SURROUNDINGS, OR ACTIVITIES THAT NORMALLY GIVE PLEASURE. THE ABILITY TO REACT WITH ADEQUATE EMOTION TO CIRCUMSTANCES OR PEOPLE IS PRODUCED.</li> <li>• DISTINGUISH FROM INERTIA.</li> </ul> <p>NORMAL INTEREST IN THE SURROUNDINGS AND IN OTHER PEOPLE 0 REDUCED ABILITY TO ENJOY USUAL INTERESTS. REDUCED ABILITY TO FEEL ANGER 1 LOSS OF INTEREST IN THE SURROUNDINGS. LOSS OF FEELINGS FOR FRIENDS AND ACQUAINTANCES 2 THE EXPERIENCE OF BEING EMOTIONALLY PARALYZED, INABILITY TO FEEL ANGER OR GRIEF, AND A COMPLETE OR EVEN PAINFUL FAILURE TO FEEL FOR CLOSE RELATIVES AND FRIENDS 3</p>
<p>⑦ <b>PESSIMISTIC THOUGHTS</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING THOUGHTS OF GUILT, INFERIORITY, SELF-REPROACH, SINFULNESS, REMORSE AND RUIN.</li> </ul> <p>NO PESSIMISTIC THOUGHTS 0 FLUCTUATING IDEAS OF FAILURE, SELF-REPROACH OR SELF-DEPRECIATION 1 PERSISTENT SELF-ACCUSATIONS, OR DEFINITE BUT STILL RATIONAL IDEAS OF GUILT OR SIN. INCREASINGLY PESSIMISTIC ABOUT THE FUTURE 2 DELUSIONS OF RUIN, REMORSE AND UNREDEEMABLE SIN. ABSURD SELF-ACCUSATIONS 3</p>
<p>⑧ <b>CONCENTRATION DIFFICULTIES</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING DIFFICULTIES IN COLLECTING ONE'S THOUGHTS MOUNTING TO INCAPACITATING LACK OF CONCENTRATION.</li> <li>• RATE ACCORDING TO INTENSITY, FREQUENCY, AND DEGREE OF INCAPACITY RECORDED.</li> <li>• DISTINGUISH FROM FAILING MEMORY AND DISRUPTED THOUGHTS.</li> </ul> <p>NO DIFFICULTIES IN CONCENTRATING 0 OCCASIONAL DIFFICULTIES IN COLLECTING ONE'S THOUGHTS 1 DIFFICULTIES IN CONCENTRATING AND SUSTAINING THOUGHTS WHICH INTERFERE WITH READING OR CONVERSATION 2 INCAPACITATING LACK OF CONCENTRATION 3</p>
<p>⑨ <b>REDUCED SLEEP</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING A SUBJECTIVE EXPERIENCE OF REDUCED DURATION OR DEPTH OF SLEEP COMPARED TO THE SUBJECT'S OWN FITFUL SLEEP.</li> </ul> <p>SLEEP AS USUAL 0 SLIGHT DIFFICULTY DROPPING OFF TO SLEEP OR SLIGHTLY REDUCED, LIGHT OR FITFUL SLEEP 1 SLEEP REDUCED OR BROKEN BY AT LEAST 2 HOURS 2 LESS THAN TWO OR THREE HOURS SLEEP 3</p>
<p>⑩ <b>REDUCED APPETITE</b></p> <ul style="list-style-type: none"> <li>• REPRESENTING THE FEELING OF A LOSS OF APPETITE COMPARED WITH WHEN WELL.</li> </ul> <p>NORMAL OR INCREASED APPETITE 0 SLIGHTLY REDUCED APPETITE 1 NO APPETITE. FOOD IS TASTLESS. NEED TO FORCE ONESELF TO EAT 2 MUST BE FORCED TO EAT. FOOD REFUSAL 3</p>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

ENCL. 8

PROTOCOL \_\_\_\_\_ PATIENT NO. \_\_\_\_\_ DATE \_\_\_\_\_ ASSESSMENT DAY \_\_\_\_\_  
DAY MONTH YEAR      0 3 7 14 21 28

86

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE  
 PUBLIC HEALTH SERVICE  
 NATIONAL INSTITUTE OF MENTAL HEALTH  
**ZUNG SDS**

**INSTRUCTIONS**

Listed below are 20 statements. Please read each one carefully and decide how much of the statement describes how you have been feeling during the past week. Decide whether the statement applies to you for **NONE OR A LITTLE OF THE TIME, SOME OF THE TIME, A GOOD PART OF THE TIME, OR MOST OR ALL OF THE TIME**. Mark the appropriate column for each statement.

EXAMPLE				
STATEMENT	NONE OR A LITTLE OF THE TIME	SOME OF THE TIME	A GOOD PART OF THE TIME	MOST OR ALL OF THE TIME
I feel nervous	☐	☐	☑	☐

If the statement "I feel nervous" describes the way you have felt "A GOOD PART OF THE TIME", you would mark column 3 "A GOOD PART OF THE TIME" as shown.

STATEMENT	NONE OR A LITTLE OF THE TIME	SOME OF THE TIME	A GOOD PART OF THE TIME	MOST OR ALL OF THE TIME
1. I feel downhearted and blue	☐	☐	☐	☐
2. Morning is when I feel the best	☐	☐	☐	☐
3. I have crying spells or feel like it	☐	☐	☐	☐
4. I have trouble sleeping at night	☐	☐	☐	☐
5. I eat as much as I used to	☐	☐	☐	☐
6. I still enjoy sex	☐	☐	☐	☐
7. I notice that I am losing weight	☐	☐	☐	☐
8. I have trouble with constipation	☐	☐	☐	☐
9. My heart beats faster than usual	☐	☐	☐	☐
10. I get tired for no reason	☐	☐	☐	☐
11. My mind is as clear as it used to be	☐	☐	☐	☐
12. I find it easy to do the things I used to do	☐	☐	☐	☐
13. I am restless and can't keep still	☐	☐	☐	☐
14. I feel hopeful about the future	☐	☐	☐	☐
15. I am more irritable than usual	☐	☐	☐	☐
16. I find it easy to make decisions	☐	☐	☐	☐
17. I feel that I am useful and needed	☐	☐	☐	☐
18. My life is pretty full	☐	☐	☐	☐
19. I feel that others would be better off if I were dead	☐	☐	☐	☐
20. I still enjoy the things I used to do	☐	☐	☐	☐

*World Medical Association*

**DECLARATION OF HELSINKI**

**RECOMMENDATIONS GUIDING MEDICAL DOCTORS IN BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS**

ADOPTED BY THE 18TH WORLD MEDICAL ASSEMBLY, HELSINKI, FINLAND, 1964, AND AS REVISED BY THE 29TH WORLD MEDICAL ASSEMBLY, TOKYO, JAPAN, 1975.

*Med. J. Aust.*, 1976, 1: 206-207.

**INTRODUCTION**

It is the mission of the medical doctor to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the doctor with the words, "The health of my patient will be my first consideration", and the International Code of Medical Ethics declares that, "Any act or advice which could weaken physical or mental resistance of a human being may be used only in his interest".

The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies *a fortiori* to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a patient, and medical research, the essential object of which is purely scientific and without direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every doctor in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Doctors are not relieved from criminal, civil and ethical responsibilities under the laws of their own countries.

**I. BASIC PRINCIPLES**

1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.

2. The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted to a specially appointed independent committee for consideration, comment and guidance.

3. Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person

and never rest on the subject of the research, even though the subject has given his or her consent.

4. Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.

5. Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.

6. The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.

7. Doctors should abstain from engaging in research projects involving human subjects unless they are satisfied that the hazards involved are believed to be predictable. Doctors should cease any investigation if the hazards are found to outweigh the potential benefits.

8. In publication of the results of his or her research, the doctor is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

9. In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The doctor should then obtain the subject's freely-given informed consent, preferably in writing.

10. When obtaining informed consent for the research project the doctor should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a doctor who is not engaged in the investigation and who is completely independent of this official relationship.

11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with national legislation.

12. The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

**II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (CLINICAL RESEARCH)**

1. In the treatment of the sick person, the doctor must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.

FCE 20124/702 i

pag. 2

88

FEBRUARY 14, 1976

THE MEDICAL JOURNAL OF AUSTRALIA

2. The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.
3. In any medical study, every patient—including those of a control group, if any—should be assured of the best proven diagnostic and therapeutic method.
4. The refusal of the patient to participate in a study must never interfere with the doctor-patient relationship.
5. If the doctor considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (1, 2).
6. The doctor can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the patient.

**III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (NON-CLINICAL BIOMEDICAL RESEARCH)**

1. In the purely scientific application of medical research carried out on a human being, it is the duty of the doctor to remain the protector of the life and health of that person on whom biomedical research is being carried out.
2. The subjects should be volunteers—either healthy persons or patients for whom the experimental design is not related to the patient's illness.
3. The investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual.
4. In research on man, the interest of science and society should never take precedence over considerations related to the well-being of the subject.



FCE 20124/702 i

Attachment A

REBOXETINE PHASE II CLINICAL TRIAL  
PROTOCOL ADDENDUM

89

Data Processing and Analyses

Data documentation will be carried out at Vanderbilt University. It will be based upon the data analysis guidelines originally developed by the ECDEU Program of the United States National Institute of Mental Health. The analyses will be conducted utilizing the SPSS-X/SPSS-PC+ statistical analysis system.

The project will involve three major data analysis components:

1) to examine the efficacy of reboxetine as compared to standard antidepressant and placebo treatment; 2) to examine the pattern of therapeutic latency for reboxetine as compared to standard antidepressant (desipramine) and placebo treatment; and 3) to explore possible differential efficacy of reboxetine in different depressive subtypes. For each of these components, the effects of treatment will be examined in two ways; one examining treatments effects along a continuum of severity of depression (i.e. regarding treatment response as a matter of degree), the other dichotomizing treatment effects into treatment response/no treatment response. The latter dichotomy will be accomplished by defining meaningful treatment response as a 50% reduction in the relevant instrument (Hamilton Depression Scale, Montgomery-Asberg Depression Rating Scale, Zung Depression Scale). The former, continuous data analyses will allow greater statistical power in terms of identifying significant treatment response patterns, while the latter, dichotomous analyses will present treatment response results in a manner which may be more clinically meaningful.

Four different instruments will be utilized as measures of depression: the Hamilton Depression Scale (HAM-D, 17-item); the Montgomery-Asberg Depression Rating Scale (MADRS); Zung Self-Rating Depression Scale (ZUNG); and the Clinical Global Impressions scale (CGI). The reliability of these instruments as used by the investigators in the present project is documented in a subsequent section. For all analyses, the primary instrument of interest will be the HAM-D, which is the most widely used rating scale for the assessment of depression.

The three components of the analysis will be structured as follows:

1) *Efficacy Evaluation*: To examine the relative efficacy of reboxetine as measured against standard antidepressant and placebo treatment, a two-way (between subjects), 3 (treatment) x 10 (center) analysis of covariance will be performed, with post-washout:pre-treatment (Day 0) depression levels utilized as the covariate. The dependent variables for these analyses will involve the post-treatment scores (Day 28) on the HAM-D (primary), the MADRS, the ZUNG and the CGI. Planned comparisons will examine post-treatment differences among the three experimental groups. No differences across treatment center are hypothesized but this possibility will be investigated; should no differences emerge, this factor will be ignored in subsequent analyses.

FCE 20124/702 i

pag. 2

90

The examination of dichotomized treatment response will be accomplished utilizing a two-way (between subjects), 3 (treatment) x 10 (center) analysis of variance, with treatment response (yes/no) utilized as the dependent variable.

In the event that a subject is discontinued or withdraws from the study and hence has incomplete data (as described elsewhere in the protocol), the last known data point will be utilized as an estimate of post-treatment response.

An estimate of the power of this design may be obtained from pilot data gathered in the Phase I trial of reboxetine. At the dosage level to be utilized in the current project, patients improved an average of 14 points on the HAM-D (30 pre-treatment, 16 post-treatment) with a standard error of approximately 3. Assuming a 20% improvement with placebo treatment and comparable response rates for reboxetine and desipramine, this yields a phi prime of 3.78. At this value, a sample of 80 subjects for each experimental treatment yields a statistical power for this design which is well in excess of .90 for the main effects comparison.

2) Therapeutic Latency Evaluation: The identification of effect onset will utilize a one way (between subjects: treatment) repeated measures analysis of covariance, with post-washout:pre-treatment (Day 0) depression levels utilized as the covariate. The repeated dependent variables for these analyses will involve four treatment scores (Days 7, 10, 14, 21, and 28) on the HAM-D (primary), the MADRS, the ZUNG and the CGI. Planned comparisons will focus upon the interaction between trial period and experimental group, utilizing results from the within-subject (i.e. period) contrasts. It is hypothesized that a treatment by period interaction will be obtained, with contrasts indicating differences in efficacy between treatments emerging as soon as Day 14.

3) Subtype Interaction Evaluation: The analyses for the identification of therapeutically responsive depressive subforms will require the use of a two-way (between subjects), 3 (experimental group) x N (depressive subtype) repeated measures analysis of variance. A total of eight different classification systems for depression will be examined; the number of depressive subtypes will vary across classification systems, ranging from three (e.g., Winokur subtypes) to seven (V-RDC subtypes). Identification of clinically significant depressive subforms will involve an examination of type by treatment interactions followed by planned contrasts between depressive subgroups. The increased complexity of these designs will reduce the statistical power of the subform analyses, but the overall sample size should allow adequate power for these analyses under the assumptions stated earlier.

In addition to the analyses described above, descriptive analyses will also be conducted to identify and isolate treatment emergent abnormalities in laboratory tests (hematology, blood chemistry, and urinalysis). As a first step, the laboratory findings for patients receiving reboxetine will be compared pre- and post-treatment, with the proportion of abnormal results before and after treatment being compared using the proportions procedure described by McNemar. If a larger incidence of abnormal test findings are noted post-treatment, similar analyses will be conducted with the desipramine and placebo groups to determine if the laboratory test changes are different from what would be expected under standard or placebo treatment.

FCE 20124/702 i

pag. 3 91

As a complement to the results of the data analyses described above, a complete reporting of scores on the primary instruments for each subject will be provided. These reports will include the following for each patient:

*Days 0,4,7,10,14,21,28:*

HAM-D total score  
CGI  
MADRS total score  
ZUNG  
Newly Observed Signs/Symptoms (NOSS)

*Screen, Days 7,14,28:*

ECG  
Laboratory tests

FCE 20124/702 i

pag: 492

Assessment Instrumentation: Inter-rater Reliability

To insure that the primary measures of depression utilized in this study will be assessed in a reliable manner, training sessions in the use of the HAM-D, MADRS, and CGI were held in Mexico City and Milan in May/June, 1987. These training sessions were conducted by Dr. T.A. Ban. As an assessment of diagnostic reliability, the investigators from each of the ten centers were asked to complete the three clinical instruments based upon videotaped interviews with four depressed patients. Reliability was calculated by assessing product-moment correlations between raters, on total scores, across the four videotapes. The results were as follows:

<u>Instrument</u>	<u>Median Inter-rater Correlation</u>
Hamilton Depression -total score	.891
Montgomery-Asberg -total score	.925
Clinical Global Impression -total score	.945

The level of inter-rater reliability represented by these figures is judged to be excellent given the limited number of videotapes and the restricted nature of the patient sample.

REBOXETINE PROTOCOL ADE 008: OPERATING PROCEDURES FOR  
TRAINING ON ASSESSMENT INSTRUMENTS, STUDY MONITORING  
AND COORDINATION.

**Aim**

The purpose of these procedures is to provide standardization of the study conduct in the different clinical centers and to assure data uniformity and compatibility by appropriate interventions during data gathering.

**Inter-rater reliability**

Prior to commencement of the clinical trial:

1. Inter-rater agreement for the instruments used in the assessment of change will be tested on the occasion of the first Investigators' Meeting by employing 4 videotapes;
2. A specially devised training program with a focus on diagnostic assessments will be conducted. In each participating center there will be 1 psychiatrist (or psychologist) responsible for all VRDC diagnoses. For the psychiatrists (psychologists) responsible for the VRDC diagnoses (1 at each center) a special 10-day training program is planned. It will be conducted in Nashville, TN, by members of the Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University. The program will consist of five lectures (on the theoretical basis of VRDC), five seminars (dealing with issues relevant to the theoretical basis and/or practical application of VRDC), VRDC demonstrations (on 10 patients) and VRDC practice sessions (10 patients). Successful completers of the programme will receive a VRDC Certificate.

During the clinical trial:

3. Inter-rater agreement for the instruments used in the assessment of diagnosis will be tested by employing 7 videotapes.

FCE 20124/702 i

pag. 2

94

#### Study monitoring

During the course of the study (12-month) five monitoring visits will be conducted by Study Monitors from Farmitalia C. Erba and two by the Scientific Coordinator from Vanderbilt University and/or his associate (on one of these two visits the diagnostic videotapes will be reviewed and discussed).

The first visit will take place after approval of the protocol by IRB. On this first visit the following documentation will be collected:

- copy of the protocol signed by the Principal Investigator;
- the written IRB approval of the study;
- the list of IRB voting members; their titles or occupations and their institutional affiliations;
- the IRB approved consent form typed on the Institute's headed letter;
- a certification about the laboratory in which the foreseen tests will be performed, and the list of the laboratory normal values or ranges of the foreseen tests.

These documents will be sent to the Study Monitor in Milan who will take care of providing the data handling center in Nashville with the normal values or ranges of the lab. tests.

Following the approval of the protocol by the IRB the drug supply will be delivered to the Clinical Investigator and the written receipt of this, signed by the Clinical Investigator will be collected on the occasion of this visit. In addition the monitoring visits schedule will be agreed.

Following the visit the form A (enclosed) will be filled in. Copy of it will be sent to the Study Monitor in Milan.

The following monitoring visits are carried out in order to:

1. verify protocol adherence: patient eligibility (page 1 of the CRF), times of assessments, completeness of data;

2. verify data consistency looking for inconsistencies or errors in the data recorded on the CRF;
3. verify accuracy of data collection by comparing CRFs with the original clinic or hospital records for:
  - pt initials
  - signed informed consent
  - study medication administration
  - attending physician notes on adverse events
  - 20% of data for laboratory tests, patient history and vital signs; in case of an error rate >15% all data need to be monitored;
4. review all adverse events including laboratory abnormalities occurred since the previous visit. Should the information of a serious, or unexpected adverse event newly emerge, the local study Monitor must inform immediately the study Monitor in Milan;
5. evaluate patient recruitment rate and treatment discontinuations;
6. verify blood samples collection and storage;
7. verify study medication storage and accountability and collect bottles of completed treatments;
8. ensure continued acceptability of facilities.

CRFs will be completed in black ink and corrections, if needed, made only by the Clinical Investigator with a single line throughout; the corrections will be initialled by the Clinical Investigator and dated. Each page of each completed CRF will be signed by the Clinical Investigator and dated.

After review for accuracy and completeness, the original and first copy of each page of the CRF will be removed (leaving the second copy with the Investigator). The original will be sent to the Study Monitor in Milan by Special Delivery Service and first copy will be sent (again by Special Delivery Service) to the Scientific Coordinator in Nashville for review and data processing. After each monitoring visit form B (enclosed) will be filled in. Copy of it will be sent to the Study Monitor in Milan.

FCE 20124/702 i

pag. 4

96

#### Study coordination

In order to obtain uniformity and standardization in the carrying out of the study, a Scientific and Ethical Advisory Board is established. All questions arising during the conduct of the study will be submitted to the Board for advice and action taking.

In particular the Board will take care of:

- queries about patient acceptability;
- possible need of protocol amendments;
- possible need of premature termination of the clinical investigation;
- acceptability of particular cases of protocol violations;
- evaluation of clinically relevant adverse events and their possible scientific and ethical consequences in terms of issues raised and/or study discontinuation.

Members of the Board will be: Prof. T. Ban (Vanderbilt University, Nashville - chairman), Dr. L. Morey (Vanderbilt University, Nashville - biometric and statistical aspects), Dr. M. Jarema (Vanderbilt University, Nashville - clinical aspects), Dr. I. Cohen (legal aspects).

Any problem or issue arising during the conduct of the study will be submitted to the Board in writing by Clinical Investigators or Study Monitors. "Ad hoc" meetings of the Board will be organized when needed; file notes of the meetings with conclusions about action taking will be circulated to Clinical Investigators and Study Monitors.



REBOXETINE PROTOCOL ADE 008  
FIRST SITE VISIT: FORM A

INVESTIGATOR:.....

CENTER:.....

VISIT DATE:.....

- |    |                                |     |                 |
|----|--------------------------------|-----|-----------------|
| 1. | <b>Documents</b>               |     | <b>obtained</b> |
|    | - Signed protocol              | yes | no              |
|    | - IRB approval                 | yes | no              |
|    | - IRB members list             | yes | no              |
|    | - Consent form approved by IRB | yes | no              |
|    | - Laboratory certification     | yes | no              |
|    | - Normal lab. values           | yes | no              |
|    | - Drug supply receipt          | yes | no              |

Comments:.....  
.....  
.....

- |    |   |
|----|---|
| 2. | <b>Drug accountability</b>  |
|    | - where is the study medication to be stored?.....<br>.....                                     |
|    | - who will be responsible for drug accountability, dispensing and administration?.....<br>..... |

- |    |  |             |
|----|--|-------------|
| 3. | <b>Plasma samples</b>                                  |             |
|    | - agreement about procedure on storage and collection? | yes      no |

- |    |                                    |             |
|----|------------------------------------|-------------|
| 4. | <b>Monitoring schedule agreed?</b> | yes      no |
|----|------------------------------------|-------------|

Date:

Monitor signature:

\_\_\_\_\_

FCE 20124/702 i

pag. 6  
REBOXETINE PROTOCOL ADX 008  
MONITORING VISIT: FORM B

98

INVESTIGATOR: .....  
CENTER: .....  
VISIT DATE: .....

1. Total No of pts: recruited: \_\_\_\_\_ terminated: \_\_\_\_\_

2. Since last visit:

- dropped-out:

pt.No. \_\_\_\_\_ due to.....  
pt.No. \_\_\_\_\_ due to.....  
pt.No. \_\_\_\_\_ due to.....

- had clinically relevant adverse events:

pt.No. \_\_\_\_\_ event:.....  
pt.No. \_\_\_\_\_ event:.....  
pt.No. \_\_\_\_\_ event:.....  
pt.No. \_\_\_\_\_ event:.....

3. CRF: reviewed/source documentation:

pt.No \_\_\_\_\_

comments:.....  
.....  
.....

collected:

pt.No \_\_\_\_\_

4. Study medication accountability:

- study medication of completed cases (bottles collected):

pt.No \_\_\_\_\_ remaining cps \_\_\_\_\_  
pt.No \_\_\_\_\_ remaining cps \_\_\_\_\_  
pt.No \_\_\_\_\_ remaining cps \_\_\_\_\_

- is the study medication being stored properly?  
yes \_\_\_\_\_ no \_\_\_\_\_

Comments:.....  
.....  
.....

Date:

Monitor signature:

\_\_\_\_\_

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

pag. 99

CONSENT FORM

Phase II controlled study of the activity and tolerability of reboxetine in comparison with placebo and desipramine in patients hospitalized for major depressive disorders.

Principal Investigator: .....

EXPLANATION

**Purpose of the study**

Reboxetine, a new potential antidepressant agent, has effects in animals which suggest that it may exert therapeutic efficacy of faster onset, in comparison with established antidepressant drugs, in patients suffering from depressive disorders. The trial is proposed in order to learn about the antidepressant effectiveness of the compound and about the onset of its activity.

**Plan of the study**

Patients participating in the study will receive in a 1:1:1 ratio either reboxetine or desipramine, a drug of established antidepressant efficacy, approved for the therapy of depressive disorders in all American and European countries, or a harmless inactive treatment (placebo). Neither patients nor doctors will know which treatment will be administered in individual cases until after the study is completed. The identity of the treatments can anyhow be determined immediately if any medical problem will develop and it will become important to learn which of the three possible treatments is being given.

The doses of the treatments will be increased from 4 mg (reboxetine) or 100 mg (desipramine) up to 8 mg (reboxetine) or 200 mg (desipramine). Treatment will be administered for 28 days. It will be discontinued in case of significant side-effects or deterioration of patient clinical condition. In addition patients participating in the study may withdraw their consent at any time without prejudice to their continued medical treatment.

During treatment, physical and psychiatric examinations will be done on frequent occasions, in order to determine possible side-effects and benefits of treatments. Blood

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

100 pag. 2

tests, urinalysis, ECG will be undertaken weekly or be-weekly. Blood pressure and pulse will be taken very frequently, particularly in the first two weeks of treatment.

**Possible discomforts and risks.**

Antidepressant drugs can cause dry mouth, blurred vision, dizziness, mild difficulty in voiding urine, postural hypotension and electrocardiographic changes.

Reboxetine has been so far administered for 28 days to about 90 patients and was well tolerated up to the dose of 5 mg twice daily. In the dose range of 3-5 mg twice daily clinically relevant improvement of depressive condition was present in the majority of patients; symptoms complained off by patients were mainly mild and transient and included most frequently headache, sweating, lassitude and nasal congestion. At higher doses orthostatic hypotension, tachycardia, dizziness, blurred vision and nausea were reported.

Patients participating in the study will be carefully monitored to detect early signs of such side-effects.

**Possible benefits**

Other drugs are available for treatment of depressive disorders but none has been of proven value in all cases; in addition for available drugs the onset of antidepressant effectiveness is delayed, usually for at least 2 weeks. This study will allow the evaluation of the onset of efficacy of reboxetine, expected to be more rapid on the basis of data obtained in animals, in comparison with desipramine. In addition it will allow the quantification of antidepressant activity of reboxetine in comparison with placebo. Under the latter treatment, improvement rates of 40-80% have been reported in Depressive Disorders: the evaluation of patient response under placebo could be useful in deciding the most appropriate treatment approach in individual cases.

**Alternative treatment.**

Patients would receive alternative pharmacological therapy with an antidepressant drug chosen on the basis of response during previous episodes, if any. Risks and benefits of receiving treatment with any of the available antidepressant drugs can be explained by .....



FCE 20124/702 i

102

ENCLOSURE 2

1

**INVESTIGATIVE CENTERS**

<b>COUNTRY</b>	<b>CENTER No.</b>	<b>NAME</b>
FRANCE	1	Rouffach Psychiatric Hospital Principal Investigator: Prof. J.P. Macher. Address: Centre Hospitalier Specialise - Secteur VII du Haut-Rhin - Rouffach
HUNGARY	2	Neuropsychiatric Dept, Janos Hospital, Budapest Principal Investigator: Prof. A. Lipcsey Address: Janos Korhaz Hospital - Diosnok u.1 11125 Budapest
	3	National Institute for Nervous and Mental Diseases, Budapest Principal Investigator: Dr. P. Gaszner Address: Orszagos Ideg es Elmegyogyiretezet, Voroshadesereg utja 116 - 1021 Budapest II
ITALY	4	Psychiatric Clinic, University of Trieste, Principal Investigator: Prof. E. Aguglia Address: Istituto Clinica Psichiatrica - Universita' di Trieste - Via S. Cilino, 16 34126 Trieste
	5	Psychiatric Clinic, University of Catania, Principal Investigator: Prof. V. Rapisarda Address: Clinica Psichiatrica - Universita' di Catania - Via Andrea Doria 6 - 95125 Catania
MEXICO	6	National Institute of Neurology, Mexico City Principal Investigator: Prof. A. Torres-Ruiz Address: Instituto Nacional de Neurologia y Neurochirurgia Insurgentes SUR 3877 C.P. 14410 COL. LA FAMA

- |        |    |  |
|--------|----|--|
|        | 7  | National Psychiatric Hospital, Acapulco<br>Principal Investigator: Dr. C. Vinas<br>Address: Instituto Nacional de Neurologia y<br>Neurochirurgia Avenida la Cima, 98 -<br>Fraccionamiento Las Playas, ACAPULCO,<br>GUERRERO 39930  |
| PANAMA | 8  | National Psychiatric Hospital, Panama City<br>Principal Investigator: Dr. L. Vergara<br>Address: Hospital Psiquiatrico Nacional<br>Centro de Investigaciones Farmacologicas<br>Universidad de Panama   |
|        | 9  | National Psychiatric Hospital, Panama City<br>Principal Investigator: Dr. R. Batista<br>Address: Hospital Psiquiatrico Nacional<br>Universidad de Panama   |
| PERU'  | 10 | Biological Psychiatry Laboratory, National<br>Institute of Mental Health, Lima<br>Principal Investigator: Dr. A. Castillo<br>Address: Instituto Nacional de Salud Mental<br>"Honorio Delgado-Hideyo Noguchi"<br>Laboratorio del Psiquiatria Biologica<br>Alameda Palao S/N Urb. Palao San Martin<br>de Porres Casilla 4274 - LIMA 31 |

FCE 20124/702 i

ENCLOSURE 3

1

104

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : ...Rouffach Psychiatric Hospital, Rouffach

PRINCIPAL INVESTIGATOR : Dr. J. P. Macher.....

<u>PATIENT N°</u>	<u>TREATMENT</u>		<u>PATIENT N°</u>	<u>TREATMENT</u>
1	P		13	P
2	D		14	P
3	R		15	D
4	D		16	R
5	P		17	D
6	R		18	R
7	R		19	R
8	R		20	R
9	P		21	P
10	D		22	D
11	D		23	D
12	P		24	P

R = REBOXETINE  
2 mg  
Batch N° 993

D = DESIPRAMINE  
50 mg

P = PLACEBO  
Batch N° 992



FCE 20124/702 i

2

105

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : Janos Korhaz, Budapest  
.....  
PRINCIPAL INVESTIGATOR : Dr. A. Lipksey  
.....

<u>PATIENT N°</u>	<u>TREATMENT</u>		<u>PATIENT N°</u>	<u>TREATMENT</u>
25	P		37	P
26	R		38	P
27	R		39	R
28	D		40	R
29	D		41	D
30	P		42	D
31	D		43	R
32	D		44	D
33	R		45	P
34	P		46	R
35	P		47	D
36	R		48	P

-----  
R = REBOXETINE      D = DESIPRAMINE      P = PLACEBO  
2 mg Batch N° 893      Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3

106

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : ..... Országos Ideg és Elmegyógyretek, Budapest

PRINCIPAL INVESTIGATOR : ..... Dr. P. Gaszner.....

<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>
49	P	61	D
50	P	62	R
51	D	63	R
52	R	64	P
53	R	65	P
54	D	66	D
55	D	67	D
56	P	68	P
57	P	69	R
58	R	70	D
59	R	71	R
60	D	72	P

R = REBOXETINE  
2 mg Batch N° 893

D = DESIPRAMINE

P = PLACEBO  
Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

4

107

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : ...Psychiatric Clinic - University of Trieste.....

PRINCIPAL INVESTIGATOR : ...Prof.: E. Aguglia.....

<u>PATIENT N°</u>	<u>TREATMENT</u>		<u>PATIENT N°</u>	<u>TREATMENT</u>
73	P		85	P
74	R		86	R
75	P		87	P
76	R		88	D
77	D		89	R
78	D		90	D
79	P		91	D
80	P		92	R
81	R		93	R
82	R		94	P
83	D		95	D
84	D		96	P

R = REBOXETINE  
2 mg Batch N° 893

D = DESIPRAMINE

P = PLACEBO  
Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

5

108

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : ..... Psychiatric Clinic, University of Catania

PRINCIPAL INVESTIGATOR : ..... Prof. Rapisarda

<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>
97	R	109	P
98	D	110	D
99	P	111	R
100	R	112	R
101	P	113	D
102	D	114	P
103	D	115	P
104	R	116	R
105	R	117	R
106	D	118	D
107	P	119	D
108	P	120	P

R = REBOXETINE  
2 mg Batch N° 893

D = DESIPRAMINE

P = PLACEBO  
Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

7

110

REBOXETINE

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : National Institute of Neurology, Acapulco

Dr. Comas Vinas

PRINCIPAL INVESTIGATOR :

<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>
145	R	157	P
146	P	158	P
147	D	159	D
148	D	160	R
149	P	161	D
150	R	162	R
151	R	163	R
152	R	164	D
153	D	165	D
154	P	166	R
155	D	167	P
156	P	168	P

R = REBOXETINE  
2 mg Batch N° 893

D = DESIPRAMINE

P = PLACEBO  
Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

8

111

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : .National.Psychiatric.Hospital,.Panama.City

PRINCIPAL INVESTIGATOR : ...Dr.:L.Vergara.....

<u>PATIENT N°</u>	<u>TREATMENT</u>		<u>PATIENT N°</u>	<u>TREATMENT</u>
169	P		181	D
170	D		182	R
171	P		183	R
172	D		184	P
173	R		185	P
174	R		186	D
175	R		187	D
176	P		188	D
177	P		189	P
178	R		190	R
179	D		191	R
180	D		192	P

R = REBOXETINE

D = DESIPRAMINE

P = PLACEBO

2 mg Batch N° 893

Batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

9

112

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

National Psychiatric Hospital, Panama City

CENTER: .....

Dr. R. Batista

PRINCIPAL INVESTIGATOR : .....

<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>
193	D	205	R	250	C
194	P	206	D	251	B
195	R	207	R	252	C
196	R	208	P	253	C
197	D	209	P	254	B
198	P	210	D	255	B
199	P	211	P	256	C
200	P	212	R	257	A
201	R	213	R	258	A
202	D	214	D		
203	D	215	P		
204	R	216	D		

R = REBOXETINE  
2mg Batch 893

D = DESIPRAMINE

P = PLACEBO  
batch N° 892

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

10

113

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

CENTER : .Biological.Psychiatric.Laboratory..Lima..

PRINCIPAL INVESTIGATOR : ....Dr.:A.:Castillo.....

<u>PATIENT N°</u>	<u>TREATMENT</u>		<u>PATIENT N°</u>	<u>TREATMENT</u>
217	P		229	R
218	D		230	D
219	D		231	P
220	R		232	P
221	R		233	D
222	P		234	R
223	P		235	P
224	P		236	R
225	R		237	D
226	D		238	D
227	D		239	R
228	R		240	P

R = REBOXETINE

D = DESIPRAMINE

P = PLACEBO

2 mg Batch N° 893

Batch N° 832

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

11

114

R E B O X E T I N E

PROTOCOL ADE 008

RANDOMIZATION CODE

National Psychiatric Hospital, Panama City  
CENTER: .....  
Dr. L. Vergara  
PRINCIPAL INVESTIGATOR : .....

<u>PATIENT N°</u>	<u>TREATMENT</u>	<u>PATIENT N°</u>	<u>TREATMENT</u>
241	R	259	A
242	R	260	B
243	D	261	C
244	R	262	B
245	D	263	A
246	p	264	C
247	p	265	C
248	p	266	C
249	D	267	A
		268	B
		269	B
		270	A
		271	A
		272	C
		273	B

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08  
Table 0 - Not evaluable patients and reason for it  
Treatment group "A"

Pt. n°	Experimental treatment	Experimental treatment		Not Evaluable due to:
		From m d y	To m d y	
25 n.e.		05.02.88	05.29.88	continuous associated treatment with nitrazepam/ gluthethimide
34 n.e.		10.11.88	11.07.88	continuous associated treatment with diazepam / nitrazepam
48 n.e.		09.30.88	10.27.88	continuous associated treatment with nitrazepam/ thioridazine
109 n.e.		09.17.88	09.22.88	self-discharge from the hospital at day 6; no assessments after day 4.

Total No of Patients : 4

Total No of Patients with adverse events : 1 (dry mouth)

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

2

REBOXETINE, Protocol ADE 08  
Table 0 - Not evaluable patients and reason for it  
Treatment group "B"

Pt. n°	Experimental treatment		Not Evaluable due to:
	From m d y	To m d y	
29 n.e.	05.17.88	05.26.88	continuous associated treatment with meprobamate
31 n.e.	10.12.88	11.08.88	continuous associated treatment with nitrazepam/ meprobamate
32 n.e.	08.04.88	09.20.88	continuous associated treatment with meprobamate
41 n.e.	10.19.88	11.15.88	continuous associated treatment with meprobamate/thioridazine/- nitrazepam
44 n.e.	08.16.88	09.12.88	continuous associated treatment with gluthethimide/diazepam
47 n.e.	10.19.88	11.16.88	continuous associated treatment with meprobamate/gluthethimide

Total No of Patients : 6

Patients with adverse events : 1 ( extrasystoles )

FCE 20124/702 i

3

REBOXETINE, Protocol ADE 08  
Table 0 - Not evaluable patients and reason for it  
Treatment group "C"

Pt. n°	Experimental treatment		Not Evaluable due to:
	From m d y	To m d y	
7 n.e.	09.20.88	05.30.88	self discharge from the hospital at day 6; no assessments after day 4.
27 n.e.	05.03.88	05.30.88	continuous associated treatment with clozapine
40 n.e.	04.19.88	05.16.88	continuous associated treatment with hexobarbital/chlordiazepoxide
43 n.e.	02.16.88	03.14.88	continuous associated treatment with clozapine

Total No of Patients : 4

Total No of Patients with adverse events : none

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

1

Table 1 - Demographic Data

Treatment Group "A"

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
001	01	SE	40	m	93	183	04-08-88
005	01	AN	51	f	60	164	05-30-88
009	01	GP	35	m	75	172	10-11-88
012	01	EV	43	f	53	161	10-21-88
013	01	MJ	31	m	59	180	11-04-88
014	01	HB	49	m	87	180	11-07-88
025	02	NA	41	f	62	166	01-17-89
030	02	ZJ	62	f	60	167	08-05-88
034	02	VS	53	f	56	160	01-16-89
035	02	KO	60	m	68	178	10-06-88
037	02	SS	49	f	62	162	09-16-88
038	02	RT	27	m	70	178	08-22-88
045	02	RK	64	f	56	158	10-01-88
048	02	BR	46	f	64	166	01-19-89
049	03	SF	42	f	58	158	08-09-87
050	03	NF	29	f	55	162	03-16-88
056	03	BM	46	m	85	184	03-11-88
057	03	MK	30	f	51	163	05-09-88
064	03	TF	53	f	60	160	04-06-88
065	03	SF	49	f	84	171	04-27-88
068	03	SM	25	f	45	161	05-12-88
072	03	MG	44	m	69	174	05-18-88
073	04	PM	65	m	85	182	01-12-88
075	04	TF	57	m	82	176	01-17-88
079	04	VL	52	m	59	172	03-26-88
080	04	LL	52	f	66	165	03-30-88
085	04	MS	58	f	64	155	07-08-88
087	04	PE	64	f	68	162	08-15-88
094	04	GR	65	m	80	175	01-04-89
096	04	CG	56	m	81	170	01-12-89
099	05	RL	49	f	90	156	03-23-88
101	05	CS	44	f	77	160	04-14-88
107	05	SM	38	f	56	152	06-20-88
108	05	CR	61	f	44	163	06-20-88
109	05	CA	49	f	65	158	11-21-88
114	05	RF	63	f	86	162	10-31-88
115	05	MA	39	m	52	163	11-02-88
120	05	LL	43	f	65	153	09-27-88
122	06	RC	21	f	55	154	05-25-88
123	06	OF	34	f	52	153	06-13-88
130	06	RV	34	f	45	148	08-05-88
131	06	LP	45	f	80	156	10-02-88
134	06	VL	28	f	53	164	11-14-88
135	06	CM	44	f	49	134	11-18-88
142	06	MC	19	f	63	160	02-14-89
146	07	DN	46	m	74	161	05-11-88
169	08	JC	56	f	61	166	09-27-87

FCE 20124/702 i

2

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
171	08	TH	55	m	74	167	09-26-87
176	08	LM	55	f	78	168	10-27-87
177	08	MC	58	m	68	166	12-27-87
184	08	CA	55	m	64	167	03-10-88
185	08	DB	60	m	74	168	02-27-88
189	08	CR	48	m	78	170	03-02-88
192	08	NS	49	f	60	165	03-10-88
244	08	MH	55	f	60	165	08-04-88
246	08	CS	52	m	60	166	08-03-88
247	08	MM	57	f	55	164	07-20-88
248	08	AH	60	m	66	168	09-12-88
259	08	WP	51	f	59	166	09-27-88
263	08	YL	49	f	58	166	10-18-88
267	08	PG	40	m	72	165	09-24-88
270	08	JR	48	f	65	155	09-22-88
271	08	GM	24	m	63	173	10-03-88
194	09	AB	45	m	63	158	08-25-87
198	09	NH	45	m	67	163	10-19-87
199	09	DE	55	f	76	162	10-16-87
200	09	RB	54	m	74	162	10-16-87
208	09	EB	38	m	83	169	03-15-88
209	09	MC	45	f	65	161	03-13-88
211	09	EO	44	f	73	158	04-18-88
215	09	RA	54	f	58	158	03-15-88
257	09	SM	41	f	60	158	07-10-88
258	09	LB	50	m	77	156	08-12-88
217	10	AF	29	f	57	150	03-07-88
222	10	SM	29	f	56	061	04-05-88
223	10	BV	59	f	71	153	04-16-88
224	10	GF	23	f	47	162	05-04-88
231	10	JV	53	m	76	163	08-05-88
232	10	GC	39	f	39	145	08-25-88
235	10	JH	51	f	51	154	10-17-88
240	10	BO	35	f	55	150	11-23-88

Summary:

Total No. of cases 81

Sex: females 51 males 30

Age: minimum 19 maximum 65 mean 46.37 yrs

Weight: minimum 39 maximum 93 mean 65.26 kgs

119

FCE 20124/702 i

3

REBOXETINE, Protocol ADE 08

Table 1 - Demographic Data

Treatment Group "B"

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
002	01	JA	39	f	50	160	03-24-88
004	01	BA	44	f	80	155	04-22-88
010	01	SP	34	f	58	158	06-15-88
011	01	CE	37	f	49	157	10-19-88
015	01	TH	54	f	49	155	11-08-88
017	01	PO	60	f	70	163	11-22-88
028	02	MF	60	f	70	161	06-08-88
029	02	PV	55	f	66	165	01-19-89
031	02	AI	23	m	62	174	01-17-89
032	02	LE	27	f	55	162	01-13-89
041	02	AK	40	f	68	172	01-16-89
042	02	SP	46	f	63	168	10-14-88
044	02	VI	45	f	67	168	01-17-89
047	02	SL	43	m	59	165	01-19-89
051	03	HT	64	f	46	158	02-13-88
054	03	TA	39	m	96	188	04-02-88
055	03	LL	43	m	89	192	04-26-88
060	03	BB	32	f	62	161	04-08-88
061	03	BF	29	f	52	159	05-29-88
066	03	CL	55	f	81	164	03-11-88
067	03	ZM	31	f	67	163	02-25-88
070	03	BL	41	f	58	159	05-18-88
077	04	KR	50	f	76	167	03-12-88
078	04	SF	56	m	68	175	03-21-88
083	04	PB	65	f	89	170	05-27-88
084	04	PL	56	f	76	165	06-01-88
088	04	SE	65	f	52	167	10-31-88
090	04	CA	46	f	75	165	12-12-88
091	04	RF	42	m	72	175	12-14-88
095	04	FG	36	m	78	180	01-12-89
098	05	DS	53	f	54	155	02-06-88
102	05	DN	57	m	51	155	04-19-88
103	05	LR	53	m	63	155	04-27-88
106	05	AM	38	f	63	160	05-20-88
110	05	DG	43	f	48	155	09-17-88
113	05	RV	45	f	84	164	10-29-88
118	05	PG	64	m	56	162	11-30-88
119	05	SG	53	m	68	170	11-25-88
124	06	YM	39	f	61	153	06-15-88
126	06	MC	41	f	48	153	07-26-88
127	06	TV	36	f	56	155	08-01-88
132	06	ML	48	m	67	167	10-11-88
133	06	MR	42	f	73	160	10-22-88
136	06	FT	38	m	83	180	11-23-88
139	06	CP	35	f	58	153	01-10-89
140	06	SA	27	m	50	165	01-03-89
147	07	SS	29	f	47	158	07-07-88
148	07	PG	29	m	59	150	07-15-88



FCE 20124/702 i

4

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
170	08	DD	58	m	70	165	09-28-87
172	08	NA	59	m	74	167	10-21-87
179	08	AM	60	m	71	168	01-06-88
180	08	AP	57	f	69	167	01-07-88
181	08	ER	39	m	72	166	02-22-88
186	08	AD	41	m	73	167	02-26-88
187	08	MM	56	m	63	166	03-15-88
188	08	EO	49	m	59	164	03-20-88
243	08	JA	54	m	70	168	08-03-88
245	08	EE	49	m	60	167	08-02-88
249	08	MR	54	f	58	167	10-02-88
260	08	JG	49	f	60	168	10-05-88
262	08	IP	60	m	78	072	09-13-88
268	08	LT	21	f	57	162	10-03-88
269	08	EC	22	m	80	170	09-13-88
273	08	EC	36	f	57	161	09-19-88
193	09	AO	52	f	68	155	09-25-87
197	09	NE	48	m	72	165	10-03-87
202	09	GG	55	f	62	158	01-27-88
203	09	AR	48	m	79	162	01-29-88
206	09	PC	46	f	56	158	03-28-88
210	09	TT	42	m	63	168	03-28-88
214	09	CF	46	f	62	161	03-28-88
216	09	JI	44	m	79	168	03-18-88
251	09	EP	52	f	63	168	08-08-88
254	09	PG	39	f	64	161	07-12-88
255	09	LG	36	m	68	062	07-15-88
218	10	JH	24	f	47	155	03-21-88
219	10	MA	22	f	56	152	03-21-88
226	10	PG	49	f	75	153	06-20-88
227	10	AC	36	f	51	155	06-27-88
230	10	EA	62	f	48	153	08-02-88
233	10	PE	60	m	66	162	08-29-88
237	10	RV	55	m	74	163	11-14-88
238	10	MM	68	f	53	155	11-17-88

Summary:

Total No. of cases 83

Sex: females 50 males 33

Age: minimum 21 maximum 68 mean 45.48 yrs

Weight: minimum 46 maximum 96 mean 64.69 kgs

FCE 20124/702 i

5

REBOXETINE, Protocol ADE 08

Table 1 - Demographic Data

Treatment Group "C"

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
003	01	RO	37	f	52	157	03-14-88
006	01	WS	23	f	53	165	08-11-88
007	01	BO	36	m	63	170	08-28-88
008	01	DO	39	m	77	184	09-20-88
016	01	AJ	57	m	66	165	11-16-88
018	01	MR	20	m	65	179	12-09-88
026	02	SK	42	m	72	175	10-06-88
027	02	CM	56	f	63	164	01-19-89
033	02	SM	41	f	54	159	08-11-88
036	02	MT	63	m	70	176	09-03-88
039	02	SI	32	f	52	161	10-03-88
040	02	MT	38	m	76	168	01-12-89
043	02	GF	31	f	64	166	01-13-89
046	02	NI	46	m	77	178	09-04-88
052	03	CK	53	f	66	173	02-17-88
053	03	VS	39	m	85	180	03-14-88
058	03	FF	51	f	54	158	04-25-88
059	03	BR	62	m	71	179	04-18-88
062	03	CZ	35	f	72	161	05-16-88
063	03	CZ	36	f	61	162	05-09-88
069	03	CK	45	f	47	158	05-23-88
071	03	SF	56	f	89	171	05-24-88
074	04	TE	63	f	53	164	01-19-88
076	04	FP	53	m	64	169	03-09-88
081	04	BS	49	f	72	168	05-16-88
082	04	MT	56	m	93	175	05-30-88
086	04	SO	56	m	74	175	08-01-88
089	04	TP	63	f	63	160	11-28-88
092	04	TY	46	f	63	160	01-01-89
093	04	DH	65	f	67	162	12-21-88
097	05	PC	34	m	69	175	01-13-88
100	05	AF	65	f	59	156	04-12-88
104	05	MG	32	f	61	160	05-06-88
105	05	HP	58	m	68	160	05-18-88
111	05	DS	57	m	68	169	09-30-88
112	05	AR	42	m	80	175	10-10-88
116	05	LS	61	f	56	159	10-31-88
117	05	DO	65	m	47	168	21-19-88
121	06	IO	62	f	69	158	04-12-88
125	06	AD	25	m	60	165	07-14-88
128	06	EZ	56	f	66	158	08-08-88
129	06	JG	40	f	54	158	08-09-88
137	06	EG	24	f	55	156	11-30-88
138	06	AR	61	f	62	156	12-20-88
141	06	SE	34	m	62	173	-
145	07	JT	46	f	67	163	05-03-88
173	08	LR	58	m	77	160	10-24-87

FCE 20124/702 i

6

Pat. No.	Ctr. No.	Pat. Init.	Age (yrs)	Sex	Weight (kg)	Height (cm)	Date of Hospitalization
174	08	AC	53	m	73	158	10-23-87
175	08	VM	52	f	66	165	10-29-87
178	08	DM	61	m	71	168	01-10-88
182	08	EM	57	m	71	167	03-11-88
183	08	LL	31	f	65	165	05-21-88
190	08	NA	60	f	70	167	02-28-88
191	08	FR	55	m	56	164	03-12-88
195	09	AT	47	m	66	168	08-28-87
196	09	RC	35	f	59	164	10-05-87
201	09	CS	52	f	79	168	01-28-88
204	09	JJ	60	m	80	165	01-29-88
205	09	DV	56	f	80	168	02-27-88
207	09	CC	42	m	66	166	03-20-88
212	09	LF	60	m	64	162	03-08-88
213	09	NS	45	m	80	168	03-22-88
220	10	BS	46	f	63	153	03-24-88
221	10	CL	57	f	48	152	03-02-88
225	10	HR	24	m	52	161	06-07-88
228	10	MY	43	f	48	145	06-28-88
229	10	JT	31	f	50	159	08-02-88
234	10	JC	47	m	52	160	09-27-88
236	10	FL	47	m	64	159	11-11-88
239	10	JB	43	f	53	147	11-21-88
241	08	JP	58	m	64	165	07-28-88
242	08	ME	51	m	64	168	08-03-88
250	09	AC	40	m	80	179	07-15-88
252	09	JL	54	m	79	169	08-01-88
253	09	CM	48	m	67	170	08-12-88
256	09	MT	32	m	66	164	07- -88
261	08	LT	53	m	77	169	10-07-88
264	08	RB	48	m	79	173	11-02-88
265	08	BS	58	m	80	172	11-05-88
266	08	MC	58	f	60	166	11-07-88
272	08	SB	24	f	62	164	09-20-88

Summary:

Total No. of cases 81

Sex: females 39 males 42

Age: minimum 20 maximum 65 mean 47.37 yrs

Weight: minimum 47 maximum 93 mean 65.83 kgs

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 2a \_Patient Diagnosis and history of the Mental Disorder

Treatment Group "A"

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
1	29622	.03	0	.00
5	29632	.05	3	.00
9	29630	.04	4	.00
12	29634	.08	.	1.00
13	29633	.50	6	6.00
14	29632	.50	1	6.00
25	2963X	.12	3	.10
30	29631	.04	8	.15
34	2963X	.08	5	.00
35	2963X	.02	10	.00
37	2963X	.06	7	.00
38	2963X	.08	2	.00
45	2963X	.06	11	.00
48	2963X	.06	5	.00
49	2963X	.67	2	8.00
50	2963X	.29	4	3.00
56	2963X	.17	4	2.00
57	2963X	.10	1	1.00
64	2963X	.42	2	5.12
65	2963X	.29	8	3.00
68	2963X	.14	2	1.00
72	2963X	.37	5	4.00
73	2963X	.12	5	1.00
75	2963X	.17	2	2.00
79	2962X	.42	0	5.00
80	2963X	.08	1	1.00
85	2963X	1.00	2	.00
87	2963X	.12	6	.00
94	2963X	.25	3	3.00
96	2963X	.25	2	3.08
99	29632	.25	16	3.00
101	29632	.25	1	3.00
107	29633	.67	6	8.00
108	29632	.12	10	.13
109	29634	.67	10	8.00
114	29633	.25	8	3.00
115	29633	.08	2	1.06
120	29622	.50	0	6.00
122	29623	1.00	0	.00
123	29632	.17	1	2.00
130	29623	1.00	0	.00
131	29622	1.50	0	18.00
134	29633	.25	3	3.00
135	2962X	4.00	0	.00
142	29622	.08	0	1.00
146	2962X	.08	.	.
169	2963X	.33	6	4.00

FCE 20124/702 i

2

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
171	2963X	.33	6	4.00
176	2963X	.33	5	4.00
177	2963X	.33	5	4.00
184	2963X	.33	7	4.00
185	2963X	.42	7	5.00
189	2963X	.33	6	4.00
192	2963X	.33	6	4.00
194	2963X	.25	4	3.00
198	2963X	.25	2	3.00
199	2963X	.25	5	3.00
200	2963X	.04	6	.00
208	2963X	.29	5	3.00
209	2963X	.31	6	3.00
211	2963X	.25	2	3.00
215	2963X	.33	6	4.00
217	2962X	.42	0	5.00
222	29623	.33	0	4.00
223	2963X	.29	1	3.00
224	2962X	.33	0	4.00
231	2962X	.67	0	8.00
232	2962X	1.00	0	12.00
235	2962x	.25	0	3.00
240	2963X	.25	15	3.00
244	2963X	.25	5	3.00
246	2963X	.25	6	3.00
247	2963X	.33	5	4.00
248	2963X	.33	6	4.00
257	2963X	.29	4	3.00
258	2963X	.22	2	2.00
259	2963X	.25	4	3.00
263	2963X	.25	4	3.00
267	2963X	.25	3	3.00
270	2963X	.25	4	3.00
271	2963X	.22	5	2.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3

REBOXETINE, Protocol ADE 08

Table 2a - Patient Diagnosis and history of the Mental Disorder

Treatment Group "B"

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
2	29632	.06	2	.
4	29632	.10	3	.00
10	29632	.01	3	.10
11	29632	.06	4	.08
15	29630	.17	1	2.06
17	29630	.12	4	.00
28	29630	.08	7	.00
29	2963X	.08	5	1.12
31	2963X	.04	1	.12
32	2963X	.05	1	.12
41	2963X	.06	3	.00
42	2963X	.12	7	.00
44	2963X	.04	3	.13
47	2963X	.06	6	.00
51	2963X	.21	2	2.00
54	2963X	.12	3	1.00
55	2963X	.12	1	1.00
60	2963X	.08	7	1.00
61	2963X	.14	8	1.00
66	2963X	.25	4	3.00
67	2963X	.17	4	2.00
70	2963X	.12	3	1.00
77	2963X	.15	15	.00
78	2963X	.12	1	.00
83	2963X	.08	4	1.00
84	2963X	.17	7	2.00
88	2963X	.17	12	2.00
90	2963X	.75	4	9.00
91	2963X	.17	3	2.00
95	2963X	.17	1	2.00
98	29633	.08	12	1.00
102	29632	.42	3	5.00
103	29632	.17	3	2.00
106	29632	.17	3	2.08
110	29632	.17	2	2.00
113	29632	.08	2	1.00
118	29632	.25	16	3.00
119	29632	.25	8	3.08
124	29623	1.17	0	14.00
126	29623	7.00	0	.00
127	29623	4.00	0	.00
132	29633	.08	1	1.00

FCE 20124/702 i

4

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
133	29633	.17	2	2.00
136	29623	3.00	0	.00
139	29633	3.00	1	.00
140	29622	.25	0	3.00
147	29622	.12	.	.
148	2962X	.17	.	.
170	2963X	.25	6	3.00
172	2963X	.33	7	4.00
179	2963X	.25	6	3.00
180	2963X	.33	7	4.00
181	2962X	.33	0	4.00
186	2963X	.33	3	4.00
187	2963X	.42	6	5.00
188	2963X	.33	5	4.00
193	2963X	.33	4	4.00
197	2963X	.25	3	3.00
202	2963X	.25	4	3.00
203	2963X	.25	3	3.00
206	2963X	.25	4	3.00
210	2963X	.25	5	3.00
214	2963X	.25	5	3.00
216	2963X	.29	6	3.00
218	2962X	2.00	0	.00
219	2962X	.58	0	7.00
226	2963X	.25	1	3.00
227	2962X	2.00	0	.17
230	2962X	2.42	0	29.00
233	2962X	.67	0	8.00
237	2963X	.08	3	.08
238	2963X	.17	2	2.10
243	2963X	.25	4	3.00
245	2963X	.67	6	8.00
249	2963X	.25	5	3.00
251	2963X	.21	3	2.00
254	2963X	.29	3	3.00
255	2963X	.29	4	3.00
260	2963X	.17	4	2.00
262	2963X	.25	6	3.00
268	2963X	.22	5	2.00
269	2963X	.27	2	3.00
273	2963X	.27	3	3.00

FCE 20124/702 i

5

REBOXETINE, Protocol ADE 08

Table 2a-Patient Diagnosis and history of the Mental Disorder

Treatment Group "C"

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
3	29632	.33	2	4.00
6	29632	.03	5	.00
7	29622	.17	0	2.00
8	29630	.08	3	.00
16	29633	.04	1	.00
18	29622	.17	0	2.00
26	2963X	.04	5	.00
27	2963X	.04	6	.23
33	2963X	.08	6	.00
36	2963X	.17	4	2.00
39	2963X	.04	2	.00
40	2963X	.06	4	.00
43	2963X	.04	5	.08
46	2963X	.06	8	.00
52	2963X	.06	4	.00
53	2963X	.31	2	3.00
58	2963X	.21	2	2.00
59	2963X	.42	1	5.00
62	2963X	.14	4	1.00
63	2963X	.12	3	1.00
69	2963X	.14	5	1.00
71	2963X	.14	5	1.00
74	2963X	.42	1	5.00
76	2963X	.08	3	1.00
81	2963X	.08	4	1.00
82	2963X	.33	6	4.00
86	2963X	.17	3	2.00
89	2963X	.17	4	2.00
92	2963X	.08	9	1.00
93	2963X	.17	4	2.00
97	29622	.33	0	4.00
100	29632	.33	4	4.00
104	29633	.25	4	3.00
105	29622	.58	0	7.00
111	29623	.42	0	5.00
112	29633	.25	2	3.00
116	29633	.33	5	4.00
117	29632	.42	12	5.00
121	29632	.25	2	3.00
125	29623	.92	0	11.00
128	2962X	10.00	0	.00
129	29623	.67	0	8.00

128

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

6

Pat. No.	DSM-III diagnosis	Duration (yrs)	No. of previous episodes	Duration of last episode (months)
137	29623	.12	0	1.00
138	29633	1.00	2	.08
141	29623	1.00	0	.00
145	2963X	.92	2	11.08
173	2963X	.33	6	4.00
174	2963X	.25	5	3.00
175	2963X	.25	5	3.00
178	2963X	.42	6	5.00
182	2963X	.33	5	4.00
183	2962X	.33	0	4.00
190	2963X	.42	7	5.00
191	2963X	.33	5	4.00
195	2963X	.33	3	4.00
196	2963X	.22	5	2.00
201	2963X	.25	5	3.00
204	2963X	.25	3	3.00
205	2963X	.33	7	4.00
207	2963X	.25	5	3.00
212	2963X	.31	5	3.00
213	2963X	.25	6	3.00
220	29623	6.00	0	.00
221	2962X	2.00	0	.00
225	2962X	.50	0	6.00
228	2962X	2.00	0	.17
229	2962X	1.42	0	17.00
234	2963X	.33	2	4.06
236	2962X	2.00	0	.00
239	2963X	.17	2	2.00
241	2963X	.25	5	3.00
242	2963X	.33	5	4.00
250	2963X	.27	4	3.00
252	2963X	.22	3	2.00
253	2963X	.21	4	2.00
256	2963X	.22	2	2.00
261	2963X	.17	5	2.00
264	2963X	.17	4	2.00
265	2963X	.17	5	2.00
266	2963X	.25	6	3.00
272	2963X	.27	4	3.00

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 2b - Patient Diagnosis and history of the Mental Disorder

Treatment Group "A"

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress	Total HAMD at admission
				yes / no	
1	.03	F	S	N	21
5	.05	R	I	N	23
9	.04	E	I	Y	19
12	.08	R	S	Y	28
13	.50	R	I	N	23
14	.50	E	I	N	21
25	.12	R	S	N	22
30	.04	R	S	N	33
34	.08	R	S	N	17
35	.02	R	A	N	28
37	.06	R	S	N	26
38	.08	R	S	N	25
45	.06	R	S	N	25
48	.06	R	S	N	20
49	.67	R	I	N	24
50	.29	R	S	Y	29
56	.17	R	S	N	22
57	.10	R	S	Y	26
64	.42	R	S	Y	29
65	.29	R	S	N	24
68	.14	R	S	Y	30
72	.37	R	I	Y	18
73	.12	R	S	N	30
75	.17	R	S	N	32
79	.42	F	A	Y	33
80	.08	E	A	N	22
85	1.00	R	A	N	23
87	.12	R	S	N	23
94	.25	R	A	N	27
96	.25	R	A	N	24
99	.25	E	I	Y	23
101	.25	R	I	N	24
107	.67	R	I	Y	30
108	.12	R	S	Y	25
109	.67	R	I	N	26
114	.25	R	S	N	35
115	.08	R	I	N	31
120	.50	F	I	Y	30
122	1.00	E	I	Y	27
123	.17	R	A	N	25
130	1.00	F	S	N	31
131	1.50	E	I	N	30
134	.25	E	I	Y	29
135	4.00	E	A	Y	26
142	.08	F	A	N	24
146	.08	F	A	N	25
169	.33	R	I	Y	28

FCE 20124/702 i

2

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress	Total HAMD at admission
				yes / no	
171	.33	R	I	N	30
176	.33	R	I	N	28
177	.33	R	I	N	27
184	.33	R	I	N	27
185	.42	R	I	N	28
189	.33	R	I	Y	27
192	.33	R	I	N	25
194	.25	R	I	N	30
198	.25	R	I	N	28
199	.25	R	I	N	30
200	.04	R	S	N	25
208	.29	R	I	Y	30
209	.31	R	I	Y	29
211	.25	R	I	N	28
215	.33	R	I	N	39
217	.42	F	I	Y	26
222	.33	F	S	N	25
223	.29	R	I	N	36
224	.33	D	I	Y	18
231	.67	F	A	Y	27
232	1.00	F	I	Y	24
235	.25	D	A	Y	28
240	.25	R	A	Y	22
244	.25	R	I	N	25
246	.25	R	I	N	24
247	.33	R	I	N	20
248	.33	R	I	N	27
257	.29	R	I	N	25
258	.22	R	I	N	28
259	.25	R	I	N	25
263	.25	R	I	Y	25
267	.25	R	I	N	21
270	.25	R	I	N	24
271	.22	R	I	N	24

\* E = exacerbation      R = recurrence  
D = different from previous condition  
F = first occurrence  
\*\* A = acute              S = subacute      I = insidious

FCE 20124/702 i

3

REBOXETINE, Protocol ADE 08

Table 2b - Patient Diagnosis and history of the Mental Disorder

Treatment Group "B"

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress	Total HAMD at admission
				yes / no	
2	.06	R	I	N	21
4	.10	E	S	N	22
10	.01	R	S	Y	22
11	.06	R	I	N	25
15	.17	R	S	Y	29
17	.12	R	S	N	29
28	.08	R	S	N	29
29	.08	R	S	N	22
31	.04	R	S	N	20
32	.05	R	S	N	18
41	.06	R	S	N	22
42	.12	R	S	N	30
44	.04	R	S	N	26
47	.06	R	S	N	20
51	.21	R	S	N	28
54	.12	R	S	Y	22
55	.12	R	S	Y	21
60	.08	R	S	Y	22
61	.14	R	S	Y	20
66	.25	R	S	Y	26
67	.17	R	S	Y	24
70	.12	R	S	Y	26
77	.15	E	S	N	28
78	.12	R	S	N	31
83	.08	R	A	N	23
84	.17	R	A	N	25
88	.17	R	A	N	29
90	.75	R	S	N	21
91	.17	E	A	N	24
95	.17	R	A	N	23
98	.08	R	A	Y	25
102	.42	R	I	Y	24
103	.17	R	S	Y	22
106	.17	R	S	Y	35
110	.17	R	S	N	27
113	.08	R	S	Y	26
118	.25	R	I	N	25
119	.25	R	I	N	27
124	1.17	F	S	Y	33
126	7.00	E	A	Y	28
127	4.00	E	S	Y	30

132

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

4

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress	Total HAMD at admission
				yes / no	
132	.08	R	A	Y	32
133	.17	E	A	Y	36
136	3.00	E	I	N	37
139	3.00	E	I	Y	39
140	.25	F	A	Y	27
147	.12	F	A	N	34
148	.17	F	S	Y	32
170	.25	R	I	N	28
172	.33	R	I	N	28
179	.25	R	I	Y	26
180	.33	R	I	N	26
181	.33	F	S	Y	29
186	.33	R	I	Y	29
187	.42	R	I	N	25
188	.33	R	I	N	26
193	.33	R	I	N	29
197	.25	R	I	N	28
202	.25	R	I	N	25
203	.25	R	I	N	34
206	.25	R	I	Y	32
210	.25	R	I	N	28
214	.25	R	I	N	30
216	.29	R	I	N	28
218	2.00	F	I	Y	22
219	.58	D	S	Y	30
226	.25	R	I	Y	30
227	2.00	F	I	Y	25
230	2.42	F	S	Y	31
233	.67	F	S	Y	28
237	.08	R	A	Y	33
238	.17	R	A	Y	23
243	.25	R	I	N	24
245	.67	R	I	N	27
249	.25	R	I	N	20
251	.21	R	I	N	21
254	.29	R	I	N	23
255	.29	R	I	N	24
260	.17	R	I	N	23
262	.25	R	I	N	24
268	.22	R	I	N	21
269	.27	R	I	N	34
273	.27	R	I	Y	26

\* E = exacerbation R = recurrence  
D = different from previous condition  
F = first occurrence

\*\* A = acute S = subacute I = insidious

FCE 20124/702 i

5

REBOXETINE, Protocol ADE 08

Table 2b - Patient Diagnosis and history of the Mental Disorder  
Treatment Group "C"

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress yes / no	Total HAMD at admission
3	.33	R	I	N	22
6	.03	R	S	Y	31
7	.17	D	S	Y	22
8	.08	E	S	N	17
16	.04	R	S	N	27
18	.17	F	S	N	17
26	.04	R	S	N	21
27	.04	R	S	N	19
33	.08	R	S	N	34
36	.17	R	S	N	30
39	.04	R	S	N	21
40	.06	R	S	N	18
43	.04	R	S	N	21
46	.06	R	S	N	32
52	.06	R	S	N	23
53	.31	R	S	N	23
58	.21	R	S	Y	25
59	.42	R	I	Y	32
62	.14	R	S	Y	23
63	.12	R	S	Y	20
69	.14	R	S	Y	21
71	.14	R	S	Y	22
74	.42	R	S	N	29
76	.08	R	A	N	23
81	.08	E	A	N	27
82	.33	E	A	N	32
86	.17	R	A	N	30
89	.17	R	S	N	19
92	.08	R	A	N	23
93	.17	R	A	N	33
97	.33	F	S	Y	30
100	.33	R	I	N	27
104	.25	R	A	Y	32
105	.58	F	I	Y	31
111	.42	F	I	Y	37
112	.25	R	I	Y	35
116	.33	R	A	N	36
117	.42	R	I	N	20
121	.25	E	S	Y	31
125	.92	F	A	N	35

134

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

6

Pat. No.	Duration (yrs)	Characteristics*	Onset**	Precipitating stress	Total HAMD at admission
				yes / no	
128	10.00	E	I	N	24
129	.67	F	A	N	38
137	.12	F	A	Y	30
138	1.00	R	I	N	37
141	1.00	F	I	N	33
145	.92	R	A	N	29
173	.33	R	I	Y	27
174	.25	R	I	Y	29
175	.25	R	I	Y	27
178	.42	R	I	N	27
182	.33	R	I	N	27
183	.33	F	S	Y	29
190	.42	R	I	N	26
191	.33	R	I	N	30
195	.33	R	I	N	34
196	.22	R	I	N	25
201	.25	R	I	N	33
204	.25	R	I	N	27
205	.33	R	I	Y	27
207	.25	R	I	Y	31
212	.31	R	I	N	34
213	.25	R	I	N	37
220	6.00	D	I	Y	24
221	2.00	D	I	Y	30
225	.50	F	S	Y	26
228	2.00	F	S	Y	36
229	1.42	F	I	Y	23
234	.33	R	A	Y	34
236	2.00	F	I	Y	30
239	.17	R	S	Y	30
241	.25	R	I	N	25
242	.33	R	I	N	24
250	.27	R	I	N	25
252	.22	R	I	N	22
253	.21	R	I	N	30
256	.22	R	I	N	23
261	.17	R	I	N	23
264	.17	R	I	N	24
265	.17	R	I	N	22
266	.25	R	I	N	22
272	.27	R	I	N	29

\* E = exacerbation R = recurrence  
D = different from previous condition  
F = first occurrence

\*\* A = acute S = subacute I = insidious

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

1

Table 3 - Previous antidepressant treatment

Treatment Group "A"

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
1	NONE	.	
5	BROMAZEPAM	3	NONE
9	MEPROBAMATE	1	NONE
12	PIPAMPERONE	1	NONE
	CLORAZEPATE	1	NONE
	TEMAZEPAM	1	NONE
13	NONE	.	
14	VILOXAZINE	2	NONE
25	MAPROTILINE	0	NONE
	THIORIDAZINE	0	NONE
30	NOVERIL	0	NONE
34	MAPROTILINE	0	NONE
34	THIORIDAZINE	0	NONE
35	MAPROTILINE	0	NONE
	AMITRIPTYLINE	0	NONE
37	LUDIOMIL	0	NONE
	MELIPRAMIN	0	NONE
38	MAPROTILINE	0	NONE
45	MAPROTILINE	0	NONE
	THIORIDAZINE	0	NONE
48	AMITRIPTYLINE	0	NONE
	THIORIDAZINE	0	NONE
	MAPROTILINE	0	NONE
49	MAPROTILINE	2	NONE
	DIBENZEPINE	1	NONE
	FLUVOXAMINE	2	NONE
50	MAPROTILINE	2	NONE
56	AMITRIPTYLINE	2	DROWSINESS
	MAPROTILINE	1	NONE
57	MAPROTILINE	2	NONE
64	AMITRIPTYLINE	1	NONE
	MAPROTILINE	2	NONE
	DIBENZAPINE	1	NONE
65	AMITRIPTYLINE	1	NONE
68	AMITRIPTYLINE	2	HYPOTENSION
72	AMITRIPTYLINE	2	DROWSINESS
73	CLORIMIPRAMINE	1	NONE
	LEVOSULPIRIDE	1	NONE

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair



FCE 20124/702 i

2

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
75	MIANEPTINE	1	NONE
79	AMINEPTINA	2	NONE
80	AMINEPTINA	2	NONE
	SULPIRIDE	2	NONE
85	SULPIRIDE	3	NONE
	AMINEPTINE	1	NONE
	TRANILCIPROMINA	1	NONE
87	AMITRIPTYLINE	3	DROWSINESS
94	CLORIMIPRAMINA	3	NONE
96	IMIPRAMINA	1	NONE
99	CLORIMIPRAMINE	3	ANTICHOLINERGIC
	MAPROTILINE	2	NONE
	NOMIFENSINE	1	NONE
	AMINEPTINE	1	NONE
101	CLORIMIPRAMINE	3	NONE
107	NDRITRIPTYLINE	3	NONE
	CLORIMIPRAMINE	2	NONE
	MAPROTILINE	2	NONE
	IMAO	4	NONE
108	CLORIMIPRAMINE	3	NONE
	MINAPRINE	4	NONE
109	CLORIMIPRAMINA	2	NONE
	MAPROTILINA	3	NONE
114	MAPROTILINA	2	NONE
	TRAZODONE	1	NONE
115	BUTRIPTILINA	1	NONE
	CLORIMIPRAMINA	2	NONE
120	MAPROTILINA	1	NONE
	MIANSERINA	2	NONE
122	NONE	.	
123	NONE	.	
130	TRIMIPRAMINE	0	DRY MOUTH
	CLORIMIPRAMINE	0	DRY MOUTH
			CONSTIPATION
	IMIPRAMINE	0	DRY MOUTH, SWEATING
	MIANSERINE	0	SOMNOLENCE
131	NONE	.	
134	AMITRIPTYLINE	2	DRY MOUTH, HEADACHE
	MIANSERINE	0	DRY MOUTH, DIZZINESS
	IMIPRAMINE	0	NONE
135	NONE	.	
142		.	
146	NONE	.	

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair

FCE 20124/702 i

3

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
169	IMIPRAMINE	2	DRY MOUTH
	DOXEPINE	2	INCREASED SALIVATION
	MAPROTILENE	2	NONE
	DESIMIPRAMINE	3	DRY MOUTH
	PROTRIPTYLINE	2	CONSTIPATION
171	AMITRIPTYLINE	2	DRY MOUTH
	NORTRIPTYLINE	2	CONSTIPATION
	PROTRIPTYLINE	1	NONE
	DOXEPINE	1	NONE
	MAPROTILENE	1	NONE
176	AMITRIPTYLINE	2	DRY MOUTH
	NORTRIPTYLINE	2	CONSTIPATION
	MAPROTILENE	1	NONE
	DOXEPINE	1	NASAL CONGESTION
	IMIPRAMINE	2	CONSTIPATION
177	IMIPRAMINE	2	DRY MOUTH
	DESIMIPRAMINE	2	CONSTIPATION
	DOXEPINE	1	NONE
	PROTRIPTYLINE	2	INCREASED SALIVATION
	MAPROTILENE	1	NONE
184	MAPROTILENE	1	SWEATING
	DOXEPINE	2	NONE
	IMIPRAMINE	1	DRY MOUTH
	DESIMIPRAMINE	1	DRY MOUTH
	AMITRIPTYLINE	2	CONSTIPATION
185	DOXEPINE	1	NONE
	IMIPRAMINE	2	DRY MOUTH
	AMITRIPTYLINE	1	DRY MOUTH
	DESIMIPRAMINE	2	DRY MOUTH
189	AMOXAPINE	1	SWEATING
	AMOXAPINE	.	NONE
	MAPROTILENE	.	NONE
	AMITRIPTYLINE	.	NONE
	IMIPRAMINE	.	CONSTIPATION
192	DOXEPINE	.	SWEATING
	IMIPRAMINE	2	DRY MOUTH
	AMOXAPINE	2	SWEATING
	MAPROTILENE	1	NONE
	DOXEPINE	1	DRY MOUTH
194	AMITRIPTYLINE	2	CONSTIPATION
	AMITRIPTYLINE	3	NONE
	IMIPRAMINE	2	DRY MOUTH
	DESIPRAMINE	2	CONSTIPATION
	AMOXAPINE	2	NASAL CONGESTION

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair

FCE 20124/702 i

4

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
198	IMIPRAMINE	2	NONE
	DESIPRAMINE	2	NONE
	DOXEPIN	1	HYPOTENSION
199	AMITRIPTYLINE	2	NONE
	AMITRIPTYLINE	2	DRY MOUTH
	IMIPRAMINE	2	HEADACHE
	DESIPRAMINE	2	BLURRED VISION
	AMOXAPINE	1	NONE
200	MAPROTILENE	1	DRY MOUTH
	AMITRIPTYLINE	2	NONE
	IMIPRAMINE	2	HEADACHE
	DESIPRAMINE	2	HYPOTENSION
208	AMOXAPINE	2	NONE
	MAPROTILENE	2	NONE
	IMIPRAMINE	2	NONE
	AMOXAPINE	2	SWEATING
	MAPROTILENE	2	NONE
209	DOXEPIN	2	NONE
	DOXEPIN	1	HEADACHE
	AMOXAPINE	1	DIZZINESS
	IMIPRAMINE	2	NONE
211	NAPROTILENE	2	NONE
	DESIPRAMINE	2	NONE
215	AMITRIPTYLINE	2	NONE
	AMOXAPINE	1	CONSTIPATION
	MAPROTILENE	1	DIZZINESS
	DESIPRAMINE	2	NONE
	AMITRIPTYLINE	2	NONE
217	DOXEPIN	2	NONE
	SULPIRIDE	1	GALACTORREA
	FLUNITRAZEPAM	3	NONE
	TRAZODONE	1	SOMNOLENCE
	CLOBAZAM	1	SOMNOLENCE
222	UNKNOWN	1	NONE
223	ALPRAZOLAM	2	NONE
	TRIAZOLAM	3	NONE
	NORTRIPTYLINE	1	NONE
	FLUFENAZINE	1	NONE
224	NONE	.	
231	MAPROTILENE	1	NONE
	NORTRIPTYLINE	1	NONE
	BUSPIRONE	1	NONE
	FLUNITRAZEPAM	2	NONE
232	BROMAZEPAM	3	WITHDRAWAL EFFECT

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair

FCE 20124/702 i

5

Pat. No.	Antidepressant drug	Efficacy*	Side Effects	
235	TRAZADONE	2	NONE	
	THIORIDAZINE	2	NONE	
	BROMZAEPPAM	2	NONE	
240	NONE	.		
244	IMIPRAMINE	2	DRY MOUTH CONSTIPATION	
	PROTRIPTILENE	1	SWEATING	
	AMOXAPINE	2	NONE	
	MAPROTIENE	1	NASAL CONGESTION	
	NORTRIPTILENE	2	DRY MOUTH	
	246	IMIPRAMINE	2	DRY MOUTH
		DOXEPINE	1	NONE
		MAPROTIENE	1	NONE
		AMOXAPINE	2	SWEATING
	247	VILOXAZINE	1	CONSTIPATION
DESIPRAMINE		2	DRY MOUTH CONSTIPATION	
NORTRIPTILENE		1	DRY MOUTH	
AMITRIPTILENE		1	DRY MOUTH	
DOXEPINE		1	NONE	
MAPROTIENE		1	SWEATING	
248		DOXEPINE	1	NONE
		PROTRIPTILENE	1	SWEATING
		VILOXAZINE	1	DRY MOUTH
		AMOXAPINE	2	NONE
	IMIPRAMINE	2	DRY MOUTH	
257	AMOXAPIN	2	NONE	
	IMIPRAMINE	2	NONE	
	DOXEPIN	2	NONE	
	IMIPRAMINE	1	NONE	
	AMITRIPTYLINE	2	NONE	
258	DESIPRAMINE	2	NONE	
259	IMIPRAMINE	2	CONSTIPATION	
	DOXEPINE	1	NONE	
	MAPROTIENE	1	NONE	
	DEMOLOX	2	SWEATING	
	VILOXAZINE	1	DROWSINESS	
263	DOXEPINE	1	NONE	
	AMOXAPINE	2	NONE	
	AMITRIPTILENE	2	DRY MOUTH	
	VILOXAZINE	1	NONE	
	NORTRIPTILENE	2	CONSTIPATION	

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

6

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
267	IMIPRAMINE	1	DRY MOUTH
	DESIPRAMINE	2	CONSTIPATION
	AMITRIPTILENE	2	CONSTIPATION
270	MAPROTILENE	2	NONE
	IMIPRAMINE	1	NASAL CONGESTION
	DOXEPINE	2	NONE
271	AMITRIPTILENE	3	NONE
	AMOXAPINE	1	SWEATING
	DOXEPINE	1	DIZZINESS
	NAPROTILENE	2	NONE
	AMITRIPTILENE	2	NONE

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

7

REBOXETINE, Protocol ADE 08

Table 3 - Previous antidepressant treatment

Treatment Group "B"

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
2	CLOMIPRAMINE	2	NONE
	BROMAZEPAM	2	NONE
4	ANAFRANIL	2	NONE
	AMITRIPTYLINE	2	NONE
10	DIAZEPAM	2	NONE
	ALIMENAZINE	.	
11	VILOXAZINE	2	NONE
	UPSTENE	3	NONE
15	XANAX	.	NONE
	ALPRAZOLAM	4	NONE
	VILOXAZINE	1	
17	MEPROBAMATE	1	NONE
	FLUNITRAZEPAM	1	NONE
28	MELIPRAMINE	1	NONE
29	THIORIDAZINE	0	NONE
	MEPROBAMATE	0	NONE
	DIBENZEPINE	0	NONE
31	TRIMIPRAMINE	0	NONE
	THIORIDAZINE	0	NONE
32	TRIMIPRAMINE	0	NONE
	MAPROTILINE	.	NONE
41	AMITRIPTYLINE	1	NONE
	TRIMIPRAMINE	0	NONE
42	DIBENZAPINE	1	NONE
	IMIPRAMINE	1	NONE
44	DIBENZAPINE	0	NONE
	THIORIDAZINE	0	NONE
47	TRIMIPRAMINE	0	NONE
	MAPROTILINE	0	NONE
51	MAPROTILINE	1	NONE
54	MAPROTILINE	1	NONE
55	AMITRIPTYLINE	1	DROWSINESS
60	AMITRIPTYLINE	2	DROWSINESS
	MOPROTILINE	2	NONE
	DIBENZAPINE	1	NONE
61	AMITRIPTYLINE	2	DROWSINESS
	MAPROTILINE	3	NONE
66	AMITRIPTYLINE	1	DROWSINESS

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

8

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
67	AMITRIPTYLINE	1	DROWSINESS
	DIBENZEPINE	2	DROWSINESS
70	AMITRIPTYLINE	2	DROWSINESS
77	AMITRIPTYLINE	2	NONE
	MAPROTILINE	2	NONE
	TRAZODONE	1	NONE
	CLOMIPRAMINE	2	NONE
	LEVOSULPIRIDE	1	NONE
78	UNKNOWN	.	
83	CLORIMIPRAMINE	3	NONE
	AMITRIPTYLINE	3	NONE
84	CLORIMIPRAMINA	3	NONE
	DESIPRAMINA	1	AGITATION
88	MIANSERINA	3	NONE
	AMITRIPTILINA	2	NONE
90	CLORIMIPRAMINA	2	URINARY RETENTION
	AMITRIPTILINA	2	NONE
91	CLORIMIPRAMINA	2	NONE
95	DOXIEPINA	1	NONE
98	CHLORIMIPRAMINE	3	ANTICHOLINERGIC
	AMITRIPTYLINE	2	ANTICHOLINERGIC
	MAPROTILINE	1	NONE
	RUBIDIOCLORURO	3	AGITATION
102	CLORIMIPRAMINE	3	ANTICHOLINERGIC
103	CLORIMIPRAMINE	4	NONE
	MIANSERINA	2	NONE
106	NONE	.	
110	SULPIRIDE	1	NONE
	AMITRIPTYLINE	2	URTICARIA
113	AMITRIPTILINA	3	NONE
118	SULPIRIDE	1	NONE
	MAPROTILINA	1	NONE
	CLORIMIPRAMINA	0	NONE
119	AMITRIPTILINA	2	NONE
	CLORIMIPRAMINA	1	NONE
124	NONE	.	
126	IMIPRAMINE	0	WEAK, DIZZY, HYPOTENSION
	AMITRIPTYLINE	0	NONE
	MAPROTILINE	0	NONE
	MIANSERIN	0	NONE
	LITHIUM	0	NONE
127	NONE	.	
132	IMIPRAMINE	.	DIURNAL HYPERSOMNIA

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

9

Pat. No.	Antidepressant drug	Efficacy*	Side Effects	
133	AMITRIPTYLINE	0	DROWSINESS, HEADACHE	
	MIANSERIN	2	NONE	
	CLORIMIPRAMINE	3	NONE	
136	NONE	.		
139	IMIPRAMINE	1	DRY MOUTH	
140		.		
147	IMIPRAMINE	0	NONE	
148	NONE	.		
170	IMIPRAMINE	2	DRY MOUTH	
	DESIMIPRAMINE	3	DRY MOUTH	
	PROTRIPTYLINE	2	CONSTIPATION	
	AMITRIPTYLINE	1	CONSTIPATION	
	MAPROTILENE	1	NONE	
	172	AMITRIPTYLINE	3	DRY MOUTH
		NORTIPTYLINE	2	CONSTIPATION
DOXEPINE		2	DIZZINESS	
179	MAPROTILENE	1	NONE	
	PROTRIPTYLINE	2	DRY MOUTH	
	DOXEPINE	2	DRY MOUTH	
	IMIPRAMINE	2	DRY MOUTH	
			CONSTIPATION	
180	AMOXAPINE	2	SWEATING	
	MAPROTILENE	1	NONE	
	AMITRIPTYLINE	2	DRY MOUTH	
	IMIPRAMINE	2	DRY MOUTH	
			CONSTIPATION	
181	MAPROTILENE	1	NONE	
	AMITRIPTYLINE	2	BLURRED VISION	
	AMOXAPINE	1	NONE	
	DOXEPINE	1	NONE	
	AMITRIPTYLINE	1	DRY MOUTH	
186	IMIPRAMINE	1	DRY MOUTH	
	IMIPRAMINE	1	DRY MOUTH	
187			CONSTIPATION	
	DESIMIPRAMINE	1	DRY MOUTH	
			CONSTIPATION	
	DOXEPINE	1	SWEATING	
	AMITRIPTYLINE	2	DRY MOUTH	
	MAPROTILENE	1	SWEATING	
	AMOXAPINE	2	DRY MOUTH	
IMIPRAMINE	2	DRY MOUTH		
			CONSTIPATION	
	DOXEPINE	1	NONE	
	MAPROTILENE	1	NONE	
	AMITRIPTYLINE	2	DRY MOUTH	

\* Efficacy 0 = very poor 3 = good  
 1 = poor 4 = very good  
 2 = fair



FCE 20124/702 i

10

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
188	DESIMIPRAMINE	2	DRY MOUTH
	AMOXAPINE	1	SWEATING
	MAPROTILENE	1	NONE
	AMITRIPTYLINE	2	DRY MOUTH
193	IMIPRAMINE	2	DRY MOUTH
	IMIPRAMINE	2	DRY MOUTH
	AMITRIPTYLINE	2	CONSTIPATION
	DESIMIPRAMINE	.	NONE
197	AMOXAPINE	1	NASAL CONGESTION
	NAVILOTILENE	1	NONE
	IMIPRAMINE	2	NASAL CONGESTION
	DESIPRAMINE	2	NONE
202	AMITRIPTYLINE	3	NONE
	DESIPRAMINE	3	NONE
	MAPROTILENE	1	STRONG HYPOTENSION
203	AMITRIPTYLINE	3	NONE
	DOXEPIN	1	HEADACHE
	IMIPRAMINE	1	NASAL CONGESTION
	DESIPRAMINE	2	
206	DOXEPIN	1	HYPOTENSION
	DESIPRAMINE	2	SWEATING
	NAVROTIENE	2	DIZZINESS
210	AMOXAPINE	2	CONSTIPATION
	IMIPRAMINE	2	NONE
	AMOXAPINE	2	NONE
	MAPROTILINE	1	SWEATING
214	DESIPRAMINE	2	NONE
	IMIPRAMINE	1	NONE
	AMOXAPINE	1	NONE
	AMITRIPTYLINE	2	NONE
216	DESIPRAMINE	2	NONE
	AMITRIPTYLINE	2	NONE
	MAPROTILENE	2	NONE
	DOXEPIN	1	DRY MOUTH
218	AMOXAPINE	1	CONSTIPATION
	DIAZEPAM	1	DIZZINESS
	LORAZEPAM	1	DROWSINESS
219	LORAZEPAM	1	NONE
	CLOMIPRAMINA	1	NONE
	CLONAZEPAM	1	NONE
	CLOBAZAM	1	NONE
226	CLOMIPRAMINE	3	NONE
	DIAZEPAM	2	NONE
	CLOBAZAM	2	NONE

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair

FCE 20124/702 i

11

Pat. No.	Antidepressant drug	Efficacy*	Side Effects	
227	TRIMIPRAMINE	1	NONE	
	CLOBAZAM	3	NONE	
	TRIAZOLAM	3	NONE	
	NITRAZEPAM	3	NONE	
230	AMITRIPTYLINE	2	NONE	
	CLOMIPRAMINE	3	NONE	
	CLORAZEPATE	2	NONE	
	FLUNITRAZEPAM	3	NONE	
	MIANSERINE	1	NONE	
233	ALPRAZOLAM	1	NONE	
	AMITRIPTYLINE	1	NONE	
	CHLORPROMAZINE	1	DROWSINESS	
237	TRIAZOLAM	2	NONE	
	THIORIDAZINE	1	DROWSINESS/DRY MOUTH	
	AMITRIPTYLINE	3	NONE	
	TRAZODONE	2	NONE	
238	SULPIRIDE	1	NONE	
	DIAZEPAM	2	NONE	
	MAPROTILENE	3	NONE	
	LORAZEPAM	2	NONE	
	ALPRAZOLAM	2	NONE	
243	MIANSERINE	3	NONE	
	IMIPRAMINE	2	DRY MOUTH CONSTIPATION	
	AMITRIPTILENE	2	DRY MOUTH	
	DOXEPINE	1	SWEATING	
	PROTRIPTILENE	1	NONE	
	MAPROTILENE	1	NONE	
	245	IMIPRAMINE	2	CONSTIPATION
		DESIPRAMINE	2	DRY MOUTH
		AMOXAPINE	2	NONE
		DOXEPINE	1	SWEATING
AMITRIPTILENE		2	DRY MOUTH	
249	IMIPRAMINE	2	DRY MOUTH	
	DOXEPINE	1	SWEATING	
	AMOXAPINE	2	CONSTIPATION	
	AMITRIPTILENE	2	DRY MOUTH	
	NORTRIPTILENE	2	DRY MOUTH	
251	DESIMIPRAMINE	2	NONE	
	MAPROTILENE	2	NONE	
	DOXEPIN	2	NONE	
254	IMIPRAMINE	2	NONE	
	DESIPRAMINE	2	NONE	
	AMITRIPTYLINE	2	NONE	

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

12

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
255	IMIPRAMINE	1	DRY MOUTH
	DESIPRAMINE	2	NONE
	MAPROTILINE	1	CONSTIPATION
	AMITRIPTYLINE	2	NONE
260	DOXEPINE	2	SWEATING
	AMOXAPINE	1	NONE
	NORTRIPTILENE	2	CONSTIPATION
	MAPROTILENE	1	NONE
	VILOXAZINE	1	DRY MOUTH
262	MAPROTILENE	1	NONE
	NORTRIPTILENE	1	DRY MOUTH
	DOXEPINE	1	DIZZINESS
	IMIPRAMINE	2	CONSTIPATION
268	AMOXAPINE	1	NONE
	IMIPRAMINE	2	CONSTIPATION
	DESIPRAMINE	2	DRY MOUTH
	DOXEPINE	2	NONE
269	AMITRIPTYLINE	2	DRY MOUTH
	AMITRIPTYLINE	2	CONSTIPATION
273	AMOXAPINE	1	NONE
	DOXEPIN	2	NONE
	MAPROTILENE	2	NONE
	DESIPRAMINE	2	DRY MOUTH

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

13

REBOXETINE, Protocol ADE 08

Table 3 - Previous antidepressant treatment

Treatment Group "C"

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
3	CLOBAZAM	1	NONE
	TOLOXATONE	1	NONE
	BROMAZEPAM	1	NONE
6	VILOXAZINE	1	NONE
	CLOMIPRAMINE	2	NONE
7	FLUVOXAMINE	0	NONE
8	CLOMIPRAMINE	1	NONE
	FLUVOXAMINE	1	NONE
16	CARBAMAZEPINE	1	NONE
	CLOMIPRAMINE	1	NONE
	MIANSERINE	1	NONE
18	DIAZEPAM	1	NONE
	NONE	.	
26	THIORIDAZINE	0	NONE
	TRIMIPRAMINE	0	NONE
27	DIBENZEPINE	0	NONE
	THIORIDAZINE	0	NONE
	MAPROTILINE	.	NONE
33	DIBENZEPINE	0	NONE
	MAPROTILINE	0	NONE
36	TEPERIN	0	NONE
	NOVERIL	1	NONE
39	TRIMIPRAMINE	0	NONE
	DIAZEPAM	1	NONE
	NITRAZEPAM	1	NONE
40	AMITRIPTYLINE	0	NONE
	IMIPRAMINE	0	NONE
	DIBENZAPINE	1	NONE
43	MAPROTILINE	0	NONE
46	LUDIOMIL	0	NONE
	TEPERIN	0	NONE
52	MAPROTILINE	1	NONE
	FLUVOXAMINE	2	NONE
53	MAPROTILINE	1	NONE
58	MAPROTILINE	2	NONE
59	DIBENZAPINE	2	NONE
62	MAPROTILINE	2	NONE
	AMITRIPTYLINE	2	DROWSINESS

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                                4 = very good  
                   2 = fair

FCE 20124/702 i

14

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
63	AMITRIPTYLINE	2	DROWSINESS
	MAPROTILINE	2	HYPOTENSION
69	AMITRIPTYLINE	2	DROWSINESS
	MAPROTILINE	2	NONE
	IMIPRAMINE	3	DROWSINESS
71	IMIPRAMINE	1	DROWSINESS
	MAPROTILINE	2	TACHYCARDIA
	NOVERIL	2	NONE
74	SULPIRIDE	1	NONE
76	AMITRIPTYLINE	3	NONE
81	AMITRIPTYLINE	1	NONE
82	AMINEPTINUM	0	NONE
	LEVOSULPIRIDE	2	NONE
	SULPIRIDE	2	NONE
86	CLOMIPRAMINE	3	NONE
89	AMITRIPTILINA	3	NONE
92	CLORIMIPRAMINA	4	NONE
93	CLORIMIPRAMINA	4	NONE
97	CLORIMIPRAMINE	0	NONE
100	MAPROTILINE	3	NONE
	AMITRIPTYLINE	1	NONE
104	AMITRIPTYLINE	2	NONE
	CLORIMIPRAMINE	3	NONE
105	SULPIRIDE	0	NONE
	NORTRIPTILINA	1	NONE
111	SULPIRIDE	1	NONE
	MAPROTILINE	1	NONE
	TRANILCIPROM+TRIFLU.	1	NONE
112	AMITRIPTILINA	1	NONE
	MIANSERINA	3	NONE
116	AMITRIPTILINA	1	NONE
	MELITRACENE	1	NONE
117	IMIPRAMINE	3	ANTICHOLINERGIC
	SULPIRIDE	2	NONE
121	TRAZODONE	2	NONE
	IMIPRAMINE	3	SWEATING, TREMOR
125	NONE	.	
128	IMIPRAMINE	1	DRY MOUTH
	DESIPRAMINE	2	EPIGASTRIC PAIN
129	NONE	.	NONE
137	NONE	.	
138	IMIPRAMINE	2	DRY MOUTH, HEADACHE
141		.	

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

15

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
145	IMIPRAMINE	0	NONE
	AMITRIPTYLINE	0	DRY MOUTH CONSTIPATION
173	IMIPRAMINE	3	DRY MOUTH, DIZZINESS
	AMITRIPTYLINE	2	DRY MOUTH
	MAPROTILENE	1	NONE
	DOXEPINE	2	DIZZINESS
	PROTRIPTYLINE	2	DRY MOUTH
174	AMITRIPTYLINE	2	DRY MOUTH
	NORTRIPTYLINE	2	CONSTIPATION
	MAPROTILENE	1	NONE
	DOXEPINE	1	NONE
175	IMIPRAMINE	2	DRY MOUTH
	AMITRIPTYLINE	2	CONSTIPATION
	DESIMIPRAMINE	2	DRY MOUTH
	MAPROTILENE	1	NONE
	PROTRIPTYLINE	2	CONSTIPATION
178	IMIPRAMINE	.	DRY MOUTH
	DOXEPINE	.	NONE
	MAPROTILENE	.	SWEATING
	AMOXAPINE	.	DRY MOUTH
	AMITRIPTYLINE	.	DRY MOUTH CONSTIPATION
182	DOXEPINE	1	SWEATING
	AMITRIPTYLINE	1	DRY MOUTH
	DESIPRAMINE	1	DRY MOUTH
	MAPROTILENE	1	NONE
183	IMIPRAMINE	1	DRY MOUTH
	DOXEPINE	1	SWEATING
190	IMIPRAMINE	1	DRY MOUTH
	AMITRIPTYLINE	2	DRY MOUTH
191	AMITRIPTYLINE	2	DRY MOUTH
	DESIMIPRAMINE	2	CONSTIPATION
	DOXEPINE	1	NONE
	AMOXAPINE	1	SWEATING
	DOXEPINE	1	SWEATING
195	AMOXAPINE	1	NONE
	MAPROTILENE	1	HEADACHE
	IMIPRAMINE	2	DRY MOUTH
	AMITRIPTYLINE	2	DRY MOUTH
	AMITRIPTYLINE	2	DRY MOUTH
	IMIPRAMINE	2	CONSTIPATION
	DESIPRAMINE	2	CONSTIPATION

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

150

FCE 20124/702 i

16

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
196	AMITRIPTYLINE	2	NONE
	IMIPRAMINE	2	CONSTIPATION
	DESIMIPRAMINE	1	NONE
201	IMIPRAMINE	2	NONE
	DESIPRAMINE	2	NONE
	AMOXAPINE	1	DRY MOUTH
	MAPROTILINE	1	NASAL CONGESTION
204	DOXEPIN	1	CONSTIPATION
	DESIPRAMINE	2	HYPOTENSION
	IMIPRAMINE	2	DIZZINESS
	MAPROMIENE	1	DRY MOUTH
205	AMITRIPTYLINE	3	NONE
	NAVROTIENE	1	SKIN RASH
	DESIMPRAMINE	2	NONE
	IMIPRAMINE	1	NONE
207	AMOXAPINE	1	SWEATING
	DOXEPIN	1	DIZZINESS
	IMIPRAMINE	2	NONE
	MAPROTILENE	2	NONE
212	AMOXAPINE	2	NONE
	AMOXAPINE	2	NONE
	AMOXAPINE	1	BLURRED VISION
	MAPROTILINE	1	DRY MOUTH
213	DESIPRAMINE	2	NONE
	AMITRIPTYLINE	2	NONE
	IMIPRAMINE	1	HEADACHE
	DESIPRAMINE	2	NONE
220	AMITRIPTYLINE	3	NONE
	MAPROTILINE	1	NASAL CONGESTION
	ALPRAZOLAM	1	NONE
	DIAZEPAM	1	NONE
221	CLORDIAZEPOXIDE	1	NONE
	CLORIMIPRAMINE	1	NONE
	TRIFLUOPERAZINE	1	NONE
225	DIAZEPAM	1	NONE
	ALPRAZOLAM	2	NONE
	MAPROTILINE	2	GASTRIC ACIDITY
228	LORAZEPAM	2	NONE
	LEVOMEPRMAZINE	1	NONE
	CLORIMIPRAMINE	1	TREMOR
229	TRIMIPRAMINE	1	SEDATION
	MAPROTILENE	1	SEDATION
	CLOBAZAM	1	SEDATION
	DIAZEPAM	1	HYPERSONMIA

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair

FCE 20124/702 i

17

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
234	ALPRAZOLAM	3	NONE
	TRIMIPRAMINE	3	NONE
	BROMAZEPAM	3	NONE
236	TRAZODONE	1	NONE
	ALPRAZOLAM	3	NONE
239	AMITRIPTYLINE	3	DRY MOUTH
	CHLORIMIPRAMINE	3	NONE
	THIORIDAZINE	1	DIZZINESS
	FLONITRAZEPAM	2	NONE
241	PROTRIPTILENE	2	CONSTIPATION
	IMIPRAMINE	2	DRY MOUTH
	MAPROTILENE	1	NONE
	DOXEPINE	1	NONE
	DESIPRAMINE	2	CONSTIPATION
242	IMIPRAMINE	2	DRY MOUTH
	DOXEPINE	1	SWEATING
	NORTRIPTILENE	2	CONSTIPATION
	AMITRIPTYLINE	2	CONSTIPATION
	MAPROTILENE	1	NONE
	IMIPRAMINE	2	NONE
	AMOXAPINE	2	SWEATING
252	MAPROTILENE	2	NONE
	DOXEPIN	1	NONE
	AMOXAPIN	1	NONE
253	AMITRIPTYLINE	2	NONE
	MAPROTILENE	.	
	DOXEPIN	1	DRY MOUTH
	AMOXAPIN	1	CONSTIPATION
255	AMITRIPTYLINE	2	NONE
	IMIPRAMINE	1	NONE
	AMITRIPTYLINE	1	NONE
261	MAPROTILENE	1	NONE
	AMITRIPTYLINE	2	DRY MOUTH
	DOXEPINE	2	NONE
	AMOXAPINE	2	NONE
	IMIPRAMINE	2	CONSTIPATION
264	MAPROTILENE	2	SWEATING
	DOXEPINE	1	NONE
	NORTRIPTILENE	2	DRY MOUTH
	IMIPRAMINE	2	CONSTIPATION
	PROTRIPTILENE	1	LASSITUDE

\* Efficacy    0 = very poor                    3 = good  
                   1 = poor                            4 = very good  
                   2 = fair



FCE 20124/702 i

18

Pat. No.	Antidepressant drug	Efficacy*	Side Effects
265	NORTRIPTYLINE	2	DRY MOUTH
	DOXEPINE	1	NONE
	AMITRIPTILENE	2	DRY MOUTH
	IMIPRAMINE	2	CONSTIPATION
	AMOXAPINE	2	DRY MOUTH
266	MAPROTIENE	1	NONE
	PROTRIPTILENE	1	DRY MOUTH
	AMITRIPTILENE	2	DRY MOUTH
	DOXEPINE	1	NONE
	NORTRIPTYLINE	2	NONE
272	DESIPRAMINE	2	DRY MOUTH
	DOXEPINE	2	NONE

\* Efficacy    0 = very poor            3 = good  
                   1 = poor                    4 = very good  
                   2 = fair

153

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08  
Table 4a- Experimental Treatment  
Treatment Group "A"

Pat. No.	No. of cps	From m d y	To m d y	Duration	Reason for Discontinuation
001	2	04 19 88	04 21 88	3	
	3	04 22 88	04 23 88	2	
	4	04 24 88	04 24 88	1	
	3	04 25 88	05 17 88	23	
				Total: 29	Completed
005	2	06 18 88	06 24 88	7	
	4	06 25 88	07 15 88	22	
				Total: 29	Completed
009	2	11 03 88	11 06 88	4	
	3	11 07 88	11 09 88	3	
	4	11 10 88	12 01 88	22	
				Total: 29	Completed
012	2	11 10 88	11 12 88	3	
	3	11 13 88	22 16 88	4	
	4	11 17 88	12 08 88	22	
				Total: 29	Completed
013	2	11 16 88	11 19 88	4	
	3	11 20 88	11 23 88	4	
	4	11 24 88	12 14 88	21	
				Total: 29	Completed
014	2	11 18 88	11 21 88	4	
	3	11 22 88	11 24 88	3	
	4	11 25 88	12 16 88	22	
				Total: 29	Completed
025	2	01 24 89	01 26 89	3	
	3	01 27 89	02 29 89	3	
	4	01 30 89	02 20 89	22	
				Total: 28	Completed

FCE 20124/702 i

2

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
030	2	08	12	88	08	14	88	3	Completed
	3	08	15	89	08	17	88	3	
	4	08	18	88	09	08	88	22	
								Total: 28	
034	2	01	24	89	01	26	89	3	Ineffectiveness/ Deterioration
	3	01	27	89	01	29	89	3	
	4	01	30	89	02	04	89	05	
								Total: 11	
035	2	10	12	88	10	14	88	3	Completed
	3	10	15	88	10	17	88	3	
	4	10	18	88	11	08	88	22	
								Total: 28	
037	2	09	23	88	09	25	88	3	Completed
	3	09	26	88	09	28	88	3	
	4	09	29	88	10	20	88	22	
								Total: 28	
038	2	08	30	88	09	01	88	3	Completed
	3	09	02	88	09	04	88	3	
	4	09	05	88	09	26	88	22	
								Total: 28	
045	2	10	14	88	10	16	88	3	Completed
	3	10	17	88	10	19	88	3	
	4	10	20	88	11	10	88	22	
								Total: 28	
048	2	01	26	89	01	28	89	3	Completed
	3	01	29	89	02	31	89	3	
	4	02	01	89	02	22	89	22	
								Total: 28	
049	2	04	08	88	04	10	88	3	Completed
	3	04	11	88	04	13	88	3	
	4	04	14	88	05	05	88	22	
								Total: 28	

34/25

48/25

FCE 20124/702 i

3

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
050	2	03	24	88	03	26	88	3	
	3	03	27	88	03	29	88	3	
	4	03	30	88	04	20	88	22	
								Total: 28	Completed
056	2	04	16	88	04	18	88	3	
	3	04	19	88	04	21	88	3	
	4	04	22	88	05	13	88	22	
								Total: 28	Completed
057	2	05	16	88	05	18	88	3	
	3	05	19	88	05	21	88	3	
	4	05	22	88	06	12	88	22	
								Total: 28	Completed
064	2	04	14	88	04	16	88	3	
	3	04	17	88	04	19	88	3	
	4	04	20	88	05	11	88	22	
								Total: 28	Completed
065	2	05	04	88	05	06	88	3	
	3	05	07	88	05	09	88	3	
	4	05	10	88	05	31	88	22	
								Total: 28	Completed
068	2	05	19	88	05	22	88	3	
	3	05	22	88	05	24	88	3	
	4	05	25	88	06	15	88	22	
								Total: 28	Completed
072	2	05	25	88	05	27	88	3	
	3	05	28	88	05	30	88	3	
	4	05	31	88	06	21	88	22	
								Total: 28	Completed
073	2	01	19	88	01	21	88	3	
	3	01	22	88	01	24	88	3	
	4	01	25	88	02	03	88	10	
								Total: 16	Ineffectiveness/ Deterioration

FCE 20124/702 i

4

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
075	2	02	23	88	02	25	88	3	Completed
	3	02	26	88	02	28	88	3	
	4	02	29	88	03	22	88	23	
								Total: 29	
079	2	03	29	88	03	31	88	3	Ineffectiveness/ Deterioration
	3	04	01	88	04	03	88	3	
	4	04	04	88	04	22	88	19	
								Total: 25	
080	2	04	05	88	04	07	88	3	Completed
	3	04	08	88	04	10	88	3	
	4	04	11	88	05	03	88	23	
								Total: 29	
085	2	07	13	88	07	15	88	3	Completed
	3	07	16	88	07	18	88	3	
	4	07	19	88	08	09	88	22	
								Total: 28	
087	2	08	20	88	08	22	88	3	Completed
	3	08	23	88	08	25	88	3	
	4	08	26	88	09	16	88	22	
								Total: 28	
094	2	01	11	89	01	13	89	3	Completed
	3	01	14	89	01	16	89	3	
	4	01	17	89	02	07	89	22	
								Total: 28	
096	2	01	20	89	01	22	89	3	Completed
	3	01	23	89	01	25	89	3	
	4	01	26	89	02	16	89	22	
								Total: 28	
099	2	03	26	88	03	28	88	3	Completed
	3	03	29	88	03	31	88	3	
	4	04	01	88	04	22	88	22	
								Total: 28	

FCE 20124/702 i

5

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
101	2	04	21	88	04	23	88	3	
	3	04	24	88	04	26	88	3	
	4	04	27	88	05	18	88	22	
								Total: 28	Completed
107	2	06	25	88	06	27	88	3	
	3	06	28	88	06	30	88	3	
	4	07	01	88	07	22	88	22	
								Total: 28	Completed
108	2	06	25	88	06	27	88	3	
	3	06	28	88	06	30	88	3	
	4	07	01	88	07	22	88	22	
								Total: 28	Completed
109 <i>bs</i>	2	12	23	88	12	25	88	3	
	3	12	26	88	12	28	88	3	
	4	12	29	88	01	19	89	22	
								Total: 28	Completed
114 <i>109</i>	2	11	03	88	11	05	88	3	
	3	11	06	88	11	08	88	3	
	4	11	09	88	11	30	88	22	
								Total: 28	Completed
115	2	11	04	88	11	06	88	3	
	3	11	07	88	11	09	88	3	
	4	11	10	88	12	01	88	22	
								Total: 28	Completed
120	2	12	23	88	12	25	88	3	
	3	12	26	88	12	28	88	3	
	4	12	29	88	01	19	89	22	
								Total: 28	Completed
122	2	06	10	88	06	12	88	3	
	3	06	13	88	06	15	88	3	
	4	06	16	88	06	27	88	12	
								Total: 18	Ineffectiveness/ Deterioration

FCE 20124/702 i

6

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
123	2	06	15	88	06	17	88	3	
	3	06	18	88	06	20	88	3	
	4	06	21	88	07	12	88	22	
								Total: 28	Completed
130	2	08	12	88	08	14	88	3	
	3	08	15	88	08	16	88	2	
								Total: 5	Ineffectiveness/ Deterioration
131	2	10	07	88	10	09	88	3	
	3	10	10	88	10	12	88	3	
	4	10	13	88	11	03	88	22	
								Total: 28	Completed
134	2	11	22	88	11	24	88	3	
	3	11	25	88	11	27	88	3	
	4	11	28	88	12	06	88	9	
								Total: 15	Ineffectiveness/ Deterioration
135	2	11	23	88	11	25	88	3	
	3	11	26	88	11	28	88	3	
	4	11	29	88	12	20	88	22	
								Total: 28	Completed
142	2	02	17	89	02	19	89	3	
	3	02	20	89	02	22	89	3	
	4	02	23	89	03	16	89	22	
								Total: 28	Completed
146	2	05	12	89	05	14	89	3	
	3	05	15	89	05	17	89	3	
	4	05	18	89	06	08	89	22	
								Total: 28	Completed
169	2	12	28	87	12	30	87	3	
	3	12	31	87	01	03	88	4	
	4	01	04	88	01	24	88	21	
								Total: 28	Completed

FCE 20124/702 i

7

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
171	2	12	28	87	12	30	87	3	Completed
	3	12	31	87	01	03	88	4	
	4	01	04	88	01	24	88	21	
								Total: 28	
176	2	01	19	88	01	21	88	3	Completed
	3	01	22	88	01	25	88	4	
	4	01	26	88	02	15	88	21	
								Total: 28	
177	2	04	01	88	04	03	88	3	Completed
	3	04	04	88	04	07	88	4	
	4	04	08	88	04	28	88	21	
								Total: 28	
184	2	06	30	88	07	02	88	3	Completed
	3	07	03	88	07	06	88	4	
	4	07	07	88	07	27	88	21	
								Total: 28	
185	2	07	01	88	07	03	88	3	Completed
	3	07	04	88	07	07	88	4	
	4	07	08	88	07	28	88	21	
								Total: 28	
189	2	07	03	88	07	05	88	3	Completed
	3	07	06	88	07	09	88	4	
	4	07	10	88	07	30	88	21	
								Total: 28	
192	2	07	05	88	07	07	88	3	Completed
	3	07	08	88	07	11	88	4	
	4	07	12	88	08	01	88	21	
								Total: 28	
194	2	12	27	87	12	30	87	4	Completed
	3	12	31	87	01	02	88	3	
	4	01	03	88	01	24	88	22	
								Total: 29	



FCE 20124/702 i

8

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
198	2	01	19	88	01	21	88	3	Completed
	3	01	22	88	01	24	88	3	
	4	01	25	88	02	15	88	22	
								<b>Total: 28</b>	
199	2	01	19	88	01	21	88	3	Completed
	3	01	22	88	01	24	88	3	
	4	01	25	88	02	15	88	22	
								<b>Total: 28</b>	
200	2	01	19	88	01	21	88	3	Completed
	3	01	22	88	01	24	88	3	
	4	01	25	88	02	15	88	22	
								<b>Total: 28</b>	
208	2	06	30	88	07	02	88	3	Completed
	3	07	03	88	07	05	88	3	
	4	07	06	88	07	27	88	22	
								<b>Total: 28</b>	
209	2	07	01	88	07	03	88	3	Completed
	3	07	04	88	07	06	88	3	
	4	07	07	88	07	28	88	22	
								<b>Total: 28</b>	
211	2	07	01	88	07	03	88	3	Completed
	3	07	04	88	07	06	88	3	
	4	07	07	88	07	28	88	22	
								<b>Total: 28</b>	
215	2	07	05	88	07	07	88	3	Completed
	3	07	08	88	07	10	88	3	
	4	07	11	88	08	01	88	22	
								<b>Total: 28</b>	
217	2	03	14	88	03	16	88	3	Completed
	3	03	17	88	04	10	88	25	
								<b>Total: 28</b>	

FCE 20124/702 i

9

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
222	2	04	12	88	04	15	88	4	Adverse Reaction
	3	04	16	88	04	18	88	3	
	4	04	19	88	05	01	88	13	
		Total: 20							
223	2	04	21	88	04	22	88	2	Ineffectiveness/ Deterioration
	3	04	23	88	04	26	88	4	
	4	04	27	88	04	30	88	4	
		Total: 10							
224	2	05	23	88	05	25	88	3	Completed
	3	05	26	88	05	29	88	4	
	4	05	30	88	06	20	88	22	
	2	06	21	88				1	
		Total: 30							
231	2	08	12	88	08	14	88	3	Completed
	3	08	15	88	08	17	88	3	
	4	08	18	88	09	07	88	21	
		Total: 27							
232	2	09	02	88	09	04	88	3	Patient Refusal
	3	09	05	88	09	08	88	4	
	4	09	09	88	09	24	88	16	
	2	09	25	88				1	
		Total: 24							
235	2	10	24	88	10	26	88	3	Completed
	3	10	27	88	10	30	88	4	
	4	10	31	88	11	20	88	21	
		Total: 28							
240	2	11	30	88	12	02	88	3	Completed
	3	12	03	88	12	05	88	3	
	4	12	06	88	12	26	88	21	
	2	12	27	88				1	
		Total: 28							

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

10

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
244	2	10	31	88	11	02	88	3	Completed
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								Total: 28	
246	2	10	31	88	11	02	88	3	Completed
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								Total: 28	
247	2	11	01	88	11	03	88	3	Completed
	3	11	04	88	11	07	88	4	
	4	11	08	88	11	28	88	21	
								Total: 28	
248	2	11	01	88	11	03	88	3	Completed
	3	11	04	88	11	07	88	4	
	4	11	08	88	11	28	88	21	
								Total: 28	
257	2	11	02	88	11	04	88	3	Completed
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								Total: 28	
258	2	11	02	88	11	04	88	3	Completed
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								Total: 28	
259	2	12	29	88	12	31	88	3	Completed
	3	01	01	89	01	04	89	4	
	4	01	05	89	01	25	89	21	
								Total: 28	
263	2	12	29	88	12	31	88	3	Completed
	3	01	01	89	01	04	89	4	
	4	01	05	89	01	25	89	21	
								Total: 28	

163

FCE 20124/702 i

11

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
267	2	01	05	89	01	07	89	3	Completed
	3	01	08	89	01	10	89	3	
	4	01	11	89	02	01	89	22	
								Total: 28	
270	2	01	05	88	01	07	89	3	Completed
	3	01	08	89	01	10	89	3	
	4	01	11	89	02	01	89	22	
								Total: 28	
271	2	01	06	88	01	08	89	3	Completed
	3	01	09	89	01	12	89	4	
	4	01	12	89	02	02	89	21	
								Total: 28	

Summary

Total No of cases: 81

Duration of treatment (days): min 5 max 30 mean 26.79

FCE 20124/702 i

12

REBOXETINE, Protocol ADE 08  
Table 4a- Experimental Treatment  
Treatment Group "B"

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
002	2	04	19	88	04	22	88	4	Completed
	3	04	23	88	04	27	88	5	
	2	04	28	88	04	30	88	3	
	4	05	01	88	05	17	88	17	
Total: 29									
004	2	05	10	88	05	12	88	3	Patient Refusal
	3	05	13	88	05	23	88	11	
Total: 14									
010	2	06	20	88	06	23	88	4	Completed
	3	06	24	88	06	27	88	4	
	4	06	28	88	07	18	88	20	
Total: 28									
011	2	11	07	88	11	10	88	4	Completed
	3	11	11	88	11	13	88	3	
	4	11	14	88	12	05	88	22	
Total: 29									
015	2	11	21	88	11	23	88	3	Completed
	3	11	24	88	11	27	88	4	
	4	11	28	88	12	19	88	22	
Total: 29									
017	2	12	05	88	12	08	88	4	Completed
	3	12	09	88	12	11	88	3	
	4	12	12	88	01	02	89	22	
Total: 29									
028	2	06	16	88	06	18	88	3	Ineffectiveness/ Deterioration
	3	06	19	88	06	21	88	3	
	4	06	22	88	07	01	88	10	
Total: 16									

FCE 20124/702 i

13

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
029	2	01	26	89	01	28	89	3	Ineffectiveness/ Deterioration
	3	01	29	89	02	31	89	3	
	4	02	01	89	02	06	89	06	
								Total: 12	
031	2	01	24	89	01	26	89	3	Completed
	3	01	27	89	02	29	89	3	
	4	01	30	89	02	20	89	22	
								Total: 28	
032	2	01	24	89	01	26	89	3	Completed
	3	01	27	89	02	29	89	3	
	4	01	30	89	02	20	89	22	
								Total: 28	
041	2	01	24	89	01	26	89	3	Completed
	3	01	27	89	01	29	89	3	
	4	01	30	89	02	20	89	22	
								Total: 28	
042	2	10	22	88	10	24	88	3	Completed
	3	10	25	88	10	27	88	3	
	4	10	28	88	11	18	88	22	
								Total: 28	
044	2	01	24	89	01	26	89	3	Completed
	3	01	27	89	01	29	89	3	
	4	01	30	89	02	20	89	22	
								Total: 28	
047	2	01	26	89	01	28	89	3	Completed
	3	01	29	89	02	31	89	3	
	4	02	01	89	02	22	89	22	
								Total: 28	
051	2	02	21	88	02	23	88	3	Completed
	3	02	24	88	02	26	88	3	
	4	02	27	88	03	20	88	22	
								Total: 28	

FCE 20124/702 i

14

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
054	2	04	15	88	04	17	88	3	
	3	04	18	88	04	20	88	3	
	4	04	21	88	05	12	88	22	
								Total: 28	Completed
055	2	05	03	88	05	05	88	3	
	3	05	06	88	05	08	88	3	
	4	05	09	88	05	30	88	22	
								Total: 28	Completed
060	2	04	15	88	04	17	88	3	
	3	04	18	88	04	20	88	3	
	4	04	21	88	05	12	88	22	
								Total: 28	Completed
061	2	05	31	88	06	02	88	3	
	3	06	03	88	06	05	88	3	
	4	06	06	88	06	27	88	22	
								Total: 28	Completed
066	2	04	09	88	04	11	88	3	
	3	04	12	88	04	14	88	3	
	4	04	15	88	05	06	88	22	
								Total: 28	Completed
067	2	04	16	88	04	18	88	3	
	3	04	19	88	04	21	88	3	
	4	04	22	88	05	13	88	22	
								Total: 28	Completed
070	2	05	25	88	05	27	88	3	
	3	05	28	88	05	30	88	3	
	4	05	31	88	06	21	88	22	
								Total: 28	Completed
077	2	03	28	88	03	30	88	3	
	3	03	31	88	04	02	88	3	
	4	04	03	88	04	24	88	22	
								Total: 28	Completed

167

FCE 20124/702 i

15

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
078	2	03	28	88	03	30	88	3	
	3	03	31	88	04	02	88	3	
	4	04	03	88	04	06	88	4	
	3	04	07	88	04	24	88	18	
Total: 28									Completed
083	2	05	31	88	06	02	88	3	
	3	06	03	88	06	05	88	3	
	4	06	06	88	06	27	88	22	
Total: 28									Completed
084	2	06	08	88	06	10	88	3	
	3	06	11	88	06	13	88	3	
	4	06	14	88	07	05	88	22	
Total: 28									Completed
088	2	11	12	88	11	14	88	3	
	3	11	15	88	11	17	88	3	
	4	11	18	88	12	09	88	22	
Total: 28									Completed
090	2	12	21	88	12	23	88	3	
	3	12	24	88	12	26	88	3	
	4	12	27	88	01	09	89	14	
	3	01	10	89	01	11	89	2	
	2	01	12	89	01	17	89	6	
Total: 28									Completed
091	2	12	21	88	12	23	88	3	
	3	12	24	88	12	26	88	3	
	4	12	27	88	01	17	89	22	
Total: 28									Completed
095	2	01	14	89	01	16	89	3	
	3	01	17	89	01	19	89	3	
	4	01	20	89	02	10	89	22	
Total: 28									Completed



FCE 20124/702 i

16

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
098	2	02	10	88	02	12	88	3	
	3	02	13	88	02	15	88	3	
	4	02	16	88	03	08	88	22	
								Total: 28	Completed
102	2	04	23	88	04	25	88	3	
	3	04	26	88	04	28	88	3	
	4	04	29	88	05	20	88	22	
								Total: 28	Completed
103	2	05	07	88	05	09	88	3	
	3	05	10	88	05	12	88	3	
	4	05	13	88	06	03	88	22	
								Total: 28	Completed
106	2	05	24	88	05	26	88	3	
	3	05	27	88	05	29	88	3	
	4	05	30	88	06	20	88	22	
								Total: 28	Completed
110	2	09	22	88	09	24	88	3	
	3	09	25	88	09	27	88	3	
	4	09	28	88	10	19	88	22	
								Total: 28	Completed
113	2	11	03	88	11	05	88	3	
	3	11	06	88	11	08	88	3	
	4	11	09	88	11	30	88	22	
								Total: 28	Completed
118	2	12	23	88	12	25	88	3	
	3	12	26	88	12	28	88	3	
	4	12	29	88	01	19	89	22	
								Total: 28	Completed
119	2	12	23	88	12	25	88	3	
	3	12	26	88	12	28	88	3	
	4	12	29	88	01	19	89	22	
								Total: 28	Completed

169

FCE 20124/702 i

17

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
124	2	06	21	88	06	23	88	3	
	3	06	24	88	06	26	88	3	
	4	06	27	88	07	18	88	22	
								Total: 28	Completed
126	2	07	29	88	07	31	88	3	
	3	08	01	88	08	03	88	3	
	4	08	04	88	08	25	88	22	
								Total: 28	Completed
127	2	08	03	88	08	05	88	3	
	3	08	06	88	08	08	88	3	
	4	08	09	88	08	30	88	22	
								Total: 28	Completed
132	2	10	18	88	10	20	88	3	
	3	10	21	88	10	23	88	3	
	4	10	24	88	11	14	88	22	
								Total: 28	Completed
133	2	10	27	88	10	29	88	3	
	3	10	30	88	11	01	88	3	
	4	11	02	88	11	23	88	22	
								Total: 28	Completed
136	2	11	25	88	11	27	88	3	
	3	11	28	88	11	30	88	3	
	4	12	01	88	12	22	88	22	
								Total: 28	Completed
139	2	01	12	89	01	14	89	3	
	3	01	15	89	01	18	89	4	
	4	01	19	89	02	08	89	21	
								Total: 28	Completed
140	2	01	12	89	01	14	89	3	
	3	01	15	89	01	17	89	3	
	4	01	18	89	02	08	89	22	
								Total: 28	Completed

170

FCE 20124/702 i

18

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
147	2	07	11	89	07	13	89	3	Ineffectiveness/ Deterioration
	3	07	14	89	07	16	89	3	
	4	07	17	89	07	27	89	11	
								Total: 17	
148	2	07	16	89	07	18	89	3	Completed
	3	07	19	89	07	21	89	3	
	4	07	22	89	08	12	89	22	
								Total: 28	
170	2	12	28	87	12	30	87	3	Completed
	3	12	31	87	01	03	88	4	
	4	01	04	88	01	24	88	21	
								Total: 28	
172	2	01	05	88	01	07	88	3	Completed
	3	01	08	88	01	11	88	4	
	4	01	12	88	02	01	88	21	
								Total: 28	
179	2	04	01	88	04	03	88	3	Completed
	3	04	04	88	04	07	88	4	
	4	04	08	88	04	14	88	7	
	3	04	15	88	04	28	88	14	
								Total: 28	
180	2	04	05	88	04	07	88	3	Completed
	3	04	08	88	04	11	88	4	
	4	04	12	88	05	02	88	21	
								Total: 28	
181	2	06	30	88	07	02	88	3	Completed
	3	07	03	88	07	06	88	4	
	4	07	07	88	07	27	88	21	
								Total: 28	
186	2	07	01	88	07	03	88	3	Completed
	3	07	04	88	07	07	88	4	
	4	07	08	88	07	28	88	21	
								Total: 28	

171

FCE 20124/702 i

19

Pat. No.	No. of cps	From		To		Duration	Reason for Discontinuation
		m	d y	m	d y		
187	2	07	01 88	07	03 88	3	
	3	07	04 88	07	07 88	4	
	4	07	08 88	07	28 88	21	
						<b>Total: 28</b>	<b>Completed</b>
188	2	07	03 88	07	05 88	3	
	3	07	06 88	07	09 88	4	
	4	07	10 88	07	30 88	21	
						<b>Total: 28</b>	<b>Completed</b>
193	2	12	28 87	12	30 87	3	
	3	12	31 87	01	02 88	3	
	4	01	03 88	01	24 88	22	
						<b>Total: 28</b>	<b>Completed</b>
197	2	01	05 88	01	07 88	3	
	3	01	08 88	01	10 88	3	
	4	01	11 88	02	01 88	22	
						<b>Total: 28</b>	<b>Completed</b>
202	2	04	01 88	04	03 88	3	
	3	04	04 88	04	06 88	3	
	4	04	07 88	04	28 88	22	
						<b>Total: 28</b>	<b>Completed</b>
203	2	04	01 88	04	03 88	3	
	3	04	04 88	04	06 88	3	
	4	04	07 88	04	28 88	22	
						<b>Total: 28</b>	<b>Completed</b>
206	2	06	30 88	07	02 88	3	
	3	07	03 88	07	05 88	3	
	4	07	06 88	07	27 88	22	
						<b>Total: 28</b>	<b>Completed</b>
210	2	07	01 88	07	03 88	3	
	3	07	04 88	07	06 88	3	
	4	07	07 88	07	28 88	22	
						<b>Total: 28</b>	<b>Completed</b>

172

FCE 20124/702 i

20

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
214	2	07	03	88	07	05	88	3	Completed
	3	07	06	88	07	08	88	3	
	4	07	09	88	07	30	88	22	
								<b>Total: 28</b>	
216	2	07	05	88	07	07	88	3	Completed
	3	07	08	88	07	10	88	3	
	4	07	11	88	08	01	88	22	
								<b>Total: 28</b>	
218	2	03	28	88	03	30	88	3	Completed
	3	03	31	88	04	03	88	4	
	4	04	04	88	04	23	88	20	
								<b>Total: 27</b>	
219	2	03	27	88	03	29	88	3	Completed
	3	03	30	88	04	01	88	3	
	4	04	02	88	04	22	88	21	
								<b>Total: 27</b>	
226	2	06	25	88	06	27	88	3	Completed
	3	06	28	88	06	30	88	3	
	4	07	01	88	07	23	88	23	
								<b>Total: 29</b>	
227	2	07	02	88	07	04	88	3	Completed
	3	07	05	88	07	07	88	3	
	4	07	08	88	07	29	88	22	
	2	07	30	88	07	30	88	1	
								<b>Total: 29</b>	
230	2	08	08	88	08	10	88	3	Ineffectiveness/ Deterioration
	3	08	11	88	08	14	88	4	
	4	08	15	88	08	18	88	4	
								<b>Total: 11</b>	

FCE 20124/702 i

21

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
233	2	09	02	88	09	04	88	3	Ineffectiveness/ Deterioration
	3	09	05	88	09	08	88	4	
	4	09	09	88	09	16	88	8	
								<b>Total: 15</b>	
237	2	11	22	88	11	24	88	3	Completed
	3	11	25	88	11	27	88	3	
	4	11	28	88	12	19	88	22	
								<b>Total: 28</b>	
238	2	11	24	88	11	27	88	4	Completed
	3	11	28	88	11	29	88	2	
	4	11	30	88	12	04	88	5	
	3	12	05	88	12	06	88	2	
	4	12	07	88	12	21	88	15	
								<b>Total: 28</b>	
243	2	10	31	88	11	02	88	3	Completed
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								<b>Total: 28</b>	
245	2	10	31	88	11	02	88	3	Completed
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								<b>Total: 28</b>	
249	2	11	01	88	11	03	88	3	Completed
	3	11	04	88	11	07	88	4	
	4	11	08	88	11	28	88	21	
								<b>Total: 28</b>	
251	2	11	01	88	11	03	88	3	Completed
	3	11	04	88	11	06	88	3	
	4	11	07	88	11	28	88	22	
								<b>Total: 28</b>	
254	2	11	02	88	11	04	88	3	Completed
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								<b>Total: 28</b>	

174

FCE 20124/702 i

22

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
255	2	11	02	88	11	04	88	3	Completed
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								<b>Total: 28</b>	
260	2	12	29	88	12	31	88	3	Completed
	3	01	01	89	01	04	89	4	
	4	01	05	89	01	25	89	21	
								<b>Total: 28</b>	
262	2	12	29	88	12	31	88	3	Completed
	3	01	01	89	01	04	89	4	
	4	01	05	89	01	25	89	21	
								<b>Total: 28</b>	
268	2	01	05	88	01	07	89	3	Completed
	3	01	08	89	01	10	89	3	
	4	01	11	89	02	01	89	22	
								<b>Total: 28</b>	
269	2	01	05	88	01	07	89	3	Completed
	3	01	08	89	01	10	89	3	
	4	01	11	89	02	01	89	22	
								<b>Total: 28</b>	
273	2	01	06	88	01	08	89	3	Completed
	3	01	09	89	01	12	89	4	
	4	01	12	89	02	02	89	21	
								<b>Total: 28</b>	

**Summary**

Total No of cases: 83

Duration of treatment (days): min 10 max 29 mean 26.85

FCE 20124/702 i

23

**REBOXETINE, Protocol ADE 08**

**Table 4a- Experimental Treatment**

**Treatment Group "C"**

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
003	2	04	27	88	05	01	88	5	
	3	05	02	88	05	09	88	8	
	2	05	10	88	05	15	88	6	
	3	05	16	88	05	25	88	10	
<b>Total: 29</b>									<b>Completed</b>
006	2	08	26	88	08	28	88	3	
	3	08	29	88	09	01	88	4	
	4	09	02	88	09	23	88	22	
<b>Total: 29</b>									<b>Completed</b>
007	2	09	20	88	09	22	88	3	
	3	09	23	88	09	26	88	4	
<b>Total: 7</b>									<b>Patient Refusal</b>
008	2	11	02	88	11	04	88	3	
	3	11	05	88	11	08	88	4	
	4	11	09	88	11	30	88	22	
<b>Total: 29</b>									<b>Completed</b>
016	2	11	28	88	12	01	88	4	
	3	12	02	88	12	04	88	3	
	4	12	05	88	12	26	88	22	
<b>Total: 29</b>									<b>Completed</b>
018	2	12	23	88	12	26	88	4	
	3	12	27	88	12	29	88	3	
	4	12	30	88	01	20	89	22	
<b>Total: 29</b>									<b>Completed</b>
026	2	10	12	88	10	14	88	3	
	3	10	15	88	10	19	88	5	
	4	10	18	88	11	08	88	22	
<b>Total: 30</b>									<b>Completed</b>

176



FCE 20124/702 i

24

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
027	2	01	26	89	01	28	89	3	
	3	01	29	89	01	31	89	3	
	4	02	01	89	02	22	89	22	
								<b>Total: 28</b>	<b>Completed</b>
033	2	08	19	88	08	21	88	3	
	3	08	22	88	08	24	88	3	
	4	08	25	88	09	15	88	22	
								<b>Total: 28</b>	<b>Completed</b>
036	2	09	13	88	09	15	88	3	
	3	09	16	88	09	18	88	3	
	4	09	19	88	10	10	88	22	
								<b>Total: 28</b>	<b>Completed</b>
039	2	10	10	88	10	12	88	3	
	3	10	13	88	10	15	88	3	
	4	10	16	88	11	06	88	22	
								<b>Total: 28</b>	<b>Completed</b>
040	2	01	24	89	01	26	89	3	
	3	01	27	89	01	29	89	3	
	4	01	30	89	02	20	89	22	
								<b>Total: 28</b>	<b>Completed</b>
043	2	01	24	89	01	26	89	3	
	3	01	27	89	01	29	89	3	
	4	01	30	89	02	20	89	22	
								<b>Total: 28</b>	<b>Completed</b>
046	2	09	13	88	09	15	88	3	
	3	09	16	88	09	18	88	3	
	4	09	19	88	10	10	88	22	
								<b>Total: 28</b>	<b>Completed</b>
052	2	02	25	88	02	27	88	3	
	3	02	28	88	03	01	88	3	
	4	03	02	88	03	24	88	22	
								<b>Total: 28</b>	<b>Completed</b>

177

FCE 20124/702 i

25

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
053	2	03	22	88	03	24	88	3	Completed
	3	03	25	88	03	27	88	3	
	4	03	28	88	04	18	88	22	
								<b>Total: 28</b>	
058	2	05	03	88	05	05	88	3	Completed
	3	05	06	88	05	08	88	3	
	4	05	09	88	05	30	88	22	
								<b>Total: 28</b>	
059	2	04	25	88	04	27	88	3	Completed
	3	04	28	88	04	30	88	3	
	4	05	01	88	05	22	88	22	
								<b>Total: 28</b>	
062	2	05	23	88	05	25	88	3	Completed
	3	05	26	88	05	28	88	3	
	4	05	29	88	06	19	88	22	
								<b>Total: 28</b>	
063	2	05	16	88	05	18	88	3	Completed
	3	05	19	88	05	21	88	3	
	4	05	22	88	06	12	88	22	
								<b>Total: 28</b>	
069	2	05	30	88	06	01	88	3	Completed
	3	06	02	88	05	04	88	3	
	4	06	05	88	06	26	88	22	
								<b>Total: 28</b>	
071	2	05	31	88	06	02	88	3	Completed
	3	06	03	88	06	05	88	3	
	4	06	06	88	06	27	88	22	
								<b>Total: 28</b>	
074	2	01	25	88	01	27	88	3	Adverse Experience
	3	01	28	88	01	30	88	3	
	4	01	31	88	02	08	88	9	
	3	02	09	88	02	11	88	3	
								<b>Total: 18</b>	

FCE 20124/702 i

26

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
076	2	03	11	88	03	13	88	3	
	3	03	14	88	03	16	88	3	
	4	03	17	88	04	07	88	22	
								<b>Total: 28</b>	<b>Completed</b>
081	2	05	20	88	05	22	88	3	
	3	05	23	88	05	25	88	3	
	4	05	26	88	06	06	88	12	
	3	06	07	88	06	16	88	10	
								<b>Total: 28</b>	<b>Completed</b>
082	2	05	21	88	05	23	88	3	
	3	05	24	88	05	26	88	3	
	4	05	27	88	06	17	88	22	
								<b>Total: 28</b>	<b>Completed</b>
086	2	08	09	88	08	11	88	3	
	3	08	12	88	08	14	88	3	
	4	08	15	88	08	25	88	11	
	3	08	26	88	09	05	88	11	
								<b>Total: 28</b>	<b>Completed</b>
089	2	12	01	88	12	03	88	3	
	3	12	04	88	12	06	88	3	
	4	12	07	88	12	28	88	22	
								<b>Total: 28</b>	<b>Completed</b>
092	2	01	03	89	01	05	89	3	
	3	01	06	89	01	08	89	3	
	4	01	09	89	01	30	89	22	
								<b>Total: 28</b>	<b>Completed</b>
093	2	01	07	89	01	09	89	3	
	3	01	10	89	01	13	89	4	
	4	01	14	89	01	23	89	10	
								<b>Total: 17</b>	<b>Ineffectiveness/ Deterioration</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

27

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
097	2	01	19	88	01	21	88	3	Completed
	3	01	22	88	01	24	88	3	
	4	01	25	88	02	15	88	22	
								<b>Total: 28</b>	
100	2	04	18	88	04	20	88	3	Completed
	3	04	21	88	04	23	88	3	
	4	04	24	88	05	12	88	19	
	2	05	13	88	05	15	88	3	
								<b>Total: 28</b>	
104	2	05	13	88	05	15	88	3	Completed
	3	05	16	88	05	18	88	3	
	4	05	19	88	06	09	88	22	
								<b>Total: 28</b>	
105	2	05	24	88	05	26	88	3	Ineffectiveness/ Deterioration
	3	05	27	88	05	29	88	3	
	4	05	30	88	06	08	88	10	
								<b>Total: 16</b>	
111	2	10	04	88	10	06	88	3	Completed
	3	10	07	88	10	09	88	3	
	4	10	10	88	10	21	88	12	
	2	10	22	88	10	31	88	10	
								<b>Total: 28</b>	
112	2	10	13	88	10	15	88	3	Completed
	3	10	16	88	10	18	88	3	
	4	10	19	88	11	08	88	21	
								<b>Total: 27</b>	
116	2	11	08	88	11	10	88	3	Completed
	3	11	11	88	11	13	88	3	
	4	11	14	88	12	05	88	22	
								<b>Total: 28</b>	

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

28

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
117	2	12	23	88	12	25	88	3	Completed
	3	12	26	88	12	28	88	3	
	4	12	29	88	01	19	89	22	
								<b>Total: 28</b>	
121	2	04	18	88	04	20	88	3	Completed
	3	04	21	88	04	23	88	3	
	4	04	24	88	05	15	88	22	
								<b>Total: 28</b>	
125	2	07	21	88	07	23	88	3	Ineffectiveness/ Deterioration
	3	07	24	88	07	26	88	3	
	4	07	27	88	08	10	88	15	
								<b>Total: 21</b>	
128	2	08	10	88	08	12	88	3	Completed
	3	08	13	88	08	15	88	3	
	4	08	16	88	09	06	88	22	
								<b>Total: 28</b>	
129	2	08	12	88	08	14	88	3	Completed
	3	08	15	88	08	17	88	3	
	4	08	18	88	09	08	88	22	
								<b>Total: 28</b>	
137	2	12	03	88	11	05	88	3	Completed
	3	12	06	88	11	08	88	3	
	4	12	09	88	12	30	88	22	
								<b>Total: 28</b>	
138	2	12	22	88	11	24	88	3	Adverse Experience
	3	12	25	88	11	27	88	3	
	4	12	28	88	01	10	89	14	
								<b>Total: 20</b>	
141	2	01	13	89	01	15	89	3	Completed
	3	01	16	89	01	18	89	3	
	4	01	19	89	02	09	89	22	
								<b>Total: 28</b>	

181

FCE 20124/702 i

29

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
145	2	05	04	89	05	06	89	3	
	3	05	07	89	05	09	89	3	
	4	05	10	89	05	31	89	22	
								<b>Total: 28</b>	<b>Completed</b>
173	2	01	05	88	01	07	88	3	
	3	01	08	88	01	11	88	4	
	4	01	12	88	02	01	88	21	
								<b>Total: 28</b>	<b>Completed</b>
174	2	01	19	88	01	21	88	3	
	3	01	22	88	01	25	88	4	
	4	01	26	88	02	15	88	21	
								<b>Total: 28</b>	<b>Completed</b>
175	2	01	19	88	01	21	88	3	
	3	01	22	88	01	25	88	4	
	4	01	26	88	02	15	88	21	
								<b>Total: 28</b>	<b>Completed</b>
178	2	04	01	88	04	03	88	3	
	3	04	04	88	04	07	88	4	
	4	04	08	88	04	28	88	21	
								<b>Total: 28</b>	<b>Completed</b>
182	2	06	30	88	07	02	88	3	
	3	07	03	88	07	06	88	4	
	4	07	07	88	07	27	88	21	
								<b>Total: 28</b>	<b>Completed</b>
183	2	06	30	88	07	02	88	3	
	3	07	03	88	07	06	88	4	
	4	07	07	88	07	27	88	21	
								<b>Total: 28</b>	<b>Completed</b>
190	2	07	01	88	07	05	88	5	
	3	07	06	88	07	09	88	2	
	4	07	10	88	07	30	88	21	
								<b>Total: 28</b>	<b>Completed</b>

182

FCE 20124/702 i

30

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
191	2	07	05	88	07	07	88	3	Completed
	3	07	08	88	07	11	88	4	
	4	07	12	88	08	01	88	21	
								<b>Total: 28</b>	
195	2	12	28	87	12	30	87	3	Completed
	3	12	31	87	01	02	88	3	
	4	01	03	88	01	24	88	22	
								<b>Total: 28</b>	
196	2	01	05	88	01	07	88	3	Completed
	3	01	08	88	01	10	88	3	
	4	01	11	88	02	01	88	22	
								<b>Total: 28</b>	
201	2	04	01	88	04	03	88	3	Completed
	3	04	04	88	04	06	88	3	
	4	04	07	88	04	28	88	22	
								<b>Total: 28</b>	
204	2	04	05	88	04	07	88	3	Completed
	3	04	08	88	04	10	88	3	
	4	04	11	88	05	02	88	22	
								<b>Total: 28</b>	
205	2	06	30	88	07	02	88	3	Completed
	3	07	03	88	07	05	88	3	
	4	07	06	88	07	27	88	22	
								<b>Total: 28</b>	
207	2	06	30	88	07	02	88	3	Completed
	3	07	03	88	07	05	88	3	
	4	07	06	88	07	27	88	22	
								<b>Total: 28</b>	
212	2	07	03	88	07	05	88	3	Completed
	3	07	06	88	07	08	88	3	
	4	07	09	88	07	30	88	22	
								<b>Total: 28</b>	

FCE 20124/702 i

31

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
213	2	07	03	88	07	05	88	3	
	3	07	06	88	07	08	88	3	
	4	07	09	88	07	30	88	22	
								<b>Total: 28</b>	<b>Completed</b>
220	2	03	31	88	04	02	88	3	
	3	04	03	88	04	05	88	3	
	4	04	06	88	04	26	88	21	
								<b>Total: 27</b>	<b>Completed</b>
221	2	04	01	88	04	03	88	3	
	3	04	04	88	04	06	88	3	
	4	04	07	88	04	17	88	11	
	3	04	18	88	04	20	88	3	
	4	04	21	88	04	27	88	7	
								<b>Total: 27</b>	<b>Completed</b>
225	2	06	14	88	06	16	88	3	
	3	06	17	88	06	19	88	3	
	4	06	20	88	07	05	88	16	
								<b>Total: 22</b>	<b>Ineffectiveness/ Deterioration</b>
228	2	07	04	88	07	06	88	3	
	3	07	07	88	07	08	88	2	
	4	07	09	88	07	14	88	6	
								<b>Total: 11</b>	<b>Ineffectiveness/ Deterioration</b>
229	2	08	08	88	08	10	88	3	
	3	08	11	88	07	14	88	4	
	4	08	15	88	09	04	88	21	
	2	09	05	88	09	05	88	1	
								<b>Total: 29</b>	<b>Completed</b>
234	2	10	03	88	10	05	88	3	
	3	10	06	88	10	08	88	3	
	4	10	09	88	10	30	88	22	
	2	10	31	88				1	
								<b>Total: 29</b>	<b>Completed</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

32

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
236	2	11	16	88	11	18	88	3	
	3	11	19	88	11	21	88	3	
	4	11	22	88	12	13	88	22	
								<b>Total: 28</b>	<b>Completed</b>
239	2	11	28	88	11	30	88	3	
	3	12	01	88	12	02	88	2	
	4	12	03	88	12	25	88	23	
	2	12	26	88				1	
								<b>Total: 29</b>	<b>Completed</b>
241	2	10	31	88	11	02	88	3	
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								<b>Total: 28</b>	<b>Completed</b>
242	2	10	31	88	11	02	88	3	
	3	11	03	88	11	06	88	4	
	4	11	07	88	11	27	88	21	
								<b>Total: 28</b>	<b>Completed</b>
250	2	11	01	88	11	03	88	3	
	3	11	04	88	11	06	88	3	
	4	11	07	88	11	28	88	22	
								<b>Total: 28</b>	<b>Completed</b>
252	2	11	01	88	11	03	88	3	
	3	11	04	88	11	06	88	3	
	4	11	07	88	11	28	88	22	
								<b>Total: 28</b>	<b>Completed</b>
253	2	11	02	88	11	04	88	3	
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								<b>Total: 28</b>	<b>Completed</b>
256	2	11	02	88	11	04	88	3	
	3	11	05	88	11	07	88	3	
	4	11	08	88	11	29	88	22	
								<b>Total: 28</b>	<b>Completed</b>

185

Pat. No.	No. of cps	From			To			Duration	Reason for Discontinuation
		m	d	y	m	d	y		
261	2	12	29	88	12	31	88	3	
	3	01	01	89	01	04	89	4	
	4	01	05	89	01	25	89	21	
								<b>Total: 28</b>	<b>Completed</b>
264	2	12	30	88	01	01	89	3	
	3	01	02	89	01	05	89	4	
	4	01	06	89	01	26	89	21	
								<b>Total: 28</b>	<b>Completed</b>
265	2	12	30	88	01	01	89	3	
	3	01	02	89	01	05	89	4	
	4	01	06	89	01	26	89	21	
								<b>Total: 28</b>	<b>Completed</b>
266	2	12	30	88	01	01	89	3	
	3	01	02	89	01	05	89	4	
	4	01	06	89	01	26	89	21	
								<b>Total: 28</b>	<b>Completed</b>
272	2	01	06	88	01	08	89	3	
	3	01	09	89	01	12	89	4	
	4	01	12	89	02	02	89	21	
								<b>Total: 28</b>	<b>Completed</b>

**Summary**

**Total No of cases: 81**

**Duration of treatment (days): min 7 max 30 mean 26.58**

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08  
Table 4b - Concomitant Medications  
Treatment Group "A"

Pat. No	Medication name	From m d y	To m d y	Reason for Administration
65	Nitrazepam	05 04 88	05 31 88	Insomnia
68	Nitrazepam	05 19 88	06 15 88	Insomnia
79	Lactulose	04 10 88	04 22 88	Constipation
79	Chloral Hydrate	04 12 88	04 22 88	Insomnia
80	Vitamins	04 27 88	05 03 88	Diet Addition
80	Gangliosydes	04 19 88	05 03 88	Paresis Sequelae
87	Chloral Hydrate	08 23 88	09 13 88	Insomnia
101	Triazolam	04 27 88	05 10 88	Severe Insomnia
123	Triazolam	06 15 88	07 14 88	Insomnia
142	Triazolam	02 17 89	03 16 89	Insomnia
222	Chlorpheniramine	04 30 88	04 30 88	Cutaneous Rash
222	Chlorpheniramine	05 02 88	05 02 88	Cutaneous Rash
223	Chloral Hydrate	04 25 88	04 29 88	Insomnia
232	Hyoscine	09 02 88	09 02 88	Abdominal Pain
235	Trimethoprim			
	Sulphamethoxazole	11 04 88	11 15 88	Pharyngitis
235	Dextromethorphan	11 07 88	11 15 88	Cough
240	Cortisone Cream	12 02 88	12 27 88	Hemorrhoids
240	Phenolphthalein	12 12 88	12 14 88	Constipation

No. of patients with concomitant medications = 12

FCE 20124/702 i

2

REBOXETINE, Protocol ADE 08  
Table 4b - Concomitant Medications  
Treatment Group "B"

Pat. No	Medication name	From m d y	To m d y	Reason for Administration
10	Oxazepam	06 24 88	07 18 88	Insomnia
15	Alimemazine	11 21 88	11 21 88	Insomnia
51	Nitrazepam	03 03 88	03 10 88	Insomnia
66	Nitrazepam	04 09 88	05 07 88	Insomnia
67	Nitrazepam	04 16 88	05 13 88	Insomnia
70	Nitrazepam	05 25 88	06 21 88	Insomnia
78	Nifedipine	03 28 88	04 14 88	Hypertension
83	Chloral Hydrate	06 11 88	06 16 88	Insomnia
83	Chloral Hydrate	06 17 88	06 18 88	Insomnia
84	Chloral Hydrate	06 11 88	06 18 88	Insomnia
84	Lactulose	06 13 88	06 15 88	Constipation
84	Nifedipine	06 09 88	06 09 88	Hypertension
84	Chloral Hydrate	06 19 88	07 05 88	Insomnia
84	Clonidine	06 16 88	06 16 88	Hypertension
84	Hydrocortisone	06 16 88	06 16 88	Hypotension
91	Chloral Hydrate	12 22 88	01 17 88	Insomnia
106	Corticosteroids	06 05 88	06 06 88	Hypotension
106	Corticosteroids	06 14 88	06 15 88	Hypotension
106	Mercapto Propionyl Glycine	06 13 88	06 14 88	Constipation
139	Triazolam	01 12 89	01 16 89	Insomnia
140	Triazolam	01 12 89	01 25 89	Insomnia
148	Triazolam	07 16 88	07 23 88	Insomnia
218	Aspirin	04 10 88	04 10 88	Fever
226	Chloral Hydrate	06 28 88	07 21 88	Insomnia
230	Diazepam	08 15 88	08 15 88	Anx./Agitation
233	Furosemide	09 09 88	09 09 88	Hypertension
233	Chloral Hydrate	09 09 88	09 16 88	Insomnia
233	Hydrochlorothiazide	09 12 88	09 16 88	Hypertension

No. of patients with concomitant medications = 18

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
Table 4b - Concomitant Medications  
Treatment Group "C"

Pat. No	Medication name	From m d y	To m d y	Reason for Administration
6	Metronidazole	09 14 88	09 26 88	Vaginal Infection
6	Alprazolam	09 01 88	09 01 88	Anxiety
6	Tinidazole	09 14 88	09 16 88	Vaginal Infection
7	Alprazolam	09 23 88	09 23 88	Anxiety
62	Nitrazepam	05 23 88	06 08 88	Insomnia
71	Nitrazepam	05 31 88	06 27 88	Insomnia
76	Cinnarizine	03 24 88	04 07 88	Tinnitus
81	Chloral Hydrate	05 21 88	05 23 88	Insomnia
81	Chloral Hydrate	05 24 88	06 09 88	Insomnia
82	Chloral Hydrate	05 25 88	06 12 88	Insomnia
86	Chloral Hydrate	08 15 88	09 05 88	Insomnia
89	Chloral Hydrate	12 02 88	12 03 88	Insomnia
89	Chloral Hydrate	12 03 88	12 24 88	Insomnia
105	Diphenoxylate	06 02 88	06 05 88	Diarrhea
105	Atropine	06 02 88	06 05 88	Diarrhea
105	Bacitracin	06 06 88	06 07 88	Diarrhea
105	Neomycin	06 06 88	06 07 88	Diarrhea
128	Ergotamine	08 27 88	09 06 88	Headache
137	Triazolam	12 03 88	12 30 88	Insomnia
145	Triazolam	05 04 88	05 06 88	Insomnia
145	Triazolam	05 07 88	05 16 88	Insomnia
145	Diazepam	05 17 88	05 31 88	Insomnia
228	Lorazepam	07 05 88	07 05 88	Insomnia
228	Chloral Hydrate	07 05 88	07 13 88	Insomnia
228	Diazepam	07 13 88	07 13 88	Great Anxiety
228	Flunitrazepam	07 13 88	07 13 88	Insomnia
229	Diazepam	09 02 88	09 02 88	Anxiety
236	Chloral Hydrate	11 19 88	11 21 88	Insomnia
239	Phenolphthalein	12 12 88	12 13 88	Constipation

No. of Patients with concomitant medications = 17

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 5a Hamilton Depression Rating Scale  
Treatment Group "A"

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 -01	3	0	3	1	2	0	4	0	1	4	1	0	0	0	2	0	0	21.00	3.00	5.00
5 -01	3	0	1	2	2	2	2	1	1	3	1	1	1	0	3	0	0	23.00	8.00	4.00
9 -01	3	1	0	2	1	0	4	1	1	2	0	0	2	0	2	0	0	19.00	5.00	3.00
12 -01	3	2	2	2	1	0	3	2	0	2	2	2	2	1	2	1	1	28.00	8.00	7.00
13 -01	3	2	2	2	2	2	2	0	2	4	0	0	0	1	1	0	0	23.00	6.00	5.00
14 -01	2	2	1	1	2	1	3	2	1	3	1	0	1	0	1	0	0	21.00	5.00	4.00
25 -01	3	0	2	1	1	1	3	3	0	2	1	1	1	2	0	1	0	22.00	6.00	2.00
30 -01	3	1	1	1	1	2	4	2	2	2	3	2	2	2	3	1	1	33.00	9.00	6.00
34 -01	2	0	0	0	0	2	3	3	1	2	2	0	0	2	0	0	0	17.00	2.00	.00
35 -01	2	1	1	1	1	1	3	3	1	3	2	1	2	2	2	1	1	28.00	7.00	5.00
37 -01	2	1	1	2	2	2	2	2	2	2	1	1	1	2	1	1	1	26.00	9.00	4.00
38 -01	3	1	1	1	1	1	3	2	2	2	1	1	1	2	1	1	1	25.00	6.00	4.00
45 -01	2	0	3	2	1	2	3	3	1	2	1	1	1	2	0	1	0	25.00	8.00	3.00
48 -01	2	1	0	1	1	1	3	1	2	2	1	1	1	2	0	1	0	20.00	6.00	1.00
49 -01	2	1	2	1	1	1	2	2	0	2	2	1	1	1	3	1	1	24.00	6.00	7.00
50 -01	3	2	2	1	1	1	3	3	0	3	2	1	1	1	3	1	1	29.00	6.00	8.00
56 -01	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	0	1	22.00	5.00	6.00
57 -01	2	2	2	1	1	1	2	2	0	3	2	1	1	1	3	1	1	26.00	6.00	8.00
64 -01	2	2	2	1	1	2	2	2	2	3	3	1	1	1	2	1	1	29.00	7.00	7.00
65 -01	2	1	2	1	2	1	2	1	0	2	2	1	1	1	3	1	1	24.00	7.00	7.00
68 -01	3	2	2	1	2	1	2	2	0	3	3	1	1	2	3	1	1	30.00	7.00	8.00
72 -01	2	1	0	1	1	1	2	2	0	1	1	1	1	1	2	0	1	18.00	5.00	4.00
73 -01	3	1	2	2	2	0	3	0	2	3	2	2	1	2	3	1	1	30.00	8.00	7.00
75 -01	3	2	1	1	2	2	3	1	2	1	3	1	1	2	2	2	1	32.00	9.00	6.00
79 -01	4	3	2	1	1	2	3	0	2	2	3	1	1	2	2	2	2	33.00	8.00	9.00
80 -01	3	2	0	2	1	2	3	1	2	1	0	1	1	2	0	1	0	22.00	8.00	2.00
85 -01	3	0	1	1	2	2	3	1	1	2	2	1	2	2	0	0	0	23.00	8.00	1.00
87 -01	3	0	0	1	1	2	3	1	1	3	3	0	2	1	1	1	0	23.00	7.00	1.00
94 -01	3	2	0	0	0	2	4	2	2	1	3	2	2	2	1	1	0	27.00	7.00	3.00
96 -01	4	2	0	2	1	1	3	1	1	2	2	0	2	2	0	0	1	24.00	6.00	3.00
99 -01	4	1	1	2	1	1	3	3	0	0	1	1	2	1	0	2	0	23.00	9.00	2.00
101 -01	3	0	1	2	1	1	3	3	0	1	3	1	2	1	2	0	0	24.00	7.00	3.00
107 -01	4	2	1	2	2	2	4	1	2	1	2	1	2	0	2	2	0	30.00	11.00	5.00
108 -01	4	0	1	1	2	2	4	3	0	0	2	1	2	1	1	1	0	25.00	9.00	2.00
109 -01	3	2	1	2	0	0	3	1	3	3	2	1	2	0	3	0	0	26.00	5.00	6.00
114 -01	4	1	1	2	2	2	3	1	2	3	3	2	2	2	3	2	0	35.00	12.00	5.00
115 -01	4	1	2	2	2	2	3	0	2	3	2	1	1	0	3	2	1	31.00	10.00	7.00
120 -01	3	0	1	2	2	2	3	1	3	3	3	2	2	0	3	0	0	30.00	10.00	4.00
122 -01	3	0	4	1	1	2	3	1	1	3	2	1	2	1	1	1	0	27.00	8.00	5.00
123 -01	3	2	2	0	1	0	3	3	1	2	1	0	1	2	2	1	1	25.00	3.00	7.00
130 -01	3	3	3	0	1	1	4	1	1	3	2	1	1	2	3	1	1	31.00	5.00	10.00
131 -01	4	3	2	0	1	1	3	1	0	2	2	1	2	2	3	2	1	30.00	7.00	9.00
134 -01	3	2	2	2	2	1	3	1	0	2	2	1	2	2	1	2	1	29.00	10.00	6.00
135 -01	2	0	2	1	2	1	1	2	0	2	3	2	2	2	1	2	1	26.00	10.00	4.00
142 -01	3	2	0	1	2	1	1	1	0	2	2	1	2	1	2	2	1	24.00	9.00	5.00
146 -01	3	0	2	1	0	2	3	0	0	4	2	1	2	1	3	0	1	25.00	6.00	6.00
169 -01	3	3	3	0	1	1	3	2	1	1	1	1	1	1	3	2	1	28.00	6.00	10.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

2

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
171	-01	3	2	3	2	2	1	3	2	0	1	2	1	1	1	3	2	1	30.00	9.00	9.00
176	-01	3	2	3	0	1	1	3	2	2	1	1	1	1	1	3	2	1	28.00	6.00	9.00
177	-01	3	2	3	0	2	1	3	2	0	1	1	1	2	1	3	2	0	27.00	8.00	8.00
184	-01	3	2	3	1	1	2	3	1	0	1	1	1	1	1	3	2	1	27.00	8.00	9.00
185	-01	3	2	2	1	1	2	3	2	0	1	2	1	1	1	3	2	1	28.00	8.00	8.00
189	-01	3	2	3	1	1	2	3	2	0	0	1	1	1	2	3	1	1	27.00	7.00	9.00
192	-01	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	1	1	25.00	7.00	8.00
194	-01	3	3	2	1	1	1	3	2	3	2	2	1	1	1	2	1	1	30.00	6.00	8.00
198	-01	3	3	2	2	1	0	3	2	2	2	2	1	1	1	2	0	1	28.00	5.00	8.00
199	-01	3	3	3	1	1	2	3	1	2	2	2	1	1	1	2	1	1	30.00	7.00	9.00
200	-01	3	2	2	0	2	1	3	1	2	2	1	1	1	1	2	0	1	25.00	5.00	7.00
208	-01	2	3	3	1	0	2	3	2	4	3	2	0	1	0	2	2	0	30.00	6.00	8.00
209	-01	4	3	1	1	1	1	3	1	3	2	2	1	1	1	1	2	1	29.00	7.00	6.00
211	-01	3	3	2	1	0	1	3	3	2	2	2	1	1	1	2	0	1	28.00	4.00	8.00
215	-01	4	3	4	2	1	2	3	2	3	3	2	1	1	2	3	2	1	39.00	9.00	11.00
217	-01	3	0	3	2	1	2	3	0	1	2	1	1	2	2	1	2	0	26.00	10.00	4.00
222	-01	3	0	1	2	2	1	4	2	1	1	1	1	2	2	0	2	0	25.00	10.00	1.00
223	-01	2	1	2	2	2	2	4	0	4	4	2	2	2	2	3	2	0	36.00	12.00	6.00
224	-01	3	1	1	0	1	0	3	3	1	3	0	1	0	0	0	1	0	18.00	3.00	2.00
231	-01	4	0	0	2	2	2	3	0	2	3	1	1	2	2	1	2	0	27.00	11.00	1.00
232	-01	4	0	0	2	1	1	4	2	0	0	1	2	2	2	1	2	0	24.00	10.00	1.00
235	-01	4	2	0	2	2	2	3	2	1	0	1	2	2	2	1	2	0	28.00	12.00	3.00
240	-01	3	1	2	1	0	1	3	0	0	2	1	1	2	2	1	2	0	22.00	7.00	4.00
244	-01	3	2	2	1	1	2	3	1	1	1	2	1	1	1	2	0	1	25.00	6.00	7.00
246	-01	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	1	0	24.00	7.00	7.00
247	-01	1	2	2	1	1	2	3	1	0	1	1	1	1	1	2	0	0	20.00	6.00	6.00
248	-01	3	2	2	1	2	1	3	1	1	1	1	1	1	1	3	2	1	27.00	8.00	8.00
257	-01	3	2	1	1	1	0	3	1	3	1	1	1	1	2	2	1	1	25.00	5.00	6.00
258	-01	4	3	2	2	0	0	3	2	3	2	2	1	1	0	2	0	1	28.00	4.00	8.00
259	-01	3	2	2	1	1	2	3	1	1	1	1	1	1	2	2	1	0	25.00	7.00	6.00
263	-01	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	1	1	25.00	7.00	8.00
267	-01	3	2	1	0	0	1	3	1	2	2	1	1	1	1	1	0	0	21.00	4.00	4.00
270	-01	3	2	2	1	0	1	3	1	1	2	2	1	1	1	2	0	1	24.00	4.00	7.00
271	-01	2	2	1	0	0	0	3	2	1	2	2	1	1	2	3	2	0	24.00	4.00	6.00

FCE 20124/702 i

3

Treatment Group "A"

Screen (Period -01)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Depressed mood	2.95	.07
2. Feelings of guilt	1.53	.11
3. Suicide	1.63	.11
4. Insomnia, early	1.19	.07
5. Insomnia, middle	1.19	.07
6. Insomnia, late	1.31	.08
7. Work and activities	2.95	.07
8. Retardation	1.51	.10
9. Agitation	1.15	.12
10. Anxiety, psychic	1.98	.11
11. Anxiety, somatic	1.65	.09
12. Somatic symptoms, gastrointestinal	1.01	.05
13. Somatic symptoms, general	1.31	.06
14. Genital symptoms	1.28	.08
15. Hypochondriasis	1.90	.11
16. Weight	1.09	.09
17. Insight	.57	.06
Total Score	26.19	.45
Factor 1 - Vegetative signs	7.09	.24
Factor 2 - Vital disturbances	5.63	.29

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

4

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 000	3	0	3	1	2	0	4	0	1	4	1	0	0	0	2	0	0	21.00	3.00	5.00
5 000	3	0	1	2	2	2	3	1	1	3	1	1	1	0	3	0	0	24.00	8.00	4.00
9 000	3	1	0	2	1	0	4	0	1	2	0	0	2	0	2	0	0	18.00	5.00	3.00
12 000	3	2	2	2	2	1	3	2	1	2	2	2	2	1	2	1	1	31.00	10.00	7.00
13 000	3	3	2	2	2	2	2	0	2	4	0	0	0	1	1	0	0	24.00	6.00	6.00
14 000	2	2	1	1	2	1	3	2	1	3	1	0	1	0	1	0	0	21.00	5.00	4.00
25 000	3	0	2	2	1	1	3	3	1	2	1	1	1	2	0	1	0	24.00	7.00	2.00
30 000	3	1	1	1	1	2	4	2	2	2	3	2	2	2	3	1	1	33.00	9.00	6.00
34 000	2	0	0	0	1	2	3	3	2	2	2	0	0	2	0	0	0	19.00	3.00	.00
35 000	2	1	1	1	1	1	3	3	1	3	2	1	2	2	2	1	1	28.00	7.00	5.00
37 000	2	1	1	2	2	2	2	2	2	2	1	1	1	2	1	1	1	26.00	9.00	4.00
38 000	3	1	1	1	1	1	3	2	2	2	1	1	1	2	1	1	1	25.00	6.00	4.00
45 000	2	0	3	2	1	2	3	3	1	2	1	1	1	2	0	1	0	25.00	8.00	3.00
48 000	2	1	0	1	1	1	3	1	2	2	1	1	1	2	0	1	0	20.00	6.00	1.00
49 000	2	2	1	1	1	1	2	2	0	2	2	1	1	1	3	1	1	24.00	6.00	7.00
50 000	3	2	2	1	1	1	3	3	0	2	2	2	1	1	3	1	1	29.00	7.00	8.00
56 000	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	0	1	22.00	5.00	6.00
57 000	2	2	2	1	1	1	2	2	0	2	2	1	1	1	2	1	1	24.00	6.00	7.00
64 000	2	2	1	1	2	1	2	2	1	2	3	1	1	1	2	1	1	26.00	7.00	6.00
65 000	2	1	2	1	1	1	2	1	0	2	1	1	1	1	2	1	1	21.00	6.00	6.00
68 000	3	2	2	1	1	1	2	2	0	2	2	1	2	2	2	1	1	27.00	7.00	7.00
72 000	2	1	0	1	1	1	2	1	0	2	2	1	1	1	2	0	1	19.00	5.00	4.00
73 000	3	1	1	2	2	0	3	0	2	3	2	2	1	2	3	1	1	29.00	8.00	6.00
75 000	3	2	1	1	2	2	4	2	2	3	3	1	1	2	1	2	1	33.00	9.00	5.00
79 000	4	3	3	1	1	2	4	0	1	3	3	1	1	2	2	1	2	34.00	7.00	10.00
80 000	3	2	0	1	1	2	3	1	2	1	1	1	1	2	0	1	0	22.00	7.00	2.00
85 000	3	0	2	1	2	2	3	1	1	2	3	1	2	2	2	0	0	27.00	8.00	4.00
87 000	3	0	0	2	1	1	3	1	1	1	3	0	2	1	1	0	0	20.00	6.00	1.00
94 000	4	2	0	0	0	1	4	2	2	1	3	1	2	2	2	0	0	26.00	4.00	4.00
96 000	4	1	0	2	1	1	3	1	1	2	2	1	2	2	0	0	0	23.00	7.00	1.00
99 000	4	1	1	2	2	1	3	3	0	0	1	1	2	1	0	0	0	22.00	8.00	2.00
101 000	3	0	1	2	1	2	3	2	3	1	2	1	2	1	2	1	0	27.00	9.00	3.00
107 000	4	2	1	2	2	2	4	2	2	3	2	1	2	0	2	0	0	31.00	9.00	5.00
108 000	4	0	1	0	2	2	4	1	2	1	2	1	2	1	1	0	0	24.00	7.00	2.00
109 000	3	1	1	2	0	0	3	1	3	3	2	1	2	0	3	0	0	25.00	5.00	5.00
114 000	4	1	1	2	2	2	3	1	2	3	3	2	2	2	3	0	0	33.00	10.00	5.00
115 000	4	1	2	2	2	3	0	2	3	2	1	1	0	3	0	1	1	29.00	8.00	7.00
120 000	3	0	1	2	2	2	3	1	3	3	3	2	2	0	3	0	0	30.00	10.00	4.00
122 000	3	0	4	2	1	2	3	1	1	3	2	1	2	1	1	1	0	28.00	9.00	5.00
123 000	3	2	3	0	1	0	3	3	1	2	1	0	1	2	2	1	1	26.00	3.00	8.00
130 000	3	3	3	0	1	1	4	1	1	3	2	1	1	2	3	1	1	31.00	5.00	10.00
131 000	4	2	2	2	1	2	3	1	0	2	2	1	2	2	3	2	1	32.00	10.00	8.00
134 000	3	2	2	2	2	1	3	1	0	2	2	1	2	2	1	2	1	29.00	10.00	6.00
135 000	2	0	2	1	2	1	1	2	0	2	3	2	2	2	1	2	1	24.00	10.00	4.00
142 000	3	2	0	1	2	1	1	1	0	2	2	1	2	1	2	2	1	26.00	9.00	5.00
146 000	3	0	2	1	0	2	3	0	0	4	2	1	2	1	3	0	1	25.00	6.00	6.00
169 000	3	2	3	1	1	1	3	2	1	1	2	2	2	1	3	2	1	31.00	9.00	9.00
171 000	3	2	3	2	1	1	3	2	1	1	1	1	1	1	3	2	0	28.00	8.00	8.00
176 000	3	2	3	0	1	1	3	2	1	1	1	1	2	1	3	2	1	28.00	7.00	9.00
177 000	3	2	3	1	2	1	3	2	1	1	1	1	2	1	3	2	0	29.00	9.00	8.00
184 000	3	2	2	1	1	2	3	0	0	1	1	1	1	1	2	2	1	24.00	8.00	7.00
185 000	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	2	0	25.00	7.00	7.00
189 000	3	2	3	1	1	2	3	2	0	1	1	1	1	2	3	1	1	28.00	7.00	9.00
192 000	3	2	2	1	1	1	2	1	0	1	1	1	1	1	2	1	0	21.00	6.00	6.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

Pat.Per. No. (dy)	Items																	Total Score	5	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17		Factor 1	Factor 2
194 000	3	3	2	1	1	1	3	2	3	2	2	1	1	1	2	1	1	30.00	6.00	8.00
198 000	3	3	2	2	1	0	3	2	2	2	2	1	1	1	2	0	1	28.00	5.00	8.00
199 000	3	3	3	1	1	2	3	1	2	2	2	1	1	1	2	1	1	30.00	7.00	9.00
200 000	3	2	2	0	2	1	3	1	2	2	1	1	1	1	2	0	1	25.00	5.00	7.00
208 000	2	3	4	1	0	2	3	2	4	3	2	0	1	0	2	2	0	31.00	6.00	9.00
209 000	4	3	1	1	1	1	3	1	3	2	2	1	1	1	1	2	1	29.00	7.00	6.00
211 000	3	3	3	1	0	1	3	3	2	2	2	1	1	1	2	0	1	29.00	4.00	9.00
215 000	4	3	0	2	1	2	3	2	3	3	2	1	1	2	3	2	1	35.00	9.00	7.00
217 000	3	0	2	2	2	2	2	0	1	3	2	1	2	1	1	0	0	24.00	9.00	3.00
222 000	3	0	0	1	0	0	3	2	0	1	0	1	2	2	1	2	0	18.00	6.00	1.00
223 000	2	0	0	2	2	2	4	0	3	4	2	1	2	2	3	0	0	29.00	9.00	3.00
224 000	3	1	0	0	1	0	3	3	2	3	0	0	0	0	0	1	0	17.00	2.00	1.00
231 000	1	2	0	2	2	1	2	1	0	1	1	0	2	2	1	0	0	18.00	7.00	3.00
232 000	3	0	0	2	1	1	2	2	0	1	1	1	2	2	1	0	0	19.00	7.00	1.00
235 000	3	2	0	2	1	2	2	1	0	1	1	1	2	2	1	0	0	21.00	8.00	3.00
240 000	3	0	1	1	0	1	4	1	0	1	0	0	2	2	1	0	0	17.00	4.00	2.00
244 000	3	2	1	1	1	1	3	1	0	0	1	1	1	1	2	0	0	19.00	5.00	5.00
246 000	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	0	21.00	5.00	6.00
247 000	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	0	22.00	5.00	7.00
248 000	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	0	0	23.00	6.00	7.00
257 000	3	3	1	1	1	0	3	1	3	1	1	1	1	2	1	1	1	25.00	5.00	6.00
258 000	4	3	2	2	0	0	3	2	3	2	2	1	.	0	2	0	1	.	.	8.00
259 000	3	1	2	1	1	2	3	1	1	1	1	1	1	2	2	1	0	24.00	7.00	5.00
263 000	3	2	2	1	1	2	3	1	1	1	2	1	1	1	2	1	1	26.00	7.00	7.00
267 000	3	2	1	0	0	1	3	1	2	1	1	1	1	1	3	1	0	22.00	4.00	6.00
270 000	3	3	2	0	0	2	3	2	2	1	2	1	1	1	2	0	1	26.00	4.00	8.00
271 000	2	2	1	1	0	0	3	2	1	2	2	1	1	2	3	2	0	25.00	5.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

6

Treatment Group "A"

Baseline (Period 000)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Depressed mood	2.93	.07
2. Feelings of guilt	1.52	.11
3. Suicide	1.51	.12
4. Insomnia, early	1.23	.07
5. Insomnia, middle	1.16	.07
6. Insomnia, late	1.25	.08
7. Work and activities	2.91	.07
8. Retardation	1.47	.09
9. Agitation	1.20	.12
10. Anxiety, psychic	1.94	.10
11. Anxiety, somatic	1.63	.09
12. Somatic symptoms, gastrointestinal	.96	.05
13. Somatic symptoms, general	1.35	.06
14. Genital symptoms	1.27	.08
15. Hypochondriasis	1.88	.11
16. Weight	.77	.08
17. Insight	.49	.06
Total Score	25.43	.49
Factor 1 - Vegetative signs	6.75	.21
Factor 2 - Vital disturbances	5.40	.27

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

7

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 042	3	0	2	1	2	0	3	0	1	4	2	0	0	0	2	0	0	20.00	3.00	4.00
5 042	3	0	1	2	1	2	3	1	1	3	1	1	1	0	3	0	0	23.00	7.00	4.00
9 042	3	1	0	2	1	0	4	0	1	2	0	0	2	0	2	0	0	18.00	5.00	3.00
12 042	3	2	2	2	2	1	3	2	1	2	2	2	2	1	2	1	1	31.00	10.00	7.00
13 042	3	3	2	2	2	2	2	0	2	4	0	0	0	1	1	0	0	24.00	6.00	6.00
14 042	2	2	1	1	2	1	3	2	1	3	1	0	1	0	1	0	0	21.00	5.00	4.00
25 042	2	0	2	2	1	1	3	3	1	2	1	1	1	2	0	0	0	22.00	6.00	2.00
30 042	3	1	1	1	1	2	3	2	2	2	3	2	2	2	3	1	1	32.00	9.00	6.00
34 042	2	0	0	0	1	2	3	3	2	2	2	0	0	2	0	0	0	19.00	3.00	.00
35 042	2	1	1	1	1	1	3	3	1	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 042	2	1	1	1	1	2	2	2	2	1	1	1	1	2	1	1	1	23.00	7.00	4.00
38 042	3	1	1	1	1	1	2	2	1	2	1	1	1	2	1	1	1	23.00	6.00	4.00
45 042	2	0	1	2	1	2	3	3	1	1	1	1	2	2	0	0	0	22.00	8.00	1.00
48 042	2	0	0	1	1	1	3	1	2	2	1	1	1	2	0	0	0	18.00	5.00	.00
49 042	2	1	1	1	1	1	2	2	0	2	1	1	1	1	3	1	1	22.00	6.00	6.00
50 042	3	2	2	1	1	2	3	3	0	2	2	1	1	1	3	1	1	29.00	7.00	8.00
56 042	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	0	1	22.00	5.00	6.00
57 042	2	2	1	1	1	1	2	2	0	2	3	1	1	1	2	1	1	24.00	6.00	6.00
64 042	2	2	2	1	1	2	2	2	2	3	3	1	1	1	2	1	1	29.00	7.00	7.00
65 042	2	1	2	1	1	1	2	2	0	2	2	1	1	1	1	0	1	21.00	5.00	5.00
68 042	3	2	2	1	2	1	3	2	0	2	2	2	1	2	2	1	1	29.00	8.00	7.00
72 042	2	1	0	1	1	1	2	1	0	1	1	1	1	2	2	0	1	18.00	5.00	4.00
73 042	3	1	1	2	2	0	3	0	1	3	3	2	1	2	3	0	1	28.00	7.00	6.00
75 042	3	3	1	1	2	2	4	2	2	3	3	1	1	2	1	1	1	33.00	8.00	6.00
79 042	4	3	1	2	2	2	3	0	1	3	2	2	1	2	0	0	2	30.00	9.00	6.00
80 042	3	2	0	2	1	1	3	1	2	2	0	1	1	2	0	0	0	21.00	6.00	2.00
85 042	3	0	1	1	1	1	3	1	1	3	2	1	1	2	0	0	0	21.00	5.00	1.00
87 042	2	0	0	1	1	2	2	1	0	2	1	0	1	1	2	0	0	16.00	5.00	2.00
94 042	4	1	0	0	1	1	4	2	1	2	3	2	2	2	2	0	0	27.00	6.00	3.00
96 042	4	1	0	1	1	2	3	1	1	2	2	1	2	2	0	0	0	23.00	7.00	1.00
99 042	4	1	0	2	1	1	3	3	0	1	1	1	2	1	0	0	0	21.00	7.00	1.00
101 042	4	0	1	2	2	2	3	2	2	1	2	1	2	1	2	0	0	27.00	9.00	3.00
107 042	4	1	1	2	1	1	4	3	2	1	2	2	2	0	0	0	0	26.00	8.00	2.00
108 042	4	0	1	2	0	0	3	2	2	1	1	1	2	2	1	1	0	23.00	6.00	2.00
109 042	3	2	1	2	0	0	3	1	2	2	2	1	2	0	3	0	0	24.00	5.00	6.00
114 042	4	1	1	2	2	2	3	1	2	2	3	2	2	3	3	1	0	34.00	11.00	5.00
115 042	3	1	1	2	2	2	3	0	2	2	2	1	1	0	2	0	0	24.00	8.00	4.00
120 042	3	0	1	2	2	2	3	1	3	3	3	2	2	0	3	0	0	30.00	10.00	4.00
122 042	2	0	2	1	0	0	3	0	1	2	2	1	2	1	1	0	0	18.00	4.00	3.00
123 042	1	2	0	1	2	1	2	1	1	2	1	0	2	1	2	0	1	20.00	6.00	5.00
130 042	4	3	3	1	0	0	4	2	2	3	2	2	2	2	3	2	1	36.00	7.00	10.00
131 042	3	0	0	0	1	2	2	1	1	2	2	1	2	2	3	2	1	25.00	8.00	4.00
134 042	1	1	0	2	1	2	2	1	0	2	2	2	2	2	0	0	1	21.00	9.00	2.00
135 042	2	0	2	1	2	2	0	2	0	1	3	1	1	2	2	0	1	22.00	7.00	5.00
142 042	2	1	0	2	1	0	1	1	0	2	1	1	2	0	2	0	1	17.00	6.00	4.00
146 042	0	0	0	1	0	0	1	0	0	0	1	0	0	0	2	0	0	5.00	1.00	2.00
169 042	3	2	2	0	1	1	3	1	1	1	1	1	2	1	3	2	0	25.00	7.00	7.00
171 042	3	2	1	1	2	2	3	2	1	1	2	1	2	2	3	2	1	31.00	10.00	7.00
176 042	3	2	3	0	1	1	3	2	1	1	1	1	1	1	3	2	1	27.00	6.00	9.00
177 042	3	2	3	1	1	1	3	2	1	1	1	1	2	1	3	2	0	28.00	8.00	8.00
184 042	3	2	2	1	1	1	3	1	0	1	1	1	1	0	2	2	1	23.00	7.00	7.00
185 042	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	2	0	25.00	7.00	7.00
189 042	3	2	3	1	1	2	3	1	1	1	2	1	1	2	3	2	1	30.00	8.00	9.00
192 042	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	1	22.00	5.00	7.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

8

Pat.No.	Per. (dy)	Items																	Total Score	Factor 1	Factor 2
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
194	042	3	3	2	1	1	1	3	2	3	2	2	1	1	1	2	2	1	31.00	7.00	8.00
198	042	3	3	2	2	1	0	3	2	2	2	2	1	1	1	2	0	1	28.00	5.00	8.00
199	042	3	3	3	1	1	1	3	1	2	2	2	1	1	1	1	1	1	28.00	6.00	8.00
200	042	3	2	2	0	2	1	3	1	1	2	1	1	1	1	2	0	1	24.00	5.00	7.00
208	042	3	3	4	1	0	0	3	2	3	3	2	1	0	0	2	2	0	29.00	4.00	9.00
209	042	3	2	1	1	1	1	3	1	3	2	2	1	1	1	2	1	1	27.00	7.00	5.00
211	042	3	3	2	1	0	1	3	3	2	2	2	1	1	1	2	0	1	28.00	4.00	8.00
215	042	4	3	4	2	1	2	3	2	3	3	2	1	1	2	3	2	1	39.00	9.00	11.00
217	042	3	0	0	1	0	2	1	0	1	2	1	1	1	1	0	0	0	14.00	5.00	.00
222	042	4	0	2	2	2	2	3	2	0	1	0	1	2	2	0	0	0	23.00	9.00	2.00
223	042	1	0	0	2	2	2	3	0	4	3	2	1	2	2	3	0	0	27.00	9.00	3.00
224	042	4	1	2	0	0	1	3	3	0	2	0	1	1	0	0	0	0	18.00	3.00	3.00
231	042	1	2	0	2	2	2	1	0	1	3	2	0	2	2	2	1	0	23.00	9.00	4.00
232	042	2	0	0	1	0	1	2	1	0	2	1	2	2	2	3	0	0	19.00	6.00	3.00
235	042	3	1	0	2	2	2	2	1	0	0	1	1	2	0	0	0	0	17.00	9.00	1.00
240	042	3	0	0	0	0	0	2	0	0	1	2	0	2	2	0	0	0	12.00	2.00	.00
244	042	3	2	1	1	1	1	2	1	0	0	1	1	1	1	2	0	0	18.00	5.00	5.00
246	042	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	0	0	22.00	6.00	6.00
247	042	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	0	22.00	5.00	7.00
248	042	3	2	1	1	1	1	3	1	0	1	1	1	1	1	2	0	0	20.00	5.00	5.00
257	042	3	3	1	1	1	0	3	1	3	1	1	1	1	2	2	1	1	26.00	5.00	7.00
258	042	4	3	2	2	0	0	3	2	3	2	2	1	1	0	3	0	1	29.00	4.00	9.00
259	042	3	2	2	1	1	2	3	1	0	1	1	1	1	2	2	1	1	25.00	7.00	7.00
263	042	3	2	2	1	1	2	3	2	0	1	2	1	1	1	3	1	1	27.00	7.00	8.00
267	042	3	2	1	0	0	1	3	1	2	2	1	1	1	1	3	1	0	23.00	4.00	6.00
270	042	3	2	2	1	0	0	3	1	1	1	2	1	1	1	2	0	1	22.00	3.00	7.00
271	042	2	2	1	1	0	0	3	2	2	2	2	1	1	2	3	2	0	26.00	5.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

9

Treatment Group "A"

Day 4 (Period 042)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Depressed mood	2.79	.09
2. Feelings of guilt	1.42	.11
3. Suicide	1.27	.11
4. Insomnia, early	1.21	.07
5. Insomnia, middle	1.06	.07
6. Insomnia, late	1.17	.08
7. Work and activities	2.72	.08
8. Retardation	1.43	.10
9. Agitation	1.12	.11
10. Anxiety, psychic	1.84	.09
11. Anxiety, somatic	1.59	.09
12. Somatic symptoms, gastrointestinal	1.04	.06
13. Somatic symptoms, general	1.28	.06
14. Genital symptoms	1.25	.09
15. Hypochondriasis	1.78	.12
16. Weight	.58	.09
17. Insight	.49	.06
Total Score	24.05	.60
Factor 1 - Vegetative signs	6.35	.22
Factor 2 - Vital disturbances	4.96	.29

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

10

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 072	3	0	2	1	2	0	3	0	1	4	2	0	0	0	2	0	0	20.00	3.00	4.00
5 072	3	0	0	2	1	1	3	1	1	3	1	1	1	0	3	0	0	21.00	6.00	3.00
9 072	3	1	0	2	1	0	3	0	1	2	0	0	2	0	2	0	0	17.00	5.00	3.00
12 072	3	2	2	2	2	1	3	2	1	2	2	2	2	1	2	0	1	30.00	9.00	7.00
13 072	3	3	2	2	2	2	2	0	2	4	1	0	0	1	1	0	0	25.00	6.00	6.00
14 072	2	2	1	1	2	1	3	2	1	3	1	0	1	0	1	0	0	21.00	5.00	4.00
25 072	2	0	1	1	1	1	2	2	0	1	1	1	1	2	0	0	0	16.00	5.00	1.00
30 072	2	0	1	1	1	2	3	2	2	2	3	2	2	2	3	0	1	29.00	8.00	5.00
34 072	2	0	1	1	1	1	3	3	2	2	2	0	0	2	0	0	0	20.00	3.00	1.00
35 072	2	1	1	1	1	3	3	1	3	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 072	1	0	0	1	1	1	2	2	1	1	1	1	1	2	1	0	1	17.00	5.00	2.00
38 072	2	0	0	1	1	1	2	2	1	1	1	1	1	2	1	0	1	18.00	5.00	2.00
45 072	1	0	0	1	1	2	2	2	1	1	1	0	1	2	0	0	0	15.00	5.00	.00
48 072	2	0	0	1	1	1	2	1	1	1	1	1	2	2	0	0	0	16.00	6.00	.00
49 072	2	1	1	1	1	1	2	2	0	2	2	1	1	1	2	1	1	22.00	6.00	5.00
50 072	3	2	1	1	1	1	2	3	0	2	2	1	2	1	3	1	1	27.00	7.00	7.00
56 072	2	2	1	1	1	2	2	0	2	2	2	1	1	1	2	0	1	22.00	5.00	6.00
57 072	1	1	1	1	1	1	2	2	0	2	2	1	1	1	2	1	0	20.00	6.00	4.00
64 072	3	2	2	1	2	1	2	2	0	2	2	1	1	1	3	1	1	27.00	7.00	8.00
65 072	2	1	2	1	1	1	2	1	0	2	2	1	1	1	2	0	0	20.00	5.00	5.00
68 072	3	2	2	1	1	1	3	2	0	2	2	1	1	1	2	1	1	26.00	6.00	7.00
72 072	2	1	0	1	1	1	2	1	0	1	1	1	1	1	2	0	1	17.00	5.00	4.00
73 072	3	0	0	2	1	0	3	0	2	3	3	2	1	2	2	0	1	25.00	6.00	3.00
75 072	3	2	0	1	2	1	3	1	2	1	1	1	1	2	2	1	1	24.00	7.00	5.00
79 072	4	4	3	1	1	1	4	0	2	3	0	2	1	2	3	0	2	33.00	6.00	12.00
80 072	3	1	2	1	0	2	1	0	1	2	3	1	1	1	1	0	0	20.00	5.00	4.00
85 072	3	0	1	1	2	1	3	1	1	3	2	1	1	2	0	0	0	22.00	6.00	1.00
87 072	2	0	0	1	1	1	2	1	0	1	1	0	1	1	0	0	0	12.00	4.00	.00
94 072	4	0	0	0	0	1	3	1	1	2	2	2	2	2	1	0	0	21.00	5.00	1.00
96 072	4	1	0	1	2	1	3	1	1	2	2	1	2	2	0	0	0	23.00	7.00	1.00
99 072	3	0	0	1	0	1	3	2	1	0	1	0	2	2	0	0	0	16.00	4.00	.00
101 072	2	0	0	2	2	2	2	1	2	1	2	0	1	1	1	0	0	19.00	7.00	1.00
107 072	3	1	0	2	1	1	3	1	1	1	1	0	2	0	2	0	0	19.00	6.00	3.00
108 072	4	1	1	1	2	1	3	1	2	3	2	1	2	2	1	0	0	27.00	7.00	3.00
109 072	3	2	1	2	0	0	3	1	2	1	2	1	2	0	2	0	0	22.00	5.00	5.00
114 072	2	0	0	1	1	1	3	1	2	1	2	1	1	2	1	1	0	20.00	6.00	1.00
115 072	2	0	0	1	0	2	2	0	1	1	1	1	0	1	0	0	0	13.00	5.00	1.00
120 072	3	0	1	2	1	2	3	1	3	2	3	2	2	0	3	0	0	28.00	9.00	4.00
122 072	1	0	2	0	0	1	3	0	1	2	2	1	2	1	3	0	0	19.00	4.00	5.00
123 072	1	0	0	0	1	0	1	1	0	1	1	0	2	1	2	0	1	12.00	3.00	3.00
131 072	2	0	0	0	0	1	1	1	1	2	1	0	1	2	2	2	1	17.00	4.00	3.00
134 072	1	1	0	2	1	1	1	0	0	1	2	1	2	2	0	0	1	16.00	7.00	2.00
135 072	4	2	2	0	1	0	3	2	1	2	3	1	2	2	2	0	1	28.00	4.00	7.00
142 072	1	1	0	2	0	0	0	0	0	1	1	1	2	0	1	2	1	13.00	7.00	3.00
146 072	1	0	0	1	0	0	0	0	0	0	2	1	0	0	2	0	0	7.00	2.00	2.00
169 072	3	2	2	0	1	1	3	2	0	1	1	1	2	1	2	2	0	24.00	7.00	6.00
171 072	3	2	2	1	1	2	3	2	1	1	1	1	1	2	3	2	1	29.00	8.00	8.00
176 072	3	2	2	0	1	1	3	2	1	1	1	1	1	1	3	2	1	26.00	6.00	8.00
177 072	3	2	3	1	1	1	3	2	1	1	1	1	1	1	3	2	0	27.00	7.00	8.00
184 072	3	2	3	1	1	2	3	1	1	1	2	1	1	1	3	2	1	29.00	8.00	9.00
185 072	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	2	0	25.00	7.00	7.00
189 072	3	2	3	1	1	1	3	1	1	1	2	1	1	2	3	1	0	27.00	6.00	8.00
192 072	3	2	2	1	1	1	3	1	0	0	2	1	1	1	2	0	1	22.00	5.00	7.00
194 072	3	3	2	1	1	1	3	2	3	2	2	1	1	1	2	1	1	30.00	6.00	8.00

FCE 20124/702 i

11

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
198 072	3	3	2	2	1	0	3	2	2	2	2	1	1	1	2	0	1	28.00	5.00	8.00
199 072	3	3	3	1	1	1	3	1	2	2	2	1	1	1	2	0	1	28.00	5.00	9.00
200 072	3	2	2	0	2	1	3	1	2	2	1	1	1	1	2	0	1	25.00	5.00	7.00
208 072	3	2	3	1	0	0	3	2	2	2	2	0	0	0	2	2	0	24.00	3.00	7.00
209 072	3	2	1	1	1	1	3	1	3	2	2	1	1	1	1	2	1	27.00	7.00	5.00
211 072	3	3	2	1	0	1	3	0	2	2	2	1	1	1	2	0	1	25.00	4.00	8.00
215 072	4	3	3	2	1	1	3	2	3	2	2	1	1	2	3	2	0	35.00	8.00	9.00
217 072	1	0	0	0	0	1	0	0	1	2	0	1	1	1	0	0	0	8.00	3.00	.00
222 072	4	0	2	1	1	2	3	2	0	1	0	1	2	2	0	0	0	21.00	7.00	2.00
223 072	2	0	0	2	2	2	4	0	3	3	2	2	1	2	3	1	0	29.00	10.00	3.00
224 072	3	0	0	0	2	2	2	2	0	0	1	1	2	1	0	0	0	16.00	7.00	.00
231 072	3	0	0	2	1	2	2	0	0	0	0	0	2	2	2	2	0	18.00	9.00	2.00
232 072	3	2	0	2	0	0	2	1	0	2	2	1	2	2	2	0	1	22.00	5.00	5.00
235 072	2	2	0	2	1	2	2	1	0	0	1	1	2	2	1	0	0	19.00	8.00	3.00
240 072	1	0	0	0	0	0	2	1	1	1	1	0	1	2	1	0	0	11.00	1.00	1.00
244 072	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	5.00	5.00
246 072	3	2	2	1	1	1	3	1	1	1	1	1	1	1	2	0	0	22.00	5.00	6.00
247 072	3	2	2	1	1	1	3	1	0	1	1	0	1	1	2	0	0	20.00	4.00	6.00
248 072	3	2	2	1	1	1	3	1	0	0	1	1	1	1	2	0	0	20.00	5.00	6.00
257 072	3	3	1	1	1	0	3	1	2	1	1	1	1	2	2	1	1	25.00	5.00	7.00
258 072	4	3	2	2	0	0	3	2	3	2	2	1	1	0	3	0	1	29.00	4.00	9.00
259 072	3	2	2	1	1	2	3	2	0	1	1	1	1	2	2	1	0	25.00	7.00	6.00
263 072	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	1	0	22.00	6.00	6.00
267 072	3	2	1	0	0	1	3	1	2	2	1	1	1	1	3	1	0	23.00	4.00	6.00
270 072	3	2	2	1	0	0	3	1	1	1	2	1	1	1	2	0	1	22.00	3.00	7.00
271 072	2	2	1	1	0	0	3	1	2	2	2	1	1	2	3	2	0	25.00	5.00	6.00



FCE 20124/702 i

12

Treatment Group "A"

Day 7 (Period 072)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.60	.09
2. Feelings of guilt	1.27	.12
3. Suicide	1.14	.11
4. Insomnia, early	1.07	.07
5. Insomnia, middle	.94	.07
6. Insomnia, late	.99	.07
7. Work and activities	2.54	.09
8. Retardation	1.22	.09
9. Agitation	1.03	.10
10. Anxiety, psychic	1.58	.10
11. Anxiety, somatic	1.51	.08
12. Somatic symptoms, gastrointestinal	.90	.06
13. Somatic symptoms, general	1.23	.06
14. Genital symptoms	1.25	.08
15. Hypochondriasis	1.75	.11
16. Weight	.51	.09
17. Insight	.43	.06
Total Score	21.95	.62
Factor 1 - Vegetative signs	5.64	.19
Factor 2 - Vital disturbances	4.59	.31

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

13

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 102	3	0	1	1	2	0	3	0	1	4	2	0	0	0	3	0	0	20.00	3.00	4.00
5 102	2	0	0	1	1	1	2	1	1	2	1	1	1	0	2	0	0	16.00	5.00	2.00
9 102	3	1	0	2	1	0	3	0	1	2	0	0	2	0	2	0	0	17.00	5.00	3.00
12 102	2	2	2	1	1	1	3	2	1	2	2	2	2	1	2	0	1	27.00	7.00	7.00
13 102	3	3	2	2	2	2	2	0	2	4	1	0	1	1	1	0	0	26.00	7.00	6.00
14 102	2	2	1	1	2	1	3	2	1	3	1	0	1	0	1	0	0	21.00	5.00	4.00
25 102	1	0	0	1	1	1	1	1	0	1	1	0	0	2	0	0	0	10.00	3.00	.00
30 102	2	0	0	1	1	1	2	2	2	2	2	3	2	2	2	3	0	27.00	11.00	2.00
34 102	2	0	1	1	1	2	3	3	2	2	2	2	0	2	0	0	0	23.00	6.00	1.00
35 102	2	1	1	1	1	1	3	3	1	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 102	1	0	0	1	1	1	1	1	0	1	1	0	0	2	0	0	0	10.00	3.00	.00
38 102	1	0	0	1	1	1	1	1	0	0	0	0	0	1	0	0	0	7.00	3.00	.00
45 102	1	0	0	1	1	1	1	1	1	1	1	0	1	2	0	0	0	12.00	4.00	.00
48 102	1	0	0	1	0	0	1	1	0	1	1	0	1	1	0	0	0	8.00	2.00	.00
49 102	2	2	2	1	1	1	2	1	0	1	1	1	1	1	1	1	0	19.00	6.00	5.00
50 102	2	2	1	1	1	1	2	2	0	2	1	1	1	1	2	1	1	22.00	6.00	6.00
56 102	2	1	0	1	1	1	2	1	0	1	1	1	1	1	2	0	0	16.00	5.00	3.00
57 102	2	1	1	1	1	1	1	1	0	1	2	1	1	1	2	1	0	18.00	6.00	4.00
64 102	3	2	2	1	2	1	2	2	0	3	3	1	1	1	3	1	1	29.00	7.00	8.00
65 102	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	1	19.00	5.00	6.00
68 102	2	2	2	1	1	1	2	2	0	2	2	1	1	2	3	1	1	26.00	6.00	8.00
72 102	2	1	0	1	1	1	2	2	0	1	1	1	1	1	2	0	0	17.00	5.00	3.00
73 102	3	0	0	2	1	0	3	2	1	2	2	2	1	2	2	0	1	24.00	6.00	3.00
75 102	3	2	1	1	2	2	3	1	2	3	3	1	1	2	3	1	1	32.00	8.00	7.00
79 102	3	3	2	0	0	2	3	0	1	4	3	1	1	1	2	1	2	29.00	5.00	9.00
80 102	3	0	2	0	0	2	3	1	0	3	3	1	1	2	1	0	0	22.00	4.00	3.00
85 102	3	0	1	1	2	1	2	1	1	1	2	1	2	2	0	1	0	21.00	8.00	1.00
87 102	1	0	0	1	2	1	2	1	0	0	1	0	2	1	0	0	0	12.00	6.00	.00
94 102	3	1	0	0	0	1	3	1	1	2	2	2	2	2	1	0	0	21.00	5.00	2.00
96 102	3	0	0	1	1	2	3	1	1	1	1	1	2	2	0	0	0	19.00	7.00	.00
99 102	2	1	0	1	0	1	2	2	0	0	1	0	2	1	0	0	0	13.00	4.00	1.00
101 102	3	0	1	2	2	2	2	1	0	1	0	0	2	1	0	0	0	17.00	8.00	1.00
107 102	4	1	1	2	2	1	2	1	1	1	2	1	1	0	2	0	0	22.00	7.00	4.00
108 102	3	0	0	2	1	1	2	1	0	0	1	1	2	2	1	0	0	17.00	7.00	1.00
109 102	3	2	1	2	1	0	3	1	2	2	2	1	2	0	3	0	0	25.00	6.00	6.00
114 102	2	0	0	1	1	1	3	1	2	1	2	1	1	2	1	1	0	20.00	6.00	1.00
115 102	2	0	0	1	0	2	2	0	1	1	1	0	1	0	1	0	0	12.00	4.00	1.00
120 102	3	0	1	2	1	2	3	1	3	2	3	2	2	0	3	0	0	28.00	9.00	4.00
122 102	3	0	3	1	0	0	3	1	2	3	3	1	2	1	2	0	0	25.00	4.00	5.00
123 102	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1.00	1.00	.00
131 102	1	0	0	0	0	0	1	0	1	1	0	0	1	1	1	1	1	9.00	2.00	2.00
134 102	4	2	0	2	2	2	3	1	1	3	2	2	2	2	2	0	1	31.00	10.00	5.00
135 102	3	2	2	2	1	2	1	1	1	4	3	1	2	2	2	0	1	30.00	8.00	7.00
142 102	0	0	0	1	0	0	0	0	0	0	1	0	2	0	1	0	1	6.00	3.00	2.00
146 102	1	0	0	0	0	0	1	0	0	0	1	1	1	0	2	0	0	7.00	2.00	2.00
169 102	3	2	2	0	1	1	3	0	0	1	1	1	1	1	2	0	0	19.00	4.00	6.00
171 102	3	2	3	1	2	1	3	2	1	1	1	1	1	2	3	2	1	30.00	8.00	9.00
176 102	3	2	2	1	2	1	3	2	0	1	1	1	2	1	3	0	1	26.00	7.00	8.00
177 102	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	0	0	23.00	5.00	7.00
184 102	3	2	3	1	1	1	3	1	1	1	2	1	1	2	3	2	1	29.00	7.00	9.00
185 102	3	2	2	1	1	1	3	1	1	1	2	1	1	1	3	2	0	26.00	7.00	7.00
189 102	3	2	2	1	1	2	3	1	2	1	2	1	1	2	3	1	0	28.00	7.00	7.00
192 102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	0	22.00	5.00	7.00
194 102	3	3	2	1	1	1	3	2	3	2	0	1	1	1	2	1	1	28.00	6.00	8.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

14

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
198	102	3	3	2	2	1	0	3	2	2	2	2	1	1	1	2	0	1	28.00	5.00	8.00
199	102	3	3	3	1	1	1	3	1	2	2	2	1	1	1	2	0	1	28.00	5.00	9.00
200	102	3	2	2	0	2	1	3	1	2	2	1	1	1	1	0	0	0	22.00	5.00	4.00
208	102	2	2	3	1	0	0	3	2	3	2	2	0	0	0	2	2	0	24.00	3.00	7.00
209	102	2	2	1	1	1	1	2	1	3	1	2	1	1	1	1	2	1	24.00	7.00	5.00
211	102	2	2	2	1	0	1	3	3	2	2	2	1	1	1	2	0	1	26.00	4.00	7.00
215	102	4	3	3	2	1	1	3	2	2	2	2	1	1	2	2	2	1	34.00	8.00	9.00
217	102	1	0	0	2	0	1	0	0	0	0	2	0	0	0	1	0	0	7.00	3.00	1.00
222	102	3	0	0	2	2	2	2	1	0	0	0	2	2	2	0	0	0	18.00	8.00	2.00
223	102	1	0	0	2	2	2	3	0	4	3	3	1	1	2	3	1	0	28.00	9.00	3.00
224	102	3	2	0	0	0	0	1	1	0	2	0	0	0	0	0	0	0	9.00	.00	2.00
231	102	1	0	0	2	0	1	0	0	0	1	1	0	1	0	0	0	0	7.00	4.00	.00
232	102	2	0	0	2	1	1	3	1	2	1	0	2	2	2	2	0	0	21.00	8.00	2.00
235	102	3	2	1	2	1	2	2	1	2	1	1	1	1	2	1	0	0	23.00	7.00	4.00
240	102	1	1	0	0	0	2	1	0	0	2	0	1	1	2	1	0	0	12.00	4.00	2.00
244	102	3	2	1	1	1	1	2	1	1	1	1	1	1	1	2	0	0	20.00	5.00	5.00
246	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	0	21.00	5.00	6.00
247	102	3	2	2	1	1	1	2	1	0	1	1	0	1	1	2	0	0	19.00	4.00	6.00
248	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	0	21.00	5.00	6.00
257	102	3	3	1	1	1	0	3	1	2	1	1	1	1	2	2	1	1	25.00	5.00	7.00
258	102	4	3	2	2	0	0	3	2	3	2	2	1	1	0	3	0	1	29.00	4.00	9.00
259	102	3	2	2	1	1	2	3	1	0	1	1	1	1	2	2	0	0	23.00	6.00	6.00
263	102	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	1	0	24.00	6.00	7.00
267	102	3	2	1	0	0	1	3	1	2	2	1	1	1	1	3	1	0	23.00	4.00	6.00
270	102	3	2	1	1	0	0	3	1	1	1	2	1	1	1	2	0	1	21.00	3.00	6.00
271	102	2	1	1	1	0	0	3	1	1	1	2	1	1	2	2	2	0	21.00	5.00	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 1

15

Treatment Group "A"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.41	.10
2. Feelings of guilt	1.25	.12
3. Suicide	1.07	.11
4. Insomnia, early	1.10	.07
5. Insomnia, middle	.94	.07
6. Insomnia, late	1.00	.07
7. Work and activities	2.30	.10
8. Retardation	1.11	.08
9. Agitation	.96	.11
10. Anxiety, psychic	1.51	.11
11. Anxiety, somatic	1.41	.09
12. Somatic symptoms, gastrointestinal	.85	.07
13. Somatic symptoms, general	1.13	.07
14. Genital symptoms	1.16	.08
15. Hypochondriasis	1.66	.11
16. Weight	.43	.08
17. Insight	.33	.06
Total Score	20.63	.81
Factor 1 - Vegetative signs	5.44	.23
Factor 2 - Vital disturbances	4.31	.32

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

16

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 142	3	0	1	1	1	0	3	0	1	4	2	0	0	0	3	0	0	19.00	2.00	4.00
5 142	2	0	0	1	1	1	2	1	1	2	1	1	1	0	2	0	0	16.00	5.00	2.00
9 142	3	1	0	2	1	0	3	0	1	2	0	0	2	0	2	0	0	17.00	5.00	3.00
12 142	2	2	2	1	1	1	3	2	1	2	2	2	2	1	2	0	1	27.00	7.00	7.00
13 142	3	3	2	2	2	2	3	0	2	4	1	0	1	1	1	0	0	27.00	7.00	6.00
14 142	2	2	1	1	2	1	2	2	1	3	1	0	1	0	1	0	0	20.00	5.00	4.00
25 142	1	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	5.00	3.00	.00
30 142	2	0	0	1	1	1	2	2	2	2	3	2	2	2	3	0	1	26.00	7.00	4.00
35 142	2	1	1	1	1	1	3	3	1	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 142	1	0	0	0	0	1	1	0	0	1	0	0	0	1	0	0	0	4.00	1.00	.00
38 142	1	0	0	1	1	1	0	0	0	0	0	0	0	1	0	0	0	5.00	3.00	.00
45 142	0	0	0	1	1	1	1	1	0	0	0	0	0	2	0	0	0	7.00	3.00	.00
48 142	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
49 142	1	1	1	1	1	1	1	1	0	1	1	1	1	1	2	0	0	15.00	5.00	4.00
50 142	2	1	1	1	1	1	2	2	0	1	1	1	1	1	2	1	0	19.00	6.00	4.00
56 142	2	1	0	1	1	0	1	1	1	1	1	1	1	0	2	0	0	14.00	4.00	3.00
57 142	1	1	1	1	1	1	2	2	0	1	1	1	1	1	2	1	0	18.00	6.00	4.00
64 142	3	2	2	1	1	1	3	1	2	2	2	1	1	1	2	1	1	27.00	6.00	7.00
65 142	2	2	2	1	1	0	2	1	0	1	1	1	1	1	2	0	1	19.00	4.00	7.00
68 142	2	2	2	1	1	1	2	2	0	2	2	1	1	1	3	1	1	25.00	6.00	8.00
72 142	2	1	0	1	1	1	1	1	0	1	1	1	1	1	2	0	0	15.00	5.00	3.00
73 142	3	0	0	1	1	0	3	2	1	2	2	2	1	2	2	0	1	23.00	5.00	3.00
75 142	2	1	0	1	1	2	3	1	1	3	3	0	1	1	2	0	1	23.00	5.00	4.00
79 142	3	2	3	0	0	2	3	0	1	3	1	1	2	1	2	0	2	26.00	5.00	9.00
80 142	3	0	2	0	0	2	2	0	1	3	3	1	1	1	1	1	0	21.00	5.00	3.00
85 142	3	0	0	0	1	1	2	1	0	1	2	1	1	2	0	0	0	15.00	4.00	.00
87 142	1	0	0	1	1	1	2	1	1	0	1	0	2	1	0	0	0	12.00	5.00	.00
94 142	2	0	0	0	0	1	2	1	0	2	0	0	2	2	0	0	0	12.00	3.00	.00
96 142	2	0	0	1	1	1	2	1	1	1	1	0	2	2	0	0	0	15.00	5.00	.00
99 142	2	1	1	1	1	1	2	2	1	1	2	1	1	1	0	0	0	18.00	5.00	2.00
101 142	1	0	0	2	1	2	1	1	1	0	0	1	1	0	0	0	0	11.00	7.00	.00
107 142	4	1	1	2	2	2	2	1	3	2	2	1	1	0	2	0	0	26.00	8.00	4.00
108 142	1	1	0	1	0	1	2	1	0	0	1	0	1	2	1	0	0	12.00	3.00	2.00
109 142	3	1	1	2	0	0	3	1	3	3	2	1	2	0	3	1	0	26.00	6.00	5.00
114 142	3	1	1	1	1	1	3	1	2	2	2	1	2	2	2	1	0	26.00	7.00	4.00
115 142	1	0	0	1	0	1	2	0	1	1	1	0	0	0	1	0	0	9.00	2.00	1.00
120 142	3	0	1	1	1	2	3	1	2	2	2	1	1	0	2	0	0	22.00	6.00	3.00
122 142	3	0	3	2	2	2	3	1	1	3	2	1	2	1	2	0	0	28.00	9.00	5.00
123 142	0	0	0	1	0	0	1	1	0	0	0	0	0	0	0	0	1	4.00	1.00	1.00
131 142	1	0	0	0	0	0	0	0	0	1	0	0	1	1	2	1	1	8.00	2.00	3.00
134 142	3	2	0	2	2	2	2	1	1	2	3	2	2	2	3	0	1	30.00	10.00	6.00
135 142	3	2	2	2	1	2	1	1	1	4	3	1	2	2	2	0	1	30.00	8.00	7.00
142 142	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	1	5.00	1.00	2.00
146 142	0	0	0	1	0	0	1	0	0	0	0	0	1	0	2	0	0	5.00	2.00	2.00
169 142	3	2	2	0	1	1	3	2	1	1	1	1	1	1	2	0	0	22.00	4.00	6.00
171 142	3	2	2	1	2	1	3	2	0	1	1	1	1	1	3	2	1	27.00	8.00	8.00
176 142	3	2	2	0	1	1	3	2	0	1	1	1	1	1	3	0	1	23.00	4.00	8.00
177 142	3	2	2	1	1	1	3	2	1	1	1	1	1	1	3	0	0	24.00	5.00	7.00
184 142	3	2	3	1	1	1	3	1	1	1	2	1	1	1	3	2	1	28.00	7.00	9.00
185 142	3	2	3	1	1	2	3	1	2	1	2	1	1	1	3	2	1	30.00	8.00	9.00
189 142	3	2	2	1	1	1	3	1	2	1	2	1	1	2	3	2	0	28.00	7.00	7.00
192 142	3	2	2	1	1	2	3	0	0	1	1	1	1	1	3	0	1	23.00	6.00	8.00
194 142	3	3	2	1	1	1	3	2	3	2	2	1	1	1	2	0	1	29.00	5.00	8.00
198 142	3	3	2	2	1	0	3	1	1	1	2	1	1	1	2	0	1	25.00	5.00	8.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

17

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
199	142	3	3	3	1	0	1	3	0	1	1	2	1	1	1	2	0	1	24.00	4.00	9.00
200	142	3	2	2	0	1	1	3	1	1	2	1	1	1	1	2	0	1	23.00	4.00	7.00
208	142	2	1	2	1	0	0	3	2	2	2	1	0	1	0	2	0	0	19.00	2.00	5.00
209	142	2	2	1	1	1	1	2	1	2	1	2	1	1	1	1	2	1	23.00	7.00	5.00
211	142	2	2	2	1	0	1	3	3	2	2	1	1	1	1	2	0	1	25.00	4.00	7.00
215	142	3	3	3	2	1	1	3	2	2	2	2	1	1	2	2	2	1	33.00	8.00	9.00
217	142	0	0	0	1	1	0	0	0	0	0	0	0	1	0	2	0	0	5.00	3.00	2.00
222	142	2	0	2	1	0	2	2	0	0	0	0	0	1	2	1	2	0	15.00	6.00	3.00
224	142	0	0	0	1	0	0	1	1	0	1	0	0	0	0	0	0	0	4.00	1.00	.00
231	142	1	0	0	1	0	0	1	1	0	0	2	0	1	1	2	0	0	10.00	2.00	2.00
232	142	2	0	0	1	0	0	2	0	1	2	2	1	2	2	2	0	0	17.00	4.00	2.00
235	142	4	2	2	2	2	2	2	1	2	2	1	0	2	2	2	1	0	29.00	9.00	6.00
240	142	3	0	0	0	0	0	2	0	1	1	1	1	2	2	2	0	0	15.00	3.00	2.00
244	142	2	2	1	1	1	1	3	1	0	1	1	1	1	1	2	0	0	19.00	5.00	5.00
246	142	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	0	22.00	5.00	7.00
247	142	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	0	21.00	5.00	6.00
248	142	2	2	1	1	1	1	2	1	0	0	1	0	1	1	2	0	0	16.00	4.00	5.00
257	142	3	3	1	1	1	0	3	1	2	1	1	1	1	2	2	1	1	25.00	5.00	7.00
258	142	3	2	1	1	0	0	3	2	2	2	2	1	1	0	2	0	1	23.00	3.00	6.00
259	142	3	2	2	1	1	1	3	1	1	1	1	1	1	2	2	0	0	23.00	5.00	6.00
263	142	3	2	1	1	1	0	3	1	0	1	1	1	1	1	2	0	0	19.00	4.00	5.00
267	142	3	2	1	0	0	1	3	1	2	2	1	1	1	1	3	1	0	23.00	4.00	6.00
270	142	2	2	1	1	0	0	3	1	1	1	2	1	1	1	2	0	1	20.00	3.00	6.00
271	142	2	1	1	1	0	0	3	1	1	1	1	1	1	2	2	2	0	20.00	5.00	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

18

Treatment Group "A"

Day 14 (Period 142)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Depressed mood	2.19	.11
2. Feelings of guilt	1.17	.11
3. Suicide	1.08	.11
4. Insomnia, early	.99	.06
5. Insomnia, middle	.78	.07
6. Insomnia, late	.88	.08
7. Work and activities	2.21	.11
8. Retardation	1.01	.08
9. Agitation	.90	.10
10. Anxiety, psychic	1.37	.12
11. Anxiety, somatic	1.27	.09
12. Somatic symptoms, gastrointestinal	.73	.06
13. Somatic symptoms, general	1.08	.06
14. Genital symptoms	1.04	.08
15. Hypochondriasis	1.74	.11
16. Weight	.36	.08
17. Insight	.38	.06
Total Score	19.18	.88
Factor 1 - Vegetative signs	4.82	.23
Factor 2 - Vital disturbances	4.37	.31

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

19

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 212	2	0	1	1	1	0	3	0	1	3	2	0	0	0	2	0	0	16.00	2.00	3.00
5 212	1	0	0	0	0	0	1	1	0	1	1	1	1	0	1	0	0	8.00	2.00	1.00
9 212	3	2	0	2	1	0	3	0	1	2	0	0	2	0	2	0	0	18.00	5.00	4.00
12 212	3	2	2	1	1	1	3	2	1	2	2	2	2	1	2	0	1	28.00	7.00	7.00
13 212	3	3	2	2	2	2	3	0	2	4	1	0	1	1	1	0	0	27.00	7.00	6.00
14 212	2	2	1	1	2	1	2	2	1	3	1	0	1	0	1	0	0	20.00	5.00	4.00
25 212	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
30 212	3	1	1	1	1	2	3	3	2	2	3	2	2	2	3	1	1	33.00	9.00	6.00
35 212	2	1	1	1	1	1	3	3	1	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 212	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
38 212	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	2.00	1.00	.00
45 212	0	0	0	1	0	0	1	1	0	0	0	0	0	2	0	0	0	5.00	1.00	.00
48 212	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
49 212	1	2	0	0	1	0	2	1	0	1	1	0	0	1	1	0	0	11.00	1.00	3.00
50 212	1	1	0	1	0	1	1	1	0	1	1	0	1	0	1	0	0	10.00	3.00	2.00
56 212	2	0	0	1	0	0	1	1	1	1	1	1	0	2	0	0	0	12.00	3.00	2.00
57 212	1	1	1	1	1	1	1	2	0	2	1	1	1	1	2	0	0	17.00	5.00	4.00
64 212	3	2	2	1	1	1	3	1	2	2	3	1	1	1	3	1	1	29.00	6.00	8.00
65 212	2	2	2	1	1	0	2	2	0	2	2	1	1	1	2	0	1	22.00	4.00	7.00
68 212	2	2	1	1	1	1	2	1	0	2	2	1	1	1	2	1	0	21.00	6.00	5.00
72 212	2	1	0	1	1	1	1	1	0	1	1	1	1	1	2	0	0	15.00	5.00	3.00
73 212	3	0	0	1	1	1	3	2	2	2	2	2	1	2	2	0	1	25.00	6.00	3.00
75 212	3	2	0	0	1	2	3	1	1	3	3	1	1	2	3	0	0	26.00	5.00	5.00
79 212	3	2	3	0	1	2	3	0	1	3	2	1	1	1	0	0	2	25.00	5.00	7.00
80 212	1	0	1	0	0	1	2	0	0	1	2	1	1	1	0	0	1	12.00	3.00	2.00
85 212	2	0	0	0	1	1	2	1	0	1	1	1	1	1	0	0	0	12.00	4.00	.00
87 212	1	0	0	0	1	0	1	1	1	2	0	0	2	1	0	0	0	10.00	3.00	.00
94 212	2	0	0	0	0	1	2	1	0	2	1	0	2	1	1	0	0	13.00	3.00	1.00
96 212	2	0	0	1	0	1	2	1	0	2	0	1	2	2	0	0	0	14.00	5.00	.00
99 212	2	0	1	1	1	0	1	2	2	1	2	0	1	0	1	0	0	15.00	3.00	2.00
101 212	0	0	0	1	1	1	0	0	2	1	2	0	0	1	2	0	0	11.00	3.00	2.00
107 212	2	1	0	2	1	1	3	2	2	1	1	0	1	0	3	0	0	20.00	5.00	4.00
108 212	1	1	1	1	0	0	1	1	1	0	2	1	1	0	1	0	0	12.00	3.00	3.00
109 212	3	1	1	2	0	0	2	0	3	2	2	1	2	0	1	0	0	20.00	5.00	3.00
114 212	3	1	1	1	1	2	3	1	1	1	3	1	2	2	3	1	0	27.00	8.00	5.00
115 212	1	0	0	1	0	1	1	0	1	1	1	0	0	0	1	0	0	8.00	2.00	1.00
120 212	3	0	1	2	1	2	3	1	2	2	2	1	2	0	2	0	0	24.00	8.00	3.00
122 212	4	0	3	2	2	2	3	1	2	4	3	1	2	1	3	0	0	33.00	9.00	6.00
123 212	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.00	.00	.00
131 212	1	0	0	0	1	0	1	0	0	1	0	0	1	0	2	1	1	9.00	3.00	3.00
135 212	2	1	0	1	1	1	1	1	0	2	2	0	1	2	2	0	1	18.00	4.00	4.00
142 212	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0	1	1	7.00	3.00	1.00
146 212	0	0	0	0	2	0	1	0	0	0	1	0	2	0	2	0	1	9.00	4.00	3.00
169 212	3	2	2	0	1	1	3	2	0	1	1	1	1	1	2	0	0	21.00	4.00	6.00
171 212	3	2	2	1	1	1	3	2	1	1	1	1	2	1	2	2	0	26.00	8.00	6.00
176 212	3	2	2	0	1	1	3	2	0	1	1	1	1	1	3	0	1	23.00	4.00	8.00
177 212	3	2	2	1	1	1	3	2	0	0	1	1	1	1	3	0	0	22.00	5.00	7.00
184 212	3	2	2	1	1	1	3	1	2	1	2	1	1	1	3	2	1	28.00	7.00	8.00
185 212	3	2	2	1	1	1	3	1	2	1	2	1	1	1	3	0	0	25.00	5.00	7.00
189 212	3	2	2	1	1	1	3	1	2	2	2	1	1	2	3	0	0	27.00	5.00	7.00
192 212	3	2	3	1	1	2	3	2	1	1	1	1	1	1	2	0	1	26.00	6.00	8.00
194 212	3	2	2	0	1	1	3	1	1	1	1	1	1	1	2	0	1	22.00	4.00	7.00
198 212	3	3	2	1	1	0	2	1	1	1	2	1	0	1	0	0	1	20.00	3.00	6.00
199 212	3	2	2	0	0	1	3	1	1	1	1	1	1	1	2	0	1	21.00	3.00	7.00



FCE 20124/702 i

20

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
200	212	3	2	2	0	1	1	3	1	1	2	1	1	1	2	0	1	23.00	4.00	7.00
208	212	2	2	2	1	0	0	2	1	2	1	1	0	0	0	1	0	15.00	1.00	5.00
209	212	1	1	1	0	1	1	2	1	2	1	2	1	0	1	0	2	17.00	5.00	2.00
211	212	1	1	2	1	0	0	3	2	1	1	1	1	1	2	0	1	19.00	3.00	6.00
215	212	3	2	2	1	1	1	3	2	2	2	2	1	1	2	2	1	29.00	6.00	7.00
217	212	0	0	0	1	0	1	0	0	1	0	1	0	0	0	0	0	4.00	2.00	.00
222	212	3	0	2	1	1	2	3	1	0	0	1	1	2	2	1	1	21.00	8.00	3.00
224	212	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1.00	.00	.00
231	212	0	0	0	0	0	0	1	1	0	1	1	0	1	0	1	0	6.00	1.00	1.00
232	212	2	0	1	1	0	1	3	0	1	2	2	2	2	3	0	0	22.00	6.00	4.00
235	212	1	0	0	0	0	0	2	1	0	0	0	0	1	2	0	0	7.00	1.00	.00
240	212	1	0	0	0	0	0	1	0	0	0	1	0	1	0	2	0	6.00	1.00	2.00
244	212	2	2	1	1	1	1	2	1	0	1	2	1	1	1	2	0	19.00	5.00	5.00
246	212	2	2	1	1	1	1	2	1	0	0	1	1	1	1	2	0	17.00	5.00	5.00
247	212	2	2	1	1	1	1	2	1	0	1	1	0	1	1	2	0	17.00	4.00	5.00
248	212	2	2	1	1	1	0	2	1	0	1	1	0	1	1	2	0	16.00	3.00	5.00
257	212	2	2	1	1	0	0	2	0	1	1	1	1	1	2	1	1	18.00	4.00	5.00
258	212	2	2	1	1	0	0	3	1	1	1	1	1	1	0	1	0	17.00	3.00	5.00
259	212	3	2	2	1	0	1	3	1	0	1	1	1	1	1	2	0	20.00	4.00	6.00
263	212	2	2	1	1	1	0	3	1	0	1	1	1	1	1	2	0	18.00	4.00	5.00
267	212	2	2	1	0	0	1	3	1	2	1	1	1	1	1	2	1	20.00	4.00	5.00
270	212	2	2	1	0	0	0	2	1	1	1	2	1	1	1	2	0	18.00	2.00	6.00
271	212	1	1	0	0	0	0	3	0	0	1	1	0	0	1	1	0	9.00	.00	2.00

FCE 20124/702 i

21

Treatment Group "A"

Day 21 (Period 212)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Depressed mood	1.90	.12
2. Feelings of guilt	1.08	.11
3. Suicide	.94	.10
4. Insomnia, early	.74	.07
5. Insomnia, middle	.65	.07
6. Insomnia, late	.71	.08
7. Work and activities	2.03	.12
8. Retardation	.96	.09
9. Agitation	.78	.09
10. Anxiety, psychic	1.25	.11
11. Anxiety, somatic	1.27	.09
12. Somatic symptoms, gastrointestinal	.66	.07
13. Somatic symptoms, general	.99	.07
14. Genital symptoms	.90	.08
15. Hypochondriasis	1.51	.11
16. Weight	.22	.06
17. Insight	.32	.06
Total Score	16.90	.93
Factor 1 - Vegetative signs	3.97	.25
Factor 2 - Vital disturbances	3.84	.29

210

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

22

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
1 282	2	0	1	1	1	0	3	0	1	4	2	0	0	0	3	0	0	18.00	2.00	4.00
5 282	0	0	0	0	0	0	1	1	0	1	1	1	1	0	1	0	0	7.00	2.00	1.00
9 282	3	2	0	2	1	0	3	0	1	2	0	0	2	0	2	0	0	18.00	5.00	4.00
12 282	3	2	2	1	1	1	3	2	1	2	2	2	2	1	2	0	1	28.00	7.00	7.00
13 282	3	3	2	1	2	2	3	0	2	4	1	0	1	1	1	0	0	26.00	6.00	6.00
14 282	2	2	1	1	2	1	2	2	1	3	1	1	1	0	1	0	0	21.00	6.00	4.00
25 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
30 282	3	1	1	1	1	2	3	3	2	2	2	2	2	2	3	1	1	32.00	9.00	6.00
35 282	2	1	1	1	1	1	3	3	1	3	2	2	1	2	2	1	1	28.00	7.00	5.00
37 282	0	0	0	0	0	1	1	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
38 282	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	2.00	1.00	.00
45 282	0	0	0	1	0	0	1	1	0	0	0	0	0	2	0	0	0	5.00	1.00	.00
48 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
49 282	1	1	0	1	1	0	2	1	0	1	1	0	1	1	2	0	1	14.00	3.00	4.00
50 282	1	1	0	1	1	0	1	1	0	1	1	0	0	0	1	0	0	9.00	2.00	2.00
56 282	1	0	0	1	0	0	1	0	1	1	1	1	1	0	2	0	0	10.00	3.00	2.00
57 282	1	1	0	1	0	1	1	1	0	2	2	1	1	0	3	0	0	15.00	4.00	4.00
64 282	3	2	2	1	1	1	3	1	2	2	3	1	1	1	3	1	1	29.00	6.00	8.00
65 282	2	1	1	1	1	0	2	2	0	1	2	1	1	1	2	0	1	19.00	4.00	5.00
68 282	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	1	0	22.00	6.00	5.00
72 282	2	1	0	1	1	1	2	1	0	1	1	1	1	1	2	0	0	16.00	5.00	3.00
75 282	3	2	0	0	1	1	3	2	2	3	2	1	1	1	1	0	0	23.00	4.00	3.00
79 282	3	2	3	1	1	2	3	0	1	3	1	1	1	1	0	0	2	25.00	6.00	7.00
80 282	1	0	0	0	0	1	1	0	0	2	2	1	0	1	0	2	0	11.00	4.00	.00
85 282	2	0	0	0	1	1	1	0	1	1	0	1	1	1	0	0	0	10.00	4.00	.00
87 282	1	0	0	1	1	0	1	0	0	1	0	0	1	1	0	0	0	7.00	3.00	.00
94 282	2	0	0	0	0	0	1	1	0	2	1	0	1	1	0	0	0	9.00	1.00	.00
96 282	2	0	0	1	2	1	2	1	0	2	0	0	2	2	0	0	0	15.00	6.00	.00
99 282	2	0	1	1	1	0	1	2	2	2	2	0	1	0	1	0	0	16.00	3.00	2.00
101 282	0	0	0	0	1	0	0	0	3	1	2	0	0	0	0	0	0	7.00	1.00	.00
107 282	3	1	1	1	1	1	3	1	2	3	1	1	2	0	0	0	1	22.00	6.00	3.00
108 282	1	1	0	0	0	0	1	1	1	0	1	0	0	0	1	0	0	7.00	.00	2.00
109 282	3	1	1	2	0	0	3	1	2	2	2	1	2	0	2	0	0	22.00	5.00	4.00
114 282	3	1	1	1	1	2	3	1	2	2	3	2	2	2	3	0	0	29.00	8.00	5.00
115 282	0	0	0	0	0	0	0	0	2	1	0	0	0	0	1	0	0	4.00	.00	1.00
120 282	3	0	1	2	1	2	3	1	2	2	2	1	2	0	2	0	0	24.00	8.00	3.00
123 282	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.00	.00	.00
131 282	1	0	0	0	0	0	0	0	0	1	0	0	1	0	2	1	1	7.00	2.00	3.00
135 282	1	0	0	0	1	1	2	0	0	1	1	1	1	2	1	0	1	13.00	4.00	2.00
142 282	1	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	4.00	1.00	1.00
146 282	1	0	0	0	0	0	1	0	0	1	1	1	1	0	1	0	0	7.00	2.00	1.00
169 282	3	2	2	0	1	1	3	2	0	0	1	1	1	1	3	0	0	21.00	4.00	7.00
171 282	3	2	3	1	1	1	3	2	2	1	1	1	1	1	3	0	0	26.00	5.00	8.00
176 282	3	2	2	0	1	1	3	2	0	1	1	1	1	1	2	0	1	22.00	4.00	7.00
177 282	3	2	2	1	1	1	3	2	0	1	1	1	1	1	3	0	0	23.00	5.00	7.00
184 282	3	2	3	1	1	1	3	1	2	2	2	1	1	1	3	2	1	30.00	7.00	9.00
185 282	3	2	2	1	1	1	3	1	1	1	2	1	1	1	3	0	0	24.00	5.00	7.00
189 282	3	2	2	1	1	2	3	1	1	1	1	1	1	2	3	1	1	27.00	7.00	8.00
192 282	3	2	2	1	1	2	3	2	0	1	2	1	1	1	3	1	1	27.00	7.00	8.00
194 282	3	2	1	0	1	1	3	1	1	1	1	1	1	1	2	0	1	21.00	4.00	6.00
198 282	2	2	2	1	1	0	2	1	1	1	2	1	1	1	1	0	1	20.00	4.00	6.00
199 282	3	2	1	0	0	2	3	1	1	1	1	1	1	1	2	0	1	21.00	4.00	6.00
200 282	3	2	2	0	1	1	3	1	2	2	1	1	1	1	2	0	1	24.00	4.00	7.00
208 282	0	1	1	0	0	0	2	1	1	1	1	0	0	0	1	0	0	9.00	.00	3.00

FCE 20124/702 i

23

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
209	282	1	1	1	0	0	1	2	1	1	1	2	1	0	1	0	2	0	15.00	4.00	2.00
211	282	1	1	2	1	0	0	3	2	1	1	1	1	1	1	2	0	1	19.00	3.00	6.00
215	282	3	2	2	1	1	0	3	1	1	1	2	1	1	2	2	1	1	25.00	5.00	7.00
217	282	1	0	0	1	0	0	1	0	0	0	0	0	1	1	0	0	0	5.00	2.00	.00
224	282	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.00	.00	.00
231	282	0	0	0	2	1	0	0	0	0	1	1	0	1	0	1	0	0	7.00	4.00	1.00
235	282	1	1	0	0	0	0	0	1	0	0	0	1	0	2	0	0	0	6.00	1.00	1.00
240	282	3	1	0	0	1	2	3	0	0	1	0	1	2	2	0	0	0	16.00	6.00	1.00
244	282	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	5.00	5.00
246	282	2	2	1	1	1	1	2	1	0	0	1	0	1	1	2	0	0	16.00	4.00	5.00
247	282	2	2	1	1	1	1	2	1	0	1	1	0	1	1	2	0	0	17.00	4.00	5.00
248	282	2	2	1	1	1	0	2	1	0	1	1	1	1	1	2	0	0	17.00	4.00	5.00
257	282	1	1	0	0	0	0	2	0	1	0	1	1	1	2	1	1	1	13.00	3.00	3.00
258	282	2	1	1	0	0	0	2	1	1	1	1	0	1	0	1	0	1	13.00	1.00	4.00
259	282	2	1	1	1	0	1	2	1	0	1	1	1	1	1	2	0	0	16.00	4.00	4.00
263	282	2	2	1	1	1	0	3	1	0	1	1	1	1	1	2	0	0	18.00	4.00	5.00
267	282	2	1	1	0	0	0	2	0	0	0	1	0	0	1	1	1	0	10.00	1.00	3.00
270	282	1	1	1	0	0	0	1	0	1	0	1	1	0	1	1	0	1	10.00	1.00	4.00
271	282	1	0	0	0	0	0	2	0	0	1	1	0	0	1	1	0	0	7.00	.00	1.00

FCE 20124/702 i

24

Treatment Group "A"

Day 28 (Period 282)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. Depressed mood	1.78	.12
2. Feelings of guilt	1.01	.10
3. Suicide	.81	.10
4. Insomnia, early	.66	.07
5. Insomnia, middle	.63	.07
6. Insomnia, late	.62	.08
7. Work and activities	1.88	.13
8. Retardation	.85	.09
9. Agitation	.68	.10
10. Anxiety, psychic	1.21	.11
11. Anxiety, somatic	1.10	.09
12. Somatic symptoms, gastrointestinal	.66	.07
13. Somatic symptoms, general	.86	.07
14. Genital symptoms	.85	.08
15. Hypochondriasis	1.37	.12
16. Weight	.22	.06
17. Insight	.34	.06
Total Score	15.52	.98
Factor 1 - Vegetative signs	3.64	.26
Factor 2 - Vital disturbances	3.53	.31

FCE 20124/702 i

25

Table 5, Hamilton Depression Rating Scale

Treatment Group "B"

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 -01	3	2	2	2	1	0	2	0	1	4	2	1	1	0	0	0	0	21.00	5.00	4.00
10 -01	3	1	1	1	1	1	4	1	1	3	2	1	1	0	1	0	0	22.00	5.00	3.00
11 -01	3	2	3	2	1	3	4	1	0	3	1	0	0	1	1	0	0	25.00	6.00	6.00
15 -01	3	3	2	1	1	2	3	1	1	3	2	1	1	0	1	2	2	29.00	8.00	8.00
17 -01	4	1	2	2	1	2	3	2	1	3	3	1	2	0	2	0	0	29.00	8.00	5.00
28 -01	2	2	1	2	2	2	3	3	1	2	2	1	1	2	3	0	0	29.00	8.00	6.00
29 -01	2	2	2	1	1	1	3	1	1	2	1	1	1	2	0	1	0	22.00	6.00	4.00
31 -01	3	0	1	1	1	1	3	2	0	2	2	1	1	2	0	0	0	20.00	5.00	1.00
32 -01	2	0	2	1	1	1	3	1	0	2	1	1	0	2	0	1	0	18.00	5.00	2.00
41 -01	2	0	3	1	1	1	3	2	1	2	2	1	0	2	0	0	1	22.00	4.00	4.00
42 -01	3	1	4	2	2	2	3	3	1	2	1	1	1	2	1	1	0	30.00	9.00	6.00
44 -01	2	0	2	1	1	2	3	3	1	2	3	1	0	2	2	1	0	26.00	6.00	4.00
47 -01	2	0	0	2	0	0	3	2	1	2	2	1	1	2	0	1	1	20.00	5.00	1.00
51 -01	2	2	2	1	1	2	3	2	0	2	3	1	1	1	3	1	1	28.00	7.00	8.00
54 -01	2	1	1	1	1	2	2	0	2	1	1	1	1	1	3	1	1	22.00	6.00	6.00
55 -01	2	1	0	1	2	1	2	2	0	2	2	1	1	1	2	0	1	21.00	6.00	4.00
60 -01	2	2	2	1	1	1	2	0	2	1	2	1	1	1	2	0	1	22.00	5.00	7.00
61 -01	2	1	1	1	1	1	2	2	0	2	1	1	1	1	2	0	1	20.00	5.00	5.00
66 -01	3	2	2	1	1	1	2	2	0	2	2	1	1	2	2	1	1	26.00	6.00	7.00
67 -01	2	2	2	2	1	1	2	2	0	2	2	1	1	1	2	0	1	24.00	6.00	7.00
70 -01	3	2	2	1	2	1	2	2	0	2	2	1	1	1	2	1	1	26.00	7.00	7.00
77 -01	4	2	3	0	1	2	3	2	0	0	1	1	2	2	1	2	2	28.00	8.00	8.00
78 -01	3	2	2	1	1	1	3	1	2	3	1	1	2	2	3	2	1	31.00	8.00	8.00
83 -01	4	1	0	2	1	1	4	3	1	3	0	1	2	0	0	0	0	23.00	7.00	1.00
84 -01	3	1	3	1	1	1	3	1	1	2	2	0	2	1	2	1	0	25.00	6.00	6.00
88 -01	3	0	1	1	2	2	3	0	2	2	3	2	1	1	3	2	1	29.00	10.00	5.00
90 -01	4	1	1	1	1	1	3	0	1	1	3	0	2	2	0	0	0	21.00	5.00	2.00
91 -01	3	2	3	1	1	1	3	0	2	3	1	1	1	1	0	0	1	24.00	5.00	6.00
95 -01	3	2	4	1	1	2	1	1	2	1	0	0	2	2	0	1	0	23.00	7.00	6.00
98 -01	4	0	0	2	2	2	4	2	0	3	2	1	1	1	0	1	0	25.00	9.00	.00
102 -01	3	0	0	1	1	1	2	2	2	3	2	1	1	1	3	1	0	24.00	6.00	3.00
103 -01	4	0	1	2	1	1	4	3	0	1	1	1	1	1	0	1	0	22.00	7.00	1.00
106 -01	3	2	1	2	1	2	4	1	1	3	3	2	2	2	3	2	1	35.00	11.00	7.00
110 -01	4	1	2	2	0	1	3	2	1	1	2	1	2	2	2	1	0	27.00	7.00	5.00
113 -01	4	1	1	1	1	2	2	1	1	2	1	1	2	1	3	2	0	26.00	9.00	5.00
118 -01	3	2	1	0	1	2	3	2	1	0	1	1	2	2	2	2	0	25.00	8.00	5.00
119 -01	3	2	2	2	1	2	4	2	0	0	2	1	2	1	2	1	0	27.00	9.00	6.00
124 -01	3	2	4	2	2	1	3	2	0	2	3	2	1	2	2	1	1	33.00	9.00	9.00
126 -01	3	3	2	1	1	2	2	1	0	2	2	1	1	2	3	1	1	28.00	7.00	9.00
127 -01	4	3	2	2	2	3	1	0	3	3	2	1	1	1	2	0	1	30.00	8.00	8.00
132 -01	4	2	2	2	2	2	2	1	1	3	2	2	1	2	1	2	1	32.00	11.00	6.00
133 -01	4	3	3	1	2	2	3	1	2	3	2	2	2	1	2	2	1	36.00	11.00	9.00
136 -01	4	3	3	2	2	2	3	1	1	3	3	2	1	1	2	2	2	37.00	11.00	10.00
139 -01	4	3	4	2	1	2	4	2	1	3	3	2	2	2	1	2	1	39.00	11.00	9.00
140 -01	2	0	1	2	1	1	4	1	1	3	3	1	1	1	2	2	1	27.00	8.00	4.00
147 -01	4	2	1	2	2	2	3	0	0	3	3	2	2	2	3	2	1	34.00	12.00	7.00
148 -01	4	2	2	2	0	2	2	0	2	3	2	1	2	2	3	2	1	32.00	9.00	8.00
170 -01	3	2	3	1	1	1	3	2	2	1	1	1	2	1	2	2	0	28.00	8.00	7.00
172 -01	3	1	3	2	2	1	3	2	0	1	1	1	1	1	3	2	1	28.00	9.00	8.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

26

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
179	-01	3	2	3	1	1	2	3	2	0	1	1	1	1	2	1	1	26.00	7.00	8.00	
180	-01	3	2	3	1	1	1	3	2	0	1	1	1	1	2	3	0	1	26.00	5.00	9.00
181	-01	3	2	3	1	1	2	3	2	0	1	1	1	1	2	3	2	1	29.00	8.00	9.00
186	-01	3	2	2	1	1	3	3	1	0	1	2	1	1	2	3	2	1	29.00	9.00	8.00
187	-01	3	1	3	1	1	2	3	2	0	1	1	1	1	1	2	1	1	25.00	7.00	7.00
188	-01	3	2	3	1	1	2	3	2	0	0	1	1	1	1	3	2	0	26.00	8.00	8.00
193	-01	3	3	3	1	1	1	3	2	2	1	1	1	1	2	2	1	29.00	7.00	9.00	
197	-01	3	3	2	2	0	2	2	2	2	3	2	0	1	1	2	0	1	28.00	5.00	8.00
202	-01	3	2	3	2	0	0	3	1	1	1	2	1	1	2	2	0	1	25.00	4.00	8.00
203	-01	4	3	3	1	1	0	3	2	3	3	2	1	1	1	3	2	1	34.00	6.00	10.00
206	-01	4	3	3	0	1	1	3	2	3	3	2	1	1	0	3	1	1	32.00	5.00	10.00
210	-01	3	3	2	1	1	0	3	2	3	3	2	1	1	0	3	0	0	28.00	4.00	8.00
214	-01	3	3	3	1	1	0	3	2	2	2	2	1	1	1	3	1	1	30.00	5.00	10.00
216	-01	2	3	1	2	1	0	3	2	2	3	2	1	1	1	3	0	1	28.00	5.00	8.00
218	-01	3	1	3	1	1	1	2	1	0	3	1	1	1	1	0	2	0	22.00	7.00	4.00
219	-01	2	2	2	2	2	3	0	4	4	4	2	1	2	0	2	0	0	30.00	9.00	6.00
226	-01	3	1	0	2	2	2	3	1	1	1	2	2	2	2	3	2	1	30.00	12.00	5.00
227	-01	3	0	1	2	2	2	3	1	0	1	2	1	2	2	1	2	0	25.00	11.00	2.00
230	-01	4	0	3	2	2	2	4	0	4	4	2	0	2	0	0	2	0	31.00	10.00	3.00
233	-01	3	0	0	2	2	2	3	0	2	2	1	2	2	3	2	0	28.00	12.00	3.00	
237	-01	3	0	2	2	2	2	4	0	3	4	1	1	2	2	3	2	0	33.00	11.00	5.00
238	-01	3	2	0	1	0	1	3	1	1	2	2	1	2	0	2	2	0	23.00	7.00	4.00
243	-01	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	1	1	24.00	7.00	7.00
245	-01	3	2	2	1	1	2	3	1	0	1	1	1	1	2	3	2	1	27.00	8.00	8.00
249	-01	3	2	2	1	1	1	3	1	0	1	1	0	1	1	2	0	0	20.00	4.00	6.00
251	-01	3	2	2	1	0	0	3	1	2	2	2	0	1	0	2	0	0	21.00	2.00	6.00
254	-01	3	3	1	2	0	0	3	1	2	1	1	1	1	1	2	1	0	23.00	5.00	6.00
255	-01	3	2	1	1	1	0	3	2	2	2	1	1	1	0	2	1	1	24.00	5.00	6.00
260	-01	3	1	2	1	2	1	3	1	0	1	1	1	1	1	3	1	0	23.00	7.00	6.00
262	-01	3	2	2	1	1	2	3	1	1	1	1	1	1	1	2	1	0	24.00	7.00	6.00
268	-01	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	1	21.00	4.00	5.00
269	-01	4	2	3	2	1	0	3	2	3	2	2	1	1	2	3	2	1	34.00	7.00	9.00
273	-01	3	3	2	1	0	1	3	2	3	2	2	1	1	0	2	0	0	26.00	4.00	7.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

27

Treatment Group "B"

Screen (Period -01)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Depressed mood	3.05	.07
2. Feelings of guilt	1.65	.11
3. Suicide	1.94	.12
4. Insomnia, early	1.37	.06
5. Insomnia, middle	1.13	.06
6. Insomnia, late	1.34	.08
7. Work and activities	2.93	.07
8. Retardation	1.43	.09
9. Agitation	1.05	.12
10. Anxiety, psychic	2.01	.11
11. Anxiety, somatic	1.72	.08
12. Somatic symptoms, gastrointestinal	1.02	.05
13. Somatic symptoms, general	1.24	.06
14. Genital symptoms	1.23	.08
15. Hypochondriasis	1.89	.12
16. Weight	1.06	.09
17. Insight	.59	.06
Total Score	26.65	.49
Factor 1 - Vegetative signs	7.17	.25
Factor 2 - Vital disturbances	6.06	.27

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

28

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 000	3	2	2	2	1	0	2	0	1	4	2	1	1	0	0	0	0	21.00	5.00	4.00
10 000	3	1	1	1	1	1	4	1	1	3	2	1	1	0	1	0	0	22.00	5.00	3.00
11 000	3	2	3	2	1	2	4	1	0	3	1	0	0	1	1	0	0	24.00	5.00	6.00
15 000	3	3	2	1	1	2	3	1	1	3	2	1	1	0	1	2	2	29.00	8.00	8.00
17 000	4	1	2	2	1	2	3	2	1	3	3	1	2	0	3	0	0	30.00	8.00	6.00
28 000	2	2	1	2	2	2	3	3	1	2	2	1	1	2	2	0	0	28.00	8.00	5.00
29 000	2	2	2	1	1	1	3	1	1	2	1	1	1	2	0	1	0	22.00	6.00	4.00
31 000	3	0	1	1	1	1	3	2	0	2	2	1	1	2	0	0	0	20.00	5.00	1.00
32 000	2	0	2	1	1	1	3	1	0	2	2	1	0	2	0	1	0	19.00	5.00	2.00
41 000	2	0	3	1	1	1	3	2	2	2	2	1	0	2	0	0	1	23.00	4.00	4.00
42 000	3	1	4	2	2	2	3	3	1	2	1	1	1	2	1	1	0	30.00	9.00	6.00
44 000	2	0	2	2	2	2	3	3	1	3	3	1	0	2	2	1	0	29.00	8.00	4.00
47 000	2	0	0	2	1	1	3	2	1	2	2	1	1	2	0	1	1	22.00	7.00	1.00
51 000	3	3	2	1	1	2	3	2	0	2	3	1	1	1	3	1	1	30.00	7.00	9.00
54 000	2	1	1	1	1	1	2	2	0	2	1	1	1	1	2	0	0	19.00	5.00	4.00
55 000	2	1	0	1	2	1	2	2	0	2	2	1	1	1	2	0	1	21.00	6.00	4.00
60 000	2	2	2	1	1	1	2	0	2	2	2	1	1	1	2	0	1	24.00	6.00	7.00
61 000	2	1	1	1	1	1	2	2	0	2	1	1	1	1	2	0	1	20.00	5.00	5.00
66 000	3	3	2	2	1	1	2	2	0	2	3	2	1	2	3	1	1	31.00	8.00	9.00
67 000	2	2	2	1	1	1	2	2	0	2	2	1	1	1	2	0	1	23.00	5.00	7.00
70 000	2	2	2	1	2	1	2	2	0	2	2	1	1	1	2	1	1	25.00	7.00	7.00
77 000	4	2	3	0	1	2	3	2	0	0	1	1	2	2	1	2	2	28.00	8.00	8.00
78 000	3	2	1	1	1	1	3	1	0	3	1	1	2	2	3	1	1	27.00	7.00	7.00
83 000	4	1	0	2	1	1	4	3	1	4	0	0	2	0	0	0	0	23.00	6.00	1.00
84 000	3	2	2	2	1	1	2	1	1	2	2	0	2	1	1	0	0	23.00	6.00	5.00
88 000	3	0	1	1	2	2	3	0	2	2	3	1	1	1	2	2	1	27.00	9.00	4.00
90 000	3	1	1	1	2	1	4	0	1	2	3	1	2	2	0	0	0	24.00	7.00	2.00
91 000	3	2	3	1	1	1	2	0	1	2	1	1	2	1	0	0	0	21.00	6.00	5.00
95 000	3	2	4	1	2	1	1	1	2	2	0	0	2	2	0	0	0	23.00	6.00	6.00
98 000	4	0	0	2	2	2	4	2	0	3	2	1	1	1	0	1	0	25.00	9.00	.00
102 000	3	0	0	1	1	1	2	2	2	3	2	1	1	1	3	0	0	23.00	5.00	3.00
103 000	4	1	0	2	1	1	3	3	0	1	1	1	1	1	0	0	0	20.00	6.00	1.00
106 000	3	2	1	2	1	2	4	1	1	3	3	2	2	2	3	2	1	35.00	11.00	7.00
110 000	4	1	2	2	1	1	3	2	1	1	2	1	2	2	2	1	0	28.00	8.00	5.00
113 000	4	1	1	1	1	2	2	1	1	2	1	1	2	1	3	0	0	24.00	7.00	5.00
118 000	3	2	1	0	1	2	3	2	1	0	1	1	2	2	2	0	0	23.00	6.00	5.00
119 000	3	2	2	2	2	2	4	2	0	0	2	1	2	1	3	1	0	29.00	10.00	7.00
124 000	3	2	4	2	2	1	3	2	0	2	3	2	1	2	2	1	1	33.00	9.00	9.00
126 000	3	3	2	1	1	2	2	1	0	2	2	1	1	2	3	1	1	28.00	7.00	9.00
127 000	4	3	2	2	2	2	3	1	0	3	2	1	1	1	2	0	1	30.00	8.00	8.00
132 000	4	2	2	2	2	2	2	1	1	2	2	2	1	2	2	1	1	31.00	10.00	7.00
133 000	4	3	3	1	2	2	3	1	2	3	2	2	2	1	2	2	1	36.00	11.00	9.00
136 000	4	3	3	2	2	2	3	1	1	3	3	2	1	1	2	2	2	37.00	11.00	10.00
139 000	4	3	4	2	1	2	4	2	1	3	3	2	2	2	1	2	1	39.00	11.00	9.00
140 000	2	0	1	2	1	1	4	1	1	3	3	1	1	1	2	2	1	27.00	8.00	4.00
147 000	4	2	1	2	2	2	3	0	0	3	3	2	2	2	3	2	0	33.00	12.00	6.00
148 000	4	2	2	2	0	2	2	0	1	3	2	1	2	2	3	2	1	31.00	9.00	8.00
170 000	3	2	3	2	2	1	3	2	2	1	2	1	2	2	3	2	0	33.00	10.00	8.00
172 000	3	1	3	2	2	1	3	2	0	0	1	1	2	1	0	2	1	25.00	10.00	5.00
179 000	3	2	3	1	2	2	3	2	0	1	1	1	1	1	2	2	1	28.00	9.00	8.00
180 000	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	0	1	24.00	5.00	8.00
181 000	3	2	3	2	1	2	3	1	1	1	1	1	1	2	3	2	1	30.00	9.00	9.00
186 000	3	2	3	1	1	2	3	2	0	1	1	1	1	1	2	3	2	28.00	8.00	8.00
187 000	3	2	3	1	1	2	3	2	0	1	1	1	1	1	2	1	1	26.00	7.00	8.00

FCE 20124/702 i

29

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
188 000	3	2	3	1	1	2	3	2	1	1	1	1	1	1	3	2	0	28.00	8.00	8.00
193 000	3	3	3	1	1	1	3	2	3	2	2	1	1	1	2	2	1	32.00	7.00	9.00
197 000	3	3	2	2	0	2	3	2	2	3	2	0	1	1	2	0	1	29.00	5.00	8.00
202 000	3	2	3	2	0	0	3	1	2	1	2	1	1	2	2	0	1	26.00	4.00	8.00
203 000	4	3	3	1	1	0	3	2	3	3	2	1	1	1	3	2	1	34.00	6.00	10.00
206 000	4	3	3	0	1	1	3	2	3	2	2	1	1	0	3	1	1	31.00	5.00	10.00
210 000	3	3	2	1	1	0	3	2	3	3	2	1	1	0	3	0	0	28.00	4.00	8.00
214 000	3	3	3	1	1	0	3	2	2	2	2	1	1	1	3	1	1	30.00	5.00	10.00
216 000	2	3	1	2	1	0	3	2	3	3	2	1	1	1	3	0	1	29.00	5.00	8.00
218 000	3	2	2	2	1	1	3	1	2	2	2	1	2	0	0	0	0	24.00	7.00	4.00
219 000	3	2	2	2	2	2	3	0	2	4	2	1	0	0	3	2	0	30.00	9.00	7.00
226 000	2	2	0	2	2	2	2	0	3	2	2	2	2	2	2	0	1	28.00	10.00	5.00
227 000	2	0	0	2	1	2	2	1	0	1	2	1	2	2	0	0	0	18.00	8.00	.00
230 000	4	0	0	2	2	2	4	0	4	3	1	0	2	0	0	0	0	24.00	8.00	.00
233 000	4	0	0	2	2	2	4	2	0	2	1	2	2	2	3	0	0	28.00	10.00	3.00
237 000	3	0	1	2	2	2	3	0	3	3	1	1	1	2	3	1	0	28.00	9.00	4.00
238 000	2	2	0	1	0	1	2	0	0	2	2	1	2	0	2	0	0	17.00	5.00	4.00
243 000	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	1	0	23.00	7.00	6.00
245 000	3	2	2	1	1	2	3	1	0	1	1	1	1	2	3	1	0	25.00	7.00	7.00
249 000	3	2	2	1	1	1	3	1	0	0	1	1	1	1	2	0	0	20.00	5.00	6.00
251 000	2	2	2	1	0	0	3	1	2	2	2	0	1	0	3	0	0	21.00	2.00	7.00
254 000	3	3	1	2	0	0	3	1	2	1	1	1	1	1	2	1	0	23.00	5.00	6.00
255 000	3	2	1	1	1	0	3	2	2	2	1	1	1	0	2	1	1	24.00	5.00	6.00
260 000	3	2	2	1	2	1	3	1	0	1	1	1	1	1	3	1	0	24.00	7.00	7.00
262 000	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	2	0	24.00	7.00	7.00
268 000	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	1	21.00	4.00	5.00
269 000	4	3	3	2	1	0	3	2	3	2	3	1	1	2	3	2	1	36.00	7.00	10.00
273 000	3	3	2	1	0	1	3	2	3	2	2	1	1	0	2	0	0	26.00	4.00	7.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

30

Treatment Group "B"

Baseline (Period 000)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Depressed mood	3.01	.07
2. Feelings of guilt	1.76	.11
3. Suicide	1.83	.12
4. Insomnia, early	1.43	.06
5. Insomnia, middle	1.22	.06
6. Insomnia, late	1.30	.08
7. Work and activities	2.89	.07
8. Retardation	1.41	.09
9. Agitation	1.06	.12
10. Anxiety, psychic	2.01	.10
11. Anxiety, somatic	1.77	.08
12. Somatic symptoms, gastrointestinal	1.05	.05
13. Somatic symptoms, general	1.24	.06
14. Genital symptoms	1.22	.08
15. Hypochondriasis	1.88	.12
16. Weight	.80	.09
17. Insight	.51	.06
Total Score	26.40	.52
Factor 1 - Vegetative signs	7.05	.23
Factor 2 - Vital disturbances	5.98	.29

FCE 20124/702 i

31

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 042	2	2	2	2	1	0	2	0	1	3	2	1	1	0	0	0	0	19.00	5.00	4.00
10 042	3	1	1	1	1	1	1	1	1	2	2	1	1	0	1	0	0	18.00	5.00	3.00
11 042	3	2	2	1	2	4	1	0	3	1	0	0	1	1	0	0	23.00	5.00	5.00	
15 042	3	3	2	1	1	2	3	1	1	3	2	1	1	0	1	1	2	28.00	7.00	8.00
17 042	4	1	2	2	1	2	3	2	2	3	3	1	2	0	3	0	0	31.00	8.00	6.00
28 042	2	2	1	2	2	1	3	3	1	2	2	1	1	2	2	0	0	27.00	7.00	5.00
29 042	2	2	2	1	1	1	3	1	1	2	1	1	1	2	0	1	0	22.00	6.00	4.00
31 042	3	0	1	1	1	1	3	2	0	1	1	1	1	2	0	0	0	18.00	5.00	1.00
32 042	2	0	2	1	1	1	3	1	0	2	1	1	0	2	0	0	0	17.00	4.00	2.00
41 042	2	0	2	1	1	1	3	2	2	2	2	1	0	2	0	0	1	22.00	4.00	3.00
42 042	2	1	3	2	2	2	3	3	1	2	1	1	1	2	1	0	0	27.00	8.00	5.00
44 042	2	0	2	2	2	2	3	3	1	3	3	1	0	2	2	0	0	28.00	7.00	4.00
47 042	2	0	0	1	1	1	3	2	1	2	2	1	1	2	0	1	0	20.00	6.00	.00
51 042	3	2	2	1	1	2	3	2	0	2	2	1	1	1	3	1	1	28.00	7.00	8.00
54 042	2	1	1	1	1	1	2	2	0	1	1	1	1	1	2	0	1	19.00	5.00	5.00
55 042	2	1	0	1	1	1	2	2	0	2	1	1	1	1	2	0	1	19.00	5.00	4.00
60 042	2	2	2	1	1	1	2	0	2	1	2	1	1	1	2	0	1	22.00	5.00	7.00
61 042	2	1	1	1	1	1	2	2	0	2	2	1	1	1	2	0	1	21.00	5.00	5.00
66 042	3	2	2	1	1	1	2	2	0	2	2	1	1	1	2	1	1	25.00	6.00	7.00
67 042	3	2	2	1	1	1	1	1	0	1	2	1	1	1	2	0	1	21.00	5.00	7.00
70 042	2	2	2	1	1	1	2	2	0	2	2	1	1	1	3	1	1	25.00	6.00	8.00
77 042	4	2	3	1	1	2	3	2	0	1	1	1	2	2	1	0	2	28.00	7.00	8.00
78 042	3	2	1	1	1	2	3	1	2	3	1	1	2	2	3	1	1	30.00	8.00	7.00
83 042	4	0	0	2	1	1	4	3	1	4	0	0	2	0	0	0	0	22.00	6.00	.00
84 042	3	2	1	2	1	1	2	1	1	2	1	1	2	1	1	0	0	22.00	7.00	4.00
88 042	3	0	1	1	1	2	2	0	2	2	3	1	2	1	2	0	0	23.00	7.00	3.00
90 042	3	1	0	1	1	1	4	0	1	1	3	1	2	2	1	0	0	22.00	6.00	2.00
91 042	3	2	2	1	2	1	3	0	2	2	1	1	2	1	0	0	0	23.00	7.00	4.00
95 042	1	2	2	1	2	1	1	1	1	2	0	0	1	1	0	0	0	16.00	5.00	4.00
98 042	4	0	0	2	2	2	4	2	0	2	2	1	1	2	0	0	0	24.00	8.00	.00
102 042	2	0	1	1	1	1	2	2	2	3	2	1	0	0	3	0	0	21.00	4.00	4.00
103 042	3	1	0	1	0	0	3	2	0	1	0	1	1	1	2	0	0	16.00	3.00	3.00
106 042	3	2	1	2	1	2	4	1	2	3	4	2	2	2	3	2	1	37.00	11.00	7.00
110 042	4	1	2	2	1	1	3	2	1	1	2	1	2	2	2	0	0	27.00	7.00	5.00
113 042	4	1	1	1	1	2	2	1	1	1	1	1	2	1	3	0	0	23.00	7.00	5.00
118 042	3	2	1	0	1	2	3	2	1	0	1	1	2	2	2	0	0	23.00	6.00	5.00
119 042	4	2	2	2	2	4	2	0	0	2	1	2	1	2	0	0	0	28.00	9.00	6.00
124 042	3	2	1	2	1	0	2	2	0	2	2	1	1	2	1	0	1	23.00	5.00	5.00
126 042	3	2	1	0	0	2	1	1	1	2	2	1	1	2	3	1	1	24.00	5.00	7.00
127 042	1	0	0	2	1	1	1	1	0	0	1	1	1	1	0	2	1	14.00	8.00	1.00
132 042	2	2	2	1	0	0	1	1	0	2	1	1	0	1	0	0	1	15.00	2.00	5.00
133 042	2	3	2	2	2	2	2	0	1	2	2	1	2	1	2	0	1	27.00	9.00	8.00
136 042	2	2	2	2	1	1	2	0	1	2	2	0	0	1	2	0	1	21.00	4.00	7.00
139 042	3	3	2	2	1	2	3	1	2	2	2	2	2	1	1	1	1	32.00	10.00	7.00
140 042	1	0	1	1	2	1	4	1	0	2	2	1	2	1	2	0	1	22.00	7.00	4.00
147 042	4	2	1	2	2	2	2	0	0	3	2	1	2	2	3	2	0	30.00	11.00	6.00
148 042	3	2	0	1	0	2	2	0	0	2	1	1	1	1	2	1	1	20.00	6.00	5.00
170 042	3	2	3	2	2	2	3	2	2	1	2	1	2	2	3	2	0	34.00	11.00	8.00
172 042	3	2	3	2	2	1	3	2	1	1	1	1	1	1	3	2	1	30.00	9.00	9.00
179 042	3	2	3	1	2	3	3	2	0	1	1	1	1	1	1	2	1	27.00	9.00	7.00
180 042	3	2	2	1	1	1	3	1	1	1	2	1	1	1	3	0	1	25.00	5.00	8.00
181 042	3	2	3	1	1	2	3	1	1	1	2	1	1	2	3	2	1	30.00	8.00	9.00
186 042	3	2	3	1	1	2	3	2	1	1	2	1	1	2	3	2	1	31.00	8.00	9.00
187 042	3	2	3	1	1	1	3	2	0	1	1	1	1	1	2	2	3	28.00	7.00	10.00

FCE 20124/702 i

32

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
188 042	3	2	3	1	1	2	3	2	0	1	1	1	1	1	2	2	0	26.00	8.00	7.00
193 042	3	3	3	1	1	1	3	2	3	2	2	1	1	1	2	2	1	32.00	7.00	9.00
197 042	3	3	2	1	0	2	3	2	2	3	2	0	1	1	2	0	1	28.00	4.00	8.00
202 042	3	2	3	2	0	0	3	1	2	1	2	1	1	2	2	0	1	26.00	4.00	8.00
203 042	4	3	3	1	1	0	3	2	2	1	2	1	1	1	3	2	1	31.00	6.00	10.00
206 042	4	3	3	0	1	1	3	2	3	2	2	1	1	0	3	1	1	31.00	5.00	10.00
210 042	3	3	2	1	1	0	3	2	3	2	2	1	1	0	3	0	0	27.00	4.00	8.00
214 042	3	3	3	1	1	0	3	2	2	2	2	1	1	1	3	1	1	30.00	5.00	10.00
216 042	2	3	1	2	1	0	3	2	3	3	2	1	1	1	3	0	1	29.00	5.00	8.00
218 042	3	2	2	2	2	3	0	0	1	2	2	2	0	0	0	0	0	23.00	10.00	4.00
219 042	3	1	2	2	2	2	3	1	0	2	0	1	1	0	1	0	0	21.00	8.00	4.00
226 042	2	2	0	2	2	2	2	0	2	1	1	2	2	1	3	0	1	25.00	10.00	6.00
227 042	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	2.00	.00	.00
230 042	4	0	0	2	2	2	4	0	4	4	0	0	1	0	0	0	0	23.00	7.00	.00
233 042	3	0	0	2	2	2	3	2	0	0	1	2	2	2	3	0	0	24.00	10.00	3.00
237 042	2	0	0	2	2	2	2	0	2	3	1	1	2	2	3	0	0	24.00	9.00	3.00
238 042	1	2	0	1	1	2	3	0	0	0	0	2	2	0	2	0	0	16.00	8.00	4.00
243 042	3	2	2	1	1	2	3	1	0	0	1	1	1	1	2	1	0	22.00	7.00	6.00
245 042	3	2	2	1	1	2	3	1	0	1	1	1	1	2	3	1	0	25.00	7.00	7.00
249 042	3	2	2	1	1	1	3	1	0	0	1	1	1	1	2	0	0	20.00	5.00	6.00
251 042	3	2	2	1	0	0	3	1	3	2	2	0	1	0	2	0	0	22.00	2.00	6.00
254 042	3	3	1	2	0	0	3	1	3	2	1	1	1	1	2	1	0	25.00	5.00	6.00
255 042	3	2	1	1	1	0	3	2	2	1	1	1	1	0	1	1	1	22.00	5.00	5.00
260 042	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	1	0	24.00	6.00	7.00
262 042	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	2	1	25.00	8.00	7.00
268 042	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	1	21.00	4.00	5.00
269 042	4	3	3	1	1	0	3	2	3	2	3	1	1	2	3	2	1	35.00	6.00	10.00
273 042	3	3	2	1	0	1	3	2	3	2	2	1	1	0	2	0	0	26.00	4.00	7.00

FCE 20124/702 i

33

Treatment Group "B"

Day 4 (Period 042)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Depressed mood	2.77	.09
2. Feelings of guilt	1.66	.11
3. Suicide	1.59	.11
4. Insomnia, early	1.30	.06
5. Insomnia, middle	1.11	.06
6. Insomnia, late	1.24	.08
7. Work and activities	2.70	.09
8. Retardation	1.34	.09
9. Agitation	1.06	.12
10. Anxiety, psychic	1.68	.10
11. Anxiety, somatic	1.55	.09
12. Somatic symptoms, gastrointestinal	.98	.05
13. Somatic symptoms, general	1.18	.07
14. Genital symptoms	1.15	.08
15. Hypochondriasis	1.79	.12
16. Weight	.55	.09
17. Insight	.54	.07
Total Score	24.18	.59
Factor 1 - Vegetative signs	6.37	.23
Factor 2 - Vital disturbances	5.57	.28

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

34

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 072	2	2	1	2	1	0	2	0	1	3	2	1	1	0	0	0	0	18.00	5.00	3.00
10 072	3	1	1	1	1	2	1	1	3	2	1	1	0	1	0	0	20.00	5.00	3.00	
11 072	3	2	2	2	1	2	4	1	0	3	1	0	0	1	1	0	23.00	5.00	5.00	
15 072	2	3	1	1	1	1	3	1	1	3	2	1	1	0	1	1	25.00	6.00	7.00	
17 072	3	1	2	2	1	2	3	2	1	3	3	1	2	0	3	0	29.00	8.00	6.00	
28 072	2	1	0	2	2	1	3	2	1	1	2	1	1	2	2	0	23.00	7.00	3.00	
29 072	2	2	2	1	1	1	3	1	1	2	1	1	1	2	0	1	22.00	6.00	4.00	
31 072	2	0	0	1	1	1	2	2	0	1	1	1	1	2	0	0	15.00	5.00	.00	
32 072	2	0	1	1	1	1	2	1	0	2	1	1	0	2	0	0	15.00	4.00	1.00	
41 072	1	0	1	1	1	1	2	2	1	2	1	1	0	2	0	0	17.00	4.00	2.00	
42 072	1	0	0	1	1	1	1	0	0	0	0	0	0	1	0	0	6.00	3.00	.00	
44 072	1	0	1	2	2	2	2	2	1	2	2	1	2	2	2	0	24.00	9.00	3.00	
47 072	2	0	0	1	1	1	2	2	1	1	1	1	1	2	0	0	16.00	5.00	.00	
51 072	3	2	2	1	1	2	2	2	3	2	2	1	1	1	2	1	29.00	7.00	7.00	
54 072	2	1	1	1	1	2	2	0	2	2	2	1	1	1	2	0	21.00	5.00	5.00	
55 072	2	1	0	1	1	1	2	1	0	1	2	1	1	1	2	0	18.00	5.00	4.00	
60 072	2	2	2	1	1	1	2	0	2	1	2	1	1	1	2	0	21.00	5.00	6.00	
61 072	2	1	0	1	1	0	2	1	0	1	1	1	1	0	2	0	15.00	4.00	4.00	
66 072	2	2	2	1	1	1	2	2	0	2	2	1	1	2	3	1	26.00	6.00	8.00	
67 072	2	2	2	1	1	1	2	1	0	1	2	1	1	1	2	0	21.00	5.00	7.00	
70 072	3	2	2	1	2	1	2	2	0	2	2	1	1	1	2	1	26.00	7.00	7.00	
77 072	4	2	3	0	1	2	3	2	0	0	1	1	1	2	1	2	27.00	7.00	8.00	
78 072	3	2	1	1	1	1	3	1	2	3	2	1	1	2	2	1	28.00	6.00	6.00	
83 072	3	0	0	1	1	1	4	3	1	3	0	0	2	0	0	0	19.00	5.00	.00	
84 072	2	1	1	1	1	1	1	0	1	1	2	1	2	1	1	0	17.00	6.00	3.00	
88 072	1	0	0	0	1	2	1	0	1	1	3	1	2	1	1	0	15.00	6.00	1.00	
90 072	3	0	0	1	0	1	2	0	1	2	2	1	2	2	0	0	17.00	5.00	.00	
91 072	3	1	2	2	1	2	2	0	2	2	1	1	1	1	0	0	21.00	7.00	3.00	
95 072	1	2	2	1	1	1	1	1	1	1	1	0	1	1	0	0	15.00	4.00	4.00	
98 072	4	0	0	2	1	1	2	2	1	3	1	2	1	1	0	0	21.00	7.00	.00	
102 072	2	0	0	1	1	1	1	1	2	1	2	1	2	1	3	0	19.00	6.00	3.00	
103 072	2	0	0	1	0	0	2	1	1	1	1	1	1	2	0	1	14.00	4.00	.00	
106 072	4	2	1	1	1	1	4	1	2	2	2	2	2	1	2	0	30.00	7.00	7.00	
110 072	2	1	1	2	1	1	2	2	1	1	2	1	1	1	1	0	20.00	6.00	3.00	
113 072	3	1	0	1	1	2	2	0	1	2	1	1	1	1	3	0	20.00	6.00	4.00	
118 072	3	1	1	0	1	2	3	2	1	0	1	1	2	2	2	0	22.00	6.00	4.00	
119 072	3	2	1	1	2	2	4	2	0	0	2	1	2	1	3	0	26.00	8.00	6.00	
124 072	1	1	0	1	1	0	1	1	0	1	1	2	1	2	1	0	15.00	5.00	3.00	
126 072	3	2	0	0	0	2	1	0	1	2	2	1	1	2	2	1	22.00	6.00	5.00	
127 072	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2.00	1.00	.00	
132 072	1	1	0	1	0	0	1	0	0	1	1	0	1	0	0	1	8.00	2.00	2.00	
133 072	1	2	2	2	2	1	1	0	0	0	1	1	1	1	1	1	18.00	8.00	6.00	
136 072	4	3	1	2	1	2	2	0	1	2	2	0	1	0	2	1	25.00	7.00	7.00	
139 072	3	2	1	0	0	0	2	1	2	1	1	1	1	2	1	1	20.00	3.00	5.00	
140 072	1	0	0	1	1	1	2	0	1	1	1	0	1	1	1	0	13.00	4.00	2.00	
147 072	4	0	0	2	2	2	4	1	0	3	2	2	2	2	3	2	31.00	12.00	3.00	
148 072	3	2	0	1	2	2	2	0	0	2	2	1	2	2	1	0	24.00	9.00	4.00	
170 072	3	3	3	1	1	1	3	2	1	1	1	1	2	2	3	2	31.00	8.00	10.00	
172 072	3	1	3	1	1	1	3	1	2	1	2	1	2	1	2	0	27.00	8.00	6.00	
179 072	3	2	3	1	1	2	3	2	0	1	1	1	1	1	2	0	26.00	8.00	7.00	
180 072	3	2	2	1	1	1	3	1	2	1	2	1	1	1	3	0	26.00	5.00	8.00	
181 072	3	2	3	1	1	1	3	2	1	1	1	1	1	2	3	2	29.00	7.00	9.00	
186 072	3	2	3	1	1	2	3	2	2	1	2	1	1	2	3	2	32.00	8.00	9.00	
187 072	3	2	2	1	1	2	3	2	0	1	1	1	1	1	2	2	26.00	8.00	7.00	

FCE 20124/702 i

35

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
188 072	3	2	2	1	1	2	3	2	0	1	1	1	1	1	3	2	0	26.00	8.00	7.00
193 072	3	3	3	1	1	1	3	2	3	2	2	1	1	1	2	2	1	32.00	7.00	9.00
197 072	3	3	2	1	0	2	3	2	2	3	2	0	1	1	2	0	1	28.00	4.00	8.00
202 072	3	2	3	2	0	0	3	1	3	1	2	1	1	2	2	0	1	27.00	4.00	8.00
203 072	4	2	2	1	1	0	3	2	3	2	2	1	1	1	3	2	1	31.00	6.00	8.00
206 072	3	3	2	0	1	1	3	2	3	2	2	1	1	0	3	1	1	29.00	5.00	9.00
210 072	3	3	2	1	1	0	3	2	2	2	2	1	1	0	2	0	0	25.00	4.00	7.00
214 072	3	2	2	0	1	0	3	2	2	1	2	1	1	1	2	1	1	25.00	4.00	7.00
216 072	3	2	2	2	1	0	3	2	2	2	2	1	1	1	3	0	1	28.00	5.00	8.00
218 072	1	2	1	0	0	1	2	0	1	2	1	1	1	2	0	1	0	16.00	4.00	3.00
219 072	3	0	0	2	1	2	2	0	2	3	2	0	1	0	0	0	0	18.00	6.00	.00
226 072	2	0	0	1	1	1	2	0	0	2	1	0	2	1	2	0	0	15.00	5.00	2.00
227 072	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	0	3.00	1.00	.00
230 072	4	0	0	2	2	2	4	0	1	1	0	0	0	2	2	0	0	20.00	6.00	2.00
233 072	3	0	0	2	2	2	4	2	0	2	1	2	2	2	3	0	1	28.00	10.00	4.00
237 072	0	0	0	2	1	2	2	0	1	0	1	1	1	2	2	1	0	16.00	8.00	2.00
238 072	1	1	0	0	0	0	3	1	0	0	1	2	2	0	1	0	0	12.00	4.00	2.00
243 072	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	1	0	23.00	6.00	7.00
245 072	3	2	2	1	1	1	3	1	0	1	1	1	1	2	3	0	0	23.00	5.00	7.00
249 072	3	2	2	1	1	2	3	1	0	0	0	0	0	0	2	0	0	17.00	4.00	6.00
251 072	3	2	2	1	0	0	3	1	1	2	2	0	1	0	2	0	0	20.00	2.00	6.00
254 072	3	3	1	2	0	0	3	1	2	2	1	1	1	1	2	1	0	24.00	5.00	6.00
255 072	3	2	1	1	1	0	3	2	2	1	1	1	1	0	1	1	1	22.00	5.00	5.00
260 072	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	1	0	23.00	6.00	7.00
262 072	3	2	2	1	1	1	3	1	1	1	1	1	1	1	2	1	1	24.00	6.00	7.00
268 072	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	1	21.00	4.00	5.00
269 072	4	3	3	2	1	0	3	2	3	2	3	1	1	2	3	2	1	36.00	7.00	10.00
273 072	3	2	2	1	0	1	3	2	3	2	2	1	1	0	2	0	0	25.00	4.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

36

Treatment Group "B"

Day 7 (Period 072)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Depressed mood	2.50	.11
2. Feelings of guilt	1.41	.11
3. Suicide	1.21	.11
4. Insomnia, early	1.10	.07
5. Insomnia, middle	.94	.06
6. Insomnia, late	1.06	.08
7. Work and activities	2.44	.10
8. Retardation	1.16	.09
9. Agitation	1.01	.10
10. Anxiety, psychic	1.48	.10
11. Anxiety, somatic	1.48	.07
12. Somatic symptoms, gastrointestinal	.91	.05
13. Somatic symptoms, general	1.11	.06
14. Genital symptoms	1.15	.08
15. Hypochondriasis	1.63	.12
16. Weight	.56	.08
17. Insight	.48	.06
Total Score	21.62	.72
Factor 1 - Vegetative signs	5.68	.21
Factor 2 - Vital disturbances	4.73	.31

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

37

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 102	2	2	0	1	1	0	2	0	2	3	2	1	1	0	0	0	0	17.00	4.00	2.00
10 102	3	1	1	1	0	1	4	1	1	3	2	1	1	0	1	0	0	21.00	4.00	3.00
11 102	2	2	2	2	1	1	3	1	0	3	1	0	0	1	1	0	0	20.00	4.00	5.00
15 102	1	3	1	1	1	1	2	1	1	3	2	1	1	0	1	1	1	22.00	6.00	6.00
17 102	2	1	1	2	1	2	3	2	1	3	3	1	2	0	3	0	0	27.00	8.00	5.00
28 102	2	1	0	2	2	1	2	2	1	1	2	1	1	2	2	0	0	22.00	7.00	3.00
29 102	2	2	2	1	1	1	3	1	1	2	1	1	1	2	0	1	0	22.00	6.00	4.00
31 102	1	0	0	1	0	0	1	1	0	0	0	0	0	2	0	0	0	6.00	1.00	.00
32 102	1	0	0	1	1	0	2	1	1	1	1	0	0	2	0	0	0	11.00	2.00	.00
41 102	1	0	0	1	1	1	2	1	1	1	1	1	0	2	0	0	0	13.00	4.00	.00
42 102	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	2.00	1.00	.00
44 102	1	0	1	1	2	2	2	2	1	1	2	1	1	2	2	0	0	21.00	7.00	3.00
47 102	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
51 102	2	1	1	1	1	1	1	1	0	2	1	1	1	1	2	0	1	18.00	5.00	5.00
54 102	2	2	2	1	1	1	2	2	0	1	1	1	1	1	2	0	1	21.00	5.00	7.00
55 102	2	1	0	1	1	1	2	1	0	1	2	1	1	1	2	0	1	18.00	5.00	4.00
60 102	2	2	2	1	1	1	2	0	2	1	2	1	1	0	2	0	1	21.00	5.00	7.00
61 102	2	1	0	1	1	0	2	1	0	1	1	1	1	0	2	0	0	14.00	4.00	3.00
66 102	3	1	1	1	1	1	2	2	0	1	2	1	1	2	3	0	1	23.00	5.00	6.00
67 102	2	2	1	1	1	1	2	0	1	2	1	1	1	1	2	0	1	20.00	5.00	6.00
70 102	2	1	1	1	1	1	2	0	0	2	2	1	1	1	3	1	1	21.00	6.00	6.00
77 102	3	2	2	0	1	2	3	2	0	0	1	1	1	2	1	1	2	24.00	6.00	7.00
78 102	1	2	1	1	1	1	0	0	2	3	2	1	0	0	2	1	1	19.00	5.00	6.00
83 102	3	0	0	1	1	1	4	3	1	3	0	0	2	0	0	0	0	19.00	5.00	.00
84 102	2	0	0	0	1	1	2	0	0	2	2	1	2	1	2	0	0	16.00	5.00	2.00
88 102	2	0	0	0	1	1	1	0	1	2	2	0	2	1	3	0	1	17.00	4.00	4.00
90 102	2	0	0	1	0	0	1	0	1	0	1	1	2	1	0	0	0	10.00	4.00	.00
91 102	2	1	1	0	2	1	1	0	1	2	1	0	2	1	0	0	1	16.00	5.00	3.00
95 102	1	2	1	1	1	1	1	1	1	2	0	0	2	2	0	0	0	16.00	5.00	3.00
98 102	1	0	0	2	2	2	2	1	1	4	2	1	2	1	0	0	0	21.00	9.00	.00
102 102	2	1	0	1	1	1	2	1	2	2	2	1	1	1	3	0	0	21.00	5.00	4.00
103 102	2	0	0	1	0	0	2	1	1	1	1	1	1	2	0	0	0	13.00	3.00	.00
106 102	4	1	1	1	1	2	4	2	1	1	1	1	2	1	2	0	1	26.00	7.00	5.00
110 102	2	1	1	2	1	1	2	2	1	1	2	1	1	1	1	0	0	20.00	6.00	3.00
113 102	2	0	0	1	1	2	2	1	1	2	2	1	2	1	2	0	0	20.00	7.00	2.00
118 102	2	1	1	0	1	2	3	2	1	0	1	1	2	2	2	0	0	21.00	6.00	4.00
119 102	3	2	1	2	2	2	4	2	0	0	2	1	2	1	3	0	0	27.00	9.00	6.00
124 102	1	1	0	1	1	0	0	0	0	0	1	2	1	2	1	0	1	12.00	5.00	3.00
126 102	2	1	0	0	0	1	1	0	1	2	1	1	1	2	2	1	1	17.00	4.00	4.00
127 102	0	2	1	0	0	0	0	1	0	0	0	1	0	1	0	0	1	7.00	1.00	4.00
132 102	1	1	0	1	0	0	1	0	0	1	1	0	0	0	0	0	1	7.00	1.00	2.00
133 102	2	3	2	0	2	2	3	0	1	2	2	1	2	1	2	1	1	27.00	8.00	8.00
136 102	2	2	1	1	1	1	1	0	0	2	1	0	1	1	2	0	1	17.00	4.00	6.00
139 102	1	0	0	0	0	0	1	0	2	1	1	0	0	2	1	1	1	11.00	1.00	2.00
140 102	0	0	0	2	0	1	1	0	0	1	1	0	1	1	1	0	1	10.00	4.00	2.00
147 102	4	0	0	1	1	0	4	0	0	3	2	1	1	2	3	2	0	24.00	6.00	3.00
148 102	2	2	0	2	1	2	2	0	0	2	2	1	2	1	2	1	0	22.00	9.00	4.00
170 102	3	1	3	1	2	1	3	2	0	1	1	1	1	2	3	0	0	25.00	6.00	7.00
172 102	3	2	3	1	1	1	3	2	1	1	1	1	1	1	3	2	0	27.00	7.00	8.00
179 102	3	2	3	1	1	1	3	2	0	1	1	1	1	1	2	0	0	23.00	5.00	7.00
180 102	3	2	2	1	2	2	3	1	2	1	2	1	1	1	3	0	1	28.00	7.00	8.00
181 102	3	2	2	1	1	1	3	1	0	1	1	1	1	2	3	1	1	25.00	6.00	8.00
186 102	3	2	2	1	1	1	3	2	1	1	2	1	1	2	3	2	1	29.00	7.00	8.00
187 102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	1	22.00	5.00	7.00

FCE 20124/702 i

38

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
188	102	3	2	2	1	1	1	3	1	1	1	1	1	1	2	0	0	22.00	5.00	6.00
193	102	3	3	2	0	1	1	3	1	0	1	1	1	1	2	1	0	22.00	5.00	7.00
197	102	3	3	2	1	0	2	3	2	2	3	2	0	1	1	2	0	28.00	4.00	8.00
202	102	3	2	3	2	0	0	3	1	3	1	2	1	1	2	2	0	27.00	4.00	8.00
203	102	3	2	1	1	1	0	3	2	2	1	2	1	1	1	2	2	26.00	6.00	6.00
206	102	3	3	2	0	1	1	3	2	2	2	2	1	0	0	3	1	27.00	4.00	9.00
210	102	3	3	2	1	1	0	3	2	2	2	2	1	1	0	2	0	25.00	4.00	7.00
214	102	3	2	2	1	1	0	3	2	2	1	2	1	1	2	2	1	27.00	5.00	7.00
216	102	2	2	1	1	1	0	3	2	2	2	2	0	1	1	2	0	23.00	3.00	6.00
218	102	1	2	0	2	2	2	1	0	1	2	1	1	1	0	0	0	16.00	8.00	2.00
219	102	0	0	0	0	0	0	2	0	2	1	1	0	0	1	0	0	7.00	.00	.00
226	102	1	0	0	2	1	2	2	0	2	2	2	1	1	2	3	0	22.00	7.00	4.00
227	102	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	3.00	1.00	.00
230	102	2	0	0	2	2	2	4	0	4	4	1	0	0	2	2	0	25.00	6.00	2.00
233	102	3	1	0	2	2	2	4	2	1	2	1	2	2	2	3	0	30.00	10.00	5.00
237	102	2	0	0	2	1	2	2	0	1	2	0	1	2	1	0	0	16.00	8.00	.00
238	102	1	0	0	0	0	1	0	0	0	0	0	1	2	0	2	0	7.00	3.00	2.00
243	102	2	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	20.00	5.00	6.00
245	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	22.00	5.00	7.00
249	102	3	2	2	1	1	1	3	1	0	0	1	0	1	1	2	0	19.00	4.00	6.00
251	102	2	2	1	1	0	0	3	1	1	1	1	0	1	0	1	0	15.00	2.00	4.00
254	102	3	3	1	2	0	0	3	1	2	1	1	1	1	1	2	1	23.00	5.00	6.00
255	102	3	2	2	1	1	0	3	1	1	1	1	1	1	0	1	1	21.00	5.00	6.00
260	102	3	2	2	1	1	1	3	1	1	1	1	1	1	1	2	1	23.00	6.00	6.00
262	102	3	2	2	1	0	1	3	1	0	1	1	1	1	1	2	1	21.00	5.00	6.00
268	102	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	21.00	4.00	5.00
269	102	4	3	3	2	1	0	3	2	3	2	3	1	1	2	3	2	36.00	7.00	10.00
273	102	2	2	2	1	0	0	3	2	2	2	2	1	1	0	2	0	22.00	3.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

39

Treatment Group "B"

Day 10 (Period 102)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Depressed mood	2.11	.11
2. Feelings of guilt	1.34	.11
3. Suicide	1.00	.11
4. Insomnia, early	1.02	.07
5. Insomnia, middle	.89	.07
6. Insomnia, late	.88	.08
7. Work and activities	2.27	.12
8. Retardation	1.01	.09
9. Agitation	.89	.10
10. Anxiety, psychic	1.41	.11
11. Anxiety, somatic	1.35	.08
12. Somatic symptoms, gastrointestinal	.78	.05
13. Somatic symptoms, general	1.05	.07
14. Genital symptoms	1.10	.08
15. Hypochondriasis	1.62	.12
16. Weight	.33	.07
17. Insight	.45	.06
Total Score	19.51	.74
Factor 1 - Vegetative signs	4.95	.23
Factor 2 - Vital disturbances	4.41	.29

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

40

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 142	2	1	0	1	1	0	2	0	1	3	2	0	0	0	0	0	0	13.00	2.00	1.00
10 142	1	1	0	0	0	1	3	1	1	3	2	1	1	0	1	0	0	16.00	3.00	2.00
11 142	2	2	2	2	1	1	3	1	0	3	1	0	0	1	1	0	0	20.00	4.00	5.00
15 142	1	2	1	1	1	1	2	1	1	3	2	1	1	0	1	1	0	20.00	6.00	4.00
17 142	2	1	1	1	0	1	2	2	1	2	2	1	1	0	2	0	0	19.00	4.00	4.00
28 142	2	1	0	2	2	1	2	2	1	1	2	1	1	2	2	0	0	22.00	7.00	3.00
31 142	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
32 142	1	0	0	1	1	0	1	1	0	1	0	0	0	2	0	0	0	8.00	2.00	.00
41 142	1	0	0	1	1	1	1	1	0	0	0	0	0	1	0	0	0	7.00	3.00	.00
42 142	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	3.00	2.00	.00
44 142	1	0	0	1	0	1	1	1	0	0	0	0	0	2	1	0	0	8.00	2.00	1.00
47 142	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
51 142	2	1	0	1	1	1	2	1	0	1	1	1	1	1	2	0	0	16.00	5.00	3.00
54 142	2	1	0	1	1	1	2	1	0	1	1	1	1	0	2	0	0	15.00	5.00	3.00
55 142	2	1	0	1	1	0	1	1	0	1	1	1	1	0	2	0	1	14.00	4.00	4.00
60 142	2	2	2	1	1	1	2	0	2	1	2	1	1	1	2	0	1	22.00	5.00	7.00
61 142	2	1	0	1	1	0	2	1	0	1	1	1	1	0	2	0	0	14.00	4.00	3.00
66 142	2	1	1	1	1	1	2	2	0	2	1	1	1	2	2	0	1	21.00	5.00	5.00
67 142	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	0	0	21.00	5.00	5.00
70 142	2	1	1	1	1	1	1	0	1	1	2	1	1	1	2	0	1	18.00	5.00	5.00
77 142	2	1	1	0	1	1	2	1	0	1	0	1	1	1	0	0	1	14.00	4.00	3.00
78 142	1	1	0	0	1	0	1	1	1	0	1	1	0	1	2	2	1	14.00	4.00	4.00
83 142	4	0	0	2	1	1	4	3	1	4	0	0	2	0	0	0	0	22.00	6.00	.00
84 142	1	2	0	0	1	1	1	1	0	1	2	0	2	1	1	0	0	14.00	4.00	3.00
88 142	1	0	0	0	0	1	1	0	1	1	3	2	2	1	2	0	0	15.00	5.00	2.00
90 142	2	0	0	1	0	1	1	0	0	1	2	1	2	1	0	0	0	12.00	5.00	.00
91 142	3	1	2	0	1	2	1	0	1	3	1	1	2	1	0	0	1	20.00	6.00	4.00
95 142	1	1	1	1	0	1	0	1	1	2	0	0	1	1	0	0	0	11.00	3.00	2.00
98 142	1	0	0	2	2	1	1	1	1	1	1	1	1	1	0	0	0	14.00	7.00	.00
102 142	3	0	0	2	1	1	1	1	2	3	2	1	1	0	3	1	0	22.00	7.00	3.00
103 142	0	0	0	1	1	0	1	2	1	0	1	0	0	1	0	0	0	8.00	2.00	.00
106 142	2	0	0	1	1	1	4	1	0	1	0	0	1	1	1	0	0	14.00	4.00	1.00
110 142	2	1	0	2	1	1	2	1	1	0	2	1	2	1	1	0	0	18.00	7.00	2.00
113 142	2	0	0	1	1	2	2	0	1	2	1	0	1	1	2	0	0	16.00	5.00	2.00
118 142	1	1	0	0	1	1	2	0	0	0	2	1	2	2	2	0	0	15.00	5.00	3.00
119 142	2	1	0	1	2	1	3	2	1	0	2	1	2	1	2	0	0	21.00	7.00	3.00
124 142	1	1	0	0	0	0	0	1	0	0	1	1	1	1	0	1	0	8.00	3.00	1.00
126 142	2	1	0	0	0	1	2	1	1	2	2	0	1	2	1	1	1	18.00	3.00	3.00
127 142	3	2	2	1	0	0	1	1	1	2	1	1	1	1	1	0	1	19.00	3.00	6.00
132 142	2	1	1	2	1	1	2	0	1	2	2	0	1	1	0	0	1	18.00	5.00	3.00
133 142	2	0	0	1	0	0	2	0	1	1	1	1	1	1	2	0	1	14.00	3.00	3.00
136 142	1	1	1	0	1	0	1	0	1	1	1	0	0	1	1	0	1	11.00	1.00	4.00
139 142	2	0	0	0	0	2	1	0	2	3	2	0	1	2	3	1	1	20.00	4.00	4.00
140 142	0	0	0	2	1	0	0	0	0	0	1	1	0	0	1	0	1	7.00	4.00	2.00
147 142	4	0	0	2	2	2	4	1	2	4	3	2	2	2	3	2	1	36.00	12.00	4.00
148 142	2	0	0	1	0	2	0	0	0	2	1	1	1	1	1	2	0	14.00	7.00	1.00
170 142	3	1	2	2	1	1	3	2	0	1	1	1	2	2	3	0	0	25.00	7.00	6.00
172 142	3	2	2	1	1	1	3	2	1	1	2	1	1	1	3	2	0	27.00	7.00	7.00
179 142	3	1	2	1	1	1	2	1	0	1	2	1	1	1	3	0	0	21.00	5.00	6.00
180 142	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	0	1	24.00	5.00	8.00
181 142	3	2	2	1	1	1	2	1	0	1	1	1	1	2	3	0	0	22.00	5.00	7.00
186 142	3	2	2	1	1	1	3	2	2	1	2	1	1	2	3	2	1	30.00	7.00	8.00
187 142	3	1	2	1	1	1	2	1	0	1	1	1	1	1	2	0	0	19.00	5.00	5.00
188 142	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	0	0	23.00	5.00	7.00

FCE 20124/702 i

41

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				
193	142	3	3	2	0	1	1	3	2	1	1	1	1	1	3	0	1	25.00	4.00	9.00	
197	142	2	3	1	1	0	1	3	1	0	2	2	0	1	1	2	0	1	21.00	3.00	7.00
202	142	2	2	3	2	0	0	3	1	2	1	2	1	1	2	2	0	1	25.00	4.00	8.00
203	142	3	2	1	1	1	0	3	2	2	1	2	1	1	1	2	1	25.00	6.00	5.00	
206	142	2	2	2	0	1	0	2	2	2	1	2	1	1	0	2	1	1	22.00	4.00	7.00
210	142	2	2	2	1	1	0	2	2	2	1	1	1	1	0	1	0	0	19.00	4.00	5.00
214	142	2	2	2	1	1	0	2	2	2	1	2	1	1	1	2	1	1	24.00	5.00	7.00
216	142	2	2	1	1	1	0	2	1	2	2	1	0	1	1	1	0	0	18.00	3.00	4.00
218	142	2	1	2	0	0	1	2	0	0	1	1	1	1	1	0	0	0	13.00	3.00	3.00
219	142	3	0	0	2	1	2	3	0	4	3	2	1	1	2	0	0	0	24.00	7.00	.00
226	142	0	0	0	1	2	1	1	0	1	2	1	0	0	1	2	0	0	12.00	4.00	2.00
227	142	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.00	.00	1.00
233	142	3	1	0	2	2	2	4	3	0	1	1	1	2	2	3	2	1	30.00	11.00	5.00
237	142	0	0	0	1	1	1	0	0	1	0	1	0	0	1	1	0	0	7.00	3.00	1.00
238	142	0	0	0	0	0	0	2	1	1	0	2	1	2	0	2	0	0	11.00	3.00	2.00
243	142	3	2	2	1	1	1	2	1	0	1	1	1	1	1	3	0	0	21.00	5.00	7.00
245	142	2	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	0	20.00	5.00	6.00
249	142	2	2	1	1	1	1	3	1	0	1	1	1	1	1	2	0	0	19.00	5.00	5.00
251	142	1	1	1	1	0	0	2	0	1	1	1	0	0	0	1	0	0	10.00	1.00	3.00
254	142	3	3	1	1	0	0	3	1	2	1	1	1	1	1	1	1	0	21.00	4.00	5.00
255	142	2	2	1	1	0	0	3	1	1	1	1	1	1	1	1	1	1	19.00	4.00	5.00
260	142	3	1	1	1	1	0	3	1	0	1	1	1	1	1	2	0	0	18.00	4.00	4.00
262	142	3	2	2	1	0	1	3	1	1	1	1	1	1	2	1	0	22.00	5.00	6.00	
268	142	3	2	0	1	1	0	3	1	1	1	2	1	1	1	2	0	1	21.00	4.00	5.00
269	142	3	3	3	2	1	0	3	2	3	2	3	1	1	2	2	2	1	34.00	7.00	9.00
273	142	2	2	1	1	0	0	3	2	2	1	2	1	1	0	2	0	0	20.00	3.00	5.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

42

Treatment Group "B"

Day 14 (Period 142)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	1.94	.11
2. Feelings of guilt	1.11	.10
3. Suicide	.80	.10
4. Insomnia, early	.98	.07
5. Insomnia, middle	.77	.06
6. Insomnia, late	.73	.07
7. Work and activities	1.96	.12
8. Retardation	1.00	.08
9. Agitation	.80	.09
10. Anxiety, psychic	1.25	.11
11. Anxiety, somatic	1.30	.08
12. Somatic symptoms, gastrointestinal	.73	.06
13. Somatic symptoms, general	.95	.07
14. Genital symptoms	.99	.07
15. Hypochondriasis	1.48	.11
16. Weight	.32	.07
17. Insight	.34	.05
Total Score	17.44	.75
Factor 1 - Vegetative signs	4.47	.22
Factor 2 - Vital disturbances	3.73	.27

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

43

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 212	2	1	0	1	0	0	1	0	1	2	1	0	0	0	0	0	0	9.00	1.00	1.00
10 212	0	1	0	0	0	1	2	1	1	2	2	1	1	0	1	0	0	13.00	3.00	2.00
11 212	1	1	1	2	1	1	2	1	0	2	1	0	0	1	1	0	0	15.00	4.00	3.00
15 212	1	1	0	1	0	0	1	1	0	2	1	1	1	0	1	1	0	12.00	4.00	2.00
17 212	1	1	1	0	0	1	2	1	1	2	2	1	1	0	2	0	0	16.00	3.00	4.00
31 212	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
32 212	1	0	0	1	0	1	1	1	0	0	0	0	0	1	0	0	0	6.00	2.00	.00
41 212	1	0	0	1	1	0	1	1	0	0	0	0	0	1	0	0	0	6.00	2.00	.00
42 212	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	2.00	1.00	.00
44 212	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
47 212	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
51 212	1	0	0	1	1	1	1	1	0	1	1	1	1	1	1	0	0	12.00	5.00	1.00
54 212	1	1	0	1	1	0	2	1	0	1	1	1	1	0	2	0	0	13.00	4.00	3.00
55 212	1	0	0	1	1	0	2	2	0	1	1	1	1	0	2	0	0	13.00	4.00	2.00
60 212	2	2	1	1	1	2	0	2	1	2	1	1	0	2	0	1	20.00	5.00	6.00	
61 212	2	1	0	1	0	0	2	1	0	1	1	1	1	0	2	0	0	13.00	3.00	3.00
66 212	3	2	2	1	1	1	2	2	0	2	2	1	1	1	3	0	1	25.00	5.00	8.00
67 212	2	2	2	1	1	1	1	1	0	2	2	1	1	1	2	0	0	20.00	5.00	6.00
70 212	2	1	0	1	1	1	1	1	0	1	2	1	1	0	2	0	0	15.00	5.00	3.00
77 212	3	2	2	0	1	1	1	1	1	0	0	1	1	1	0	0	1	16.00	4.00	5.00
78 212	0	0	0	0	0	1	1	0	1	1	0	1	0	1	2	0	1	9.00	2.00	3.00
83 212	3	0	0	1	0	2	0	2	0	4	2	0	1	1	0	0	0	16.00	4.00	.00
84 212	1	0	1	0	1	1	1	1	0	1	2	0	2	1	1	0	0	13.00	4.00	2.00
88 212	1	0	0	0	0	1	1	0	0	1	2	1	1	1	1	0	0	10.00	3.00	1.00
90 212	1	0	0	1	0	1	2	0	0	0	2	1	2	1	0	0	0	11.00	5.00	.00
91 212	1	1	1	0	1	2	1	0	0	1	1	0	1	1	0	0	0	11.00	4.00	2.00
95 212	0	1	0	1	1	0	2	1	0	2	0	0	0	1	0	0	0	9.00	2.00	1.00
98 212	0	0	0	1	1	1	0	0	1	1	1	1	0	1	0	0	0	8.00	4.00	.00
102 212	2	0	0	1	1	0	1	1	2	2	2	1	1	1	2	0	0	17.00	4.00	2.00
103 212	0	0	0	1	0	1	0	0	0	1	0	0	0	1	0	0	0	4.00	2.00	.00
106 212	1	0	0	1	1	1	3	0	1	0	0	0	1	1	1	0	0	11.00	4.00	1.00
110 212	1	0	0	1	0	1	2	1	0	1	1	0	1	1	0	0	0	10.00	3.00	.00
113 212	1	0	0	0	1	1	1	0	1	1	1	0	1	0	1	0	0	9.00	3.00	1.00
118 212	1	0	0	0	0	1	1	0	0	0	2	1	1	0	1	0	0	8.00	3.00	1.00
119 212	3	1	0	1	2	1	2	2	1	1	2	1	2	2	2	0	0	23.00	7.00	3.00
124 212	0	1	0	0	0	0	0	1	0	0	1	0	1	1	0	0	0	5.00	1.00	1.00
126 212	1	1	0	1	0	1	1	0	0	2	1	1	1	2	1	0	1	14.00	4.00	3.00
127 212	1	0	0	2	1	0	0	1	0	1	1	0	1	1	0	1	1	11.00	5.00	1.00
132 212	1	1	0	2	0	0	1	0	0	1	1	0	0	0	0	0	1	8.00	2.00	2.00
133 212	1	0	0	1	0	0	1	0	1	1	0	1	0	0	1	0	1	8.00	2.00	2.00
136 212	2	1	0	0	1	0	1	0	0	1	1	0	2	1	1	1	1	13.00	3.00	3.00
139 212	1	0	0	0	0	2	0	0	1	1	1	0	1	2	1	0	1	11.00	3.00	2.00
140 212	0	0	0	2	0	1	0	0	0	1	1	0	0	0	0	0	1	6.00	3.00	1.00
148 212	3	2	0	1	0	2	1	0	0	2	2	1	1	1	2	0	0	18.00	5.00	4.00
170 212	3	1	2	1	1	1	3	1	0	1	1	1	2	2	3	0	0	23.00	6.00	6.00
172 212	3	1	2	1	1	1	2	1	2	1	2	1	1	1	3	0	0	23.00	5.00	6.00
179 212	3	2	2	1	1	2	3	1	1	1	2	1	1	1	3	0	0	25.00	6.00	7.00
180 212	3	2	2	1	1	1	3	1	2	1	2	1	1	1	3	0	1	26.00	5.00	8.00
181 212	2	2	2	1	1	1	2	1	0	1	1	1	1	1	2	0	0	19.00	5.00	6.00
186 212	3	2	2	1	1	2	3	1	2	1	2	1	1	2	3	0	0	27.00	6.00	7.00
187 212	2	2	2	1	1	0	2	1	0	1	1	1	1	1	2	0	0	18.00	4.00	6.00
188 212	3	1	2	1	1	1	2	1	0	1	1	1	1	1	2	0	1	20.00	5.00	6.00
193 212	3	2	2	0	1	1	3	2	0	1	1	1	1	1	3	0	1	23.00	4.00	8.00
197 212	2	3	1	1	0	1	2	1	1	2	1	0	1	1	1	0	1	19.00	3.00	6.00



FCE 20124/702 i

44

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
202	2	1	2	1	0	0	2	1	1	1	1	1	1	2	1	0	1	18.00	3.00	5.00
203	2	1	1	1	0	0	3	1	1	1	1	1	1	1	1	2	1	19.00	5.00	4.00
206	2	1	1	0	1	0	2	1	1	1	1	1	0	1	1	1	1	16.00	4.00	4.00
210	2	2	1	1	0	0	2	1	2	1	1	1	0	1	0	0	0	16.00	3.00	4.00
214	1	1	1	1	0	0	2	1	1	1	2	1	1	1	1	1	1	17.00	4.00	4.00
216	2	2	1	1	0	0	2	1	1	1	1	0	1	1	1	0	0	15.00	2.00	4.00
218	3	2	2	0	0	0	2	0	0	1	0	1	2	0	0	1	0	14.00	4.00	4.00
219	1	0	0	2	2	2	2	0	2	3	1	0	2	2	0	1	0	20.00	9.00	.00
226	1	0	0	2	1	2	1	0	1	1	1	0	2	1	3	0	1	17.00	7.00	4.00
227	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	3.00	1.00	.00
237	0	0	0	2	0	0	0	0	1	0	0	0	0	0	1	2	0	6.00	4.00	1.00
238	0	1	0	0	0	0	2	0	1	1	0	1	2	0	2	0	0	10.00	3.00	3.00
243	3	1	1	1	1	1	2	1	0	0	1	1	1	1	2	0	0	17.00	5.00	4.00
245	2	2	2	1	1	1	2	1	1	1	1	1	1	2	0	0	0	20.00	5.00	6.00
249	2	2	1	1	1	0	2	1	0	0	1	0	1	1	2	0	0	15.00	3.00	5.00
251	1	1	1	0	0	0	2	0	1	1	1	0	0	0	1	0	0	9.00	.00	3.00
254	2	1	1	1	0	0	2	1	1	1	1	1	1	1	1	0	0	15.00	3.00	3.00
255	2	1	1	1	0	0	3	1	1	1	1	1	1	0	1	1	1	17.00	4.00	4.00
260	2	2	1	1	0	0	3	1	0	1	1	1	1	1	2	0	0	17.00	3.00	5.00
262	2	2	1	1	0	0	2	1	0	1	1	1	1	1	2	0	0	16.00	3.00	5.00
268	2	1	0	1	0	0	3	1	1	1	1	1	1	1	2	0	1	17.00	3.00	4.00
269	3	2	2	1	0	0	3	2	3	2	3	1	1	2	2	2	1	30.00	5.00	7.00
273	2	1	1	0	0	0	2	1	1	1	1	1	1	0	1	0	0	13.00	2.00	3.00

FCE 20124/702 i

45

Treatment Group "B"

Day 21 (Period 212)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Depressed mood	1.55	.11
2. Feelings of guilt	.91	.09
3. Suicide	.66	.09
4. Insomnia, early	.84	.06
5. Insomnia, middle	.48	.06
6. Insomnia, late	.62	.08
7. Work and activities	1.56	.10
8. Retardation	.73	.07
9. Agitation	.57	.08
10. Anxiety, psychic	1.05	.08
11. Anxiety, somatic	1.06	.08
12. Somatic symptoms, gastrointestinal	.62	.06
13. Somatic symptoms, general	.87	.06
14. Genital symptoms	.83	.07
15. Hypochondriasis	1.21	.11
16. Weight	.18	.05
17. Insight	.30	.05
Total Score	14.05	.70
Factor 1 - Vegetative signs	3.62	.18
Factor 2 - Vital disturbances	3.08	.26

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

46

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
2 282	1	1	0	1	0	0	1	0	1	2	1	0	0	0	0	0	8.00	1.00	1.00	
10 282	0	1	0	0	0	0	2	1	1	2	2	1	1	0	1	0	12.00	2.00	2.00	
11 282	1	1	0	1	1	1	1	1	0	2	1	0	0	1	1	0	12.00	3.00	2.00	
15 282	0	1	0	1	0	0	1	0	0	1	1	0	1	0	1	0	7.00	2.00	2.00	
17 282	0	1	0	0	0	1	1	1	1	1	1	0	0	0	1	0	8.00	1.00	2.00	
31 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	3.00	1.00	.00	
32 282	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	2.00	2.00	.00	
41 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	3.00	1.00	.00	
42 282	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	2.00	1.00	.00	
44 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	3.00	1.00	.00	
47 282	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	4.00	1.00	.00	
51 282	1	0	0	1	0	1	1	1	0	1	1	1	1	1	0	0	11.00	4.00	1.00	
54 282	1	0	0	1	1	0	2	1	0	1	1	1	1	0	2	0	12.00	4.00	2.00	
55 282	1	0	0	1	1	0	1	1	0	1	1	1	1	0	2	0	11.00	4.00	2.00	
60 282	2	2	1	1	1	2	0	2	1	1	1	1	1	0	2	0	18.00	5.00	5.00	
61 282	2	1	0	1	0	0	2	1	0	1	1	1	1	0	2	0	13.00	3.00	3.00	
66 282	2	2	2	1	1	1	2	2	0	2	2	1	1	2	3	0	25.00	5.00	8.00	
67 282	2	2	0	1	1	1	2	2	0	2	2	1	1	1	2	0	21.00	5.00	5.00	
70 282	1	1	0	1	1	1	1	1	0	1	1	1	1	0	2	0	13.00	5.00	3.00	
77 282	3	2	2	0	0	1	1	1	0	3	0	1	1	1	0	0	16.00	3.00	4.00	
78 282	0	2	0	0	1	0	1	0	1	2	0	1	0	1	2	0	11.00	2.00	4.00	
83 282	3	0	0	1	1	1	3	2	1	3	0	0	1	2	0	0	18.00	4.00	.00	
84 282	2	0	1	0	2	1	2	1	0	1	2	0	2	1	1	0	16.00	5.00	2.00	
88 282	1	0	0	0	0	1	0	0	0	1	2	1	1	1	0	0	9.00	3.00	1.00	
90 282	3	0	0	0	1	1	3	0	1	1	2	1	2	2	1	0	19.00	5.00	2.00	
91 282	1	0	0	0	1	1	2	0	0	0	2	1	1	1	1	0	11.00	4.00	1.00	
95 282	0	1	0	1	0	0	1	1	0	1	0	0	1	1	0	0	7.00	2.00	1.00	
98 282	0	0	0	1	1	1	0	0	1	1	1	0	0	0	0	0	6.00	3.00	.00	
102 282	1	0	0	1	1	0	1	1	2	1	2	0	0	0	2	0	12.00	2.00	2.00	
103 282	0	0	0	0	1	0	1	0	0	0	0	0	0	1	0	0	3.00	1.00	.00	
106 282	2	0	0	1	1	1	3	0	1	1	0	0	0	1	0	1	12.00	4.00	.00	
110 282	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	2.00	.00	1.00	
113 282	1	0	0	0	1	1	1	0	1	1	1	0	1	0	1	0	9.00	3.00	1.00	
118 282	0	0	0	0	0	0	1	0	0	0	1	1	1	0	1	0	5.00	2.00	1.00	
119 282	3	1	1	1	2	1	2	2	1	1	2	1	1	1	2	0	22.00	6.00	4.00	
124 282	0	1	0	0	0	1	0	0	0	1	1	0	0	0	0	0	4.00	1.00	1.00	
126 282	1	1	0	0	0	1	1	0	0	1	1	1	1	1	1	0	11.00	3.00	3.00	
127 282	1	0	0	0	0	0	0	0	1	1	1	0	0	0	1	0	6.00	.00	2.00	
132 282	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	1	5.00	2.00	1.00	
133 282	0	0	0	1	0	0	1	0	0	1	0	1	0	0	0	1	5.00	2.00	1.00	
136 282	4	3	0	1	1	0	1	0	1	1	2	0	0	2	1	1	19.00	3.00	5.00	
139 282	0	0	0	0	0	0	0	0	1	1	1	0	1	2	1	0	8.00	1.00	2.00	
140 282	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	1	3.00	1.00	1.00	
148 282	1	0	0	0	0	2	0	0	1	3	2	0	0	1	3	0	13.00	2.00	3.00	
170 282	3	1	2	0	1	1	2	1	1	1	2	1	2	2	2	0	22.00	5.00	5.00	
172 282	2	1	2	1	1	0	2	1	2	1	2	1	2	1	3	0	22.00	5.00	6.00	
179 282	3	2	2	1	1	1	3	1	1	1	2	1	1	1	2	0	23.00	5.00	6.00	
180 282	3	2	2	0	1	1	3	1	2	1	2	1	1	1	3	0	24.00	4.00	7.00	
181 282	3	2	1	1	1	0	2	1	0	1	1	1	1	2	2	0	19.00	4.00	5.00	
186 282	3	2	2	1	1	1	3	2	1	1	1	1	1	1	3	0	24.00	5.00	7.00	
187 282	2	2	2	1	1	0	2	1	1	1	2	1	1	1	2	0	20.00	4.00	6.00	
188 282	2	2	2	1	1	1	3	1	1	1	2	1	1	1	2	0	23.00	5.00	7.00	
193 282	3	2	2	0	1	1	3	1	0	1	1	1	1	1	2	0	21.00	4.00	7.00	
197 282	2	2	1	1	0	0	1	1	1	2	1	0	0	1	1	0	15.00	1.00	5.00	

FCE 20124/702 i

47

Pat. Per. No.	Per. (dy)	Items																	Total Score	Factor 1	Factor 2
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
202	282	2	1	2	1	0	0	2	1	2	1	1	1	1	2	1	0	1	19.00	3.00	5.00
203	282	2	1	0	1	0	0	2	1	1	1	1	1	1	1	1	1	1	16.00	4.00	3.00
206	282	2	1	1	0	0	0	1	1	1	1	0	0	0	1	0	1	11.00	.00	4.00	
210	282	2	1	1	1	0	0	2	1	1	1	1	0	0	0	1	0	0	12.00	1.00	3.00
214	282	1	1	1	1	0	0	2	1	1	1	2	1	1	1	1	1	1	17.00	4.00	4.00
216	282	1	1	1	0	0	0	2	1	1	1	0	0	1	1	1	0	0	11.00	1.00	3.00
218	282	4	2	2	0	2	1	3	1	1	2	1	2	2	2	0	2	0	27.00	9.00	4.00
219	282	3	0	0	2	1	0	2	0	2	2	2	0	0	0	2	0	0	16.00	3.00	2.00
226	282	0	0	0	1	1	1	2	0	1	2	2	0	2	1	3	0	0	16.00	5.00	3.00
227	282	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.00	.00	.00
237	282	0	0	0	2	1	2	1	0	1	2	0	0	1	0	2	0	0	12.00	6.00	2.00
238	282	3	0	0	0	1	0	3	1	0	2	1	1	2	0	2	0	0	16.00	4.00	2.00
243	282	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	5.00	5.00
245	282	2	2	1	1	0	1	2	1	0	0	1	1	1	1	2	0	0	16.00	4.00	5.00
249	282	2	2	1	1	1	0	2	1	0	1	1	0	1	1	2	0	0	16.00	3.00	5.00
251	282	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	0	4.00	.00	.00
254	282	1	1	0	0	0	0	1	0	0	0	1	0	0	1	1	0	0	6.00	.00	2.00
255	282	1	1	1	1	0	0	3	1	0	1	1	1	1	0	1	0	1	14.00	3.00	4.00
260	282	2	2	1	1	0	0	3	1	0	1	1	1	1	1	2	0	0	17.00	3.00	5.00
262	282	2	2	1	1	1	1	3	1	1	1	1	1	1	1	2	0	0	20.00	5.00	5.00
268	282	2	1	0	1	0	0	1	0	0	1	1	1	0	1	1	0	1	11.00	2.00	3.00
269	282	2	2	1	0	0	0	2	1	1	1	2	1	1	2	2	0	1	19.00	2.00	6.00
273	282	1	1	1	0	0	0	2	0	0	0	0	0	0	0	1	0	0	6.00	.00	3.00

FCE 20124/702 i

48

Treatment Group "B"

Day 28 (Period 282)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Depressed mood	1.40	.13
2. Feelings of guilt	.86	.10
3. Suicide	.53	.09
4. Insomnia, early	.64	.06
5. Insomnia, middle	.51	.07
6. Insomnia, late	.45	.06
7. Work and activities	1.49	.11
8. Retardation	.60	.07
9. Agitation	.56	.07
10. Anxiety, psychic	1.03	.08
11. Anxiety, somatic	1.04	.08
12. Somatic symptoms, gastrointestinal	.53	.06
13. Somatic symptoms, general	.69	.07
14. Genital symptoms	.75	.08
15. Hypochondriasis	1.21	.11
16. Weight	.09	.04
17. Insight	.26	.05
Total Score	12.64	.77
Factor 1 - Vegetative signs	2.91	.21
Factor 2 - Vital disturbances	2.86	.24

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

49

REBOXETINE, Protocol ADE 08

Table 5, Hamilton Depression Rating Scale

Treatment Group "C"

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 -01	4	2	2	1	1	0	4	0	0	2	1	2	1	0	2	0	0	22.00	5.00	6.00
6 -01	3	2	3	1	2	1	3	1	1	3	3	2	1	2	2	1	0	31.00	8.00	7.00
8 -01	3	1	0	1	1	0	3	0	1	2	1	0	2	0	2	0	0	17.00	4.00	3.00
16 -01	3	2	3	2	1	1	3	2	1	3	1	2	1	0	2	0	0	27.00	7.00	7.00
18 -01	2	1	0	0	1	0	2	2	0	2	2	1	2	1	1	0	0	17.00	4.00	2.00
26 -01	2	0	0	2	1	1	2	2	2	2	1	1	1	2	1	0	1	21.00	6.00	2.00
27 -01	2	0	0	1	1	1	3	2	1	1	1	1	1	2	1	1	0	19.00	6.00	1.00
33 -01	3	2	2	2	2	2	3	3	1	3	3	2	1	2	2	1	0	34.00	10.00	6.00
36 -01	3	0	1	2	2	2	3	3	1	3	2	2	1	2	1	1	1	30.00	10.00	3.00
39 -01	2	0	2	1	1	2	2	2	1	2	1	1	1	1	1	0	0	21.00	7.00	3.00
40 -01	2	0	0	2	0	1	3	2	1	2	2	0	1	2	0	0	0	18.00	4.00	.00
43 -01	2	0	2	1	2	2	3	2	0	2	1	1	0	2	0	1	0	21.00	7.00	2.00
46 -01	3	0	3	2	2	2	3	3	1	2	2	1	2	2	1	1	2	32.00	10.00	6.00
52 -01	2	2	1	1	1	1	2	2	0	2	2	1	1	1	2	1	1	23.00	6.00	6.00
53 -01	3	1	1	1	1	2	2	2	1	1	1	1	1	2	1	1	1	23.00	7.00	4.00
58 -01	2	1	2	1	1	1	2	2	0	2	3	1	1	1	3	1	1	25.00	6.00	7.00
59 -01	3	3	2	1	2	1	2	3	0	3	3	1	1	2	3	1	1	32.00	7.00	9.00
62 -01	2	2	1	1	1	1	2	0	2	2	2	1	1	1	2	1	1	23.00	6.00	6.00
63 -01	2	2	1	1	1	1	1	0	0	2	2	1	1	2	2	0	1	20.00	5.00	6.00
69 -01	2	2	0	1	1	1	2	2	0	2	2	1	1	1	2	0	1	21.00	5.00	5.00
71 -01	2	1	0	2	0	2	2	1	0	2	2	1	1	2	3	0	1	22.00	6.00	5.00
74 -01	3	0	0	2	1	1	3	1	1	3	4	1	2	1	3	2	1	29.00	9.00	4.00
76 -01	3	0	1	1	1	2	3	1	0	0	3	1	1	1	2	2	1	23.00	8.00	4.00
81 -01	3	0	3	2	2	1	2	0	1	3	3	1	1	2	2	0	1	27.00	7.00	6.00
82 -01	3	0	3	2	1	2	4	1	1	3	3	1	2	2	2	2	0	32.00	10.00	5.00
86 -01	4	4	2	1	1	1	4	1	0	3	1	1	1	2	0	2	2	30.00	7.00	8.00
89 -01	3	0	1	2	2	2	3	0	1	1	1	1	1	1	0	0	0	19.00	8.00	1.00
92 -01	1	2	2	1	0	0	3	1	1	3	0	1	2	2	2	1	1	23.00	5.00	7.00
93 -01	4	2	2	1	2	2	4	0	2	4	2	1	2	2	2	0	1	33.00	8.00	7.00
97 -01	4	3	2	2	1	1	3	1	3	3	2	1	1	1	0	2	0	30.00	8.00	5.00
100 -01	4	0	3	2	2	2	3	3	0	1	1	2	1	1	0	2	0	27.00	11.00	3.00
104 -01	4	2	2	2	2	2	4	3	1	3	2	1	1	1	0	2	0	32.00	10.00	4.00
105 -01	4	1	2	0	1	2	4	3	1	2	2	1	2	2	2	2	0	31.00	8.00	5.00
111 -01	4	1	3	2	2	2	4	3	1	3	2	2	2	2	2	2	0	37.00	12.00	6.00
112 -01	3	2	3	2	2	2	4	1	2	2	2	2	2	2	2	2	0	35.00	12.00	7.00
116 -01	4	1	2	2	2	2	3	1	2	3	3	2	2	2	3	2	0	36.00	12.00	6.00
117 -01	2	1	1	2	0	0	2	1	0	2	2	1	2	0	2	2	0	20.00	7.00	4.00
121 -01	3	2	2	2	2	1	3	1	1	3	2	1	2	2	2	1	1	31.00	9.00	7.00
125 -01	3	3	3	1	1	2	3	1	1	3	2	2	2	2	3	2	1	35.00	10.00	10.00
128 -01	2	1	2	1	0	0	3	1	1	2	1	2	1	2	3	1	1	24.00	5.00	7.00
129 -01	4	2	4	2	0	2	3	2	3	4	2	1	2	2	2	1	2	38.00	8.00	10.00
137 -01	2	0	2	2	2	1	3	2	1	1	3	2	2	2	2	2	1	30.00	11.00	5.00
138 -01	4	2	1	2	2	2	4	1	2	3	3	2	2	2	3	1	1	37.00	11.00	7.00
141 -01	2	3	2	2	2	2	2	2	1	3	2	2	2	1	2	2	1	33.00	12.00	8.00
145 -01	3	3	1	2	2	2	3	1	0	0	3	2	2	0	2	2	1	29.00	12.00	7.00
173 -01	3	2	3	2	1	1	3	2	1	1	2	1	1	1	2	1	0	27.00	7.00	7.00
174 -01	3	2	3	2	2	1	3	2	1	1	1	1	1	1	3	1	1	29.00	8.00	9.00

FCE 20124/702 i

50

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
175 -01	3	2	3	2	2	1	3	2	0	1	1	1	1	1	1	2	1	27.00	9.00	7.00
178 -01	3	2	3	1	1	2	3	2	0	1	1	1	1	1	2	2	1	27.00	8.00	8.00
182 -01	3	2	2	1	1	2	3	1	1	1	1	1	1	1	3	2	1	27.00	8.00	8.00
183 -01	3	2	3	1	1	2	3	2	1	1	1	1	1	1	3	2	1	29.00	8.00	9.00
190 -01	3	2	3	1	1	2	3	2	0	0	1	1	1	1	3	1	1	26.00	7.00	9.00
191 -01	3	2	3	2	1	2	3	2	0	1	1	1	1	1	2	3	2	30.00	9.00	9.00
195 -01	3	3	3	2	1	1	3	2	3	2	2	1	1	1	3	2	1	34.00	8.00	10.00
196 -01	3	3	2	2	2	0	3	0	0	1	1	1	1	1	3	1	1	25.00	7.00	9.00
201 -01	2	2	2	2	1	1	3	2	3	3	2	1	1	2	3	2	1	33.00	8.00	8.00
204 -01	3	3	3	0	1	2	3	2	1	3	2	1	1	0	2	0	0	27.00	5.00	8.00
205 -01	3	2	2	2	0	0	3	2	2	4	2	0	0	1	3	1	0	27.00	3.00	7.00
207 -01	3	3	0	2	1	1	3	2	4	3	1	1	1	2	3	0	1	31.00	6.00	7.00
212 -01	4	3	2	2	1	0	3	3	3	3	2	1	1	0	3	2	1	34.00	7.00	9.00
213 -01	3	3	4	2	1	1	3	3	4	3	2	1	1	1	3	2	0	37.00	8.00	10.00
220 -01	3	2	1	2	1	2	2	1	0	1	1	1	2	2	1	2	0	24.00	10.00	4.00
221 -01	3	4	2	2	2	1	3	3	0	4	1	1	2	0	0	2	0	30.00	10.00	6.00
225 -01	3	0	0	2	2	2	2	1	1	2	2	1	2	2	2	2	0	26.00	11.00	2.00
228 -01	3	2	4	2	2	2	3	0	3	3	2	1	2	2	3	2	0	36.00	11.00	9.00
229 -01	3	2	2	0	0	0	4	2	0	0	0	2	2	2	2	2	0	23.00	6.00	6.00
234 -01	3	2	2	2	2	2	4	2	0	3	1	2	2	2	3	2	0	34.00	12.00	7.00
236 -01	3	1	3	2	2	2	4	1	1	2	1	1	2	0	2	2	1	30.00	11.00	7.00
239 -01	3	2	2	2	1	2	4	1	0	1	1	2	2	2	3	2	0	30.00	11.00	7.00
241 -01	3	2	2	1	1	2	3	1	0	2	1	1	1	1	3	1	0	25.00	7.00	7.00
242 -01	3	2	2	2	1	2	3	1	0	1	1	1	1	1	2	1	0	24.00	8.00	6.00
250 -01	2	3	2	0	0	1	3	2	3	2	2	0	0	1	2	1	1	25.00	2.00	8.00
252 -01	3	2	3	1	1	0	3	1	1	1	1	0	1	1	2	0	1	22.00	3.00	8.00
253 -01	3	2	2	1	0	1	3	2	3	2	2	1	1	2	3	1	1	30.00	5.00	8.00
256 -01	3	2	1	0	1	1	3	1	2	1	2	1	1	1	2	0	1	23.00	4.00	6.00
261 -01	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	1	0	23.00	7.00	6.00
264 -01	3	2	2	1	1	2	3	1	1	1	1	1	1	1	2	1	0	24.00	7.00	6.00
265 -01	2	2	2	1	1	2	3	1	0	1	1	1	1	1	2	1	0	22.00	7.00	6.00
266 -01	3	2	2	1	1	2	3	1	0	0	1	1	1	1	2	1	0	22.00	7.00	6.00
272 -01	4	2	2	2	1	0	3	2	1	2	2	1	1	1	2	2	1	29.00	7.00	7.00

FCE 20124/702 i

51

Treatment Group "C"

Screen (Period -01)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.90	.07
2. Feelings of guilt	1.69	.11
3. Suicide	1.93	.11
4. Insomnia, early	1.48	.07
5. Insomnia, middle	1.21	.07
6. Insomnia, late	1.35	.08
7. Work and activities	2.95	.07
8. Retardation	1.55	.10
9. Agitation	1.01	.12
10. Anxiety, psychic	2.03	.11
11. Anxiety, somatic	1.70	.09
12. Somatic symptoms, gastrointestinal	1.16	.06
13. Somatic symptoms, general	1.30	.06
14. Genital symptoms	1.35	.08
15. Hypochondriasis	2.00	.10
16. Weight	1.23	.09
17. Insight	.58	.06
Total Score	27.40	.59
Factor 1 - Vegetative signs	7.72	.27
Factor 2 - Vital disturbances	6.19	.25

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

52

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 000	4	2	2	1	1	0	4	0	0	2	1	2	1	0	2	0	0	22.00	5.00	6.00
6 000	3	2	3	1	2	1	3	1	1	3	3	2	1	2	2	1	0	31.00	8.00	7.00
8 000	3	1	0	1	1	1	3	1	1	2	0	0	2	0	3	0	0	19.00	5.00	4.00
16 000	3	2	2	2	1	1	3	2	1	3	1	2	1	0	2	0	0	26.00	7.00	6.00
18 000	2	1	0	0	1	0	2	1	0	2	2	1	2	1	2	0	0	17.00	4.00	3.00
26 000	2	0	0	2	1	1	2	2	2	2	1	1	1	2	1	0	1	21.00	6.00	2.00
27 000	2	0	0	1	1	1	3	2	1	1	1	1	1	2	1	1	0	19.00	6.00	1.00
33 000	3	2	2	2	2	2	3	3	1	3	3	2	1	2	2	1	0	34.00	10.00	6.00
36 000	3	0	1	2	2	2	3	3	1	3	2	2	1	2	1	1	1	30.00	10.00	3.00
39 000	2	0	2	1	1	2	2	2	1	2	1	1	1	1	1	1	0	21.00	7.00	3.00
40 000	2	0	0	2	1	1	3	2	1	3	2	0	1	2	0	0	0	20.00	5.00	.00
43 000	2	0	2	1	2	2	3	2	0	2	1	1	0	2	0	1	0	21.00	7.00	2.00
46 000	3	0	3	2	2	2	3	3	1	2	2	1	2	2	1	1	2	32.00	10.00	6.00
52 000	2	2	1	1	1	0	2	1	0	2	2	1	1	1	2	1	1	21.00	5.00	6.00
53 000	2	2	1	1	2	2	2	2	0	1	1	1	1	1	2	1	1	23.00	8.00	6.00
58 000	3	2	2	1	1	1	2	2	0	2	3	1	1	1	2	1	1	26.00	6.00	7.00
59 000	2	2	2	2	1	1	3	3	0	2	3	2	1	1	2	0	1	28.00	7.00	7.00
62 000	3	2	2	1	1	1	2	0	2	2	2	1	1	1	2	1	1	25.00	6.00	7.00
63 000	2	2	1	1	1	1	0	0	2	2	2	1	1	1	2	0	1	19.00	5.00	6.00
69 000	2	2	0	1	1	1	2	1	0	2	2	1	1	1	2	0	1	20.00	5.00	5.00
71 000	2	1	0	2	1	2	2	1	0	1	1	1	1	2	3	0	1	21.00	7.00	5.00
74 000	3	0	0	2	1	1	3	1	1	3	4	1	2	1	2	2	1	28.00	9.00	3.00
76 000	3	0	1	1	1	2	3	1	1	1	3	1	1	1	2	2	1	25.00	8.00	4.00
81 000	3	0	3	2	2	1	3	0	1	3	3	1	1	2	2	0	1	28.00	7.00	6.00
82 000	3	0	3	2	1	2	3	1	1	3	3	1	2	2	2	2	0	31.00	10.00	5.00
86 000	4	4	2	1	1	1	3	1	1	3	1	1	1	2	0	2	2	30.00	7.00	8.00
89 000	3	0	1	2	2	2	3	0	1	3	1	1	2	2	0	0	0	23.00	9.00	1.00
92 000	4	2	2	1	1	1	3	1	1	4	1	1	2	2	2	1	1	30.00	7.00	7.00
93 000	4	2	1	1	2	2	4	0	2	4	2	1	2	2	2	0	0	31.00	8.00	5.00
97 000	4	3	1	2	1	1	3	0	2	3	1	1	1	1	0	2	0	26.00	8.00	4.00
100 000	4	0	3	2	2	2	3	3	1	1	2	2	1	1	0	0	0	27.00	9.00	3.00
104 000	4	3	1	1	1	1	4	3	0	0	1	1	2	2	0	0	0	24.00	6.00	4.00
105 000	4	2	2	2	0	2	4	3	0	2	2	2	2	1	2	2	0	32.00	10.00	6.00
111 000	4	1	3	2	2	2	3	3	1	3	2	2	2	2	2	1	2	35.00	12.00	5.00
112 000	3	2	3	2	2	2	4	1	2	2	2	2	2	2	2	0	0	33.00	10.00	7.00
116 000	4	1	2	2	2	2	3	1	2	3	3	2	2	2	3	0	0	34.00	10.00	6.00
117 000	2	1	1	2	0	0	2	1	0	2	2	1	2	0	2	1	0	19.00	6.00	4.00
121 000	2	1	2	2	2	0	3	1	1	2	2	1	2	2	2	1	1	27.00	8.00	6.00
125 000	3	2	3	2	2	2	4	2	1	4	1	2	2	2	3	2	1	38.00	12.00	9.00
128 000	2	1	2	1	0	0	3	1	1	2	1	2	1	2	3	1	1	24.00	5.00	7.00
129 000	4	2	4	2	0	2	3	2	3	4	2	1	2	2	2	1	2	38.00	8.00	10.00
137 000	2	0	2	2	2	1	3	2	1	1	3	2	2	2	2	2	1	30.00	11.00	5.00
138 000	4	2	1	2	2	2	4	1	2	3	3	2	2	2	3	1	1	37.00	11.00	7.00
141 000	2	3	2	2	2	2	2	1	3	2	2	2	1	2	2	1	3	33.00	12.00	8.00
145 000	3	3	1	2	2	2	3	1	0	0	3	2	2	0	2	2	1	29.00	12.00	7.00
173 000	3	2	3	2	1	2	3	2	2	1	2	1	1	1	3	2	0	31.00	9.00	8.00
174 000	3	2	3	2	2	1	3	2	1	1	2	1	1	1	2	1	1	29.00	8.00	8.00
175 000	3	2	3	2	2	1	3	2	0	1	1	1	1	1	3	2	1	29.00	9.00	9.00
178 000	3	2	3	1	1	2	3	2	0	1	1	1	1	1	3	1	1	27.00	7.00	9.00
182 000	3	2	3	1	1	2	3	2	0	1	1	1	1	1	3	2	1	28.00	8.00	9.00
183 000	3	1	2	1	1	2	3	1	1	1	1	1	1	1	3	2	1	26.00	8.00	7.00
190 000	3	2	3	1	1	2	3	2	0	1	1	1	1	1	3	2	1	28.00	8.00	9.00
191 000	3	2	3	1	2	2	3	2	1	1	2	1	1	2	3	2	0	31.00	9.00	8.00
195 000	3	3	3	2	1	1	3	2	3	2	2	1	1	1	3	2	1	34.00	8.00	10.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

Pat.Per. No. (dy)	Items																	Total Score	53	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17		Factor 1	Factor 2
196 000	3	3	2	2	2	0	3	0	0	1	1	1	1	1	3	1	1	25.00	7.00	9.00
201 000	2	2	2	2	1	1	3	2	3	3	2	1	1	2	3	2	1	33.00	8.00	8.00
204 000	3	3	3	0	1	2	3	2	1	3	2	1	1	0	2	0	0	27.00	5.00	8.00
205 000	3	2	2	2	0	0	3	2	2	4	2	0	0	1	3	1	0	27.00	3.00	7.00
207 000	3	3	0	2	1	1	3	2	4	3	1	1	1	2	3	0	1	31.00	6.00	7.00
212 000	4	3	2	2	1	0	3	3	3	3	2	1	1	0	3	2	1	34.00	7.00	9.00
213 000	3	3	3	2	1	1	3	3	4	3	2	1	1	1	3	2	0	36.00	8.00	9.00
220 000	3	1	1	2	2	2	3	1	0	2	0	1	2	2	0	0	0	22.00	9.00	2.00
221 000	3	1	0	0	0	0	3	3	0	1	1	1	2	0	0	2	0	17.00	5.00	1.00
225 000	3	0	0	2	2	2	2	1	0	2	1	2	2	1	2	0	0	22.00	10.00	2.00
228 000	3	2	2	2	2	2	4	0	3	3	0	1	0	2	3	0	0	29.00	7.00	7.00
229 000	3	2	2	0	0	1	3	2	0	0	1	2	2	2	2	0	0	22.00	5.00	6.00
234 000	3	2	0	2	2	2	4	2	0	1	1	1	2	2	2	0	0	26.00	9.00	4.00
236 000	3	2	2	2	2	2	3	2	0	0	1	1	1	0	3	1	1	26.00	9.00	8.00
239 000	3	2	1	1	2	2	2	2	0	1	2	2	2	2	2	0	0	26.00	9.00	5.00
241 000	3	2	2	1	1	2	3	1	1	2	2	1	1	1	3	1	0	27.00	7.00	7.00
242 000	3	1	2	1	1	2	3	1	0	1	1	1	1	1	2	1	0	22.00	7.00	5.00
250 000	1	2	2	0	0	1	3	2	3	2	2	0	0	1	2	1	1	23.00	2.00	7.00
252 000	3	2	3	1	1	0	3	1	1	1	1	0	1	1	2	0	1	22.00	3.00	8.00
253 000	3	2	2	1	0	1	3	2	3	2	2	1	1	2	3	1	1	30.00	5.00	8.00
256 000	3	2	1	0	1	1	3	1	2	1	2	1	1	1	2	0	1	23.00	4.00	6.00
261 000	3	2	2	1	1	2	3	1	1	1	1	1	1	1	3	1	0	25.00	7.00	7.00
264 000	3	2	2	1	1	2	3	1	1	1	2	1	1	1	3	1	0	26.00	7.00	7.00
265 000	3	2	2	1	1	2	3	1	1	1	2	1	1	1	3	1	0	26.00	7.00	7.00
266 000	3	2	2	1	1	2	3	1	1	1	1	1	1	1	2	1	0	24.00	7.00	6.00
272 000	4	2	2	2	1	0	3	2	1	2	2	1	1	1	2	2	1	29.00	7.00	7.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

54

Treatment Group "C"

Baseline (Period 000)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.93	.08
2. Feelings of guilt	1.62	.11
3. Suicide	1.78	.11
4. Insomnia, early	1.45	.07
5. Insomnia, middle	1.25	.07
6. Insomnia, late	1.35	.08
7. Work and activities	2.93	.06
8. Retardation	1.55	.10
9. Agitation	1.04	.11
10. Anxiety, psychic	1.98	.11
11. Anxiety, somatic	1.70	.09
12. Somatic symptoms, gastrointestinal	1.19	.06
13. Somatic symptoms, general	1.29	.06
14. Genital symptoms	1.31	.07
15. Hypochondriasis	2.04	.10
16. Weight	.95	.09
17. Insight	.55	.06
Total Score	26.89	.56
Factor 1 - Vegetative signs	7.47	.24
Factor 2 - Vital disturbances	5.99	.26

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

55

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 042	4	2	2	1	1	0	2	0	0	3	1	2	1	0	2	0	0	21.00	5.00	6.00
6 042	3	2	3	1	2	1	3	1	1	3	2	2	1	2	2	1	0	30.00	8.00	7.00
8 042	3	1	0	1	1	1	3	0	1	2	0	0	2	0	3	0	0	18.00	5.00	4.00
16 042	3	2	2	2	1	1	3	2	1	3	1	2	1	0	2	0	0	26.00	7.00	6.00
18 042	2	1	0	0	1	0	2	1	0	2	2	1	2	1	2	0	0	17.00	4.00	3.00
26 042	2	0	0	2	1	1	2	2	2	1	1	1	1	2	1	0	1	20.00	6.00	2.00
27 042	2	0	0	1	1	1	2	2	1	1	0	0	1	2	0	0	0	14.00	4.00	.00
33 042	3	2	2	2	2	1	3	3	1	2	3	2	1	2	2	1	0	32.00	9.00	6.00
36 042	2	0	1	2	2	1	3	3	1	2	2	2	2	1	1	1	1	28.00	10.00	3.00
39 042	2	0	1	1	1	2	2	2	1	2	1	1	1	1	1	0	0	20.00	7.00	2.00
40 042	2	0	0	2	1	1	3	2	1	3	2	0	1	2	0	0	0	20.00	5.00	.00
43 042	2	0	2	1	2	2	2	2	0	2	1	1	0	2	0	0	0	19.00	6.00	2.00
46 042	2	0	2	2	2	2	3	3	1	2	2	1	2	2	1	1	2	30.00	10.00	5.00
52 042	2	2	1	1	1	1	1	2	0	2	2	1	1	1	2	1	1	22.00	6.00	6.00
53 042	2	2	1	1	1	1	1	2	0	2	1	1	1	1	2	1	1	21.00	6.00	6.00
58 042	3	2	2	1	1	1	2	2	0	2	3	1	1	1	3	1	1	27.00	6.00	8.00
59 042	3	2	2	1	2	1	3	2	0	2	3	1	1	1	3	0	1	28.00	6.00	8.00
62 042	2	2	1	1	1	1	2	0	2	2	2	1	1	1	2	1	1	23.00	6.00	6.00
63 042	2	2	1	1	1	1	1	0	0	2	2	1	1	1	2	0	1	19.00	5.00	6.00
69 042	2	1	0	1	1	1	2	2	0	2	2	1	1	1	2	0	1	20.00	5.00	4.00
71 042	2	1	0	2	1	2	2	1	0	1	1	1	1	2	3	0	1	21.00	7.00	5.00
74 042	3	1	0	2	1	1	3	1	1	4	4	1	1	1	3	0	1	28.00	6.00	5.00
76 042	3	1	1	2	1	2	3	0	1	3	3	1	1	1	2	1	1	27.00	8.00	5.00
81 042	2	0	1	2	2	1	1	0	3	3	2	1	0	2	1	0	1	22.00	6.00	3.00
82 042	3	0	1	2	1	2	4	1	0	2	0	1	2	2	2	2	0	25.00	10.00	3.00
86 042	4	4	3	1	2	2	3	1	1	3	1	1	1	2	0	0	2	31.00	7.00	9.00
89 042	2	0	1	2	2	2	3	0	1	3	2	1	2	2	1	0	0	24.00	9.00	2.00
92 042	3	2	2	1	1	1	2	1	1	2	2	1	2	2	2	0	0	25.00	6.00	6.00
93 042	4	2	1	1	2	2	4	1	2	4	2	1	2	2	2	0	0	32.00	8.00	5.00
97 042	3	2	2	2	1	1	3	0	2	3	1	1	1	1	0	0	0	23.00	6.00	4.00
100 042	4	0	2	2	2	2	3	3	1	1	2	1	2	1	0	0	0	25.00	9.00	2.00
104 042	4	3	1	1	1	1	4	3	0	0	1	1	2	2	0	0	0	24.00	6.00	4.00
105 042	4	1	2	2	1	2	4	2	0	2	2	1	2	1	2	0	0	28.00	8.00	5.00
111 042	4	1	3	2	2	2	3	3	1	3	2	2	2	2	1	0	0	33.00	10.00	5.00
112 042	2	1	2	2	1	2	3	1	1	2	2	1	2	2	2	1	0	27.00	9.00	5.00
116 042	4	1	2	2	2	3	1	2	3	3	3	2	2	2	3	0	0	34.00	10.00	6.00
117 042	3	1	1	2	0	0	2	1	0	2	2	1	2	0	2	0	0	19.00	5.00	4.00
121 042	2	0	0	2	2	0	0	0	0	2	2	0	0	1	1	1	0	13.00	5.00	1.00
125 042	2	2	1	1	2	2	3	1	1	3	1	1	1	2	2	1	1	27.00	8.00	6.00
128 042	1	0	0	0	0	1	1	1	0	0	0	1	1	2	2	0	1	11.00	3.00	3.00
129 042	3	1	2	2	0	2	2	1	2	4	2	1	1	2	2	0	1	28.00	6.00	6.00
137 042	1	0	0	0	0	0	1	1	1	1	2	1	0	1	2	0	1	12.00	1.00	3.00
138 042	2	1	0	1	1	2	4	1	1	2	2	1	2	2	3	0	1	26.00	7.00	5.00
141 042	1	2	0	2	2	2	2	1	1	2	1	2	1	1	1	0	1	22.00	9.00	4.00
145 042	3	3	0	2	2	2	3	0	0	3	0	2	2	2	0	0	0	24.00	10.00	3.00
173 042	3	2	3	2	1	2	3	2	1	1	2	1	1	1	3	1	0	29.00	8.00	8.00
174 042	3	2	3	2	2	1	3	2	1	1	1	1	1	1	3	1	1	29.00	8.00	9.00
175 042	3	2	3	2	2	1	3	2	0	1	1	1	1	1	3	2	1	29.00	9.00	9.00
178 042	3	2	3	1	1	2	3	2	0	1	1	1	1	1	3	0	1	26.00	6.00	9.00
182 042	3	2	3	1	1	2	3	2	1	1	1	1	1	0	3	2	1	28.00	8.00	9.00
183 042	3	2	3	1	1	2	3	1	0	1	1	1	1	2	3	2	1	28.00	8.00	9.00
190 042	3	2	3	1	1	2	3	2	1	1	1	1	1	3	2	1	1	29.00	8.00	9.00
191 042	3	2	3	1	2	2	3	2	1	1	2	1	1	2	3	0	1	30.00	7.00	9.00
195 042	3	3	3	2	1	1	3	2	3	2	2	1	1	1	3	2	1	34.00	8.00	10.00

FCE 20124/702 i

56

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
196	042	3	2	3	2	2	0	3	0	0	1	1	1	1	3	1	1	25.00	7.00	9.00
201	042	2	2	2	2	1	1	3	2	3	3	2	1	1	2	2	2	32.00	8.00	7.00
204	042	3	3	3	0	1	2	3	2	2	3	2	1	1	0	2	0	28.00	5.00	8.00
205	042	3	2	2	2	0	0	3	2	2	4	2	0	0	1	3	1	27.00	3.00	7.00
207	042	3	3	0	2	1	1	3	2	4	3	1	1	1	0	3	0	29.00	6.00	7.00
212	042	4	3	2	2	1	0	3	3	3	3	2	1	1	0	3	2	34.00	7.00	9.00
213	042	3	3	4	2	1	1	3	3	4	3	2	1	1	1	3	2	37.00	8.00	10.00
220	042	1	2	0	2	2	2	2	0	0	1	2	1	1	2	1	0	19.00	8.00	3.00
221	042	3	0	0	0	0	0	3	2	0	1	1	1	2	0	0	0	13.00	3.00	.00
225	042	3	0	0	2	2	2	2	0	0	4	2	1	2	2	1	0	23.00	9.00	1.00
228	042	1	0	2	2	2	2	4	0	4	4	2	1	1	2	3	0	30.00	8.00	5.00
229	042	3	0	0	0	0	2	3	2	0	1	1	1	2	2	3	0	20.00	5.00	3.00
234	042	3	4	0	2	2	2	2	2	0	2	1	2	2	2	2	0	28.00	10.00	6.00
236	042	2	0	0	2	2	2	2	0	0	2	0	1	0	0	3	0	16.00	7.00	3.00
239	042	3	0	0	2	2	2	2	1	0	0	2	2	2	2	2	0	22.00	10.00	2.00
241	042	3	2	2	1	1	2	3	1	0	2	2	1	1	1	3	1	27.00	7.00	8.00
242	042	3	2	2	1	1	2	3	1	0	1	1	1	1	2	1	0	23.00	7.00	6.00
250	042	2	3	2	0	0	1	3	2	3	2	2	0	0	1	2	1	25.00	2.00	8.00
252	042	3	2	3	1	1	0	3	1	1	1	1	1	1	2	0	1	23.00	4.00	8.00
253	042	3	2	2	1	0	1	3	2	3	2	2	1	1	2	3	1	30.00	5.00	8.00
256	042	3	3	1	0	1	1	3	1	2	1	2	1	1	2	0	1	24.00	4.00	7.00
261	042	3	2	2	1	1	2	3	1	0	1	1	1	1	3	1	0	24.00	7.00	7.00
264	042	3	2	2	1	1	1	3	1	0	1	1	1	1	2	1	0	22.00	6.00	6.00
265	042	3	2	2	1	1	2	3	1	1	1	2	1	1	2	3	1	27.00	7.00	7.00
266	042	3	2	2	1	1	1	3	1	1	1	1	1	1	2	1	0	23.00	6.00	6.00
272	042	4	3	2	2	1	1	3	2	2	3	2	1	1	2	2	1	33.00	8.00	8.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

57

Treatment Group "C"

Day 4 (Period 042)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.71	.09
2. Feelings of guilt	1.51	.12
3. Suicide	1.48	.13
4. Insomnia, early	1.40	.07
5. Insomnia, middle	1.23	.07
6. Insomnia, late	1.34	.08
7. Work and activities	2.64	.09
8. Retardation	1.39	.10
9. Agitation	.99	.12
10. Anxiety, psychic	2.01	.11
11. Anxiety, somatic	1.59	.09
12. Somatic symptoms, gastrointestinal	1.06	.05
13. Somatic symptoms, general	1.19	.06
14. Genital symptoms	1.31	.08
15. Hypochondriasis	1.99	.11
16. Weight	.56	.08
17. Insight	.51	.06
Total Score	24.90	.61
Factor 1 - Vegetative signs	6.78	.22
Factor 2 - Vital disturbances	5.49	.29

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

58

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 072	4	1	1	1	1	0	2	0	0	3	1	2	1	0	2	0	0	19.00	5.00	4.00
6 072	3	2	2	1	2	1	3	0	1	3	2	2	0	2	2	1	0	27.00	7.00	6.00
8 072	3	0	0	1	1	1	3	0	2	2	0	1	2	0	3	0	0	19.00	6.00	3.00
16 072	2	2	2	2	1	1	3	2	1	2	1	2	1	0	2	0	0	24.00	7.00	6.00
18 072	2	1	0	0	0	0	2	1	0	2	2	1	2	1	2	0	0	16.00	3.00	3.00
26 072	1	0	0	1	1	1	2	2	1	1	0	0	1	1	1	0	0	13.00	4.00	1.00
27 072	2	0	0	1	1	1	1	1	1	1	0	1	0	2	0	0	0	12.00	4.00	.00
33 072	2	1	1	2	2	2	2	3	1	2	3	2	1	2	1	0	0	27.00	9.00	3.00
36 072	1	0	0	1	1	1	1	1	0	0	1	0	0	2	0	0	0	9.00	3.00	.00
39 072	2	0	0	1	1	2	2	1	1	2	1	1	1	1	1	0	0	17.00	6.00	1.00
40 072	2	0	0	1	1	1	2	2	1	2	1	0	1	2	0	0	0	16.00	4.00	.00
43 072	1	0	0	1	1	1	1	1	0	1	1	1	0	2	0	0	0	11.00	4.00	.00
46 072	1	0	1	1	2	2	2	2	1	2	1	1	1	2	0	0	0	19.00	7.00	1.00
52 072	2	1	1	1	1	1	1	2	0	2	2	1	1	1	2	1	1	21.00	6.00	5.00
53 072	2	2	1	1	1	2	2	1	0	1	1	1	1	0	2	1	1	20.00	7.00	6.00
58 072	2	1	2	1	1	1	1	2	0	2	1	1	1	1	2	1	1	21.00	6.00	6.00
59 072	3	2	2	1	1	1	2	3	0	2	2	1	1	1	2	0	1	25.00	5.00	7.00
62 072	2	2	1	1	1	1	2	0	2	2	2	1	1	1	2	1	1	23.00	6.00	6.00
63 072	2	1	1	1	1	1	1	0	0	2	2	1	1	1	2	0	1	18.00	5.00	5.00
69 072	2	1	0	1	1	1	2	2	0	2	2	1	1	1	2	0	1	20.00	5.00	4.00
71 072	2	1	0	2	1	2	2	1	0	1	1	1	1	2	3	0	0	20.00	7.00	4.00
74 072	2	0	0	1	1	1	2	0	1	2	4	1	1	1	2	0	1	20.00	5.00	3.00
76 072	3	1	1	2	1	2	3	0	1	2	3	1	1	1	2	0	1	25.00	7.00	5.00
81 072	1	0	0	1	2	2	0	0	2	1	2	0	2	2	1	0	1	17.00	7.00	2.00
82 072	3	0	2	1	0	0	3	1	0	0	0	1	2	2	1	0	0	16.00	4.00	3.00
86 072	3	3	2	1	1	2	3	0	0	2	2	1	1	2	0	0	1	24.00	6.00	6.00
89 072	2	0	0	2	2	2	2	0	1	1	1	1	1	2	1	0	0	18.00	8.00	1.00
92 072	2	1	1	1	1	0	2	1	1	2	1	0	2	2	0	0	0	17.00	4.00	2.00
93 072	4	2	1	1	2	2	4	1	2	3	2	1	2	2	2	2	0	33.00	10.00	5.00
97 072	2	1	1	1	2	1	3	1	2	3	1	1	1	1	0	0	0	21.00	6.00	2.00
100 072	4	0	2	1	2	2	2	3	1	1	2	1	2	1	0	0	0	24.00	8.00	2.00
104 072	3	2	1	1	0	0	3	2	0	1	1	0	1	2	0	0	0	17.00	2.00	3.00
105 072	4	1	2	2	2	2	4	2	1	2	2	1	2	1	2	2	0	32.00	11.00	5.00
111 072	3	1	3	1	1	1	3	2	1	3	2	2	2	2	2	0	0	29.00	7.00	6.00
112 072	2	1	1	1	0	1	3	1	1	1	1	1	1	1	2	1	0	19.00	5.00	4.00
116 072	3	1	2	2	1	2	3	1	1	3	2	1	2	2	3	0	0	29.00	8.00	6.00
117 072	3	1	1	2	0	0	2	1	0	2	2	1	2	0	2	0	0	19.00	5.00	4.00
121 072	2	0	0	1	1	0	0	0	0	1	2	0	0	1	1	0	0	9.00	2.00	1.00
125 072	2	2	0	2	2	2	2	1	1	2	1	1	1	2	2	0	1	24.00	8.00	5.00
128 072	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	0	1	8.00	2.00	3.00
129 072	2	1	2	2	0	2	3	1	1	3	2	2	2	2	2	0	1	28.00	8.00	6.00
137 072	1	0	0	0	1	0	1	1	0	0	1	1	0	1	2	0	1	10.00	2.00	3.00
138 072	2	1	0	1	1	2	4	1	1	2	2	2	2	2	2	0	1	26.00	8.00	4.00
141 072	1	2	0	0	0	2	2	1	0	1	1	1	1	1	1	1	1	16.00	5.00	4.00
145 072	1	3	1	2	2	2	3	0	0	0	1	0	2	1	0	0	1	19.00	8.00	5.00
173 072	3	1	2	1	1	1	3	2	1	1	2	1	1	1	3	1	0	25.00	6.00	6.00
174 072	3	2	3	1	1	2	3	2	2	1	2	1	1	1	3	1	1	30.00	7.00	9.00
175 072	3	2	3	2	2	1	3	2	1	1	1	1	1	1	3	1	0	28.00	8.00	8.00
178 072	3	2	2	1	1	2	3	2	0	1	1	1	1	1	3	0	1	25.00	6.00	8.00
182 072	3	2	2	1	1	2	3	1	1	1	1	1	1	2	0	2	1	25.00	8.00	5.00
183 072	3	2	3	1	1	2	3	1	0	1	1	1	1	2	3	2	1	28.00	8.00	9.00
190 072	3	2	2	1	1	1	3	1	0	1	2	1	1	1	3	2	0	25.00	7.00	7.00
191 072	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	1	22.00	5.00	7.00
195 072	3	2	3	1	1	1	3	2	2	2	2	1	1	1	2	2	1	30.00	7.00	8.00

FCE 20124/702 i

59

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
196 072	3	2	2	2	1	0	3	0	0	1	1	1	1	1	3	1	1	23.00	6.00	8.00
201 072	2	2	2	2	1	1	3	2	3	3	2	1	1	2	3	2	1	33.00	8.00	8.00
204 072	3	3	3	0	1	2	3	2	2	3	2	1	1	0	2	0	0	28.00	5.00	8.00
205 072	3	2	2	2	0	0	3	2	3	2	2	0	0	2	2	1	0	26.00	3.00	6.00
207 072	3	3	0	2	1	1	3	2	4	3	1	1	1	0	3	0	1	29.00	6.00	7.00
212 072	4	3	2	2	1	0	3	3	3	3	2	1	1	0	3	2	1	34.00	7.00	9.00
213 072	3	3	3	2	1	1	3	3	3	3	2	1	1	1	2	2	0	34.00	8.00	8.00
220 072	3	0	0	2	2	2	2	1	0	3	2	1	2	2	2	2	0	26.00	11.00	2.00
221 072	3	0	0	0	0	0	2	3	0	1	0	1	2	1	0	0	0	13.00	3.00	.00
225 072	3	0	0	2	2	2	2	0	0	2	2	1	2	2	2	0	0	22.00	9.00	2.00
228 072	3	0	0	2	2	2	4	1	0	0	0	1	0	2	3	0	0	20.00	7.00	3.00
229 072	0	0	0	0	0	0	1	0	0	0	0	1	2	1	2	0	0	7.00	3.00	2.00
234 072	4	0	0	2	2	2	4	3	0	2	0	0	2	2	2	0	1	26.00	8.00	3.00
236 072	0	0	0	2	1	2	2	0	0	0	0	0	0	1	1	0	0	9.00	5.00	1.00
239 072	3	0	0	2	2	2	3	0	0	0	2	2	2	2	3	0	0	23.00	10.00	3.00
241 072	3	2	2	1	1	1	3	1	0	1	2	1	1	1	3	0	0	23.00	5.00	7.00
242 072	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	1	0	23.00	7.00	6.00
250 072	2	3	2	0	0	1	3	2	2	1	2	0	0	1	2	0	1	22.00	1.00	8.00
252 072	3	2	3	2	1	0	3	1	1	1	1	1	1	1	1	0	1	23.00	5.00	7.00
253 072	3	2	2	1	0	1	3	2	3	2	2	1	1	2	3	1	0	29.00	5.00	7.00
256 072	3	3	1	0	1	1	3	1	2	1	2	1	1	1	2	0	1	24.00	4.00	7.00
261 072	3	2	2	1	1	2	3	1	1	1	1	1	1	1	3	1	0	25.00	7.00	7.00
264 072	3	2	2	1	1	2	3	1	1	1	1	1	1	1	2	1	0	24.00	7.00	6.00
265 072	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	2	0	25.00	8.00	7.00
266 072	3	2	1	1	1	1	3	1	0	1	1	1	1	1	2	1	0	21.00	6.00	5.00
272 072	3	2	2	2	1	1	3	2	1	2	2	1	1	1	2	2	1	29.00	8.00	7.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

60

Treatment Group "C"

Day 7 (Period 072)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.46	.10
2. Feelings of guilt	1.26	.11
3. Suicide	1.19	.12
4. Insomnia, early	1.21	.07
5. Insomnia, middle	1.05	.07
6. Insomnia, late	1.23	.08
7. Work and activities	2.46	.10
8. Retardation	1.23	.10
9. Agitation	.83	.11
10. Anxiety, psychic	1.55	.10
11. Anxiety, somatic	1.41	.09
12. Somatic symptoms, gastrointestinal	.95	.06
13. Somatic symptoms, general	1.13	.07
14. Genital symptoms	1.29	.07
15. Hypochondriasis	1.79	.11
16. Weight	.51	.08
17. Insight	.41	.06
Total Score	21.95	.71
Factor 1 - Vegetative signs	6.07	.24
Factor 2 - Vital disturbances	4.65	.28

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

61

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 102	3	1	0	1	1	0	2	0	0	3	1	2	1	0	2	0	0	17.00	5.00	3.00
6 102	3	2	2	1	2	1	3	0	1	3	2	2	0	2	2	1	0	27.00	7.00	6.00
8 102	3	0	0	1	1	0	3	0	2	2	0	1	2	0	3	0	0	18.00	5.00	3.00
16 102	2	2	1	1	1	0	3	2	1	1	1	1	1	0	2	0	0	19.00	4.00	5.00
18 102	2	1	0	0	0	0	2	1	0	2	1	1	2	1	1	0	0	14.00	3.00	2.00
26 102	1	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	6.00	4.00	.00
27 102	1	0	0	1	1	0	2	1	1	1	0	0	0	2	0	0	0	10.00	2.00	.00
33 102	2	0	0	1	1	2	2	2	1	1	2	1	2	2	0	0	0	19.00	7.00	.00
36 102	1	0	0	1	0	1	1	0	0	0	0	0	2	0	0	0	0	6.00	2.00	.00
39 102	1	0	0	1	0	0	1	0	0	1	0	0	1	1	0	0	0	6.00	2.00	.00
40 102	1	0	0	1	0	0	1	1	1	0	0	0	1	1	0	0	0	7.00	2.00	.00
43 102	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
46 102	1	0	0	1	1	2	2	1	1	2	1	1	1	2	0	0	0	16.00	6.00	.00
52 102	2	2	1	1	1	1	2	1	0	1	1	1	1	0	2	1	1	19.00	6.00	6.00
53 102	2	2	1	1	1	1	1	2	0	1	1	1	1	0	1	0	1	17.00	5.00	5.00
58 102	2	1	1	1	1	1	2	1	0	1	2	1	1	1	2	1	1	20.00	6.00	5.00
59 102	2	2	1	1	1	1	2	1	0	1	2	1	1	1	1	0	1	19.00	5.00	5.00
62 102	2	2	1	1	1	1	2	0	2	2	2	1	1	1	2	1	1	23.00	6.00	6.00
63 102	2	2	1	1	1	1	2	0	0	2	2	1	1	1	2	0	1	20.00	5.00	6.00
69 102	2	1	0	1	1	1	2	1	0	2	2	1	1	1	2	0	1	19.00	5.00	4.00
71 102	2	0	0	1	1	2	2	1	0	1	1	1	1	2	3	0	1	19.00	6.00	4.00
74 102	1	0	0	1	0	1	0	1	1	2	4	1	2	1	3	0	1	19.00	5.00	4.00
76 102	1	0	0	1	1	1	2	0	1	2	2	0	1	1	2	0	1	16.00	4.00	3.00
81 102	1	0	0	1	2	2	0	0	1	1	1	0	1	1	0	0	0	11.00	6.00	.00
82 102	3	1	1	1	0	0	3	1	0	0	1	2	2	2	0	0	0	17.00	5.00	2.00
86 102	2	2	0	1	1	1	2	0	0	0	1	1	1	1	0	0	0	13.00	5.00	2.00
89 102	1	0	0	2	1	2	1	0	1	1	1	1	2	2	2	0	1	18.00	8.00	3.00
92 102	0	0	1	1	1	1	1	0	0	1	0	0	1	1	0	0	0	8.00	4.00	1.00
93 102	4	1	1	1	1	2	4	1	2	3	2	1	2	2	1	0	0	28.00	7.00	3.00
97 102	2	0	2	0	1	2	2	0	2	1	1	1	1	1	0	0	0	16.00	5.00	2.00
100 102	3	0	2	2	1	1	3	2	1	1	2	2	1	1	0	0	0	22.00	7.00	2.00
104 102	3	2	1	1	0	0	3	2	0	1	1	0	1	2	0	0	0	17.00	2.00	3.00
105 102	4	2	2	1	1	2	4	3	1	1	2	1	2	2	2	0	0	30.00	7.00	6.00
111 102	3	1	2	2	2	2	3	2	1	2	1	1	1	2	2	0	0	27.00	8.00	5.00
112 102	1	1	1	1	0	1	2	1	1	1	1	1	1	1	1	0	0	15.00	4.00	3.00
116 102	3	1	1	2	1	2	3	0	1	2	2	1	1	2	3	0	0	25.00	7.00	5.00
117 102	2	1	1	2	0	0	2	2	0	2	2	2	2	0	1	0	0	19.00	6.00	3.00
121 102	1	0	0	1	0	0	0	0	0	0	1	0	0	1	1	0	0	5.00	1.00	1.00
125 102	3	3	1	2	1	2	2	1	1	3	1	1	1	2	2	0	1	27.00	7.00	7.00
128 102	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	0	1	7.00	2.00	3.00
129 102	1	1	2	2	0	2	2	1	1	1	1	0	1	2	2	0	1	20.00	5.00	6.00
137 102	1	0	0	0	1	1	0	1	0	0	1	0	0	1	2	0	1	9.00	2.00	3.00
138 102	1	0	0	2	0	1	3	1	1	1	1	1	1	2	3	0	1	19.00	5.00	4.00
141 102	1	1	0	0	0	2	1	1	0	1	1	1	1	1	1	0	1	13.00	4.00	3.00
145 102	1	1	0	2	2	2	3	0	1	2	2	1	1	0	3	0	0	21.00	8.00	4.00
173 102	3	2	3	1	2	1	3	2	1	1	2	1	1	1	3	1	0	28.00	7.00	8.00
174 102	3	2	2	1	2	2	3	1	1	1	2	1	1	1	3	1	1	28.00	8.00	8.00
175 102	3	2	2	2	1	1	3	2	0	1	1	1	1	1	3	0	1	25.00	6.00	8.00
178 102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	0	22.00	5.00	7.00
182 102	3	2	2	1	1	1	3	1	1	1	1	1	1	0	2	0	1	22.00	5.00	7.00
183 102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	1	22.00	5.00	7.00
190 102	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	0	0	23.00	5.00	7.00
191 102	2	2	2	1	1	1	2	1	0	1	1	1	1	1	2	0	1	20.00	5.00	7.00
195 102	3	2	2	1	1	1	3	1	1	1	2	1	1	1	2	2	1	26.00	7.00	7.00

FCE 20124/702 i

62

Pat. Per. No.	Per. (dy)	Items																Total Score	Factor 1	Factor 2
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16			
196	102	2	2	1	1	1	0	3	0	0	1	1	1	1	2	0	0	17.00	4.00	5.00
201	102	2	2	2	2	1	1	3	2	3	3	2	1	1	2	3	2	33.00	8.00	8.00
204	102	2	3	3	0	1	2	2	2	1	3	1	1	0	0	2	0	23.00	4.00	8.00
205	102	2	1	1	2	0	0	2	1	2	1	1	0	0	1	2	1	17.00	3.00	4.00
207	102	2	2	0	2	1	1	3	2	3	2	1	1	1	0	2	0	24.00	6.00	5.00
212	102	3	3	2	2	1	0	3	2	2	3	2	1	1	0	2	2	30.00	7.00	8.00
213	102	2	2	2	1	0	1	3	2	3	3	2	1	1	1	2	2	28.00	6.00	6.00
220	102	1	0	0	2	2	2	1	0	0	1	0	1	2	2	0	0	14.00	9.00	.00
221	102	3	0	0	0	0	0	3	3	0	0	0	1	2	0	0	0	12.00	3.00	.00
225	102	2	0	0	2	2	2	2	0	2	2	2	0	2	2	2	0	22.00	8.00	2.00
228	102	4	0	0	2	2	2	4	0	3	4	2	0	0	2	3	0	28.00	6.00	3.00
229	102	2	2	0	1	0	0	4	0	1	0	0	0	2	2	4	0	18.00	3.00	6.00
234	102	4	0	0	2	2	2	4	2	0	2	0	0	1	2	2	0	23.00	7.00	2.00
236	102	2	2	0	2	2	2	1	0	0	0	0	0	2	2	3	0	18.00	8.00	5.00
239	102	1	0	0	2	1	2	0	1	0	0	1	2	1	2	1	0	14.00	8.00	1.00
241	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	3	0	22.00	5.00	7.00
242	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	0	21.00	5.00	6.00
250	102	2	2	1	0	0	0	2	1	2	1	1	0	0	1	1	0	15.00	.00	5.00
252	102	2	2	2	1	1	0	2	1	0	1	1	0	1	1	1	0	17.00	3.00	6.00
253	102	2	2	2	1	0	1	3	2	2	2	2	1	1	2	3	1	28.00	5.00	8.00
256	102	3	3	1	0	1	1	3	1	2	1	2	1	1	1	2	0	24.00	4.00	7.00
261	102	3	2	2	1	1	1	3	1	1	1	1	1	1	1	3	1	24.00	6.00	7.00
264	102	3	2	2	1	1	1	3	1	1	1	2	1	1	1	3	2	26.00	7.00	7.00
265	102	3	2	2	1	1	2	3	1	0	1	1	1	1	1	2	2	24.00	8.00	6.00
266	102	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	1	22.00	6.00	6.00
272	102	3	2	2	2	1	0	3	2	2	1	2	1	1	1	2	2	28.00	7.00	7.00

FCE 20124/702 i

63

Treatment Group "C"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Depressed mood	2.14	.10
2. Feelings of guilt	1.20	.11
3. Suicide	.96	.10
4. Insomnia, early	1.15	.07
5. Insomnia, middle	.88	.07
6. Insomnia, late	1.03	.08
7. Work and activities	2.24	.12
8. Retardation	.95	.09
9. Agitation	.77	.10
10. Anxiety, psychic	1.27	.10
11. Anxiety, somatic	1.19	.09
12. Somatic symptoms, gastrointestinal	.81	.06
13. Somatic symptoms, general	1.05	.06
14. Genital symptoms	1.18	.07
15. Hypochondriasis	1.69	.12
16. Weight	.30	.07
17. Insight	.39	.05
Total Score	19.19	.74
Factor 1 - Vegetative signs	5.21	.22
Factor 2 - Vital disturbances	4.24	.29

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

64

Pat. Per. No.	Per. (dy)	Items																	Total Score	Factor 1	Factor 2
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3	142	3	1	0	1	1	0	2	0	0	3	1	1	1	0	2	0	0	16.00	4.00	3.00
6	142	3	2	2	1	2	1	3	0	1	3	2	2	0	2	2	1	0	27.00	7.00	6.00
8	142	3	0	0	1	1	0	3	0	1	2	0	1	2	0	2	0	0	16.00	5.00	2.00
16	142	2	2	1	1	1	0	2	2	1	1	1	1	1	0	2	0	0	18.00	4.00	5.00
18	142	2	1	0	0	0	0	2	1	0	2	1	1	2	1	1	0	0	14.00	3.00	2.00
26	142	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
27	142	1	0	0	1	0	0	1	1	0	1	0	0	0	2	0	0	0	7.00	1.00	.00
33	142	1	0	0	0	1	1	1	1	1	0	1	0	1	1	0	0	0	9.00	3.00	.00
36	142	1	0	0	0	0	1	1	0	0	0	0	0	1	2	0	0	0	6.00	2.00	.00
39	142	1	0	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	5.00	1.00	.00
40	142	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
43	142	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
46	142	1	0	0	1	1	1	1	1	0	1	0	0	0	2	0	0	0	9.00	3.00	.00
52	142	1	1	1	1	1	1	1	1	0	1	1	1	1	1	2	1	1	17.00	6.00	5.00
53	142	1	1	0	1	1	1	1	1	0	2	1	1	1	0	2	0	0	14.00	5.00	3.00
58	142	2	1	2	1	1	1	2	1	0	1	2	1	1	1	2	1	0	20.00	6.00	5.00
59	142	2	2	1	1	1	0	2	1	0	2	2	1	1	1	2	0	1	20.00	4.00	6.00
62	142	2	1	0	1	1	1	1	0	2	1	1	1	1	0	2	1	1	17.00	6.00	4.00
63	142	2	1	1	1	1	1	1	0	0	1	1	1	1	1	2	0	1	16.00	5.00	5.00
69	142	2	0	0	1	1	0	1	1	1	1	1	1	1	1	0	0	0	12.00	4.00	1.00
71	142	1	0	0	1	1	2	1	1	0	1	1	1	1	1	2	0	0	14.00	6.00	2.00
74	142	0	0	0	0	0	1	0	0	0	0	3	1	2	1	2	0	0	10.00	4.00	2.00
76	142	0	0	0	1	0	1	1	0	0	0	2	0	1	1	2	0	0	9.00	3.00	2.00
81	142	1	0	0	0	0	1	1	0	1	0	2	0	2	1	0	0	0	9.00	3.00	.00
82	142	2	1	1	1	0	0	3	1	0	0	1	1	2	1	0	0	0	14.00	4.00	2.00
86	142	2	2	0	1	2	2	1	0	1	1	0	1	1	1	0	0	0	15.00	7.00	2.00
89	142	2	0	0	1	1	1	1	0	1	1	2	1	2	2	0	0	1	16.00	6.00	1.00
92	142	0	0	0	1	1	1	0	0	0	0	0	0	1	1	0	0	0	5.00	4.00	.00
93	142	4	1	1	1	2	2	4	1	2	3	2	1	2	2	1	1	0	30.00	9.00	3.00
97	142	2	0	1	1	1	1	2	0	1	1	1	1	1	1	0	0	0	14.00	5.00	1.00
100	142	2	0	0	1	1	1	2	1	1	1	0	0	1	0	0	0	0	11.00	4.00	.00
104	142	3	2	1	1	1	0	3	1	0	1	1	0	1	2	0	0	0	17.00	3.00	3.00
105	142	4	3	3	1	1	2	4	3	2	3	3	2	2	2	3	0	0	38.00	8.00	9.00
111	142	2	1	2	2	2	2	3	1	1	1	1	1	1	2	2	0	0	24.00	8.00	5.00
112	142	1	0	0	1	0	0	2	1	0	0	0	0	1	1	1	0	0	8.00	2.00	1.00
116	142	2	1	1	2	1	2	3	0	1	1	2	1	1	1	3	0	0	22.00	7.00	5.00
117	142	2	0	1	1	0	0	2	1	0	2	2	2	2	0	1	0	0	16.00	5.00	2.00
121	142	1	0	1	0	2	1	2	1	0	2	1	1	0	1	2	0	0	15.00	4.00	3.00
125	142	2	3	1	2	1	2	2	1	0	2	1	0	1	1	2	0	1	22.00	6.00	7.00
128	142	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	0	1	7.00	2.00	3.00
129	142	1	1	1	1	0	2	1	1	0	0	1	0	1	2	2	0	1	15.00	4.00	5.00
137	142	1	0	0	0	0	1	0	1	1	0	0	0	0	2	0	1	7.00	1.00	3.00	
138	142	1	0	0	1	0	1	4	1	1	1	2	1	1	2	3	0	1	20.00	4.00	4.00
141	142	1	1	0	0	0	0	1	0	0	1	1	1	1	1	0	1	10.00	2.00	3.00	
145	142	0	3	0	2	2	2	0	0	1	0	1	0	0	0	0	0	0	11.00	6.00	3.00
173	142	2	2	2	1	1	1	3	1	0	1	1	1	1	1	3	1	0	22.00	6.00	7.00
174	142	3	2	2	2	1	2	3	2	1	1	1	1	1	3	1	1	28.00	8.00	8.00	
175	142	3	1	2	1	1	1	2	2	1	1	1	0	1	1	3	0	0	21.00	4.00	6.00
178	142	3	2	2	1	0	1	2	1	0	1	1	1	1	1	3	0	1	21.00	4.00	8.00
182	142	2	2	2	1	1	0	2	1	0	1	1	1	1	0	2	0	0	17.00	4.00	6.00
183	142	2	2	2	1	1	0	2	1	0	1	1	1	1	1	2	0	0	18.00	4.00	6.00
190	142	3	2	2	1	1	1	3	1	0	0	1	1	1	1	3	0	0	21.00	5.00	7.00
191	142	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	1	19.00	5.00	6.00
195	142	3	2	1	0	1	1	3	1	1	1	1	1	1	1	1	1	1	21.00	5.00	5.00

FCE 20124/702 i

65

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
196	142	1	1	1	1	0	1	0	0	1	1	1	1	1	2	1	1	15.00	5.00	5.00
201	142	2	2	1	1	0	2	1	2	2	2	1	1	1	2	1	1	23.00	5.00	6.00
204	142	2	1	1	0	1	1	2	1	1	1	0	0	0	1	0	0	13.00	2.00	3.00
205	142	1	1	1	1	0	0	2	2	2	1	1	1	0	1	2	1	17.00	3.00	4.00
207	142	2	2	0	1	1	1	2	1	3	2	1	1	1	0	2	0	21.00	5.00	5.00
212	142	2	2	2	1	0	0	2	1	2	1	2	1	0	0	2	1	20.00	3.00	7.00
213	142	2	1	1	1	0	0	2	1	2	2	1	1	1	1	2	2	20.00	5.00	4.00
220	142	1	0	0	2	1	2	1	0	0	0	1	0	1	2	0	0	11.00	6.00	.00
221	142	3	0	0	0	0	0	4	3	0	0	0	1	2	1	0	2	16.00	5.00	.00
225	142	3	0	0	2	2	2	2	0	1	2	2	0	1	1	0	0	18.00	7.00	.00
229	142	3	0	0	2	1	1	4	0	2	2	0	0	2	1	4	0	22.00	6.00	4.00
234	142	2	0	0	1	1	2	2	1	0	0	0	0	0	1	1	0	11.00	4.00	1.00
236	142	1	0	0	2	1	2	1	0	0	0	0	0	1	0	2	0	10.00	6.00	2.00
239	142	0	0	0	1	1	2	0	1	0	0	0	2	0	2	3	0	12.00	6.00	3.00
241	142	3	2	2	1	1	1	2	1	0	1	2	1	1	1	2	0	21.00	5.00	6.00
242	142	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	18.00	5.00	5.00
250	142	2	2	1	0	0	0	2	1	1	1	1	0	0	1	1	0	14.00	.00	5.00
252	142	2	2	2	1	0	0	2	1	1	1	1	0	1	1	1	0	17.00	2.00	6.00
253	142	2	1	1	1	0	0	2	1	2	1	1	1	1	2	2	1	20.00	4.00	5.00
256	142	2	3	1	0	1	1	3	1	1	1	2	1	1	1	2	0	22.00	4.00	7.00
261	142	3	2	2	1	1	1	3	1	1	1	1	1	1	3	1	1	25.00	6.00	8.00
264	142	3	2	1	1	1	1	3	1	1	1	2	1	1	1	2	1	23.00	6.00	5.00
265	142	3	2	2	1	1	1	3	1	0	1	1	1	1	1	2	1	22.00	6.00	6.00
266	142	3	2	1	1	1	1	3	1	0	1	1	1	1	2	0	0	20.00	5.00	5.00
272	142	2	2	2	1	1	0	3	2	1	2	2	1	1	1	2	2	26.00	6.00	7.00

FCE 20124/702 i

66

Treatment Group "C"

Day 14 (Period 142)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. Depressed mood	1.84	.11
2. Feelings of guilt	1.03	.11
3. Suicide	.77	.09
4. Insomnia, early	.94	.06
5. Insomnia, middle	.76	.07
6. Insomnia, late	.82	.08
7. Work and activities	1.87	.12
8. Retardation	.81	.07
9. Agitation	.59	.08
10. Anxiety, psychic	1.00	.09
11. Anxiety, somatic	1.03	.08
12. Somatic symptoms, gastrointestinal	.71	.06
13. Somatic symptoms, general	.94	.07
14. Genital symptoms	1.00	.07
15. Hypochondriasis	1.51	.12
16. Weight	.28	.06
17. Insight	.32	.05
Total Score	16.20	.73
Factor 1 - Vegetative signs	4.44	.21
Factor 2 - Vital disturbances	3.62	.28

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

67

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 212	2	1	0	1	1	0	2	0	0	2	1	1	1	0	2	0	0	14.00	4.00	3.00
6 212	4	2	2	2	1	3	1	0	3	2	2	1	2	2	1	0	0	30.00	9.00	6.00
8 212	3	0	0	1	1	1	3	0	1	3	0	1	2	0	2	0	0	18.00	6.00	2.00
16 212	1	2	1	1	1	0	2	1	1	1	1	1	0	1	0	0	0	15.00	4.00	4.00
18 212	1	1	0	0	0	0	2	1	0	2	1	1	2	1	1	0	0	13.00	3.00	2.00
26 212	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
27 212	1	0	0	1	0	0	1	1	0	0	0	0	0	2	0	0	0	6.00	1.00	.00
33 212	1	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	3.00	.00	.00
36 212	0	0	0	1	0	0	1	0	0	0	0	0	0	2	0	0	0	4.00	1.00	.00
39 212	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
40 212	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
43 212	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1.00	1.00	.00
46 212	1	0	0	0	1	1	1	0	0	1	0	0	0	1	0	0	0	6.00	2.00	.00
52 212	1	1	1	1	1	0	1	1	0	1	1	0	1	0	2	0	0	12.00	3.00	4.00
53 212	1	1	0	1	1	0	1	1	0	1	0	0	1	0	1	0	0	9.00	3.00	2.00
58 212	1	1	1	1	1	1	2	1	0	1	2	1	1	1	2	0	0	17.00	5.00	4.00
59 212	1	1	0	1	1	0	1	1	0	1	2	1	1	1	1	0	0	13.00	4.00	2.00
62 212	1	1	0	1	1	0	1	0	2	1	1	1	1	0	2	0	0	13.00	4.00	3.00
63 212	2	1	1	1	1	1	1	0	0	1	1	1	1	0	2	0	0	14.00	5.00	4.00
69 212	2	0	0	1	1	0	1	1	1	1	1	1	0	2	0	0	0	13.00	4.00	2.00
71 212	1	0	0	1	1	2	1	1	0	1	1	0	1	1	2	0	0	13.00	5.00	2.00
74 212	0	0	0	0	0	1	1	0	1	1	2	0	0	1	1	0	0	8.00	1.00	1.00
76 212	0	0	0	1	0	1	1	0	0	0	1	0	0	0	1	0	0	5.00	2.00	1.00
81 212	0	0	0	0	0	2	0	0	0	0	2	0	2	1	0	0	0	7.00	4.00	.00
82 212	1	0	0	1	1	0	3	0	0	0	2	1	2	1	0	0	0	12.00	5.00	.00
86 212	1	0	0	2	1	1	0	0	1	1	0	0	0	1	0	0	0	8.00	4.00	.00
89 212	2	0	0	1	1	1	1	0	1	1	2	0	1	1	0	0	0	12.00	4.00	.00
92 212	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	4.00	2.00	1.00
93 212	4	1	1	1	2	2	3	1	1	2	2	0	2	2	0	0	0	24.00	7.00	2.00
97 212	1	0	1	0	1	1	2	0	2	1	1	1	1	1	0	0	0	13.00	4.00	1.00
100 212	1	0	0	2	0	1	2	1	0	1	0	1	1	0	0	0	0	10.00	5.00	.00
104 212	3	1	1	0	0	0	2	2	0	1	1	0	2	2	0	0	0	15.00	2.00	2.00
111 212	2	1	2	2	2	2	3	1	1	2	1	2	2	2	0	0	0	26.00	9.00	5.00
112 212	1	0	0	0	0	0	2	0	0	0	1	1	1	0	1	1	0	8.00	3.00	1.00
116 212	0	0	0	2	2	2	1	0	0	1	0	0	0	0	1	0	0	9.00	6.00	1.00
117 212	1	0	0	1	0	0	1	1	0	1	1	1	1	0	1	0	0	9.00	3.00	1.00
121 212	0	0	0	1	0	0	0	0	0	1	2	0	1	1	0	0	0	6.00	2.00	.00
125 212	3	2	2	2	2	3	2	0	3	2	1	2	2	2	0	1	1	31.00	9.00	7.00
128 212	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	6.00	3.00	2.00
129 212	1	1	0	0	0	2	1	1	0	0	0	1	1	2	1	0	1	12.00	4.00	3.00
137 212	1	0	0	0	0	0	0	0	1	1	1	1	0	2	0	1	1	9.00	2.00	3.00
138 212	1	1	0	0	1	1	4	1	0	1	2	1	1	2	2	0	1	19.00	4.00	4.00
141 212	0	1	0	0	0	0	1	0	0	1	2	0	1	0	0	0	1	7.00	1.00	2.00
145 212	0	3	0	2	2	2	0	0	1	0	1	0	0	0	0	0	0	11.00	6.00	3.00
173 212	2	2	2	1	1	1	2	2	0	1	1	1	0	1	2	0	0	19.00	4.00	6.00
174 212	2	2	2	1	1	1	2	1	0	1	1	1	1	1	2	0	0	19.00	5.00	6.00
175 212	3	1	2	1	1	1	2	1	1	1	2	0	1	1	2	0	0	20.00	4.00	5.00
178 212	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	5.00	5.00
182 212	3	2	1	1	1	0	2	1	0	1	1	1	1	0	2	0	0	17.00	4.00	5.00
183 212	2	2	2	1	1	0	2	1	1	1	1	1	1	1	2	0	0	19.00	4.00	6.00
190 212	2	2	2	1	1	0	2	1	0	1	1	1	1	1	2	0	0	18.00	4.00	6.00
191 212	2	2	1	1	0	1	2	1	0	0	1	1	1	1	2	0	0	16.00	4.00	5.00
195 212	2	2	1	0	0	1	3	1	1	1	1	1	1	1	1	0	1	18.00	3.00	5.00
196 212	1	0	0	0	0	0	0	1	0	1	1	0	0	1	2	1	0	8.00	1.00	2.00



FCE 20124/702 i

68

Pat. Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
201	2	2	1	1	1	0	2	1	2	1	2	1	1	1	2	1	1	22.00	5.00	6.00
204	1	1	0	0	0	0	2	0	0	1	1	0	0	1	0	0	0	7.00	.00	1.00
205	1	1	1	0	0	0	1	1	1	1	1	0	0	1	1	0	0	10.00	.00	3.00
207	1	1	0	1	0	0	2	1	1	1	0	0	0	0	1	0	1	10.00	1.00	3.00
212	2	1	1	0	0	1	2	1	1	1	1	1	0	1	0	1	15.00	3.00	4.00	
213	1	1	1	1	0	0	2	1	1	2	1	1	1	1	1	2	0	17.00	5.00	3.00
220	3	0	0	2	2	2	3	0	0	2	1	1	2	2	0	2	0	22.00	11.00	.00
221	3	0	0	0	0	0	4	3	0	1	1	1	2	0	0	0	0	15.00	3.00	.00
225	1	0	0	2	2	2	2	0	2	3	1	0	2	1	2	0	0	20.00	8.00	2.00
229	3	0	0	0	0	1	2	0	0	2	0	1	2	1	2	0	0	14.00	4.00	2.00
234	0	0	0	2	1	2	0	0	0	0	0	1	1	1	1	0	0	9.00	7.00	1.00
236	0	0	0	0	0	0	0	0	0	2	2	0	0	0	2	0	0	6.00	.00	2.00
239	0	0	0	1	1	2	0	0	0	1	1	2	1	2	3	0	0	14.00	7.00	3.00
241	2	2	2	1	1	1	2	1	0	1	1	1	1	1	2	0	0	19.00	5.00	6.00
242	3	2	1	0	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	4.00	5.00
250	1	1	1	0	0	0	1	1	1	1	1	0	0	1	1	0	1	11.00	.00	4.00
252	1	1	0	0	0	0	1	1	0	0	1	0	0	1	0	0	1	7.00	.00	2.00
253	2	1	1	0	0	0	2	1	1	1	1	1	1	2	1	0	1	16.00	2.00	4.00
256	2	2	1	0	0	1	3	1	1	1	2	1	1	1	2	0	1	20.00	3.00	6.00
261	3	2	2	1	1	1	3	2	1	1	1	1	1	1	2	0	1	24.00	5.00	7.00
264	3	2	2	1	1	2	3	1	0	1	1	1	1	1	3	2	1	26.00	8.00	8.00
265	3	2	1	1	1	1	3	1	1	1	1	1	1	1	3	0	0	22.00	5.00	6.00
266	2	2	1	1	1	1	2	1	0	1	1	1	1	1	2	0	0	18.00	5.00	5.00
272	2	1	1	1	0	0	2	1	1	1	1	1	1	1	1	2	1	18.00	5.00	4.00

FCE 20124/702 i

69

Treatment Group "C"

Day 21 (Period 212)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Depressed mood	1.45	.12
2. Feelings of guilt	.83	.10
3. Suicide	.56	.08
4. Insomnia, early	.78	.07
5. Insomnia, middle	.63	.08
6. Insomnia, late	.68	.08
7. Work and activities	1.58	.12
8. Retardation	.65	.07
9. Agitation	.40	.07
10. Anxiety, psychic	.96	.08
11. Anxiety, somatic	.97	.08
12. Somatic symptoms, gastrointestinal	.62	.06
13. Somatic symptoms, general	.88	.07
14. Genital symptoms	.87	.07
15. Hypochondriasis	1.18	.10
16. Weight	.17	.06
17. Insight	.22	.05
Total Score	13.44	.75
Factor 1 - Vegetative signs	3.76	.27
Factor 2 - Vital disturbances	2.79	.25

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

70

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
3 282	2	1	0	1	0	0	2	0	0	1	1	1	1	0	2	0	0	12.00	3.00	3.00
6 282	4	2	2	2	1	3	1	0	3	2	2	1	2	2	1	0	0	30.00	9.00	6.00
8 282	3	0	0	1	1	1	3	0	1	3	1	1	2	0	3	0	0	20.00	6.00	3.00
16 282	1	1	0	0	1	0	2	1	0	1	1	0	1	0	1	0	0	10.00	2.00	2.00
18 282	1	1	0	0	0	0	1	0	0	2	1	0	2	1	1	0	0	10.00	2.00	2.00
26 282	1	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	3.00	1.00	.00
27 282	1	0	0	1	0	0	1	1	0	0	0	0	0	1	0	0	0	5.00	1.00	.00
33 282	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	2.00	.00	.00
36 282	0	0	0	0	0	1	1	0	0	0	0	0	0	2	0	0	0	4.00	1.00	.00
39 282	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
40 282	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	4.00	1.00	.00
43 282	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1.00	1.00	.00
46 282	1	0	0	0	0	1	0	0	1	0	0	0	0	1	0	0	0	4.00	1.00	.00
52 282	1	1	0	1	1	0	2	1	0	1	1	1	1	0	1	0	1	13.00	4.00	3.00
53 282	1	1	0	1	1	0	1	1	0	1	0	0	0	0	1	0	0	8.00	2.00	2.00
58 282	2	1	1	1	0	1	1	1	0	1	1	1	1	1	2	0	0	15.00	4.00	4.00
59 282	1	1	0	1	1	0	1	1	0	1	1	1	1	1	2	0	0	13.00	4.00	3.00
62 282	2	0	0	2	2	0	2	0	2	2	2	0	2	0	2	0	0	18.00	6.00	2.00
63 282	1	0	0	1	1	0	1	0	0	1	1	0	1	0	1	0	0	8.00	3.00	1.00
69 282	1	0	0	1	0	0	1	1	1	1	1	1	0	0	1	0	0	9.00	2.00	1.00
71 282	1	0	0	1	1	1	1	0	0	1	1	0	1	1	2	0	0	11.00	4.00	2.00
76 282	0	0	0	0	0	0	1	0	0	0	2	0	0	0	2	0	0	5.00	.00	2.00
81 282	0	0	0	1	0	0	1	0	0	1	0	0	1	0	0	0	0	4.00	2.00	.00
82 282	0	0	1	1	0	0	2	0	0	1	2	1	2	1	1	0	0	12.00	4.00	2.00
86 282	0	0	0	1	1	1	1	0	0	0	0	0	1	1	0	0	0	6.00	4.00	.00
89 282	2	0	0	2	1	2	2	0	0	1	1	0	2	1	2	0	0	16.00	7.00	2.00
92 282	0	0	0	1	0	1	1	0	0	0	1	0	0	0	0	0	0	4.00	2.00	.00
97 282	2	1	1	1	1	1	1	1	1	1	2	1	1	1	0	0	0	16.00	5.00	2.00
100 282	0	0	0	0	1	0	0	0	2	1	1	0	0	0	0	0	0	5.00	1.00	.00
104 282	3	1	1	0	0	0	2	2	0	1	1	0	1	1	0	0	0	13.00	1.00	2.00
111 282	3	1	2	2	2	2	3	1	1	1	2	1	2	2	2	0	0	27.00	9.00	5.00
112 282	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	2.00	2.00	.00
116 282	0	0	0	1	1	2	0	0	0	0	0	0	0	0	0	0	0	4.00	4.00	.00
117 282	0	0	0	0	0	0	1	0	1	1	1	1	0	0	0	0	0	5.00	1.00	.00
121 282	0	0	0	0	0	0	0	0	0	1	2	0	0	1	0	0	0	4.00	.00	.00
128 282	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	2.00	2.00	.00
129 282	1	0	0	0	0	2	0	1	0	0	0	0	1	2	1	0	0	8.00	3.00	1.00
137 282	1	0	1	0	0	0	1	1	1	1	2	2	2	0	2	0	1	15.00	4.00	4.00
141 282	0	1	0	0	0	0	0	0	0	1	1	1	1	1	0	0	1	7.00	2.00	2.00
145 282	0	3	0	2	2	2	0	0	1	0	1	0	0	0	0	0	0	11.00	6.00	3.00
173 282	2	1	1	1	0	0	1	1	0	1	1	0	1	1	2	0	0	13.00	2.00	4.00
174 282	2	1	2	1	0	0	2	1	0	1	1	0	1	1	2	0	0	15.00	2.00	5.00
175 282	2	1	1	1	0	0	1	1	1	1	1	0	1	1	2	0	0	14.00	2.00	4.00
178 282	2	2	1	1	1	0	2	1	0	1	1	1	1	1	3	0	0	18.00	4.00	6.00
182 282	2	2	1	1	1	1	2	1	0	0	1	1	1	1	2	0	0	17.00	5.00	5.00
183 282	2	1	1	0	1	1	2	1	0	1	1	0	0	1	1	0	0	13.00	2.00	3.00
190 282	2	2	2	1	1	0	2	1	0	1	1	1	1	1	2	0	0	18.00	4.00	6.00
191 282	2	1	1	1	1	0	2	1	0	1	1	1	1	1	2	0	0	16.00	4.00	4.00
195 282	1	1	0	0	0	1	3	0	1	1	1	0	0	1	1	0	1	12.00	1.00	3.00
196 282	0	0	0	0	0	0	0	0	0	1	1	0	0	1	2	0	0	5.00	.00	2.00
201 282	1	1	0	1	0	0	2	1	1	0	2	0	0	1	1	1	1	13.00	2.00	3.00
204 282	1	0	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	4.00	.00	1.00
205 282	1	1	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	5.00	.00	1.00
207 282	1	0	0	0	0	0	1	0	1	1	1	0	0	1	1	0	1	8.00	.00	2.00

FCE 20124/702 i

71

Pat.Per. No. (dy)	Items																	Total Score	Factor 1	Factor 2
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17			
212	282	1	1	0	0	0	0	1	1	0	1	1	0	0	0	0	0	6.00	.00	1.00
213	282	1	1	0	0	0	0	1	0	0	1	1	0	0	1	1	0	7.00	.00	2.00
220	282	0	0	0	2	1	2	1	0	1	0	2	0	1	1	1	0	12.00	6.00	1.00
221	282	1	0	0	0	0	0	3	2	0	0	0	0	2	1	0	0	9.00	2.00	.00
229	282	0	0	0	0	0	1	2	1	0	0	1	0	2	1	2	0	10.00	3.00	2.00
234	282	1	0	0	1	1	2	0	0	0	0	0	0	1	2	0	0	8.00	5.00	.00
236	282	1	0	0	0	0	0	0	0	0	1	0	0	2	0	2	0	6.00	2.00	2.00
239	282	0	0	0	1	2	1	0	1	0	0	1	1	0	2	1	0	10.00	5.00	1.00
241	282	2	2	1	1	0	1	2	1	0	1	1	1	1	1	2	0	17.00	4.00	5.00
242	282	2	2	1	0	1	1	2	1	0	1	1	1	1	2	0	0	17.00	4.00	5.00
250	282	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4.00	.00	3.00
252	282	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1.00	.00	.00
253	282	0	0	0	0	0	0	1	0	0	0	1	0	0	1	1	0	4.00	.00	1.00
256	282	2	2	1	0	0	1	2	1	1	1	2	1	1	1	1	0	18.00	3.00	5.00
261	282	3	2	1	1	1	1	3	2	1	1	1	1	1	2	0	0	22.00	5.00	5.00
264	282	3	2	2	1	1	1	3	1	0	1	1	1	1	2	1	0	22.00	6.00	6.00
265	282	2	2	1	1	1	0	3	1	0	1	1	1	1	2	0	0	18.00	4.00	5.00
266	282	2	2	1	1	1	0	2	1	0	1	1	1	1	2	0	0	17.00	4.00	5.00
272	282	1	1	1	0	0	0	1	0	1	1	1	0	0	1	1	0	10.00	.00	4.00

Treatment Group "C"

Day 28 (Period 282)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. Depressed mood	1.11	.11
2. Feelings of guilt	.66	.09
3. Suicide	.38	.07
4. Insomnia, early	.64	.07
5. Insomnia, middle	.47	.07
6. Insomnia, late	.47	.08
7. Work and activities	1.25	.11
8. Retardation	.49	.07
9. Agitation	.27	.06
10. Anxiety, psychic	.71	.08
11. Anxiety, somatic	.86	.08
12. Somatic symptoms, gastrointestinal	.38	.06
13. Somatic symptoms, general	.70	.08
14. Genital symptoms	.78	.07
15. Hypochondriasis	1.04	.11
16. Weight	.05	.03
17. Insight	.12	.04
Total Score	10.40	.74
Factor 1 - Vegetative signs	2.71	.25
Factor 2 - Vital disturbances	2.21	.22

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 5b - Clinical Global Impressions

Treatment Group "A"

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	0	.	.	.
5	0	5	0	0
9	0	4	0	0
12	0	6	0	0
13	0	5	0	0
14	0	4	0	0
25	0	5	0	0
30	0	6	0	0
34	0	5	0	0
35	0	6	0	0
37	0	5	0	0
38	0	5	0	0
45	0	5	0	0
48	0	5	0	0
49	0	4	0	0
50	0	5	0	0
56	0	4	0	0
57	0	4	0	0
64	0	5	0	0
65	0	4	0	0
68	0	5	0	0
72	0	4	0	0
73	0	5	0	0
75	0	6	0	0
79	0	6	0	0
80	0	5	0	0
85	0	4	0	0
87	0	4	0	0
94	0	5	0	0
96	0	5	0	0
99	0	4	0	0
101	0	4	0	0
107	0	5	0	0
108	0	4	0	0
109	0	4	0	0
114	0	6	0	0
115	0	5	0	0
120	0	5	0	0
122	0	6	0	0
123	0	5	0	0
130	0	5	0	0
131	0	6	0	0
134	0	5	0	0

FCE 20124/702 i

2

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
135	0	5	0	0
142	0	4	0	0
146	0	5	0	0
169	0	4	0	0
171	0	6	0	0
176	0	5	0	0
177	0	5	0	0
184	0	4	0	0
185	0	4	0	0
189	0	5	0	0
192	0	3	0	0
194	0	5	0	0
198	0	5	0	0
199	0	5	0	0
200	0	5	0	0
208	0	5	0	0
209	0	5	0	0
211	0	5	0	0
215	0	6	0	0
217	0	5	0	0
222	0	5	0	0
223	0	6	0	0
224	0	5	0	0
231	0	4	0	0
232	0	5	0	0
235	0	5	0	0
240	0	4	0	0
244	0	3	0	0
246	0	4	0	0
247	0	4	0	0
248	0	4	0	0
257	0	5	0	0
258	0	5	0	0
259	0	4	0	0
263	0	4	0	0
267	0	5	0	0
270	0	4	0	0
271	0	5	0	0

FCE 20124/702 i

3

**Treatment Group "A"**

**Baseline (Period 0)**

**Number of Observations = 81**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
1. Severity	4.77	.08
2. Global Improvement	.00	.00
3. Efficacy	.00	.00



FCE 20124/702 i

4

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	4	.	.	.
5	4	5	4	13
9	4	4	4	13
12	4	6	4	13
13	4	5	4	13
14	4	4	4	13
25	4	5	4	13
30	4	6	4	13
34	4	5	4	13
35	4	6	4	13
37	4	5	4	13
38	4	5	4	13
45	4	5	4	13
48	4	5	4	13
49	4	4	4	13
50	4	5	4	14
56	4	4	4	14
57	4	4	4	13
64	4	5	4	13
65	4	4	4	13
68	4	5	4	13
72	4	4	4	13
73	4	5	4	13
75	4	6	4	13
79	4	6	4	13
80	4	5	4	13
85	4	4	4	13
87	4	4	3	9
94	4	5	4	14
96	4	5	4	13
99	4	4	4	13
101	4	4	4	13
107	4	5	3	9
108	4	4	3	10
109	4	4	4	13
114	4	6	4	13
115	4	5	3	9
120	4	5	4	13
122	4	4	2	6
123	4	4	2	5
130	4	7	5	13
131	4	5	3	10
134	4	4	3	9
135	4	5	4	9
142	4	4	2	5
146	4	4	2	5
169	4	4	4	14
171	4	5	4	13
176	4	5	4	14
177	4	5	4	13

FCE 20124/702 i

5

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
184	4	4	4	13
185	4	4	4	14
189	4	5	4	14
192	4	4	4	13
194	4	5	4	16
198	4	5	4	13
199	4	5	4	13
200	4	5	4	13
208	4	5	4	14
209	4	5	4	13
211	4	5	4	13
215	4	6	4	13
217	4	4	3	9
222	4	6	4	13
223	4	6	3	9
224	4	5	4	13
231	4	4	3	10
232	4	5	3	9
235	4	4	3	10
240	4	4	3	9
244	4	3	4	14
246	4	4	4	14
247	4	4	4	14
248	4	4	4	14
257	4	5	4	13
258	4	5	4	13
259	4	4	4	14
263	4	5	5	14
267	4	5	4	13
270	4	4	4	13
271	4	5	4	13

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

6

**Treatment Group "A"**

Day 4 (Period 4)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Severity	4.73	.08
2. Global Improvement	3.77	.06
3. Efficacy	12.22	.25

FCE 20124/702 i

7

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	7	4	4	13
5	7	5	4	13
9	7	4	4	13
12	7	5	4	13
13	7	5	4	13
14	7	4	4	13
25	7	5	3	9
30	7	6	4	13
34	7	5	4	13
35	7	6	4	13
37	7	4	3	9
38	7	4	3	9
45	7	4	3	5
48	7	5	3	9
49	7	4	4	13
50	7	5	4	13
56	7	4	4	14
57	7	3	3	9
64	7	5	4	13
65	7	4	4	13
68	7	5	4	13
72	7	4	4	13
73	7	5	4	13
75	7	6	3	9
79	7	6	4	13
80	7	5	4	13
85	7	4	4	13
87	7	4	3	9
94	7	5	4	14
96	7	5	4	13
99	7	4	3	9
101	7	4	3	9
107	7	4	3	9
108	7	5	5	13
109	7	4	4	13
114	7	4	2	5
115	7	3	2	5
120	7	5	4	13
122	7	4	2	6
123	7	2	1	5
131	7	3	2	6
134	7	3	2	6
135	7	6	6	13
142	7	2	2	5
146	7	4	2	6
169	7	4	4	13
171	7	4	4	13
176	7	5	4	13
177	7	5	4	14
184	7	4	4	13

FCE 20124/702 i

8

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
185	7	4	4	14
189	7	5	5	14
192	7	4	4	13
194	7	5	4	13
198	7	5	4	13
199	7	5	4	13
200	7	5	4	13
208	7	5	4	14
209	7	5	4	13
211	7	5	4	13
215	7	6	4	13
217	7	3	2	5
222	7	5	4	13
223	7	6	4	13
224	7	5	3	9
231	7	4	3	9
232	7	5	3	9
235	7	4	3	10
240	7	3	2	5
244	7	3	4	14
246	7	4	4	14
247	7	4	4	13
248	7	4	4	14
257	7	5	4	13
258	7	5	4	13
259	7	4	4	13
263	7	4	4	13
267	7	5	4	13
270	7	4	4	13
271	7	4	4	13

FCE 20124/702 i

9

**Treatment Group "A"**

Day 7 (Period 7)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Severity	4.43	.10
2. Global Improvement	3.60	.09
3. Efficacy	11.38	.32

270

FCE 20124/702 i

10

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	10	4	4	13
5	10	4	3	10
9	10	4	4	13
12	10	6	4	13
13	10	5	4	13
14	10	4	4	13
25	10	3	2	1
30	10	6	3	9
34	10	5	4	13
35	10	6	4	13
37	10	2	2	5
38	10	2	2	1
45	10	2	2	1
48	10	4	2	5
49	10	4	4	13
50	10	4	3	9
56	10	3	3	9
57	10	3	3	9
64	10	5	4	13
65	10	4	4	13
68	10	5	4	13
72	10	4	4	13
73	10	5	4	13
75	10	6	5	13
79	10	6	4	13
80	10	5	4	13
85	10	4	4	13
87	10	4	3	10
94	10	5	3	10
96	10	5	3	9
99	10	4	3	9
101	10	4	3	9
107	10	4	3	9
108	10	4	3	10
109	10	4	4	13
114	10	4	2	5
115	10	3	2	5
120	10	5	4	13
122	10	5	4	14
123	10	1	1	1
131	10	1	1	2
134	10	6	5	13
135	10	6	5	13
142	10	1	1	1
146	10	3	2	5
169	10	4	4	13
171	10	5	4	13
176	10	4	4	13
177	10	5	4	13
184	10	4	4	13
185	10	4	4	14

271

FCE 20124/702 i

11

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
189	10	4	4	14
192	10	4	4	13
194	10	5	4	13
198	10	5	4	13
199	10	5	4	13
200	10	5	4	14
208	10	5	4	13
209	10	5	4	13
211	10	5	4	13
215	10	6	4	13
217	10	3	2	5
222	10	5	3	9
223	10	6	4	13
224	10	4	2	6
231	10	3	2	5
232	10	5	4	13
235	10	4	3	10
240	10	3	2	6
244	10	3	4	13
246	10	4	4	13
247	10	4	4	13
248	10	4	4	13
257	10	5	4	13
258	10	5	4	13
259	10	4	4	14
263	10	4	4	14
267	10	5	4	13
270	10	4	4	13
271	10	4	3	9

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

12

**Treatment Group "A"**

**Day 10 (Period 10)**

**Number of Observations = 80**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
<b>1. Severity</b>	<b>4.23</b>	<b>.13</b>
<b>2. Global Improvement</b>	<b>3.44</b>	<b>.10</b>
<b>3. Efficacy</b>	<b>10.63</b>	<b>.43</b>

FCE 20124/702 i

13

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	14	4	4	13
5	14	4	3	9
9	14	4	4	13
12	14	5	3	9
13	14	6	5	13
14	14	4	4	13
25	14	2	1	1
30	14	5	3	9
35	14	6	4	13
37	14	2	2	1
38	14	2	2	1
45	14	2	1	1
48	14	2	2	1
49	14	4	4	13
50	14	4	3	9
56	14	3	3	9
57	14	3	3	9
64	14	5	4	13
65	14	4	4	13
68	14	5	4	13
72	14	4	4	13
73	14	5	4	13
75	14	6	4	13
79	14	6	3	9
80	14	5	4	13
85	14	4	3	9
87	14	3	3	10
94	14	4	2	6
96	14	4	3	9
99	14	3	3	10
101	14	3	2	5
107	14	4	5	13
108	14	3	2	6
109	14	4	4	13
114	14	4	3	9
115	14	3	1	1
120	14	4	3	9
122	14	6	4	14
123	14	2	2	1
131	14	1	1	2
134	14	6	5	13
135	14	6	5	13
142	14	1	1	1
146	14	3	2	5
169	14	4	4	13
171	14	5	4	13
176	14	4	4	13
177	14	5	4	14
184	14	4	4	13
185	14	5	5	9
189	14	4	4	13

274

FCE 20124/702 i

14

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
192	14	4	4	13
194	14	5	4	13
198	14	5	4	13
199	14	5	4	13
200	14	5	4	13
208	14	5	4	13
209	14	5	4	9
211	14	5	4	13
215	14	6	4	13
217	14	2	1	2
222	14	4	2	5
224	14	2	2	2
231	14	3	2	5
232	14	5	3	9
235	14	6	5	15
240	14	4	3	10
244	14	3	4	13
246	14	4	4	14
247	14	4	4	13
248	14	3	3	9
257	14	5	4	13
258	14	5	4	13
259	14	4	4	14
263	14	4	4	14
267	14	5	4	13
270	14	3	3	9
271	14	4	3	9

FCE 20124/702 i

15

**Treatment Group "A"**

**Day 14 (Period 14)**

**Number of Observations = 78**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
1. Severity	4.05	.14
2. Global Improvement	3.33	.12
3. Efficacy	9.86	.48

276

FCE 20124/702 i

16

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	21	4	4	13
5	21	3	2	5
9	21	4	4	13
12	21	5	3	9
13	21	6	5	13
14	21	4	4	13
25	21	2	2	1
30	21	5	3	9
35	21	6	4	13
37	21	1	1	1
38	21	2	2	1
45	21	2	2	1
48	21	2	1	1
49	21	3	2	5
50	21	3	2	5
56	21	3	2	5
57	21	3	3	9
64	21	5	4	13
65	21	4	4	13
68	21	4	3	9
72	21	4	4	13
73	21	5	4	13
75	21	6	4	13
79	21	6	4	13
80	21	3	2	5
85	21	3	2	5
87	21	3	2	5
94	21	4	2	6
96	21	4	2	5
99	21	3	3	10
101	21	2	1	2
107	21	5	3	9
108	21	3	2	6
109	21	4	3	13
114	21	5	3	9
115	21	2	1	1
120	21	4	3	9
122	21	6	5	14
123	21	1	1	1
131	21	1	1	2
135	21	4	2	6
142	21	1	1	1
146	21	3	2	6
169	21	4	4	13
171	21	4	4	13
176	21	4	4	13
177	21	4	4	13
184	21	4	4	13
185	21	4	4	14
189	21	4	4	13

277

FCE 20124/702 i

17

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
192	21	5	5	14
194	21	4	4	9
198	21	5	4	13
199	21	4	4	9
200	21	5	4	13
208	21	4	3	9
209	21	4	3	9
211	21	5	4	14
215	21	5	4	13
217	21	2	1	2
222	21	5	4	16
224	21	1	1	1
231	21	3	2	2
232	21	4	3	10
235	21	3	2	6
240	21	2	1	2
244	21	3	4	14
246	21	3	3	14
247	21	3	3	10
248	21	3	3	10
257	21	5	4	13
258	21	5	3	13
259	21	4	4	14
263	21	3	3	10
267	21	4	3	9
270	21	3	3	9
271	21	3	2	5

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

18

**Treatment Group "A"**

Day 21 (Period 21)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Severity	3.65	.14
2. Global Improvement	2.94	.13
3. Efficacy	8.75	.52

FCE 20124/702 i

19

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
1	28	4	4	13
5	28	3	2	5
9	28	4	4	13
12	28	6	4	13
13	28	6	5	13
14	28	4	4	13
25	28	2	1	1
30	28	5	3	9
35	28	6	4	13
37	28	1	1	1
38	28	2	1	1
45	28	2	1	1
48	28	1	1	1
49	28	3	2	5
50	28	3	2	5
56	28	3	2	5
57	28	3	3	9
64	28	5	4	13
65	28	4	4	13
68	28	4	3	9
72	28	4	4	13
75	28	5	3	9
79	28	6	4	13
80	28	2	2	1
85	28	3	2	5
87	28	2	2	6
94	28	3	2	6
96	28	3	2	5
99	28	3	3	11
101	28	2	1	2
107	28	4	4	13
108	28	2	2	2
109	28	4	4	13
114	28	5	3	9
115	28	2	1	2
120	28	4	3	9
123	28	1	1	1
131	28	1	1	2
135	28	2	2	6
142	28	1	1	2
146	28	1	1	1
169	28	4	3	9
171	28	4	4	13
176	28	4	4	13
177	28	4	4	13
184	28	5	5	13
185	28	4	4	14
189	28	4	4	13
192	28	5	5	14
194	28	4	3	3



FCE 20124/702 i

20

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
198	28	5	4	13
199	28	4	3	9
200	28	5	4	13
208	28	4	3	9
209	28	4	3	9
211	28	4	3	9
215	28	5	4	13
217	28	2	1	2
224	28	1	1	1
231	28	3	2	2
235	28	3	2	2
240	28	4	3	9
244	28	3	4	13
246	28	3	3	14
247	28	3	3	9
248	28	3	3	9
257	28	4	3	9
258	28	4	3	9
259	28	3	3	9
263	28	3	3	9
267	28	4	3	10
270	28	2	2	5
271	28	3	2	5

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

21

**Treatment Group "A"**

Day 28 (Period 28)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. Severity	3.40	.15
2. Global Improvement	2.79	.14
3. Efficacy	8.00	.53

FCE 20124/702 i

22

Table 5b - Clinical Global Impressions

Treatment Group "B"

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	0	5	0	0
10	0	5	0	0
11	0	5	0	0
15	0	5	0	0
17	0	6	0	0
28	0	5	0	0
29	0	6	0	0
31	0	5	0	0
32	0	5	0	0
41	0	6	0	0
42	0	6	0	0
44	0	6	0	0
47	0	5	0	0
51	0	5	0	0
54	0	4	0	0
55	0	4	0	0
60	0	4	0	0
61	0	4	0	0
66	0	5	0	0
67	0	4	0	0
70	0	4	0	0
77	0	6	0	0
78	0	5	0	0
83	0	6	0	0
84	0	4	0	0
88	0	3	0	0
90	0	4	0	0
91	0	4	0	0
95	0	4	0	0
98	0	5	0	0
102	0	3	0	0
103	0	4	0	0
106	0	5	0	0
110	0	5	0	0
113	0	4	0	0
118	0	4	0	0
119	0	5	0	0
124	0	6	0	0
126	0	5	0	0
127	0	6	0	0
132	0	6	0	0
133	0	6	0	0
136	0	7	0	0
139	0	7	0	0
140	0	5	0	0
147	0	6	0	0

283

FCE 20124/702 i

23

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
148	0	5	0	0
170	0	6	0	0
172	0	5	0	0
179	0	5	0	0
180	0	4	0	0
181	0	5	0	0
186	0	5	0	0
187	0	5	0	0
188	0	5	0	0
193	0	5	0	0
197	0	5	0	0
202	0	4	0	0
203	0	5	0	0
206	0	5	0	0
210	0	5	0	0
214	0	5	0	0
216	0	5	0	0
218	0	5	0	0
219	0	5	0	0
226	0	4	0	0
227	0	5	0	0
230	0	7	0	0
233	0	6	0	0
237	0	5	0	0
238	0	4	0	0
243	0	5	0	0
245	0	5	0	0
249	0	4	0	0
251	0	5	0	0
254	0	5	0	0
255	0	5	0	0
260	0	4	0	0
262	0	4	0	0
268	0	5	0	0
269	0	6	0	0
273	0	5	0	0

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

24

**Treatment Group "B"**

**Baseline (Period 0)**

**Number of Observations = 82**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
1. Severity	4.96	.09
2. Global Improvement	.00	.00
3. Efficacy	.00	.00

FCE 20124/702 i

25

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	4	5	4	13
10	4	5	4	13
11	4	5	4	13
15	4	5	4	13
17	4	6	4	13
28	4	5	4	13
29	4	6	4	13
31	4	5	4	13
32	4	5	4	13
41	4	6	4	13
42	4	6	4	13
44	4	6	4	13
47	4	5	4	13
51	4	5	4	15
54	4	4	4	13
55	4	4	4	13
60	4	4	4	13
61	4	4	4	13
66	4	5	4	13
67	4	4	4	13
70	4	4	4	13
77	4	6	4	13
78	4	5	4	13
83	4	6	4	13
84	4	4	4	14
88	4	3	4	14
90	4	4	4	14
91	4	4	4	13
95	4	4	3	9
98	4	5	4	13
102	4	3	3	10
103	4	3	3	10
106	4	5	4	13
110	4	5	4	13
113	4	4	4	13
118	4	4	4	13
119	4	5	4	13
124	4	4	2	6
126	4	5	3	10
127	4	3	2	2
132	4	4	2	6
133	4	5	3	11
136	4	5	2	5
139	4	6	3	10
140	4	4	3	10
147	4	6	4	13
148	4	5	4	13
170	4	5	4	13
172	4	5	4	14
179	4	5	4	13

286

FCE 20124/702 i

26

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
180	4	4	4	14
181	4	5	4	14
186	4	5	4	14
187	4	5	4	14
188	4	5	4	14
193	4	5	4	13
197	4	5	4	13
202	4	5	4	13
203	4	5	4	12
206	4	5	4	13
210	4	5	4	16
214	4	5	4	13
216	4	5	4	13
218	4	5	3	10
219	4	5	3	10
226	4	5	4	14
227	4	2	1	2
230	4	7	4	14
233	4	5	3	9
237	4	4	3	10
238	4	4	4	14
243	4	5	4	13
245	4	5	4	14
249	4	4	4	13
251	4	5	4	13
254	4	5	4	13
255	4	5	4	13
260	4	4	4	14
262	4	4	4	13
268	4	5	4	13
269	4	6	4	14
273	4	5	4	13

287

FCE 20124/702 i

27

**Treatment Group "B"**

**Day 4 (Period 4)**

**Number of Observations = 82**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
<b>1. Severity</b>	<b>4.76</b>	<b>.09</b>
<b>2. Global Improvement</b>	<b>3.73</b>	<b>.07</b>
<b>3. Efficacy</b>	<b>12.28</b>	<b>.27</b>



FCE 20124/702 i

28

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	7	5	3	9
10	7	5	4	13
11	7	5	4	13
15	7	5	4	14
17	7	6	4	13
28	7	5	3	9
29	7	6	4	13
31	7	5	3	9
32	7	5	3	9
41	7	5	3	9
42	7	2	1	1
44	7	5	3	9
47	7	5	3	9
51	7	5	4	14
54	7	4	4	13
55	7	4	4	13
60	7	4	4	13
61	7	3	3	9
66	7	5	4	13
67	7	4	4	13
70	7	4	4	13
77	7	6	4	13
78	7	5	4	15
83	7	6	4	13
84	7	4	4	14
88	7	3	3	10
90	7	4	3	10
91	7	4	3	9
95	7	4	3	9
98	7	5	4	14
102	7	3	3	10
103	7	3	2	5
106	7	5	4	14
110	7	4	3	9
113	7	4	3	9
118	7	4	4	14
119	7	5	4	13
124	7	3	2	6
126	7	5	3	10
127	7	1	1	2
132	7	2	1	2
133	7	3	2	6
136	7	5	2	5
139	7	4	2	6
140	7	3	2	6
147	7	6	4	14
148	7	5	4	13
170	7	5	4	13
172	7	5	4	13
179	7	5	4	13

289

FCE 20124/702 i

29

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
180	7	4	4	13
181	7	5	4	14
186	7	5	4	13
187	7	5	4	13
188	7	5	4	13
193	7	5	4	13
197	7	5	4	13
202	7	5	4	13
203	7	5	4	13
206	7	5	4	16
210	7	5	4	16
214	7	5	4	13
216	7	5	4	13
218	7	4	3	10
219	7	5	3	9
226	7	4	3	10
227	7	2	1	1
230	7	6	3	10
233	7	5	4	14
237	7	3	2	6
238	7	4	3	10
243	7	4	4	14
245	7	4	4	13
249	7	4	4	13
251	7	5	4	13
254	7	5	4	14
255	7	5	4	13
260	7	4	4	14
262	7	4	4	14
268	7	5	4	13
269	7	6	4	13
273	7	5	4	13

290

FCE 20124/702 i

30

**Treatment Group "B"**

Day 7 (Period 7)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Severity	4.46	.11
2. Global Improvement	3.43	.09
3. Efficacy	11.15	.38

FCE 20124/702 i

31

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	10	5	3	9
10	10	5	4	14
11	10	5	3	9
15	10	5	3	10
17	10	6	4	13
28	10	5	3	9
29	10	6	4	13
31	10	3	2	5
32	10	3	3	5
41	10	3	2	5
42	10	1	1	1
44	10	5	3	9
47	10	3	2	1
51	10	4	3	10
54	10	4	4	13
55	10	4	4	13
60	10	4	4	13
61	10	3	3	9
66	10	5	4	13
67	10	4	4	13
70	10	4	4	13
77	10	6	3	9
78	10	4	3	11
83	10	6	3	9
84	10	4	3	10
88	10	3	3	10
90	10	3	2	6
91	10	4	3	9
95	10	4	3	9
98	10	4	3	5
102	10	3	3	10
103	10	3	2	5
106	10	5	4	14
110	10	4	3	9
113	10	4	3	9
118	10	4	4	14
119	10	5	4	13
124	10	2	2	6
126	10	3	2	6
127	10	2	2	2
132	10	1	1	2
133	10	5	3	11
136	10	4	2	5
139	10	2	1	2
140	10	2	2	2
147	10	6	4	14
148	10	5	5	13
170	10	5	4	13
172	10	4	4	14
179	10	5	4	13

292

FCE 20124/702 i

32

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
180	10	4	4	13
181	10	4	4	13
186	10	4	4	14
187	10	4	4	13
188	10	4	4	14
193	10	5	4	13
197	10	5	4	13
202	10	5	4	13
203	10	5	4	13
206	10	5	4	13
210	10	5	4	13
214	10	5	4	13
216	10	5	4	13
218	10	4	3	9
219	10	3	2	5
226	10	4	3	10
227	10	2	2	1
230	10	7	6	14
233	10	5	4	14
237	10	4	3	9
238	10	4	2	6
243	10	4	4	14
245	10	4	4	13
249	10	4	4	13
251	10	5	4	9
254	10	5	4	13
255	10	5	4	13
260	10	4	4	14
262	10	4	4	13
268	10	5	4	13
269	10	6	4	14
273	10	4	3	9

FCE 20124/702 i

33

**Treatment Group "B"**

Day 10 (Period 10)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Severity	4.17	.13
2. Global Improvement	3.32	.10
3. Efficacy	10.15	.43

FCE 20124/702 i

34

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	14	5	3	9
10	14	4	3	10
11	14	4	3	9
15	14	4	3	10
17	14	5	3	13
28	14	5	4	13
31	14	2	1	1
32	14	3	2	5
41	14	2	1	1
42	14	1	1	1
44	14	3	2	1
47	14	2	1	1
51	14	4	3	10
54	14	3	3	9
55	14	3	3	9
60	14	4	4	13
61	14	3	3	9
66	14	4	3	9
67	14	4	4	13
70	14	3	3	9
77	14	4	2	5
78	14	4	3	10
83	14	6	4	13
84	14	3	3	10
88	14	3	3	10
90	14	3	2	6
91	14	4	3	9
95	14	2	2	5
98	14	3	2	6
102	14	3	3	10
103	14	2	2	5
106	14	4	3	10
110	14	3	2	6
113	14	3	2	5
118	14	3	2	6
119	14	4	3	9
124	14	2	1	2
126	14	3	2	6
127	14	3	2	6
132	14	4	2	6
133	14	3	2	2
136	14	3	1	1
139	14	4	2	6
140	14	2	1	2
147	14	6	4	14
148	14	4	3	9
170	14	4	3	10
172	14	4	4	13
179	14	4	3	10
180	14	4	4	9

FCE 20124/702 i

35

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
181	14	4	4	14
186	14	4	4	13
187	14	4	3	10
188	14	4	4	14
193	14	4	4	13
197	14	5	4	14
202	14	5	4	14
203	14	5	4	13
206	14	5	3	9
210	14	5	3	9
214	14	5	4	13
216	14	4	3	10
218	14	4	3	6
219	14	6	4	13
226	14	3	2	6
227	14	1	1	1
233	14	6	4	14
237	14	3	1	2
238	14	4	3	6
243	14	4	4	14
245	14	4	4	13
249	14	4	4	13
251	14	4	3	9
254	14	5	3	9
255	14	5	4	13
260	14	4	3	9
262	14	4	4	14
268	14	5	4	13
269	14	5	3	9
273	14	4	3	9

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

36

**Treatment Group "B"**

Day 14 (Period 14)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Severity	3.76	.12
2. Global Improvement	2.86	.11
3. Efficacy	8.69	.45

297

FCE 20124/702 i

37

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	21	4	2	5
10	21	4	3	9
11	21	4	2	5
15	21	3	2	5
17	21	4	2	6
31	21	2	1	1
32	21	2	1	1
41	21	2	1	1
42	21	1	1	1
44	21	2	1	1
47	21	2	1	1
51	21	3	2	1
54	21	3	3	9
55	21	3	3	13
60	21	4	4	13
61	21	3	3	9
66	21	5	4	13
67	21	4	4	13
70	21	3	3	9
77	21	3	2	5
78	21	2	2	2
83	21	6	3	9
84	21	3	3	10
88	21	2	2	6
90	21	3	2	6
91	21	4	3	9
95	21	2	2	5
98	21	2	2	6
102	21	3	3	10
103	21	2	1	1
106	21	4	3	10
110	21	2	1	2
113	21	2	1	1
118	21	2	2	6
119	21	4	3	9
124	21	1	1	2
126	21	3	2	6
127	21	2	2	2
132	21	2	2	6
133	21	1	1	2
136	21	3	1	1
139	21	2	1	2
140	21	1	1	2
148	21	4	3	9
170	21	4	3	10
172	21	3	3	9
179	21	5	4	14
180	21	4	4	13
181	21	3	3	10
186	21	4	4	14

298

FCE 20124/702 i

38

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
187	21	3	3	10
188	21	4	3	10
193	21	4	4	13
197	21	4	3	10
202	21	4	3	9
203	21	5	3	9
206	21	4	3	9
210	21	4	3	9
214	21	4	3	9
216	21	4	3	10
218	21	5	3	9
219	21	5	3	9
226	21	3	2	7
227	21	2	1	1
237	21	2	1	2
238	21	4	2	6
243	21	3	3	13
245	21	3	3	14
249	21	3	3	10
251	21	3	3	9
254	21	4	3	5
255	21	5	4	13
260	21	3	3	9
262	21	3	3	9
268	21	4	3	9
269	21	5	4	10
273	21	3	2	5

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

39

**Treatment Group "B"**

Day 21 (Period 21)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Severity	3.19	.13
2. Global Improvement	2.47	.11
3. Efficacy	7.18	.46

300

FCE 20124/702 i

40

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
2	28	3	2	5
10	28	3	2	5
11	28	3	2	5
15	28	2	2	1
17	28	3	2	2
31	28	2	1	1
32	28	2	1	1
41	28	1	1	1
42	28	1	1	1
44	28	2	1	1
47	28	2	1	1
51	28	3	2	1
54	28	3	2	5
55	28	3	2	5
60	28	4	4	13
61	28	3	3	9
66	28	5	4	13
67	28	4	4	13
70	28	3	2	5
77	28	4	2	5
78	28	2	2	2
83	28	5	3	9
84	28	4	3	9
88	28	2	2	5
90	28	4	3	11
91	28	2	2	5
95	28	2	2	5
98	28	2	1	2
102	28	3	2	6
103	28	2	1	1
106	28	3	3	9
110	28	2	1	10
113	28	2	1	1
118	28	2	1	2
119	28	4	3	9
124	28	1	1	2
126	28	2	1	2
127	28	1	1	2
132	28	1	1	2
133	28	1	1	2
136	28	4	2	5
139	28	1	1	2
140	28	1	1	2
148	28	3	2	6
170	28	4	3	10
172	28	3	3	9
179	28	4	3	9
180	28	4	4	14
181	28	3	3	10
186	28	4	4	13

301

FCE 20124/702 i

41

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
187	28	3	3	9
188	28	4	3	10
193	28	4	4	13
197	28	4	3	12
202	28	4	3	10
203	28	4	3	9
206	28	4	3	9
210	28	4	3	9
214	28	4	3	9
216	28	4	3	10
218	28	6	4	14
219	28	5	3	9
226	28	3	2	6
227	28	1	1	1
237	28	3	2	6
238	28	4	3	10
243	28	3	3	13
245	28	3	3	13
249	28	3	3	9
251	28	2	2	5
254	28	2	2	1
255	28	4	3	9
260	28	4	4	9
262	28	4	4	14
268	28	4	3	9
269	28	4	3	5
273	28	2	2	5

302

FCE 20124/702 i

42

**Treatment Group "B"**

Day 28 (Period 28)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Severity	2.99	.13
2. Global Improvement	2.34	.11
3. Efficacy	6.58	.48

303

FCE 20124/702 i

43

Table 5b - Clinical Global Impressions

Treatment Group "C"

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	0	5	0	0
6	0	5	0	0
8	0	4	0	0
16	0	6	0	0
18	0	4	0	0
26	0	5	0	0
27	0	5	0	0
33	0	6	0	0
36	0	6	0	0
39	0	5	0	0
40	0	5	0	0
43	0	5	0	0
46	0	6	0	0
52	0	4	0	0
53	0	4	0	0
58	0	5	0	0
59	0	5	0	0
62	0	4	0	0
63	0	4	0	0
69	0	4	0	0
71	0	4	0	0
74	0	5	0	0
76	0	5	0	0
81	0	4	0	0
82	0	5	0	0
86	0	6	0	0
89	0	4	0	0
92	0	6	0	0
93	0	6	0	0
97	0	5	0	0
100	0	5	0	0
104	0	4	0	0
105	0	5	0	0
111	0	6	0	0
112	0	5	0	0
116	0	6	0	0
117	0	4	0	0
121	0	5	0	0
125	0	6	0	0
128	0	5	0	0
129	0	7	0	0
137	0	6	0	0
138	0	6	0	0
141	0	6	0	0
145	0	5	0	0
173	0	5	0	0

304



FCE 20124/702 i

43

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
174	0	5	0	0
175	0	5	0	0
178	0	5	0	0
182	0	5	0	0
183	0	4	0	0
190	0	5	0	0
191	0	5	0	0
195	0	5	0	0
196	0	5	0	0
201	0	5	0	0
204	0	5	0	0
205	0	5	0	0
207	0	5	0	0
212	0	5	0	0
213	0	6	0	0
220	0	5	0	0
221	0	6	0	0
225	0	5	0	0
228	0	6	0	0
229	0	5	0	0
234	0	5	0	0
236	0	5	0	0
239	0	5	0	0
241	0	5	0	0
242	0	4	0	0
250	0	5	0	0
252	0	5	0	0
253	0	5	0	0
256	0	5	0	0
261	0	5	0	0
264	0	4	0	0
265	0	5	0	0
266	0	4	0	0
272	0	6	0	0

305

FCE 20124/702 i

44

Treatment Group "C"

Baseline (Period 0)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Severity	5.04	.08
2. Global Improvement	.00	.00
3. Efficacy	.00	.00

FCE 20124/702 i

45

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	4	5	4	13
6	4	5	4	13
8	4	4	4	13
16	4	6	4	13
18	4	4	4	13
26	4	5	4	13
27	4	5	3	9
33	4	6	4	13
36	4	6	4	13
39	4	5	4	13
40	4	5	4	13
43	4	5	4	13
46	4	6	4	13
52	4	4	4	13
53	4	4	4	14
58	4	5	4	13
59	4	5	4	13
62	4	4	4	14
63	4	4	4	14
69	4	4	4	14
71	4	4	4	14
74	4	5	4	13
76	4	5	5	13
81	4	4	3	11
82	4	5	4	13
86	4	6	5	13
89	4	4	4	13
92	4	5	3	9
93	4	6	4	13
97	4	5	4	13
100	4	5	4	13
104	4	4	4	13
105	4	5	4	13
111	4	6	4	14
112	4	5	3	9
116	4	6	4	13
117	4	4	4	13
121	4	3	2	6
125	4	5	3	10
128	4	3	2	5
129	4	5	3	10
137	4	2	2	6
138	4	5	3	10
141	4	4	3	10
145	4	5	3	9
173	4	5	4	13
174	4	5	4	13
175	4	5	4	14
178	4	5	4	14
182	4	5	4	14

307

FCE 20124/702 i

46

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
183	4	4	4	13
190	4	5	4	14
191	4	5	4	14
195	4	5	4	13
196	4	5	4	14
201	4	5	4	13
204	4	5	4	13
205	4	5	4	13
207	4	5	4	13
212	4	5	4	13
213	4	6	4	13
220	4	4	3	9
221	4	6	3	9
225	4	5	5	13
228	4	6	5	13
229	4	5	4	14
234	4	5	3	10
236	4	5	3	10
239	4	5	3	10
241	4	5	4	13
242	4	4	4	14
250	4	5	4	13
252	4	5	4	13
253	4	5	4	13
256	4	5	4	13
261	4	5	4	14
264	4	4	4	13
265	4	5	4	14
266	4	4	4	13
272	4	6	4	14

308

FCE 20124/702 i

47

**Treatment Group "C"**

**Day 4 (Period 4)**

**Number of Observations = 80**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
1. Severity	4.84	.08
2. Global Improvement	3.80	.07
3. Efficacy	12.35	.22

309

FCE 20124/702 i

48

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	7	5	4	13
6	7	5	4	13
8	7	4	4	13
16	7	6	3	9
18	7	4	4	13
26	7	4	3	9
27	7	4	3	9
33	7	5	3	9
36	7	4	2	5
39	7	5	3	9
40	7	4	3	9
43	7	4	2	5
46	7	5	3	9
52	7	4	4	13
53	7	4	4	14
58	7	4	3	9
59	7	5	4	13
62	7	4	4	14
63	7	4	4	14
69	7	4	4	14
71	7	4	4	14
74	7	4	3	9
76	7	5	4	14
81	7	3	2	6
82	7	4	3	10
86	7	5	3	10
89	7	4	3	9
92	7	4	2	6
93	7	6	4	13
97	7	5	3	9
100	7	5	4	13
104	7	4	3	9
105	7	5	4	13
111	7	5	3	9
112	7	4	2	5
116	7	5	3	9
117	7	4	4	14
121	7	3	2	2
125	7	5	3	10
128	7	3	2	5
129	7	5	3	10
137	7	2	2	2
138	7	5	3	10
141	7	3	2	6
145	7	4	3	10
173	7	5	4	13
174	7	5	4	13
175	7	5	4	14
178	7	5	4	14
182	7	4	4	14

310

FCE 20124/702 i

49

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
183	7	4	4	14
190	7	4	4	14
191	7	4	4	13
195	7	5	4	16
196	7	5	4	16
201	7	5	4	13
204	7	5	4	13
205	7	5	4	13
207	7	5	4	13
212	7	5	4	13
213	7	6	4	13
220	7	5	4	13
221	7	4	3	9
225	7	5	3	10
228	7	5	3	9
229	7	3	2	6
234	7	6	4	14
236	7	3	2	6
239	7	5	4	14
241	7	5	4	14
242	7	4	4	13
250	7	5	4	13
252	7	5	4	13
253	7	5	4	13
256	7	5	4	13
261	7	5	4	14
264	7	4	4	13
265	7	5	4	14
266	7	4	4	14
272	7	5	3	9

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

50

**Treatment Group "C"**

**Day 7 (Period 7)**

**Number of Observations = 80**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
1. Severity	4.49	.09
2. Global Improvement	3.43	.08
3. Efficacy	11.08	.36

312



FCE 20124/702 i

51

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	10	5	4	13
6	10	5	4	13
8	10	4	4	13
16	10	5	3	9
18	10	4	3	9
26	10	2	1	1
27	10	3	3	5
33	10	3	2	5
36	10	2	2	1
39	10	2	1	1
40	10	2	1	1
43	10	2	1	1
46	10	4	3	5
52	10	4	4	13
53	10	4	4	14
58	10	4	3	9
59	10	4	3	9
62	10	4	4	14
63	10	4	4	14
69	10	4	4	13
71	10	4	3	9
74	10	3	2	5
76	10	4	3	10
81	10	3	2	6
82	10	4	3	10
86	10	4	2	6
89	10	3	3	9
92	10	2	2	2
93	10	6	4	13
97	10	4	3	9
100	10	4	3	9
104	10	4	3	9
105	10	5	4	14
111	10	4	3	10
112	10	3	2	6
116	10	5	3	9
117	10	4	4	14
121	10	2	1	2
125	10	5	3	10
128	10	3	2	5
129	10	4	2	6
137	10	2	2	2
138	10	4	2	6
141	10	3	1	2
145	10	4	3	10
173	10	5	4	13
174	10	5	4	13
175	10	5	4	13
178	10	4	4	13
182	10	4	3	9

313

FCE 20124/702 i

52

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
183	10	4	4	13
190	10	4	4	14
191	10	4	3	9
195	10	5	4	16
196	10	4	3	12
201	10	5	4	13
204	10	5	4	13
205	10	4	3	9
207	10	5	4	13
212	10	5	4	13
213	10	5	3	10
220	10	4	2	5
221	10	5	3	9
225	10	4	3	10
228	10	6	4	13
229	10	4	3	10
234	10	5	4	13
236	10	4	2	5
239	10	4	2	6
241	10	4	4	13
242	10	4	4	13
250	10	4	3	9
252	10	5	3	9
253	10	5	4	13
256	10	5	4	13
261	10	5	4	14
264	10	4	4	14
265	10	4	4	13
266	10	4	4	14
272	10	5	4	9

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

53

**Treatment Group "C"**

Day 10 (Period 10)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Severity	4.02	.11
2. Global Improvement	3.09	.11
3. Efficacy	9.46	.45

315

FCE 20124/702 i

54

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	14	5	4	13
6	14	5	4	13
8	14	4	4	14
16	14	5	3	9
18	14	4	3	9
26	14	2	1	1
27	14	3	2	1
33	14	3	2	5
36	14	2	1	1
39	14	2	1	1
40	14	2	1	1
43	14	2	1	1
46	14	3	2	1
52	14	3	3	9
53	14	3	3	10
58	14	4	3	9
59	14	4	3	9
62	14	3	3	9
63	14	3	3	9
69	14	3	3	9
71	14	3	2	5
74	14	2	2	6
76	14	2	2	6
81	14	2	2	6
82	14	4	3	10
86	14	4	2	6
89	14	3	3	9
92	14	1	1	2
93	14	6	4	13
97	14	4	2	5
100	14	3	2	5
104	14	4	3	10
105	14	6	5	15
111	14	4	3	10
112	14	2	1	1
116	14	4	2	5
117	14	4	3	10
121	14	3	2	6
125	14	5	3	10
128	14	3	2	5
129	14	4	2	6
137	14	1	1	1
138	14	4	2	6
141	14	2	1	2
145	14	4	2	6
173	14	4	4	10
174	14	5	4	13
175	14	4	3	10
178	14	4	3	9
182	14	3	3	9

316

FCE 20124/702 i

55

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
183	14	3	3	9
190	14	4	4	14
191	14	3	3	9
195	14	4	3	12
196	14	4	3	9
201	14	4	3	9
204	14	4	3	9
205	14	4	3	9
207	14	4	3	9
212	14	4	3	10
213	14	4	3	5
220	14	4	2	6
221	14	5	3	10
225	14	4	3	10
229	14	5	4	14
234	14	4	2	6
236	14	3	2	6
239	14	3	2	5
241	14	4	4	13
242	14	3	3	13
250	14	4	3	9
252	14	4	3	9
253	14	5	3	9
256	14	5	4	13
261	14	5	4	14
264	14	4	4	14
265	14	4	4	14
266	14	4	4	14
272	14	5	4	9

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

317

FCE 20124/702 i

56

**Treatment Group "C"**

**Day 14 (Period 14)**

**Number of Observations = 79**

<b>Variable</b>	<b>Mean</b>	<b>S.E. Mean</b>
<b>1. Severity</b>	<b>3.62</b>	<b>.12</b>
<b>2. Global Improvement</b>	<b>2.73</b>	<b>.11</b>
<b>3. Efficacy</b>	<b>8.14</b>	<b>.44</b>

FCE 20124/702 1

57

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	21	5	3	9
6	21	5	5	13
8	21	4	4	14
16	21	4	2	5
18	21	3	3	9
26	21	2	1	1
27	21	3	2	1
33	21	2	1	1
36	21	1	1	1
39	21	2	1	1
40	21	2	1	1
43	21	1	1	1
46	21	2	2	1
52	21	3	3	9
53	21	3	2	5
58	21	3	2	5
59	21	3	2	5
62	21	3	2	5
63	21	3	3	9
69	21	3	3	9
71	21	3	2	5
74	21	2	2	3
76	21	2	2	2
81	21	2	2	6
82	21	3	2	6
86	21	3	2	6
89	21	3	3	9
92	21	1	1	2
93	21	6	4	13
97	21	3	2	6
100	21	3	2	5
104	21	4	3	10
111	21	4	4	15
112	21	2	1	1
116	21	2	1	1
117	21	3	2	6
121	21	2	1	2
125	21	6	4	14
128	21	2	1	2
129	21	2	2	6
137	21	2	2	2
138	21	4	2	6
141	21	1	1	2
145	21	4	2	6
173	21	4	3	10
174	21	4	3	9
175	21	4	3	9
178	21	3	3	10
182	21	3	3	10
183	21	3	3	10

319

FCE 20124/702 i

58

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
190	21	3	3	10
191	21	2	2	5
195	21	3	3	12
196	21	3	2	5
201	21	4	3	10
204	21	3	2	5
205	21	2	2	9
207	21	3	2	5
212	21	4	3	10
213	21	3	2	5
220	21	4	3	10
221	21	5	3	9
225	21	4	3	9
229	21	4	3	6
234	21	3	2	5
236	21	2	1	2
239	21	3	2	6
241	21	3	3	13
242	21	3	3	13
250	21	3	2	5
252	21	2	2	5
253	21	4	3	5
256	21	5	4	9
261	21	4	4	13
264	21	4	4	13
265	21	4	4	14
266	21	3	3	9
272	21	4	3	10



FCE 20124/702 i

59

**Treatment Group "C"**

Day 21 (Period 21)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Severity	3.09	.12
2. Global Improvement	2.41	.11
3. Efficacy	6.81	.45

321

FCE 20124/702 i

60

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
3	28	4	3	9
6	28	5	5	13
8	28	4	4	14
16	28	3	2	5
18	28	2	2	5
26	28	2	1	1
27	28	2	2	1
33	28	1	1	1
36	28	1	1	1
39	28	2	1	1
40	28	2	1	1
43	28	1	1	1
46	28	2	1	1
52	28	3	3	9
53	28	3	2	5
58	28	3	2	5
59	28	3	2	1
62	28	2	2	5
63	28	2	2	5
69	28	2	2	5
71	28	3	2	5
76	28	1	1	2
81	28	2	2	2
82	28	3	2	5
86	28	2	1	2
89	28	3	3	9
92	28	1	1	2
97	28	3	2	6
100	28	2	1	1
104	28	3	3	9
111	28	5	5	13
112	28	2	1	1
116	28	2	1	1
117	28	2	1	2
121	28	1	1	2
128	28	1	1	2
129	28	2	2	2
137	28	3	2	6
141	28	1	1	2
145	28	4	2	6
173	28	3	2	5
174	28	3	2	5
175	28	3	2	6
178	28	3	3	9
182	28	3	3	10
183	28	2	2	5
190	28	3	3	9
191	28	2	2	6
195	28	2	2	5
196	28	2	2	5

FCE 20124/702 i

61

Pat. No.	Per. (dy)	Severity	Global Improvement	Efficacy
201	28	3	3	5
204	28	2	2	1
205	28	2	2	5
207	28	2	2	5
212	28	3	2	6
213	28	2	2	1
220	28	3	2	5
221	28	4	2	6
229	28	3	2	6
234	28	2	1	1
236	28	2	1	2
239	28	3	2	6
241	28	3	3	9
242	28	3	3	13
250	28	2	2	1
252	28	1	1	1
253	28	2	2	1
256	28	4	3	9
261	28	4	4	14
264	28	4	4	13
265	28	3	3	9
266	28	3	3	10
272	28	3	2	5

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

62

**Treatment Group "C"**

Day 28 (Period 28)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. Severity	2.52	.11
2. Global Improvement	2.07	.11
3. Efficacy	5.04	.44

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08  
 Table 5c - Montgomery Asberg Depression Rating Scale  
 Treatment Group "A"

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	000	2	2	2	2	1	2	1	2	2	0	16.00
5	000	2	2	3	1	1	2	2	1	3	0	17.00
9	000	2	2	2	0	2	1	1	0	2	0	12.00
12	000	1	2	2	2	2	2	2	3	2	1	19.00
13	000	2	2	2	2	1	2	2	2	2	1	18.00
14	000	2	2	2	1	1	2	1	1	2	0	14.00
25	000	2	1	2	2	2	2	2	1	2	1	17.00
30	000	2	2	2	1	2	2	3	2	2	1	19.00
34	000	2	1	2	1	2	2	2	1	1	0	14.00
35	000	2	2	2	1	2	2	2	2	2	1	18.00
37	000	2	2	2	1	2	2	2	2	2	1	18.00
38	000	2	2	2	1	2	2	2	2	2	1	18.00
45	000	2	1	2	2	2	2	2	1	2	1	17.00
48	000	2	1	2	0	2	2	1	1	2	1	14.00
49	000	2	2	2	1	1	2	2	1	1	1	15.00
50	000	2	2	2	2	1	2	2	2	1	1	17.00
56	000	2	2	2	1	1	2	2	1	1	0	14.00
57	000	2	2	2	1	1	2	2	1	1	1	15.00
64	000	2	2	2	1	1	2	2	2	2	1	17.00
65	000	2	2	2	1	2	2	1	2	2	1	17.00
68	000	2	2	2	2	1	2	2	2	2	1	18.00
72	000	2	1	2	0	1	2	1	0	1	0	10.00
73	000	3	2	2	1	2	2	2	2	2	2	20.00
75	000	2	2	2	0	2	2	2	2	2	2	18.00
79	000	2	2	2	2	2	2	2	2	2	2	20.00
80	000	2	2	2	1	2	1	1	1	2	2	16.00
85	000	2	1	2	1	2	2	2	2	2	1	17.00
87	000	2	2	2	0	1	2	1	1	2	1	14.00
94	000	3	2	3	0	2	2	1	2	0	1	16.00
96	000	3	2	3	0	3	2	2	2	2	0	19.00
99	000	2	0	2	1	2	2	1	3	2	2	17.00
101	000	2	1	2	1	2	2	1	2	2	2	17.00
107	000	3	2	3	1	2	2	2	2	3	1	21.00
108	000	2	1	2	1	2	1	1	2	2	1	15.00
109	000	3	2	2	1	2	2	2	3	2	0	19.00
114	000	3	2	3	1	2	2	2	2	3	1	21.00
115	000	3	2	2	2	2	2	1	1	3	2	20.00
120	000	2	1	2	1	2	2	1	1	3	1	16.00
122	000	3	2	2	3	2	3	1	2	2	2	22.00
123	000	2	1	1	0	1	1	2	2	0	1	11.00
130	000	2	2	1	2	2	2	2	2	2	2	19.00
131	000	3	1	2	1	1	2	1	2	3	2	18.00
134	000	2	2	1	2	2	1	2	2	2	2	18.00
135	000	2	1	1	2	1	2	0	0	2	2	13.00

FCE 20124/702 i

2

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
142	000	2	1	2	0	1	2	2	1	2	1	14.00
146	000	1	1	1	0	3	0	0	2	1	0	9.00
169	000	3	1	2	1	2	2	1	1	2	1	16.00
171	000	3	1	3	2	2	2	1	1	2	1	18.00
176	000	3	1	3	2	2	2	1	1	2	1	18.00
177	000	3	1	3	2	2	2	1	1	2	1	18.00
184	000	2	1	3	2	1	2	2	1	2	1	17.00
185	000	3	1	2	2	1	2	2	1	2	1	17.00
189	000	3	1	3	2	2	2	2	1	2	1	19.00
192	000	2	1	2	1	1	1	1	1	1	0	11.00
194	000	2	2	2	1	1	2	1	2	1	1	15.00
198	000	2	2	2	1	1	2	2	2	2	1	17.00
199	000	2	2	2	1	1	2	2	2	2	0	16.00
200	000	2	2	2	1	1	2	2	1	2	0	15.00
208	000	2	2	2	3	2	2	2	2	1	1	19.00
209	000	2	2	2	1	2	2	1	1	2	2	17.00
211	000	2	1	2	1	1	1	1	2	2	1	14.00
215	000	2	2	2	3	2	2	2	2	3	2	22.00
217	000	3	3	2	3	3	3	2	3	3	3	28.00
222	000	3	1	3	0	2	2	0	1	1	2	15.00
223	000	3	3	3	1	2	2	1	2	3	2	22.00
224	000	2	1	2	0	2	2	2	2	1	1	15.00
231	000	1	1	1	0	1	1	1	1	2	0	9.00
232	000	2	1	3	0	1	2	1	1	1	2	14.00
235	000	2	1	3	0	1	2	1	1	2	1	14.00
240	000	2	1	2	1	1	2	1	2	1	1	14.00
244	000	2	1	2	1	1	1	2	1	2	1	14.00
246	000	3	1	2	1	1	2	2	1	2	1	16.00
247	000	2	1	3	2	1	2	1	1	2	1	16.00
248	000	3	1	2	1	1	2	2	1	1	1	15.00
257	000	2	2	2	1	1	2	2	1	1	2	16.00
258	000	2	2	2	1	1	2	2	1	2	0	15.00
259	000	2	1	2	2	1	2	1	1	2	1	15.00
263	000	2	1	3	2	1	1	1	1	2	1	15.00
267	000	2	2	2	1	1	2	2	1	1	1	15.00
270	000	2	2	2	1	1	1	1	1	1	0	12.00
271	000	2	2	2	1	1	2	1	1	1	2	15.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3

Treatment Group "A"

Baseline (Period 000)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Reported sadness	2.21	.05
2. Inner tension	1.57	.06
3. Apparent sadness	2.12	.06
4. Suicidal thoughts	1.17	.09
5. Inertia	1.56	.06
6. Inability to feel	1.86	.05
7. Pessimistic thoughts	1.52	.07
8. Concentration difficulties	1.49	.07
9. Reduced sleep	1.83	.07
10. Reduced appetite	1.06	.08
Total score	16.40	.34

327

FCE 20124/702 i

4

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	042	2	2	2	1	1	2	1	2	2	0	15.00
5	042	2	2	3	1	1	2	2	1	3	0	17.00
9	042	2	2	2	0	2	1	1	0	2	0	12.00
12	042	1	2	2	2	2	2	2	3	2	1	19.00
13	042	2	2	2	2	1	2	2	2	2	1	18.00
14	042	2	2	2	1	1	2	1	1	1	0	13.00
25	042	1	1	2	2	2	2	2	1	2	1	16.00
30	042	2	2	3	1	2	2	2	2	2	1	19.00
34	042	2	2	2	0	2	2	2	2	2	1	17.00
35	042	2	2	2	1	2	2	2	2	2	1	18.00
37	042	2	1	2	1	2	2	2	2	1	1	16.00
38	042	2	2	2	1	1	2	2	2	1	1	16.00
45	042	2	1	2	1	2	2	2	1	2	1	16.00
48	042	2	1	2	0	2	2	1	1	2	1	14.00
49	042	2	2	1	1	1	2	2	2	1	1	15.00
50	042	2	2	2	2	1	2	2	2	2	1	18.00
56	042	2	2	2	0	1	2	2	2	1	0	14.00
57	042	2	1	2	1	1	2	2	1	1	1	14.00
64	042	2	2	2	2	1	2	3	2	2	1	19.00
65	042	2	2	1	2	1	1	1	1	1	1	13.00
68	042	2	2	2	2	1	2	2	2	2	1	18.00
72	042	2	1	1	0	1	0	1	1	1	0	8.00
73	042	3	2	2	1	2	2	1	1	2	2	18.00
75	042	2	2	2	0	2	2	3	2	2	1	18.00
79	042	2	2	3	1	2	2	2	3	3	2	22.00
80	042	2	2	2	0	1	1	1	2	2	2	15.00
85	042	2	1	2	1	2	2	1	1	2	1	15.00
87	042	1	1	1	0	1	1	1	1	1	0	8.00
94	042	3	2	3	0	3	2	2	2	0	0	17.00
96	042	3	2	3	0	2	2	2	2	2	0	18.00
99	042	2	1	2	1	2	2	1	3	2	2	18.00
101	042	2	2	2	1	2	2	0	2	3	1	17.00
107	042	3	2	3	1	2	1	1	1	3	1	18.00
108	042	2	1	2	0	2	1	1	2	1	1	13.00
109	042	3	2	2	1	2	2	2	2	2	0	18.00
114	042	3	2	3	1	2	2	1	1	3	1	19.00
115	042	2	2	2	1	2	2	1	1	3	2	18.00
120	042	2	1	2	1	2	2	1	1	3	1	16.00
122	042	2	1	1	2	1	2	1	2	0	0	12.00
123	042	1	1	1	0	1	0	2	2	1	0	9.00
130	042	4	2	4	4	2	4	2	2	2	2	28.00
131	042	2	1	1	0	0	1	0	2	2	2	11.00
134	042	1	1	1	0	1	1	2	2	2	2	13.00
135	042	2	2	1	2	1	2	0	0	2	0	12.00
142	042	1	1	1	0	1	1	1	1	1	1	9.00
146	042	0	1	0	0	0	0	0	0	0	0	1.00
169	042	2	1	2	1	2	2	1	1	2	1	15.00
171	042	3	1	3	2	2	2	1	1	2	1	18.00
176	042	2	1	3	2	2	2	1	1	2	1	17.00
177	042	3	1	3	2	2	2	1	1	2	1	18.00
184	042	2	1	2	2	1	2	1	1	2	1	15.00



FCE 20124/702 i

5

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
185	042	3	1	2	2	1	2	2	1	2	1	17.00
189	042	3	1	3	2	1	2	2	1	2	1	18.00
192	042	2	1	3	2	1	2	1	1	1	1	15.00
194	042	2	2	2	1	1	2	2	1	1	1	15.00
198	042	2	2	2	1	1	2	2	2	2	1	17.00
199	042	2	2	2	1	1	2	2	2	2	0	16.00
200	042	2	2	2	1	1	2	2	1	2	0	15.00
208	042	2	2	2	2	2	2	2	2	1	1	18.00
209	042	2	2	2	1	2	2	1	1	2	2	17.00
211	042	2	1	2	1	1	1	1	2	2	1	14.00
215	042	2	2	2	2	2	2	2	3	2	2	21.00
217	042	2	2	1	0	1	0	1	1	1	2	11.00
222	042	3	2	3	1	2	2	1	2	3	2	21.00
223	042	2	3	3	0	2	2	0	2	3	2	19.00
224	042	3	2	3	2	1	2	2	2	1	1	19.00
231	042	0	1	2	0	0	1	1	1	2	0	8.00
232	042	2	2	1	0	1	1	1	0	1	2	11.00
235	042	2	1	2	0	1	1	1	1	2	1	12.00
240	042	1	1	2	0	1	2	0	1	0	0	8.00
244	042	2	1	2	1	1	1	2	1	1	0	12.00
246	042	3	1	2	1	1	2	2	1	2	1	16.00
247	042	2	1	2	1	1	2	2	1	2	1	15.00
248	042	3	1	2	1	1	2	1	1	1	1	14.00
257	042	2	2	2	1	1	2	2	1	1	2	16.00
258	042	2	2	2	1	1	2	2	1	2	0	15.00
259	042	2	1	3	1	1	2	1	1	2	1	15.00
263	042	2	1	3	2	1	2	2	1	2	1	17.00
267	042	2	2	2	1	1	2	1	1	1	1	14.00
270	042	2	2	2	1	1	1	1	1	1	0	12.00
271	042	2	2	2	1	1	2	1	1	1	2	15.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

6

Treatment Group "A"

Day 4 (Period 042)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Reported sadness	2.06	.07
2. Inner tension	1.58	.06
3. Apparent sadness	2.06	.08
4. Suicidal thoughts	1.01	.09
5. Inertia	1.38	.06
6. Inability to feel	1.74	.07
7. Pessimistic thoughts	1.43	.07
8. Concentration difficulties	1.42	.07
9. Reduced sleep	1.73	.08
10. Reduced appetite	.94	.08
Total score	15.36	.42

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

7

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	072	2	2	1	1	1	2	1	1	2	0	13.00
5	072	3	2	3	0	1	2	2	1	1	0	15.00
9	072	2	2	2	0	1	1	1	0	2	0	11.00
12	072	1	2	2	2	2	2	2	3	2	1	19.00
13	072	2	2	2	2	1	2	2	2	2	1	18.00
14	072	2	2	2	1	1	2	1	1	1	0	13.00
25	072	1	1	1	1	1	2	2	1	1	0	11.00
30	072	2	2	2	1	2	2	2	2	2	1	18.00
34	072	2	2	2	1	2	2	2	2	2	1	18.00
35	072	2	2	2	1	2	2	2	2	2	1	18.00
37	072	1	1	1	0	2	1	1	1	1	0	9.00
38	072	2	1	1	0	1	2	2	2	1	0	12.00
45	072	1	1	2	1	1	2	2	1	2	0	13.00
48	072	1	1	1	0	1	2	1	1	2	0	10.00
49	072	2	1	2	1	1	2	1	2	1	1	14.00
50	072	2	2	2	2	1	2	2	2	2	1	18.00
56	072	2	2	1	0	1	2	2	2	1	0	13.00
57	072	1	1	1	1	1	2	2	2	1	1	13.00
64	072	2	2	2	2	1	2	2	2	1	1	17.00
65	072	2	1	2	1	1	2	2	1	1	1	14.00
68	072	2	2	2	2	1	2	2	2	1	1	17.00
72	072	2	1	2	0	1	1	1	1	1	0	10.00
73	072	3	2	2	0	2	2	1	1	1	2	16.00
75	072	2	1	2	0	2	2	2	2	2	1	16.00
79	072	3	1	3	2	3	3	3	2	1	1	22.00
80	072	2	1	2	1	1	2	1	1	2	1	14.00
85	072	2	1	2	0	2	1	1	1	2	1	13.00
87	072	1	1	1	0	1	1	1	2	1	0	9.00
94	072	3	1	3	0	2	2	1	2	0	0	14.00
96	072	3	2	3	0	2	2	2	2	2	0	18.00
99	072	2	1	2	0	2	2	1	3	1	0	14.00
101	072	1	1	1	0	2	0	0	1	3	0	9.00
107	072	2	2	2	0	1	2	1	1	2	1	14.00
108	072	3	2	2	0	2	1	1	1	2	1	15.00
109	072	3	2	2	1	2	2	2	2	2	0	18.00
114	072	1	1	2	0	2	2	1	1	1	1	12.00
115	072	1	1	1	0	1	1	0	0	1	1	7.00
120	072	2	1	2	1	2	2	1	1	3	0	15.00
122	072	2	1	1	1	1	2	1	1	1	1	12.00
123	072	0	1	0	0	0	0	1	1	1	0	4.00
131	072	1	0	1	0	0	0	0	2	0	1	5.00
134	072	0	1	0	0	0	1	2	1	2	2	9.00
135	072	3	2	2	2	3	2	2	1	1	0	18.00
142	072	1	1	1	0	0	1	1	1	1	1	8.00
146	072	1	1	1	0	0	1	1	1	1	1	8.00
169	072	2	1	2	1	2	2	1	1	1	1	14.00
171	072	3	1	3	2	2	2	1	1	2	1	18.00
176	072	2	1	3	2	2	2	1	1	2	1	17.00
177	072	3	1	2	2	2	2	1	1	2	1	17.00
184	072	2	1	3	2	1	2	2	1	2	1	17.00
185	072	3	1	2	2	1	2	1	1	2	1	16.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

8

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
189	072	3	1	3	2	1	2	2	1	2	1	18.00
192	072	3	1	3	1	1	2	1	1	1	1	15.00
194	072	2	2	2	1	1	2	1	2	1	1	15.00
198	072	2	2	2	1	1	2	2	2	2	1	17.00
199	072	2	2	2	1	1	2	2	1	2	0	15.00
200	072	2	2	2	1	1	2	2	2	2	0	16.00
208	072	2	2	2	2	2	2	2	2	1	1	18.00
209	072	2	2	2	1	2	1	1	1	2	2	16.00
211	072	2	1	2	1	1	1	1	2	2	1	14.00
215	072	2	2	2	2	2	2	2	2	2	2	20.00
217	072	0	1	1	0	1	0	0	1	1	2	7.00
222	072	3	1	3	2	1	2	1	2	2	1	18.00
223	072	3	3	2	0	2	2	0	2	3	2	19.00
224	072	2	1	3	0	1	2	1	1	2	1	14.00
231	072	1	1	1	0	1	1	1	1	2	0	9.00
232	072	2	2	2	0	1	2	1	0	1	2	13.00
235	072	2	1	2	0	1	2	2	1	3	2	16.00
240	072	1	1	1	0	1	1	0	1	0	0	6.00
244	072	2	1	2	1	1	1	2	1	2	0	13.00
246	072	3	1	2	1	1	2	2	1	2	1	16.00
247	072	2	1	2	1	1	2	2	1	1	1	14.00
248	072	2	1	3	1	1	2	2	1	2	1	16.00
257	072	2	2	2	1	1	2	2	1	1	2	16.00
258	072	2	2	2	1	1	2	2	1	2	0	15.00
259	072	2	1	3	1	1	2	1	1	2	1	15.00
263	072	2	1	2	2	1	2	2	1	2	1	16.00
267	072	2	2	2	1	1	2	2	1	1	1	15.00
270	072	2	2	2	1	1	1	1	1	1	0	12.00
271	072	2	2	2	1	1	2	1	1	1	2	15.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

9

Treatment Group "A"

Day 7 (Period 072)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	1.94	.08
2. Inner tension	1.41	.06
3. Apparent sadness	1.90	.08
4. Suicidal thoughts	.83	.08
5. Inertia	1.29	.07
6. Inability to feel	1.71	.06
7. Pessimistic thoughts	1.40	.07
8. Concentration difficulties	1.34	.07
9. Reduced sleep	1.55	.07
10. Reduced appetite	.79	.07
Total score	14.15	.41

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

10

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	102	2	2	1	0	1	1	1	1	2	0	11.00
5	102	1	2	2	0	1	2	2	1	1	0	12.00
9	102	2	2	1	0	1	1	1	0	2	0	10.00
12	102	1	2	1	2	2	2	2	3	2	1	18.00
13	102	2	2	2	2	1	2	2	2	1	1	17.00
14	102	2	2	2	1	1	2	1	1	1	0	13.00
25	102	1	1	1	0	1	1	1	1	1	0	8.00
30	102	2	2	2	0	2	2	2	2	2	0	16.00
34	102	2	2	2	1	2	2	3	2	2	0	18.00
35	102	2	2	2	1	2	2	2	2	2	1	18.00
37	102	1	1	1	0	1	1	1	1	1	0	8.00
38	102	1	1	1	0	1	1	1	1	1	0	8.00
45	102	1	1	1	0	1	1	1	1	2	0	9.00
48	102	1	1	1	0	1	1	1	1	1	0	8.00
49	102	2	1	2	1	0	1	1	1	1	1	11.00
50	102	2	2	2	1	1	2	2	2	1	1	16.00
56	102	1	1	2	0	1	1	1	1	1	0	9.00
57	102	1	1	1	1	1	1	1	1	1	1	10.00
64	102	2	2	2	2	1	2	2	2	1	1	17.00
65	102	2	2	1	1	1	2	2	1	1	1	14.00
68	102	2	2	2	2	1	2	2	1	1	1	16.00
72	102	2	1	2	0	1	2	1	1	1	0	11.00
73	102	3	2	2	0	2	1	1	1	1	2	15.00
75	102	2	2	2	0	2	1	2	2	2	1	16.00
79	102	3	2	2	2	2	2	3	2	2	1	21.00
80	102	2	2	2	1	1	2	1	0	1	1	13.00
85	102	2	1	2	1	1	1	1	1	2	2	14.00
87	102	1	1	1	0	2	1	1	1	1	0	9.00
94	102	2	1	2	0	2	1	1	2	0	0	11.00
96	102	2	1	2	0	2	1	1	1	2	0	12.00
99	102	1	1	2	0	2	2	1	3	1	0	13.00
101	102	2	1	2	0	2	1	0	1	3	0	12.00
107	102	3	1	3	0	1	1	1	1	2	1	14.00
108	102	2	1	2	0	2	1	1	1	2	1	13.00
109	102	3	2	2	1	2	2	2	2	2	0	18.00
114	102	1	1	2	0	2	2	1	1	1	1	12.00
115	102	1	1	1	0	1	1	0	0	1	0	6.00
120	102	2	1	2	1	2	2	1	1	3	0	15.00
122	102	2	3	2	2	1	2	1	1	0	0	14.00
123	102	0	0	0	0	0	0	0	0	1	0	1.00
131	102	0	0	0	0	0	0	0	1	0	0	1.00
134	102	0	2	2	0	2	2	2	1	3	3	17.00
135	102	2	2	2	2	2	2	2	1	2	1	18.00
142	102	0	0	0	0	0	0	0	1	1	0	2.00
146	102	0	1	1	1	0	0	0	1	0	1	5.00
169	102	2	1	2	1	2	2	1	1	2	0	14.00
171	102	2	1	3	2	2	2	1	2	2	1	18.00
176	102	2	1	3	2	2	2	1	1	1	1	16.00
177	102	3	1	2	1	2	2	1	1	2	1	16.00
184	102	3	1	3	2	1	2	2	1	2	1	18.00
185	102	3	1	2	2	1	2	2	1	2	1	17.00

FCE 20124/702 i

11

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
189	102	3	1	3	2	1	2	1	1	2	1	17.00
192	102	2	1	3	2	1	2	2	1	1	1	16.00
194	102	2	2	2	1	1	2	1	2	1	1	15.00
198	102	2	2	2	1	1	2	2	2	2	1	17.00
199	102	2	2	2	1	1	2	2	2	2	0	16.00
200	102	2	2	2	1	1	2	2	1	2	0	15.00
208	102	2	2	2	2	2	2	2	1	1	1	17.00
209	102	2	2	2	1	1	1	1	1	2	2	15.00
211	102	2	1	2	1	1	1	1	2	2	1	14.00
215	102	2	2	2	2	2	2	2	2	2	2	20.00
217	102	1	2	0	0	0	0	1	0	1	0	5.00
222	102	2	0	2	0	2	2	1	0	3	0	12.00
223	102	2	3	2	0	0	2	0	2	3	2	16.00
224	102	2	1	2	0	0	1	2	0	0	0	8.00
231	102	1	1	1	0	0	0	0	0	1	0	4.00
232	102	2	2	2	0	1	2	2	1	2	2	16.00
235	102	2	1	2	1	1	2	1	0	2	2	14.00
240	102	0	1	1	0	0	1	0	0	1	2	6.00
244	102	2	1	2	1	1	1	2	1	1	0	12.00
246	102	3	1	2	1	1	2	2	1	1	1	15.00
247	102	2	1	2	1	1	2	2	1	1	1	14.00
248	102	2	1	3	1	1	2	2	1	2	1	16.00
257	102	2	2	2	1	1	2	2	1	1	2	16.00
258	102	2	2	2	1	1	2	2	1	2	0	15.00
259	102	2	1	2	1	1	2	2	1	2	1	15.00
263	102	2	1	2	2	1	2	2	1	2	1	16.00
267	102	2	2	2	1	1	2	2	1	1	1	15.00
270	102	2	2	2	1	1	1	1	1	1	0	12.00
271	102	1	2	1	1	1	1	1	1	1	2	12.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

12

Treatment Group "A"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	1.76	.08
2. Inner tension	1.42	.07
3. Apparent sadness	1.79	.07
4. Suicidal thoughts	.79	.08
5. Inertia	1.19	.07
6. Inability to feel	1.51	.07
7. Pessimistic thoughts	1.34	.08
8. Concentration difficulties	1.14	.07
9. Reduced sleep	1.48	.08
10. Reduced appetite	.71	.08
Total score	13.12	.49

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

13

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	142	2	2	1	0	1	1	1	1	1	0	10.00
5	142	1	2	2	0	1	2	2	1	1	0	12.00
9	142	2	1	1	0	1	1	1	0	2	0	9.00
12	142	1	2	1	2	2	2	2	3	2	0	17.00
13	142	2	2	2	2	1	2	2	2	1	1	17.00
14	142	2	2	2	1	1	2	1	1	1	0	13.00
25	142	1	0	0	0	0	0	0	1	1	0	3.00
30	142	2	2	2	0	2	2	2	2	2	1	17.00
35	142	2	2	2	1	2	2	2	2	2	1	18.00
37	142	1	1	0	0	1	0	0	0	1	0	4.00
38	142	1	0	0	0	0	0	1	1	1	0	4.00
45	142	0	1	0	0	1	1	0	0	1	0	4.00
48	142	1	0	0	0	0	1	1	1	1	0	5.00
49	142	1	1	1	1	0	1	1	1	1	0	8.00
50	142	2	1	2	1	0	1	2	2	1	1	13.00
56	142	1	1	1	0	1	2	1	1	1	0	9.00
57	142	1	1	1	1	1	2	1	1	1	1	11.00
64	142	2	2	2	2	1	2	2	2	2	1	18.00
65	142	2	1	2	2	1	2	1	2	1	1	15.00
68	142	2	2	2	2	1	2	2	2	1	1	17.00
72	142	2	1	1	0	1	2	1	1	1	0	10.00
73	142	3	2	2	0	2	1	1	1	1	2	15.00
75	142	1	1	1	0	2	2	1	2	2	0	12.00
79	142	3	2	2	2	2	2	2	2	2	1	20.00
80	142	2	2	1	2	2	2	1	0	1	1	14.00
85	142	2	1	1	0	1	1	1	1	1	1	10.00
87	142	1	1	1	0	2	1	1	1	1	0	9.00
94	142	2	1	2	0	2	0	0	1	0	0	8.00
96	142	2	1	1	0	1	1	1	1	1	0	9.00
99	142	2	1	2	1	1	2	1	2	1	1	14.00
101	142	1	1	1	0	1	0	0	1	2	1	8.00
107	142	3	2	3	1	1	0	1	2	3	1	17.00
108	142	1	1	1	0	1	1	1	1	1	0	8.00
109	142	3	2	2	1	2	2	1	2	2	1	18.00
114	142	2	1	2	1	2	2	1	1	1	1	14.00
115	142	1	1	1	0	1	1	0	0	1	0	6.00
120	142	2	1	2	1	2	2	1	1	2	0	14.00
122	142	2	2	2	2	2	2	2	2	2	0	18.00
123	142	0	0	0	0	1	0	0	0	1	0	2.00
131	142	0	0	0	0	0	0	0	1	0	0	1.00
134	142	3	2	3	1	1	1	2	1	3	3	20.00
135	142	2	2	2	2	1	2	2	1	2	2	18.00
142	142	0	0	0	0	0	0	0	1	0	0	1.00
146	142	0	1	0	0	0	0	0	1	1	0	3.00
169	142	2	1	2	1	2	2	1	1	2	1	15.00
171	142	3	1	3	2	2	2	1	1	2	1	18.00
176	142	2	1	3	1	2	2	1	1	2	1	16.00
177	142	3	1	2	2	2	2	1	1	2	1	17.00
184	142	3	1	3	2	1	2	2	1	2	1	18.00
185	142	3	1	3	2	1	2	2	1	2	1	18.00
192	142	3	1	3	1	1	2	2	1	1	0	15.00

FCE 20124/702 i

14

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
194	142	2	2	2	1	1	2	2	1	1	0	14.00
198	142	2	1	2	1	1	1	2	2	2	1	15.00
199	142	2	2	2	1	1	2	2	1	2	0	15.00
200	142	2	2	2	1	1	2	2	1	2	0	15.00
208	142	2	2	2	2	1	2	2	1	1	1	16.00
209	142	2	2	2	1	1	1	1	1	2	1	14.00
211	142	2	1	2	1	1	1	1	2	2	1	14.00
215	142	2	2	2	2	2	2	2	2	2	2	20.00
217	142	0	1	0	0	0	0	0	0	1	0	2.00
222	142	1	0	1	1	1	1	1	1	2	0	9.00
224	142	0	1	1	0	1	0	0	0	1	0	4.00
231	142	1	1	1	0	0	1	1	1	1	0	7.00
232	142	1	2	1	0	1	2	1	0	1	1	10.00
235	142	2	2	2	2	1	2	2	0	2	1	16.00
240	142	1	1	2	0	1	1	1	0	1	2	10.00
244	142	2	1	2	1	1	1	2	1	1	0	12.00
246	142	3	1	2	1	1	2	2	1	2	1	16.00
247	142	2	1	3	1	1	2	2	1	1	1	15.00
248	142	2	1	2	1	1	1	2	1	1	0	12.00
257	142	2	2	2	1	1	2	2	1	1	2	16.00
258	142	2	2	2	1	1	1	1	1	2	0	13.00
259	142	2	1	2	1	1	2	2	1	1	1	14.00
263	142	2	1	2	1	1	2	1	1	2	1	14.00
267	142	2	2	2	1	1	2	2	1	1	1	15.00
270	142	1	2	1	1	1	1	1	1	1	0	10.00
271	142	1	1	1	1	1	1	1	0	1	1	9.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

15

Treatment Group "A"

Day 14 (Period 142)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Reported sadness	1.70	.09
2. Inner tension	1.29	.07
3. Apparent sadness	1.57	.10
4. Suicidal thoughts	.83	.09
5. Inertia	1.10	.07
6. Inability to feel	1.38	.08
7. Pessimistic thoughts	1.22	.08
8. Concentration difficulties	1.08	.07
9. Reduced sleep	1.39	.07
10. Reduced appetite	.61	.08
Total score	12.17	.58

FCE 20124/702 i

16

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	212	2	2	1	0	1	1	1	1	1	0	10.00
5	212	1	1	1	0	1	1	1	1	0	0	7.00
9	212	2	1	1	0	1	1	2	0	2	0	10.00
12	212	2	2	2	2	2	2	2	3	2	0	19.00
13	212	2	2	2	2	1	2	2	2	1	1	17.00
14	212	2	2	2	1	1	2	1	1	1	0	13.00
25	212	1	0	0	0	0	0	0	1	1	0	3.00
30	212	2	2	2	1	2	2	2	2	2	1	18.00
35	212	2	2	2	1	2	2	2	2	2	1	18.00
37	212	0	1	0	0	1	0	0	0	1	0	3.00
38	212	0	0	0	0	0	0	1	1	1	0	3.00
45	212	1	1	0	0	0	0	0	1	1	0	4.00
48	212	1	0	0	0	0	1	1	1	0	0	4.00
49	212	1	1	1	0	0	0	1	0	0	0	4.00
50	212	1	1	1	0	0	1	1	1	1	0	7.00
56	212	1	1	1	0	0	0	1	0	0	0	4.00
57	212	1	1	1	1	0	2	1	1	1	1	10.00
64	212	2	2	2	2	1	2	2	2	2	1	18.00
65	212	2	1	2	2	1	2	2	1	1	1	15.00
68	212	2	1	1	2	1	2	1	2	1	1	14.00
72	212	2	1	1	0	1	2	1	1	1	0	10.00
73	212	3	2	2	0	2	1	2	1	1	2	16.00
75	212	2	2	2	0	2	2	2	2	2	0	16.00
79	212	2	2	2	2	2	2	2	2	2	1	19.00
80	212	1	1	1	0	1	1	0	0	0	1	6.00
85	212	1	1	1	0	1	1	1	1	1	1	9.00
87	212	1	1	1	0	1	0	0	1	0	0	5.00
94	212	1	1	1	0	1	1	1	1	0	0	7.00
96	212	1	1	1	0	1	1	1	1	1	0	8.00
99	212	1	1	1	0	1	1	0	1	1	0	7.00
101	212	0	0	0	0	0	0	0	1	1	0	2.00
107	212	1	1	2	0	2	2	1	1	2	0	12.00
108	212	0	1	1	1	1	0	1	1	1	1	8.00
109	212	3	2	2	1	2	2	1	1	2	0	16.00
114	212	3	2	2	1	2	2	1	1	2	1	17.00
115	212	1	1	1	0	1	0	0	0	1	0	5.00
120	212	2	1	2	1	2	2	1	1	2	0	14.00
122	212	3	3	3	3	2	2	2	2	3	0	23.00
123	212	0	0	0	0	0	0	0	0	0	0	.00
131	212	0	0	0	0	0	0	0	1	1	0	2.00
135	212	1	1	1	0	1	1	1	1	1	0	8.00
142	212	0	1	0	0	0	0	0	0	0	0	1.00
146	212	1	2	1	0	1	1	0	0	0	0	6.00
169	212	2	1	2	1	2	2	1	1	1	1	14.00
171	212	3	1	2	1	2	2	1	1	2	1	16.00
176	212	2	1	2	1	2	2	1	1	1	1	14.00
177	212	2	1	2	2	1	2	1	1	2	1	15.00
184	212	3	1	2	2	1	2	2	1	2	1	17.00
185	212	3	1	2	2	1	2	1	1	1	1	15.00
189	212	3	1	2	2	1	2	2	1	2	1	17.00
192	212	3	1	3	2	2	2	2	1	2	1	19.00

340

FCE 20124/702 1

17

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
194	212	1	2	1	1	1	2	1	1	1	0	11.00
198	212	2	1	2	1	1	2	2	1	2	1	15.00
199	212	2	2	1	1	1	2	2	1	1	0	13.00
200	212	2	2	2	1	1	2	2	1	2	0	15.00
208	212	1	1	1	1	1	1	1	1	1	0	9.00
209	212	1	1	1	1	1	1	1	1	1	1	10.00
211	212	2	1	2	1	1	1	1	1	1	0	11.00
215	212	2	1	2	2	2	1	2	2	2	2	18.00
217	212	0	1	0	0	0	0	0	0	1	0	2.00
222	212	3	1	3	2	2	2	2	2	2	2	21.00
224	212	0	1	0	0	0	0	0	0	0	0	1.00
231	212	0	1	1	0	0	1	0	0	0	0	3.00
232	212	1	2	2	0	1	1	1	0	1	2	11.00
235	212	0	0	1	0	1	1	1	0	0	0	4.00
240	212	0	1	0	0	0	1	0	0	0	0	2.00
244	212	2	1	2	1	1	1	2	1	1	0	12.00
246	212	2	1	2	1	1	1	1	1	1	1	12.00
247	212	2	1	2	2	1	1	1	1	1	0	12.00
248	212	2	1	2	1	1	1	2	1	1	0	12.00
257	212	1	1	1	1	1	1	1	1	1	1	10.00
258	212	1	1	1	1	1	1	1	1	1	0	9.00
259	212	2	1	2	1	1	2	2	1	1	1	14.00
263	212	2	1	2	1	1	2	1	1	1	0	12.00
267	212	2	2	2	1	1	1	1	1	1	1	13.00
270	212	1	1	1	1	1	1	1	1	0	0	8.00
271	212	1	1	1	1	0	1	0	0	0	0	5.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

18

Treatment Group "A"

Day 21 (Period 212)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. Reported sadness	1.48	.10
2. Inner tension	1.17	.07
3. Apparent sadness	1.35	.09
4. Suicidal thoughts	.77	.09
5. Inertia	1.00	.08
6. Inability to feel	1.22	.09
7. Pessimistic thoughts	1.06	.08
8. Concentration difficulties	.95	.07
9. Reduced sleep	1.08	.08
10. Reduced appetite	.44	.07
Total score	10.52	.64

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

342

FCE 20124/702 i

19

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
1	282	2	2	1	0	1	1	1	1	1	0	10.00
5	282	0	1	0	0	1	1	1	1	0	0	5.00
9	282	2	1	1	0	1	1	2	0	2	0	10.00
12	282	2	2	2	2	2	2	2	3	2	0	19.00
13	282	2	2	2	2	1	2	2	2	1	1	17.00
14	282	2	2	2	1	1	2	1	1	1	0	13.00
25	282	1	0	0	0	0	0	0	1	1	0	3.00
30	282	2	2	2	0	2	2	2	2	2	1	17.00
35	282	2	2	2	1	2	2	2	2	2	1	18.00
37	282	0	1	0	0	1	0	0	0	1	0	3.00
38	282	0	0	0	0	0	0	1	1	1	0	3.00
45	282	0	0	0	0	1	0	1	1	1	0	4.00
48	282	1	0	0	0	0	0	0	1	1	0	3.00
49	282	1	1	1	0	1	1	1	1	1	0	8.00
50	282	1	1	1	0	0	0	1	1	1	0	6.00
56	282	1	1	1	0	1	0	1	1	0	0	6.00
57	282	1	1	2	0	1	2	1	1	1	1	11.00
64	282	2	2	2	2	1	2	2	2	2	1	18.00
65	282	2	1	2	1	1	2	2	1	1	1	14.00
68	282	1	1	2	1	1	2	2	1	1	1	13.00
72	282	2	1	2	0	1	1	1	1	1	0	10.00
75	282	2	1	2	0	2	2	1	2	1	1	14.00
79	282	3	2	2	2	2	2	2	2	2	1	20.00
80	282	1	1	1	0	1	0	0	0	1	1	6.00
85	282	1	1	1	0	1	1	0	1	1	1	8.00
87	282	1	1	1	0	1	0	1	0	1	0	6.00
94	282	1	1	1	0	1	0	0	1	0	0	5.00
96	282	2	1	2	0	1	1	1	1	1	0	10.00
99	282	1	1	1	0	1	1	0	1	1	0	7.00
101	282	0	1	0	0	0	0	0	0	1	0	2.00
107	282	2	2	1	1	2	2	1	2	1	1	15.00
108	282	0	1	1	0	1	0	0	1	1	0	5.00
109	282	3	2	2	1	2	2	1	2	2	0	17.00
114	282	3	2	2	1	2	2	1	1	2	1	17.00
115	282	0	0	0	0	0	0	0	0	0	0	.00
120	282	2	1	2	1	2	2	1	1	2	0	14.00
123	282	0	0	0	0	0	0	0	0	0	0	.00
131	282	0	0	0	0	0	0	0	0	1	1	2.00
135	282	0	1	1	0	1	1	0	1	1	0	6.00
142	282	0	1	0	0	0	0	0	0	0	0	1.00
146	282	0	0	0	0	0	0	0	0	0	1	1.00
169	282	2	1	2	1	2	2	1	1	1	1	14.00
171	282	3	1	2	2	2	2	1	1	2	1	17.00
176	282	2	1	2	1	2	2	1	1	1	1	14.00
177	282	2	1	2	1	2	2	1	1	2	1	15.00
184	282	2	1	3	2	1	2	2	1	2	1	17.00
185	282	3	1	2	1	1	2	2	1	1	1	15.00
189	282	3	1	2	2	2	3	2	1	2	1	19.00
192	282	3	1	2	2	1	2	2	1	1	1	16.00
194	282	1	1	1	1	1	1	1	1	1	0	9.00
198	282	2	1	2	1	1	1	2	2	2	1	15.00

FCE 20124/702 i

20

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
199	282	1	1	1	1	1	2	2	1	1	0	11.00
200	282	2	2	2	1	1	2	2	1	1	0	14.00
208	282	1	1	1	1	0	1	1	0	0	0	6.00
209	282	1	1	1	1	1	1	1	1	1	1	10.00
211	282	2	1	1	1	1	1	2	2	1		13.00
215	282	2	1	2	1	1	1	2	2	2		15.00
217	282	0	1	0	0	1	0	1	0	1	0	4.00
222	282	3	1	3	2	2	2	2	2	2	2	21.00
224	282	0	1	1	0	0	0	0	0	0	0	2.00
231	282	0	1	0	0	0	1	1	1	1	0	5.00
235	282	0	1	0	0	0	1	1	0	0	0	3.00
240	282	2	2	2	0	1	1	2	0	2	1	13.00
244	282	2	1	2	1	1	1	2	1	1	0	12.00
246	282	2	1	2	1	1	1	1	1	1	1	12.00
247	282	2	1	2	1	1	1	1	1	1	0	11.00
248	282	1	1	2	1	1	1	1	1	1	0	10.00
257	282	0	1	1	1	1	1	1	1	0	1	8.00
258	282	1	1	1	1	1	1	1	1	1	0	9.00
259	282	1	1	2	1	1	1	1	1	1	1	11.00
263	282	2	1	1	1	1	1	1	1	2	0	11.00
267	282	1	1	1	1	0	1	1	0	0	0	6.00
270	282	0	1	0	1	0	1	1	1	0	0	5.00
271	282	0	1	0	1	0	1	0	0	0	0	3.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

344



FCE 20124/702 i

21

Treatment Group "A"

Day 28 (Period 282)

Number of Observations = 74

Variable	Mean	S.E. Mean
1. Reported sadness	1.32	.11
2. Inner tension	1.07	.06
3. Apparent sadness	1.26	.10
4. Suicidal thoughts	.66	.08
5. Inertia	.97	.08
6. Inability to feel	1.11	.09
7. Pessimistic thoughts	1.03	.08
8. Concentration difficulties	.97	.08
9. Reduced sleep	1.07	.08
10. Reduced appetite	.45	.06
Total score	9.91	.65

345

FCE 20124/702 i

22

REBOXETINE, Protocol ADE 08

Table 5c - Montgomery Asberg Depression Rating Scale

Treatment Group "B"

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	000	2	2	2	1	1	2	2	1	2	0	15.00
10	000	2	1	2	1	2	1	1	2	1	1	14.00
11	000	2	2	2	1	2	2	2	2	1	1	17.00
15	000	2	2	1	2	2	0	2	2	2	2	17.00
17	000	2	2	2	2	2	2	1	3	2	1	19.00
28	000	2	2	2	1	2	3	3	2	2	0	19.00
29	000	2	1	2	1	2	2	2	1	2	1	16.00
31	000	1	2	2	1	2	2	2	1	1	0	14.00
32	000	2	2	2	2	2	2	1	2	1	1	17.00
41	000	2	2	2	2	2	2	2	1	2	0	17.00
42	000	2	2	2	3	2	2	3	2	3	2	23.00
44	000	2	2	2	1	2	2	2	2	2	1	18.00
47	000	2	2	2	0	2	2	2	1	2	1	16.00
51	000	2	2	2	2	1	2	2	2	2	1	18.00
54	000	1	1	1	1	2	2	1	2	1	0	12.00
55	000	2	1	2	0	1	2	2	2	1	0	13.00
60	000	2	2	2	2	1	2	2	1	1	0	15.00
61	000	2	1	1	1	1	2	2	1	1	0	12.00
66	000	2	2	2	2	2	2	2	2	2	2	20.00
67	000	2	2	2	1	1	2	1	1	1	0	13.00
70	000	2	2	2	2	1	2	2	1	1	1	16.00
77	000	3	1	3	2	2	2	2	3	2	2	22.00
78	000	2	1	2	0	2	2	2	2	2	1	16.00
83	000	3	3	3	0	2	2	2	3	2	0	20.00
84	000	2	1	2	2	1	1	2	1	2	1	15.00
88	000	2	1	1	0	2	2	1	1	2	1	13.00
90	000	2	1	1	1	2	2	1	2	1	1	14.00
91	000	3	2	2	2	2	2	1	1	1	0	16.00
95	000	2	2	3	3	1	1	2	1	1	0	16.00
98	000	3	1	3	1	2	2	0	2	3	2	19.00
102	000	2	2	2	0	1	1	1	1	2	2	14.00
103	000	2	1	2	0	2	2	1	2	1	1	14.00
106	000	2	2	2	1	2	2	2	2	2	2	19.00
110	000	2	1	2	1	2	2	2	1	3	2	18.00
113	000	2	2	2	1	2	2	1	1	2	1	16.00
118	000	2	1	3	1	2	2	1	2	2	2	18.00
119	000	2	1	2	2	2	2	2	2	2	1	18.00
124	000	2	2	1	3	2	2	3	2	1	2	20.00
126	000	2	2	1	1	2	2	2	1	1	2	16.00
127	000	2	1	2	2	2	2	2	2	2	0	17.00
132	000	2	1	2	2	2	1	1	2	2	1	16.00
133	000	2	2	2	2	2	3	3	2	2	1	21.00
136	000	3	2	2	2	1	2	2	2	3	0	19.00
139	000	3	2	3	3	2	3	2	3	3	3	27.00

FCE 20124/702 i

23

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
140	000	1	2	1	1	1	2	0	0	2	1	11.00
147	000	3	3	2	1	2	3	1	2	3	2	22.00
148	000	3	1	2	1	2	2	2	1	2	2	18.00
170	000	3	1	3	2	2	2	1	1	2	1	18.00
172	000	2	1	3	2	2	2	1	1	2	1	17.00
179	000	3	1	3	2	2	2	2	1	2	1	19.00
180	000	3	1	2	2	1	2	1	1	1	1	15.00
181	000	3	1	2	2	1	2	2	1	2	1	17.00
186	000	3	1	3	2	1	2	2	1	2	1	18.00
187	000	3	1	3	2	1	2	1	1	2	1	17.00
188	000	3	1	3	2	1	2	2	1	2	1	18.00
193	000	2	2	2	1	1	2	2	2	2	1	17.00
197	000	2	1	2	1	1	1	1	1	2	0	12.00
202	000	2	2	2	2	1	2	1	2	2	0	16.00
203	000	2	2	2	2	1	2	2	2	2	2	19.00
206	000	2	2	2	2	2	2	2	1	2	1	18.00
210	000	2	2	2	1	1	2	2	2	2	0	16.00
214	000	2	2	2	2	2	2	2	2	2	1	19.00
216	000	2	2	2	2	2	2	2	2	2	0	18.00
218	000	2	2	2	3	2	2	2	2	2	2	21.00
219	000	2	2	2	1	2	2	2	1	3	2	19.00
226	000	1	2	1	0	1	1	2	1	3	2	14.00
227	000	2	1	1	0	1	2	1	0	2	2	12.00
230	000	3	3	3	1	2	2	0	2	2	0	18.00
233	000	3	1	3	0	2	2	2	2	3	2	20.00
237	000	2	2	2	1	0	2	2	0	2	2	15.00
238	000	1	2	1	1	1	2	1	0	2	2	13.00
243	000	3	1	3	1	1	2	2	1	2	1	17.00
245	000	3	1	2	2	1	2	2	1	1	1	16.00
249	000	2	1	3	1	1	2	1	1	1	1	14.00
251	000	2	2	2	1	1	1	2	2	1	0	14.00
254	000	2	2	2	1	1	2	2	1	2	1	16.00
255	000	2	2	2	1	1	2	2	1	1	2	16.00
260	000	2	1	2	1	1	2	2	1	2	1	15.00
262	000	2	1	2	2	1	2	2	1	2	1	16.00
268	000	2	2	2	1	1	1	1	1	2	0	13.00
269	000	2	2	2	2	2	3	2	2	2	2	21.00
273	000	2	2	2	2	2	2	2	2	2	0	18.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

24

Treatment Group "B"

Baseline (Period 000)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Reported sadness	2.17	.06
2. Inner tension	1.62	.06
3. Apparent sadness	2.06	.06
4. Suicidal thoughts	1.40	.09
5. Inertia	1.56	.06
6. Inability to feel	1.93	.05
7. Pessimistic thoughts	1.68	.07
8. Concentration difficulties	1.49	.07
9. Reduced sleep	1.85	.07
10. Reduced appetite	1.04	.09
Total score	16.80	.31

348

FCE 20124/702 i

25

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	042	2	2	2	0	1	2	2	1	2	0	14.00
10	042	2	1	2	1	2	1	1	2	1	1	14.00
11	042	2	2	2	1	2	2	2	2	1	1	17.00
15	042	2	2	1	2	2	0	2	2	2	2	17.00
17	042	2	2	2	2	2	2	1	3	2	1	19.00
28	042	2	1	2	1	2	3	2	2	2	0	17.00
29	042	2	1	2	1	2	2	2	1	2	1	16.00
31	042	1	2	2	1	2	2	2	1	1	0	14.00
32	042	2	2	2	2	2	2	1	2	1	0	16.00
41	042	2	2	2	2	2	2	2	1	2	0	17.00
42	042	2	2	2	2	2	2	2	3	1	1	20.00
44	042	2	2	2	1	2	2	2	2	2	0	17.00
47	042	2	2	2	0	2	2	2	1	1	1	15.00
51	042	2	1	2	2	1	2	2	2	2	1	17.00
54	042	1	1	1	1	2	2	0	2	1	0	11.00
55	042	2	1	2	0	1	2	1	2	1	0	12.00
60	042	2	2	2	1	1	2	2	2	1	0	15.00
61	042	2	1	1	1	1	2	1	1	1	0	11.00
66	042	2	2	2	2	2	2	2	2	2	1	19.00
67	042	2	2	2	1	1	2	2	1	1	0	14.00
70	042	2	2	2	2	1	2	2	1	1	1	16.00
77	042	3	1	3	2	2	2	2	3	2	2	22.00
78	042	2	1	2	1	2	2	2	2	2	1	17.00
83	042	3	3	3	0	3	3	3	3	2	0	23.00
84	042	2	2	2	2	1	1	1	1	2	1	15.00
88	042	2	1	1	0	2	1	1	1	2	1	12.00
90	042	2	1	1	0	2	1	1	2	1	1	12.00
91	042	3	2	2	2	1	2	2	0	1	0	15.00
95	042	1	1	1	1	1	0	1	1	1	0	8.00
98	042	2	2	2	1	2	2	1	2	2	2	18.00
102	042	1	2	1	0	1	1	0	2	1	1	10.00
103	042	1	1	2	0	1	1	1	1	1	1	10.00
106	042	2	2	2	2	2	2	1	2	2	2	19.00
110	042	2	1	2	1	2	2	2	1	3	1	17.00
113	042	2	2	2	1	2	2	1	1	2	1	16.00
118	042	2	1	3	1	2	2	1	2	2	1	17.00
119	042	2	1	3	2	2	2	2	2	2	1	19.00
124	042	1	1	1	1	2	1	2	2	1	1	13.00
126	042	2	1	1	1	1	1	2	1	1	2	13.00
127	042	0	1	1	0	0	0	1	2	2	1	8.00
132	042	1	0	1	1	1	0	1	2	1	1	9.00
133	042	1	1	1	2	2	2	2	2	1	1	15.00
136	042	1	1	1	1	1	2	2	1	2	0	12.00
139	042	2	1	2	2	2	2	2	3	3	3	22.00
140	042	1	1	1	0	1	2	0	0	2	1	9.00
147	042	3	2	2	0	3	3	1	2	3	2	21.00
148	042	3	2	2	0	2	1	0	2	2	2	16.00
170	042	3	1	3	2	2	2	1	1	2	1	18.00
172	042	2	1	3	2	2	2	1	1	2	1	17.00
179	042	3	1	3	2	2	2	1	1	2	1	18.00
180	042	3	1	2	1	1	2	1	1	1	1	14.00

FCE 20124/702 i

26

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
181	042	3	1	3	2	1	2	2	1	2	1	18.00
186	042	3	1	2	2	1	2	2	1	2	1	17.00
187	042	3	1	3	2	1	2	1	1	2	1	17.00
188	042	3	1	3	2	1	2	1	1	2	1	17.00
193	042	2	2	2	1	1	2	2	2	2	1	17.00
197	042	2	1	2	1	1	1	1	1	2	0	12.00
202	042	2	2	2	2	1	2	1	2	2	0	16.00
203	042	2	2	2	2	1	2	2	2	2	2	19.00
206	042	2	2	2	2	1	2	2	1	2	1	17.00
210	042	2	2	2	1	1	2	2	2	2	0	16.00
214	042	2	2	2	2	2	2	2	2	2	1	19.00
216	042	2	2	2	2	2	2	2	2	2	0	18.00
218	042	2	1	2	2	1	2	2	2	3	2	19.00
219	042	2	2	2	1	1	2	2	2	3	2	19.00
226	042	2	2	2	0	2	2	1	1	3	2	17.00
227	042	0	0	0	0	0	0	0	0	0	0	.00
230	042	2	3	3	0	3	2	0	2	2	0	17.00
233	042	3	1	3	0	2	2	1	1	3	1	17.00
237	042	2	1	2	0	0	1	1	0	3	2	12.00
238	042	2	1	1	0	1	1	1	0	2	2	11.00
243	042	3	1	3	1	1	2	2	1	2	1	17.00
245	042	3	1	3	2	1	2	2	1	2	1	18.00
249	042	2	1	3	1	1	2	1	1	1	1	14.00
251	042	2	2	2	1	1	2	2	2	1	0	15.00
254	042	2	2	2	1	1	2	2	1	2	1	16.00
255	042	2	2	2	1	1	2	2	1	1	2	16.00
260	042	2	1	2	1	1	2	2	1	2	1	15.00
262	042	2	1	3	2	1	2	1	1	2	1	16.00
268	042	2	2	2	1	1	1	1	1	2	0	13.00
269	042	2	3	2	2	2	2	2	2	2	2	21.00
273	042	2	2	2	2	2	2	2	2	2	0	18.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

27

Treatment Group "B"

Day 4 (Period 042)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Reported sadness	2.01	.07
2. Inner tension	1.49	.07
3. Apparent sadness	1.99	.07
4. Suicidal thoughts	1.17	.08
5. Inertia	1.49	.07
6. Inability to feel	1.76	.07
7. Pessimistic thoughts	1.48	.07
8. Concentration difficulties	1.49	.08
9. Reduced sleep	1.79	.07
10. Reduced appetite	.91	.08
Total score	15.57	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

28

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	072	2	2	2	0	0	1	1	1	2	0	11.00
10	072	2	1	2	1	2	1	1	2	1	1	14.00
11	072	2	2	2	1	2	2	2	2	1	1	17.00
15	072	2	2	1	1	2	0	2	2	1	1	14.00
17	072	2	2	2	2	2	2	1	3	2	1	19.00
28	072	2	1	2	0	2	2	2	2	2	0	15.00
29	072	2	1	2	1	2	2	2	1	2	1	16.00
31	072	1	1	1	1	1	2	2	1	1	0	11.00
32	072	2	1	1	2	2	1	1	1	1	0	12.00
41	072	1	2	2	1	2	2	1	1	2	0	14.00
42	072	1	0	0	0	1	0	0	1	1	0	4.00
44	072	1	2	2	1	2	2	1	2	2	0	15.00
47	072	2	1	2	0	2	2	2	1	1	0	13.00
51	072	2	2	2	2	1	2	2	2	2	1	18.00
54	072	2	1	1	1	2	2	1	2	1	0	13.00
55	072	2	1	1	0	1	2	1	2	1	0	11.00
60	072	2	2	2	1	1	2	2	1	1	0	14.00
61	072	2	1	1	0	1	2	1	1	1	0	10.00
66	072	2	2	2	2	2	2	2	1	2	1	18.00
67	072	2	2	2	1	1	2	1	1	1	0	13.00
70	072	2	2	2	1	1	2	1	1	1	1	14.00
77	072	3	0	3	2	2	2	2	3	2	2	21.00
78	072	3	1	2	0	1	0	1	2	2	1	13.00
83	072	3	3	3	0	2	2	2	2	2	0	19.00
84	072	2	2	1	1	1	1	1	0	1	0	10.00
88	072	1	1	1	0	1	0	1	1	1	0	7.00
90	072	1	1	1	0	1	1	0	1	0	0	6.00
91	072	2	1	2	1	1	1	2	1	2	0	13.00
95	072	1	1	1	1	1	0	1	1	1	0	8.00
98	072	2	1	2	1	2	2	0	3	2	2	17.00
102	072	1	2	1	0	1	1	0	2	1	2	11.00
103	072	1	1	1	0	1	0	0	1	1	1	7.00
106	072	2	2	2	1	2	2	2	2	2	2	19.00
110	072	2	1	2	1	1	1	1	0	1	0	10.00
113	072	2	2	2	0	2	1	1	1	2	1	14.00
118	072	2	1	3	1	2	2	1	2	2	1	17.00
119	072	2	1	2	1	2	2	2	2	2	1	17.00
124	072	1	1	1	0	1	0	2	2	1	0	9.00
126	072	1	1	1	0	1	1	1	1	1	2	10.00
127	072	0	0	0	0	0	0	0	1	0	1	2.00
132	072	0	0	0	0	1	0	1	1	1	0	4.00
133	072	1	0	0	1	1	0	1	1	2	0	7.00
136	072	2	2	1	1	1	2	3	2	2	0	16.00
139	072	1	1	1	1	2	1	1	2	1	2	13.00
140	072	1	1	1	0	0	1	0	0	1	0	5.00
147	072	3	2	2	0	2	2	0	2	3	2	18.00
148	072	3	1	2	0	2	1	1	2	2	1	15.00
170	072	2	1	3	2	2	2	1	1	2	1	17.00
172	072	2	1	3	2	1	2	1	1	2	1	16.00
179	072	3	1	3	2	2	2	1	1	2	1	18.00
180	072	2	1	2	2	2	2	1	1	1	0	14.00

352



FCE 20124/702 i

29

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
181	072	3	2	2	2	1	2	2	1	2	1	18.00
186	072	3	1	3	2	1	2	2	1	2	1	18.00
187	072	3	1	2	2	1	2	1	1	2	1	16.00
188	072	3	1	2	2	1	2	1	1	2	1	16.00
193	072	2	2	2	1	1	2	2	2	2	1	17.00
197	072	2	2	2	1	1	2	2	1	2	0	15.00
202	072	2	2	2	2	1	2	1	2	2	0	16.00
203	072	2	2	2	2	1	2	2	2	2	2	19.00
206	072	2	2	2	2	1	2	2	1	2	1	17.00
210	072	2	2	2	1	1	2	2	2	1	0	15.00
214	072	2	2	2	1	1	1	2	2	2	1	16.00
216	072	2	2	2	1	1	2	2	2	2	0	16.00
218	072	1	2	1	1	0	1	2	0	2	1	11.00
219	072	2	2	2	0	0	3	1	2	2	0	14.00
226	072	1	1	2	0	1	0	1	0	2	1	9.00
227	072	0	0	0	0	0	0	0	0	0	1	1.00
230	072	3	2	3	0	2	2	0	1	2	0	15.00
233	072	3	1	3	0	3	2	2	0	3	2	19.00
237	072	1	1	0	0	1	1	0	0	3	2	9.00
238	072	2	1	1	0	2	1	1	0	0	2	10.00
243	072	3	1	3	1	1	1	1	1	1	1	14.00
245	072	2	1	3	2	1	2	2	1	2	1	17.00
249	072	2	1	2	2	1	2	2	1	1	1	15.00
251	072	2	2	2	1	1	1	2	1	1	0	13.00
254	072	2	2	2	1	1	2	2	1	2	1	16.00
255	072	2	2	2	1	1	2	2	1	1	2	16.00
260	072	2	1	2	1	1	2	1	1	2	1	14.00
262	072	2	1	3	2	1	2	2	1	2	1	17.00
268	072	2	2	2	1	1	1	1	1	2	0	13.00
269	072	2	2	2	2	2	2	2	2	2	2	20.00
273	072	2	2	2	2	2	2	2	2	2	0	18.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

30

Treatment Group "B"

Day 7 (Period 072)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Reported sadness	1.88	.08
2. Inner tension	1.38	.07
3. Apparent sadness	1.77	.09
4. Suicidal thoughts	.93	.08
5. Inertia	1.30	.07
6. Inability to feel	1.48	.08
7. Pessimistic thoughts	1.30	.08
8. Concentration difficulties	1.30	.08
9. Reduced sleep	1.57	.07
10. Reduced appetite	.73	.08
Total score	13.65	.47

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

31

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	102	2	2	1	0	0	1	1	1	2	0	10.00
10	102	2	1	2	1	1	1	1	2	1	1	13.00
11	102	2	2	1	1	1	2	2	1	1	1	14.00
15	102	1	2	1	1	1	0	2	2	1	1	12.00
17	102	2	2	1	2	2	2	1	3	2	1	18.00
28	102	2	1	1	0	2	2	2	2	2	0	14.00
29	102	2	1	2	1	2	2	2	1	2	1	16.00
31	102	1	1	0	0	1	1	1	1	1	0	7.00
32	102	1	1	1	1	1	1	1	1	1	0	9.00
41	102	1	1	1	1	2	2	1	1	2	0	12.00
42	102	0	0	0	0	0	0	0	0	1	0	1.00
44	102	1	1	1	1	2	2	1	2	2	0	13.00
47	102	1	0	1	0	1	1	1	1	1	0	7.00
51	102	1	1	1	1	1	1	1	1	1	1	10.00
54	102	2	1	1	1	1	2	2	2	1	0	13.00
55	102	2	1	1	0	1	1	2	1	1	0	10.00
60	102	2	2	2	1	1	2	2	1	1	0	14.00
61	102	2	1	1	0	1	2	1	1	1	0	10.00
66	102	2	2	2	2	2	2	2	2	2	1	19.00
67	102	2	2	1	1	1	2	2	1	1	0	13.00
70	102	2	2	2	1	2	2	1	1	1	1	15.00
77	102	2	1	2	2	2	1	2	2	2	2	18.00
78	102	1	1	1	1	1	1	1	1	1	1	10.00
83	102	3	2	3	0	2	2	2	2	2	0	18.00
84	102	1	1	2	1	1	1	0	1	1	0	9.00
88	102	1	1	1	0	1	1	1	1	1	0	8.00
90	102	1	1	1	0	1	1	0	1	0	0	6.00
91	102	1	1	1	1	1	1	2	0	1	0	9.00
95	102	1	1	1	1	0	1	1	1	0	0	7.00
98	102	1	2	1	0	2	1	0	2	2	2	13.00
102	102	1	2	1	0	1	0	0	1	1	1	8.00
103	102	1	1	1	0	1	0	0	1	1	1	7.00
106	102	3	1	3	1	3	1	1	2	1	1	17.00
110	102	2	1	1	1	1	1	1	0	2	0	10.00
113	102	1	2	2	0	2	1	1	1	2	1	13.00
118	102	2	1	3	1	2	2	1	2	2	1	17.00
119	102	2	1	2	1	2	2	2	2	2	1	17.00
124	102	1	1	1	0	1	1	1	1	0	0	7.00
126	102	1	1	0	0	0	1	1	1	1	1	7.00
127	102	1	0	1	1	0	0	0	0	0	1	4.00
132	102	0	0	0	0	1	0	1	1	1	0	4.00
133	102	1	1	1	2	2	2	2	2	1	1	15.00
136	102	1	1	1	1	0	1	2	1	1	0	9.00
139	102	0	1	1	0	1	0	0	1	0	0	4.00
140	102	0	1	0	0	0	1	0	0	1	0	3.00
147	102	3	2	2	0	2	2	1	2	1	2	17.00
148	102	2	1	2	0	1	1	1	2	2	1	13.00
170	102	2	1	3	2	1	2	1	2	2	1	17.00
172	102	2	1	3	2	1	2	1	1	2	1	16.00
179	102	3	1	2	2	2	2	1	1	1	0	15.00
180	102	2	2	2	1	2	2	2	1	2	0	16.00

355

FCE 20124/702 i

32

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
181	102	2	1	3	2	1	2	2	1	2	1	17.00
186	102	3	1	2	2	1	2	2	1	2	1	17.00
187	102	2	1	3	2	1	2	1	1	1	1	15.00
188	102	3	1	2	1	1	2	2	1	1	1	15.00
193	102	2	1	2	1	1	2	2	2	2	0	15.00
197	102	2	1	2	1	1	1	1	1	2	0	12.00
202	102	2	2	2	2	1	2	1	2	2	0	16.00
203	102	2	2	2	2	1	2	2	2	2	2	19.00
206	102	2	2	2	2	1	2	2	1	2	1	17.00
210	102	2	2	2	1	1	2	2	2	1	0	15.00
214	102	2	2	2	1	1	1	2	2	2	1	16.00
216	102	2	2	2	1	1	1	2	2	1	0	14.00
218	102	1	1	1	1	1	2	1	2	2	2	14.00
219	102	0	1	0	0	1	2	1	1	0	0	6.00
226	102	1	2	2	0	1	1	1	1	2	2	13.00
227	102	0	1	0	0	0	0	0	0	0	0	1.00
230	102	3	3	3	0	0	2	0	3	3	0	17.00
233	102	3	1	3	0	1	2	1	1	3	2	17.00
237	102	1	1	1	0	1	1	1	0	2	2	10.00
238	102	0	0	1	0	2	1	1	0	0	2	7.00
243	102	2	1	3	1	1	2	2	1	2	1	16.00
245	102	3	1	3	2	1	2	2	1	2	1	18.00
249	102	2	1	3	1	1	2	2	1	1	1	15.00
251	102	1	1	1	1	1	1	1	1	1	0	9.00
254	102	2	2	2	1	1	2	2	1	2	1	16.00
255	102	2	2	2	1	1	2	2	1	1	2	16.00
260	102	2	1	2	2	1	2	2	1	2	0	15.00
262	102	2	1	2	2	1	2	2	1	2	1	16.00
268	102	2	2	2	1	1	1	1	1	2	0	13.00
269	102	2	2	2	2	2	2	2	2	2	2	20.00
273	102	1	2	1	2	1	2	2	2	1	0	14.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

33

Treatment Group "B"

Day 10 (Period 102)

Number of Observations = 82

Variable	Mean	S.E. Mean
1. Reported sadness	1.61	.09
2. Inner tension	1.28	.07
3. Apparent sadness	1.57	.09
4. Suicidal thoughts	.88	.08
5. Inertia	1.15	.07
6. Inability to feel	1.43	.07
7. Pessimistic thoughts	1.28	.08
8. Concentration difficulties	1.26	.07
9. Reduced sleep	1.39	.08
10. Reduced appetite	.66	.08
Total score	12.50	.50

FCE 20124/702 i

34

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	142	2	1	1	0	0	1	1	0	1	0	7.00
10	142	1	2	1	0	1	0	1	2	1	0	9.00
11	142	2	2	1	1	1	2	2	1	1	1	14.00
15	142	1	2	1	1	1	0	2	2	1	1	12.00
17	142	2	2	1	2	2	2	1	2	2	1	17.00
28	142	2	1	1	0	2	2	2	2	2	0	14.00
31	142	1	0	0	0	1	0	0	1	1	0	4.00
32	142	1	1	1	0	1	1	1	1	1	0	8.00
41	142	1	0	0	0	1	1	1	1	1	0	6.00
42	142	0	0	0	0	0	0	0	0	1	0	1.00
44	142	1	0	0	0	1	1	0	1	1	0	5.00
47	142	1	0	0	0	1	0	0	1	1	0	4.00
51	142	1	1	1	0	0	2	1	1	1	1	9.00
54	142	2	1	1	0	1	1	1	1	1	0	9.00
55	142	2	1	1	0	1	1	1	1	1	0	9.00
60	142	2	2	2	1	1	2	2	2	1	0	15.00
61	142	1	1	1	0	1	2	2	1	1	0	10.00
66	142	2	1	2	1	1	2	2	2	1	1	15.00
67	142	2	2	2	1	1	2	2	1	1	0	14.00
70	142	2	1	1	1	1	2	1	1	1	1	12.00
77	142	1	0	1	1	1	2	2	1	1	1	11.00
78	142	1	0	1	1	1	0	1	1	1	1	8.00
83	142	3	3	3	0	2	2	3	2	2	0	20.00
84	142	1	1	1	0	1	1	1	0	1	0	7.00
88	142	1	2	1	0	1	0	1	1	1	1	9.00
90	142	1	1	1	0	1	1	0	1	1	0	7.00
91	142	3	1	2	1	1	1	2	0	1	0	12.00
95	142	1	1	0	1	1	0	1	1	0	0	6.00
98	142	1	1	0	0	1	1	0	1	2	2	9.00
102	142	2	2	2	0	1	0	0	1	2	1	11.00
103	142	0	1	0	0	0	0	1	1	1	0	4.00
106	142	1	1	1	0	2	1	0	2	1	0	9.00
110	142	2	1	2	0	2	2	1	1	1	0	12.00
113	142	1	1	1	0	2	1	1	1	2	1	11.00
118	142	1	0	1	0	1	1	1	1	1	0	7.00
119	142	2	1	1	1	2	1	1	2	1	1	13.00
124	142	1	1	1	0	0	1	1	0	0	0	5.00
126	142	0	1	1	0	1	1	1	1	0	1	7.00
127	142	2	1	2	1	1	1	1	1	1	1	12.00
132	142	1	1	1	1	1	1	1	2	0	0	10.00
133	142	1	1	0	0	1	1	1	2	0	0	7.00
136	142	1	0	0	1	0	1	1	0	1	0	5.00
139	142	1	2	2	0	1	1	0	2	2	0	11.00
140	142	0	0	0	0	0	1	0	0	2	1	4.00
147	142	3	2	3	0	2	2	2	2	3	2	21.00
148	142	0	1	1	0	1	1	1	2	2	2	11.00
170	142	2	1	2	2	1	2	1	1	2	1	15.00
172	142	2	1	2	1	2	2	1	1	2	1	15.00
179	142	2	1	2	2	1	2	2	1	1	1	15.00
180	142	2	1	2	2	1	2	1	1	1	0	13.00
181	142	2	1	2	2	1	2	2	1	2	1	16.00

358

FCE 20124/702 i

35

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
186	142	3	1	2	2	1	2	1	1	2	1	16.00
187	142	2	1	2	1	1	2	1	1	1	0	12.00
188	142	2	1	3	2	1	2	1	1	1	1	15.00
189	142	2	1	3	2	1	2	1	1	2	1	16.00
193	142	2	1	2	1	2	2	1	1	2	1	15.00
197	142	2	1	2	1	1	1	1	1	2	0	12.00
202	142	2	2	2	2	1	2	1	2	2	0	16.00
203	142	2	2	2	1	1	2	2	2	2	2	18.00
206	142	2	1	1	1	1	1	1	1	1	1	11.00
210	142	1	1	1	1	1	1	1	1	1	0	9.00
214	142	2	2	2	1	1	1	2	2	2	1	16.00
216	142	1	1	1	1	1	1	1	1	1	0	9.00
218	142	1	0	2	2	1	1	1	2	1	2	13.00
219	142	3	3	2	0	0	1	1	2	3	2	17.00
226	142	0	2	1	0	0	1	1	0	2	0	7.00
227	142	0	0	0	0	0	0	1	0	0	0	1.00
233	142	3	1	3	0	2	2	1	1	3	2	18.00
237	142	0	0	0	0	0	0	1	0	1	0	2.00
238	142	1	2	1	0	1	1	0	0	0	2	8.00
243	142	3	1	2	1	1	2	2	1	2	1	16.00
245	142	2	1	2	2	1	2	2	1	1	1	15.00
249	142	2	1	3	1	1	2	2	1	1	1	15.00
251	142	1	1	1	1	1	1	1	1	1	0	9.00
254	142	1	1	2	1	1	1	1	1	1	1	11.00
255	142	2	2	2	1	1	1	2	2	1	1	15.00
260	142	2	1	2	1	1	2	1	1	1	1	13.00
262	142	2	1	3	1	1	2	1	1	2	1	15.00
268	142	2	2	2	1	1	1	1	1	2	0	13.00
269	142	2	2	2	2	2	2	2	1	1	1	18.00
273	142	1	2	1	1	1	1	1	2	1	0	11.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

36

Treatment Group "B"

Day 14 (Period 142)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. Reported sadness	1.51	.09
2. Inner tension	1.12	.08
3. Apparent sadness	1.37	.10
4. Suicidal thoughts	.69	.08
5. Inertia	1.01	.06
6. Inability to feel	1.25	.08
7. Pessimistic thoughts	1.12	.07
8. Concentration difficulties	1.12	.07
9. Reduced sleep	1.30	.07
10. Reduced appetite	.60	.07
Total score	11.10	.50

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

360



FCE 20124/702 i

37

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	212	1	1	1	0	0	1	1	0	1	0	6.00
10	212	0	2	1	0	1	0	1	2	1	0	8.00
11	212	1	2	1	0	1	1	2	1	1	0	10.00
15	212	1	1	1	0	1	0	1	1	1	0	7.00
17	212	1	1	1	1	1	1	1	2	1	0	10.00
31	212	1	0	0	0	1	0	0	1	1	0	4.00
32	212	1	1	0	0	1	0	1	1	1	0	6.00
41	212	1	0	0	0	1	0	0	1	1	0	4.00
42	212	0	0	0	0	0	0	0	0	1	0	1.00
44	212	1	0	0	0	0	1	0	1	1	0	4.00
47	212	1	0	0	0	0	0	0	1	1	0	3.00
51	212	1	1	1	0	0	1	1	1	1	0	7.00
54	212	1	1	1	0	1	1	1	1	1	0	8.00
55	212	1	1	1	0	1	1	1	1	1	0	8.00
60	212	2	1	1	0	1	2	2	2	1	0	12.00
61	212	1	1	1	0	1	2	1	1	1	0	9.00
66	212	2	2	2	2	2	2	2	2	1	1	18.00
67	212	2	1	2	1	1	2	2	2	1	0	14.00
70	212	2	1	1	0	1	2	1	1	1	1	11.00
77	212	2	1	1	2	1	1	1	1	1	1	12.00
78	212	0	1	0	1	1	0	0	1	1	1	6.00
83	212	3	3	3	0	2	2	1	3	2	0	19.00
84	212	1	1	1	1	1	0	0	0	1	0	6.00
88	212	1	1	1	0	1	0	1	0	0	1	6.00
90	212	1	0	1	0	2	1	1	1	1	0	8.00
91	212	1	1	1	1	0	1	1	0	1	0	7.00
95	212	0	1	0	0	1	1	1	1	0	0	5.00
98	212	0	0	0	0	1	0	0	1	1	1	4.00
102	212	1	2	1	0	1	0	0	1	1	1	8.00
103	212	0	0	0	0	0	0	1	0	1	0	2.00
106	212	0	1	1	0	2	1	0	1	1	0	7.00
110	212	1	1	1	0	1	1	0	0	1	0	6.00
113	212	0	0	1	0	1	1	0	1	1	0	5.00
118	212	1	0	1	0	1	1	0	0	1	0	5.00
119	212	2	1	2	1	1	0	1	2	1	1	12.00
124	212	0	0	1	0	0	1	1	0	0	0	3.00
126	212	0	1	1	0	1	1	1	1	1	1	8.00
127	212	0	1	1	0	0	0	0	0	2	0	4.00
132	212	0	1	0	0	1	0	1	1	2	0	6.00
133	212	0	1	0	0	1	1	0	1	0	0	4.00
136	212	1	1	1	1	1	1	1	0	1	0	8.00
139	212	0	1	1	0	0	1	0	1	2	0	6.00
140	212	0	1	0	0	0	1	0	0	1	0	3.00
147	212	3	2	3	0	2	2	2	2	3	2	21.00
148	212	2	1	1	0	2	2	1	2	2	1	14.00
170	212	2	1	2	1	1	2	1	1	2	1	14.00
172	212	2	1	2	1	1	2	1	1	1	1	13.00
179	212	3	1	2	2	1	2	2	1	1	0	15.00
180	212	2	1	2	1	1	2	1	1	1	0	12.00
181	212	2	1	2	1	1	1	1	1	1	1	12.00
186	212	3	1	2	2	1	2	1	1	1	1	15.00

361

FCE 20124/702 i

38

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
187	212	2	1	2	1	1	1	1	1	1	0	11.00
188	212	2	1	2	1	1	2	2	1	1	0	13.00
193	212	2	1	2	1	2	2	1	1	1	1	14.00
197	212	1	1	1	1	1	1	1	1	1	0	9.00
202	212	1	1	1	1	1	1	1	1	1	0	9.00
203	212	1	1	1	1	1	1	1	1	1	1	10.00
206	212	1	1	1	1	1	1	1	0	1	0	8.00
210	212	1	1	1	1	1	1	1	1	1	0	9.00
214	212	1	1	1	1	1	1	1	1	1	1	10.00
216	212	1	1	1	1	1	1	1	1	1	0	9.00
218	212	2	1	2	1	1	2	2	2	0	1	14.00
219	212	1	2	2	0	1	2	1	2	3	0	14.00
226	212	0	1	0	0	0	0	1	0	2	0	4.00
227	212	0	1	0	0	0	0	1	0	0	0	2.00
237	212	0	0	0	0	0	0	0	0	1	0	1.00
238	212	1	1	1	0	1	1	1	0	0	2	8.00
243	212	2	1	2	1	1	2	2	1	1	0	13.00
245	212	2	1	2	1	1	2	2	1	1	1	14.00
249	212	1	1	2	1	1	1	1	1	1	1	11.00
251	212	0	1	1	0	1	1	0	0	0	0	4.00
254	212	1	1	1	1	0	1	1	0	1	0	7.00
255	212	1	1	1	1	1	1	1	1	1	1	10.00
260	212	2	1	2	1	1	1	1	1	1	1	12.00
262	212	2	1	2	1	1	2	1	1	2	1	14.00
268	212	1	2	1	1	1	1	1	1	1	0	10.00
269	212	2	2	2	2	2	2	2	2	2	2	20.00
273	212	0	1	1	1	0	1	1	1	0	0	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

39

Treatment Group "B"

Day 21 (Period 212)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Reported sadness	1.10	.10
2. Inner tension	.97	.06
3. Apparent sadness	1.10	.08
4. Suicidal thoughts	.53	.07
5. Inertia	.90	.06
6. Inability to feel	1.03	.08
7. Pessimistic thoughts	.90	.07
8. Concentration difficulties	.92	.07
9. Reduced sleep	1.05	.07
10. Reduced appetite	.37	.06
Total score	8.87	.50

FCE 20124/702 i

40

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
2	282	1	1	1	0	0	0	0	0	1	0	4.00
10	282	0	2	1	0	1	0	1	2	1	0	8.00
11	282	1	1	1	0	1	1	1	1	1	0	8.00
15	282	0	1	0	0	1	0	1	1	1	0	5.00
17	282	0	1	1	0	1	1	1	1	1	0	7.00
31	282	1	0	0	0	0	0	0	1	1	0	3.00
32	282	0	1	0	0	0	0	0	1	1	0	3.00
41	282	1	0	0	0	0	0	0	1	1	0	3.00
42	282	0	0	0	0	0	0	0	0	1	0	1.00
44	282	1	0	0	0	0	0	0	1	1	0	3.00
47	282	1	0	0	0	0	0	0	1	1	0	3.00
51	282	1	0	1	0	0	0	0	1	1	0	4.00
54	282	1	1	1	0	1	0	1	1	1	0	7.00
55	282	1	1	1	0	1	1	1	1	1	0	8.00
60	282	1	2	2	1	1	2	2	2	1	0	14.00
61	282	1	1	2	0	1	1	1	1	1	0	9.00
66	282	2	2	2	2	1	2	2	2	1	1	17.00
67	282	2	2	1	0	1	2	2	2	1	0	13.00
70	282	1	1	0	0	1	1	1	0	1	1	7.00
77	282	1	1	2	2	1	1	2	1	1	1	13.00
78	282	0	1	0	0	1	1	1	1	1	1	7.00
83	282	2	2	2	0	2	1	1	2	1	0	13.00
84	282	1	2	2	0	2	2	1	1	1	0	12.00
88	282	0	1	1	0	0	0	0	0	0	0	2.00
90	282	2	1	1	0	2	1	1	1	0	0	9.00
91	282	1	1	1	0	0	0	1	0	1	0	5.00
95	282	0	1	0	0	1	1	1	1	0	0	5.00
98	282	0	1	0	0	0	0	0	0	2	0	3.00
102	282	0	1	1	0	1	0	0	1	1	1	6.00
103	282	0	0	0	0	1	0	0	0	1	0	2.00
106	282	0	1	1	0	2	1	1	1	1	0	8.00
110	282	0	0	0	0	0	0	0	0	0	0	.00
113	282	0	0	1	0	1	1	0	1	1	0	5.00
118	282	0	0	0	0	1	0	0	0	0	0	1.00
119	282	2	1	2	1	1	0	1	2	1	1	12.00
124	282	0	1	1	0	0	0	0	0	0	0	2.00
126	282	0	1	1	0	0	0	1	1	1	1	6.00
127	282	0	1	1	0	0	0	0	1	0	0	3.00
132	282	0	0	0	0	1	0	0	1	0	0	2.00
133	282	0	0	0	0	1	0	0	1	0	1	3.00
136	282	1	2	2	0	0	2	1	0	1	0	9.00
139	282	0	1	1	0	0	0	0	1	0	0	3.00
140	282	0	1	0	0	0	1	0	0	1	0	3.00
147	282	3	2	3	0	2	2	2	2	3	2	21.00
148	282	0	1	0	0	0	0	1	1	0	0	3.00
170	282	2	1	2	1	1	1	1	1	1	0	11.00
172	282	2	1	1	1	1	2	1	1	1	1	12.00
179	282	2	1	2	1	1	2	1	1	1	1	13.00
180	282	2	1	2	1	1	2	1	1	1	0	12.00
181	282	2	1	2	1	1	1	1	1	1	1	12.00
186	282	2	1	2	2	1	2	2	1	1	1	15.00

FCE 20124/702 i

41

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
187	282	1	1	2	1	1	2	1	1	1	0	11.00
188	282	2	1	2	1	1	2	2	1	1	1	14.00
193	282	2	1	2	1	2	2	1	1	1	1	14.00
197	282	1	1	1	1	1	1	1	0	1	0	8.00
202	282	1	1	1	1	1	1	1	1	0	0	9.00
203	282	0	1	1	1	1	1	1	1	1	1	9.00
206	282	1	1	1	1	1	1	1	0	0	0	7.00
210	282	1	1	1	1	1	1	1	0	1	0	8.00
214	282	1	1	1	1	1	1	1	1	1	1	10.00
216	282	1	1	1	1	1	1	1	1	0	0	9.00
218	282	3	2	3	2	2	2	2	1	1	2	20.00
219	282	2	2	2	0	0	2	1	2	2	0	13.00
226	282	0	1	0	0	1	1	1	0	1	0	5.00
227	282	0	0	0	0	0	0	0	0	0	0	.00
237	282	0	1	0	0	0	0	1	1	2	0	5.00
238	282	2	2	2	0	1	2	1	0	1	2	13.00
243	282	2	1	2	1	1	1	2	1	1	0	12.00
245	282	1	1	1	1	1	1	2	1	1	0	10.00
249	282	1	1	2	1	1	1	1	1	1	0	10.00
251	282	0	0	0	0	0	1	0	0	0	0	1.00
254	282	0	1	0	0	0	0	1	0	0	0	2.00
255	282	0	1	1	1	0	1	1	1	1	1	8.00
260	282	2	1	2	1	1	1	1	1	1	0	11.00
262	282	2	1	2	1	1	2	2	1	1	1	14.00
268	282	0	1	1	1	1	1	0	0	1	0	6.00
269	282	1	1	1	1	1	1	1	1	1	1	10.00
273	282	0	1	0	0	0	1	0	0	0	0	2.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

42

Treatment Group "B"

Day 28 (Period 282)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Reported sadness	.87	.10
2. Inner tension	.96	.06
3. Apparent sadness	1.03	.09
4. Suicidal thoughts	.42	.07
5. Inertia	.76	.07
6. Inability to feel	.85	.09
7. Pessimistic thoughts	.82	.07
8. Concentration difficulties	.82	.07
9. Reduced sleep	.86	.06
10. Reduced appetite	.32	.06
Total score	7.71	.54

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

43

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	000	2	1	2	1	2	2	2	2	2	0	16.00
6	000	2	2	2	2	2	2	2	1	2	2	19.00
8	000	2	1	2	0	2	1	1	1	1	1	12.00
16	000	3	3	2	2	2	2	1	2	1	1	19.00
18	000	2	2	2	0	1	1	2	2	1	0	13.00
26	000	2	2	1	0	2	2	1	1	2	1	14.00
27	000	1	1	2	0	2	2	2	2	2	1	15.00
33	000	1	2	2	2	3	2	2	2	3	1	20.00
36	000	2	2	2	1	2	2	2	2	2	1	18.00
39	000	1	1	2	2	2	2	2	2	2	1	17.00
40	000	2	2	2	0	2	2	2	2	2	0	16.00
43	000	2	2	2	1	2	2	2	2	2	1	18.00
46	000	2	1	2	3	2	2	2	2	2	1	19.00
52	000	2	1	2	1	1	1	2	1	1	1	13.00
53	000	2	2	2	1	1	2	2	1	1	1	15.00
58	000	2	2	2	2	1	2	2	2	2	2	19.00
59	000	2	2	2	2	2	2	3	2	2	0	19.00
62	000	2	2	2	1	1	2	2	1	1	1	15.00
63	000	2	2	2	1	1	2	2	1	1	0	14.00
69	000	2	2	1	0	1	2	2	2	1	0	13.00
71	000	1	1	1	0	1	1	2	1	2	0	10.00
74	000	2	1	2	0	2	2	1	1	2	2	15.00
76	000	1	1	2	0	2	2	1	2	2	1	14.00
81	000	2	2	2	2	2	2	1	1	2	0	16.00
82	000	3	2	2	2	3	2	1	2	2	2	21.00
86	000	2	2	2	2	2	2	3	2	2	2	21.00
89	000	1	1	1	1	1	1	0	2	3	2	13.00
92	000	3	2	3	2	2	2	2	2	1	0	19.00
93	000	3	2	3	2	3	2	1	2	2	1	21.00
97	000	3	2	2	2	1	2	2	3	3	2	22.00
100	000	3	1	2	2	2	1	1	2	2	2	18.00
104	000	3	1	3	1	2	3	2	2	1	1	19.00
105	000	3	2	3	1	2	2	2	2	2	2	21.00
111	000	3	1	3	2	2	2	1	1	3	1	19.00
112	000	2	2	2	2	2	2	1	3	2	2	20.00
116	000	3	2	3	2	2	2	2	2	3	2	23.00
117	000	2	1	2	1	2	1	1	2	1	2	15.00
121	000	2	2	1	1	2	2	2	2	2	1	17.00
125	000	3	3	3	1	2	3	2	3	2	2	24.00
128	000	2	1	1	2	2	2	1	1	1	2	15.00
129	000	3	1	3	3	1	2	2	2	2	2	21.00
137	000	2	2	2	2	2	2	0	1	3	3	19.00
138	000	3	2	3	0	2	2	2	2	3	2	21.00
141	000	3	2	2	1	1	2	2	2	2	1	18.00
145	000	3	3	2	0	2	3	2	1	3	2	21.00
173	000	3	1	3	2	2	2	1	1	2	1	18.00
174	000	3	1	2	2	2	2	1	1	2	1	17.00
175	000	3	1	3	2	2	2	1	1	2	1	18.00
178	000	3	1	2	2	2	2	2	1	2	1	18.00
182	000	3	1	3	2	2	2	2	1	2	1	19.00
183	000	3	1	2	2	1	2	2	1	2	1	17.00

367

FCE 20124/702 i

44

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
190	000	3	1	3	2	1	2	2	1	2	1	18.00
191	000	3	1	3	2	2	2	1	1	2	1	18.00
195	000	2	2	2	1	1	2	2	2	1	2	17.00
196	000	2	2	2	1	1	1	1	1	1	1	13.00
201	000	2	2	2	1	1	2	2	2	3	1	18.00
204	000	2	2	2	2	1	2	2	1	2	0	16.00
205	000	2	2	2	1	1	2	2	1	1	1	15.00
207	000	2	2	2	1	2	1	2	1	3	0	16.00
212	000	2	2	2	2	2	2	2	2	2	2	20.00
213	000	2	2	2	3	2	2	3	2	3	2	23.00
220	000	2	2	2	1	1	2	1	0	3	2	16.00
221	000	3	1	3	0	2	2	2	1	0	2	16.00
225	000	2	2	2	0	1	1	1	2	3	2	16.00
228	000	2	3	3	2	2	2	1	0	3	1	19.00
229	000	3	1	3	1	2	2	2	2	1	2	19.00
234	000	2	1	3	1	1	2	2	1	3	2	18.00
236	000	2	1	3	1	1	2	2	0	3	1	16.00
239	000	2	1	2	1	2	1	2	0	2	2	15.00
241	000	3	1	3	2	1	2	1	1	2	1	17.00
242	000	3	1	2	1	1	1	1	1	2	1	14.00
250	000	2	2	2	1	1	1	2	1	2	1	15.00
252	000	2	2	2	2	1	2	1	1	2	0	15.00
253	000	2	1	2	2	1	2	2	1	2	1	16.00
256	000	2	2	2	1	1	2	2	1	2	1	16.00
261	000	2	1	3	2	1	2	2	1	2	1	17.00
264	000	2	1	3	2	1	2	1	1	2	1	16.00
265	000	2	1	3	2	1	2	1	1	2	1	16.00
266	000	2	1	3	2	1	2	1	1	2	1	16.00
272	000	2	2	2	2	2	2	2	2	3	2	21.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

45

Treatment Group "C"

Baseline (Period 000)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	2.26	.07
2. Inner tension	1.60	.07
3. Apparent sadness	2.22	.06
4. Suicidal thoughts	1.38	.09
5. Inertia	1.63	.06
6. Inability to feel	1.88	.05
7. Pessimistic thoughts	1.66	.07
8. Concentration difficulties	1.44	.07
9. Reduced sleep	2.00	.08
10. Reduced appetite	1.21	.08
Total score	17.28	.31

FCE 20124/702 i

46

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	042	2	1	2	1	2	2	2	2	2	0	16.00
6	042	2	2	2	2	2	2	2	1	2	2	19.00
8	042	2	1	2	0	2	1	1	1	1	1	12.00
16	042	3	3	2	2	2	2	1	2	1	1	19.00
18	042	2	2	2	0	1	1	2	2	1	0	13.00
26	042	2	1	1	0	2	2	1	1	2	0	12.00
27	042	1	1	2	0	1	2	2	2	2	0	13.00
33	042	1	2	2	2	2	2	2	2	2	1	18.00
36	042	2	1	2	1	2	2	2	2	2	1	17.00
39	042	1	1	2	1	2	2	2	2	2	1	16.00
40	042	2	2	2	0	2	2	2	2	2	0	16.00
43	042	2	2	2	1	2	2	2	2	2	0	17.00
46	042	2	1	2	2	2	2	2	2	2	1	18.00
52	042	1	2	2	1	1	2	2	1	1	1	14.00
53	042	2	1	2	1	1	2	2	1	1	1	14.00
58	042	2	2	2	2	2	2	2	2	2	1	19.00
59	042	2	2	2	2	2	2	2	2	2	0	18.00
62	042	2	1	2	1	1	2	2	1	1	1	14.00
63	042	2	1	2	1	1	2	2	1	1	0	13.00
69	042	2	1	2	0	1	2	1	1	1	0	11.00
71	042	1	1	1	0	1	2	2	1	2	0	11.00
74	042	2	2	2	0	2	2	1	1	2	1	15.00
76	042	1	2	2	0	1	2	1	2	2	1	14.00
81	042	1	2	1	1	1	0	1	2	2	0	11.00
82	042	2	1	2	1	2	2	1	2	2	2	17.00
86	042	2	2	2	2	2	2	3	2	2	1	20.00
89	042	1	1	1	0	1	1	0	1	3	1	10.00
92	042	2	1	2	1	1	1	1	1	1	0	11.00
93	042	3	2	3	2	3	2	1	2	2	1	21.00
97	042	2	2	2	2	1	1	2	2	3	2	19.00
100	042	3	1	2	1	2	1	1	2	2	2	17.00
104	042	3	1	3	1	2	3	2	2	1	1	19.00
105	042	3	2	2	1	2	2	2	2	2	2	20.00
111	042	3	1	3	2	2	2	1	1	3	1	19.00
112	042	1	1	2	1	2	2	1	1	3	1	15.00
116	042	3	2	3	2	2	2	2	2	3	0	21.00
117	042	3	1	2	1	2	1	1	2	1	1	15.00
121	042	1	0	0	0	0	1	1	2	2	0	7.00
125	042	2	2	2	1	2	3	2	2	1	1	18.00
128	042	1	0	1	0	0	0	0	1	1	2	6.00
129	042	2	1	1	2	1	2	1	2	2	2	16.00
137	042	1	1	1	0	1	1	0	0	0	2	7.00
138	042	2	2	2	0	2	2	1	2	2	1	16.00
141	042	2	1	1	0	1	1	2	2	2	1	13.00
145	042	1	0	1	0	1	1	1	1	3	1	10.00
173	042	3	1	3	2	2	2	1	1	2	1	18.00
174	042	2	1	3	2	2	2	1	1	2	1	17.00
175	042	3	1	3	2	2	2	1	1	2	1	18.00
178	042	3	1	3	2	1	2	1	1	2	1	17.00
182	042	2	1	3	2	1	2	2	1	1	1	16.00
183	042	2	1	3	2	1	2	1	1	2	1	16.00

370

FCE 20124/702 i

47

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
190	042	3	1	3	2	1	2	2	1	2	1	18.00
191	042	3	1	3	2	2	2	2	1	2	1	19.00
195	042	2	2	2	1	1	2	2	2	1	2	17.00
196	042	2	2	2	1	1	1	1	1	1	1	13.00
201	042	2	2	2	1	1	2	2	2	3	1	18.00
204	042	2	2	2	2	1	2	2	1	2	0	16.00
205	042	2	2	2	1	1	2	2	1	1	1	15.00
207	042	2	2	2	1	2	2	2	1	3	0	17.00
212	042	2	2	2	2	2	2	2	2	2	2	20.00
213	042	2	2	2	3	2	2	3	2	2	2	22.00
220	042	1	1	1	0	1	1	1	0	3	2	11.00
221	042	1	1	2	0	1	1	0	2	0	1	9.00
225	042	1	2	2	0	1	1	2	0	3	2	14.00
228	042	2	3	2	1	2	2	1	2	3	1	19.00
229	042	0	1	3	0	2	2	1	1	1	2	13.00
234	042	2	1	3	0	1	2	1	2	3	2	17.00
236	042	2	2	2	0	1	2	0	1	2	1	13.00
239	042	2	0	2	0	1	2	0	0	3	2	12.00
241	042	3	1	3	2	1	2	2	1	2	1	18.00
242	042	3	1	2	1	1	1	2	1	2	1	15.00
250	042	2	2	2	1	1	1	2	1	2	1	15.00
252	042	2	2	2	2	1	2	1	1	2	0	15.00
253	042	2	2	2	2	1	2	2	1	2	1	17.00
256	042	2	2	2	1	1	2	2	1	2	1	16.00
261	042	2	1	3	2	1	2	2	1	2	1	17.00
264	042	2	1	2	1	1	2	1	1	2	1	14.00
265	042	2	1	3	2	1	2	2	1	2	1	17.00
266	042	2	1	2	2	1	2	1	1	2	1	15.00
272	042	2	2	2	2	2	2	2	2	2	2	20.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

48

Treatment Group "C"

Day 4 (Period 042)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	1.96	.07
2. Inner tension	1.41	.07
3. Apparent sadness	2.06	.07
4. Suicidal thoughts	1.10	.09
5. Inertia	1.44	.06
6. Inability to feel	1.76	.06
7. Pessimistic thoughts	1.49	.08
8. Concentration difficulties	1.40	.07
9. Reduced sleep	1.89	.08
10. Reduced appetite	1.00	.07
Total score	15.51	.38

372

FCE 20124/702 i

49

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	072	2	1	2	0	2	2	2	2	2	0	15.00
6	072	2	2	2	2	2	2	2	1	2	2	19.00
8	072	2	1	2	0	2	1	1	1	1	1	12.00
16	072	2	2	2	2	2	2	1	2	1	1	17.00
18	072	2	2	2	0	1	1	2	2	0	0	12.00
26	072	1	1	1	0	1	1	1	1	2	0	9.00
27	072	1	1	1	0	1	1	2	2	1	0	10.00
33	072	1	1	1	1	2	1	2	2	2	0	13.00
36	072	1	0	1	0	1	1	0	1	1	0	6.00
39	072	1	0	1	0	2	2	2	2	2	0	12.00
40	072	2	1	2	0	2	2	1	1	2	0	13.00
43	072	1	1	1	0	1	1	1	1	1	0	8.00
46	072	1	1	1	1	2	1	2	2	2	1	14.00
52	072	1	2	2	1	1	2	2	1	1	1	14.00
53	072	2	1	2	1	1	2	2	1	1	1	14.00
58	072	2	1	1	1	1	2	2	2	1	1	14.00
59	072	2	2	2	2	2	2	2	2	2	0	18.00
62	072	2	2	2	1	1	2	1	1	1	1	14.00
63	072	2	1	2	1	1	2	2	2	1	0	14.00
69	072	2	1	2	0	1	2	1	1	1	0	11.00
71	072	2	1	1	0	1	1	1	1	2	0	10.00
74	072	2	1	2	0	1	2	1	1	2	1	13.00
76	072	1	1	2	0	1	2	1	2	2	1	13.00
81	072	1	2	1	0	1	0	1	2	1	0	9.00
82	072	2	1	1	2	2	1	1	2	1	1	14.00
86	072	2	1	1	1	1	2	3	2	2	1	16.00
89	072	1	1	1	0	1	0	1	0	2	0	7.00
92	072	1	1	1	1	2	1	1	1	1	0	10.00
93	072	3	2	3	1	3	2	1	2	2	1	20.00
97	072	2	1	1	1	1	1	1	2	2	1	13.00
100	072	3	1	2	1	2	1	1	2	2	2	17.00
104	072	2	1	2	1	2	2	1	2	1	0	14.00
105	072	3	2	2	1	2	2	2	2	2	2	20.00
111	072	2	1	2	2	2	2	1	1	1	1	15.00
112	072	1	1	1	1	2	2	1	0	1	1	11.00
116	072	3	2	2	2	2	2	2	1	3	0	19.00
117	072	3	1	2	1	2	1	1	2	1	0	14.00
121	072	1	0	1	0	0	1	1	0	1	0	5.00
125	072	2	2	2	0	2	2	2	2	1	1	16.00
128	072	0	0	0	0	0	0	0	0	0	2	2.00
129	072	1	1	1	2	2	2	1	2	2	2	16.00
137	072	0	1	1	0	0	1	0	0	0	2	5.00
138	072	2	2	2	0	2	2	1	2	2	1	16.00
141	072	1	1	1	0	1	1	1	2	2	1	11.00
145	072	1	0	1	0	1	1	2	2	3	0	11.00
173	072	3	1	3	2	2	2	1	1	2	1	18.00
174	072	2	1	3	2	1	2	1	1	2	1	16.00
175	072	3	1	3	2	2	2	1	1	2	1	18.00
178	072	2	1	3	1	2	2	1	1	1	1	15.00
182	072	2	1	3	2	1	2	2	1	2	1	17.00
183	072	2	1	3	2	1	2	1	1	2	1	16.00

373

FCE 20124/702 i

50

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
190	072	3	1	2	2	1	2	2	1	2	1	17.00
191	072	3	1	3	2	1	2	2	1	2	1	18.00
195	072	2	2	2	1	1	2	2	1	1	2	16.00
196	072	2	2	2	1	1	1	1	1	1	1	13.00
201	072	2	2	2	1	1	2	2	2	3	1	18.00
204	072	2	2	2	2	1	2	2	1	2	0	16.00
205	072	2	2	2	1	2	2	2	1	1	0	15.00
207	072	2	2	2	1	2	1	2	1	3	0	16.00
212	072	2	2	2	2	2	2	2	2	2	2	20.00
213	072	2	2	2	2	2	2	2	3	1	1	20.00
220	072	2	2	2	0	1	1	1	1	3	2	15.00
221	072	2	1	3	0	1	3	0	1	0	2	13.00
225	072	2	2	2	0	2	1	1	1	3	2	16.00
228	072	2	1	3	0	2	2	0	1	3	1	15.00
229	072	0	1	1	0	1	0	0	0	0	1	4.00
234	072	3	1	3	0	2	2	1	1	3	1	17.00
236	072	0	1	1	0	1	1	0	0	2	0	6.00
239	072	2	1	2	0	1	2	1	0	2	2	13.00
241	072	3	1	2	2	1	2	2	1	2	1	17.00
242	072	3	1	2	1	1	1	1	1	2	1	14.00
250	072	2	1	2	1	1	2	2	1	2	1	15.00
252	072	2	2	2	2	1	2	2	1	2	0	16.00
253	072	2	2	2	2	1	2	2	1	2	1	17.00
256	072	2	2	2	1	1	2	2	1	2	1	16.00
261	072	2	1	3	2	1	2	2	1	2	1	17.00
264	072	2	1	3	1	1	2	2	1	2	1	16.00
265	072	2	1	3	2	1	2	2	1	2	1	17.00
266	072	2	1	2	2	1	1	1	1	2	1	14.00
272	072	2	1	2	2	1	2	2	1	2	2	17.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

51

Treatment Group "C"

Day 7 (Period 072)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	1.84	.08
2. Inner tension	1.25	.06
3. Apparent sadness	1.86	.08
4. Suicidal thoughts	.93	.09
5. Inertia	1.37	.07
6. Inability to feel	1.60	.07
7. Pessimistic thoughts	1.38	.07
8. Concentration difficulties	1.25	.07
9. Reduced sleep	1.69	.08
10. Reduced appetite	.84	.08
Total score	14.00	.44

375

FCE 20124/702 i

52

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	102	2	1	2	0	2	2	1	2	1	0	13.00
6	102	2	2	2	2	2	2	1	2	2	2	19.00
8	102	2	1	2	0	2	1	1	1	1	0	11.00
16	102	2	1	2	1	2	2	1	2	1	0	14.00
18	102	2	1	2	0	1	1	2	1	0	0	10.00
26	102	1	1	0	0	0	0	0	1	1	0	4.00
27	102	1	1	1	0	1	1	1	1	1	0	8.00
33	102	1	0	0	0	1	1	1	1	1	0	6.00
36	102	1	0	0	0	1	0	0	1	1	0	4.00
39	102	1	0	0	0	1	1	0	1	1	0	5.00
40	102	1	1	1	0	1	0	0	1	1	0	6.00
43	102	1	0	0	0	1	0	0	1	1	0	4.00
46	102	1	1	1	0	2	1	2	1	2	0	11.00
52	102	2	1	2	1	1	2	1	1	1	1	13.00
53	102	2	2	2	1	1	2	1	1	1	0	13.00
58	102	1	2	1	1	1	2	2	2	1	1	14.00
59	102	2	1	2	1	1	2	2	1	1	0	13.00
62	102	2	1	2	1	1	2	2	1	1	1	14.00
63	102	2	2	1	1	1	2	2	1	1	0	13.00
69	102	2	1	2	0	1	2	1	1	1	0	11.00
71	102	1	1	1	0	1	2	1	1	2	0	10.00
74	102	1	1	1	0	1	1	1	1	1	1	9.00
76	102	0	1	1	0	1	1	1	1	1	0	7.00
81	102	1	1	1	0	1	0	0	1	2	0	7.00
82	102	2	1	1	2	2	1	1	1	1	1	13.00
86	102	1	1	1	1	1	1	2	1	2	1	12.00
89	102	1	1	1	0	1	1	0	1	2	0	8.00
92	102	1	0	1	0	1	1	1	0	1	0	6.00
93	102	3	2	3	1	3	1	1	2	1	0	17.00
97	102	2	2	1	1	1	1	0	2	2	1	13.00
100	102	2	1	2	1	2	1	1	2	2	2	16.00
104	102	2	1	2	1	2	2	1	2	0	0	13.00
105	102	3	2	3	1	2	2	2	2	2	2	21.00
111	102	2	1	2	2	2	2	1	1	2	0	15.00
112	102	1	1	1	1	2	2	1	0	1	1	11.00
116	102	2	1	2	1	2	2	1	1	3	0	15.00
117	102	2	1	2	1	2	1	1	2	1	0	13.00
121	102	0	1	0	0	0	1	0	1	0	0	3.00
125	102	2	3	2	1	2	2	2	2	1	1	18.00
128	102	0	0	1	0	0	0	0	0	0	2	3.00
129	102	1	1	1	1	0	1	1	2	2	0	10.00
137	102	0	1	1	0	0	1	0	0	0	2	5.00
138	102	1	1	1	0	2	1	0	1	1	1	9.00
141	102	1	1	1	0	1	1	1	1	2	1	10.00
145	102	3	1	2	1	2	2	1	2	3	2	19.00
173	102	3	1	2	2	2	2	1	1	2	1	17.00
174	102	2	1	2	2	2	2	1	1	2	1	16.00
175	102	2	1	2	2	2	2	1	1	2	1	16.00
178	102	2	1	2	1	1	2	1	1	1	0	12.00
182	102	2	1	2	2	1	2	1	1	2	1	15.00
183	102	2	1	3	1	1	2	2	1	2	1	16.00



FCE 20124/702 i

53

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
190	102	3	1	2	2	1	2	2	1	2	1	17.00
191	102	2	1	2	1	1	2	2	1	1	1	14.00
195	102	2	2	2	1	1	1	1	1	1	1	13.00
196	102	1	1	1	1	1	1	1	0	1	1	9.00
201	102	2	1	2	1	1	2	2	2	2	1	16.00
204	102	2	2	2	2	1	2	2	1	2	0	16.00
205	102	1	2	1	1	1	1	2	1	1	1	12.00
207	102	2	2	2	1	1	1	1	1	2	0	13.00
212	102	2	2	2	1	1	1	1	2	1	2	15.00
213	102	2	2	2	2	2	1	2	2	2	1	18.00
220	102	1	1	1	0	0	0	0	0	3	2	8.00
221	102	2	1	3	0	1	2	0	2	0	2	13.00
225	102	1	2	2	0	1	0	1	1	3	1	12.00
228	102	3	3	3	0	2	2	0	1	3	0	17.00
229	102	2	1	2	0	2	2	2	1	1	0	13.00
234	102	3	1	3	0	2	1	1	1	2	1	15.00
236	102	1	0	1	0	1	1	2	0	3	0	9.00
239	102	0	0	1	0	1	1	0	0	2	1	6.00
241	102	3	1	2	1	1	1	2	1	2	1	15.00
242	102	2	1	2	1	1	1	2	1	2	1	14.00
250	102	1	1	1	1	1	1	1	0	1	0	8.00
252	102	1	2	2	1	1	1	1	1	2	0	12.00
253	102	2	2	2	2	1	2	2	1	2	1	17.00
256	102	2	2	2	1	1	2	2	1	2	1	16.00
261	102	2	1	3	2	1	2	2	1	2	1	17.00
264	102	2	1	2	1	1	2	2	1	2	1	15.00
265	102	2	3	2	2	1	2	1	1	2	1	17.00
266	102	2	1	2	2	1	2	2	1	2	1	16.00
272	102	1	2	2	2	1	2	2	1	2	2	17.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

54

Treatment Group "C"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. Reported sadness	1.64	.08
2. Inner tension	1.20	.07
3. Apparent sadness	1.61	.08
4. Suicidal thoughts	.80	.08
5. Inertia	1.24	.07
6. Inability to feel	1.38	.07
7. Pessimistic thoughts	1.14	.08
8. Concentration difficulties	1.09	.06
9. Reduced sleep	1.50	.08
10. Reduced appetite	.68	.08
Total score	12.26	.48

378

FCE 20124/702 i

55

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	142	2	1	2	0	2	2	1	2	1	0	13.00
6	142	2	2	2	2	2	2	1	2	2	2	19.00
8	142	2	1	2	0	1	2	1	1	1	1	12.00
16	142	1	1	2	1	2	2	1	2	1	0	13.00
18	142	2	1	2	0	1	1	2	1	0	0	10.00
26	142	1	0	0	0	0	0	0	1	1	0	3.00
27	142	1	1	0	0	0	1	1	1	1	0	6.00
33	142	0	0	0	0	1	0	0	1	1	0	3.00
36	142	1	0	0	0	0	0	0	1	1	0	3.00
39	142	1	0	0	0	1	0	0	1	1	0	4.00
40	142	1	1	1	0	1	0	1	1	1	0	7.00
43	142	1	1	0	0	0	0	0	1	1	0	4.00
46	142	1	1	1	0	1	1	1	1	1	0	8.00
52	142	1	2	1	1	1	1	1	1	1	1	11.00
53	142	1	1	1	0	0	1	1	1	1	1	8.00
58	142	1	1	2	1	2	2	2	1	1	1	14.00
59	142	2	1	2	2	1	1	1	1	1	0	12.00
62	142	2	1	1	0	1	2	1	1	1	1	11.00
63	142	2	1	1	1	1	1	1	1	1	0	10.00
69	142	2	1	1	0	1	1	1	1	1	0	9.00
71	142	1	1	1	0	0	1	1	1	1	0	7.00
74	142	0	1	0	0	0	0	1	0	1	0	3.00
76	142	0	0	1	0	1	1	0	1	1	0	5.00
81	142	1	1	0	0	1	0	1	1	0	0	5.00
82	142	1	0	1	1	2	1	1	2	2	0	11.00
86	142	1	1	1	0	1	1	2	1	2	1	11.00
89	142	1	1	1	0	1	0	0	1	1	0	6.00
92	142	0	0	0	0	1	0	1	1	1	0	4.00
93	142	3	2	3	1	3	1	1	2	1	0	17.00
97	142	0	1	1	1	1	1	1	1	2	1	10.00
100	142	1	1	1	0	1	1	0	1	1	0	7.00
104	142	2	1	2	1	2	2	2	1	1	0	14.00
105	142	3	2	3	3	2	2	3	2	2	2	24.00
111	142	2	1	2	2	1	2	1	1	2	0	14.00
112	142	0	1	1	0	1	1	0	0	1	1	6.00
116	142	2	1	2	1	2	2	1	1	3	0	15.00
117	142	2	1	1	1	2	1	1	2	1	0	12.00
121	142	1	1	1	0	1	1	1	1	2	1	10.00
125	142	1	1	1	1	1	2	2	1	2	0	12.00
128	142	0	0	1	0	0	0	0	0	0	2	3.00
129	142	0	1	1	1	0	1	1	1	2	0	8.00
137	142	0	1	1	0	0	1	0	0	0	0	3.00
138	142	1	0	0	0	1	1	1	1	1	1	7.00
141	142	0	1	0	0	0	0	1	1	1	2	6.00
145	142	0	0	0	1	0	1	1	2	3	0	8.00
173	142	2	1	2	2	2	2	2	1	2	1	17.00
174	142	2	1	2	2	2	2	1	1	2	1	16.00
175	142	2	1	2	2	2	2	1	1	1	0	14.00
178	142	2	1	2	1	1	1	1	1	1	0	11.00
182	142	2	1	2	1	1	2	1	1	1	1	13.00
183	142	2	1	2	1	1	2	2	1	1	1	14.00

FCE 20124/702 i

56

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
190	142	3	1	2	2	1	2	2	1	1	1	16.00
191	142	2	1	2	1	1	2	2	1	1	1	14.00
195	142	1	1	1	1	0	1	2	1	1	1	10.00
196	142	0	1	1	1	1	1	1	0	1	1	8.00
201	142	1	1	1	1	1	1	1	2	1	1	11.00
204	142	1	1	1	1	1	1	1	1	0	1	9.00
205	142	1	2	1	1	1	1	2	1	1	1	12.00
207	142	1	1	1	1	1	1	1	2	0	1	10.00
212	142	1	1	1	1	1	1	1	1	1	1	10.00
213	142	1	1	1	1	1	1	1	1	1	1	10.00
220	142	0	1	2	0	0	0	0	2	0	0	5.00
221	142	0	1	2	0	2	2	0	1	0	1	9.00
225	142	1	2	2	0	1	0	1	1	3	1	12.00
229	142	3	2	3	0	2	2	1	1	1	1	16.00
234	142	1	1	1	0	1	1	0	1	2	0	8.00
236	142	0	1	0	0	0	1	1	0	3	0	6.00
239	142	0	1	2	0	0	1	1	0	2	2	9.00
241	142	2	1	2	1	1	2	2	1	2	1	15.00
242	142	2	1	2	1	1	1	2	1	2	1	14.00
250	142	1	1	1	1	1	1	0	1	0	0	8.00
252	142	1	1	1	1	1	1	1	1	0	0	9.00
253	142	1	2	1	1	1	1	1	1	1	1	11.00
256	142	2	1	2	1	1	2	2	1	1	1	14.00
261	142	2	1	3	2	1	2	2	1	2	1	17.00
264	142	2	1	2	1	1	2	2	1	2	1	15.00
265	142	2	1	2	2	1	2	2	1	2	1	16.00
266	142	2	1	2	1	1	2	2	1	2	1	15.00
272	142	1	1	1	2	1	2	2	1	2	2	15.00

FCE 20124/702 i

57

Treatment Group "C"

Day 14 (Period 142)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. Reported sadness	1.23	.09
2. Inner tension	.97	.05
3. Apparent sadness	1.29	.09
4. Suicidal thoughts	.71	.08
5. Inertia	1.00	.07
6. Inability to feel	1.16	.08
7. Pessimistic thoughts	1.10	.08
8. Concentration difficulties	.97	.05
9. Reduced sleep	1.33	.08
10. Reduced appetite	.57	.07
Total score	10.34	.49

381

FCE 20124/702 i

58

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	212	2	1	1	0	1	2	1	2	1	0	11.00
6	212	2	2	2	2	2	2	2	1	2	3	20.00
8	212	2	1	2	0	1	2	0	1	1	1	11.00
16	212	1	1	1	1	1	1	1	2	1	0	10.00
18	212	1	1	1	0	1	1	2	1	0	0	8.00
26	212	0	0	0	0	0	0	0	1	1	0	2.00
27	212	1	1	0	0	0	1	1	1	1	0	6.00
33	212	0	0	0	0	1	0	0	1	1	0	3.00
36	212	0	0	0	0	0	0	0	1	1	0	2.00
39	212	1	0	0	0	1	0	0	1	1	0	4.00
40	212	1	0	0	0	1	0	0	1	1	0	4.00
43	212	0	0	0	0	1	0	0	1	1	0	3.00
46	212	1	0	0	0	0	1	0	0	1	0	3.00
52	212	1	1	1	0	0	2	1	1	1	1	9.00
53	212	1	1	1	0	0	1	0	1	1	1	7.00
58	212	1	1	1	1	1	1	1	1	1	0	9.00
59	212	1	1	1	0	0	1	1	1	1	0	7.00
62	212	1	1	1	0	0	1	1	1	1	0	7.00
63	212	2	1	1	1	1	2	1	1	1	0	11.00
69	212	1	1	1	0	0	1	1	1	1	0	7.00
71	212	1	0	1	0	0	1	1	1	1	0	6.00
74	212	0	1	0	0	1	0	0	0	1	0	3.00
76	212	0	0	0	0	1	1	0	1	1	0	4.00
81	212	0	0	0	0	0	0	0	1	1	0	2.00
82	212	0	0	1	0	2	1	1	2	2	1	10.00
86	212	1	1	0	0	0	1	1	0	2	0	6.00
89	212	1	1	1	0	0	0	0	1	1	0	5.00
92	212	0	0	0	0	0	0	1	1	1	0	3.00
93	212	3	3	3	1	2	1	1	1	1	0	16.00
97	212	0	1	1	1	1	1	1	1	2	1	10.00
100	212	1	1	1	0	1	1	0	1	2	1	9.00
104	212	2	1	3	0	2	1	1	1	0	0	11.00
111	212	2	1	2	2	2	2	2	2	3	1	19.00
112	212	0	0	0	0	1	1	0	0	0	1	3.00
116	212	0	0	0	0	0	0	0	0	3	0	3.00
117	212	1	1	0	0	1	0	0	1	1	0	5.00
121	212	0	1	0	0	0	0	0	2	0	0	3.00
125	212	3	2	2	2	2	3	2	2	2	2	22.00
128	212	0	0	1	0	0	0	0	0	0	1	2.00
129	212	0	0	1	0	0	0	1	1	2	1	6.00
137	212	0	1	1	0	0	0	0	1	0	1	4.00
138	212	1	1	0	0	1	1	1	1	2	1	9.00
141	212	0	1	0	0	0	0	1	0	0	0	2.00
145	212	0	0	0	1	0	1	1	2	3	0	8.00
173	212	2	1	2	1	1	1	1	1	2	0	12.00
174	212	2	1	2	1	1	2	1	1	1	0	12.00
175	212	2	1	2	1	2	2	1	1	1	0	13.00
178	212	2	1	1	1	1	1	1	1	1	0	10.00
182	212	1	1	2	1	1	2	2	1	1	1	13.00
183	212	1	1	2	1	1	2	2	1	1	1	13.00
190	212	2	1	2	1	1	2	2	1	1	1	14.00

FCE 20124/702 i

59

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
191	212	1	1	2	1	1	1	2	1	1	1	12.00
195	212	1	0	1	1	0	0	0	0	0	0	3.00
196	212	0	0	0	0	0	0	0	0	0	0	.00
201	212	1	1	1	1	1	1	0	0	1	1	8.00
204	212	0	1	1	1	0	1	0	0	0	0	4.00
205	212	0	1	1	1	1	1	1	0	0	1	7.00
207	212	0	0	1	0	0	1	1	0	1	0	4.00
212	212	1	1	1	1	1	1	1	1	1	1	10.00
213	212	1	1	0	1	0	1	1	1	1	0	7.00
220	212	2	3	2	0	1	2	1	1	3	2	17.00
221	212	2	1	3	0	2	2	0	1	0	1	12.00
225	212	1	2	1	0	1	1	1	1	3	0	11.00
229	212	2	1	2	0	1	1	1	1	1	1	11.00
234	212	0	1	1	0	0	0	0	0	2	0	4.00
236	212	0	1	0	0	0	0	0	0	0	0	1.00
239	212	0	1	1	0	0	0	0	0	2	1	5.00
241	212	2	1	2	1	1	1	2	1	2	1	14.00
242	212	2	1	2	1	1	1	2	1	1	1	13.00
250	212	0	1	0	1	0	0	1	0	0	0	3.00
252	212	0	1	0	1	1	1	0	0	0	0	4.00
253	212	1	1	1	1	1	1	1	1	1	0	9.00
256	212	2	2	2	1	1	2	1	1	1	0	13.00
261	212	2	1	3	1	1	2	2	1	2	1	16.00
264	212	2	1	3	1	1	2	2	1	2	2	17.00
265	212	2	1	2	2	1	2	2	1	2	1	16.00
266	212	2	1	2	1	1	1	1	1	1	1	12.00
272	212	1	1	1	1	1	1	1	1	1	1	10.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

60

Treatment Group "C"

Day 21 (Period 212)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. Reported sadness	.97	.10
2. Inner tension	.85	.07
3. Apparent sadness	1.04	.10
4. Suicidal thoughts	.49	.07
5. Inertia	.72	.07
6. Inability to feel	.95	.09
7. Pessimistic thoughts	.79	.08
8. Concentration difficulties	.86	.06
9. Reduced sleep	1.13	.09
10. Reduced appetite	.47	.07
Total score	8.27	.56

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

61

Pat. No.	Per. (dy)	Items:										Total Score
		1	2	3	4	5	6	7	8	9	10	
3	282	1	1	1	0	1	1	1	2	1	0	9.00
6	282	2	2	2	2	2	2	1	2	3	20.00	
8	282	2	1	2	0	1	2	0	1	1	11.00	
16	282	1	1	1	0	1	1	0	1	0	6.00	
18	282	1	1	1	0	1	1	1	1	0	7.00	
26	282	0	0	0	0	0	0	0	1	0	1.00	
27	282	1	1	1	0	0	0	1	1	0	6.00	
33	282	0	0	0	0	1	0	0	1	0	3.00	
36	282	0	0	0	0	0	0	0	1	0	2.00	
39	282	1	0	0	0	1	0	0	0	0	3.00	
40	282	1	1	0	0	1	0	0	1	0	5.00	
43	282	0	0	0	0	0	0	0	1	0	2.00	
46	282	1	0	0	0	0	1	0	0	0	3.00	
52	282	1	1	1	0	1	1	1	1	1	9.00	
53	282	1	1	1	0	0	0	1	0	1	5.00	
58	282	1	1	1	1	1	1	1	1	0	9.00	
59	282	1	1	1	0	0	1	1	1	0	7.00	
62	282	1	0	1	0	0	1	1	1	0	6.00	
63	282	1	1	1	0	0	0	1	0	1	5.00	
69	282	1	0	1	0	0	0	1	1	0	5.00	
71	282	1	0	1	0	1	0	1	1	0	6.00	
76	282	0	0	0	0	0	0	0	1	0	2.00	
81	282	0	1	0	0	1	0	0	0	1	3.00	
82	282	0	1	1	1	2	1	0	1	1	9.00	
86	282	0	1	0	0	0	0	1	1	2	5.00	
89	282	1	1	1	0	2	1	0	1	2	9.00	
92	282	0	0	0	0	1	0	0	0	1	2.00	
93	282	3	3	3	1	2	1	1	1	0	16.00	
97	282	1	1	1	0	1	1	0	1	1	8.00	
100	282	0	0	0	0	0	0	0	1	0	1.00	
104	282	2	1	2	0	2	1	1	1	0	10.00	
111	282	2	1	2	2	2	2	2	2	3	19.00	
112	282	0	0	0	0	0	0	0	0	1	2.00	
116	282	0	0	0	0	0	0	0	0	1	1.00	
117	282	0	1	0	0	1	0	0	1	0	3.00	
121	282	0	1	0	0	0	0	0	1	0	2.00	
128	282	0	0	0	0	0	0	0	0	1	1.00	
129	282	0	0	0	0	0	0	0	0	2	3.00	
137	282	1	1	1	0	1	1	0	1	0	7.00	
141	282	0	1	0	0	0	0	1	2	0	5.00	
145	282	0	0	0	1	0	1	1	2	3	8.00	
173	282	1	1	1	1	1	1	1	1	0	9.00	
174	282	1	1	1	1	1	1	1	1	0	9.00	
175	282	1	1	1	1	1	2	1	1	1	10.00	
178	282	1	1	1	1	1	2	1	1	0	10.00	
182	282	1	1	2	1	1	1	2	1	1	12.00	
183	282	1	1	1	1	1	1	2	1	1	10.00	
190	282	1	1	2	1	1	2	1	1	1	12.00	
191	282	1	1	1	1	1	1	1	1	1	10.00	
195	282	0	0	0	0	0	1	0	0	0	1.00	
196	282	0	0	0	0	0	0	0	0	0	.00	

385

FCE 20124/702 i

62

Pat. No.	Per. (dy)	Items:										Total Score	
		1	2	3	4	5	6	7	8	9	10		
201	282	0	1	0	0	0	1	1	1	1	1	1	6.00
204	282	0	0	0	0	0	0	0	0	0	0	0	.00
205	282	0	0	0	0	0	0	1	0	0	0	0	1.00
207	282	0	0	1	0	0	1	0	0	0	0	0	2.00
212	282	0	1	0	0	1	1	0	1	0	0	0	4.00
213	282	0	1	0	0	0	1	0	0	0	0	0	2.00
220	282	0	1	1	0	1	0	0	0	3	0	0	6.00
221	282	1	1	1	0	1	1	0	1	0	2	0	8.00
229	282	0	0	1	0	1	1	0	0	0	0	0	3.00
234	282	0	1	0	0	0	0	0	1	2	0	0	4.00
236	282	0	1	0	0	0	0	1	0	0	0	0	2.00
239	282	0	1	0	0	0	0	0	0	2	2	0	5.00
241	282	2	1	2	1	1	1	2	1	1	1	1	13.00
242	282	2	1	2	1	1	1	1	1	1	0	0	11.00
250	282	0	0	0	0	0	0	1	0	0	0	0	1.00
252	282	0	0	0	0	0	0	0	0	0	0	0	.00
253	282	0	1	0	0	0	1	1	0	0	0	0	3.00
256	282	1	1	1	1	0	1	1	1	1	0	0	8.00
261	282	2	1	2	1	1	2	2	1	2	1	1	15.00
264	282	2	1	2	2	1	2	2	1	2	1	1	16.00
265	282	2	1	2	1	1	2	1	1	1	1	1	13.00
266	282	1	1	2	1	1	1	1	1	1	1	1	11.00
272	282	0	1	0	1	0	1	1	0	0	0	0	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

63

Treatment Group "C"

Day 28 (Period 282)

Number of Observations = 74

Variable	Mean	S.E. Mean
1. Reported sadness	.68	.09
2. Inner tension	.70	.07
3. Apparent sadness	.73	.09
4. Suicidal thoughts	.34	.06
5. Inertia	.61	.07
6. Inability to feel	.69	.08
7. Pessimistic thoughts	.62	.08
8. Concentration difficulties	.72	.07
9. Reduced sleep	.88	.09
10. Reduced appetite	.35	.07
Total score	6.31	.54

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

387

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 5d - Zung Self-rating Depression Scale

Treatment Group "A"

PAT PER No. (day)	Items:																				Total Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1 000	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00
5 000	4	3	1	3	3	4	1	2	2	3	4	3	2	3	3	3	4	3	2	3	56.00
9 000	3	3	2	2	3	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	52.00
12 000	3	3	1	3	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	56.00
13 000	3	4	1	4	3	4	2	1	1	1	3	4	1	3	3	3	3	3	1	3	51.00
14 000	3	3	1	2	4	4	1	1	2	2	3	4	2	3	2	4	3	3	2	3	52.00
25 000	4	4	3	4	3	4	2	3	3	3	4	4	2	4	3	4	4	4	3	4	69.00
30 000	4	4	3	4	3	4	2	4	4	4	4	4	3	4	4	4	4	4	3	4	74.00
34 000	4	4	2	3	3	4	2	4	2	2	4	4	3	4	4	4	4	4	2	4	67.00
35 000	4	4	3	4	4	4	2	2	4	4	4	3	4	4	4	4	4	4	2	4	72.00
37 000	4	4	4	4	3	4	2	4	2	3	3	4	3	4	4	4	4	4	2	4	70.00
38 000	4	4	2	4	4	4	2	2	3	4	4	3	4	4	4	4	4	4	2	4	70.00
45 000	4	3	3	4	3	4	2	3	2	4	4	4	2	4	3	4	4	4	3	4	68.00
48 000	4	4	3	3	4	2	3	2	3	4	4	3	4	4	4	4	4	4	1	4	67.00
50 000	4	4	4	4	3	4	4	3	4	4	3	4	3	4	4	4	4	4	3	4	75.00
56 000	3	4	4	4	3	4	2	3	4	4	3	4	2	4	2	4	4	4	3	4	69.00
57 000	3	4	4	4	4	4	2	4	4	4	4	4	1	4	4	4	4	4	4	4	74.00
64 000	4	4	4	4	4	3	3	4	4	4	4	3	4	3	4	3	4	3	4	4	74.00
65 000	3	4	4	3	4	4	2	2	4	4	4	3	4	3	4	3	3	2	4	4	68.00
68 000	4	4	4	4	4	4	3	4	4	4	4	3	4	4	4	4	4	4	4	4	78.00
72 000	4	4	4	3	4	3	1	2	4	3	3	3	2	4	2	4	3	3	2	3	61.00
73 000	4	4	3	4	4	4	2	2	4	4	4	3	4	3	3	4	4	3	4	4	71.00
75 000	4	4	3	1	3	4	4	1	2	3	4	4	4	4	2	4	4	4	4	4	67.00
79 000	4	4	4	4	4	4	4	2	4	3	4	4	4	3	4	4	4	4	2	4	74.00
80 000	4	4	2	4	4	4	1	4	4	4	4	4	4	4	4	4	4	4	1	4	72.00
85 000	4	4	1	3	3	4	1	2	2	3	4	4	2	4	3	3	4	4	1	3	59.00
87 000	3	4	1	3	4	4	1	4	3	2	3	4	1	4	3	4	3	3	1	4	59.00
94 000	4	4	3	2	4	4	2	1	2	4	4	4	3	4	3	4	3	4	3	4	66.00
96 000	4	4	3	2	3	4	2	2	1	4	4	3	2	4	2	4	4	4	3	4	63.00
99 000	4	4	2	4	3	4	2	2	2	3	4	4	1	4	1	4	4	3	1	4	60.00
101 000	4	3	3	4	4	3	1	3	2	4	4	3	3	3	3	4	3	4	2	4	64.00
107 000	4	4	3	4	4	4	2	3	3	4	4	4	2	4	2	4	4	4	1	4	68.00
108 000	4	4	3	1	3	4	3	2	2	4	4	4	2	3	2	4	4	4	1	4	62.00
109 000	3	3	3	3	4	3	1	2	2	3	4	4	4	4	3	4	4	4	3	4	65.00
114 000	4	4	4	4	3	4	2	2	3	4	3	4	3	4	2	4	4	4	3	4	69.00
115 000	4	4	4	4	3	4	1	4	4	3	4	4	4	3	4	3	3	3	3	4	71.00
120 000	4	4	4	4	3	3	2	2	2	4	3	4	4	4	3	4	4	4	3	4	69.00
122 000	4	4	4	4	4	3	2	2	2	4	4	4	4	4	2	4	4	4	4	4	71.00
123 000	4	4	3	1	4	4	1	1	4	4	4	4	4	3	1	4	4	4	2	4	64.00
130 000	4	4	3	2	4	4	3	2	2	4	4	3	3	3	2	4	4	4	3	3	65.00
131 000	4	4	4	1	4	4	1	4	2	4	4	4	3	4	4	4	3	4	4	4	70.00
134 000	3	3	3	4	4	4	2	3	3	2	3	3	4	3	1	4	4	4	2	3	62.00
135 000	3	4	2	4	3	4	3	2	4	4	3	4	3	4	1	3	3	4	2	4	64.00
142 000	3	4	3	3	4	3	2	1	2	3	4	3	3	3	1	3	3	3	1	4	56.00
146 000	2	4	3	1	3	3	1	1	1	1	4	3	3	3	1	3	3	4	1	3	48.00
169 000	4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	62.00
171 000	4	3	3	2	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
176 000	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	61.00

FCE 20124/702 i

2

PAT PER No. (day)	Items:																				Total Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
177 000	4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	62.00
184 000	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
185 000	4	3	3	3	4	4	2	1	1	3	4	4	1	4	2	4	4	4	3	4	62.00
189 000	4	3	3	3	4	4	1	2	1	2	4	4	1	4	1	4	4	4	3	4	60.00
192 000	3	3	3	3	4	4	2	1	2	3	4	4	1	3	1	4	4	4	4	4	61.00
194 000	4	4	3	4	4	4	3	2	2	4	4	4	2	4	2	4	4	4	4	4	70.00
198 000	3	4	4	4	3	4	1	1	2	3	4	4	2	4	3	3	4	4	3	4	64.00
199 000	4	4	4	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	66.00
200 000	4	4	3	3	3	4	2	1	2	3	4	4	3	4	3	3	4	4	3	4	65.00
208 000	3	4	3	3	3	4	2	2	2	4	4	4	2	4	2	4	4	4	3	4	65.00
209 000	3	4	3	3	3	4	2	2	2	4	4	4	2	4	2	4	4	4	3	4	65.00
211 000	4	4	3	3	3	3	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
215 000	4	4	3	4	3	4	2	1	2	3	4	4	3	4	4	4	4	4	4	4	69.00
217 000	3	4	3	3	3	4	2	4	1	3	3	3	1	3	2	3	3	4	2	3	57.00
222 000	1	3	2	3	3	3	3	1	2	2	3	4	2	4	2	3	3	3	4	4	55.00
223 000	4	3	1	4	4	4	3	4	3	4	4	4	4	3	1	4	4	3	1	4	66.00
224 000	3	4	2	2	3	3	2	4	2	2	3	3	4	3	4	3	4	4	2	3	60.00
231 000	3	3	3	4	4	3	3	2	1	1	3	3	3	4	1	4	4	4	1	4	58.00
232 000	2	3	1	4	4	4	4	4	3	4	3	4	3	3	2	4	4	3	2	4	65.00
235 000	4	3	4	4	4	4	4	1	4	2	4	4	3	4	4	4	3	4	2	4	70.00
240 000	4	4	4	1	3	3	2	2	1	3	3	3	1	3	3	4	4	4	1	3	56.00
244 000	4	3	3	3	4	4	3	2	1	3	4	4	1	4	1	4	4	4	3	4	63.00
246 000	3	4	3	2	4	4	2	2	1	3	4	4	1	4	1	3	4	4	3	3	59.00
247 000	3	4	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	61.00
248 000	4	3	3	3	4	4	2	2	1	2	4	4	1	4	1	4	4	4	3	4	61.00
257 000	4	4	4	4	4	4	3	1	1	4	4	4	4	4	3	4	3	4	3	4	70.00
258 000	4	3	3	4	3	3	1	1	1	4	4	4	3	4	3	4	3	4	2	4	62.00
259 000	3	3	3	2	3	4	2	1	1	2	4	4	1	4	1	4	4	4	3	4	57.00
263 000	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
267 000	4	4	4	3	4	4	3	2	2	3	4	4	3	4	3	4	4	4	3	4	70.00
270 000	3	3	2	3	3	3	1	1	1	3	4	4	3	4	3	4	4	4	2	4	59.00
271 000	3	4	3	4	4	4	4	2	2	3	4	4	3	4	4	4	4	4	3	4	71.00

Number of cases read 8 Numer f cseslised 8

FCE 20124/702 i

3

Treatment Group "A"

Baseline (Period 000)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.56	.07
2. Morning is when I feel best	3.66	.05
3. I have crying spells or feel like it	2.91	.10
4. I have trouble sleeping at night	3.16	.10
5. I eat as much as I used to	3.56	.06
6. I still enjoy sex	3.80	.05
7. I notice that I am losing weight	2.23	.11
8. I have trouble with constipation	2.08	.11
9. My heart beats faster than usual	2.16	.11
10. I get tired for no reason	3.17	.09
11. My mind is as clear as it used to be	3.74	.05
12. I find it easy to do the things I used to do	3.84	.04
13. I am restless and can't keep still	2.39	.12
14. I feel hopeful about the future	3.78	.05
15. I am more irritable than usual	2.40	.12
16. I find it easy to make decisions	3.79	.05
17. I feel that I am useful and needed	3.75	.05
18. My life is pretty full	3.76	.05
19. I feel that others would be better off if I were dead	2.54	.10
20. I still enjoy the things I used to do	3.83	.04
Total score	64.10	.71

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

4

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	042	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00
5	042	4	3	1	3	3	4	1	2	2	3	4	3	2	3	3	3	4	3	3	3	57.00
9	042	3	3	2	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	53.00
12	042	3	3	1	3	4	4	2	2	3	3	3	3	3	3	3	3	3	3	3	3	58.00
13	042	3	4	1	4	3	4	2	1	1	1	3	4	1	3	3	3	3	3	1	3	51.00
14	042	3	4	1	2	4	4	1	1	2	2	3	4	1	3	2	4	3	3	2	3	52.00
25	042	4	4	3	4	3	4	2	3	2	3	4	4	3	4	3	4	4	4	2	4	68.00
30	042	4	4	3	3	3	4	2	4	3	4	4	4	3	4	3	4	4	4	2	4	70.00
34	042	4	4	2	3	3	4	2	4	2	4	4	4	4	4	4	4	4	4	2	4	70.00
35	042	4	4	3	4	4	4	3	2	2	4	4	4	2	4	4	4	4	4	2	4	70.00
37	042	4	4	3	3	3	4	2	3	2	3	4	4	2	4	4	4	4	4	2	4	67.00
38	042	4	4	2	4	3	4	2	2	2	3	4	4	3	4	1	4	4	4	2	4	64.00
45	042	4	3	2	4	3	4	2	3	2	3	4	4	2	4	3	3	4	4	2	4	64.00
48	042	4	4	2	3	3	4	2	3	2	3	4	4	3	4	4	4	4	4	1	4	66.00
49	042	3	3	3	3	3	4	4	3	3	3	4	4	3	3	4	3	4	3	3	3	66.00
50	042	4	4	4	4	3	4	4	3	4	4	3	4	3	4	4	4	4	4	3	4	75.00
56	042	3	4	3	3	3	4	2	3	4	4	3	4	2	4	2	4	4	3	3	4	66.00
57	042	3	4	4	4	4	4	2	4	4	4	4	4	1	4	4	4	4	4	4	4	74.00
64	042	4	4	3	3	3	3	3	3	3	4	3	3	3	3	3	3	4	4	4	3	66.00
65	042	3	4	3	3	4	4	2	2	4	3	3	4	3	4	3	4	3	3	3	4	66.00
68	042	4	4	4	4	4	4	3	4	4	4	4	4	3	4	4	4	4	4	4	4	78.00
72	042	3	3	3	3	4	3	1	2	3	3	3	3	2	3	2	3	3	3	2	3	55.00
73	042	4	4	3	4	3	4	4	3	2	4	3	4	3	4	2	3	3	4	3	4	68.00
75	042	1	3	1	3	4	3	1	4	1	2	3	4	1	4	1	4	4	4	4	4	56.00
79	042	4	4	4	4	4	4	4	2	4	3	4	4	4	2	4	4	4	4	3	4	74.00
80	042	4	4	1	1	4	4	1	1	2	4	4	4	3	4	3	3	4	4	1	4	60.00
85	042	4	4	1	3	3	4	2	3	2	3	4	4	2	3	3	3	4	4	1	3	60.00
87	042	4	3	2	3	4	4	1	3	3	2	3	4	3	3	3	4	4	4	2	3	62.00
94	042	3	3	3	2	3	4	1	1	2	4	4	4	2	4	2	4	3	3	3	4	59.00
96	042	4	4	3	2	4	4	1	1	1	4	4	4	3	4	2	4	4	4	3	3	63.00
99	042	4	4	2	4	3	4	1	2	2	3	4	4	2	4	1	4	4	3	1	4	60.00
101	042	4	4	3	4	4	3	1	2	2	4	4	4	2	3	3	4	3	4	2	4	64.00
107	042	4	4	3	4	3	4	2	3	4	4	4	4	3	4	2	4	4	4	2	4	70.00
108	042	3	4	1	4	3	4	2	3	2	4	3	3	2	4	2	4	4	4	2	4	62.00
109	042	3	4	3	3	4	3	1	1	2	4	4	4	4	4	3	4	4	4	3	4	66.00
114	042	4	4	4	4	3	4	3	2	3	4	3	4	3	4	3	4	4	4	2	3	69.00
115	042	3	4	3	4	4	3	4	2	3	4	3	4	3	4	3	4	3	4	3	3	68.00
120	042	4	4	4	4	3	3	3	1	2	4	3	4	4	4	4	4	4	4	3	4	70.00
146	042	1	3	1	2	3	4	1	1	2	2	3	3	1	4	1	4	4	3	1	4	48.00
122	042	3	4	3	1	3	4	1	2	2	3	4	4	4	4	4	4	4	4	2	4	64.00
123	042	1	4	1	2	4	4	1	1	2	2	4	3	1	3	1	4	3	3	1	4	49.00
130	042	4	4	4	2	4	4	4	1	3	4	4	4	4	4	3	4	4	4	4	4	73.00
131	042	2	3	2	1	3	4	2	4	1	2	4	3	2	3	1	4	4	3	1	3	52.00
134	042	2	4	2	3	4	4	2	3	2	1	3	3	3	3	4	4	3	3	1	4	58.00
135	042	2	4	1	3	4	4	2	1	2	2	3	4	2	4	2	4	3	3	1	4	55.00
142	042	3	3	2	3	3	3	2	1	2	2	3	3	2	3	1	3	3	3	1	3	49.00
169	042	4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	62.00
171	042	4	3	3	3	4	4	2	1	2	3	4	4	1	4	1	4	4	4	3	4	62.00
176	042	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
177	042	4	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	3	4	3	4	60.00
184	042	3	3	3	3	4	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	59.00
185	042	4	3	3	3	4	4	2	1	2	3	4	4	1	4	3	4	4	4	3	4	64.00
189	042	4	3	3	3	4	4	2	1	2	2	4	4	1	4	2	4	4	4	3	4	62.00
192	042	3	3	3	3	4	4	2	1	2	3	4	4	1	4	2	4	4	4	3	4	62.00

FCE 20124/702 i

5

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
194	042	4	4	3	4	4	4	3	2	2	4	4	4	2	4	2	4	4	4	3	4	69.00
198	042	3	4	4	4	3	4	1	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
199	042	4	4	4	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	66.00
200	042	4	4	3	3	3	4	2	1	2	3	4	4	3	4	3	4	4	4	3	4	66.00
208	042	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
209	042	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
211	042	4	4	3	3	3	3	2	2	2	3	4	4	2	4	1	3	3	4	2	4	60.00
215	042	4	4	4	4	3	4	2	2	2	4	4	4	3	4	3	4	4	4	3	4	70.00
217	042	2	4	2	3	3	3	2	4	1	2	3	3	1	3	2	3	3	3	1	3	51.00
222	042	4	4	2	4	4	4	4	2	1	4	4	4	4	4	4	4	4	4	4	4	73.00
223	042	4	3	1	4	4	4	2	3	3	4	4	4	4	3	1	3	4	3	1	4	63.00
224	042	3	3	2	2	3	3	2	4	2	2	3	3	4	3	3	3	4	4	2	4	59.00
231	042	2	4	2	3	4	3	4	1	1	4	4	4	4	4	1	4	4	4	1	4	62.00
232	042	2	3	1	3	4	4	2	2	3	4	3	4	4	3	3	4	4	4	2	4	63.00
235	042	2	4	1	4	3	4	4	1	4	2	4	4	4	3	1	4	4	4	1	3	61.00
240	042	3	4	2	1	4	3	2	2	1	4	4	3	2	4	4	4	3	3	1	3	57.00
244	042	4	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	61.00
246	042	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
247	042	3	4	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	61.00
248	042	3	3	3	2	4	4	1	1	2	3	4	4	1	4	2	4	3	4	3	3	58.00
257	042	4	4	4	4	4	4	3	1	1	4	4	4	4	4	4	4	4	4	3	4	72.00
258	042	4	3	3	4	3	3	1	1	1	4	4	4	4	4	3	4	3	4	2	4	63.00
259	042	3	3	3	2	4	4	2	1	1	3	4	4	2	4	2	4	4	4	3	4	61.00
263	042	3	3	2	2	4	4	2	2	1	1	4	4	2	4	1	4	3	4	3	4	57.00
267	042	4	4	3	3	4	4	3	2	2	3	4	4	3	4	3	4	4	4	3	4	69.00
270	042	3	3	2	3	3	4	1	1	1	3	4	4	3	4	3	4	3	4	2	4	59.00
271	042	3	4	3	3	4	4	4	2	2	4	4	4	3	4	3	4	4	4	2	4	69.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

6

Treatment Group "A"

Day 4 (Period 042)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.33	.09
2. Morning is when I feel best	3.63	.05
3. I have crying spells or feel like it	2.56	.11
4. I have trouble sleeping at night	3.07	.09
5. I eat as much as I used to	3.54	.06
6. I still enjoy sex	3.83	.04
7. I notice that I am losing weight	2.12	.11
8. I have trouble with constipation	1.95	.11
9. My heart beats faster than usual	2.05	.10
10. I get tired for no reason	3.14	.09
11. My mind is as clear as it used to be	3.70	.05
12. I find it easy to do the things I used to do	3.84	.04
13. I am restless and can't keep still	2.37	.12
14. I feel hopeful about the future	3.75	.05
15. I am more irritable than usual	2.41	.12
16. I find it easy to make decisions	3.79	.05
17. I feel that I am useful and needed	3.72	.05
18. My life is pretty full	3.73	.05
19. I feel that others would be better off if I were dead	2.40	.10
20. I still enjoy the things I used to do	3.77	.05
Total score	62.69	.73

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

7

PAT PER No. (day)	Items:																					Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	072	3	4	1	2	4	4	1	1	3	2	3	4	1	4	2	3	3	3	1	3	52.00
5	072	4	3	1	3	4	4	1	2	2	3	4	3	1	3	3	3	4	3	3	4	58.00
9	072	3	3	2	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	53.00
12	072	3	3	1	3	4	4	2	2	2	3	3	3	3	3	3	3	3	3	3	3	57.00
13	072	3	4	1	4	3	4	2	1	1	1	3	4	1	3	3	3	3	3	1	3	51.00
14	072	3	4	1	3	4	4	1	1	2	2	3	4	1	3	2	4	3	3	2	3	53.00
25	072	4	3	2	3	3	4	1	3	1	2	3	3	2	3	3	3	3	3	2	3	54.00
30	072	4	4	3	4	3	4	3	4	4	4	4	4	3	4	4	4	4	4	2	4	74.00
34	072	4	4	2	4	3	4	2	4	2	4	4	4	4	4	4	4	4	4	3	4	72.00
35	072	4	4	2	4	3	4	2	2	2	4	4	4	1	4	4	4	4	4	2	4	66.00
37	072	3	3	2	3	3	4	1	3	2	2	3	4	3	3	3	3	3	3	1	3	55.00
38	072	4	3	2	3	4	4	1	2	2	2	4	4	3	4	3	4	4	4	2	4	63.00
45	072	3	3	1	3	3	4	1	3	2	3	3	3	2	3	3	3	3	3	2	3	54.00
48	072	3	4	2	3	3	4	1	3	2	2	4	4	3	4	4	4	4	4	1	4	63.00
49	072	3	3	3	3	4	3	3	3	4	3	3	3	2	3	3	3	3	3	3	3	61.00
50	072	4	4	4	4	3	4	4	3	4	4	3	4	3	4	3	4	4	4	3	4	74.00
56	072	3	4	3	3	3	4	1	2	3	3	3	4	2	3	2	4	3	3	3	3	59.00
57	072	3	3	3	3	3	3	2	3	3	3	3	3	1	3	2	4	3	3	3	3	57.00
64	072	3	3	3	3	3	4	3	3	3	4	4	4	2	3	3	3	4	4	3	4	66.00
65	072	4	3	4	4	4	4	3	2	4	3	3	4	2	3	3	3	4	3	3	4	67.00
68	072	4	4	4	4	4	3	3	4	4	3	4	3	4	4	4	4	4	4	4	4	76.00
72	072	3	4	3	3	4	3	1	2	3	3	3	3	1	3	2	3	3	3	2	3	55.00
73	072	4	4	3	3	3	4	3	2	2	4	3	4	2	3	3	4	4	4	3	4	66.00
75	072	3	4	3	1	3	4	3	1	2	3	3	4	4	4	1	4	4	4	4	4	63.00
79	072	4	4	4	4	4	4	4	1	4	3	4	4	4	2	4	4	4	4	1	4	71.00
80	072	4	4	1	4	4	4	1	1	4	4	4	4	4	4	4	4	4	4	1	4	68.00
85	072	4	4	1	3	3	4	1	2	2	3	4	3	2	3	3	3	4	3	1	3	56.00
87	072	4	4	2	3	4	4	1	4	2	3	4	4	2	4	2	4	4	4	2	4	65.00
94	072	3	3	2	2	3	4	2	1	2	4	4	3	3	3	2	4	4	3	3	4	59.00
96	072	4	3	2	2	4	4	1	1	1	4	4	3	2	3	2	4	3	3	1	4	55.00
99	072	3	4	3	3	3	4	1	2	2	4	4	3	2	4	2	3	4	4	2	3	60.00
101	072	3	3	1	4	3	3	1	1	2	3	3	4	2	3	1	4	4	3	1	4	53.00
107	072	3	3	1	3	3	4	1	3	2	3	3	3	2	3	2	3	3	3	1	3	52.00
108	072	3	3	2	3	4	4	2	1	2	4	4	4	2	4	1	4	3	4	2	4	60.00
109	072	4	4	3	3	4	4	1	1	2	4	4	4	3	4	3	4	4	4	3	4	67.00
114	072	3	3	2	2	4	4	3	2	2	4	3	3	2	3	2	3	3	3	3	3	57.00
115	072	3	4	2	3	3	4	2	1	2	3	4	3	2	3	2	3	3	3	1	4	55.00
120	072	4	4	4	4	3	3	2	2	2	4	3	4	3	4	4	4	4	4	3	4	69.00
146	072	1	3	1	1	4	3	1	1	2	2	3	3	1	3	1	3	3	4	1	3	44.00
122	072	4	3	4	1	3	4	1	2	2	4	4	4	4	4	4	4	4	4	4	4	68.00
123	072	1	3	1	1	4	4	1	1	1	3	4	3	1	3	1	3	3	3	1	3	45.00
131	072	2	3	1	1	3	4	2	4	1	1	3	4	1	3	1	3	4	3	1	3	48.00
134	072	2	4	1	3	4	4	1	3	3	1	3	3	2	3	3	3	3	3	1	3	53.00
135	072	3	4	3	2	3	4	2	1	3	4	3	4	4	4	4	3	4	4	4	3	66.00
142	072	2	3	2	4	3	3	3	1	1	2	4	3	2	3	1	3	3	3	1	3	50.00
169	072	3	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	61.00
171	072	4	3	3	2	3	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	59.00
176	072	3	3	3	3	4	4	2	1	2	3	4	4	1	4	2	4	3	4	3	4	61.00
177	072	4	3	2	3	4	4	2	1	1	3	4	4	2	4	2	4	3	4	3	4	61.00
184	072	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00
185	072	3	3	3	3	4	4	2	1	2	3	4	4	1	4	3	4	4	4	3	4	63.00
189	072	3	3	3	3	4	4	1	1	2	3	4	4	1	4	2	4	4	4	3	4	61.00
192	072	3	3	3	3	4	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
194	072	4	4	4	4	4	4	3	2	2	3	4	4	2	4	2	4	4	4	3	4	69.00

FCE 20124/702 i

8

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
198	072	3	4	4	4	4	4	1	1	2	3	4	4	2	4	2	3	4	4	3	4	64.00
199	072	4	4	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	4	3	4	66.00
200	072	4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
208	072	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
209	072	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
211	072	4	4	3	3	3	2	2	2	3	3	4	2	4	2	4	4	4	4	2	4	62.00
215	072	4	4	4	4	3	4	2	2	2	4	4	4	3	4	3	4	4	4	4	4	71.00
217	072	2	4	2	3	3	3	2	4	1	2	3	3	1	3	2	3	3	3	1	3	51.00
222	072	2	4	3	4	3	4	2	2	1	3	4	4	1	3	2	4	4	4	2	4	60.00
223	072	4	4	2	4	4	4	4	1	3	4	4	4	3	3	1	4	4	4	2	4	67.00
224	072	2	3	1	2	3	3	2	2	2	3	3	3	2	3	2	3	3	3	2	4	51.00
231	072	2	4	3	3	4	4	3	4	1	1	4	4	3	4	1	4	4	3	1	3	60.00
232	072	3	3	2	3	4	4	3	4	2	3	4	4	4	4	3	4	3	4	3	4	68.00
235	072	3	4	1	3	4	3	3	1	2	2	4	4	3	4	1	3	3	3	1	4	56.00
240	072	2	4	2	1	4	4	1	2	1	2	3	4	4	4	2	4	4	3	1	3	55.00
244	072	3	3	3	2	4	4	2	1	1	3	4	3	1	4	2	4	4	3	3	3	57.00
246	072	3	3	3	3	4	4	2	2	1	3	4	4	1	3	2	4	4	3	3	4	60.00
247	072	3	3	3	2	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	60.00
248	072	3	3	2	3	3	4	1	1	2	3	4	4	1	4	2	3	3	4	2	4	56.00
257	072	4	4	4	4	4	3	1	1	4	4	4	4	4	4	3	4	4	4	2	4	70.00
258	072	4	3	3	4	3	3	1	1	1	4	4	4	4	4	3	4	3	4	2	4	63.00
259	072	3	3	2	2	4	4	2	1	1	2	4	4	1	4	2	4	3	4	3	4	57.00
263	072	3	4	2	2	4	4	2	1	2	2	4	4	1	4	2	3	4	4	2	4	58.00
267	072	4	4	3	3	4	4	3	2	2	3	4	4	3	4	3	4	4	4	3	4	69.00
270	072	3	3	2	3	3	4	1	1	1	3	4	4	3	4	2	4	3	4	2	4	58.00
271	072	3	4	3	4	4	4	3	2	2	3	4	4	3	4	3	4	4	4	2	4	68.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

9

Treatment Group "A"

Day 7 (Period 072)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.21	.08
2. Morning is when I feel best	3.51	.06
3. I have crying spells or feel like it	2.45	.11
4. I have trouble sleeping at night	2.96	.09
5. I eat as much as I used to	3.53	.06
6. I still enjoy sex	3.84	.04
7. I notice that I am losing weight	1.94	.10
8. I have trouble with constipation	1.90	.11
9. My heart beats faster than usual	1.98	.09
10. I get tired for no reason	3.00	.09
11. My mind is as clear as it used to be	3.64	.05
12. I find it easy to do the things I used to do	3.74	.05
13. I am restless and can't keep still	2.15	.11
14. I feel hopeful about the future	3.60	.06
15. I am more irritable than usual	2.33	.10
16. I find it easy to make decisions	3.64	.05
17. I feel that I am useful and needed	3.61	.05
18. My life is pretty full	3.60	.06
19. I feel that others would be better off if I were dead	2.31	.10
20. I still enjoy the things I used to do	3.69	.05
Total score	60.61	.76

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

10

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	102	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00
5	102	3	3	1	3	4	4	1	2	2	3	4	3	1	3	3	3	4	3	2	4	56.00
9	102	3	3	2	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	53.00
12	102	2	3	1	2	4	4	2	2	2	3	4	3	2	3	2	3	3	3	3	3	54.00
13	102	4	4	1	4	3	4	2	1	2	1	3	4	1	3	3	3	3	3	1	3	53.00
14	102	3	4	1	3	4	4	1	1	2	2	3	4	1	3	2	4	3	3	2	3	53.00
25	102	2	3	1	2	3	4	1	2	1	2	3	3	2	3	2	3	3	1	3	3	47.00
30	102	4	4	2	3	3	4	2	4	4	4	4	4	3	4	4	4	4	4	2	4	71.00
34	102	4	4	3	3	3	4	2	4	2	4	4	4	3	4	4	4	4	4	3	4	71.00
35	102	3	4	2	4	3	4	2	2	2	4	4	4	1	4	4	4	4	4	2	4	65.00
37	102	3	3	2	2	4	4	1	2	1	2	3	3	2	3	2	3	3	1	3	3	50.00
38	102	3	3	1	3	4	3	1	2	2	2	3	3	2	3	2	3	3	1	3	3	50.00
45	102	3	3	2	3	3	4	1	2	2	2	4	3	1	3	2	3	4	4	1	3	53.00
48	102	2	3	1	2	3	4	1	3	2	2	3	3	2	3	2	3	3	1	3	3	49.00
49	102	3	3	3	3	3	3	3	3	3	3	4	4	2	4	3	3	3	3	3	3	62.00
50	102	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	4	3	3	2	3	59.00
56	102	3	4	3	3	3	3	1	2	3	3	3	3	2	3	2	3	3	3	3	3	56.00
57	102	3	3	3	3	3	3	2	3	3	3	3	3	1	3	3	3	3	3	3	3	57.00
64	102	4	4	3	4	4	4	3	3	4	4	4	4	3	3	3	3	3	4	4	3	71.00
65	102	3	4	3	3	4	3	3	3	4	3	3	3	2	3	3	3	3	3	3	3	62.00
68	102	3	4	4	4	3	4	3	3	3	4	4	4	2	4	4	3	4	4	4	3	71.00
72	102	4	3	3	3	4	3	1	2	3	3	3	3	2	3	2	3	3	3	2	3	56.00
73	102	3	4	3	3	3	4	3	2	1	4	3	4	2	4	2	4	3	4	3	4	63.00
75	102	3	4	3	1	3	4	4	1	2	3	4	4	4	4	2	4	4	4	4	4	66.00
79	102	4	4	4	4	4	4	4	1	3	3	3	4	4	3	4	4	4	4	2	3	70.00
80	102	4	4	1	1	4	4	1	1	1	4	3	4	4	4	4	3	4	1	4	4	60.00
85	102	4	4	1	3	3	4	1	2	2	3	4	3	2	3	2	3	3	4	1	3	55.00
87	102	3	4	3	4	4	4	1	4	1	3	3	3	3	3	4	3	3	3	2	3	61.00
94	102	3	3	2	2	3	4	1	1	1	4	4	3	2	3	1	3	3	4	2	3	52.00
96	102	4	3	1	1	4	4	1	1	1	4	4	3	2	4	2	3	3	1	3	3	52.00
99	102	3	4	2	2	3	3	1	1	3	4	3	3	2	3	1	4	3	3	3	4	55.00
101	102	2	4	2	4	3	3	1	1	1	4	4	3	2	3	2	3	4	4	2	3	55.00
107	102	3	3	2	4	4	4	2	4	3	3	4	4	2	4	2	4	4	4	1	4	65.00
108	102	2	3	1	4	3	4	1	4	2	4	3	3	1	3	1	4	3	4	1	3	54.00
109	102	4	4	4	4	3	4	3	1	2	4	3	4	3	4	3	4	4	4	3	4	69.00
114	102	3	3	2	3	3	4	3	2	2	4	3	3	2	3	2	3	3	3	3	3	57.00
115	102	2	3	2	3	4	4	1	1	2	2	4	3	2	3	3	3	4	4	1	4	55.00
120	102	4	4	4	4	3	4	3	2	3	4	3	4	3	4	3	4	4	4	2	3	69.00
146	102	2	3	1	1	3	3	1	1	2	2	3	3	1	3	1	4	4	3	1	4	46.00
122	102	4	4	4	1	4	4	1	2	2	4	4	4	4	4	4	4	4	4	4	4	70.00
123	102	1	3	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	49.00
131	102	1	3	1	1	4	3	2	3	1	1	3	4	1	4	1	3	4	4	1	3	48.00
134	102	3	4	4	4	4	4	2	2	2	3	3	4	4	3	4	3	3	1	4	4	64.00
135	102	4	4	2	4	3	4	2	1	4	4	3	3	3	3	3	3	3	3	2	3	61.00
142	102	1	3	1	1	4	4	1	1	2	1	4	4	1	4	1	4	4	4	1	4	50.00
169	102	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00
171	102	3	3	3	3	4	4	2	2	2	3	4	4	2	4	1	4	4	4	3	4	63.00
176	102	3	3	3	3	4	4	2	2	2	3	4	3	2	4	2	4	4	4	3	4	63.00
177	102	3	3	3	3	4	4	2	1	2	2	4	3	2	4	1	4	4	4	3	4	60.00
184	102	3	3	3	3	4	4	2	2	2	3	4	4	1	4	2	4	4	4	3	4	63.00
185	102	3	3	3	2	4	4	2	1	2	3	4	4	1	4	3	4	4	4	3	4	62.00
PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	

FCE 20124/702 i

11

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
189	102	3	3	3	3	4	4	2	2	2	3	4	4	1	4	2	4	4	4	3	4	63.00
192	102	3	3	3	3	4	4	2	1	2	3	4	4	1	4	3	4	4	4	3	4	63.00
194	102	3	4	4	4	4	4	3	2	2	4	4	4	2	4	2	4	4	4	3	4	69.00
198	102	3	3	3	4	4	4	1	1	2	3	3	4	3	4	3	4	4	4	3	4	64.00
199	102	4	4	4	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	66.00
200	102	4	4	3	3	3	4	2	1	2	3	4	4	3	4	3	4	4	4	3	4	66.00
208	102	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
209	102	3	4	3	3	3	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00
211	102	4	4	3	3	3	3	2	2	2	3	3	4	2	4	2	4	3	3	2	4	60.00
215	102	4	4	4	3	3	4	2	2	2	4	4	4	3	4	3	4	4	4	3	4	69.00
217	102	2	3	2	2	3	3	2	2	2	2	3	3	1	3	1	3	3	4	1	3	48.00
222	102	2	3	2	3	3	4	2	2	1	2	3	4	2	3	2	3	3	3	2	3	52.00
223	102	2	4	3	4	4	4	4	2	2	3	3	4	4	4	1	4	4	4	1	4	65.00
224	102	2	3	1	1	4	3	1	2	1	1	4	4	1	4	1	3	3	3	1	4	47.00
231	102	2	3	2	2	3	4	4	1	1	1	4	4	4	4	1	4	4	4	1	4	57.00
232	102	3	4	3	3	4	4	2	2	2	3	3	4	1	3	3	4	4	4	3	4	63.00
235	102	4	4	1	4	4	4	1	1	2	4	3	4	4	4	4	4	4	4	2	4	66.00
240	102	2	3	2	1	3	3	1	1	1	3	4	3	3	4	2	3	3	4	1	3	50.00
244	102	3	3	3	2	4	4	2	2	1	3	4	3	1	3	2	4	3	4	3	4	58.00
246	102	3	3	2	3	3	4	1	1	2	3	4	4	1	3	1	4	3	4	3	4	56.00
247	102	3	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	61.00
248	102	3	3	2	2	3	3	1	1	1	2	4	3	1	4	1	4	3	3	2	4	50.00
257	102	4	4	4	4	4	4	3	1	1	4	4	4	4	4	3	4	4	4	2	4	70.00
258	102	4	3	3	4	3	3	1	1	1	3	3	4	3	4	3	4	3	4	2	4	60.00
259	102	3	3	2	2	3	4	2	1	1	2	4	4	1	3	1	3	4	4	3	4	54.00
263	102	2	3	2	2	4	4	2	1	2	3	4	4	2	4	1	3	4	4	3	4	58.00
267	102	4	4	3	3	4	4	3	2	2	3	4	4	3	4	3	4	4	4	3	4	69.00
270	102	2	3	2	3	3	4	1	1	1	3	4	4	3	4	2	4	3	4	2	4	57.00
271	102	3	4	3	3	4	4	3	2	2	3	4	4	3	4	3	4	4	4	2	4	67.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

12

Treatment Group "A"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.00	.09
2. Morning is when I feel best	3.45	.06
3. I have crying spells or feel like it	2.41	.11
4. I have trouble sleeping at night	2.81	.11
5. I eat as much as I used to	3.51	.06
6. I still enjoy sex	3.79	.05
7. I notice that I am losing weight	1.86	.10
8. I have trouble with constipation	1.85	.10
9. My heart beats faster than usual	1.91	.09
10. I get tired for no reason	2.92	.10
11. My mind is as clear as it used to be	3.59	.06
12. I find it easy to do the things I used to do	3.63	.05
13. I am restless and can't keep still	2.10	.11
14. I feel hopeful about the future	3.59	.06
15. I am more irritable than usual	2.25	.11
16. I find it easy to make decisions	3.59	.06
17. I feel that I am useful and needed	3.54	.06
18. My life is pretty full	3.66	.05
19. I feel that others would be better off if I were dead	2.23	.10
20. I still enjoy the things I used to do	3.61	.05
Total score	59.30	.79

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

13

PAT No.	PER (day)	Items:																				Total Score	
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
1	142	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00	
5	142	3	3	1	3	4	4	1	2	2	2	4	3	1	3	3	3	4	3	2	4	55.00	
9	142	3	3	2	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	53.00	
12	142	2	3	1	2	4	4	2	2	2	3	4	3	2	3	2	3	3	3	3	3	54.00	
13	142	4	4	1	4	3	4	2	1	2	1	3	4	1	4	4	3	3	3	1	3	55.00	
14	142	3	4	1	3	4	4	1	1	2	2	3	4	1	3	3	4	3	3	2	3	54.00	
25	142	2	3	1	2	4	3	1	2	1	2	4	4	1	3	2	4	4	4	1	4	52.00	
30	142	4	4	3	3	3	4	2	4	3	4	4	4	3	4	3	4	4	4	2	4	70.00	
35	142	4	4	2	4	3	4	2	2	2	3	4	4	1	4	3	3	4	4	2	4	63.00	
37	142	2	3	1	2	4	3	1	3	1	2	3	3	2	3	2	3	2	3	3	1	3	48.00
38	142	2	3	1	2	4	3	1	1	1	1	4	4	1	3	2	3	3	4	1	4	48.00	
45	142	2	3	1	2	4	4	1	2	2	2	4	4	2	4	2	4	4	4	1	4	56.00	
48	142	2	3	1	2	4	3	1	3	2	2	4	4	1	3	2	3	4	4	1	4	53.00	
49	142	4	4	4	2	3	3	3	2	3	3	3	3	2	3	3	3	3	3	3	3	60.00	
50	142	3	3	3	3	3	3	2	2	2	2	3	3	2	3	2	3	4	3	2	3	54.00	
56	142	2	3	3	3	3	3	1	1	2	2	3	3	2	3	2	3	3	3	2	3	50.00	
57	142	2	3	2	2	3	3	2	2	2	2	3	3	1	3	2	3	3	3	2	3	49.00	
64	142	3	4	3	3	4	3	3	2	3	4	3	4	3	4	4	4	4	3	4	4	69.00	
65	142	3	4	3	4	4	3	3	2	4	3	3	3	2	4	3	3	4	3	3	3	64.00	
68	142	2	4	4	4	3	3	3	3	4	3	3	3	2	3	4	3	3	3	4	3	64.00	
72	142	3	3	3	3	4	3	1	2	3	3	3	3	1	3	2	3	3	3	2	3	54.00	
73	142	3	4	3	2	3	4	3	2	2	3	3	4	3	4	2	4	4	4	3	4	64.00	
75	142	3	4	3	1	3	4	3	1	2	3	4	3	3	4	1	4	4	4	4	4	62.00	
79	142	4	4	4	4	4	4	4	4	1	3	3	3	4	4	3	4	4	4	3	4	72.00	
80	142	4	4	1	1	4	4	1	1	3	4	3	4	4	4	4	4	3	4	1	4	62.00	
85	142	3	4	1	2	4	4	1	2	2	2	4	3	2	3	1	4	4	4	1	3	54.00	
87	142	3	4	2	4	4	4	1	4	1	2	3	4	2	3	3	3	3	3	2	3	58.00	
94	142	2	3	2	1	4	4	1	1	2	3	3	4	2	3	2	4	3	3	2	3	52.00	
96	142	3	3	2	1	4	4	1	1	1	4	4	3	2	3	2	4	4	4	1	3	54.00	
99	142	3	3	2	2	3	3	1	1	2	3	3	3	2	3	1	3	3	3	2	3	49.00	
101	142	2	4	2	4	4	3	1	1	1	3	4	4	2	3	1	3	3	4	1	4	54.00	
107	142	4	4	3	4	3	4	1	3	2	2	4	4	4	4	2	4	4	4	1	4	65.00	
108	142	2	3	1	2	3	3	1	2	1	3	3	3	2	3	2	3	3	3	1	3	47.00	
109	142	4	4	4	4	3	4	3	1	2	4	3	4	3	4	3	4	4	4	3	4	69.00	
114	142	3	3	3	2	4	4	3	2	2	4	3	4	3	4	2	3	3	3	3	3	61.00	
115	142	2	3	2	2	4	4	1	1	2	2	4	3	2	3	2	3	4	4	1	4	53.00	
120	142	4	4	3	3	3	4	2	1	3	4	4	4	3	4	3	4	4	4	3	3	67.00	
146	142	2	4	2	2	3	4	1	2	2	2	3	4	2	3	1	4	4	4	2	4	55.00	
122	142	4	4	4	4	3	4	1	3	1	4	4	4	4	4	4	4	4	4	4	4	72.00	
123	142	1	3	1	2	4	4	1	1	1	2	4	4	1	4	1	4	4	4	1	4	51.00	
131	142	1	4	1	1	4	3	1	3	1	1	3	4	1	4	1	4	4	4	1	3	49.00	
134	142	4	4	4	4	4	4	4	2	4	2	3	4	4	3	2	4	4	4	1	4	69.00	
135	142	4	4	2	4	3	4	2	1	4	4	3	3	3	3	3	3	3	3	2	3	61.00	
142	142	1	4	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00	
169	142	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00	
171	142	3	3	2	2	3	4	1	1	1	3	3	4	1	4	2	3	3	4	2	3	52.00	
176	142	3	3	3	3	4	4	2	2	2	3	4	4	2	4	2	3	4	4	3	4	63.00	
177	142	3	3	3	3	4	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00	
184	142	3	3	3	3	4	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00	
185	142	3	3	3	2	4	4	1	2	2	3	4	4	1	4	3	4	4	4	3	4	62.00	
189	142	3	3	3	3	4	4	2	2	2	3	4	4	1	3	2	4	4	4	3	4	62.00	
192	142	3	3	3	3	4	4	2	1	2	3	4	4	1	4	1	4	4	4	3	4	61.00	
194	142	3	4	4	4	4	4	2	2	2	4	4	4	1	4	2	4	4	4	3	4	67.00	



FCE 20124/702 i

14

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
198	142	3	4	2	2	4	4	1	1	2	3	3	4	3	4	3	4	4	4	3	4	62.00
199	142	3	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
200	142	4	4	3	3	3	4	1	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
208	142	3	4	3	3	3	4	2	2	2	3	4	3	2	4	2	3	4	4	3	4	62.00
209	142	3	4	3	3	3	4	2	2	2	3	4	3	2	4	2	3	4	4	3	4	62.00
211	142	4	4	3	3	3	3	2	2	2	3	3	4	2	4	2	3	3	4	2	4	60.00
215	142	4	4	3	4	3	4	2	2	2	3	4	4	3	4	3	4	4	4	3	4	68.00
217	142	2	3	2	1	3	3	1	1	1	1	3	4	1	3	2	3	3	3	1	3	44.00
222	142	2	3	2	2	3	4	2	2	1	2	3	4	2	3	1	3	3	3	2	3	50.00
224	142	1	4	1	1	4	3	1	1	2	2	4	4	1	4	1	4	4	4	1	4	51.00
231	142	2	3	2	2	4	4	4	1	1	1	4	4	2	4	1	4	4	4	1	4	56.00
232	142	2	3	2	2	3	4	2	3	3	3	3	4	3	3	4	4	3	4	3	4	62.00
235	142	4	4	4	4	4	4	4	1	4	1	4	4	4	4	4	4	4	4	2	4	72.00
240	142	4	3	2	1	3	3	4	2	1	2	4	3	2	4	2	4	4	4	1	3	56.00
244	142	3	3	2	2	3	4	1	2	1	3	4	4	1	3	1	3	4	4	3	4	55.00
246	142	3	3	2	2	3	4	1	1	2	3	4	4	1	3	1	3	3	4	2	4	53.00
247	142	3	3	2	3	3	4	1	1	1	2	3	4	1	4	1	4	3	4	3	4	54.00
248	142	3	3	2	2	3	3	1	2	1	2	3	3	1	4	2	3	3	3	2	3	49.00
257	142	4	3	4	4	4	4	3	1	1	4	3	3	4	4	3	4	4	4	2	4	67.00
258	142	3	3	3	4	3	3	1	1	1	3	4	4	3	3	3	3	3	4	2	4	58.00
259	142	2	3	2	2	3	4	1	1	1	2	3	4	1	3	1	4	4	4	2	4	51.00
263	142	2	3	2	2	3	4	2	1	1	2	4	4	1	3	1	4	4	4	2	4	53.00
267	142	3	3	2	2	4	4	3	2	2	3	4	4	3	4	2	4	3	4	3	4	63.00
270	142	2	4	2	2	3	4	1	1	2	3	3	3	3	4	3	3	3	4	2	3	55.00
271	142	3	4	2	3	4	4	3	2	2	3	4	4	2	4	2	3	3	4	2	4	62.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

15

Treatment Group "A"

Day 14 (Period 142)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.86	.09
2. Morning is when I feel best	3.47	.06
3. I have crying spells or feel like it	2.33	.11
4. I have trouble sleeping at night	2.59	.11
5. I eat as much as I used to	3.53	.06
6. I still enjoy sex	3.72	.05
7. I notice that I am losing weight	1.77	.10
8. I have trouble with constipation	1.72	.09
9. My heart beats faster than usual	1.87	.09
10. I get tired for no reason	2.65	.10
11. My mind is as clear as it used to be	3.54	.06
12. I find it easy to do the things I used to do	3.69	.05
13. I am restless and can't keep still	2.00	.11
14. I feel hopeful about the future	3.56	.06
15. I am more irritable than usual	2.17	.10
16. I find it easy to make decisions	3.54	.06
17. I feel that I am useful and needed	3.59	.06
18. My life is pretty full	3.69	.05
19. I feel that others would be better off if I were dead	2.17	.10
20. I still enjoy the things I used to do	3.64	.05
Total score	58.10	.78

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

16

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	212	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00
5	212	2	3	1	1	4	4	1	2	2	2	4	3	1	3	2	3	4	3	2	4	51.00
9	212	3	4	2	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	54.00
12	212	3	3	1	2	4	4	2	2	2	3	4	3	2	3	3	3	3	3	3	3	56.00
13	212	4	4	1	4	3	4	2	1	2	1	3	4	1	4	4	3	3	3	1	3	55.00
14	212	3	4	1	3	4	4	1	1	2	2	3	4	1	3	3	4	3	3	2	3	54.00
25	212	2	3	1	2	4	3	1	2	1	2	4	4	1	4	2	4	4	4	1	4	53.00
30	212	4	4	3	3	3	4	1	4	3	4	4	4	3	4	3	4	3	4	2	4	68.00
35	212	4	4	2	3	3	4	2	2	2	3	4	4	3	4	3	3	4	4	1	4	63.00
37	212	2	3	1	2	4	3	1	2	1	2	4	4	1	4	2	3	3	3	1	3	49.00
38	212	2	3	1	2	4	3	1	1	1	1	4	4	1	3	1	3	4	4	1	4	48.00
45	212	2	3	1	2	3	4	1	2	2	2	4	4	1	4	1	3	4	4	1	3	51.00
48	212	2	3	1	2	4	3	1	2	1	1	4	4	1	3	2	3	4	4	1	4	50.00
49	212	2	3	3	2	3	3	2	2	2	2	3	3	2	3	2	3	3	3	2	3	51.00
50	212	2	3	2	2	4	3	2	2	2	2	3	3	1	3	2	3	4	4	1	4	52.00
56	212	2	3	2	2	3	3	1	1	2	2	3	3	2	3	2	3	3	3	2	3	48.00
57	212	2	3	2	2	3	3	2	2	2	2	3	3	1	3	3	3	3	3	2	3	50.00
64	212	4	4	3	3	3	4	3	3	3	4	3	4	2	4	3	3	4	4	3	4	68.00
65	212	4	3	4	3	4	4	3	2	4	3	3	3	2	3	2	3	3	3	2	3	61.00
68	212	3	3	3	3	3	4	3	3	3	3	3	3	2	3	4	3	4	4	3	3	63.00
72	212	3	4	3	3	4	3	1	2	3	3	3	3	1	3	2	3	3	3	2	3	55.00
73	212	3	4	3	2	3	4	3	2	1	4	3	4	2	4	2	4	4	4	3	4	63.00
75	212	4	4	3	1	3	4	3	1	2	3	4	3	4	4	1	4	4	4	3	4	63.00
79	212	4	4	4	4	4	4	4	4	1	3	3	3	4	4	3	4	4	4	3	4	72.00
80	212	3	4	1	1	4	4	1	1	2	2	4	4	1	3	1	3	3	4	1	4	51.00
85	212	3	4	1	2	4	4	1	2	1	2	4	3	2	4	2	4	4	4	1	4	56.00
87	212	3	4	1	3	4	4	1	4	1	2	4	4	2	4	2	4	4	3	2	4	60.00
94	212	2	3	1	2	4	3	1	2	1	3	3	3	1	3	2	3	3	3	2	3	48.00
96	212	3	3	2	1	3	4	1	1	1	3	3	3	2	3	2	3	4	3	1	3	49.00
99	212	2	3	2	1	4	3	1	1	2	2	4	3	2	3	2	3	3	3	1	3	48.00
101	212	1	3	1	2	3	3	1	1	1	1	3	3	2	4	2	4	4	3	1	4	47.00
107	212	4	3	2	4	4	4	1	1	1	3	4	4	3	3	1	4	4	4	3	4	61.00
108	212	2	4	1	2	3	3	1	1	2	2	3	4	1	3	1	3	3	3	1	3	46.00
109	212	4	4	3	4	3	4	3	1	2	4	3	3	3	4	3	3	3	4	2	3	63.00
114	212	4	4	3	2	4	4	4	2	2	4	3	4	3	4	2	4	4	4	4	4	69.00
115	212	2	4	2	2	4	4	1	1	2	2	4	3	2	4	2	3	4	4	1	4	55.00
120	212	4	4	3	3	3	3	3	2	3	4	3	4	3	4	3	4	4	4	3	3	67.00
146	212	1	3	1	1	3	3	1	2	1	2	3	4	2	4	1	3	4	3	1	3	46.00
122	212	4	4	4	4	3	4	1	2	2	4	4	4	4	4	4	4	4	4	4	4	72.00
123	212	1	4	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00
131	212	1	3	1	1	4	3	2	3	1	1	3	3	1	4	1	4	4	4	1	4	49.00
135	212	2	3	2	2	4	4	1	1	2	1	4	3	3	3	1	3	3	3	1	4	50.00
142	212	1	4	2	1	4	4	1	1	1	1	4	4	2	4	2	4	4	4	1	4	53.00
169	212	3	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	4	4	62.00
171	212	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00
176	212	3	3	3	3	4	4	2	1	3	3	3	4	2	4	2	3	4	4	3	4	62.00
177	212	3	3	3	3	4	4	2	1	2	3	4	4	2	4	3	4	4	4	3	4	64.00
184	212	3	3	3	3	4	4	2	1	2	3	4	3	1	4	2	4	4	4	3	3	60.00
185	212	3	3	3	3	4	4	2	1	2	3	4	4	1	4	3	4	4	4	3	4	63.00
189	212	3	3	3	3	4	4	2	2	2	3	4	4	1	3	2	4	4	4	3	4	62.00
192	212	3	3	3	3	4	4	2	2	2	3	4	4	1	4	2	4	4	4	3	4	63.00
194	212	3	4	4	3	4	4	1	1	1	3	4	4	1	4	2	4	3	3	3	3	59.00
198	212	3	4	2	2	4	4	1	1	2	2	4	4	2	4	3	4	4	4	3	3	60.00
199	212	3	3	3	3	3	4	1	1	2	3	3	4	2	4	2	4	4	4	3	4	60.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

17

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
200	212	4	4	3	3	3	4	1	1	2	3	3	4	2	4	2	4	4	4	3	4	62.00
208	212	3	4	3	3	3	4	2	2	2	3	4	3	2	3	2	3	3	4	2	3	58.00
209	212	3	4	3	3	3	4	2	2	2	3	4	3	2	3	2	3	3	4	2	3	58.00
211	212	3	3	3	3	3	3	2	2	2	3	3	3	2	4	2	3	3	4	2	4	57.00
215	212	3	4	4	3	3	4	2	2	2	3	4	4	3	4	3	4	4	4	3	4	67.00
217	212	1	4	2	1	3	4	1	1	1	2	3	3	1	4	1	3	4	3	1	3	46.00
224	212	2	4	1	1	4	3	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00
231	212	2	4	2	2	4	4	1	1	1	1	4	4	2	4	1	4	4	4	1	4	54.00
232	212	3	3	2	2	4	4	2	3	4	3	3	4	4	4	3	4	3	4	2	4	65.00
235	212	1	4	1	1	4	4	1	1	1	1	4	4	2	4	1	4	4	4	1	4	51.00
240	212	1	4	2	1	4	4	1	2	1	2	3	4	1	4	1	4	4	4	1	3	51.00
244	212	2	3	2	2	3	4	1	1	2	3	3	3	1	3	1	3	4	4	2	3	50.00
246	212	2	3	2	2	3	4	1	1	1	3	3	3	1	3	1	3	3	3	2	3	47.00
247	212	3	3	2	2	3	4	1	2	1	2	3	3	1	4	2	4	3	3	2	3	51.00
248	212	2	3	2	2	3	4	1	2	1	3	3	4	1	3	1	3	4	3	2	3	50.00
257	212	3	3	4	4	4	4	3	1	1	3	4	4	3	4	3	4	4	4	2	4	66.00
258	212	3	3	3	4	3	3	1	1	1	3	3	4	3	3	3	3	3	3	2	3	55.00
259	212	2	3	2	2	3	4	1	1	1	2	3	3	1	3	1	4	3	3	2	3	47.00
263	212	3	3	2	2	3	4	2	1	1	1	3	4	1	4	2	3	4	4	2	3	52.00
267	212	3	3	2	2	4	4	3	2	2	3	3	4	3	4	2	3	3	4	2	4	60.00
270	212	2	4	2	2	3	4	1	1	2	3	3	3	2	3	2	3	3	3	1	3	50.00
271	212	2	3	2	2	3	4	3	1	2	2	3	3	2	3	2	3	3	4	1	3	51.00

FCE 20124/702 i

18

Treatment Group "A"

Day 21 (Period 212)

Number of Observations = 76

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.66	.10
2. Morning is when I feel best	3.45	.06
3. I have crying spells or feel like it	2.20	.11
4. I have trouble sleeping at night	2.33	.10
5. I eat as much as I used to	3.55	.06
6. I still enjoy sex	3.75	.05
7. I notice that I am losing weight	1.62	.09
8. I have trouble with constipation	1.63	.09
9. My heart beats faster than usual	1.71	.08
10. I get tired for no reason	2.46	.10
11. My mind is as clear as it used to be	3.49	.06
12. I find it easy to do the things I used to do	3.59	.06
13. I am restless and can't keep still	1.80	.10
14. I feel hopeful about the future	3.61	.06
15. I am more irritable than usual	2.01	.09
16. I find it easy to make decisions	3.47	.06
17. I feel that I am useful and needed	3.61	.06
18. My life is pretty full	3.63	.06
19. I feel that others would be better off if I were dead	1.99	.10
20. I still enjoy the things I used to do	3.54	.06
Total score	56.09	.80

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

19

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1	282	3	4	1	2	4	4	1	1	1	2	3	4	1	4	2	3	3	3	1	3	50.00
5	282	1	3	1	1	4	4	1	2	2	2	4	4	1	3	2	3	4	4	1	4	51.00
9	282	2	4	1	2	4	4	1	1	1	2	4	4	1	3	2	3	3	3	3	4	52.00
12	282	3	3	1	2	4	4	2	2	2	3	4	3	2	3	3	3	3	3	3	3	56.00
13	282	4	4	1	4	3	4	2	1	2	1	4	4	1	4	4	3	4	4	1	3	58.00
14	282	3	4	1	3	4	4	1	1	2	2	3	4	1	3	3	4	3	3	2	3	54.00
25	282	2	3	1	2	4	3	1	2	1	2	4	4	1	4	2	4	4	4	1	4	53.00
30	282	4	4	2	3	3	4	2	4	3	3	4	4	3	4	4	4	4	4	1	4	68.00
35	282	4	4	2	3	3	4	1	2	2	3	4	4	1	4	3	3	4	4	2	4	61.00
37	282	2	3	1	2	4	3	1	2	1	2	4	4	1	4	2	3	4	4	1	4	52.00
38	282	2	3	1	2	4	3	1	1	1	1	4	4	1	4	2	3	4	4	1	4	50.00
45	282	2	3	1	2	4	4	1	2	2	1	4	4	1	4	1	3	4	4	1	4	52.00
48	282	2	3	1	2	4	3	1	2	1	1	4	4	1	3	1	3	4	4	1	4	49.00
49	282	2	3	2	2	4	3	1	2	1	1	3	3	2	3	1	3	3	4	1	4	48.00
50	282	2	4	1	1	4	4	1	2	1	1	3	4	1	4	1	4	4	4	1	4	51.00
56	282	2	3	2	1	3	3	1	1	2	1	4	3	1	3	2	3	3	1	3	3	45.00
57	282	2	3	2	2	3	4	1	2	2	2	3	3	1	3	1	3	3	3	1	4	48.00
64	282	4	4	3	3	3	4	3	2	3	4	4	4	3	4	3	4	4	4	4	4	71.00
65	282	3	4	3	3	4	3	3	2	4	3	3	3	2	3	3	3	4	3	2	3	61.00
68	282	3	3	3	3	4	3	3	3	3	3	3	3	2	3	4	3	3	3	3	3	61.00
72	282	3	3	3	3	4	3	1	2	3	3	3	3	2	3	2	3	3	3	2	3	55.00
75	282	3	4	3	1	3	4	2	1	2	3	3	4	4	4	1	4	3	4	4	4	61.00
79	282	4	4	4	4	4	4	3	1	3	3	3	4	4	3	4	4	3	4	3	4	70.00
80	282	2	3	1	1	4	4	1	1	1	1	4	3	1	3	1	4	4	3	1	4	47.00
85	282	2	4	1	2	4	4	1	2	2	3	4	3	1	3	2	4	4	4	1	4	55.00
87	282	2	4	1	2	4	3	1	3	1	2	4	3	2	4	2	3	4	4	1	4	54.00
94	282	2	3	2	2	4	3	1	2	1	3	3	3	2	4	2	3	4	4	2	3	53.00
96	282	3	4	2	1	4	4	1	1	1	3	3	3	2	3	1	3	4	3	3	3	52.00
99	282	2	3	2	1	4	3	1	1	2	2	4	3	2	3	2	3	3	3	1	3	48.00
101	282	1	3	1	2	3	3	1	1	1	1	3	3	2	4	2	4	4	3	1	4	47.00
107	282	2	4	2	2	3	4	1	2	2	4	4	4	4	4	3	4	4	4	2	4	63.00
108	282	1	3	1	1	4	3	1	1	1	2	3	3	1	4	1	3	4	3	1	4	45.00
109	282	4	4	4	4	3	3	2	1	3	4	3	4	3	4	3	4	4	4	3	4	68.00
114	282	4	4	3	3	4	4	4	2	2	4	3	4	3	4	3	4	4	4	3	4	70.00
115	282	1	4	1	1	4	4	1	1	1	1	4	4	2	3	3	3	4	4	1	4	51.00
120	282	4	4	3	4	3	4	2	1	3	4	3	3	3	4	3	4	4	4	3	3	66.00
146	282	1	4	1	1	3	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	49.00
123	282	1	4	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00
131	282	1	4	1	1	4	3	2	3	1	1	3	3	3	4	1	4	4	4	1	3	51.00
135	282	1	3	2	1	3	4	1	1	1	2	3	3	1	3	2	3	3	3	1	3	44.00
142	282	1	4	1	1	4	4	1	1	2	1	4	4	1	4	1	4	4	4	1	4	51.00
169	282	4	3	3	3	3	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	61.00
171	282	3	3	3	3	4	4	2	1	2	3	4	4	1	4	1	4	4	4	3	4	61.00
176	282	3	3	3	3	4	4	2	1	2	2	4	4	1	4	3	4	4	4	3	4	62.00
177	282	3	3	3	3	4	4	2	1	2	3	4	4	2	4	3	3	4	4	2	4	62.00
184	282	3	3	3	3	4	4	2	1	2	3	4	3	1	4	3	3	4	4	3	3	60.00
185	282	3	3	3	3	4	4	2	1	2	3	4	4	1	4	3	4	3	4	3	4	62.00
189	282	3	3	3	3	4	4	2	2	2	3	4	4	1	4	3	4	4	4	2	4	63.00
192	282	3	3	3	3	4	4	2	2	2	3	4	4	1	4	3	4	4	4	3	4	64.00
194	282	3	3	3	3	3	4	1	1	2	3	3	4	2	4	2	4	4	4	3	3	59.00
198	282	3	3	3	2	4	4	1	1	2	2	3	3	2	3	2	3	4	4	2	3	54.00
199	282	2	3	2	2	3	4	1	1	2	3	3	3	2	4	2	3	4	4	2	3	53.00
200	282	3	3	2	2	3	4	1	1	2	2	4	4	2	4	2	4	3	4	2	4	56.00
208	282	3	3	2	2	3	4	2	2	2	3	3	3	2	4	2	3	3	4	2	3	55.00

FCE 20124/702 i

20

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
209	282	3	3	2	2	3	4	2	2	2	3	3	3	2	4	2	3	3	4	2	3	55.00
211	282	3	3	3	2	3	3	1	2	2	3	3	3	2	4	2	3	3	4	2	3	54.00
215	282	2	3	3	2	3	4	2	2	2	3	3	4	2	3	2	4	4	4	3	4	59.00
217	282	2	3	2	3	3	3	1	1	2	2	3	3	1	3	2	3	3	3	1	3	47.00
224	282	1	4	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00
231	282	2	3	2	1	4	4	1	1	1	1	4	4	2	4	1	4	4	4	1	4	52.00
235	282	1	4	1	1	4	4	1	1	2	1	4	4	4	4	1	4	4	4	1	3	53.00
240	282	3	4	3	1	3	3	1	3	1	3	4	4	4	3	3	4	4	4	1	3	59.00
244	282	2	3	2	2	3	4	1	2	1	2	3	3	1	3	1	3	4	3	2	3	48.00
246	282	2	3	2	2	3	4	1	1	1	2	3	3	1	3	1	3	3	3	2	3	46.00
247	282	2	3	2	2	3	4	1	1	2	2	3	3	1	3	2	3	3	3	2	3	48.00
248	282	2	3	2	2	3	4	1	1	2	2	3	3	1	3	1	3	3	3	2	3	47.00
257	282	3	3	4	3	3	4	2	1	1	3	4	4	2	3	3	4	4	3	2	3	59.00
258	282	3	3	3	3	3	3	1	1	1	3	3	3	3	3	3	3	3	3	2	3	53.00
259	282	2	3	2	2	3	4	1	1	1	2	3	3	1	3	2	3	3	3	2	3	47.00
263	282	2	3	2	2	3	4	2	1	1	2	4	3	1	3	2	4	3	4	2	3	51.00
267	282	3	3	2	1	4	4	2	1	1	2	3	3	3	4	3	3	3	3	2	3	53.00
270	282	1	3	1	1	3	4	1	1	1	1	3	3	1	3	1	3	3	3	1	3	41.00
271	282	2	3	2	1	3	4	2	2	1	2	3	3	2	3	2	3	3	3	1	3	48.00

FCE 20124/702 i

21

Treatment Group "A"

Day 28 (Period 282)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.42	.11
2. Morning is when I feel best	3.36	.06
3. I have crying spells or feel like it	2.03	.10
4. I have trouble sleeping at night	2.10	.10
5. I eat as much as I used to	3.53	.06
6. I still enjoy sex	3.74	.05
7. I notice that I am losing weight	1.47	.08
8. I have trouble with constipation	1.53	.08
9. My heart beats faster than usual	1.66	.08
10. I get tired for no reason	2.26	.11
11. My mind is as clear as it used to be	3.51	.06
12. I find it easy to do the things I used to do	3.51	.06
13. I am restless and can't keep still	1.74	.11
14. I feel hopeful about the future	3.58	.06
15. I am more irritable than usual	2.07	.10
16. I find it easy to make decisions	3.45	.06
17. I feel that I am useful and needed	3.63	.06
18. My life is pretty full	3.63	.06
19. I feel that others would be better off if I were dead	1.85	.10
20. I still enjoy the things I used to do	3.51	.06
Total score	54.56	.80



FCE 20124/702 i

22

Table 5d - Zung Self-rating Depression Scale

		Treatment Group "B"																				
PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	000	3	3	1	3	3	4	1	1	3	2	3	3	1	3	3	4	3	3	3	3	53.00
10	000	3	3	1	2	3	4	1	1	3	3	4	3	3	3	3	3	3	3	3	2	54.00
11	000	4	3	2	4	3	4	2	1	2	3	4	4	1	3	2	3	4	3	3	3	58.00
15	000	4	3	2	4	3	3	1	1	3	2	3	3	1	3	3	4	3	3	2	3	54.00
17	000	4	3	1	2	3	4	1	1	1	3	3	3	2	3	3	4	3	4	3	3	54.00
28	000	4	4	3	4	4	4	1	3	3	4	4	4	2	4	3	4	4	4	2	4	69.00
29	000	4	4	3	3	3	4	2	4	3	4	4	4	3	4	4	4	4	4	3	4	72.00
31	000	4	4	2	4	4	4	1	3	2	3	4	4	3	4	3	4	4	4	2	4	67.00
32	000	4	4	3	4	4	4	4	4	2	3	4	4	3	4	4	4	4	4	3	4	74.00
41	000	4	4	4	4	3	4	1	3	2	4	4	4	3	4	4	4	4	4	3	4	71.00
42	000	4	4	3	4	3	4	3	3	2	4	4	4	4	4	4	4	4	4	3	4	73.00
44	000	4	4	3	4	3	4	2	3	3	4	4	4	2	4	3	4	4	4	3	4	70.00
47	000	4	4	3	3	4	4	2	4	3	4	4	4	3	4	4	4	4	4	1	4	71.00
51	000	4	4	4	4	4	4	4	3	4	4	4	4	3	4	3	4	4	4	4	4	77.00
54	000	3	4	3	4	4	4	3	4	3	4	3	3	2	3	3	3	4	4	3	3	67.00
55	000	3	4	3	3	3	4	2	3	3	3	3	3	3	3	3	3	3	3	3	3	61.00
60	000	3	4	3	3	3	4	4	3	3	4	4	3	3	4	3	4	4	3	3	3	68.00
61	000	3	4	2	3	3	3	2	2	4	4	3	3	2	3	2	3	3	3	3	3	58.00
66	000	4	4	3	4	4	4	3	2	4	3	4	4	2	4	3	4	4	4	4	4	72.00
67	000	3	4	3	4	4	4	3	3	3	3	3	3	3	4	2	4	3	4	3	3	66.00
70	000	3	4	3	3	4	4	3	3	4	4	3	4	3	3	2	3	4	3	4	4	68.00
77	000	4	4	4	4	4	4	4	2	3	4	4	4	4	4	1	4	4	4	4	4	74.00
78	000	4	4	3	3	4	4	1	1	1	4	4	4	3	4	2	4	4	4	4	4	66.00
83	000	4	4	3	3	4	4	2	2	2	4	4	4	4	4	3	4	4	4	4	4	71.00
84	000	4	4	3	4	4	3	1	4	3	4	4	3	3	4	3	3	3	4	1	3	65.00
88	000	4	4	3	3	4	4	4	1	1	4	3	4	3	4	3	3	3	4	2	3	64.00
90	000	4	4	4	3	3	4	1	4	1	3	3	4	2	4	2	4	4	4	2	4	64.00
91	000	4	4	3	3	3	4	2	3	1	4	4	4	3	4	3	4	4	4	3	4	68.00
95	000	3	4	3	3	4	4	1	1	1	3	4	4	2	4	2	4	3	4	3	4	61.00
98	000	4	4	2	4	4	4	4	1	2	3	4	4	1	4	3	4	4	4	4	4	68.00
102	000	4	3	3	4	4	3	2	4	2	2	3	3	4	3	2	3	3	4	1	3	60.00
103	000	1	4	2	3	3	3	1	2	1	2	3	3	2	3	1	4	3	3	1	4	49.00
106	000	4	4	3	3	3	3	1	1	4	4	3	3	4	4	4	3	4	4	2	3	64.00
110	000	4	4	4	4	4	4	4	2	2	4	4	4	3	4	3	4	4	4	3	4	73.00
113	000	4	4	4	3	4	3	4	3	3	4	3	4	3	4	3	4	4	4	3	4	72.00
118	000	4	4	2	1	4	4	4	2	2	4	3	4	1	4	1	4	4	4	3	4	63.00
119	000	4	4	4	4	4	3	2	2	2	4	4	4	1	3	1	4	4	4	3	4	65.00
124	000	3	3	3	2	3	4	4	3	2	3	4	4	1	4	3	4	3	4	4	3	64.00
126	000	4	4	2	3	4	4	2	2	2	4	4	4	3	4	2	4	4	4	2	4	66.00
127	000	4	4	4	4	4	1	1	4	4	4	4	4	3	4	3	4	4	4	4	4	72.00
132	000	4	4	4	3	3	4	2	1	1	3	4	4	3	4	2	4	3	3	3	4	63.00
133	000	4	4	4	2	4	3	2	1	2	4	4	4	4	4	4	4	4	4	4	4	70.00
136	000	3	4	4	4	4	4	2	1	2	4	4	4	3	4	4	4	4	4	3	4	70.00
139	000	4	4	4	4	4	4	1	2	4	4	4	4	3	3	3	4	4	4	3	4	71.00
140	000	2	4	2	4	4	3	2	1	2	4	3	3	2	3	2	4	3	4	2	3	57.00
147	000	3	4	1	4	3	4	1	4	2	4	4	4	4	4	3	4	3	3	1	4	64.00
148	000	3	4	4	4	4	4	2	1	1	3	4	3	1	3	1	3	3	4	1	4	57.00
170	000	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00
172	000	3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	61.00
179	000	4	3	3	3	3	3	2	1	3	4	4	1	4	2	4	4	4	3	4	4	62.00

FCE 20124/702 i

23

PAT PER No. (day)	Items:																				Total Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
180 000	4	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	62.00
181 000	4	3	3	3	4	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
186 000	4	3	3	3	4	4	2	1	1	2	3	3	1	4	1	4	4	4	4	3	58.00
187 000	4	3	3	3	4	4	2	1	1	3	4	4	1	4	2	4	4	4	4	4	63.00
188 000	3	3	3	3	4	4	1	1	2	3	4	4	1	3	1	4	3	4	4	4	59.00
193 000	4	4	4	4	4	4	3	2	2	3	4	4	2	4	2	4	4	4	3	4	69.00
197 000	3	4	4	4	3	4	1	1	2	4	4	4	2	4	2	4	4	4	4	4	66.00
202 000	3	3	3	2	3	4	2	2	2	3	3	3	2	4	3	4	4	4	2	3	59.00
203 000	4	4	3	3	3	4	2	1	2	3	4	4	2	4	3	4	4	4	3	4	65.00
206 000	4	4	3	3	3	3	2	2	2	3	4	4	2	4	2	4	2	4	4	3	64.00
210 000	3	4	3	3	3	3	1	2	2	3	4	4	2	4	2	4	4	4	3	4	62.00
214 000	3	4	3	3	3	4	2	2	2	3	4	4	3	4	3	4	4	4	3	4	66.00
216 000	3	4	3	3	3	4	1	2	2	3	4	4	3	4	3	4	4	4	3	4	65.00
218 000	3	3	4	3	4	3	3	3	2	3	4	4	4	3	2	4	4	3	4	3	66.00
219 000	2	4	2	4	3	3	2	3	4	2	4	3	4	4	2	3	4	3	2	3	61.00
226 000	2	3	2	4	4	3	4	2	1	1	3	4	4	3	2	3	3	4	1	3	56.00
227 000	1	4	1	1	4	4	4	1	1	1	3	3	1	3	1	3	3	3	1	3	46.00
230 000	4	4	3	4	4	4	4	1	2	4	4	4	4	3	4	3	4	4	1	4	69.00
233 000	4	4	4	4	4	4	4	2	4	4	3	4	4	4	2	4	3	4	1	4	71.00
237 000	2	4	2	4	4	4	3	1	1	4	3	4	4	4	1	4	4	4	2	4	63.00
238 000	3	4	3	3	4	4	4	4	2	4	4	4	4	4	1	4	4	3	1	4	68.00
243 000	4	3	3	3	4	4	2	2	1	2	4	4	1	4	1	4	4	4	3	4	61.00
249 000	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
251 000	4	4	4	4	3	3	1	3	2	4	4	4	4	4	3	4	4	4	4	4	71.00
254 000	4	4	3	4	3	4	3	3	2	4	3	3	3	3	3	4	4	4	3	4	68.00
255 000	4	4	3	4	4	4	3	1	2	4	4	4	4	4	4	3	3	4	3	4	70.00
260 000	3	4	2	2	4	4	2	1	2	3	4	4	1	4	1	4	4	4	3	4	60.00
262 000	3	3	3	2	4	4	2	1	1	3	4	4	2	4	1	4	4	4	3	4	60.00
268 000	4	4	3	4	3	3	1	1	2	3	4	4	3	4	3	4	4	4	3	4	65.00
269 000	4	4	4	4	3	4	2	2	2	4	4	4	4	4	4	4	3	4	3	4	71.00
273 000	3	4	3	4	3	3	1	2	1	4	4	4	4	4	4	3	3	4	4	4	66.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

24

Treatment Group "B"

Baseline (Period 000)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.49	.08
2. Morning is when I feel best	3.74	.05
3. I have crying spells or feel like it	2.95	.09
4. I have trouble sleeping at night	3.32	.08
5. I eat as much as I used to	3.59	.05
6. I still enjoy sex	3.77	.05
7. I notice that I am losing weight	2.25	.12
8. I have trouble with constipation	2.07	.12
9. My heart beats faster than usual	2.09	.10
10. I get tired for no reason	3.35	.08
11. My mind is as clear as it used to be	3.72	.05
12. I find it easy to do the things I used to do	3.75	.05
13. I am restless and can't keep still	2.52	.12
14. I feel hopeful about the future	3.74	.05
15. I am more irritable than usual	2.44	.11
16. I find it easy to make decisions	3.79	.05
17. I feel that I am useful and needed	3.70	.05
18. My life is pretty full	3.80	.04
19. I feel that others would be better off if I were dead	2.79	.10
20. I still enjoy the things I used to do	3.73	.05
Total score	64.60	.67

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

25

PAT	PER	Items:																				Total Score			
		No.	(day)	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18		19	20	
2	042			3	3	1	2	3	4	1	1	3	2	3	3	1	3	3	4	3	3	3	3	52.00	
10	042			3	3	1	2	3	4	1	1	3	3	4	3	2	3	3	3	3	3	3	2	3	53.00
11	042			4	3	2	4	3	4	2	1	2	3	4	4	1	3	2	3	4	3	3	3	58.00	
15	042			4	4	2	4	3	3	1	1	3	2	3	3	1	3	3	4	3	3	2	3	55.00	
17	042			4	3	1	2	3	4	1	1	1	3	3	3	2	3	3	4	3	4	3	3	54.00	
28	042			4	4	2	4	4	4	1	3	3	4	4	4	3	4	3	4	4	4	4	2	4	69.00
29	042			4	4	3	3	3	4	2	4	3	4	4	4	3	4	4	4	4	4	4	3	4	72.00
31	042			4	4	2	4	4	4	1	2	2	3	4	4	3	4	3	4	4	4	4	2	4	66.00
32	042			4	4	3	3	3	4	2	3	3	4	4	4	3	4	4	4	4	4	4	3	4	71.00
41	042			4	4	4	4	3	4	1	3	2	4	4	4	3	3	4	4	4	4	4	3	3	69.00
42	042			4	4	3	4	3	4	2	3	2	4	4	4	3	4	4	4	4	4	4	3	4	71.00
44	042			4	4	2	4	3	4	1	3	3	4	4	4	2	4	3	4	4	4	4	2	4	67.00
47	042			4	4	3	3	3	4	2	3	3	4	4	4	3	4	3	4	4	4	4	1	4	68.00
51	042			4	4	4	4	3	3	4	3	4	4	4	4	3	4	4	4	4	4	4	4	4	76.00
54	042			4	3	3	3	3	3	3	3	3	3	3	3	2	3	3	3	4	4	3	3	62.00	
55	042			3	4	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60.00
60	042			3	4	3	3	3	4	3	3	3	4	4	3	3	4	3	4	4	4	3	3	3	67.00
61	042			3	3	3	3	3	2	2	4	3	3	3	2	3	2	3	2	3	3	3	3	3	57.00
66	042			4	4	3	4	4	4	3	3	4	3	4	4	1	4	4	4	4	4	3	3	4	71.00
67	042			4	3	3	3	3	4	3	3	3	3	3	3	3	4	2	4	3	3	3	3	3	63.00
70	042			4	3	4	4	3	3	3	3	4	3	3	3	3	4	2	4	3	3	3	3	3	65.00
77	042			4	4	4	4	4	4	4	2	3	4	3	4	4	4	1	4	4	4	4	4	4	73.00
78	042			2	3	1	2	3	4	1	1	1	3	3	3	1	3	1	3	3	3	3	2	3	46.00
83	042			4	4	3	2	3	4	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	70.00
84	042			4	4	3	4	4	3	1	4	3	4	4	3	3	4	3	3	3	4	1	3	65.00	
88	042			4	4	3	3	4	4	4	1	1	3	3	4	3	3	3	3	3	3	3	2	4	62.00
90	042			4	4	3	2	3	4	1	3	1	3	3	3	1	3	1	3	3	4	2	3	54.00	
91	042			4	4	3	4	3	3	1	3	1	4	4	4	2	3	2	3	4	4	3	4	63.00	
95	042			2	4	2	2	4	4	1	1	1	1	3	4	2	3	2	4	4	4	2	4	54.00	
98	042			4	4	2	4	4	4	2	2	1	3	3	4	2	4	3	4	4	4	4	4	4	66.00
102	042			3	3	3	4	4	3	1	4	2	2	3	3	4	3	2	3	3	4	1	3	58.00	
103	042			2	3	1	2	3	3	1	3	1	1	3	3	2	3	2	3	3	3	1	3	46.00	
106	042			4	4	4	3	4	4	1	1	3	4	4	4	3	4	3	4	4	4	4	2	4	68.00
110	042			4	4	4	4	4	4	3	2	2	4	4	4	3	4	3	4	4	4	4	4	4	73.00
113	042			4	4	4	3	4	3	3	3	3	4	3	4	3	4	3	4	4	4	4	3	4	71.00
118	042			4	4	2	1	3	4	3	2	2	4	3	4	1	4	1	4	4	4	4	3	4	61.00
119	042			4	4	4	4	4	3	2	2	2	4	4	4	1	4	1	4	4	4	4	4	4	67.00
124	042			2	4	1	1	4	4	1	3	1	2	3	3	2	4	1	3	4	4	1	3	51.00	
126	042			4	4	2	3	4	4	3	2	3	4	4	4	4	4	2	4	4	4	4	2	4	69.00
127	042			1	4	1	1	4	4	1	1	1	1	4	3	1	3	1	3	3	4	1	3	45.00	
132	042			2	3	1	1	3	3	1	2	1	1	3	3	1	3	1	3	3	3	1	3	42.00	
133	042			2	3	2	4	3	3	2	1	3	4	4	3	1	3	2	3	4	4	2	3	56.00	
136	042			2	4	2	3	4	3	1	1	2	3	3	3	2	3	1	3	3	3	1	3	50.00	
139	042			3	4	3	4	4	4	2	2	1	4	3	4	3	3	1	3	3	3	2	4	60.00	
140	042			2	3	1	3	3	4	3	1	3	4	3	3	2	3	3	3	3	3	3	3	56.00	
147	042			3	4	1	4	3	4	1	4	2	3	4	4	4	3	3	4	3	3	1	4	62.00	
148	042			1	3	4	3	4	3	2	1	4	1	3	4	1	3	1	3	3	4	1	3	52.00	
170	042			3	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	62.00	
172	042			4	3	3	3	4	4	1	1	1	3	4	4	1	4	2	4	3	4	3	4	60.00	
179	042			3	3	3	3	4	4	2	2	2	3	4	4	2	4	2	4	4	4	3	4	64.00	
180	042			4	3	3	3	4	4	1	1	1	2	4	4	1	4	1	4	3	4	3	4	58.00	
181	042			4	3	3	3	4	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00	
186	042			4	3	3	3	4	4	2	1	1	3	3	3	1	4	1	4	4	4	3	3	58.00	
187	042			4	3	3	3	4	4	2	1	2	3	3	4	1	4	2	4	3	3	3	3	59.00	

FCE 20124/702 i

26

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
188	042	3	3	3	3	4	4	2	2	2	3	3	4	1	4	1	4	4	4	4	4	62.00
193	042	4	3	4	4	4	4	3	2	2	3	4	4	2	4	2	4	4	4	4	3	68.00
197	042	3	4	4	4	3	4	1	1	2	4	4	4	2	4	2	4	4	4	3	4	65.00
202	042	3	3	3	2	3	4	2	2	2	3	3	3	2	4	3	4	4	4	2	3	59.00
203	042	4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
206	042	4	4	3	3	3	3	2	3	2	2	4	4	2	4	2	4	4	4	3	4	64.00
210	042	3	4	3	3	3	3	1	2	2	3	4	4	2	4	2	4	4	4	3	4	62.00
214	042	3	4	3	3	3	4	2	2	2	3	4	4	3	4	3	4	4	4	3	4	66.00
216	042	3	4	3	3	3	4	2	2	2	3	4	4	1	4	3	4	4	4	3	4	64.00
218	042	2	3	3	4	4	4	2	3	3	3	4	4	2	4	3	4	4	3	4	4	67.00
219	042	2	3	1	4	3	3	2	2	1	2	3	3	4	3	1	3	3	3	2	3	51.00
226	042	2	3	2	4	4	3	4	2	1	1	3	4	4	3	2	3	3	4	1	3	56.00
227	042	1	4	1	1	4	4	4	1	1	1	3	3	1	3	1	3	3	3	1	3	46.00
230	042	4	4	4	4	3	4	4	1	4	3	3	4	4	4	4	3	4	4	4	4	73.00
233	042	2	4	3	4	4	4	4	1	4	4	4	1	4	1	3	4	4	1	4	4	64.00
237	042	2	4	1	4	4	4	3	2	1	3	3	4	4	3	1	3	4	4	1	4	59.00
238	042	4	4	2	2	4	4	4	4	4	4	4	4	4	1	4	4	4	1	4	4	70.00
243	042	4	3	3	3	4	4	2	1	1	2	4	4	1	4	2	4	4	3	3	3	59.00
249	042	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
251	042	4	4	3	4	3	3	1	2	2	4	4	4	4	4	3	4	4	4	4	4	69.00
254	042	4	4	3	4	3	4	3	3	2	4	4	4	3	4	3	4	4	4	3	3	70.00
255	042	4	4	3	4	4	4	3	1	2	4	4	4	4	4	4	4	3	4	3	4	71.00
260	042	3	4	3	2	4	4	2	1	1	2	4	4	2	4	1	3	4	4	3	4	59.00
262	042	3	3	2	2	4	4	2	1	1	3	4	4	2	3	2	4	4	4	3	4	59.00
268	042	4	4	3	3	3	3	1	1	2	3	4	4	3	4	3	4	4	4	3	4	64.00
269	042	4	4	4	4	4	4	2	2	2	4	4	4	4	4	4	4	3	4	3	4	72.00
273	042	4	4	4	3	3	4	1	1	1	3	4	4	3	4	3	3	3	4	3	4	63.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

27

Treatment Group "B"

Day 4 (Period 042)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.33	.10
2. Morning is when I feel best	3.62	.05
3. I have crying spells or feel like it	2.68	.11
4. I have trouble sleeping at night	3.12	.10
5. I eat as much as I used to	3.49	.06
6. I still enjoy sex	3.73	.05
7. I notice that I am losing weight	2.01	.11
8. I have trouble with constipation	2.04	.11
9. My heart beats faster than usual	2.10	.11
10. I get tired for no reason	3.07	.10
11. My mind is as clear as it used to be	3.59	.05
12. I find it easy to do the things I used to do	3.69	.05
13. I am restless and can't keep still	2.30	.12
14. I feel hopeful about the future	3.64	.05
15. I am more irritable than usual	2.30	.11
16. I find it easy to make decisions	3.65	.05
17. I feel that I am useful and needed	3.63	.05
18. My life is pretty full	3.72	.05
19. I feel that others would be better off if I were dead	2.57	.10
20. I still enjoy the things I used to do	3.60	.05
Total score	61.89	.83

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

28

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	072	3	3	1	2	3	4	1	1	2	2	3	3	1	3	3	4	3	3	3	3	51.00
10	072	3	3	1	2	3	4	1	1	2	3	4	3	2	3	3	3	3	3	2	3	52.00
11	072	4	3	2	4	3	4	2	1	2	3	4	4	1	3	2	3	4	3	3	3	58.00
15	072	3	4	2	4	3	3	1	1	4	2	3	3	1	3	3	4	3	3	2	3	55.00
17	072	4	3	1	2	3	4	1	1	1	3	3	3	2	3	3	4	3	4	3	3	54.00
28	072	4	4	2	4	4	4	1	3	4	3	4	4	2	4	3	3	4	4	1	4	66.00
29	072	4	4	3	3	3	4	2	4	2	4	4	4	3	4	4	4	4	4	3	4	71.00
31	072	3	4	2	4	4	4	1	2	2	2	3	4	3	4	3	4	4	4	2	4	63.00
32	072	3	4	3	3	3	4	1	3	2	3	4	4	3	4	3	4	4	4	2	4	65.00
41	072	3	4	3	4	3	4	1	3	2	3	4	4	2	4	3	4	4	4	2	3	64.00
42	072	2	3	1	2	4	3	1	2	2	1	4	4	1	4	1	3	4	4	1	3	50.00
44	072	4	4	2	4	3	4	1	3	2	3	4	4	2	4	3	4	4	4	2	4	65.00
47	072	4	4	2	3	3	4	1	3	3	4	4	4	2	4	3	4	4	4	1	4	65.00
51	072	4	4	4	4	3	3	3	3	4	4	4	4	3	4	3	3	4	4	3	4	72.00
54	072	3	4	3	3	3	3	2	3	3	3	3	3	2	3	3	3	3	3	3	3	59.00
55	072	3	4	3	3	3	1	2	3	3	3	3	3	3	4	4	3	3	3	3	3	60.00
60	072	3	3	3	3	3	2	2	3	3	3	3	3	1	3	3	4	4	3	3	3	58.00
61	072	3	3	3	3	3	1	2	3	3	3	3	3	2	3	2	3	3	4	3	3	56.00
66	072	4	4	4	3	3	4	3	4	4	4	3	4	2	4	3	4	4	4	3	4	71.00
67	072	3	4	3	3	4	3	2	2	3	4	3	3	2	3	2	3	3	3	3	3	59.00
70	072	3	3	3	3	4	4	3	3	3	3	3	3	3	2	3	3	3	3	3	3	61.00
77	072	4	4	4	4	4	4	1	2	4	4	4	4	4	4	1	4	4	4	4	4	72.00
78	072	2	3	1	1	3	4	3	2	1	1	3	3	2	3	1	3	4	3	2	3	48.00
83	072	4	4	3	3	4	4	2	2	2	4	3	3	4	4	3	4	4	4	4	4	69.00
84	072	4	4	2	3	4	3	1	3	3	3	4	3	3	4	2	3	3	3	3	4	62.00
88	072	2	3	2	3	3	4	2	1	1	2	3	3	3	3	2	3	3	3	1	3	50.00
90	072	3	4	3	3	3	4	1	4	1	4	3	3	1	4	1	4	3	4	1	3	57.00
91	072	3	3	3	4	4	3	1	3	1	3	4	3	1	4	1	4	4	4	2	4	59.00
95	072	2	3	2	3	4	3	1	1	1	3	3	4	2	3	2	4	4	4	1	3	53.00
98	072	4	4	2	4	4	4	1	4	1	3	4	4	1	4	2	4	4	4	4	4	66.00
102	072	2	4	2	3	4	3	1	2	2	1	3	3	4	3	1	3	3	3	1	3	51.00
103	072	2	3	1	2	3	4	3	1	1	2	3	3	2	3	2	3	3	3	1	3	48.00
106	072	3	3	3	3	4	3	2	1	3	4	3	4	3	3	3	4	3	4	2	3	61.00
110	072	2	4	3	2	4	3	1	1	2	4	4	4	1	4	1	4	3	3	2	3	55.00
113	072	4	3	4	3	3	3	2	2	3	4	3	4	3	4	3	4	4	3	3	4	66.00
118	072	4	4	2	1	3	4	3	3	2	3	3	4	1	4	1	4	3	4	3	4	60.00
119	072	4	4	4	4	4	3	2	2	2	4	4	4	1	3	1	4	4	4	3	3	64.00
124	072	1	3	1	1	3	4	1	4	2	1	3	4	1	3	1	3	4	3	2	3	48.00
126	072	2	3	2	2	4	4	1	2	2	3	3	3	3	3	3	4	4	4	2	4	58.00
127	072	1	4	1	1	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	50.00
132	072	1	3	1	1	4	4	1	3	1	2	3	4	1	4	2	4	4	4	1	3	51.00
133	072	2	4	1	3	4	4	2	1	4	2	3	3	2	3	1	3	3	3	1	3	52.00
136	072	3	4	4	4	4	4	1	1	2	3	3	3	1	3	2	3	4	3	2	4	58.00
139	072	2	3	2	1	3	4	4	2	1	3	3	4	2	4	1	3	3	3	1	4	53.00
140	072	2	3	1	2	3	3	2	1	2	2	3	3	2	4	4	3	3	3	1	3	50.00
147	072	4	4	1	4	4	4	2	3	1	3	4	4	3	4	2	3	3	4	1	4	62.00
148	072	1	3	4	3	4	3	2	1	4	1	3	4	1	3	1	3	3	4	1	3	52.00
170	072	3	3	3	2	3	3	1	2	2	3	4	4	1	4	1	4	4	4	3	4	58.00
172	072	3	3	3	2	4	4	2	1	2	3	4	3	1	3	1	4	4	4	3	4	58.00
179	072	3	3	2	2	4	4	2	2	3	3	4	3	3	4	3	4	4	4	3	4	64.00
180	072	3	3	3	4	4	1	1	2	3	4	3	1	4	2	4	3	4	3	4	4	59.00
181	072	3	3	3	3	4	4	1	2	1	3	4	4	1	3	1	3	4	4	3	4	58.00
186	072	4	3	3	3	4	4	2	2	1	3	3	4	1	4	1	4	4	4	3	4	61.00
187	072	3	3	3	3	4	4	2	2	2	2	3	3	1	4	2	4	4	4	3	3	59.00

FCE 20124/702 i

29

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
188	072	3	3	3	3	4	4	2	2	2	3	4	4	1	4	2	4	4	4	3	4	63.00
193	072	4	3	4	4	4	4	3	2	1	4	4	4	2	4	1	4	4	4	3	4	67.00
197	072	3	4	4	4	3	4	1	1	2	3	4	4	2	4	2	3	4	4	3	4	63.00
202	072	3	3	3	2	3	4	2	2	2	3	3	3	2	4	3	3	3	4	2	3	57.00
203	072	4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
206	072	4	4	3	3	3	2	3	2	3	3	4	2	4	2	4	2	4	4	3	4	64.00
210	072	3	4	3	3	3	3	1	2	2	3	4	4	2	4	2	4	4	4	3	4	62.00
214	072	3	4	3	3	3	4	2	2	2	3	4	4	3	4	2	4	4	4	3	4	65.00
216	072	3	4	3	3	3	4	1	2	2	3	4	4	3	4	3	4	4	4	3	4	65.00
218	072	2	3	2	2	4	4	4	2	2	3	3	4	2	4	2	4	4	4	2	3	60.00
219	072	2	4	2	4	3	4	2	2	2	2	4	4	2	4	2	3	3	4	2	4	59.00
226	072	2	4	2	3	4	3	1	1	2	1	3	3	2	3	1	4	3	4	1	3	50.00
227	072	1	4	1	1	3	4	3	4	1	1	3	3	1	3	1	3	3	3	1	3	47.00
230	072	4	4	3	4	4	4	3	1	3	4	4	4	4	3	3	4	4	4	1	4	69.00
233	072	4	4	3	4	4	4	2	4	2	4	3	4	4	4	1	4	3	4	1	4	67.00
237	072	2	3	1	4	4	4	3	2	1	2	3	4	2	4	1	3	4	3	1	4	55.00
238	072	2	4	2	1	4	4	3	1	1	4	3	4	1	4	1	4	4	4	1	4	56.00
243	072	3	3	3	3	4	4	1	2	2	3	4	4	1	4	1	4	4	4	3	3	60.00
249	072	3	3	3	3	4	4	2	2	1	3	4	4	1	3	1	3	4	4	2	4	58.00
251	072	4	4	3	4	3	3	1	3	2	4	4	4	4	4	3	4	4	4	4	4	70.00
254	072	4	4	3	4	3	4	3	3	2	4	4	4	4	4	4	4	4	4	3	3	72.00
255	072	4	4	4	4	4	4	3	1	2	4	4	4	4	4	4	4	3	4	3	4	72.00
260	072	3	3	2	2	4	4	2	1	1	2	4	4	1	4	1	4	3	4	2	4	55.00
262	072	3	3	3	3	4	1	1	1	1	2	4	4	1	4	2	4	4	4	3	4	58.00
268	072	4	4	3	4	3	4	2	1	2	3	4	4	3	4	3	4	4	4	3	4	67.00
269	072	4	4	4	4	3	4	1	2	2	4	4	4	4	4	4	4	3	4	3	4	70.00
273	072	3	4	3	3	3	4	1	1	1	3	4	4	3	4	3	4	3	4	3	4	62.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

30

Treatment Group "B"

Day 7 (Period 072)

Number of Observations = 81

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.01	.10
2. Morning is when I feel best	3.54	.06
3. I have crying spells or feel like it	2.54	.10
4. I have trouble sleeping at night	2.93	.10
5. I eat as much as I used to	3.48	.06
6. I still enjoy sex	3.70	.05
7. I notice that I am losing weight	1.81	.10
8. I have trouble with constipation	2.00	.10
9. My heart beats faster than usual	2.02	.09
10. I get tired for no reason	2.89	.10
11. My mind is as clear as it used to be	3.52	.06
12. I find it easy to do the things I used to do	3.64	.05
13. I am restless and can't keep still	2.07	.11
14. I feel hopeful about the future	3.65	.05
15. I am more irritable than usual	2.12	.11
16. I find it easy to make decisions	3.64	.05
17. I feel that I am useful and needed	3.60	.05
18. My life is pretty full	3.72	.05
19. I feel that others would be better off if I were dead	2.31	.10
20. I still enjoy the things I used to do	3.58	.06
Total score	59.80	.74

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

31

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	102	3	3	1	2	4	4	1	1	2	2	3	3	1	3	3	4	3	3	2	4	52.00
10	102	3	3	1	2	3	4	1	1	2	3	4	3	2	3	3	3	3	3	2	3	52.00
11	102	4	3	2	3	3	4	2	1	2	3	4	3	1	3	2	3	3	3	2	3	54.00
15	102	3	4	1	3	3	4	1	1	4	2	3	3	1	3	3	4	3	3	2	3	54.00
17	102	3	3	1	2	3	4	1	1	1	3	3	3	2	3	2	4	3	4	2	3	51.00
28	102	4	4	2	4	4	4	1	3	3	3	4	4	2	4	4	4	4	4	1	4	67.00
29	102	4	4	2	3	3	4	2	4	2	4	4	4	3	4	4	4	4	4	3	4	70.00
31	102	2	3	1	3	4	4	1	2	1	2	3	3	2	3	2	3	3	3	1	3	49.00
32	102	3	3	2	3	4	4	1	3	2	3	3	3	2	3	2	3	3	3	2	3	55.00
41	102	3	3	2	3	3	4	1	3	1	2	3	3	2	3	2	3	3	3	2	3	52.00
42	102	1	3	1	2	4	3	1	2	2	1	4	4	1	4	1	4	4	4	1	4	51.00
44	102	3	4	2	4	3	4	1	2	2	3	3	3	3	4	3	4	4	3	2	3	60.00
47	102	3	3	1	2	4	3	1	3	2	2	3	3	1	3	2	3	3	3	1	3	49.00
51	102	3	3	3	3	3	3	2	3	3	3	3	3	2	3	2	3	3	3	2	3	56.00
54	102	2	3	2	3	3	3	2	3	3	2	3	3	2	3	3	3	3	3	3	3	55.00
55	102	3	3	3	3	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	58.00
60	102	4	4	4	3	3	2	3	3	3	3	3	4	2	3	3	3	3	3	3	3	62.00
61	102	2	3	2	2	3	3	1	1	3	3	3	3	1	3	2	3	3	3	3	3	50.00
66	102	4	4	3	3	3	4	3	4	4	4	4	3	1	4	3	3	4	4	3	3	68.00
67	102	3	3	3	3	3	2	3	3	3	3	3	3	2	3	3	3	3	3	2	3	57.00
70	102	3	3	3	3	3	3	2	3	2	3	3	2	3	2	3	3	3	3	2	3	55.00
77	102	2	4	2	2	3	4	2	4	1	3	4	3	3	4	1	4	4	4	4	4	62.00
78	102	2	3	1	1	3	4	2	1	1	2	3	3	2	4	1	4	3	3	1	3	47.00
83	102	4	4	3	4	3	4	2	2	2	3	3	4	4	4	3	4	4	3	3	3	66.00
84	102	4	4	2	3	4	3	1	3	3	3	4	3	2	3	2	3	3	3	3	4	60.00
88	102	2	3	3	2	3	4	1	1	1	3	3	3	3	3	2	3	3	3	1	3	50.00
90	102	4	4	3	3	3	1	3	1	2	3	3	1	3	1	3	3	4	1	3	3	52.00
91	102	3	3	3	4	4	3	2	3	1	3	3	3	1	4	1	4	4	4	1	4	58.00
95	102	2	4	2	3	4	3	1	1	1	3	3	4	2	3	2	4	4	3	2	4	55.00
98	102	2	4	1	4	4	4	2	2	1	4	3	3	4	3	3	3	3	3	2	3	58.00
102	102	2	4	2	3	4	3	1	2	2	1	3	3	3	3	1	3	3	3	2	3	51.00
103	102	2	3	1	2	3	4	1	1	1	2	3	3	1	3	2	3	3	3	1	3	45.00
106	102	2	4	3	2	4	3	2	3	2	4	4	3	3	3	2	3	4	4	1	4	60.00
110	102	3	3	2	3	3	3	1	1	2	3	4	4	1	3	1	4	3	3	2	3	52.00
113	102	3	3	3	4	3	3	2	2	3	4	4	3	3	4	3	4	4	3	3	3	64.00
118	102	3	4	2	1	3	4	2	3	2	3	3	4	1	4	1	4	3	4	3	4	58.00
119	102	4	4	4	4	3	2	2	2	4	4	4	1	3	1	4	4	4	3	4	4	65.00
124	102	2	3	1	1	4	4	1	3	2	1	3	4	2	4	1	3	3	3	2	3	50.00
126	102	3	3	2	3	4	4	1	2	2	4	3	4	3	3	2	3	3	4	2	4	59.00
127	102	2	4	3	2	4	4	1	1	2	2	4	3	1	4	2	4	4	4	2	4	57.00
132	102	1	3	1	1	4	4	1	3	1	2	3	4	1	4	2	4	4	4	1	3	51.00
133	102	1	3	4	4	3	3	1	2	4	3	4	4	1	3	1	3	4	4	2	4	58.00
136	102	2	3	3	2	4	3	1	1	2	2	3	3	2	3	2	3	3	3	2	3	50.00
139	102	1	3	1	1	4	4	2	1	1	2	3	3	1	3	1	3	4	3	1	3	45.00
140	102	1	3	1	4	3	3	1	2	1	2	3	3	2	3	2	3	3	4	1	3	48.00
147	102	3	4	2	2	4	4	1	3	1	2	4	4	2	3	3	3	3	4	1	4	57.00
148	102	2	4	2	1	4	4	2	3	4	2	4	3	3	4	1	4	3	3	1	4	58.00
170	102	3	3	3	2	3	3	2	1	1	3	4	4	1	4	1	4	4	3	3	4	56.00
172	102	3	3	2	2	4	4	2	2	2	3	4	4	1	4	2	3	3	3	2	3	56.00
179	102	3	3	2	3	4	4	1	2	3	2	4	4	2	3	3	4	4	4	3	4	62.00
180	102	3	3	3	2	3	4	1	1	2	3	3	3	1	4	2	4	3	3	2	4	54.00
181	102	3	3	3	2	3	4	1	1	1	3	3	4	1	3	1	4	4	4	3	4	55.00
186	102	3	3	3	3	4	4	2	2	2	3	3	3	1	4	2	4	4	4	3	3	60.00
187	102	3	3	3	2	4	4	2	2	2	2	4	3	1	4	3	3	4	4	3	3	59.00

FCE 20124/702 i

32

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
188	102	3	3	3	3	4	4	2	1	1	3	3	3	1	4	1	4	4	4	3	3	57.00
193	102	3	3	4	4	4	4	3	2	2	4	4	4	2	4	2	4	4	4	3	4	68.00
197	102	3	4	4	4	3	4	1	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
202	102	3	3	3	2	3	4	2	1	2	3	3	3	2	4	2	3	3	4	2	3	55.00
203	102	4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
206	102	4	4	3	3	3	3	2	3	2	3	3	3	2	4	2	4	4	4	3	4	63.00
210	102	3	4	3	3	3	3	1	2	2	3	3	4	2	4	2	4	4	4	3	4	61.00
214	102	3	4	3	3	3	4	2	2	2	3	4	3	2	3	2	4	4	4	3	4	62.00
216	102	3	4	3	3	3	4	1	2	2	3	4	4	3	4	3	4	4	4	3	4	65.00
218	102	2	3	2	4	4	4	2	2	2	2	3	3	2	3	2	4	3	3	2	3	55.00
219	102	1	4	1	1	4	3	1	2	1	2	4	3	2	4	2	3	3	3	1	3	48.00
226	102	2	4	2	3	4	3	1	1	1	1	3	3	2	3	1	4	3	4	1	3	50.00
227	102	2	3	1	1	3	4	1	1	1	1	3	3	1	3	1	3	3	3	1	4	43.00
233	102	4	4	3	4	4	4	2	4	2	4	3	4	4	4	1	4	3	4	1	4	67.00
237	102	2	3	1	4	4	4	3	2	1	2	3	4	2	4	1	3	4	3	1	4	55.00
238	102	2	4	1	1	4	4	4	1	2	4	4	4	2	4	1	4	4	4	1	3	58.00
243	102	3	3	2	3	4	4	2	1	2	2	4	4	1	4	1	4	3	4	2	3	56.00
249	102	3	3	2	3	4	4	2	2	1	3	4	4	1	3	1	4	3	4	3	4	58.00
251	102	4	4	3	4	3	3	1	3	2	4	4	4	4	4	4	4	4	4	4	4	71.00
254	102	4	4	3	3	3	4	3	3	2	4	4	4	4	4	4	4	4	4	3	3	71.00
255	102	4	4	4	4	4	4	3	1	2	3	4	4	3	4	3	4	3	4	3	4	69.00
260	102	3	3	2	2	3	4	2	1	2	2	4	4	1	3	1	4	3	4	3	4	55.00
262	102	3	3	2	2	3	4	1	1	1	2	4	4	1	4	1	3	4	4	2	4	53.00
268	102	4	4	3	3	3	4	1	1	1	3	.	4	3	4	3	4	4	4	3	4	.
269	102	4	4	4	4	4	4	2	2	2	4	4	4	4	4	4	4	3	4	3	4	72.00
273	102	3	4	3	3	3	3	1	1	2	2	3	4	2	4	2	4	3	4	3	4	58.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

33

Treatment Group "B"

Day 10 (Period 102)

Number of Observations = 80

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.81	.10
2. Morning is when I feel best	3.44	.06
3. I have crying spells or feel like it	2.32	.10
4. I have trouble sleeping at night	2.73	.10
5. I eat as much as I used to	3.46	.06
6. I still enjoy sex	3.65	.05
7. I notice that I am losing weight	1.61	.08
8. I have trouble with constipation	1.96	.10
9. My heart beats faster than usual	1.94	.09
10. I get tired for no reason	2.71	.09
11. My mind is as clear as it used to be	3.44	.06
12. I find it easy to do the things I used to do	3.45	.06
13. I am restless and can't keep still	1.95	.10
14. I feel hopeful about the future	3.50	.06
15. I am more irritable than usual	2.04	.10
16. I find it easy to make decisions	3.56	.06
17. I feel that I am useful and needed	3.44	.06
18. My life is pretty full	3.54	.06
19. I feel that others would be better off if I were dead	2.18	.10
20. I still enjoy the things I used to do	3.48	.06
Total score	57.13	.74

FCE 20124/702 i

34

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	142	3	3	1	2	4	4	1	1	2	2	3	3	1	3	3	4	3	3	2	4	52.00
10	142	2	3	1	1	3	4	1	1	3	2	4	3	2	3	2	3	3	3	2	3	49.00
11	142	3	3	1	3	3	4	2	1	2	3	4	3	1	3	2	3	3	3	2	3	52.00
15	142	3	4	1	3	3	4	1	1	4	2	3	3	1	3	2	4	3	3	2	3	53.00
17	142	3	3	1	2	3	4	1	1	3	2	3	4	2	3	2	4	3	4	2	3	53.00
28	142	4	4	2	4	4	4	1	3	3	3	4	4	2	4	3	4	4	4	1	4	66.00
31	142	2	3	1	2	4	3	1	2	1	1	4	3	1	3	2	3	3	3	1	4	47.00
32	142	2	3	1	2	4	4	1	3	2	2	3	3	2	3	2	3	3	3	1	3	50.00
41	142	2	3	1	2	4	3	1	3	1	2	3	3	2	3	2	3	3	3	1	3	48.00
42	142	1	3	1	2	4	3	1	2	1	1	4	4	1	4	1	4	4	4	1	4	50.00
44	142	2	3	1	2	4	4	1	2	2	2	3	3	1	3	2	3	3	3	1	3	48.00
47	142	2	3	1	2	4	3	1	3	1	1	4	4	2	4	1	3	3	4	1	4	51.00
51	142	2	3	2	2	3	3	2	2	3	3	3	3	1	3	2	3	3	3	2	3	51.00
54	142	2	3	2	3	3	3	2	3	2	2	3	3	2	3	2	3	3	3	2	3	52.00
55	142	2	3	2	2	3	3	1	2	2	2	3	3	2	3	2	3	3	3	3	3	50.00
60	142	3	3	3	2	3	3	2	2	3	3	3	3	2	3	3	3	3	3	3	3	56.00
61	142	2	3	2	2	4	3	1	1	2	2	3	3	1	3	2	3	3	3	3	3	49.00
66	142	4	4	3	3	3	4	3	3	4	3	4	4	1	4	3	3	4	4	3	4	68.00
67	142	3	3	3	3	4	2	3	3	3	3	3	3	2	3	2	3	3	3	3	3	58.00
70	142	2	3	2	2	3	3	1	2	2	1	3	3	2	3	3	3	3	3	2	3	49.00
77	142	2	4	3	2	3	3	1	1	1	2	4	3	2	4	1	3	4	4	4	4	55.00
78	142	2	3	1	1	3	4	1	1	1	2	3	3	1	4	1	4	4	3	1	3	46.00
83	142	4	4	3	2	3	4	2	2	2	4	4	4	4	4	3	4	4	4	4	4	69.00
84	142	4	4	2	3	4	3	1	2	2	2	4	3	1	3	2	3	3	3	2	3	54.00
88	142	2	3	1	2	3	4	1	1	1	2	4	3	3	3	2	3	4	4	1	3	50.00
90	142	4	4	3	3	3	4	1	3	1	2	3	3	1	4	1	3	3	4	1	3	54.00
91	142	3	3	3	4	4	3	1	3	1	4	4	4	1	4	2	4	4	4	3	4	63.00
95	142	2	4	3	1	4	4	1	1	1	3	4	3	2	3	3	3	4	4	2	4	56.00
98	142	1	3	1	4	4	3	1	4	1	3	3	3	1	3	1	3	3	3	2	3	50.00
102	142	3	3	1	3	3	3	2	1	2	2	3	3	2	3	1	3	3	3	1	3	48.00
103	142	1	3	1	4	4	3	1	1	1	2	3	3	1	3	1	3	3	3	1	3	45.00
106	142	2	3	2	2	3	4	1	3	2	3	4	3	3	3	3	3	3	3	2	3	55.00
110	142	3	3	2	2	3	3	1	1	2	3	4	4	1	3	1	3	3	3	2	3	51.00
113	142	3	3	2	3	3	3	2	2	3	3	3	3	2	4	3	4	3	3	2	3	57.00
118	142	2	3	1	1	4	4	1	4	1	3	4	3	1	3	1	3	3	3	2	3	50.00
119	142	3	3	3	3	3	3	1	2	2	3	4	3	2	3	2	4	3	3	2	3	55.00
124	142	1	3	1	1	4	4	1	3	2	1	4	4	1	4	1	4	4	4	1	4	52.00
126	142	3	3	2	3	4	4	2	2	2	4	4	4	3	3	2	4	3	3	1	4	60.00
127	142	2	3	3	1	4	4	2	1	2	2	4	3	3	4	2	4	3	4	2	4	57.00
132	142	3	4	3	2	4	3	1	1	1	3	3	3	3	3	1	3	3	3	2	3	52.00
133	142	1	4	1	2	3	3	1	1	2	1	3	3	1	3	1	3	3	3	1	3	43.00
136	142	2	4	1	1	4	3	1	1	2	2	3	3	2	3	1	3	3	3	1	3	46.00
139	142	2	3	2	1	4	4	2	1	2	3	3	3	2	4	1	3	4	4	1	3	52.00
140	142	1	3	1	2	3	3	2	2	1	1	3	3	1	3	2	3	3	3	2	4	46.00
147	142	4	4	2	3	3	4	2	3	1	2	4	4	3	3	3	3	3	4	1	4	60.00
148	142	2	3	1	4	4	3	2	4	2	1	4	3	2	4	2	3	3	3	1	4	55.00
170	142	3	3	2	2	3	4	1	2	1	3	4	4	1	3	1	4	3	4	3	4	55.00
172	142	3	3	2	2	3	4	1	2	2	3	3	4	1	3	1	4	3	4	3	4	55.00
179	142	3	3	2	2	4	4	1	2	3	3	4	3	3	3	3	4	3	4	2	4	60.00
180	142	3	3	2	2	3	4	1	1	1	3	4	3	1	3	2	3	3	3	2	4	51.00
181	142	3	3	2	3	3	4	2	2	2	3	4	3	1	4	2	3	4	4	3	4	59.00
186	142	3	3	2	2	3	4	1	1	2	3	3	3	1	4	2	4	4	4	3	3	55.00
187	142	3	3	2	3	4	4	2	1	2	2	3	3	1	4	2	3	4	4	3	3	56.00
188	142	3	3	3	3	4	4	2	2	2	3	3	3	1	4	1	4	3	3	3	3	57.00

421

FCE 20124/702 i

35

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
193	142	3	3	4	4	4	4	3	1	2	3	4	4	2	4	2	4	4	4	3	4	66.00
197	142	3	4	3	4	3	4	1	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
202	142	3	3	3	2	3	4	1	1	2	3	3	3	2	4	2	3	3	4	2	3	54.00
203	142	3	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
206	142	4	4	3	3	3	3	2	3	2	2	3	3	2	4	1	4	3	4	2	4	59.00
210	142	3	4	3	3	3	3	1	2	2	3	3	4	2	4	2	4	4	4	3	4	61.00
214	142	3	4	3	3	3	4	2	2	2	3	4	4	3	4	2	4	4	4	3	4	65.00
216	142	3	4	3	3	3	4	1	2	2	3	4	4	2	4	2	4	4	4	3	4	63.00
218	142	2	3	4	2	4	4	2	2	2	2	3	3	2	3	2	4	3	3	2	3	55.00
219	142	3	4	3	4	4	4	2	4	2	2	4	4	3	4	3	3	3	4	2	4	66.00
226	142	1	3	1	2	3	3	1	1	2	1	3	4	3	3	2	4	4	4	1	3	49.00
227	142	1	3	1	1	3	3	3	3	1	1	3	3	1	3	1	3	3	3	1	3	44.00
233	142	4	4	4	4	4	4	2	4	2	4	4	4	2	4	1	3	4	4	1	4	67.00
237	142	1	3	1	2	4	3	3	2	1	1	4	3	1	4	1	4	4	4	1	4	51.00
238	142	2	4	1	1	4	4	1	1	2	4	3	4	4	4	1	4	4	3	1	4	56.00
243	142	3	3	2	2	4	4	1	1	2	2	4	3	1	4	2	4	3	3	2	4	54.00
249	142	3	3	2	2	3	4	1	1	2	3	4	4	1	3	1	3	3	4	2	4	53.00
251	142	4	4	3	3	3	3	1	2	2	3	4	3	3	4	3	3	3	4	3	3	61.00
254	142	3	4	3	3	3	4	3	3	2	2	3	3	4	3	4	4	3	4	3	3	64.00
255	142	4	4	3	4	4	4	3	1	2	3	4	4	3	3	3	3	3	3	3	3	64.00
260	142	2	3	2	2	3	4	1	1	1	3	4	4	1	3	1	3	3	4	2	4	51.00
262	142	3	3	3	2	3	4	2	1	1	2	4	4	1	3	1	3	3	4	2	4	53.00
268	142	4	4	3	4	3	4	2	1	1	3	4	4	3	4	3	4	3	4	3	4	65.00
269	142	4	4	4	4	3	4	2	2	2	4	4	4	4	4	4	4	3	4	3	4	71.00
273	142	2	3	2	2	3	3	1	2	1	2	3	3	2	3	2	3	3	3	2	3	48.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

36

Treatment Group "B"

Day 14 (Period 142)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.61	.10
2. Morning is when I feel best	3.33	.05
3. I have crying spells or feel like it	2.09	.10
4. I have trouble sleeping at night	2.47	.10
5. I eat as much as I used to	3.42	.06
6. I still enjoy sex	3.61	.06
7. I notice that I am losing weight	1.48	.07
8. I have trouble with constipation	1.90	.10
9. My heart beats faster than usual	1.85	.08
10. I get tired for no reason	2.44	.09
11. My mind is as clear as it used to be	3.53	.06
12. I find it easy to do the things I used to do	3.37	.05
13. I am restless and can't keep still	1.85	.10
14. I feel hopeful about the future	3.43	.06
15. I am more irritable than usual	1.91	.09
16. I find it easy to make decisions	3.42	.06
17. I feel that I am useful and needed	3.30	.05
18. My life is pretty full	3.51	.06
19. I feel that others would be better off if I were dead	2.04	.09
20. I still enjoy the things I used to do	3.48	.06
Total score	55.03	.73

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

37

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	212	3	3	1	1	4	4	1	1	2	1	3	4	1	3	2	4	3	3	2	4	50.00
10	212	2	4	1	1	4	4	1	1	2	2	4	3	1	3	2	3	3	4	2	4	51.00
11	212	2	3	1	3	4	4	2	1	2	2	4	3	1	3	2	3	4	3	2	3	52.00
15	212	2	4	1	2	3	4	1	1	2	2	4	3	1	3	2	4	3	3	2	3	50.00
17	212	3	3	1	2	4	4	1	1	2	2	3	3	2	3	2	4	3	4	2	3	52.00
31	212	2	3	1	2	4	3	1	2	1	1	4	4	1	3	2	3	4	4	1	4	50.00
32	212	2	4	1	2	4	3	1	2	1	1	4	4	2	4	2	4	4	4	1	4	54.00
41	212	2	3	1	2	4	3	1	2	1	2	4	4	1	4	1	4	4	3	1	4	51.00
42	212	1	4	1	2	4	3	1	2	1	1	4	4	1	4	1	4	4	4	1	4	51.00
44	212	2	3	1	2	4	3	1	2	2	1	4	4	1	4	2	3	4	4	1	4	52.00
47	212	2	3	1	2	4	3	1	2	1	2	4	4	1	4	1	3	3	4	1	4	50.00
51	212	2	3	2	2	3	4	1	1	2	2	3	4	1	4	1	4	4	3	1	4	51.00
54	212	2	3	2	2	3	3	3	2	2	2	3	4	1	3	2	3	3	3	2	3	51.00
55	212	2	3	2	1	3	3	1	2	2	2	3	3	2	3	1	3	4	3	2	4	49.00
60	212	2	4	2	3	3	3	2	3	3	3	3	3	2	3	3	3	3	3	3	3	57.00
61	212	2	3	2	1	4	4	1	1	2	2	3	3	1	3	1	3	3	3	2	3	47.00
66	212	3	4	4	4	3	4	4	4	4	4	3	3	1	4	3	4	4	4	3	3	70.00
67	212	3	3	3	3	3	4	2	3	3	3	3	3	1	3	2	3	3	3	3	3	57.00
70	212	2	3	2	2	3	3	1	1	1	1	4	4	1	3	2	3	3	3	2	3	47.00
77	212	2	3	3	2	3	3	1	1	1	2	4	3	1	4	1	3	3	4	4	4	52.00
78	212	1	4	1	1	4	3	1	1	1	1	4	3	1	4	1	4	4	4	1	3	47.00
83	212	4	4	3	2	3	4	2	1	1	4	4	4	4	4	3	4	4	4	3	4	66.00
84	212	4	4	2	3	4	3	1	2	3	2	4	3	2	3	3	3	3	3	2	3	57.00
88	212	1	3	2	3	4	4	1	1	1	2	3	4	2	3	3	4	4	4	1	4	54.00
90	212	4	4	3	2	4	4	1	3	1	3	3	3	1	4	2	3	3	4	1	3	56.00
91	212	1	3	1	2	4	4	2	3	1	1	4	3	1	3	1	3	3	3	1	3	47.00
95	212	2	4	2	3	4	3	1	1	1	2	3	3	3	3	2	3	3	3	2	4	52.00
98	212	1	3	1	2	3	3	1	1	1	1	4	4	1	4	2	4	4	3	2	4	49.00
102	212	2	3	2	3	3	3	1	2	1	2	3	3	2	3	1	3	3	3	1	3	47.00
103	212	1	4	1	2	4	3	1	1	1	1	4	4	1	3	2	4	3	3	1	3	47.00
106	212	2	4	2	3	3	3	1	4	2	2	4	3	2	3	2	3	3	3	1	3	53.00
110	212	2	3	2	1	4	3	1	1	2	3	4	4	1	3	1	3	3	3	2	4	50.00
113	212	2	3	2	2	4	3	1	1	1	3	3	3	2	3	2	3	4	3	2	3	50.00
118	212	2	4	1	1	4	4	1	3	1	2	4	3	1	3	1	3	3	3	1	4	49.00
119	212	3	4	2	3	4	4	1	1	1	4	3	3	2	3	2	4	3	3	2	3	55.00
124	212	1	4	1	1	4	3	1	3	1	1	4	4	1	4	1	3	3	4	1	3	48.00
126	212	2	3	1	3	3	3	3	3	2	3	3	4	3	4	2	3	3	3	2	4	57.00
127	212	1	3	1	2	3	4	1	1	1	1	3	3	1	3	1	3	3	4	1	3	43.00
132	212	1	3	1	3	4	4	1	3	1	2	3	3	2	3	2	3	4	4	1	3	51.00
133	212	1	3	1	2	3	3	1	1	2	1	4	4	1	4	1	3	4	4	1	3	47.00
136	212	2	3	2	1	4	3	1	1	2	2	3	3	3	3	2	4	3	3	1	3	49.00
139	212	2	3	1	2	4	4	2	1	2	3	3	3	2	4	1	3	3	3	1	3	50.00
140	212	1	3	1	2	4	4	1	3	1	2	4	3	2	3	2	4	3	3	1	3	50.00
148	212	3	4	3	4	4	4	1	4	3	1	4	3	1	3	2	3	3	3	1	4	58.00
170	212	2	3	2	2	3	4	1	2	1	3	3	3	1	4	2	4	3	4	3	4	54.00
172	212	2	3	2	2	3	4	1	2	2	3	4	4	2	3	2	3	3	4	3	4	56.00
179	212	3	3	3	2	3	4	2	2	2	2	4	3	2	4	2	3	4	4	3	4	59.00
180	212	2	3	2	2	3	4	1	2	1	3	3	3	1	3	2	3	3	3	2	4	50.00
181	212	2	3	2	2	4	4	1	2	2	3	3	3	1	3	2	3	3	4	3	4	54.00
186	212	2	3	2	2	3	4	1	2	2	3	3	3	1	4	2	.	3	4	3	3	.
187	212	3	3	2	2	3	4	1	2	2	2	3	3	1	3	2	3	3	3	2	3	50.00
188	212	2	3	2	2	4	4	1	2	1	2	3	3	1	3	3	3	3	3	2	3	50.00
243	212	2	4	2	1	3	4	1	2	1	3	4	3	1	3	2	4	3	3	2	3	51.00
249	212	3	3	2	2	3	4	1	1	1	2	3	3	1	3	1	3	3	3	2	3	47.00



FCE 20124/702 i

38

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
260	212	2	3	2	2	3	4	2	1	1	2	3	4	1	4	1	3	3	4	2	4	51.00
262	212	3	3	2	2	3	4	2	1	1	3	4	3	1	3	1	4	4	4	2	4	54.00
268	212	4	3	3	3	3	4	1	2	1	3	4	4	3	4	3	4	3	4	2	4	62.00
269	212	3	3	3	3	3	4	2	1	1	3	3	4	3	4	3	3	3	4	2	4	59.00
273	212	2	3	1	2	3	3	1	1	1	2	3	3	2	3	1	3	3	3	1	3	44.00
193	212	3	3	3	3	4	4	3	1	1	3	3	4	1	4	1	4	4	4	3	4	60.00
197	212	3	4	3	3	3	4	3	1	1	3	3	3	2	4	2	3	4	4	3	4	60.00
202	212	3	3	2	2	3	4	1	1	1	2	3	3	2	4	2	3	3	4	2	3	51.00
203	212	3	3	2	2	3	4	2	1	2	3	3	3	2	4	2	3	4	4	2	4	56.00
206	212	3	3	3	2	3	3	2	3	2	3	3	3	2	3	2	3	3	3	2	3	54.00
210	212	3	3	3	2	3	3	1	1	2	3	3	4	2	4	2	3	4	4	2	4	56.00
214	212	3	3	3	3	3	4	2	2	2	3	4	4	3	4	3	4	4	4	3	4	65.00
216	212	3	3	3	2	3	4	1	2	2	3	4	4	2	4	2	3	3	4	2	4	58.00
251	212	3	3	3	3	3	3	2	2	2	3	3	3	2	3	2	.	3	3	3	3	.
254	212	3	3	2	3	3	4	3	2	2	2	3	3	2	3	3	3	3	3	2	3	55.00
255	212	3	4	3	3	4	4	3	1	1	2	3	4	2	3	2	3	3	3	2	3	56.00
218	212	2	3	2	2	3	4	4	4	2	4	3	3	2	4	2	4	4	4	2	3	61.00
219	212	1	3	2	3	4	4	1	2	2	2	4	3	3	3	1	3	3	4	2	3	53.00
226	212	2	3	2	3	3	3	1	2	3	1	4	4	4	3	1	3	4	4	1	4	55.00
227	212	2	3	1	1	3	3	2	3	1	1	3	3	1	3	1	3	3	3	1	3	44.00
237	212	1	4	1	3	4	4	2	1	1	1	4	4	1	4	1	4	4	4	1	4	53.00
238	212	2	4	1	1	4	4	1	1	2	4	4	4	2	4	1	4	4	3	1	4	55.00

FCE 20124/702 i

39

Treatment Group "B"

Day 21 (Period 212)

Number of Observations = 76

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.22	.09
2. Morning is when I feel best	3.29	.05
3. I have crying spells or feel like it	1.88	.09
4. I have trouble sleeping at night	2.18	.08
5. I eat as much as I used to	3.46	.06
6. I still enjoy sex	3.61	.06
7. I notice that I am losing weight	1.45	.09
8. I have trouble with constipation	1.79	.10
9. My heart beats faster than usual	1.58	.08
10. I get tired for no reason	2.22	.10
11. My mind is as clear as it used to be	3.46	.06
12. I find it easy to do the things I used to do	3.39	.06
13. I am restless and can't keep still	1.62	.09
14. I feel hopeful about the future	3.42	.06
15. I am more irritable than usual	1.79	.08
16. I find it easy to make decisions	3.34	.06
17. I feel that I am useful and needed	3.36	.06
18. My life is pretty full	3.49	.06
19. I feel that others would be better off if I were dead	1.83	.09
20. I still enjoy the things I used to do	3.49	.06
Total score	52.82	.59

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

40

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
2	282	2	3	1	1	4	4	1	1	2	1	3	4	1	4	1	4	3	3	2	4	49.00
10	282	1	4	1	1	4	4	1	1	1	2	4	3	1	4	2	3	3	4	1	4	49.00
11	282	2	4	1	3	4	4	2	1	2	2	4	3	1	3	1	3	4	3	1	4	52.00
15	282	1	4	1	2	4	4	1	1	2	2	4	4	1	3	2	4	3	3	1	4	51.00
17	282	2	4	1	1	4	4	1	1	1	1	4	4	1	3	1	4	3	4	1	4	49.00
31	282	2	3	1	2	4	3	1	2	1	1	4	4	2	4	2	4	4	4	1	4	53.00
32	282	2	4	1	2	4	3	1	2	1	1	4	4	2	4	2	3	4	4	1	4	53.00
41	282	2	3	1	2	4	3	1	2	1	2	4	4	2	4	2	4	4	4	1	4	54.00
42	282	1	4	1	2	4	3	1	2	1	1	4	4	1	4	1	4	4	4	1	4	51.00
44	282	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	51.00
47	282	2	3	1	2	4	3	1	2	2	2	4	3	1	3	1	3	4	4	1	4	50.00
51	282	1	4	1	1	4	4	1	2	1	1	4	4	1	4	1	4	4	4	1	4	51.00
54	282	2	3	1	1	4	3	2	2	1	2	3	3	1	3	2	3	3	3	1	4	47.00
55	282	2	3	1	1	4	4	1	1	2	1	4	4	1	3	1	4	4	4	1	4	50.00
60	282	3	3	3	2	3	3	2	2	3	3	3	3	2	3	3	3	3	3	3	3	56.00
61	282	2	3	2	2	4	4	1	1	2	2	3	3	1	3	1	3	3	4	2	3	49.00
66	282	4	4	4	4	3	4	4	3	4	4	4	4	1	4	3	4	4	4	3	4	73.00
67	282	3	3	3	3	3	4	2	3	3	3	3	3	1	3	2	3	3	3	3	3	57.00
70	282	2	3	2	2	3	4	1	1	1	1	4	4	1	4	2	3	3	3	2	3	49.00
77	282	2	3	2	1	4	3	1	1	1	2	3	3	1	3	1	3	3	3	4	4	48.00
78	282	2	4	1	2	4	3	1	1	2	1	4	4	3	3	2	4	4	4	1	4	54.00
83	282	4	4	3	1	4	4	1	1	2	4	3	4	4	4	4	3	3	3	4	4	64.00
84	282	4	3	2	3	4	3	1	2	3	3	3	3	4	4	3	3	3	3	2	3	59.00
88	282	2	3	1	2	3	4	2	1	2	1	3	3	2	4	2	4	4	3	1	4	51.00
90	282	4	3	3	3	4	4	1	4	1	4	3	3	1	4	1	4	3	4	1	3	58.00
91	282	1	3	1	3	4	4	1	3	2	2	4	3	1	3	1	3	3	3	1	3	49.00
95	282	2	4	2	2	4	3	1	1	1	1	3	3	2	3	2	3	4	4	1	3	49.00
98	282	1	3	1	4	4	3	1	1	1	1	4	4	1	4	1	4	4	4	2	4	52.00
102	282	1	4	2	3	3	3	1	2	1	2	3	3	2	3	1	4	3	3	1	4	49.00
103	282	1	3	1	1	4	3	1	1	1	1	4	3	1	4	1	3	4	4	1	4	46.00
106	282	2	3	2	3	4	3	1	3	2	3	4	3	2	3	2	3	3	3	1	4	54.00
110	282	1	4	1	1	4	4	1	1	1	1	3	3	1	4	1	4	3	3	1	4	46.00
113	282	2	3	2	2	4	3	1	1	1	3	3	3	2	3	2	3	4	3	2	4	51.00
118	282	1	4	1	1	4	4	1	3	1	2	4	3	1	4	1	3	4	4	1	4	51.00
119	282	3	4	2	3	3	3	1	1	1	4	3	3	2	3	2	4	3	3	2	3	53.00
124	282	1	4	1	1	4	3	1	2	1	1	3	4	1	4	1	3	4	4	1	4	48.00
126	282	2	3	1	3	3	3	1	2	2	3	3	3	2	3	2	3	3	3	1	3	49.00
127	282	1	3	1	1	3	3	1	1	1	1	3	4	1	3	1	3	4	4	2	3	44.00
132	282	1	3	1	1	4	4	1	2	1	1	3	3	1	4	1	3	4	4	1	3	46.00
133	282	1	4	1	1	3	4	2	1	2	1	3	3	1	4	2	4	4	4	1	4	50.00
136	282	2	4	2	2	3	3	1	2	3	2	4	3	4	3	2	3	4	3	1	3	54.00
139	282	1	4	1	1	4	4	1	2	1	2	3	3	1	4	1	4	4	4	1	4	50.00
140	282	1	4	1	1	4	4	1	1	1	1	4	3	1	3	1	4	3	3	1	3	45.00
148	282	3	4	3	4	4	4	1	4	3	1	4	3	1	3	2	3	3	3	1	4	58.00
170	282	2	3	2	2	3	4	1	1	2	3	3	3	1	3	1	3	3	3	2	4	49.00
172	282	2	3	2	2	3	4	1	1	2	3	3	3	1	3	2	3	3	3	2	4	50.00
179	282	2	3	2	2	3	4	1	2	2	2	4	3	2	4	2	3	4	4	2	4	55.00
180	282	2	3	1	2	3	4	1	2	1	3	3	3	1	3	2	3	3	3	2	4	49.00
181	282	2	3	2	2	3	4	1	1	2	3	3	3	1	3	2	4	3	3	2	3	50.00
186	282	2	3	2	2	3	4	1	1	2	2	3	3	1	3	1	3	4	4	2	3	49.00
187	282	2	3	2	2	3	4	1	2	2	2	3	3	1	3	2	3	3	3	2	3	49.00
188	282	2	3	2	2	4	4	1	2	2	2	3	3	1	3	2	3	3	3	2	3	50.00
193	282	3	3	3	3	3	4	3	1	1	3	3	4	1	4	1	4	4	4	3	4	59.00
197	282	3	3	2	2	3	4	1	1	2	2	3	3	1	3	1	3	3	4	3	3	50.00

427

FCE 20124/702 i

41

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
202	282	2	3	2	2	3	4	2	1	1	2	3	3	2	4	2	3	3	4	2	3	51.00
203	282	3	3	2	2	3	4	2	1	2	3	3	3	2	4	2	3	3	4	2	4	55.00
206	282	3	4	3	3	3	3	2	3	2	3	3	3	2	4	2	3	3	4	2	3	58.00
210	282	2	3	3	2	3	3	1	1	2	2	3	3	2	3	2	3	3	4	2	3	50.00
214	282	3	3	2	2	3	4	2	2	2	2	3	4	2	4	2	4	3	4	2	4	57.00
216	282	2	3	2	2	3	4	1	2	2	2	4	4	2	4	2	4	3	4	2	4	56.00
218	282	4	3	4	2	4	4	4	4	2	4	3	3	2	4	2	4	4	4	2	3	66.00
219	282	2	4	2	3	4	4	2	2	1	2	4	3	3	3	3	3	4	3	2	3	57.00
226	282	2	4	1	2	4	3	1	2	1	1	4	3	2	3	1	3	4	3	1	4	49.00
227	282	2	3	4	1	3	3	3	1	1	3	4	3	4	1	3	3	3	1	4		53.00
237	282	1	4	1	2	4	4	3	1	1	1	4	4	1	4	1	3	4	3	1	4	51.00
238	282	4	4	2	1	4	4	1	2	2	4	4	4	4	4	1	4	4	4	1	4	62.00
243	282	2	3	2	2	3	4	1	1	2	2	3	3	1	3	2	4	3	3	2	3	49.00
249	282	2	3	2	2	3	4	1	2	1	2	3	3	1	3	1	3	3	3	2	3	47.00
251	282	3	3	3	3	3	3	1	2	1	3	3	3	2	3	2	3	3	3	1	3	51.00
254	282	2	3	2	1	3	4	2	2	1	1	3	3	1	3	3	4	3	3	1	3	48.00
255	282	3	4	3	3	4	4	2	1	1	2	3	3	2	3	2	3	3	3	2	3	54.00
260	282	2	3	2	2	3	4	1	1	1	2	3	3	1	4	2	3	3	4	2	3	49.00
262	282	3	3	2	2	3	4	1	1	1	2	4	4	2	3	1	3	3	4	2	3	51.00
268	282	3	4	2	2	3	4	1	1	2	3	3	3	2	3	2	3	3	4	2	3	53.00
269	282	2	3	2	2	3	4	1	1	1	2	3	4	2	4	3	3	3	4	3	4	54.00
273	282	1	3	1	1	3	4	1	1	1	1	3	3	1	3	1	3	3	3	1	3	41.00

FCE 20124/702 i

42

Treatment Group "B"

Day 28 (Period 282)

Number of Observations = 76

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.09	.10
2. Morning is when I feel best	3.37	.06
3. I have crying spells or feel like it	1.79	.09
4. I have trouble sleeping at night	1.99	.09
5. I eat as much as I used to	3.53	.06
6. I still enjoy sex	3.64	.06
7. I notice that I am losing weight	1.33	.08
8. I have trouble with constipation	1.67	.09
9. My heart beats faster than usual	1.57	.08
10. I get tired for no reason	2.01	.11
11. My mind is as clear as it used to be	3.39	.06
12. I find it easy to do the things I used to do	3.33	.05
13. I am restless and can't keep still	1.57	.09
14. I feel hopeful about the future	3.46	.06
15. I am more irritable than usual	1.68	.08
16. I find it easy to make decisions	3.36	.06
17. I feel that I am useful and needed	3.41	.06
18. My life is pretty full	3.51	.06
19. I feel that others would be better off if I were dead	1.63	.09
20. I still enjoy the things I used to do	3.57	.06
Total score	51.89	.57

FCE 20124/702 i

43

Table 5d - Zung Self-rating Depression Scale

PAT PER No. (day)	Treatment Group "C"																				Total Score
	Items: 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
3 000	4	3	1	2	3	4	1	2	2	3	4	3	3	3	3	3	4	4	3	3	58.00
6 000	3	3	1	2	3	3	2	2	3	3	4	3	2	3	2	3	3	3	2	3	53.00
8 000	4	3	1	2	3	4	1	2	1	3	4	3	2	3	2	3	3	3	1	4	52.00
16 000	4	4	1	4	3	4	1	1	2	4	4	4	3	4	4	4	3	4	3	3	64.00
18 000	3	3	1	2	4	4	3	1	2	3	4	3	1	3	3	3	4	3	2	4	56.00
26 000	4	4	2	4	3	4	2	2	2	3	4	4	2	4	4	4	4	4	1	4	65.00
27 000	4	4	2	3	3	4	2	3	3	4	4	4	3	4	4	4	4	4	2	4	69.00
33 000	4	4	3	4	3	4	2	4	3	3	4	4	2	4	3	4	4	4	2	4	69.00
36 000	4	4	2	4	3	4	2	4	3	3	4	4	3	4	4	4	4	4	2	4	70.00
39 000	4	4	3	4	3	4	2	3	2	3	4	4	3	4	4	4	4	4	2	4	69.00
40 000	4	4	2	3	3	4	1	2	2	4	4	4	3	4	4	4	4	4	2	4	66.00
43 000	4	4	4	4	3	4	3	3	2	4	4	4	3	4	3	4	4	4	3	4	72.00
46 000	4	4	2	4	3	4	3	2	2	4	4	4	2	4	4	4	4	4	3	4	69.00
52 000	3	4	3	3	4	3	3	3	3	4	4	3	3	3	3	3	4	3	3	3	65.00
53 000	3	4	3	4	3	3	3	3	4	4	3	3	3	3	3	3	4	3	3	4	66.00
58 000	4	4	4	4	4	4	4	3	4	4	4	4	2	4	2	4	4	4	4	4	75.00
59 000	4	4	4	4	3	4	4	2	4	4	4	4	2	4	3	4	4	4	4	4	74.00
62 000	3	4	3	3	3	4	4	2	3	3	3	3	2	4	3	4	4	4	3	4	66.00
63 000	3	4	4	3	3	3	1	2	3	4	3	4	2	4	3	3	3	4	3	4	63.00
69 000	3	4	3	3	4	3	1	2	3	3	3	4	2	4	2	3	3	3	3	4	60.00
71 000	3	4	4	4	4	1	3	3	3	3	3	3	4	2	4	4	4	3	3	3	66.00
74 000	4	4	3	3	3	4	3	4	3	3	3	4	2	3	1	4	3	3	2	4	63.00
76 000	3	4	3	3	4	4	3	3	4	3	3	4	3	3	3	4	3	3	2	4	66.00
81 000	3	4	2	4	4	4	1	2	4	3	3	3	4	2	3	3	3	2	3	3	58.00
86 000	4	4	1	4	4	4	3	3	1	4	4	3	4	4	2	4	4	4	3	3	67.00
89 000	4	4	3	4	4	4	2	1	1	4	4	4	2	4	3	4	3	4	2	4	65.00
92 000	4	4	4	3	4	4	2	1	1	4	4	4	3	4	3	4	4	4	4	4	69.00
93 000	4	4	4	3	4	4	2	3	1	4	4	4	4	4	3	4	4	4	4	4	72.00
97 000	4	4	3	4	3	4	2	4	1	3	4	4	3	4	4	4	4	4	1	3	67.00
100 000	4	4	3	4	4	4	4	3	1	3	4	4	2	4	2	4	4	4	3	4	69.00
104 000	4	4	1	2	3	4	1	3	1	4	3	4	2	4	1	4	4	4	2	4	59.00
105 000	4	3	4	4	3	3	3	2	2	4	4	4	3	4	2	4	4	4	3	4	68.00
111 000	4	4	4	4	3	4	3	4	1	4	4	4	1	4	2	4	4	4	4	4	70.00
112 000	4	3	.	4	4	4	1	3	4	4	4	3	3	4	3	4	4	4	4	4	.
116 000	4	4	4	4	4	4	4	2	2	4	3	4	4	4	3	4	4	4	4	4	74.00
117 000	3	3	2	3	4	4	4	2	2	3	3	3	2	4	3	4	4	3	3	3	62.00
121 000	3	4	2	4	3	4	1	1	2	1	3	3	1	3	1	4	4	4	2	3	53.00
125 000	4	4	2	3	3	3	1	1	1	2	4	4	3	3	3	4	4	3	1	4	57.00
128 000	3	3	2	2	4	4	3	1	2	4	4	4	1	4	4	4	3	4	2	3	61.00
129 000	4	3	4	4	4	3	3	4	4	4	3	1	4	4	3	4	4	4	4	4	71.00
137 000	4	4	2	4	4	4	3	1	3	2	4	4	3	3	1	4	3	3	1	4	61.00
138 000	4	4	4	4	4	4	2	2	2	4	3	4	4	3	2	4	3	3	2	4	66.00
141 000	3	4	3	4	4	4	3	3	1	4	4	4	4	3	2	4	4	4	2	4	68.00
145 000	2	4	1	1	4	4	2	1	1	3	3	3	2	3	1	3	4	4	2	3	51.00
173 000	4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	62.00
174 000	4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	3	3	4	62.00
175 000	3	3	3	3	4	4	2	2	2	3	4	3	1	4	1	4	4	3	3	4	60.00
178 000	4	3	3	3	3	3	2	2	1	3	4	4	1	4	1	4	4	4	3	4	60.00
182 000	4	3	3	3	4	4	3	1	1	3	4	4	1	4	1	4	4	4	3	4	62.00
183 000	4	3	3	3	4	4	3	1	1	3	4	4	1	4	1	4	4	4	3	4	62.00

430

FCE 20124/702 i

44

PAT PER No. (day)	Items:																				Total Score	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
190	000	4	3	3	3	4	4	2	1	2	4	4	4	1	4	1	4	4	4	4	4	64.00
191	000	4	3	3	3	4	4	1	2	1	4	4	4	1	4	1	4	4	4	4	4	63.00
195	000	4	4	4	4	3	4	2	1	2	4	4	4	2	4	2	4	4	4	4	4	68.00
196	000	4	4	3	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	4	4	66.00
201	000	4	4	3	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	65.00
204	000	4	4	4	3	3	1	2	2	3	4	4	3	4	3	4	4	4	4	3	4	67.00
205	000	3	3	4	4	4	3	2	2	3	4	4	1	4	2	4	4	4	3	4	4	66.00
207	000	4	4	4	3	4	2	2	2	3	4	4	2	4	3	4	4	4	3	4	4	68.00
212	000	3	4	3	3	3	2	2	2	3	4	4	2	4	3	4	4	4	3	4	4	64.00
213	000	4	4	4	3	4	2	2	2	4	4	4	4	4	4	4	4	4	4	4	4	73.00
220	000	2	3	4	4	4	4	2	2	1	4	4	4	3	1	4	4	4	4	4	4	66.00
221	000	4	3	1	1	4	3	4	1	2	4	3	3	2	3	1	3	4	3	2	4	55.00
225	000	3	3	3	3	3	3	3	3	4	3	3	3	3	2	3	3	4	1	4	4	60.00
228	000	4	4	4	4	4	3	4	4	3	4	4	1	4	1	4	4	4	1	4	4	69.00
229	000	4	4	2	2	3	4	2	2	2	3	3	4	3	3	3	3	4	4	2	4	61.00
234	000	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	4	75.00
236	000	4	4	4	4	4	4	4	1	4	4	4	4	4	1	4	4	4	1	4	4	71.00
239	000	4	4	2	4	4	4	2	4	1	4	4	4	1	3	4	4	4	4	4	4	69.00
241	000	3	3	3	3	4	4	1	2	1	3	4	4	1	4	2	4	4	4	3	3	60.00
242	000	3	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
250	000	4	4	4	4	4	2	1	2	4	4	4	3	4	3	4	4	4	4	4	4	71.00
252	000	4	4	4	3	3	1	2	2	4	4	4	3	4	3	4	4	4	4	4	4	69.00
253	000	4	4	3	4	4	3	1	1	4	4	4	3	4	3	4	4	4	3	3	4	68.00
256	000	4	4	3	4	4	4	2	1	1	4	4	4	4	3	4	3	4	2	4	4	67.00
261	000	3	3	3	3	4	4	2	1	1	2	4	4	1	4	1	4	4	4	3	4	59.00
264	000	3	4	3	2	4	4	2	1	2	3	4	4	1	4	1	3	3	4	3	4	59.00
265	000	3	4	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	2	4	60.00
266	000	2	4	3	2	4	4	2	1	1	3	4	4	1	4	2	4	4	4	3	4	60.00
272	000	4	4	4	4	4	4	4	2	2	4	4	4	3	4	4	4	4	4	4	4	75.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

45

Treatment Group "C"

Baseline (Period 000)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.63	.06
2. Morning is when I feel best	3.68	.05
3. I have crying spells or feel like it	2.90	.11
4. I have trouble sleeping at night	3.37	.09
5. I eat as much as I used to	3.57	.06
6. I still enjoy sex	3.82	.04
7. I notice that I am losing weight	2.37	.11
8. I have trouble with constipation	2.09	.11
9. My heart beats faster than usual	2.03	.10
10. I get tired for no reason	3.39	.08
11. My mind is as clear as it used to be	3.78	.05
12. I find it easy to do the things I used to do	3.77	.05
13. I am restless and can't keep still	2.29	.11
14. I feel hopeful about the future	3.76	.05
15. I am more irritable than usual	2.41	.12
16. I find it easy to make decisions	3.81	.04
17. I feel that I am useful and needed	3.81	.04
18. My life is pretty full	3.78	.05
19. I feel that others would be better off if I were dead	2.73	.11
20. I still enjoy the things I used to do	3.82	.04
Total score	64.74	.63

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 1

46

PAT	PER	No. (day)	Items:																				Total Score
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
3	042		4	4	1	2	3	4	1	2	2	3	4	4	3	3	3	3	4	4	3	3	60.00
6	042		3	3	1	2	3	3	2	2	3	3	4	3	2	3	2	3	3	3	2	3	53.00
8	042		4	3	1	2	3	4	1	2	1	3	4	3	2	3	2	3	3	3	1	4	52.00
16	042		4	4	1	4	3	4	1	1	2	4	4	4	3	4	4	4	3	4	3	3	64.00
18	042		3	3	1	2	4	4	3	1	2	3	4	3	1	3	3	3	4	3	2	4	56.00
26	042		4	4	2	4	3	4	1	2	2	3	4	4	2	4	3	4	4	4	1	4	63.00
27	042		4	4	2	3	3	4	2	3	3	4	4	4	3	4	4	4	4	4	1	4	68.00
33	042		4	4	3	4	3	4	2	4	3	3	4	4	2	4	3	4	4	4	2	4	69.00
36	042		4	4	2	4	3	4	2	4	3	3	4	4	3	4	3	4	4	4	2	4	69.00
39	042		4	4	3	4	3	4	1	3	2	3	4	4	3	4	4	4	4	4	2	4	68.00
40	042		4	4	2	3	3	4	1	2	2	4	4	4	3	4	4	4	4	4	2	4	66.00
43	042		4	4	4	4	3	4	2	3	2	4	4	4	3	4	3	4	4	4	3	4	71.00
46	042		4	4	3	4	3	4	3	2	2	4	4	4	2	4	4	4	4	4	2	4	69.00
52	042		4	3	4	3	3	3	3	3	3	3	3	3	3	3	3	3	4	3	3	3	63.00
53	042		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	4	3	62.00
58	042		4	4	4	4	4	4	4	3	4	4	4	4	2	4	2	4	4	4	4	4	75.00
59	042		4	4	4	4	3	4	3	2	4	4	4	4	2	4	3	4	4	4	4	4	73.00
62	042		4	3	3	3	4	3	4	2	3	3	3	3	2	4	3	3	4	4	3	3	64.00
63	042		4	3	3	3	3	1	2	3	4	3	4	2	3	3	3	3	4	3	3	3	60.00
69	042		4	3	3	3	4	4	1	2	3	3	3	3	2	3	2	3	4	4	3	3	60.00
71	042		4	3	3	4	4	4	1	3	3	3	3	4	3	4	3	4	4	4	3	4	68.00
74	042		4	4	3	3	4	4	2	4	3	3	3	4	2	3	1	4	4	3	2	4	64.00
76	042		4	4	3	3	4	4	3	3	4	4	3	4	3	4	3	4	3	3	2	4	69.00
81	042		3	3	3	4	4	4	1	1	1	3	3	3	2	4	4	3	3	4	2	3	58.00
86	042		4	4	1	2	3	4	2	2	1	4	4	3	4	4	2	3	4	3	4	3	61.00
89	042		4	4	3	4	4	4	2	1	1	4	4	4	2	4	3	3	3	4	2	4	64.00
92	042		4	4	4	2	3	4	3	1	1	4	4	4	2	3	3	4	4	4	4	4	66.00
93	042		4	4	4	2	4	4	3	2	1	4	4	4	3	4	2	4	4	4	4	4	69.00
97	042		4	4	3	4	4	4	1	4	1	3	4	4	4	4	4	4	4	4	1	4	69.00
100	042		4	4	3	3	4	4	4	3	1	3	4	4	2	4	2	4	4	4	3	4	68.00
104	042		4	4	1	2	3	4	1	3	1	4	3	4	2	4	1	4	4	4	2	4	59.00
105	042		4	3	3	3	3	4	3	1	3	4	3	4	3	4	2	4	4	4	3	4	66.00
111	042		4	4	4	4	3	4	3	4	1	4	4	4	1	4	2	4	4	4	4	4	70.00
112	042		3	3	3	4	3	4	3	1	3	4	4	3	3	4	3	4	3	3	3	3	64.00
116	042		4	4	4	3	4	4	3	2	2	4	3	4	3	4	3	4	4	4	4	4	71.00
117	042		4	3	3	3	4	4	4	2	2	3	3	3	2	4	3	4	4	3	3	3	64.00
121	042		1	4	1	2	4	4	1	3	2	2	3	4	1	4	1	3	4	3	1	3	51.00
125	042		3	3	2	3	4	3	1	1	2	2	4	4	4	3	3	4	3	3	2	4	58.00
128	042		1	3	1	1	3	4	2	1	1	3	3	3	1	3	1	3	3	3	1	3	44.00
129	042		2	4	2	3	4	4	3	4	4	3	3	4	3	3	2	3	4	4	2	3	64.00
137	042		1	3	1	1	3	4	1	1	1	2	3	3	2	3	1	3	3	3	1	3	43.00
138	042		3	4	3	3	3	4	2	1	1	4	3	4	3	3	2	3	3	3	1	3	56.00
141	042		2	4	2	4	3	4	3	4	1	2	4	4	2	3	2	3	3	3	1	4	58.00
145	042		2	4	1	1	4	4	2	1	1	3	3	3	2	3	1	3	4	4	2	3	51.00
173	042		4	3	3	3	4	4	1	1	1	3	4	4	1	3	1	4	4	4	3	4	59.00
174	042		4	3	3	3	4	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
175	042		3	3	3	2	4	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	58.00
178	042		4	3	3	3	4	4	1	1	1	3	4	3	1	4	1	4	3	4	3	4	58.00
182	042		4	3	3	2	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	60.00
183	042		4	3	3	3	4	4	3	1	1	3	4	4	1	4	1	4	4	4	3	4	62.00
190	042		4	3	3	3	4	4	2	2	2	3	4	4	1	4	1	4	4	4	3	4	63.00
191	042		4	3	3	3	4	4	2	1	1	3	4	4	1	4	1	4	4	4	3	4	61.00
195	042		4	4	4	4	3	4	2	1	2	4	4	4	2	4	2	4	4	4	4	4	68.00
196	042		4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00

433

FCE 20124/702 i

47

PAT PER No. (day)	Items:																					Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
220	042	2	3	1	4	3	4	2	1	1	2	3	4	3	4	4	3	4	3	2	3	56.00
221	042	2	3	1	1	3	3	2	1	2	2	4	4	2	3	2	3	3	3	1	3	48.00
225	042	3	3	3	4	4	4	3	4	3	3	3	4	2	4	2	3	3	4	1	4	64.00
228	042	4	3	3	4	3	3	1	3	3	3	4	4	4	4	1	4	4	4	1	4	64.00
229	042	2	3	2	2	3	4	2	2	2	3	4	4	2	3	3	3	3	4	2	4	57.00
234	042	4	3	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	1	4	75.00
236	042	4	4	4	4	4	4	4	4	1	4	4	4	4	4	1	4	4	4	1	4	71.00
239	042	4	4	2	4	4	4	2	4	1	4	4	4	1	3	4	4	4	4	4	4	69.00
201	042	4	4	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	4	3	4	64.00
204	042	4	4	4	4	3	3	1	2	2	3	4	4	3	4	3	4	4	4	3	4	67.00
205	042	3	3	4	4	4	4	3	2	2	3	4	4	1	4	2	4	4	4	3	4	66.00
207	042	4	4	4	4	3	4	2	2	2	3	4	4	2	4	3	4	4	4	3	4	68.00
212	042	3	4	3	3	3	2	2	2	3	4	4	2	4	2	4	4	4	4	3	4	63.00
213	042	4	4	4	4	3	3	2	2	2	4	4	4	4	4	4	4	4	4	4	4	72.00
241	042	3	3	3	3	4	4	1	1	1	3	4	4	1	4	2	4	4	4	3	4	60.00
242	042	3	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	61.00
250	042	4	4	4	4	4	4	2	1	2	4	4	4	3	4	3	4	4	4	4	4	71.00
252	042	4	4	3	4	3	3	1	2	2	4	4	4	3	4	3	4	4	4	4	4	68.00
253	042	4	4	3	4	4	3	1	1	4	4	4	4	4	3	4	4	4	4	3	3	69.00
256	042	4	4	3	4	3	4	1	1	1	4	4	4	3	4	4	4	4	4	3	4	67.00
261	042	3	3	3	2	4	4	2	1	2	2	4	4	1	4	1	4	4	4	3	4	59.00
264	042	3	4	2	2	4	4	2	2	1	3	4	4	2	4	1	3	3	4	3	4	59.00
265	042	3	3	3	2	4	4	1	1	1	3	4	4	1	4	1	4	4	4	2	4	57.00
266	042	3	4	2	2	4	4	2	1	1	2	4	4	1	4	1	3	3	4	3	4	56.00
272	042	4	4	4	4	4	4	4	2	2	4	4	4	4	4	4	4	4	4	4	4	76.00

FCE 20124/702 i

48

Treatment Group "C"

Day 4 (Period 042)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.52	.09
2. Morning is when I feel best	3.56	.06
3. I have crying spells or feel like it	2.73	.11
4. I have trouble sleeping at night	3.10	.10
5. I eat as much as I used to	3.51	.06
6. I still enjoy sex	3.85	.04
7. I notice that I am losing weight	2.09	.11
8. I have trouble with constipation	2.04	.12
9. My heart beats faster than usual	1.91	.10
10. I get tired for no reason	3.27	.07
11. My mind is as clear as it used to be	3.73	.05
12. I find it easy to do the things I used to do	3.81	.04
13. I am restless and can't keep still	2.27	.11
14. I feel hopeful about the future	3.75	.05
15. I am more irritable than usual	2.38	.12
16. I find it easy to make decisions	3.68	.05
17. I feel that I am useful and needed	3.75	.05
18. My life is pretty full	3.77	.05
19. I feel that others would be better off if I were dead	2.59	.11
20. I still enjoy the things I used to do	3.73	.05
Total score	63.04	.75

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

49

PAT	PER	Items:																				Total Score	
		No.	(day)	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18		19
3	072	4	4	1	2	3	4	1	2	2	3	4	4	3	3	3	3	3	4	4	3	3	60.00
6	072	3	3	1	2	3	3	2	2	2	3	4	3	2	3	2	3	3	3	3	2	3	52.00
8	072	4	3	1	2	3	4	1	3	1	3	4	3	2	3	2	3	3	3	1	4	53.00	
16	072	4	3	1	3	3	4	1	1	2	4	4	3	3	3	4	4	3	4	3	3	60.00	
18	072	3	3	1	1	4	4	3	1	2	3	4	3	1	3	3	3	4	3	2	4	55.00	
26	072	3	3	1	3	3	4	1	2	2	2	3	3	3	3	3	3	3	3	1	3	52.00	
27	072	3	4	3	3	3	4	2	3	2	3	4	4	3	4	4	4	4	4	1	4	66.00	
33	072	3	4	2	4	3	4	2	4	3	3	4	4	2	4	3	4	4	4	2	4	67.00	
36	072	2	3	1	2	4	4	1	3	2	2	3	3	1	3	2	3	3	3	1	3	49.00	
39	072	4	4	2	4	3	4	1	3	2	3	4	4	3	4	3	4	4	4	1	4	65.00	
40	072	3	4	1	3	3	4	1	2	2	4	4	4	3	3	3	4	3	3	2	3	59.00	
43	072	3	4	2	3	3	4	1	3	2	2	3	3	2	3	2	3	3	3	1	3	53.00	
45	072	3	4	2	4	4	4	1	3	2	2	3	4	2	3	3	4	4	4	2	4	62.00	
52	072	3	3	3	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3	59.00	
53	072	4	3	3	3	3	3	3	3	3	3	4	3	3	3	3	3	3	3	3	3	62.00	
58	072	3	4	4	4	4	4	4	2	4	4	4	4	1	4	2	4	4	4	4	4	72.00	
59	072	4	4	4	4	3	4	2	3	4	4	4	4	2	4	3	4	4	3	4	4	72.00	
62	072	3	4	4	3	4	3	3	2	3	3	3	3	2	3	3	3	3	3	3	3	61.00	
63	072	3	4	4	3	3	3	1	2	3	3	3	3	2	3	3	3	3	3	3	3	61.00	
69	072	3	4	3	3	4	3	1	2	4	3	4	3	2	4	1	3	4	4	3	4	58.00	
71	072	3	4	3	4	4	4	1	3	3	3	3	3	2	3	3	3	4	4	3	4	62.00	
74	072	3	4	3	2	3	4	2	4	3	2	3	3	1	3	1	3	3	3	2	3	62.00	
76	072	3	4	3	3	4	4	2	3	4	3	3	4	3	3	3	4	3	3	2	4	65.00	
81	072	3	3	3	4	4	4	1	1	2	3	3	3	2	3	2	3	3	3	2	3	55.00	
86	072	3	3	1	3	3	3	1	2	1	2	3	4	1	3	1	3	3	3	1	3	47.00	
89	072	4	4	3	3	3	4	2	1	1	4	4	3	2	3	2	4	3	4	1	4	59.00	
92	072	3	3	2	2	3	3	1	1	1	4	4	3	2	3	2	3	3	3	1	3	50.00	
93	072	4	4	4	2	4	4	2	2	1	4	4	4	3	4	3	4	4	4	4	4	69.00	
97	072	3	4	2	4	4	4	1	2	1	3	4	4	2	4	3	4	4	4	1	4	62.00	
100	072	4	4	3	4	4	4	2	1	1	3	4	4	2	4	2	4	4	4	3	4	65.00	
104	072	4	4	1	1	4	4	1	4	2	4	4	4	2	4	2	4	4	4	1	4	62.00	
105	072	4	3	3	4	4	4	3	2	4	1	4	4	2	4	2	4	4	4	3	4	67.00	
111	072	4	4	3	3	3	4	3	4	1	4	4	4	1	4	2	4	4	4	4	4	68.00	
112	072	3	3	2	2	3	3	2	1	2	3	4	3	2	3	3	3	3	3	3	3	54.00	
116	072	4	4	4	3	3	4	3	2	2	4	3	4	2	4	3	4	4	4	3	3	67.00	
117	072	4	3	3	3	4	4	2	2	2	3	3	3	1	4	3	4	4	3	3	3	61.00	
121	072	1	4	1	1	4	4	1	3	2	1	3	4	1	4	1	3	4	3	1	4	50.00	
125	072	3	3	2	3	4	3	1	1	1	2	3	3	2	3	3	3	3	3	1	3	50.00	
128	072	1	3	2	1	4	4	2	1	1	3	3	3	3	3	1	3	3	3	1	3	48.00	
129	072	2	3	2	3	3	4	2	4	4	3	3	3	3	2	3	4	4	2	3	60.00		
137	072	2	3	1	2	3	4	2	1	2	2	3	3	2	3	1	3	3	3	1	3	47.00	
141	072	2	3	2	1	3	3	2	3	2	2	3	3	3	3	1	3	3	3	1	3	49.00	
145	072	3	3	2	3	3	4	2	1	2	3	3	4	3	4	1	3	3	4	2	3	56.00	
173	072	3	3	2	2	3	4	1	2	2	3	3	3	1	3	1	4	3	4	3	4	54.00	
174	072	3	3	3	3	4	4	2	1	1	3	4	3	1	3	2	4	3	4	3	4	58.00	
175	072	3	3	3	2	4	4	2	1	1	3	4	4	1	4	1	4	3	3	2	4	56.00	
178	072	3	3	2	2	3	4	1	2	1	3	4	4	1	3	1	3	4	4	3	4	55.00	
182	072	4	3	2	2	3	4	2	1	1	3	3	3	1	4	1	3	3	3	3	3	52.00	
183	072	4	3	3	3	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	62.00	
190	072	3	3	2	3	3	4	1	2	2	3	4	3	1	4	2	4	4	4	3	3	58.00	
191	072	3	3	3	2	4	4	2	2	1	3	4	4	1	4	1	4	4	4	3	4	60.00	
195	072	4	4	3	4	3	4	2	1	2	4	4	4	2	4	2	4	4	4	4	4	67.00	
196	072	4	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00	
201	072	4	4	3	3	3	4	1	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00	

FCE 20124/702 i

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
204	072	4	4	4	4	3	3	1	2	2	3	4	4	3	4	3	4	4	4	3	4	67.00
205	072	3	3	4	4	4	4	3	2	2	3	4	4	1	4	2	4	4	4	3	4	66.00
207	072	4	4	4	4	3	4	2	2	2	3	3	4	2	4	2	3	4	4	3	4	65.00
212	072	3	4	3	3	3	2	2	2	3	4	4	1	4	2	4	4	4	3	4	62.00	
213	072	4	4	4	4	3	4	2	2	4	4	4	4	4	4	4	4	4	4	4	73.00	
220	072	2	3	2	4	4	3	2	1	2	2	3	3	2	4	1	3	4	4	1	3	53.00
221	072	2	4	1	1	4	4	2	1	1	4	3	3	2	3	3	3	3	4	1	3	52.00
225	072	3	3	3	3	3	3	3	2	3	3	4	4	3	3	4	3	4	1	4	62.00	
228	072	4	4	1	4	4	3	4	1	1	1	4	4	2	4	1	4	3	4	1	4	58.00
229	072	2	3	2	2	3	3	2	2	3	4	3	2	3	2	3	3	3	1	3	52.00	
234	072	3	3	3	4	4	4	4	1	2	3	4	4	3	3	1	4	4	4	1	4	63.00
236	072	1	4	1	4	4	3	1	1	1	1	3	3	4	4	1	4	4	4	1	4	53.00
239	072	1	3	2	4	4	4	2	4	1	2	3	3	1	4	1	3	4	4	2	4	56.00
241	072	3	3	3	2	4	4	2	2	1	3	4	4	1	4	2	4	4	4	3	4	61.00
242	072	3	3	3	2	4	3	2	1	1	3	4	4	1	4	1	4	4	4	3	4	58.00
250	072	4	4	3	4	4	4	2	1	2	4	4	4	3	4	3	4	4	4	4	4	70.00
252	072	4	4	3	4	3	3	2	3	2	4	4	4	3	4	3	4	4	4	4	4	70.00
253	072	4	4	3	4	4	4	3	1	1	4	4	4	4	4	3	4	4	4	3	3	69.00
256	072	4	4	3	4	3	4	1	1	1	4	4	4	4	4	3	4	3	4	2	4	65.00
261	072	3	3	3	2	4	4	2	1	2	2	4	4	1	4	2	4	4	4	3	4	60.00
264	072	3	4	2	2	4	4	1	1	2	3	4	4	1	3	1	4	3	4	3	4	57.00
265	072	3	3	3	2	3	4	1	1	1	3	4	4	1	4	2	4	4	4	2	4	57.00
266	072	3	4	2	2	4	4	2	1	1	2	4	4	1	4	1	4	3	3	2	3	54.00
272	072	4	4	4	4	4	4	4	2	2	4	4	4	4	4	4	4	4	4	3	4	75.00

50

FCE 20124/702 i

51

Treatment Group "C"

Day 7 (Period 072)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	3.17	.09
2. Morning is when I feel best	3.51	.06
3. I have crying spells or feel like it	2.49	.11
4. I have trouble sleeping at night	2.90	.11
5. I eat as much as I used to	3.47	.06
6. I still enjoy sex	3.74	.05
7. I notice that I am losing weight	1.87	.09
8. I have trouble with constipation	1.96	.11
9. My heart beats faster than usual	1.91	.10
10. I get tired for no reason	2.96	.09
11. My mind is as clear as it used to be	3.63	.06
12. I find it easy to do the things I used to do	3.58	.06
13. I am restless and can't keep still	2.06	.11
14. I feel hopeful about the future	3.55	.06
15. I am more irritable than usual	2.17	.10
16. I find it easy to make decisions	3.59	.06
17. I feel that I am useful and needed	3.56	.06
18. My life is pretty full	3.63	.06
19. I feel that others would be better off if I were dead	2.32	.11
20. I still enjoy the things I used to do	3.59	.06
Total score	59.67	.76

FCE 20124/702 i

52

PAT PER No. (day)	Items:																				Total Score	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
3	102	4	3	1	2	3	4	1	2	2	3	4	3	3	3	3	3	4	4	3	4	59.00
6	102	3	3	1	2	3	3	2	2	2	3	4	3	2	3	2	3	3	3	2	3	52.00
8	102	3	3	1	2	4	4	1	3	1	3	4	3	2	3	2	3	3	3	1	4	53.00
16	102	3	3	1	2	4	4	1	1	2	3	4	3	2	3	3	4	3	3	3	3	55.00
18	102	3	4	1	1	4	4	3	1	2	3	4	3	1	3	2	3	4	3	2	4	55.00
26	102	2	3	1	2	3	3	1	2	1	2	3	3	2	3	2	3	3	3	1	3	46.00
27	102	3	3	2	2	3	4	1	3	2	2	3	3	2	3	2	3	3	3	1	3	51.00
33	102	3	4	1	3	3	4	2	4	3	3	3	3	2	3	2	3	3	3	1	3	56.00
36	102	2	3	1	2	4	4	1	2	2	2	4	3	1	3	2	3	3	3	1	3	49.00
39	102	2	3	1	2	4	3	1	2	1	2	3	3	2	3	2	3	3	3	1	3	47.00
40	102	2	3	1	2	4	3	1	2	2	2	3	3	2	3	2	3	3	3	1	3	48.00
43	102	2	3	1	2	4	4	1	2	2	1	4	3	1	4	1	3	3	3	1	3	48.00
46	102	3	3	1	3	4	4	1	2	2	2	3	4	2	3	3	3	4	3	1	4	55.00
52	102	3	3	3	3	3	3	2	2	3	3	3	3	3	3	3	3	3	3	3	3	58.00
53	102	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	60.00
58	102	2	4	4	3	3	3	2	4	4	3	3	1	4	2	3	3	3	3	4	4	61.00
59	102	3	4	4	4	3	4	2	3	4	3	3	4	3	4	3	4	4	3	4	3	69.00
62	102	3	4	4	3	3	3	2	3	3	3	3	2	3	3	3	3	3	3	3	3	60.00
63	102	3	3	3	4	3	1	2	3	3	3	3	1	3	3	3	3	3	3	3	3	56.00
69	102	3	3	3	4	3	1	2	3	3	3	3	2	3	1	3	3	4	3	3	3	56.00
71	102	3	4	3	4	4	1	3	3	3	3	3	2	3	3	3	3	3	3	3	3	61.00
74	102	3	4	3	2	3	4	2	4	3	2	3	3	1	3	1	3	3	3	2	3	55.00
76	102	2	3	3	2	3	4	2	2	3	2	3	3	2	3	2	3	4	3	2	3	54.00
81	102	2	3	2	2	4	3	1	1	1	3	3	3	2	3	2	3	3	3	1	3	48.00
86	102	4	3	1	3	4	3	2	3	1	3	3	4	1	3	1	3	3	3	1	3	52.00
89	102	3	3	3	4	4	4	2	1	1	3	4	4	2	4	2	4	3	4	1	4	60.00
92	102	1	3	2	1	3	4	1	1	1	1	4	3	2	3	1	3	3	4	1	3	45.00
93	102	4	4	4	2	3	4	1	3	1	4	4	4	3	3	2	4	4	4	4	3	65.00
97	102	3	4	2	4	4	1	2	1	2	3	4	2	3	4	4	4	4	1	4	4	60.00
100	102	3	4	2	4	4	2	1	1	3	4	4	2	4	2	4	4	4	4	2	4	62.00
104	102	4	4	1	1	4	4	1	4	2	4	4	4	2	4	2	4	4	4	1	4	62.00
105	102	4	3	4	4	4	3	4	1	3	4	4	4	3	4	2	4	4	4	3	4	70.00
111	102	4	4	4	4	4	3	4	1	3	4	3	2	4	3	4	4	4	4	4	4	71.00
112	102	2	3	2	1	4	3	2	3	2	4	4	3	2	3	2	3	3	3	2	3	54.00
116	102	4	4	3	4	3	4	3	2	2	4	3	4	3	4	3	4	3	3	3	4	67.00
117	102	4	3	3	3	4	2	3	2	3	3	3	1	4	3	4	4	3	3	3	3	61.00
121	102	1	4	1	2	4	1	2	2	1	3	3	1	4	1	4	4	4	1	3	3	50.00
125	102	4	3	2	3	4	3	1	1	2	3	4	3	3	3	4	3	3	1	4	4	57.00
128	102	1	4	1	1	3	3	4	1	1	3	3	3	1	3	1	4	3	3	1	3	47.00
129	102	1	3	2	4	4	3	1	3	1	2	3	3	1	4	2	3	3	3	2	3	51.00
137	102	2	3	2	2	4	4	2	1	1	2	3	3	2	3	1	3	3	3	1	3	48.00
141	102	1	3	1	1	3	3	2	2	2	1	3	3	2	4	1	3	4	4	1	3	47.00
145	102	2	4	2	3	4	4	2	2	2	3	3	3	3	4	1	3	3	3	2	4	57.00
173	102	3	3	2	2	3	4	1	1	2	3	3	3	2	3	2	3	4	3	3	4	54.00
174	102	3	3	3	2	3	4	1	1	1	3	3	3	2	4	2	3	3	4	3	4	55.00
175	102	3	3	2	2	3	4	1	1	1	3	3	3	1	3	1	3	3	4	3	4	51.00
178	102	3	3	2	2	4	4	1	2	2	3	4	3	2	4	2	3	4	4	3	4	59.00
182	102	3	3	3	2	3	4	1	1	1	3	3	3	1	3	1	4	4	4	3	3	53.00
183	102	3	3	3	3	4	4	2	1	2	3	4	3	1	4	1	4	4	4	3	4	60.00
190	102	3	3	2	2	4	4	1	2	1	3	3	3	1	3	2	4	4	4	3	3	55.00
191	102	3	3	2	2	4	4	2	1	2	3	4	3	1	4	2	4	3	4	3	3	57.00
195	102	4	3	3	4	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	64.00
196	102	4	4	3	3	3	4	2	1	2	3	3	4	2	4	2	4	4	4	3	4	63.00
201	102	4	4	3	3	3	4	2	1	2	3	4	3	2	4	2	4	4	4	3	4	63.00

FCE 20124/702 i

53

PAT No.	PER (day)	Items:																				Total Score	
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
204	102	4	4	4	4	3	3	1	2	2	3	4	4	2	4	3	4	4	4	3	4	66.00	
205	102	3	3	4	4	4	4	3	2	2	4	4	4	2	4	2	4	4	4	4	3	4	68.00
207	102	4	4	3	3	3	4	2	2	2	3	3	3	2	4	2	3	4	4	3	4	62.00	
212	102	3	4	3	3	3	3	2	2	2	3	4	4	2	4	2	4	4	4	3	4	63.00	
213	102	4	4	3	4	3	4	2	2	2	4	4	4	3	4	3	4	4	4	3	4	69.00	
220	102	2	4	2	4	4	4	3	1	2	1	3	3	2	4	1	3	4	4	1	3	55.00	
221	102	2	3	2	2	3	3	2	2	2	3	4	3	2	3	1	3	4	3	2	3	52.00	
225	102	2	3	2	4	3	3	2	3	2	3	3	3	2	3	2	3	3	4	1	4	55.00	
228	102	4	4	4	4	4	4	1	4	1	1	4	4	4	3	1	3	4	4	1	4	63.00	
229	102	3	3	3	2	3	4	2	2	2	3	3	4	2	4	2	3	3	4	2	3	57.00	
234	102	3	3	3	4	4	4	4	1	2	3	4	4	3	3	1	4	4	4	1	4	63.00	
236	102	2	4	2	4	4	3	1	1	1	1	3	4	1	4	1	4	4	4	1	4	53.00	
239	102	1	3	1	4	4	4	1	2	1	1	4	3	2	4	1	4	4	3	1	3	51.00	
241	102	3	3	2	3	3	4	1	1	1	3	4	4	1	4	1	4	4	4	3	4	57.00	
242	102	3	3	3	3	4	4	2	2	1	3	4	3	2	4	2	4	3	4	3	4	61.00	
250	102	4	4	3	4	4	4	2	1	1	3	4	4	2	3	3	4	4	4	3	4	65.00	
252	102	4	4	3	4	3	3	2	3	2	4	4	4	3	4	3	4	4	4	3	3	68.00	
253	102	4	4	3	4	4	4	3	1	1	4	4	4	4	4	3	4	4	4	3	3	69.00	
256	102	4	4	3	4	3	4	1	1	1	3	4	4	3	4	3	4	3	4	2	4	63.00	
261	102	3	3	2	2	4	4	2	1	2	3	4	4	1	4	1	4	3	4	3	4	58.00	
264	102	2	3	2	2	3	4	2	1	1	2	4	4	2	4	1	4	3	4	2	4	54.00	
265	102	3	3	2	2	3	4	1	2	1	3	4	4	2	3	1	4	3	4	2	3	54.00	
266	102	3	4	2	3	4	4	2	1	1	3	4	4	1	3	2	4	3	3	2	3	56.00	
272	102	4	4	4	4	4	4	4	2	2	4	4	4	4	4	1	3	3	4	2	4	69.00	



FCE 20124/702 i

Treatment Group "C"

54

Day 10 (Period 102)

Number of Observations = 78

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.91	.10
2. Morning is when I feel best	3.40	.06
3. I have crying spells or feel like it	2.36	.11
4. I have trouble sleeping at night	2.79	.11
5. I eat as much as I used to	3.53	.06
6. I still enjoy sex	3.69	.05
7. I notice that I am losing weight	1.78	.10
8. I have trouble with constipation	1.91	.10
9. My heart beats faster than usual	1.81	.09
10. I get tired for no reason	2.78	.09
11. My mind is as clear as it used to be	3.51	.06
12. I find it easy to do the things I used to do	3.38	.06
13. I am restless and can't keep still	1.99	.09
14. I feel hopeful about the future	3.49	.06
15. I am more irritable than usual	1.96	.09
16. I find it easy to make decisions	3.49	.06
17. I feel that I am useful and needed	3.47	.06
18. My life is pretty full	3.55	.06
19. I feel that others would be better off if I were dead	2.18	.11
20. I still enjoy the things I used to do	3.49	.06
Total score	57.47	.74

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

55

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
3	142	4	3	1	2	3	4	1	2	2	3	4	3	3	3	3	3	4	4	3	4	59.00
6	142	4	3	1	2	3	3	2	2	2	3	3	3	2	3	3	3	3	3	2	3	53.00
8	142	3	4	1	2	3	4	1	3	1	3	4	4	2	3	2	3	3	3	1	4	54.00
16	142	3	3	1	2	4	4	1	1	2	3	4	3	2	3	3	4	3	3	3	3	55.00
18	142	3	4	1	1	4	4	3	1	2	3	4	3	1	3	2	3	4	3	1	4	54.00
26	142	2	3	1	2	4	3	1	2	1	1	4	4	1	3	2	3	3	3	1	4	48.00
27	142	2	3	1	2	4	3	1	3	2	2	4	3	1	3	2	3	4	3	1	3	50.00
33	142	2	3	1	2	4	3	1	2	2	1	3	3	1	3	2	3	3	3	1	4	47.00
36	142	2	3	1	2	4	4	1	2	2	1	4	3	1	3	2	3	3	3	1	3	48.00
39	142	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	51.00
40	142	2	3	1	2	4	3	1	2	2	2	3	3	2	3	2	3	4	4	1	3	50.00
43	142	2	3	1	2	4	3	1	2	2	1	4	4	1	4	1	3	4	3	1	3	49.00
46	142	2	3	1	2	4	4	1	2	1	2	3	3	2	3	2	3	3	3	1	3	48.00
52	142	2	3	2	2	3	3	2	2	3	2	3	3	2	3	2	3	3	3	2	3	51.00
53	142	2	3	2	3	3	3	2	2	2	2	3	3	2	3	2	3	3	3	2	3	51.00
58	142	2	4	3	3	3	3	2	4	4	4	3	3	1	4	2	3	3	3	2	3	58.00
59	142	2	4	3	3	3	3	2	1	3	3	3	3	2	4	2	3	3	3	3	3	56.00
62	142	2	3	3	2	3	3	2	2	2	2	3	3	2	3	2	3	3	3	2	3	51.00
63	142	2	3	2	2	4	3	1	2	2	2	3	3	1	3	2	3	3	3	2	3	49.00
69	142	2	3	2	2	4	3	1	2	2	2	3	3	2	3	1	3	3	3	2	3	49.00
71	142	2	3	2	3	4	4	1	3	3	2	3	3	2	3	3	3	3	3	2	3	55.00
74	142	2	4	2	2	3	4	2	3	3	2	3	3	1	3	1	3	3	3	1	3	51.00
76	142	2	3	3	1	3	4	1	2	3	2	3	3	1	3	1	3	3	3	1	3	48.00
81	142	2	3	2	3	4	4	1	1	2	4	4	4	3	2	3	2	3	3	2	3	54.00
82	142	4	4	2	3	3	4	3	1	2	4	4	4	2	4	3	4	4	4	3	4	66.00
86	142	2	3	1	2	4	3	1	2	1	1	3	3	1	3	2	3	4	4	2	3	48.00
89	142	3	3	3	2	3	4	1	1	1	2	3	3	2	4	2	4	3	4	1	3	52.00
92	142	1	3	1	1	4	4	1	1	1	1	3	3	1	4	2	3	3	4	1	3	45.00
93	142	4	4	3	2	3	4	1	2	1	3	4	3	2	4	2	3	4	4	4	3	60.00
97	142	4	4	2	3	3	4	1	2	1	3	3	4	1	4	2	3	4	4	1	4	57.00
100	142	3	3	1	1	3	4	1	1	1	1	3	3	1	3	1	3	4	3	4	3	47.00
104	142	3	4	1	2	4	4	1	4	2	4	3	4	1	4	2	4	3	4	1	4	59.00
105	142	4	4	4	4	4	4	4	1	3	4	4	4	3	4	3	4	4	4	4	4	74.00
111	142	4	4	3	4	4	4	2	3	1	4	4	4	2	4	3	4	3	4	3	4	68.00
112	142	2	3	1	2	3	3	2	1	1	2	4	3	1	3	1	3	3	3	1	3	45.00
116	142	2	3	2	3	3	3	1	2	2	3	3	3	1	3	1	3	3	3	1	3	48.00
117	142	3	3	2	2	3	3	2	4	2	3	3	3	1	3	3	4	4	3	1	3	55.00
121	142	1	4	1	2	4	4	1	2	1	1	3	3	1	3	1	4	4	4	1	3	48.00
125	142	3	3	1	3	3	3	1	1	1	2	3	3	3	3	2	4	3	3	1	3	49.00
128	142	1	3	1	1	3	3	1	2	1	2	3	3	1	3	1	3	3	3	1	3	42.00
129	142	1	4	1	2	4	3	1	4	2	2	3	3	2	4	1	4	3	3	1	3	51.00
137	142	2	3	2	1	4	4	2	1	1	2	3	3	2	3	1	3	3	3	1	3	47.00
138	142	2	3	1	2	3	4	1	3	2	3	3	3	3	3	1	3	4	4	1	3	52.00
141	142	1	4	2	1	3	4	1	2	1	1	3	3	1	3	1	3	4	4	1	4	47.00
145	142	2	3	2	3	3	4	2	1	2	2	4	3	3	4	1	3	3	3	2	4	54.00
173	142	3	3	3	2	3	4	1	1	2	3	3	3	1	3	1	3	3	4	3	4	53.00
174	142	2	3	2	2	3	4	1	1	1	3	3	3	2	4	2	3	3	3	3	4	52.00
175	142	2	3	2	2	3	4	1	2	2	3	3	3	1	3	1	3	3	3	2	4	50.00
178	142	2	3	2	2	3	4	1	1	2	3	4	3	1	3	1	3	4	4	3	4	53.00
182	142	3	3	2	2	3	4	1	2	2	3	3	3	1	3	1	3	3	4	3	3	52.00
183	142	3	3	3	2	3	4	2	2	2	3	3	3	1	4	1	4	3	4	2	3	55.00
190	142	2	3	2	2	3	4	1	2	1	3	3	3	1	4	2	4	4	4	3	3	54.00
191	142	2	3	2	2	3	4	1	1	2	3	3	3	1	3	2	4	3	4	3	3	52.00
195	142	3	4	3	4	3	4	2	1	1	3	3	4	2	3	2	4	4	4	2	4	60.00

FCE 20124/702 i

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
196	142	3	4	3	3	3	4	2	1	2	3	4	4	2	4	2	4	4	4	3	4	63.00
201	142	4	3	3	3	3	4	1	1	2	3	4	4	2	4	2	4	3	4	3	3	60.00
204	142	3	3	3	3	3	3	1	2	2	2	3	3	2	4	2	3	3	4	2	3	54.00
205	142	3	3	3	3	3	4	1	1	1	3	3	4	2	3	1	3	3	4	3	3	54.00
207	142	3	3	3	3	3	4	2	2	2	3	3	3	2	3	2	3	3	4	2	3	56.00
212	142	3	4	3	3	3	3	2	2	2	3	4	4	2	4	2	4	4	4	3	4	63.00
213	142	3	4	3	3	3	4	2	2	2	4	3	4	2	4	3	3	4	4	2	4	63.00
220	142	1	3	4	4	4	4	1	1	2	1	3	4	2	4	1	4	4	4	1	3	55.00
221	142	4	3	1	1	4	3	4	1	2	2	3	3	2	4	1	4	4	4	2	3	55.00
225	142	2	3	2	4	3	3	2	3	3	3	3	3	2	3	3	3	3	4	1	4	57.00
229	142	2	3	3	2	3	4	2	2	2	2	3	3	2	4	2	3	3	3	1	3	52.00
234	142	2	4	2	3	4	3	1	3	2	2	4	4	2	4	2	3	4	3	1	3	56.00
236	142	1	4	2	4	4	4	1	1	1	1	4	4	2	4	1	4	4	4	1	4	55.00
239	142	1	4	1	4	4	4	1	4	1	1	4	4	1	4	1	3	4	3	1	3	53.00
241	142	3	3	2	2	3	4	1	1	1	3	4	4	1	4	2	4	3	4	3	3	55.00
242	142	3	3	2	2	3	4	2	1	2	3	3	3	1	4	2	4	3	4	2	4	55.00
250	142	3	4	2	3	3	4	1	1	2	3	3	4	3	4	3	4	4	4	3	3	61.00
252	142	3	3	3	3	3	3	2	3	1	3	3	3	3	3	2	3	3	3	3	3	56.00
253	142	4	4	3	4	4	4	3	1	1	3	4	4	4	4	3	4	4	4	3	3	68.00
256	142	4	4	3	4	3	4	1	1	1	3	4	4	3	4	1	4	3	4	1	4	60.00
261	142	3	3	2	2	4	4	2	1	2	3	4	4	2	4	2	3	4	4	2	4	59.00
264	142	3	3	2	2	3	4	2	2	1	3	4	4	1	4	2	3	3	4	3	3	56.00
265	142	3	3	2	2	3	4	2	1	2	3	4	3	2	4	2	4	3	4	2	3	56.00
266	142	3	4	2	1	3	4	2	1	1	2	4	4	2	3	1	3	3	3	2	3	51.00
272	142	3	3	3	3	4	4	3	2	1	3	3	3	2	4	2	3	3	4	2	3	58.00

56

FCE 20124/702 i

57

Treatment Group "C"

Day 14 (Period 142)

Number of Observations = 79

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.52	.10
2. Morning is when I feel best	3.32	.05
3. I have crying spells or feel like it	2.01	.09
4. I have trouble sleeping at night	2.38	.09
5. I eat as much as I used to	3.38	.05
6. I still enjoy sex	3.66	.05
7. I notice that I am losing weight	1.52	.08
8. I have trouble with constipation	1.81	.09
9. My heart beats faster than usual	1.73	.08
10. I get tired for no reason	2.47	.10
11. My mind is as clear as it used to be	3.38	.05
12. I find it easy to do the things I used to do	3.33	.05
13. I am restless and can't keep still	1.71	.08
14. I feel hopeful about the future	3.47	.06
15. I am more irritable than usual	1.82	.08
16. I find it easy to make decisions	3.33	.05
17. I feel that I am useful and needed	3.38	.05
18. My life is pretty full	3.53	.06
19. I feel that others would be better off if I were dead	1.91	.10
20. I still enjoy the things I used to do	3.33	.05
Total score	53.99	.64

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

58

PAT No.	PER (day)	Items:																				Total Score	
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
3	212	3	3	1	2	3	4	1	2	2	3	4	3	2	3	3	3	4	3	3	4	56.00	
6	212	3	3	1	2	3	3	2	2	2	3	3	3	2	3	3	3	3	3	3	2	3	52.00
8	212	3	4	1	2	3	4	1	2	1	3	4	4	2	3	2	3	3	3	1	4	53.00	
16	212	2	3	1	2	4	4	1	1	2	2	4	3	1	3	1	4	3	4	2	4	51.00	
18	212	3	4	1	1	4	4	3	1	2	3	4	3	1	3	2	3	4	3	1	4	54.00	
26	212	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	3	3	1	4	49.00	
27	212	2	3	1	2	4	3	1	2	1	2	4	4	1	4	1	4	4	4	1	3	51.00	
33	212	1	3	1	2	3	3	1	2	2	1	4	4	1	3	2	3	4	4	1	4	49.00	
36	212	2	3	1	2	4	4	1	2	1	2	4	4	1	3	1	3	3	3	1	4	49.00	
39	212	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	51.00	
40	212	2	3	1	2	4	3	1	2	1	1	4	4	1	3	2	3	4	4	1	4	50.00	
43	212	2	3	1	2	4	3	1	2	1	1	4	4	2	4	2	3	4	4	1	4	52.00	
46	212	2	3	1	2	4	3	1	2	1	1	4	3	1	3	2	3	3	3	1	3	46.00	
52	212	2	3	2	2	3	4	1	1	3	2	3	3	2	3	2	3	3	3	2	3	50.00	
53	212	2	3	2	2	3	3	2	2	2	2	3	3	2	3	2	3	4	3	2	3	51.00	
58	212	2	4	3	3	3	3	3	2	3	3	3	3	1	3	2	3	3	3	2	3	55.00	
59	212	2	3	2	2	3	3	2	1	2	2	3	3	2	3	2	3	3	3	2	3	49.00	
62	212	2	3	2	2	3	4	2	2	2	2	3	3	2	3	2	3	3	3	2	4	52.00	
63	212	2	3	2	2	4	3	1	2	2	2	3	3	1	3	2	3	3	3	1	4	49.00	
69	212	2	3	2	1	4	3	1	2	2	2	4	3	3	3	3	3	3	3	2	3	52.00	
71	212	2	3	2	2	4	4	1	2	2	2	3	3	2	3	2	3	3	3	2	3	51.00	
76	212	1	3	1	1	3	4	2	1	2	2	3	3	1	3	1	3	3	3	1	4	45.00	
81	212	2	3	2	2	4	4	1	1	2	3	4	4	2	3	2	4	3	3	1	4	54.00	
82	212	4	4	2	3	3	4	3	1	2	4	4	4	2	4	2	4	4	4	2	4	64.00	
86	212	2	3	1	3	4	3	1	1	1	2	4	4	1	3	2	3	4	4	2	3	51.00	
89	212	2	3	2	1	4	3	1	1	1	2	3	3	1	3	1	3	3	3	1	3	44.00	
92	212	1	3	1	1	4	4	1	1	1	1	4	4	1	3	2	3	4	4	1	3	47.00	
93	212	3	4	3	2	3	4	1	2	1	4	4	3	2	4	2	3	4	4	3	3	59.00	
97	212	3	4	3	2	3	4	1	3	3	3	4	3	3	4	3	4	4	4	1	3	62.00	
100	212	2	3	1	2	3	4	1	1	1	2	4	3	1	3	2	3	3	4	1	3	47.00	
104	212	4	4	1	1	4	4	1	4	2	4	4	4	1	4	2	4	4	4	1	4	61.00	
111	212	3	4	3	4	3	4	1	3	1	4	4	3	2	4	1	4	4	4	2	4	62.00	
112	212	1	3	1	1	3	4	1	2	2	3	4	4	1	4	1	3	4	4	1	4	51.00	
116	212	1	3	1	3	4	4	1	2	2	2	3	4	1	3	1	3	3	3	1	4	49.00	
117	212	2	3	1	1	3	3	1	4	2	3	3	3	1	3	3	3	3	3	1	3	49.00	
121	212	2	3	2	2	3	4	1	2	2	2	3	3	1	3	1	3	4	3	1	3	48.00	
125	212	4	3	3	1	3	4	2	1	2	2	4	3	2	3	3	4	4	3	1	4	56.00	
128	212	1	4	1	1	3	3	1	1	1	1	4	4	1	4	1	4	4	4	1	3	47.00	
129	212	2	4	1	1	3	4	2	3	1	1	3	3	1	3	1	3	3	3	1	3	46.00	
137	212	2	3	2	1	3	4	1	1	1	1	3	3	2	3	2	3	3	3	1	3	45.00	
138	212	2	3	1	3	3	4	1	3	2	3	3	4	3	4	1	3	4	4	1	3	55.00	
141	212	1	4	1	1	4	4	1	2	2	1	3	4	1	4	2	3	4	4	1	4	51.00	
145	212	2	3	2	3	3	4	2	1	2	2	4	3	3	4	1	3	3	3	2	4	54.00	
173	212	2	3	2	2	3	4	1	2	1	2	3	3	1	3	2	3	4	4	3	4	52.00	
174	212	2	3	2	2	3	4	2	2	2	3	3	3	1	3	2	3	3	3	2	4	52.00	
175	212	2	3	2	2	3	4	1	2	2	2	3	3	1	3	2	3	3	3	2	4	50.00	
178	212	2	3	2	2	3	4	2	1	2	2	3	3	3	1	3	2	3	3	3	2	4	51.00
182	212	2	3	2	2	3	4	1	2	1	2	3	3	1	3	2	3	3	3	2	3	48.00	
183	212	2	3	2	2	3	3	1	2	1	3	3	3	1	3	2	4	3	3	2	3	49.00	
190	212	2	3	2	1	3	3	1	1	2	2	3	3	1	3	2	3	3	3	2	3	46.00	
191	212	2	3	2	2	3	3	1	1	1	2	3	3	1	3	2	3	3	3	2	3	46.00	
195	212	3	3	3	3	3	4	1	1	1	2	3	3	2	3	1	3	3	3	2	3	50.00	
196	212	2	3	2	3	3	4	2	1	1	3	3	3	2	3	1	4	3	4	2	3	52.00	
201	212	3	3	3	3	3	4	2	1	2	2	3	3	2	4	2	3	3	4	2	3	55.00	

445

FCE 20124/702 i

59

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
204	212	2	3	2	3	3	3	1	1	2	3	3	3	2	4	2	3	3	3	2	3	51.00
205	212	2	3	2	2	3	4	2	1	1	3	3	3	1	3	2	3	3	3	2	3	49.00
207	212	2	3	2	2	3	4	1	1	2	2	3	3	2	3	2	3	3	3	2	3	49.00
212	212	3	3	3	3	3	3	2	2	2	3	3	4	1	4	2	4	3	4	2	3	57.00
213	212	3	3	3	3	3	3	2	2	2	3	3	3	2	4	2	3	3	4	2	4	57.00
220	212	4	3	4	4	4	4	1	1	4	4	3	3	4	4	1	3	3	4	1	3	62.00
221	212	4	3	1	1	3	4	4	2	4	4	4	3	4	3	2	4	4	3	2	4	63.00
225	212	2	3	1	4	4	3	3	2	3	3	3	3	3	3	2	3	3	4	1	3	56.00
229	212	2	3	2	2	4	3	2	2	2	2	3	3	2	4	2	3	3	3	1	3	51.00
234	212	2	4	2	3	4	3	1	3	2	2	3	3	2	4	1	3	4	4	1	3	54.00
236	212	1	4	1	1	4	4	1	2	1	1	3	3	1	4	1	3	4	4	1	3	47.00
239	212	1	4	2	4	3	4	1	4	1	1	4	4	1	4	2	3	4	3	1	3	54.00
241	212	2	3	2	2	3	4	1	1	2	3	3	3	1	3	1	3	3	4	2	3	49.00
242	212	2	3	2	2	3	4	1	2	1	3	3	3	1	4	1	4	3	3	2	4	51.00
250	212	3	3	3	2	3	4	2	1	1	2	3	3	2	3	2	3	3	3	2	3	51.00
252	212	2	3	2	2	3	3	2	3	2	2	3	3	2	3	2	3	3	3	2	3	51.00
253	212	3	3	3	3	3	3	2	2	2	3	4	3	3	3	2	3	3	3	3	3	57.00
256	212	4	4	3	4	3	4	1	1	1	3	4	4	3	4	3	4	3	4	2	4	63.00
261	212	3	3	2	2	3	4	2	1	1	3	4	3	2	4	2	4	4	4	2	4	57.00
264	212	3	3	2	2	4	4	2	1	2	2	4	3	1	3	1	4	3	3	2	3	52.00
265	212	2	3	2	2	3	4	1	1	1	3	3	4	1	3	2	3	3	3	2	3	49.00
266	212	2	3	2	1	3	4	1	1	1	3	3	3	1	3	2	3	3	3	2	3	47.00
272	212	2	3	2	2	3	4	2	1	1	2	3	3	2	3	1	3	3	3	2	3	48.00

FCE 20124/702 i

Treatment Group "C"

60

Day 21 (Period 212)

Number of Observations = 77

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	2.23	.09
2. Morning is when I feel best	3.19	.05
3. I have crying spells or feel like it	1.82	.08
4. I have trouble sleeping at night	2.09	.09
5. I eat as much as I used to	3.32	.05
6. I still enjoy sex	3.64	.06
7. I notice that I am losing weight	1.43	.07
8. I have trouble with constipation	1.73	.09
9. My heart beats faster than usual	1.68	.08
10. I get tired for no reason	2.32	.10
11. My mind is as clear as it used to be	3.42	.06
12. I find it easy to do the things I used to do	3.29	.05
13. I am restless and can't keep still	1.61	.09
14. I feel hopeful about the future	3.34	.05
15. I am more irritable than usual	1.81	.07
16. I find it easy to make decisions	3.22	.05
17. I feel that I am useful and needed	3.35	.05
18. My life is pretty full	3.39	.06
19. I feel that others would be better off if I were dead	1.61	.07
20. I still enjoy the things I used to do	3.40	.06
Total score	51.88	.53

447

FCE 20124/702 i

61

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
3	282	3	3	1	2	4	4	1	2	2	2	4	3	2	3	1	3	4	3	3	4	54.00
6	282	3	3	1	2	3	4	2	2	2	3	3	3	2	3	2	3	3	3	3	2	52.00
8	282	3	4	1	2	3	4	1	3	1	3	4	4	2	3	2	3	3	3	1	4	54.00
16	282	2	4	1	2	4	4	1	1	2	2	4	4	1	3	1	4	3	4	1	4	52.00
18	282	2	4	1	1	4	4	3	1	2	2	4	3	1	3	1	3	4	3	1	4	51.00
26	282	2	4	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	52.00
27	282	2	3	1	2	4	3	1	2	1	2	4	4	1	4	1	4	4	4	1	3	51.00
33	282	1	3	1	2	4	3	2	2	1	1	4	4	1	3	2	3	4	4	1	4	50.00
36	282	2	3	1	2	4	4	1	1	1	1	4	4	1	3	2	3	4	4	1	4	50.00
39	282	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	51.00
40	282	2	3	1	2	4	3	1	2	1	1	4	4	1	4	2	3	4	4	1	4	51.00
43	282	2	3	1	2	4	3	1	2	1	1	4	4	2	4	2	3	4	4	1	4	52.00
46	282	2	3	1	2	4	3	1	2	1	1	4	4	1	3	2	3	3	3	1	4	48.00
52	282	2	3	2	2	4	4	1	2	2	1	3	3	1	3	2	3	3	4	2	3	50.00
53	282	2	3	1	1	4	4	1	3	2	2	3	3	1	3	1	3	4	3	1	4	49.00
58	282	2	4	2	2	3	3	2	2	3	3	4	4	1	3	2	3	3	4	1	4	55.00
59	282	2	3	2	1	3	3	1	1	2	1	4	3	1	4	1	4	3	4	1	4	48.00
62	282	1	3	1	1	3	4	1	1	1	1	3	3	1	3	2	3	3	3	1	4	43.00
63	282	1	3	1	2	4	3	1	2	1	1	3	3	1	3	2	4	4	3	1	4	47.00
69	282	1	3	1	1	4	3	1	2	1	1	4	4	3	4	1	4	4	4	2	4	52.00
71	282	2	3	1	2	4	4	1	2	2	1	3	3	2	3	2	3	3	3	2	3	49.00
76	282	1	3	1	1	3	4	1	1	2	1	3	3	1	4	1	3	4	4	1	4	46.00
81	282	2	3	2	1	4	4	1	1	2	3	4	4	2	4	2	4	3	3	1	4	54.00
82	282	2	4	1	3	4	4	3	1	1	4	4	4	1	4	3	4	4	4	3	4	62.00
86	282	1	3	1	2	4	3	1	1	1	1	3	3	2	3	1	4	4	4	1	4	47.00
89	282	2	4	3	1	4	3	1	1	1	2	3	3	1	3	1	3	3	3	1	3	46.00
92	282	1	3	1	1	4	4	2	1	1	2	4	4	2	4	2	3	3	4	1	4	51.00
97	282	4	4	3	4	4	4	1	4	3	4	4	4	4	4	3	4	4	4	1	4	71.00
100	282	2	3	1	2	3	4	1	1	1	2	4	3	1	3	2	3	3	4	1	3	47.00
104	282	3	4	1	2	4	4	1	3	2	3	3	4	1	4	2	4	3	4	1	4	57.00
111	282	4	4	3	4	3	4	1	3	1	4	4	4	2	4	1	4	4	4	3	4	65.00
112	282	1	3	1	2	3	4	1	2	1	2	4	4	1	4	1	4	4	4	1	4	51.00
116	282	1	3	1	3	4	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	51.00
117	282	1	4	1	1	4	4	1	2	2	2	4	3	2	4	2	4	4	4	1	4	54.00
121	282	1	4	1	2	4	4	1	2	2	2	4	3	1	4	1	4	4	4	1	3	52.00
128	282	1	4	1	1	3	4	1	1	1	1	4	4	1	4	1	4	4	4	1	4	49.00
129	282	1	4	1	1	4	4	1	3	1	1	4	3	4	4	1	4	3	3	1	4	52.00
137	282	2	3	3	2	3	4	1	1	1	2	3	3	3	3	2	3	3	3	1	3	49.00
141	282	1	4	1	1	3	3	1	2	1	1	3	4	2	4	1	4	4	4	1	4	49.00
145	282	2	3	2	3	3	4	2	1	2	2	4	3	3	4	1	3	3	3	2	4	54.00
173	282	2	3	1	1	3	4	1	1	2	2	3	3	1	3	2	3	3	3	2	4	47.00
174	282	2	3	1	1	3	4	1	2	1	3	3	3	2	3	2	3	3	3	2	3	48.00
175	282	2	3	2	2	3	3	1	2	1	2	3	3	1	3	2	3	3	3	2	4	48.00
178	282	2	3	2	1	3	4	1	1	2	2	3	3	1	3	2	3	3	3	2	4	48.00
182	282	2	3	1	1	3	4	1	2	2	2	3	3	1	3	2	3	3	3	2	3	47.00
183	282	2	3	2	2	3	3	1	2	2	3	3	3	1	3	2	3	3	3	2	3	49.00
190	282	2	3	2	1	3	3	1	1	2	2	3	3	1	3	2	3	3	3	2	3	46.00
191	282	2	3	2	1	3	3	1	2	1	2	3	3	2	4	2	3	3	3	2	3	48.00
195	282	2	3	2	2	3	3	2	1	1	3	3	3	1	3	1	3	3	3	2	3	47.00
196	282	2	3	2	2	3	4	1	1	1	2	3	3	1	3	1	3	3	.	2	3	.
201	282	2	3	2	2	3	4	2	1	2	2	3	3	2	3	1	3	3	4	2	3	50.00
204	282	1	3	2	2	3	3	1	1	2	2	3	3	1	3	1	3	3	3	1	3	44.00
205	282	1	3	2	2	3	3	2	1	1	2	3	3	2	3	2	3	3	3	2	3	47.00
207	282	1	3	2	1	3	4	1	1	2	2	3	3	1	3	1	3	3	3	1	3	44.00



FCE 20124/702 i

62

PAT No.	PER (day)	Items:																				Total Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
212	282	2	3	2	2	3	3	2	2	2	3	3	3	2	4	2	3	3	4	2	3	53.00
213	282	2	3	2	1	3	3	1	1	2	2	3	3	2	3	2	3	3	4	2	3	48.00
220	282	2	3	2	4	4	4	1	2	2	1	3	4	4	4	1	4	4	4	1	3	57.00
221	282	4	3	1	1	3	3	4	1	4	4	4	3	3	4	1	4	3	4	2	3	59.00
229	282	2	3	1	1	3	3	2	1	2	2	3	3	2	3	2	3	3	3	1	3	46.00
234	282	2	4	2	2	4	3	1	2	2	2	4	4	2	4	1	4	4	4	1	4	56.00
236	282	2	4	2	1	4	4	1	2	1	1	3	4	1	3	2	4	4	3	1	3	50.00
239	282	1	3	1	4	3	4	2	4	1	2	4	4	2	4	1	4	4	4	1	3	56.00
250	282	2	3	2	2	3	4	1	1	1	2	3	3	2	3	2	3	3	3	2	3	48.00
252	282	1	4	1	1	3	3	1	2	1	1	4	4	1	4	1	4	4	4	1	4	49.00
253	282	2	3	2	1	3	3	2	1	1	2	3	3	2	3	2	3	3	3	1	3	46.00
256	282	3	3	3	3	3	4	1	1	1	2	4	3	3	4	3	4	3	3	2	3	56.00
241	282	2	3	2	2	3	4	1	1	1	3	3	3	1	3	2	3	3	3	2	3	48.00
242	282	2	3	2	2	3	4	1	2	2	3	3	3	1	3	2	3	3	3	2	3	50.00
261	282	3	3	2	2	3	4	1	1	1	2	4	4	2	4	2	3	4	4	2	4	55.00
264	282	2	3	2	2	4	4	2	1	2	3	4	3	2	4	1	3	4	4	2	3	55.00
265	282	2	4	2	2	3	4	1	1	1	2	3	3	1	3	2	4	3	3	2	3	49.00
266	282	2	3	2	2	3	4	1	1	1	2	3	3	1	3	2	3	3	3	2	3	47.00
272	282	1	3	1	1	3	4	1	1	1	1	3	3	1	3	3	3	3	3	1	3	43.00

FCE 20124/702 i

63

Treatment Group "C"

Day 28 (Period 282)

Number of Observations = 73

Variable	Mean	S.E. Mean
1. I feel down hearted and blue	1.89	.08
2. Morning is when I feel best	3.26	.05
3. I have crying spells or feel like it	1.53	.07
4. I have trouble sleeping at night	1.79	.09
5. I eat as much as I used to	3.42	.06
6. I still enjoy sex	3.62	.06
7. I notice that I am losing weight	1.27	.07
8. I have trouble with constipation	1.62	.09
9. My heart beats faster than usual	1.49	.07
10. I get tired for no reason	1.96	.10
11. My mind is as clear as it used to be	3.48	.06
12. I find it easy to do the things I used to do	3.38	.06
13. I am restless and can't keep still	1.59	.09
14. I feel hopeful about the future	3.44	.06
15. I am more irritable than usual	1.66	.07
16. I find it easy to make decisions	3.36	.06
17. I feel that I am useful and needed	3.41	.06
18. My life is pretty full	3.50	.06
19. I feel that others would be better off if I were dead	1.47	.07
20. I still enjoy the things I used to do	3.52	.06
Total score	50.72	.56

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08  
Table 5e - Vital Signs  
Treatment Group "A"

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
1	0	130	70	86	120	70	90	36.8	93.00
1	1	130	60	84	120	60	84	37.0	.
1	3	140	70	88	140	90	88	37.2	.
1	6	120	90	84	120	80	84	36.9	.
1	7	.	.	.	.	.	.	.	93.00
1	12	140	90	88	130	90	92	37.0	.
1	14	130	90	92	130	90	92	37.0	93.00
1	21	120	80	76	110	80	76	37.2	93.00
1	28	140	90	92	120	75	96	36.8	93.00
5	0	100	60	64	100	65	64	36.5	60.00
5	1	100	60	88	95	70	88	37.4	.
5	3	90	60	80	90	60	80	37.3	.
5	6	110	60	90	100	60	90	36.8	.
5	7	.	.	.	.	.	.	.	51.00
5	12	120	80	80	110	80	80	36.8	.
5	14	120	80	72	110	80	76	36.7	52.00
5	21	110	70	80	110	70	80	37.1	51.00
5	28	120	80	72	110	70	72	36.8	51.00
9	0	120	80	72	120	90	80	36.7	75.00
9	1	130	80	80	120	90	80	36.6	.
9	3	130	70	80	120	70	84	36.7	.
9	6	120	80	72	130	90	76	37.0	.
9	7	.	.	.	.	.	.	.	75.00
9	12	140	80	84	130	80	88	37.0	.
9	14	130	80	76	150	70	76	37.1	76.00
9	21	140	90	76	160	90	84	37.0	76.00
9	28	120	80	80	130	90	84	37.1	76.00
12	0	130	80	80	120	70	80	36.6	53.00
12	1	130	80	75	120	75	80	36.6	.
12	3	135	70	.	130	70	.	36.8	.
12	6	125	70	78	110	60	78	36.7	.
12	7	.	.	.	.	.	.	.	52.00
12	12	120	80	.	110	70	.	36.7	.
12	14	130	80	.	120	70	.	36.8	52.00
12	21	120	60	.	110	60	.	36.5	52.00
12	28	130	70	78	120	70	.	36.7	52.00
13	0	130	80	80	120	70	80	36.9	59.00
13	1	130	70	76	120	70	80	36.9	.
13	3	120	70	76	120	60	73	37.0	.
13	6	130	70	.	120	70	.	36.8	.
13	7	.	.	.	.	.	.	.	59.00
13	12	130	70	76	130	70	76	37.0	.
13	14	130	70	76	120	70	72	36.9	59.00
13	21	140	70	80	140	70	76	36.5	60.00

FCE 20124/702 i

2

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
13	28	130	70	76	120	70	76	36.5	60.00
14	0	140	80	80	130	70	80	36.7	87.00
14	1	130	70	76	120	70	76	36.5	.
14	3	120	70	76	110	70	72	36.9	.
14	6	140	70	76	130	70	72	36.7	.
14	7	.	.	.	.	.	.	.	87.00
14	12	130	70	80	120	70	80	36.8	.
14	14	130	70	76	120	70	72	37.0	87.00
14	21	140	70	80	130	70	76	36.5	88.00
14	28	110	70	76	110	70	72	36.9	80.00
25	0	135	80	82	130	80	84	36.5	61.00
25	1	130	80	82	125	80	84	36.3	.
25	3	140	80	84	140	85	86	36.3	.
25	6	140	80	82	140	80	84	36.2	.
25	7	.	.	.	.	.	.	.	63.00
25	9	140	80	84	140	80	86	36.2	.
25	12	145	80	88	140	75	88	36.4	.
25	14	140	80	82	140	75	80	36.2	64.00
25	21	130	80	82	130	80	84	36.5	64.00
25	28	135	80	.	130	80	.	36.4	64.00
30	0	150	90	86	145	90	88	36.4	60.00
30	1	140	80	88	140	85	90	36.6	.
30	3	130	80	84	120	80	86	36.4	.
30	6	130	80	82	130	80	88	36.2	.
30	7	.	.	.	.	.	.	.	61.00
30	12	140	80	90	135	70	92	36.2	.
30	14	140	80	82	140	75	84	36.4	61.00
30	21	150	90	84	140	90	86	36.4	60.00
30	28	130	80	86	125	80	88	36.2	61.50
34	0	140	80	84	140	75	86	36.4	56.00
34	1	140	80	82	135	80	84	36.4	.
34	3	140	85	84	145	85	86	36.2	.
34	6	140	80	80	140	80	86	36.4	.
34	7	.	.	.	.	.	.	.	55.00
34	9	150	80	82	145	80	84	36.2	.
34	12	140	80	88	135	80	90	36.6	.
35	0	160	80	86	180	80	90	36.8	67.00
35	1	140	80	80	150	85	82	36.2	.
35	3	130	80	82	130	80	82	36.2	.
35	6	140	80	82	145	80	84	36.4	.
35	7	.	.	.	.	.	.	.	69.00
35	12	140	80	80	140	80	80	36.4	.
35	14	140	80	82	140	80	84	36.2	69.00
35	21	140	80	82	140	80	80	37.0	69.00
35	28	140	80	90	140	80	86	36.2	69.00

FCE 20124/702 i

3

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
37	0	130	80	82	130	75	86	36.4	61.00
37	1	140	80	78	135	80	80	36.2	.
37	3	130	80	82	130	80	84	36.4	.
37	6	120	70	80	120	70	82	36.5	.
37	7	.	.	.	.	.	.	.	62.00
37	12	130	80	78	130	75	80	36.3	.
37	14	140	80	80	135	75	82	36.4	63.00
37	21	140	80	76	135	80	78	36.4	64.00
37	28	145	80	78	140	80	80	36.5	64.00
38	0	130	80	78	130	80	80	36.2	70.00
38	1	130	80	82	135	80	84	36.5	.
38	3	130	80	82	130	85	84	36.2	.
38	6	120	80	80	125	85	82	36.3	.
38	7	.	.	.	.	.	.	.	71.00
38	12	135	90	86	140	90	86	36.6	.
38	14	140	80	84	140	85	86	36.6	74.00
38	21	140	90	84	140	90	86	36.2	74.00
38	28	130	90	86	135	90	88	36.2	73.50
45	0	155	90	82	150	90	84	36.4	57.00
45	1	160	100	88	155	100	88	36.6	.
45	3	150	85	82	150	80	82	36.4	.
45	6	150	90	80	155	90	82	36.7	.
45	7	.	.	.	.	.	.	.	56.00
45	12	120	90	86	130	90	84	36.6	.
45	14	155	80	82	160	80	86	36.2	60.00
45	21	150	90	80	150	90	82	36.4	60.00
45	28	120	80	76	120	80	70	36.8	60.00
48	0	140	80	80	140	80	82	36.4	65.00
48	1	130	80	78	135	80	78	36.4	.
48	3	135	85	82	140	85	84	36.4	.
48	6	130	85	78	130	80	80	36.4	.
48	7	.	.	.	.	.	.	.	66.00
48	9	140	80	82	140	80	80	36.4	.
48	12	135	80	80	130	80	82	36.4	.
48	14	140	80	80	135	80	82	36.4	67.00
48	21	140	90	82	140	90	84	36.3	66.00
48	28	130	80	78	125	80	80	36.4	64.00
49	0	130	80	78	130	80	82	36.2	55.00
49	1	130	80	78	130	80	80	36.3	.
49	3	135	85	81	130	80	83	36.2	.
49	7	.	.	.	.	.	.	.	54.50
49	6	130	80	80	125	75	82	36.3	.
49	9	130	80	80	130	80	81	36.2	.
49	12	130	80	76	125	70	74	36.4	.
49	14	130	80	.	120	70	.	36.2	54.50

FCE 20124/702 i

4

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
					130	85	.	36.7	57.00
49	21	140	90	.	130	80	78	36.8	57.00
49	28	130	80	76	130	80	80	36.5	55.00
50	0	130	80	82	125	80	80	36.2	.
50	1	130	80	76	125	80	84	36.1	.
50	3	130	80	82	120	80	83	36.2	.
50	6	120	80	79	120	80	.	.	54.50
50	7	.	.	.	.	75	80	36.2	.
50	9	125	80	76	120	75	78	36.5	.
50	12	120	80	80	120	80	78	36.2	54.00
50	14	130	80	76	125	80	80	36.8	54.00
50	21	120	80	78	120	80	80	36.7	54.00
50	28	120	80	76	120	80	77	36.2	85.00
56	0	130	80	.	130	80	80	36.2	.
56	1	140	90	82	130	80	80	36.2	.
56	3	130	90	76	130	80	78	36.2	.
56	6	160	80	.	130	80	.	.	85.50
56	7	.	.	.	.	.	79	36.2	.
56	9	140	90	76	135	85	74	36.4	.
56	12	140	85	72	130	80	73	36.2	85.50
56	14	130	80	74	130	80	72	36.2	86.00
56	21	130	90	68	130	80	70	36.4	86.00
56	28	135	90	72	130	80	82	36.3	50.50
57	0	130	80	80	120	80	84	36.2	.
57	1	120	80	82	120	70	84	36.4	.
57	3	120	80	82	110	70	80	36.2	.
57	6	120	80	78	110	70	.	.	50.00
57	7	.	.	.	.	.	78	36.4	.
57	9	120	80	76	120	80	74	36.2	.
57	12	120	80	76	115	70	74	36.2	50.00
57	14	120	80	76	110	70	78	36.4	51.00
57	21	120	80	75	120	80	76	36.4	51.00
57	28	120	80	74	110	70	76	36.4	59.50
64	0	140	90	82	135	85	84	36.5	.
64	1	140	90	86	135	85	86	36.4	.
64	3	140	90	82	135	80	84	36.6	.
64	6	140	90	82	135	80	86	36.2	.
64	7	.	.	.	.	.	.	.	59.00
64	9	140	85	82	140	85	84	36.4	.
64	12	130	80	79	125	80	83	36.1	.
64	14	130	90	82	125	85	84	36.3	58.00
64	21	135	90	84	130	85	82	36.3	59.00
64	28	135	85	80	130	80	82	36.4	59.00
65	0	140	90	76	130	80	82	36.4	83.50
65	1	140	80	79	130	80	82	36.2	.
65	3	145	90	79	140	90	80	36.1	.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

5

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
65	6	140	90	80	130	80	84	36.2	.
65	7	.	.	.	.	.	.	.	84.00
65	9	145	80	76	130	80	78	36.2	.
65	12	140	90	75	135	90	74	36.2	.
65	14	140	90	76	135	90	78	36.3	84.00
65	21	130	80	74	120	75	76	36.2	84.00
65	28	130	80	74	130	80	77	36.4	84.00
65	0	120	80	90	120	80	94	36.4	44.50
68	0	120	80	90	120	80	92	36.2	.
68	1	120	80	86	115	75	92	36.2	.
68	3	120	80	86	120	80	89	36.2	.
68	6	120	80	82	115	70	84	36.4	.
68	7	.	.	.	.	.	.	.	44.50
68	9	120	80	82	110	80	86	36.3	.
68	12	120	80	84	120	80	87	36.2	.
68	14	120	80	82	120	80	85	36.2	44.00
68	21	120	80	84	115	75	86	36.4	43.50
68	28	120	80	82	120	80	86	36.2	43.50
72	0	130	80	.	130	70	.	36.2	69.00
72	1	130	80	76	120	80	84	36.3	.
72	3	130	80	83	125	75	87	36.2	.
72	6	130	80	74	120	70	81	36.2	.
72	7	.	.	.	.	.	.	.	69.00
72	9	130	80	84	130	85	83	36.2	.
72	12	120	80	76	120	80	74	36.3	.
72	14	130	80	74	120	76	78	36.3	69.00
72	21	130	80	74	120	80	77	36.2	69.50
72	28	130	80	72	120	80	76	36.3	69.50
73	0	150	85	80	130	80	86	36.4	84.50
73	1	160	85	82	140	80	87	36.5	.
73	3	160	85	75	130	80	80	36.7	.
73	6	150	80	82	130	75	86	36.7	.
73	7	.	.	.	.	.	.	.	84.00
73	12	140	80	80	130	80	86	36.7	.
73	14	160	85	84	140	80	86	36.6	84.20
73	21	150	90	82	140	80	84	36.6	84.00
75	0	150	90	70	130	80	75	36.6	82.00
75	1	140	85	80	130	80	84	36.6	.
75	3	140	80	79	130	80	84	36.8	.
75	6	150	85	80	130	85	86	36.7	.
75	7	.	.	.	.	.	.	.	82.50
75	12	140	85	78	130	80	82	37.6	.
75	14	150	90	75	130	85	80	36.6	82.00
75	21	140	85	80	130	80	85	36.8	82.00
75	28	140	80	83	120	80	87	36.6	82.30
79	0	105	85	70	100	80	72	36.4	58.50

FCE 20124/702 i

6

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
79	1	115	90	72	100	80	78	36.4	.
79	3	110	85	75	100	80	80	36.5	.
79	6	120	90	68	105	85	72	36.6	.
79	7	.	.	.	.	.	.	.	59.00
79	12	110	90	76	100	85	78	36.4	.
79	14	110	80	72	110	90	70	36.4	59.30
79	21	110	80	64	110	85	60	36.4	60.50
79	28	110	80	65	105	80	72	36.2	61.00
80	0	130	80	70	120	85	75	36.8	66.00
80	1	140	90	80	120	80	85	36.6	.
80	3	130	85	72	130	80	80	36.6	.
80	6	150	100	84	130	100	88	36.5	.
80	7	.	.	.	.	.	.	.	66.00
80	12	115	90	70	110	90	75	36.2	.
80	14	130	100	60	120	90	66	36.8	65.50
80	21	140	95	72	140	95	72	36.6	65.50
80	28	130	90	70	120	90	75	36.8	64.00
85	0	130	80	72	115	80	76	36.4	64.00
85	1	130	80	60	115	80	76	36.4	.
85	3	115	75	72	110	80	76	36.4	.
85	6	120	70	76	110	80	88	36.4	.
85	7	.	.	.	.	.	.	.	63.00
85	9	130	75	76	130	80	82	36.4	.
85	12	120	90	76	120	100	76	36.4	.
85	14	115	80	76	120	85	80	36.4	63.50
85	21	120	85	80	120	80	80	36.4	63.40
85	28	130	85	76	100	80	100	36.4	63.00
87	0	125	80	80	120	80	80	36.2	68.80
87	1	130	90	72	120	90	96	36.4	.
87	3	120	80	72	130	80	76	36.4	.
87	6	120	70	72	115	80	80	36.4	.
87	7	.	.	.	.	.	.	.	69.00
87	9	115	70	76	110	75	80	36.6	.
87	12	150	95	68	130	80	80	36.4	.
87	14	130	80	64	130	80	72	36.6	69.00
87	21	120	80	68	130	80	72	36.6	69.00
87	28	100	60	60	115	80	60	36.5	69.00
94	0	120	85	76	110	80	80	36.6	79.50
94	1	105	70	80	110	75	84	36.5	.
94	3	105	70	80	90	75	88	36.6	.
94	6	100	70	76	100	80	84	36.6	.
94	7	.	.	.	.	.	.	.	76.50
94	9	100	70	80	100	70	88	36.6	.
94	12	120	70	72	110	75	76	36.6	.
94	14	100	70	80	95	70	88	36.6	76.00



FCE 20124/702 i

7

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
94	21	105	70	80	100	70	84	36.6	76.00
94	28	105	75	80	95	70	88	36.6	77.00
96	0	130	95	80	130	90	84	36.6	81.00
96	1	120	85	76	120	90	84	36.6	.
96	3	130	85	76	135	80	84	36.5	.
96	6	135	85	92	120	80	98	36.6	.
96	7	.	.	.	.	.	.	.	80.00
96	9	140	90	76	130	85	80	36.6	.
96	12	140	90	76	130	90	80	36.6	.
96	14	135	85	76	140	90	84	36.5	80.50
96	21	130	80	72	120	85	76	36.5	81.00
96	28	130	80	76	120	85	84	36.7	82.00
99	0	126	74	78	132	78	76	37.0	90.00
99	1	132	82	86	128	86	90	36.9	.
99	3	136	86	84	128	88	90	36.8	.
99	6	102	64	86	114	76	88	36.6	.
99	7	.	.	.	.	.	.	.	92.00
99	9	104	68	86	112	78	90	36.8	.
99	12	118	76	82	116	78	90	36.7	.
99	14	136	86	88	132	88	90	36.6	92.00
99	21	118	76	90	112	76	92	36.7	93.00
99	28	136	86	88	132	88	88	36.6	92.00
101	0	130	94	98	128	90	96	36.8	76.00
101	1	134	92	98	128	90	94	36.9	.
101	3	142	92	92	136	90	94	36.8	.
101	6	120	92	80	118	94	74	36.8	.
101	7	.	.	.	.	.	.	.	78.00
101	9	110	88	87	106	86	87	36.7	.
101	12	104	72	86	100	72	88	36.3	.
101	14	130	88	96	126	86	92	36.4	80.00
101	21	128	90	96	126	86	94	36.5	80.00
101	28	128	88	96	132	94	96	36.5	81.00
107	0	130	76	82	126	80	88	36.2	56.00
107	1	136	80	94	138	76	92	36.7	.
107	3	140	90	100	136	88	102	36.4	.
107	6	120	62	100	122	70	94	36.8	.
107	7	.	.	.	.	.	.	.	58.00
107	9	102	70	90	128	88	100	36.9	.
107	12	132	76	102	132	78	104	36.1	.
107	14	120	66	100	130	82	102	36.7	.
107	21	140	76	90	142	78	92	36.9	56.00
107	28	142	66	93	146	80	96	36.6	56.00
108	0	108	74	80	118	76	84	36.2	44.00
108	1	126	82	66	120	86	80	36.0	.
108	3	118	84	74	128	90	80	36.2	.

FCE 20124/702 i

8

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
108	6	108	72	84	122	76	88	35.8	.
108	7	.	.	.	.	.	.	.	44.00
108	7	.	.	.	.	.	.	.	.
108	9	124	70	82	130	76	84	36.8	.
108	12	116	70	86	124	80	88	35.6	.
108	14	108	78	80	108	76	82	36.6	44.00
108	14	108	80	78	120	80	82	36.8	45.50
108	21	116	80	82	118	76	86	36.2	46.00
108	28	124	84	82	120	85	80	36.9	65.00
108	28	124	90	72	120	85	78	36.7	.
109	0	130	95	70	130	90	82	36.5	.
109	1	140	95	78	130	80	82	36.5	.
109	3	130	85	78	130	80	76	36.6	.
109	3	130	72	72	145	100	76	36.6	65.00
109	6	150	100	.	.	.	.	.	.
109	7	.	.	.	.	.	76	36.3	.
109	7	.	.	.	.	.	85	36.3	.
109	9	130	85	72	125	85	84	36.3	.
109	9	130	80	80	130	85	76	36.7	64.00
109	12	130	90	72	130	80	76	36.4	64.00
109	14	135	85	72	130	80	76	36.4	64.00
109	14	135	85	68	130	80	73	36.7	64.00
109	21	135	85	68	140	85	74	36.1	86.00
109	21	135	90	68	140	85	74	36.1	86.00
109	28	140	90	70	120	80	78	36.2	.
109	28	140	85	70	120	80	78	36.2	.
114	0	125	85	72	120	80	82	36.1	.
114	1	120	85	72	120	80	82	36.1	.
114	1	120	70	78	105	65	84	36.1	.
114	3	110	70	78	105	65	84	36.1	.
114	3	110	75	80	100	70	84	36.1	85.50
114	6	105	75	80	100	70	84	36.1	.
114	7	.	.	.	.	.	.	.	.
114	7	.	.	.	.	.	86	35.9	.
114	9	105	75	82	100	70	92	36.4	.
114	9	105	70	84	105	65	84	36.7	85.00
114	12	110	70	84	105	65	84	36.7	85.00
114	12	110	70	84	105	65	84	36.7	85.00
114	14	115	75	80	110	70	88	36.6	84.00
114	14	115	70	84	110	65	88	36.6	84.00
114	21	110	70	84	110	65	88	36.3	84.00
114	21	110	75	84	105	70	88	36.3	84.00
114	28	105	75	84	105	70	76	36.2	52.00
115	0	115	75	72	115	70	76	36.2	52.00
115	0	115	75	72	115	70	76	36.2	52.00
115	1	120	80	80	115	75	84	36.1	.
115	1	120	80	80	115	75	84	36.1	.
115	3	115	75	70	115	70	74	36.0	.
115	3	115	75	70	115	70	74	36.0	.
115	6	110	70	80	110	65	84	36.3	.
115	6	110	70	80	110	65	84	36.3	52.00
115	7	.	.	.	.	.	.	.	.
115	7	.	.	.	.	.	84	36.1	.
115	9	110	75	80	110	70	78	36.2	.
115	9	110	75	80	110	70	78	36.2	.
115	12	110	80	72	105	75	80	36.1	55.00
115	12	110	80	72	105	75	80	36.1	55.00
115	14	115	80	74	115	75	84	35.9	56.00
115	14	115	80	74	115	75	84	35.9	56.00
115	21	110	80	78	105	70	76	36.1	56.00
115	21	110	80	78	105	70	76	36.1	56.00
115	28	110	75	72	105	70	76	36.5	65.00
120	0	120	75	72	115	70	76	36.5	65.00
120	1	115	75	72	115	70	78	36.4	.
120	1	115	75	72	115	70	78	36.4	.
120	3	120	80	80	115	75	84	36.7	.
120	3	120	80	80	115	75	84	36.7	.
120	6	120	75	72	115	72	76	36.7	.
120	6	120	75	72	115	72	76	36.7	65.00
120	7	.	.	.	.	.	.	.	.
120	7	.	.	.	.	.	76	36.3	.
120	9	125	80	68	120	75	80	36.5	.
120	9	125	80	68	120	75	80	36.5	.
120	12	120	80	76	120	70	72	36.4	65.00
120	12	120	80	76	120	70	72	36.4	65.00
120	14	125	75	68	120	70	72	36.4	65.00
120	14	125	75	68	120	70	72	36.4	65.00

FCE 20124/702 i

9

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
120	21	130	85	68	125	80	72	36.6	65.00
120	28	120	75	68	115	70	76	36.8	65.10
122	0	120	80	90	130	90	88	35.4	55.00
122	1	110	70	80	120	80	84	36.5	.
122	3	110	90	80	120	90	82	36.4	.
122	6	120	80	84	130	80	88	36.3	.
122	7	.	.	.	.	.	.	.	55.50
122	9	120	90	84	130	90	90	36.4	.
122	12	120	80	88	130	80	88	36.2	.
122	14	120	70	80	120	70	88	36.5	55.50
122	14	120	70	80	120	70	88	36.5	55.50
123	0	130	80	80	110	70	92	36.0	52.50
123	1	110	70	74	110	80	84	36.5	.
123	3	100	60	70	110	60	80	36.3	.
123	6	110	60	73	110	70	80	36.4	.
123	7	.	.	.	.	.	.	.	52.00
123	9	110	70	74	110	60	84	36.2	.
123	12	100	70	72	90	60	82	36.2	.
123	14	110	60	70	110	70	80	36.0	52.50
123	21	110	70	87	110	80	83	36.3	54.20
123	28	110	80	90	110	80	85	36.0	52.80
130	0	100	70	80	100	70	82	36.2	45.00
130	1	100	60	82	110	70	86	36.7	.
130	3	100	60	72	110	70	76	36.2	.
131	0	100	70	60	100	70	64	35.8	80.60
131	1	100	70	70	100	70	88	36.8	.
131	3	100	70	72	100	70	76	36.5	.
131	6	100	70	71	100	70	74	36.5	.
131	7	.	.	.	.	.	.	.	79.50
131	9	100	70	73	110	70	70	36.3	.
131	12	100	60	74	100	70	76	36.2	.
131	14	100	60	60	100	70	62	36.5	79.00
131	21	130	90	73	130	90	83	36.0	78.30
131	28	120	80	80	130	80	84	36.3	79.50
134	0	100	80	84	100	70	86	36.7	53.00
134	1	100	70	84	100	70	88	36.7	.
134	3	110	80	76	100	80	76	36.0	.
134	6	130	100	70	100	70	78	37.0	.
134	7	.	.	.	.	.	.	.	53.00
134	9	110	90	84	110	80	89	36.0	.
134	12	100	60	88	110	80	88	36.5	.
134	14	110	70	80	110	70	86	37.0	55.50
135	0	120	70	80	110	80	80	36.0	49.10
135	1	120	70	82	110	70	80	36.1	.
135	3	120	80	80	120	80	80	36.2	.
135	6	110	70	84	110	70	80	36.8	.

FCE 20124/702 i

10

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
135	7	.	.	.	.	.	.	37.0	49.10
135	9	110	70	74	110	80	87	36.5	.
135	12	110	60	80	120	90	84	37.1	49.50
135	14	100	60	84	95	55	92	36.3	50.50
135	21	110	70	80	100	60	84	36.5	50.50
135	28	100	60	80	110	70	78	37.0	63.70
142	0	110	70	82	100	60	88	37.0	.
142	1	110	60	70	100	70	80	36.4	.
142	3	110	70	70	100	60	76	36.0	.
142	6	110	70	72	100	70	74	.	62.60
142	7	.	.	.	.	.	.	36.3	.
142	9	100	70	76	100	60	71	36.0	.
142	12	110	70	78	120	70	80	36.8	65.20
142	14	100	70	60	110	70	80	36.3	64.50
142	21	100	70	72	100	70	80	36.3	66.00
142	28	100	70	76	100	70	80	36.1	74.00
146	0	110	80	60	100	90	50	35.8	.
146	1	130	80	70	130	70	66	35.7	.
146	3	110	70	70	110	80	72	35.6	.
146	6	120	80	70	100	80	72	.	74.00
146	7	.	.	.	.	.	.	35.0	.
146	9	120	80	60	120	90	64	36.0	.
146	12	120	80	80	110	70	70	35.5	74.50
146	14	120	100	85	120	90	85	36.2	75.00
146	21	130	110	88	120	110	84	36.5	74.50
146	28	120	80	88	130	80	90	36.6	60.20
169	0	125	70	88	125	70	90	36.6	.
169	1	125	70	88	125	70	90	36.6	.
169	3	125	70	88	125	70	88	36.6	.
169	6	125	70	88	125	70	90	36.6	60.00
169	7	.	.	.	.	.	.	36.6	.
169	9	125	70	86	125	70	88	36.6	.
169	12	125	70	88	125	75	90	36.6	.
169	14	125	70	88	125	70	90	36.6	60.80
169	21	125	70	86	125	70	90	36.7	61.20
169	28	125	75	86	125	75	88	36.6	61.30
171	0	130	70	88	130	70	90	36.6	73.80
171	1	130	70	86	125	70	88	36.6	.
171	3	130	70	88	125	70	90	36.6	.
171	6	130	70	88	130	75	92	36.6	.
171	7	.	.	.	.	.	.	36.6	72.80
171	9	130	70	86	130	70	90	36.6	.
171	12	130	70	88	125	70	88	36.6	.
171	14	125	70	88	125	70	88	36.6	71.20
171	21	125	75	88	125	75	90	36.7	70.80

FCE 20124/702 i

11

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
171	28	125	70	88	125	70	90	36.6	71.00
176	0	125	70	88	120	70	90	36.6	77.20
176	1	125	70	88	120	70	88	36.6	.
176	3	125	70	88	125	70	90	36.6	.
176	6	125	70	88	125	70	90	36.6	.
176	7	.	.	.	.	.	.	.	76.80
176	9	125	70	86	125	70	90	36.6	.
176	12	125	70	88	120	70	90	36.6	.
176	14	125	70	88	120	70	90	36.6	76.90
176	21	125	70	88	120	70	90	36.6	76.80
176	28	125	70	86	120	70	90	36.7	77.00
177	0	130	75	88	130	70	90	36.6	67.00
177	1	135	70	86	130	70	90	36.6	.
177	3	130	70	88	130	70	90	36.7	.
177	6	130	70	86	130	70	90	36.6	.
177	7	.	.	.	.	.	.	.	67.00
177	9	130	70	86	130	70	90	36.6	.
177	12	130	70	88	130	70	90	36.6	.
177	14	130	70	86	130	70	88	36.6	67.20
177	21	130	70	88	130	70	90	36.7	67.60
177	28	130	70	88	130	70	90	36.6	67.70
184	0	130	70	88	130	70	90	36.6	64.00
184	1	130	70	88	130	70	90	36.7	.
184	3	130	70	86	125	70	90	36.6	.
184	6	130	70	88	130	70	90	36.6	.
184	7	.	.	.	.	.	.	.	63.10
184	9	130	70	88	125	70	90	36.7	.
184	12	130	70	86	125	70	90	36.6	.
184	14	130	70	86	125	70	88	36.7	62.70
184	21	125	70	86	130	70	92	36.7	62.20
184	28	130	70	86	125	70	92	36.6	62.60
185	0	130	75	88	130	70	90	36.6	73.20
185	1	130	70	86	130	70	88	36.6	.
185	3	130	70	88	130	65	90	36.7	.
185	6	130	70	82	130	70	86	36.6	.
185	7	.	.	.	.	.	.	.	72.00
185	9	130	70	86	130	70	90	36.6	.
185	12	130	70	86	125	70	90	36.6	.
185	14	130	70	82	130	70	88	36.6	71.30
185	21	130	70	86	125	70	88	36.7	72.80
185	28	130	70	86	125	70	90	36.7	73.10
189	0	130	80	88	130	75	90	36.6	78.00
189	1	130	80	88	130	75	90	36.6	.
189	3	130	70	88	130	70	90	36.6	.
189	6	130	70	86	130	70	88	36.7	.

FCE 20124/702 i

12

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
189	7	.	.	.	.	.	92	36.6	77.00
189	9	130	70	88	130	70	90	36.7	76.20
189	14	130	70	82	125	70	90	36.7	76.10
189	21	125	70	80	130	75	99	36.6	76.40
189	28	130	70	88	125	75	88	36.6	60.40
192	0	130	75	86	130	70	88	36.6	.
192	1	130	70	88	130	75	88	36.6	.
192	3	130	75	86	130	70	88	36.6	.
192	6	130	70	86	130	.	.	.	60.10
192	7	.	.	.	.	.	88	36.6	.
192	9	130	70	88	130	70	90	36.7	.
192	12	130	70	88	130	70	88	36.7	60.6
192	14	130	70	86	125	70	88	36.6	60.10
192	21	125	75	86	130	75	90	36.6	59.80
192	28	130	70	86	125	75	88	36.5	63.10
194	0	120	82	86	120	82	84	36.6	.
194	1	120	84	82	124	84	84	36.5	.
194	3	120	82	82	124	84	82	36.5	.
194	6	120	82	82	124	.	.	.	63.10
194	7	.	.	.	.	.	82	.	.
194	9	120	82	82	120	84	84	36.6	.
194	12	122	82	82	124	84	86	36.7	63.10
194	14	124	82	84	124	84	84	36.6	63.10
194	21	124	82	82	124	82	86	36.6	63.20
194	28	122	82	82	124	84	88	36.9	74.50
198	0	140	82	84	146	86	88	37.0	.
198	1	146	84	84	152	86	86	37.1	.
198	3	142	84	82	150	86	88	37.0	.
198	6	146	84	86	148	86	88	37.0	74.20
198	7	.	.	.	.	.	.	.	.
198	9	146	84	86	146	84	88	37.0	.
198	12	142	82	84	146	86	88	37.0	.
198	14	144	82	84	148	86	86	37.1	72.50
198	21	142	80	82	146	86	86	37.0	72.00
198	28	142	80	82	144	82	84	37.0	72.00
199	0	120	70	82	120	72	82	36.7	76.20
199	1	120	70	.	120	72	.	36.6	.
199	3	120	70	80	120	72	72	36.7	.
199	6	120	70	82	120	72	82	36.7	.
199	7	.	.	.	.	.	.	.	76.20
199	9	120	70	82	120	70	82	36.7	.
199	12	120	72	82	120	72	82	36.6	.
199	14	120	72	82	120	72	84	37.6	76.10
199	21	120	70	82	122	72	82	37.5	76.10
199	28	122	72	84	122	72	84	36.6	76.10

FCE 20124/702 i

13

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
200	0	130	82	80	135	84	82	36.7	73.60
200	1	130	80	82	132	82	84	37.1	.
200	3	130	82	82	132	82	84	36.7	.
200	6	130	82	80	32	84	80	36.7	.
200	7	.	.	.	.	.	.	.	73.70
200	9	130	80	80	132	82	80	36.7	.
200	12	130	82	80	132	82	80	36.7	.
200	14	132	82	78	132	82	80	36.8	73.60
200	21	134	82	82	136	84	84	36.6	73.70
200	28	134	82	84	136	82	86	36.6	73.60
208	0	100	70	80	100	70	80	36.9	82.50
208	1	100	70	80	100	70	80	36.9	.
208	3	100	70	80	100	70	82	37.0	.
208	6	100	70	82	100	72	84	37.0	.
208	7	.	.	.	.	.	.	.	82.50
208	9	100	70	84	100	70	84	37.0	.
208	12	100	70	82	100	72	82	36.9	.
208	14	100	70	82	100	70	82	36.9	82.00
208	21	100	70	80	100	70	82	36.9	82.00
208	28	100	70	82	100	70	82	36.9	82.00
209	0	110	70	86	110	70	88	36.7	64.00
209	1	110	70	86	110	70	88	36.7	.
209	3	110	70	88	110	72	88	36.7	.
209	6	110	72	86	110	72	88	36.7	.
209	7	.	.	.	.	.	.	.	63.50
209	9	110	72	86	110	72	86	36.8	.
209	12	110	70	86	110	70	86	36.6	.
209	14	110	70	86	110	72	88	36.7	63.00
209	21	110	70	86	110	72	88	36.7	62.50
209	28	110	70	86	110	70	88	36.6	62.00
211	0	128	68	80	132	72	82	36.7	76.00
211	1	132	70	80	134	72	82	36.8	.
211	3	130	72	82	134	74	84	36.8	.
211	6	130	70	80	134	74	82	36.8	.
211	7	.	.	.	.	.	.	.	72.50
211	9	130	70	80	132	70	82	36.8	.
211	12	130	70	82	134	72	84	36.9	.
211	14	130	70	82	134	74	84	36.9	72.50
211	21	128	70	84	134	72	86	36.8	72.50
211	28	130	70	82	134	72	84	36.8	72.50
215	0	110	70	84	110	70	84	37.0	58.00
215	1	110	70	82	110	72	84	37.0	.
215	3	110	70	84	110	70	84	37.0	.
215	6	110	72	84	110	72	86	36.9	.
215	7	.	.	.	.	.	.	.	57.50

463

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

14

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
215	9	110	70	84	110	72	84	36.9	.
215	12	110	70	84	112	72	86	37.0	.
215	14	110	72	84	110	74	86	37.1	57.00
215	21	110	70	86	110	70	86	37.0	56.00
215	28	110	70	86	110	72	86	37.0	55.50
217	0	100	60	64	90	60	84	37.1	55.00
217	1	120	60	64	100	60	68	37.0	.
217	3	120	80	84	110	70	84	37.2	.
217	6	120	80	84	110	70	86	37.1	.
217	7	.	.	.	.	.	.	.	55.00
217	12	120	60	72	120	70	72	37.4	.
217	14	125	80	84	80	40	104	37.7	55.50
217	21	100	60	68	80	40	78	37.5	56.00
217	28	100	60	68	80	50	80	37.0	56.00
217	0	100	60	60	90	70	80	37.3	55.00
222	1	90	60	64	80	60	86	37.0	.
222	3	90	60	64	80	60	88	37.0	.
222	6	90	60	54	80	60	80	37.0	.
222	7	.	.	.	.	.	.	.	56.00
222	12	110	70	68	90	70	88	37.1	.
222	14	110	70	68	90	70	88	37.0	54.50
222	21	115	70	70	90	75	85	36.9	54.00
223	0	140	90	88	140	90	89	37.1	61.00
223	1	140	70	80	150	80	100	36.4	.
223	3	150	85	88	150	85	112	36.9	.
223	6	140	85	100	140	80	120	36.9	.
223	7	.	.	.	.	.	.	.	70.00
223	12	100	60	86	100	60	94	36.5	.
224	0	110	70	68	110	70	80	36.8	47.00
224	1	110	70	70	110	70	80	36.8	.
224	3	110	70	68	110	70	80	36.9	.
224	6	100	60	104	80	40	120	37.1	.
224	7	.	.	.	.	.	.	.	48.00
224	9	.	.	.	.	.	.	.	.
224	12	100	60	86	100	60	94	36.5	.
224	14	100	60	88	100	60	96	36.6	49.00
224	21	110	60	76	100	60	96	37.0	51.00
224	28	110	60	80	120	70	96	36.8	51.00
231	1	110	80	84	140	90	108	37.0	.
231	0	110	85	82	140	90	104	37.0	75.50
231	3	110	70	72	110	80	88	37.0	.
231	6	130	80	88	140	80	100	37.0	.
231	7	.	.	.	.	.	.	.	74.50
231	9	.	.	.	.	.	.	.	.
231	12	120	80	76	130	80	82	36.6	.



FCE 20124/702 i

15

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
231	14	120	80	76	140	90	88	36.6	75.00
231	21	110	70	68	110	70	74	36.8	76.70
231	28	90	60	60	95	60	64	36.5	76.00
232	0	110	70	60	110	70	76	36.8	38.00
232	1	110	70	60	110	70	76	36.8	.
232	3	120	80	76	110	70	84	37.1	.
232	6	105	60	68	100	70	88	36.8	.
232	7	.	.	.	.	.	.	.	38.30
232	12	100	70	72	95	60	74	36.7	.
232	14	100	65	72	95	60	72	36.9	38.70
232	21	100	60	64	80	60	76	36.8	38.50
232	21	100	60	64	80	60	76	36.8	38.50
232	21	100	60	64	80	60	76	36.8	38.50
232	21	100	60	64	80	60	76	36.8	38.50
235	0	120	70	86	130	70	102	36.9	52.50
235	1	120	70	88	130	80	104	37.0	.
235	3	100	60	72	120	70	80	37.1	.
235	6	100	60	72	120	70	80	36.8	.
235	7	.	.	.	.	.	.	.	52.50
235	12	110	70	72	110	70	80	36.7	.
235	14	120	70	72	110	70	80	36.7	51.50
235	21	120	60	68	100	60	76	36.4	52.00
235	21	120	60	68	100	60	76	36.4	52.00
235	28	110	70	84	120	70	100	36.5	55.00
235	28	110	70	84	120	70	100	36.5	55.00
240	0	100	80	72	90	70	80	36.7	54.00
240	1	110	60	76	80	60	84	36.7	.
240	3	100	60	72	80	60	88	37.1	.
240	6	100	60	72	90	60	72	36.6	.
240	7	.	.	.	.	.	.	.	54.00
240	12	100	70	92	100	60	100	36.6	.
240	14	110	70	80	100	60	86	36.6	53.50
240	14	110	70	80	100	60	86	36.6	53.50
240	21	100	80	84	90	70	100	37.1	53.50
240	21	100	80	84	90	70	100	37.1	53.50
240	28	110	80	100	90	60	120	37.3	53.50
240	28	110	80	100	90	60	120	37.3	53.50
244	0	125	75	82	125	70	86	36.6	59.50
244	1	125	70	86	125	70	82	36.6	.
244	3	125	70	86	125	70	82	36.6	.
244	3	125	70	86	125	70	82	36.6	.
244	6	125	70	82	125	70	84	36.6	.
244	7	.	.	.	.	.	.	.	59.70
244	9	125	70	88	125	70	86	36.6	.
244	9	125	70	88	125	70	86	36.6	.
244	12	125	70	82	125	70	86	36.6	.
244	14	125	70	82	125	75	86	36.6	59.80
244	14	125	70	82	125	75	86	36.6	59.80
244	21	125	70	86	125	70	86	36.7	59.80
244	21	125	70	86	125	70	86	36.7	59.80
244	28	125	70	82	120	75	84	36.6	59.80
244	28	125	70	82	120	75	84	36.6	59.80
246	0	120	70	86	120	70	84	36.6	59.80
246	1	125	70	84	120	70	86	36.6	.
246	1	125	70	84	120	70	86	36.6	.
246	3	125	70	84	120	70	86	36.6	.
246	6	125	70	86	120	70	88	36.6	.
246	7	.	.	.	.	.	.	.	59.70
246	9	125	70	88	125	70	90	36.6	.

465

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

16

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
246	12	125	70	84	120	70	86	36.7	.
246	14	125	70	82	125	70	84	36.6	59.90
246	21	125	70	82	125	70	84	36.6	60.00
246	28	125	70	88	125	70	88	36.6	60.10
247	0	130	70	82	130	70	86	36.6	54.70
247	1	130	70	82	130	70	84	36.6	.
247	3	130	70	86	130	70	88	36.6	.
247	6	130	70	86	125	70	88	36.6	.
247	7	.	.	.	.	.	.	.	55.00
247	9	130	70	88	120	70	88	36.6	.
247	12	130	70	84	125	70	88	36.7	.
247	14	125	70	86	125	70	88	36.6	55.20
247	21	125	70	82	125	75	86	36.6	55.80
247	28	125	70	86	125	70	88	36.5	56.00
248	0	125	70	82	125	70	86	36.6	66.00
248	1	125	70	82	125	70	86	36.6	.
248	3	125	70	86	125	75	86	36.6	.
248	6	125	70	86	125	70	88	36.6	.
248	7	.	.	.	.	.	.	.	66.20
248	9	125	70	88	125	70	90	36.6	.
248	12	125	70	86	125	70	88	36.6	.
248	14	125	70	88	125	70	96	36.6	66.40
248	21	125	70	88	125	70	98	36.6	66.60
248	28	125	70	88	125	70	88	36.6	67.10
257	0	100	70	88	100	70	88	36.7	60.00
257	1	100	70	88	100	70	88	36.8	.
257	3	100	72	88	100	72	90	36.7	.
257	6	100	70	88	100	70	88	36.7	.
257	7	.	.	.	.	.	.	.	60.50
257	9	100	70	88	100	70	88	36.7	.
257	12	100	70	88	100	70	88	36.8	.
257	14	100	70	88	100	70	88	36.7	60.50
257	21	100	70	88	100	70	88	36.7	60.50
257	28	100	70	88	100	72	90	36.7	60.00
258	0	120	90	92	120	90	92	37.0	76.50
258	1	120	90	90	120	90	90	37.0	.
258	3	120	90	90	120	90	90	37.0	.
258	6	120	90	90	120	90	90	37.0	.
258	7	.	.	.	.	.	.	.	76.50
258	9	120	90	90	120	90	90	37.1	.
258	12	120	90	90	120	90	92	37.1	.
258	14	120	90	90	120	90	92	37.0	77.00
258	21	120	90	90	120	92	90	37.1	76.00
258	28	120	90	88	120	90	90	37.0	76.50
259	0	110	65	80	110	70	82	36.6	58.40

FCE 20124/702 i

17

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
259	1	110	60	80	110	65	82	36.6	.
259	3	110	65	80	115	65	84	36.6	.
259	6	110	60	78	110	70	80	36.5	.
259	7	.	.	.	.	.	.	.	58.60
259	9	110	60	78	110	65	80	36.6	.
259	12	110	65	78	110	65	78	36.5	.
259	14	115	65	80	115	65	78	36.6	58.80
259	21	115	65	78	115	60	80	36.6	59.20
259	28	110	65	78	115	65	80	36.6	59.70
263	0	115	60	78	115	60	82	36.6	57.40
263	1	110	65	80	110	65	84	36.6	.
263	3	115	65	80	110	60	86	36.6	.
263	6	110	65	80	110	70	86	36.6	.
263	7	.	.	.	.	.	.	.	57.40
263	9	110	65	80	110	70	86	36.5	.
263	12	110	60	80	115	60	86	36.6	.
263	14	115	65	82	115	70	84	36.6	57.80
263	21	115	65	82	115	60	84	36.5	58.20
263	28	115	65	82	115	65	84	36.6	58.80
267	0	110	70	90	110	70	92	37.0	71.00
267	1	110	70	92	110	70	92	36.9	.
267	3	110	70	90	110	70	92	36.9	.
267	6	110	70	92	110	70	92	36.9	.
267	7	.	.	.	.	.	.	.	65.50
267	9	110	70	90	110	65	92	36.9	.
267	12	110	70	90	110	70	92	36.9	.
267	14	110	70	92	110	72	92	36.9	65.20
267	21	110	70	90	110	70	92	36.8	64.70
267	28	110	70	92	110	70	92	36.9	64.30
270	0	130	90	90	130	90	90	36.7	65.10
270	1	130	90	90	130	90	90	36.6	.
270	3	130	90	88	130	90	88	36.7	.
270	6	130	90	88	130	90	90	36.7	.
270	7	.	.	.	.	.	.	.	65.30
270	9	130	90	86	130	85	90	36.7	.
270	12	130	90	90	130	90	90	36.7	.
270	14	130	90	90	130	92	90	36.7	65.70
270	21	130	90	90	130	90	90	36.7	65.90
270	28	130	90	90	130	90	90	36.6	66.30
271	0	130	80	92	130	80	92	36.8	62.80
271	1	130	80	92	130	80	92	36.9	.
271	3	130	80	92	130	82	92	36.9	.
271	6	130	80	92	130	80	92	36.9	.
271	7	.	.	.	.	.	.	.	62.50
271	9	130	80	90	130	75	92	36.8	.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

18

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
271	12	130	80	94	130	82	94	36.9	.
271	14	130	80	92	130	82	94	36.9	62.00
271	21	130	82	94	130	84	94	36.8	61.70
271	28	130	80	90	135	82	92	36.8	61.30
909	0	140	85	88	130	70	92	36.0	75.00
909	1	135	75	72	130	80	78	36.5	.
909	3	120	70	80	115	75	80	35.7	.
909	6	130	80	78	125	75	86	36.2	.
925	0	135	80	84	140	80	82	36.2	60.00
925	1	140	80	82	140	80	84	36.4	.
925	3	140	80	82	140	80	86	36.4	.
925	6	130	80	82	130	75	84	36.5	61.50
925	7	.	.	.	.	.	.	.	.
925	12	130	80	84	125	80	86	36.4	.
925	14	140	80	82	140	80	84	36.3	63.00
925	21	120	80	82	120	80	84	36.2	64.00
925	28	140	80	84	135	70	86	36.5	65.00
934	0	150	90	88	145	90	90	36.5	56.00
934	1	135	80	86	140	80	88	36.4	.
934	3	140	80	84	145	80	88	36.6	.
934	6	135	80	74	140	85	78	36.4	.
934	7	.	.	.	.	.	.	.	57.00
934	12	140	80	84	140	80	84	36.6	.
934	14	140	80	82	145	80	84	36.2	58.00
934	21	150	80	82	145	80	82	36.6	57.50
934	28	150	80	86	155	90	88	36.6	58.00
948	0	120	80	82	120	80	86	36.4	68.00
948	1	130	80	84	135	80	84	36.3	.
948	3	130	80	84	130	80	86	36.4	.
948	6	135	80	80	130	80	82	36.6	.
948	7	.	.	.	.	.	.	.	61.00
948	12	120	80	82	125	85	84	36.5	.
948	14	236	80	76	130	80	78	36.4	63.00
948	21	120	80	78	125	80	82	36.5	64.50
948	28	125	80	78	130	80	82	36.4	65.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

19

REBOXETINE, Protocol ADE 08  
Table 5e - Vital Signs  
Treatment Group "B"

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
2	0	100	60	84	100	70	88	37.0	60.00
2	1	110	60	80	100	70	84	37.0	.
2	3	100	70	76	90	60	80	36.9	.
2	6	100	60	74	100	70	80	37.0	.
2	7	.	.	.	.	.	.	.	51.00
2	12	100	70	80	100	70	88	37.0	.
2	14	100	60	88	100	65	92	37.0	52.00
2	21	110	70	92	100	80	96	36.7	52.00
2	28	110	80	96	100	75	100	36.4	53.00
4	0	105	80	80	100	80	80	37.0	80.00
4	1	110	70	84	110	80	88	36.8	.
4	3	100	60	92	100	60	96	36.8	.
4	6	115	70	92	110	70	96	37.0	.
4	7	.	.	.	.	.	.	.	80.00
10	0	110	70	74	110	70	76	36.8	58.00
10	1	110	70	80	110	60	84	36.7	.
10	3	100	70	.	100	70	.	36.7	.
10	6	110	80	80	100	70	84	36.7	.
10	7	.	.	.	.	.	.	.	58.00
10	12	100	70	80	90	70	80	36.7	.
10	14	90	60	90	90	50	90	36.8	58.00
10	21	90	60	92	90	60	96	36.7	58.00
10	28	100	70	92	100	70	92	36.8	58.00
11	0	120	70	76	110	70	76	36.8	44.00
11	1	120	80	72	110	70	72	37.0	.
11	3	120	70	78	110	70	76	36.9	.
11	6	110	70	.	100	70	.	37.0	.
11	7	.	.	.	.	.	.	.	44.00
11	12	120	70	76	110	70	76	37.0	.
11	14	120	70	72	110	60	72	36.9	44.00
11	21	110	70	76	110	60	72	37.0	44.00
11	28	120	80	.	110	70	.	36.8	45.00
15	0	140	80	78	130	70	80	36.7	47.00
15	1	140	80	78	130	70	78	36.7	.
15	3	140	80	75	130	70	75	36.6	.
15	6	120	80	75	115	70	77	36.6	.
15	7	.	.	.	.	.	.	.	47.00
15	12	130	80	88	110	70	92	36.7	.
15	14	120	70	86	110	60	88	36.6	48.00
15	21	130	80	80	115	60	84	36.7	48.00
15	28	120	70	78	110	65	82	36.6	48.00
17	0	140	80	80	130	70	84	36.7	70.00
17	1	140	80	80	130	80	84	36.6	.
17	3	130	80	.	130	70	.	36.7	.
17	6	140	80	82	130	70	82	36.7	.

FCE 20124/702 i

20

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
2	0	100	60	84	100	70	88	37.0	60.00
2	1	110	60	80	100	70	84	37.0	.
2	3	100	70	76	90	60	80	36.9	.
2	6	100	60	74	100	70	80	37.0	.
2	7	.	.	.	.	.	.	.	51.00
2	12	100	70	80	100	70	88	37.0	.
2	14	100	60	88	100	65	92	37.0	52.00
2	21	110	70	92	100	80	96	36.7	52.00
2	28	110	80	96	100	75	100	36.4	53.00
4	0	105	80	80	100	80	80	37.0	80.00
4	1	110	70	84	110	80	88	36.8	.
4	3	100	60	92	100	60	96	36.8	.
4	6	115	70	92	110	70	96	37.0	.
4	7	.	.	.	.	.	.	.	80.00
10	0	110	70	74	110	70	76	36.8	58.00
10	1	110	70	80	110	60	84	36.7	.
10	3	100	70	.	100	70	.	36.7	.
10	6	110	80	80	100	70	84	36.7	.
10	7	.	.	.	.	.	.	.	58.00
10	12	100	70	80	90	70	80	36.7	.
10	14	90	60	90	90	50	90	36.8	58.00
10	21	90	60	92	90	60	96	36.7	58.00
10	28	100	70	92	100	70	92	36.8	58.00
11	0	120	70	76	110	70	76	36.8	44.00
11	1	120	80	72	110	70	72	37.0	.
11	3	120	70	78	110	70	76	36.9	.
11	6	110	70	.	100	70	.	37.0	.
11	7	.	.	.	.	.	.	.	44.00
11	12	120	70	76	110	70	76	37.0	.
11	14	120	70	72	110	60	72	36.9	44.00
11	21	110	70	76	110	60	72	37.0	44.00
11	28	120	80	.	110	70	.	36.8	45.00
15	0	140	80	78	130	70	80	36.7	47.00
15	1	140	80	78	130	70	78	36.7	.
15	3	140	80	75	130	70	75	36.6	.
15	6	120	80	75	115	70	77	36.6	.
15	7	.	.	.	.	.	.	.	47.00
15	12	130	80	88	110	70	92	36.7	.
15	14	120	70	86	110	60	88	36.6	48.00
15	21	130	80	80	115	60	84	36.7	48.00
15	28	120	70	78	110	65	82	36.6	48.00
17	0	140	80	80	130	70	84	36.7	70.00
17	1	140	80	80	130	80	84	36.6	.
17	3	130	80	.	130	70	.	36.7	.
17	6	140	80	82	130	70	82	36.7	.

470

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

21

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
									70.00
17	7	.	.	.	.	.	92	36.6	.
17	12	140	80	92	130	70	96	36.7	71.00
17	14	140	80	92	130	70	92	36.7	71.00
17	21	140	80	92	140	70	92	36.7	71.00
17	28	140	80	88	130	70	92	36.7	71.00
28	0	140	80	82	135	80	84	36.2	68.00
28	1	150	80	88	150	75	92	36.4	.
28	3	140	70	90	135	70	92	36.4	.
28	6	140	80	90	140	75	92	36.5	.
28	7	.	.	.	.	.	.	.	76.00
28	7	.	.	.	.	.	92	36.7	.
28	12	140	80	90	130	75	92	36.6	66.00
28	14	150	80	90	140	80	92	36.6	65.00
29	0	130	80	80	135	80	82	36.4	.
29	1	135	80	78	135	75	80	36.4	.
29	3	120	75	78	120	75	82	36.4	.
29	6	130	80	78	135	80	82	36.4	.
29	7	.	.	.	.	.	.	.	65.00
29	7	.	.	.	.	.	80	36.4	.
29	9	130	80	78	130	80	80	36.4	.
29	9	135	80	82	130	80	84	36.4	.
29	12	135	80	82	130	80	86	36.6	62.50
31	0	130	80	84	130	80	84	36.6	.
31	1	140	80	82	140	75	84	36.2	.
31	3	145	80	80	140	80	80	36.3	.
31	3	145	80	80	140	80	84	36.5	.
31	6	150	80	82	140	75	84	36.5	.
31	7	.	.	.	.	.	.	.	63.00
31	7	.	.	.	.	.	.	.	.
31	9	150	80	84	150	80	86	36.6	.
31	9	150	80	84	150	80	86	36.6	.
31	12	140	80	80	140	75	82	36.4	.
31	12	140	80	80	140	75	82	36.4	.
31	14	145	80	82	140	80	82	36.3	64.00
31	14	145	80	82	140	80	82	36.3	64.00
31	21	145	80	80	140	80	82	36.4	65.00
31	21	145	80	80	140	80	82	36.4	65.00
31	28	140	80	82	145	80	84	36.5	65.00
31	28	140	80	82	145	80	84	36.5	65.00
32	0	120	80	84	120	80	86	36.4	54.00
32	1	130	80	84	130	80	88	36.4	.
32	3	120	80	88	115	70	88	36.6	.
32	3	120	80	88	115	70	88	36.6	.
32	6	140	80	86	140	75	86	36.6	.
32	6	140	80	86	140	75	86	36.6	.
32	7	.	.	.	.	.	.	.	56.00
32	7	.	.	.	.	.	.	.	.
32	9	135	80	80	140	80	82	36.3	.
32	9	135	80	80	140	80	82	36.3	.
32	12	130	80	82	130	80	82	36.3	.
32	12	130	80	82	130	80	82	36.3	.
32	14	130	80	78	130	80	80	36.4	57.00
32	14	130	80	78	130	80	80	36.4	57.00
32	21	120	80	78	125	80	80	36.2	57.00
32	21	120	80	78	125	80	80	36.2	57.00
32	28	125	85	76	130	80	78	36.7	57.00
32	28	125	85	76	130	80	78	36.7	57.00
41	0	135	80	82	130	80	84	36.2	68.00
41	1	135	80	82	130	80	82	36.4	.
41	3	140	80	82	140	80	84	36.4	.
41	3	140	80	82	140	80	84	36.4	.
41	6	140	80	84	135	75	86	36.4	.
41	6	140	80	84	135	75	86	36.4	.
41	7	.	.	.	.	.	.	.	69.00
41	7	.	.	.	.	.	.	.	69.00
41	9	140	80	82	135	80	84	36.3	.
41	9	140	80	82	135	80	84	36.3	.

FCE 20124/702 i

22

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
41	12	130	80	84	130	70	84	36.4	.
41	14	135	80	76	130	80	78	36.3	70.00
41	21	140	80	84	145	80	84	36.6	71.00
41	28	145	80	82	140	80	80	36.4	68.00
42	0	140	80	88	135	80	92	36.3	62.00
42	1	120	80	90	120	75	92	36.2	.
42	3	135	80	84	140	80	86	36.4	.
42	6	140	80	82	140	75	84	36.4	.
42	7	.	.	.	.	.	.	.	65.00
42	12	120	80	82	120	80	84	36.4	.
42	14	130	80	86	140	85	88	36.6	65.00
42	21	100	80	76	125	85	78	36.4	66.00
42	28	140	80	82	145	85	80	36.3	65.50
44	0	140	80	88	140	85	90	36.4	66.00
44	1	135	80	84	130	80	86	36.5	.
44	3	150	80	80	140	75	84	36.4	.
44	6	140	80	78	145	80	80	36.4	.
44	7	.	.	.	.	.	.	.	68.00
44	9	140	80	82	135	80	82	36.2	.
44	12	140	80	78	140	80	80	36.2	.
44	14	130	80	74	130	80	76	36.5	66.00
44	21	135	80	76	130	80	78	36.4	69.00
44	28	130	80	78	130	80	76	36.5	68.00
47	0	130	80	80	125	80	84	36.2	58.00
47	1	120	80	84	120	80	84	36.4	.
47	3	125	80	82	120	80	84	36.3	.
47	6	140	80	80	135	80	82	36.4	.
47	7	.	.	.	.	.	.	.	58.00
47	9	130	76	80	130	78	84	36.4	.
47	12	130	80	80	135	80	84	36.4	.
47	14	130	80	82	125	80	84	36.4	60.00
47	21	135	80	76	130	80	76	36.2	60.00
47	28	130	80	78	135	80	80	36.4	61.00
51	0	140	90	82	130	85	84	36.2	46.00
51	1	140	90	84	130	85	84	36.1	.
51	3	140	90	80	110	80	86	36.2	.
51	6	145	90	78	120	80	82	36.3	.
51	7	.	.	.	.	.	.	.	45.50
51	9	140	90	80	130	80	78	36.2	.
51	12	130	90	76	125	85	78	36.2	.
51	14	135	90	77	130	85	80	36.2	46.00
51	21	130	90	80	125	85	76	36.2	46.00
51	28	130	90	76	130	85	77	36.2	46.50
54	0	130	80	78	125	80	81	36.2	96.00
54	1	130	80	76	130	80	80	36.3	.



FCE 20124/702 i

23

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
54	3	130	80	80	120	80	82	36.2	.
54	6	130	80	76	120	80	78	36.3	.
54	7	.	.	.	.	.	.	.	96.00
54	9	140	80	74	130	80	76	36.2	.
54	12	130	80	72	120	80	74	36.3	.
54	14	140	80	70	130	80	76	36.3	96.50
54	21	130	80	76	130	80	72	36.2	96.50
54	28	130	80	70	125	75	74	36.2	96.50
55	0	130	80	76	130	80	78	36.2	89.00
55	1	130	90	76	120	80	74	36.3	.
55	3	140	90	72	130	80	76	36.2	.
55	6	140	90	72	135	85	74	36.2	.
55	7	.	.	.	.	.	.	.	89.00
55	9	140	90	72	135	80	75	36.3	.
55	12	130	80	72	125	80	76	37.3	.
55	14	140	90	72	130	80	74	36.2	89.00
55	21	130	80	74	125	80	76	36.1	90.00
55	28	135	90	72	130	80	74	36.0	90.00
60	0	130	80	76	120	80	82	36.2	62.00
60	1	130	80	76	130	80	74	36.2	.
60	3	120	80	76	120	80	78	36.2	.
60	6	120	80	76	115	70	84	36.2	.
60	7	.	.	.	.	.	.	.	62.00
60	9	120	80	76	120	80	78	36.2	.
60	12	130	80	72	125	75	72	36.2	.
60	14	130	80	68	120	70	72	36.2	62.50
60	21	120	80	76	125	80	80	36.2	62.50
60	28	120	80	76	125	80	78	36.2	62.50
61	0	120	80	84	125	80	87	36.2	52.00
61	1	130	80	82	120	85	85	36.2	.
61	3	120	80	78	120	80	84	36.3	.
61	6	125	80	81	125	80	84	36.2	.
61	7	.	.	.	.	.	.	.	52.00
61	9	120	80	76	110	80	81	36.2	.
61	12	130	80	76	125	80	79	36.4	.
61	14	120	80	78	120	80	82	36.2	52.50
61	21	130	80	74	125	80	79	36.2	52.50
61	28	125	80	74	120	80	78	36.3	53.00
66	0	140	80	84	135	80	82	36.3	80.50
66	1	145	90	80	135	90	82	36.2	.
66	3	140	90	80	135	80	81	36.3	.
66	6	140	90	76	140	80	82	36.3	.
66	7	.	.	.	.	.	.	.	80.00
66	9	140	90	76	145	90	80	36.2	.
66	12	150	90	76	140	80	79	36.2	.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

24

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
66	14	150	90	76	140	80	74	36.2	80.00
66	21	150	80	76	145	80	74	36.2	80.00
66	28	140	90	74	140	80	76	36.3	80.00
67	0	120	80	74	125	80	77	36.2	67.00
67	1	130	80	70	120	70	78	36.2	.
67	3	120	80	76	115	70	75	36.2	.
67	6	130	80	.	120	80	.	36.4	.
67	7	.	.	.	.	.	.	.	67.00
67	9	120	80	70	115	75	74	36.2	.
67	12	125	80	72	120	70	69	36.4	.
67	14	120	80	76	115	75	74	36.3	67.00
67	21	125	80	74	120	75	77	36.3	67.00
67	28	125	80	72	120	70	74	36.5	67.00
70	0	120	80	84	115	80	86	36.4	57.50
70	1	125	80	76	120	80	82	36.2	.
70	3	130	90	76	120	80	79	36.2	.
70	6	120	80	74	115	80	76	36.2	.
70	7	.	.	.	.	.	.	.	47.00
70	9	130	85	76	120	80	77	36.2	.
70	12	120	80	74	120	80	76	36.4	.
70	14	125	80	72	120	80	75	36.4	57.00
70	21	120	80	76	120	80	74	36.4	57.00
70	28	120	80	70	120	75	76	36.4	57.00
77	0	130	90	80	115	80	85	36.6	77.00
77	1	130	90	85	120	85	87	36.6	.
77	3	130	80	88	120	80	90	36.5	.
77	6	130	80	851	150	800	883	6.6	.
77	7	.	.	.	.	.	.	.0	76.00
77	12	120	90	72	120	80	75	36.5	.
77	14	130	90	72	130	80	75	36.5	75.30
77	21	140	100	76	130	95	76	36.6	76.00
77	28	140	100	76	140	100	80	.	75.50
78	0	150	100	75	130	95	76	36.6	68.00
78	1	175	110	65	170	110	70	36.8	.
78	3	140	90	72	130	90	72	36.6	.
78	6	170	110	72	150	105	72	36.4	.
78	7	.	.	.	.	.	.	.	67.00
78	12	140	90	88	130	90	90	36.5	.
78	14	150	90	70	105	85	75	36.5	65.50
78	21	140	95	92	130	95	99	36.2	67.00
78	28	160	100	64	130	100	72	36.4	67.50
83	0	150	90	70	140	90	74	36.6	89.00
83	1	140	100	65	140	90	68	36.6	.
83	3	170	95	80	140	90	80	36.6	.
83	6	150	90	76	120	90	72	36.7	.

474

FCE 20124/702 i

25

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
83	7	.	.	.	.	.	.	.	89.20
83	9	130	80	76	120	80	72	36.6	.
83	12	140	90	74	130	90	70	36.6	.
83	14	140	80	74	140	90	70	36.8	89.00
83	21	130	80	70	120	80	74	36.6	89.30
83	28	140	90	60	130	90	70	36.8	89.30
84	0	160	90	72	150	100	76	36.6	76.50
84	1	110	70	72	110	90	72	36.6	.
84	3	130	75	76	130	80	72	36.4	.
84	6	135	90	94	140	90	90	36.6	.
84	7	.	.	.	.	.	.	.	77.00
84	9	110	80	70	110	75	74	36.8	.
84	12	125	85	70	120	80	70	36.8	.
84	14	130	80	70	110	90	70	36.7	78.00
84	21	115	80	72	120	90	76	36.6	78.00
84	28	120	80	74	120	90	76	36.8	78.00
88	0	130	85	80	130	80	80	36.4	53.00
88	1	130	90	80	130	80	84	36.4	.
88	3	130	80	76	130	80	80	36.6	.
88	6	110	80	88	95	76	96	36.4	.
88	7	.	.	.	.	.	.	.	54.55
88	9	100	70	76	100	70	80	36.5	.
88	12	110	70	80	110	75	84	36.4	.
88	14	120	75	80	115	70	84	36.5	53.60
88	21	105	70	76	110	70	80	36.4	54.60
88	28	120	80	72	120	80	76	36.4	54.60
90	0	90	60	80	100	70	84	36.4	75.00
90	1	100	70	84	95	70	88	36.4	.
90	3	100	70	92	90	70	82	36.5	.
90	6	110	80	76	100	70	76	36.4	.
90	7	.	.	.	.	.	.	.	75.00
90	9	110	80	92	100	70	100	36.4	.
90	12	100	80	84	95	75	96	36.4	.
90	14	110	80	86	95	75	82	36.4	75.00
90	21	105	70	72	90	70	80	36.6	75.00
90	28	115	85	80	90	70	86	36.5	73.50
91	0	120	90	80	110	90	88	36.6	71.50
91	1	120	90	80	115	85	84	36.6	.
91	3	130	85	76	120	85	82	36.6	.
91	6	140	100	76	100	85	88	36.6	.
91	7	.	.	.	.	.	.	.	71.50
91	9	120	80	92	95	80	104	36.6	.
91	12	110	90	86	100	80	92	36.4	.
91	14	110	85	80	100	80	88	36.4	70.70
91	21	110	80	92	100	80	100	36.6	70.00

475

FCE 20124/702 i

26

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
91	28	110	80	96	100	80	96	36.4	70.00
95	0	115	75	72	115	70	76	36.6	77.50
95	1	115	75	80	110	75	84	36.5	.
95	3	110	70	80	100	70	88	36.7	.
95	6	120	80	80	100	70	84	36.6	.
95	7	.	.	.	.	.	.	.	76.50
95	9	110	75	80	105	70	84	36.5	.
95	12	120	80	76	120	75	84	36.6	.
95	14	115	80	80	115	80	88	36.6	76.00
95	21	120	80	76	110	75	80	36.7	75.50
95	28	110	75	80	115	75	80	36.6	75.50
98	0	95	55	56	95	60	58	36.7	54.00
98	1	100	60	62	95	60	58	36.6	.
98	3	108	55	72	105	60	70	36.9	.
98	6	110	55	72	104	60	74	36.0	.
98	7	.	.	.	.	.	.	.	54.00
98	9	108	55	72	104	62	76	36.7	.
98	12	110	75	70	108	78	78	36.5	.
98	14	108	70	68	98	66	70	36.9	54.00
98	21	128	80	76	120	72	82	36.8	55.00
98	28	116	70	72	112	66	78	36.6	55.50
102	0	120	80	78	120	84	82	36.8	51.00
102	1	120	82	76	118	86	78	36.7	.
102	3	122	80	78	128	84	82	36.8	.
102	6	132	86	96	130	86	94	36.8	.
102	7	.	.	.	.	.	.	.	51.00
102	9	124	76	78	128	82	80	36.8	.
102	12	130	86	82	128	84	84	36.4	.
102	14	126	86	88	122	84	88	36.5	50.00
102	21	110	68	82	112	74	90	36.7	53.00
102	28	112	68	82	110	78	96	36.4	53.00
103	0	106	66	70	102	68	72	36.8	63.00
103	1	90	52	60	94	68	66	36.7	.
103	3	102	58	78	106	68	88	36.7	.
103	6	96	58	72	102	72	76	36.8	.
103	7	.	.	.	.	.	.	.	62.50
103	9	98	56	66	86	52	72	36.3	.
103	12	106	76	76	104	70	76	36.7	.
103	14	96	66	66	92	60	70	36.6	63.00
103	21	120	72	78	102	66	84	36.2	63.00
103	28	102	64	80	100	60	84	36.7	63.00
106	0	110	70	72	110	70	72	36.5	64.00
106	1	120	80	84	115	80	86	36.2	.
106	3	120	75	80	120	75	88	36.5	.
106	6	110	75	72	110	75	78	36.4	.

476

FCE 20124/702 i

27

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
106	7	.	.	.	.	.	.	.	66.00
106	9	120	75	82	120	80	88	36.4	.
106	12	105	80	74	100	75	92	37.0	.
106	14	110	80	72	110	75	78	36.0	63.00
106	21	110	70	82	110	70	82	35.5	66.00
106	28	110	75	82	110	80	88	35.2	66.00
110	0	105	75	80	100	75	88	35.7	48.70
110	1	110	75	88	110	70	88	35.7	.
110	3	100	70	88	95	70	96	35.9	.
110	6	100	70	80	100	65	86	36.4	.
110	7	.	.	.	.	.	.	.	49.50
110	9	100	75	88	95	75	96	36.2	.
110	12	95	70	92	80	60	100	35.2	.
110	14	85	65	92	75	60	100	35.9	49.50
110	21	100	80	80	95	75	88	35.9	50.00
110	28	90	70	84	80	60	92	35.6	50.00
113	0	130	80	80	125	75	76	36.1	.
113	1	120	80	72	115	75	74	36.2	.
113	3	110	75	70	110	70	82	36.1	.
113	6	110	70	78	105	65	82	36.1	.
113	7	.	.	.	.	.	.	.	83.00
113	9	115	75	76	110	68	82	36.2	.
113	12	120	80	72	115	75	78	36.2	.
113	14	125	75	80	120	70	84	36.3	83.50
113	21	110	80	72	105	75	80	36.4	84.00
113	28	115	75	80	110	70	84	36.3	83.50
118	0	115	85	68	110	80	72	36.5	56.00
118	1	115	80	68	110	70	76	36.7	.
118	3	120	85	68	110	75	76	36.3	.
118	6	115	80	78	110	75	78	36.4	.
118	7	.	.	.	.	.	.	.	56.00
118	9	115	80	66	110	80	70	36.3	.
118	12	125	85	68	120	80	72	36.5	.
118	14	120	80	72	115	75	76	36.7	56.00
118	21	130	75	70	125	75	76	36.6	56.50
118	28	115	75	68	110	70	72	36.6	57.00
119	0	120	82	76	116	84	80	36.8	68.00
119	1	120	80	76	118	84	82	36.8	.
119	3	118	80	72	110	82	76	36.7	.
119	6	120	80	74	115	84	80	36.7	.
119	7	.	.	.	.	.	.	.	68.00
119	9	120	80	78	122	84	84	36.8	.
119	12	116	76	76	110	82	80	36.6	.
119	14	116	78	80	110	82	84	36.7	68.00
119	21	110	82	78	106	84	84	36.6	68.00

FCE 20124/702 i

28

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
119	28	110	80	78	106	82	82	36.6	68.00
124	0	100	80	67	100	80	72	36.2	61.30
124	1	110	70	68	120	80	69	35.5	.
124	3	120	90	77	150	90	63	36.4	.
124	6	100	90	85	110	70	78	36.5	.
124	7	.	.	.	.	.	.	.	62.30
124	9	110	70	87	110	80	81	36.6	.
124	12	110	70	75	120	70	83	36.6	.
124	14	110	90	80	110	80	88	36.8	61.50
124	21	120	80	78	130	90	90	35.7	62.10
124	28	130	90	88	130	90	90	36.5	62.00
126	0	110	70	108	110	80	103	36.0	48.40
126	1	120	80	94	110	70	92	36.5	.
126	3	110	70	87	110	80	90	36.5	.
126	6	110	70	92	120	80	92	36.5	.
126	7	.	.	.	.	.	.	.	47.20
126	9	110	70	90	110	80	90	36.0	.
126	12	120	90	88	120	70	88	36.6	.
126	14	130	80	84	130	80	84	36.5	46.50
126	21	120	80	82	130	90	90	37.4	46.50
126	28	120	80	111	130	70	104	36.7	46.50
127	0	110	70	78	130	90	92	36.5	54.00
127	1	110	70	72	120	80	72	36.0	.
127	3	120	70	84	130	90	88	36.4	.
127	6	110	70	86	140	100	90	36.0	.
127	7	.	.	.	.	.	.	.	53.50
127	9	120	80	80	120	80	84	36.5	.
127	12	120	80	80	120	80	82	36.0	.
127	14	120	70	72	110	70	76	37.0	53.60
127	21	120	80	82	130	90	82	36.5	53.20
127	28	110	70	84	110	90	92	36.5	53.10
132	0	130	90	76	110	80	88	36.0	67.70
132	1	130	80	90	110	80	92	36.0	.
132	3	140	90	88	140	89	94	35.0	.
132	6	130	90	98	110	70	94	36.0	.
132	7	.	.	.	.	.	.	.	68.70
132	9	130	90	88	110	80	90	36.7	.
132	12	130	90	88	110	90	92	36.0	.
132	14	170	90	80	180	90	88	36.0	68.50
132	21	120	90	96	150	90	100	36.0	68.70
132	28	140	90	100	150	100	104	36.5	68.00
133	0	140	90	81	110	90	88	36.8	73.10
133	1	150	100	88	150	100	92	36.5	.
133	3	130	90	90	150	100	104	36.8	.
133	6	130	80	92	130	90	100	36.0	.

478

FCE 20124/702 i

29

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
133	7	.	.	.	.	.	.		72.30
133	9	130	90	88	120	80	103	36.5	.
133	12	140	90	96	140	110	106	37.0	.
133	14	130	90	92	130	80	88	36.6	72.00
133	21	130	90	94	140	100	98	36.0	72.10
133	28	130	70	96	150	100	98	36.8	71.70
136	0	110	70	84	140	90	88	36.7	83.50
136	1	110	70	84	140	90	88	36.7	.
136	3	110	70	94	130	80	84	37.0	.
136	6	120	90	97	180	80	99	36.0	.
136	7	.	.	.	.	.	.		82.80
136	9	120	80	100	140	90	88	37.0	.
136	12	120	70	100	110	80	84	36.8	.
136	14	140	90	88	140	90	86	36.0	84.00
136	21	120	80	82	120	80	82	36.2	83.00
136	28	130	90	84	130	90	84	36.3	82.00
136	28	130	90	84	130	90	84	36.0	58.00
139	0	100	70	76	110	70	84	36.0	.
139	1	110	70	88	90	60	92	37.0	.
139	3	120	90	84	120	80	100	36.5	.
139	6	130	90	88	110	90	104	36.0	.
139	7	.	.	.	.	.	.		57.00
139	9	110	70	88	100	80	104	36.0	.
139	12	110	90	108	100	90	110	36.2	.
139	14	130	90	100	120	80	108	37.2	56.00
139	21	130	90	100	140	90	100	36.4	56.00
139	28	110	80	88	130	80	82	36.4	56.20
140	0	110	80	68	110	80	100	36.5	50.00
140	1	110	80	68	110	80	100	36.0	.
140	3	120	70	88	110	80	120	36.0	.
140	6	120	90	80	130	90	108	36.5	.
140	7	.	.	.	.	.	.		50.80
140	9	130	90	88	130	90	90	36.0	.
140	12	120	80	84	110	90	100	36.4	.
140	14	140	100	80	110	80	100	36.0	50.50
140	21	110	70	86	100	70	90	36.6	50.90
140	28	110	60	100	140	80	100	36.7	50.80
147	0	110	75	82	110	85	84	36.5	45.50
147	1	110	70	80	110	80	84	36.5	.
147	3	110	70	72	110	70	80	36.3	.
147	6	110	70	104	90	50	96	36.0	.
147	7	.	.	.	.	.	.		.
147	9	100	70	90	90	60	80	36.7	.
147	12	100	80	64	100	80	60	36.2	.
147	14	120	80	90	110	90	88	36.6	45.50
148	0	110	70	80	100	70	86	36.8	58.50

479

FCE 20124/702 i

30

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
148	1	110	70	82	100	75	86	37.0	.
148	3	110	80	100	110	80	96	37.2	.
148	6	120	70	82	100	70	80	36.5	.
148	7	.	.	.	.	.	.	.	58.00
148	9	120	70	80	110	70	80	37.0	.
148	12	120	80	80	130	70	80	37.0	.
148	14	110	90	100	100	80	80	36.5	58.00
148	21	110	80	90	110	70	80	37.0	58.50
148	28	110	80	80	110	90	85	36.8	59.00
170	0	130	70	88	130	70	90	36.6	69.00
170	1	130	70	86	130	70	88	36.6	.
170	3	130	70	8	612	507	9	36.0	.06
170	6	130	70	88	130	70	90	36.7	.
170	7	.	.	.	.	.	.	.	68.60
170	9	130	70	88	130	70	90	36.6	.
170	12	125	70	88	125	70	92	36.5	.
170	14	130	70	88	130	70	88	36.7	69.00
170	21	130	70	86	130	70	90	36.6	69.80
170	28	125	70	88	125	70	90	36.6	70.10
172	0	125	70	88	125	70	90	36.6	73.20
172	1	125	70	88	125	70	90	36.6	.
172	3	125	70	88	125	70	90	36.6	.
172	6	125	75	86	125	70	90	36.6	.
172	7	.	.	.	.	.	.	.	72.20
172	9	125	75	88	125	70	86	36.6	.
172	12	125	70	88	120	70	96	36.6	.
172	14	125	70	88	120	70	92	36.6	71.40
172	21	120	70	88	120	70	92	36.6	72.20
172	28	120	70	88	120	65	92	36.6	73.60
179	0	125	80	88	120	80	88	36.6	71.00
179	1	120	80	86	120	80	88	36.7	.
179	3	125	80	86	120	80	86	36.6	.
179	6	125	80	88	120	80	88	36.6	.
179	7	.	.	.	.	.	.	.	70.20
179	9	125	70	88	110	70	92	36.6	.
179	12	120	80	86	115	75	90	36.6	.
179	14	125	80	88	125	80	90	36.6	70.20
179	21	110	60	92	100	60	98	36.6	71.00
179	28	125	70	86	125	70	88	36.6	71.30
180	0	130	80	86	130	75	88	36.6	69.20
180	1	130	75	86	130	75	90	36.6	.
180	3	130	70	88	130	70	90	36.6	.
180	6	130	75	88	130	70	88	36.6	.
180	7	.	.	.	.	.	.	.	69.10
180	9	130	75	86	130	70	90	36.6	.

480



FCE 20124/702 i

31

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
180	12	130	70	88	130	70	90	36.7	.
180	14	130	70	86	130	70	88	36.6	69.40
180	21	130	70	88	130	70	90	36.7	69.20
180	28	125	70	88	125	75	90	36.6	69.60
181	0	130	70	88	130	70	90	36.6	71.50
181	1	130	70	86	130	70	88	36.6	.
181	3	130	75	88	130	70	90	36.6	.
181	6	130	70	86	130	70	88	36.7	.
181	7	.	.	.	.	.	.	.	70.40
181	9	130	70	88	130	70	90	36.7	.
181	12	130	70	86	125	70	90	36.6	.
181	14	130	70	86	125	70	88	36.7	71.20
181	21	130	70	86	130	70	88	36.6	72.20
181	28	125	70	88	130	75	90	36.6	72.40
186	0	125	70	88	125	70	90	36.6	72.20
186	1	120	75	88	120	70	90	36.6	.
186	3	125	70	82	130	70	86	36.6	.
186	6	125	70	82	125	80	90	36.6	.
186	7	.	.	.	.	.	.	.	72.20
186	9	125	70	86	120	70	90	36.6	.
186	12	125	70	80	130	70	86	36.7	.
186	14	125	70	82	125	70	90	36.6	71.20
186	21	125	70	80	125	70	88	36.6	72.20
186	28	125	70	80	130	70	88	36.6	72.60
187	0	125	70	88	125	70	90	36.6	62.20
187	1	125	70	86	125	70	88	36.6	.
187	3	125	70	88	125	75	90	36.6	.
187	6	125	75	88	125	75	90	36.6	.
187	7	.	.	.	.	.	.	.	61.80
187	9	125	75	88	125	70	90	36.6	.
187	12	125	75	88	120	70	90	36.6	.
187	14	125	70	86	125	70	88	36.6	62.10
187	21	125	70	86	125	75	88	36.6	62.80
187	28	125	70	86	125	70	88	36.6	63.20
188	0	120	80	88	120	75	90	36.6	58.10
188	1	120	70	88	120	70	90	36.6	.
188	3	125	80	86	125	75	88	36.7	.
188	6	125	70	88	125	70	90	36.6	.
188	9	125	70	86	125	70	88	36.6	.
188	12	125	80	88	125	75	88	36.6	.
188	14	125	70	86	125	70	86	36.7	59.10
188	21	125	70	88	125	70	90	36.6	59.80
188	28	125	75	86	125	75	90	36.6	60.10
193	0	130	80	88	130	80	88	36.5	67.90
193	1	130	80	86	130	80	86	36.5	.

481

FCE 20124/702 i

32

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
193	3	128	80	86	130	80	86	36.4	.
193	6	128	80	86	130	80	86	36.5	.
193	7	.	.	.	.	.	.	.	65.60
193	9	130	80	86	130	80	86	36.6	.
193	12	130	80	86	132	82	86	36.5	.
193	14	130	80	86	132	80	86	36.5	65.70
193	21	128	80	84	128	80	84	36.4	65.70
193	28	130	80	86	130	80	86	36.5	65.70
197	0	120	70	86	124	74	88	36.9	72.50
197	1	120	70	88	124	74	90	36.9	.
197	3	120	70	.	126	76	.	36.8	.
197	6	122	70	88	124	74	90	36.9	.
197	7	.	.	.	.	.	.	.	72.60
197	9	122	70	88	124	72	88	36.8	.
197	12	124	74	90	126	76	92	37.0	.
197	14	122	72	88	124	74	92	36.9	72.60
197	21	124	78	92	128	80	96	37.1	72.50
197	28	128	80	96	136	88	100	37.2	72.50
202	0	110	70	80	110	70	82	36.7	62.00
202	1	110	70	80	110	72	82	36.7	.
202	3	110	70	.	110	72	.	36.7	.
202	6	110	70	80	110	72	82	36.8	.
202	7	.	.	.	.	.	.	.	62.50
202	9	110	70	80	110	70	82	36.9	.
202	12	110	72	82	115	74	84	36.8	.
202	14	110	70	84	110	74	86	37.0	62.50
202	21	110	72	84	112	72	84	36.8	62.50
202	28	110	72	80	110	74	82	36.0	62.50
203	0	100	70	82	105	72	84	36.8	78.50
203	1	100	70	84	700	72	84	36.8	.
203	3	100	72	82	105	72	84	36.9	.
203	6	100	70	84	100	70	84	37.0	.
203	7	.	.	.	.	.	.	.	78.00
203	9	100	70	84	100	70	84	37.0	.
203	12	100	70	82	105	72	84	37.0	.
203	14	100	70	82	100	72	84	37.0	77.00
203	21	100	70	84	100	72	84	37.0	76.20
203	28	100	70	82	100	72	84	37.0	76.00
206	0	110	70	82	110	70	82	36.8	56.00
206	1	110	70	.	110	70	.	36.8	.
206	3	110	70	82	110	70	82	36.8	.
206	6	110	70	82	110	72	84	36.9	.
206	7	.	.	.	.	.	.	.	55.00
206	9	110	70	84	110	72	84	36.9	.
206	12	110	80	82	110	70	84	36.8	.

482

FCE 20124/702 i

33

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
206	14	110	70	82	110	70	82	36.8	54.50
206	21	110	70	82	110	70	82	36.7	54.00
206	28	110	70	82	110	70	82	36.8	54.00
210	0	120	80	86	120	80	88	36.6	62.50
210	1	120	80	86	120	80	86	36.6	.
210	3	120	80	86	120	82	88	36.6	.
210	6	120	80	86	120	80	88	36.7	.
210	7	.	.	.	.	.	.	.	62.50
210	9	120	80	88	120	82	88	36.7	.
210	12	120	80	86	120	80	88	36.7	.
210	14	120	80	86	120	80	86	36.6	63.00
210	21	120	80	86	120	82	86	36.6	63.20
210	28	120	82	88	120	82	88	36.8	63.50
214	0	120	80	84	120	86	86	36.7	61.50
214	1	120	80	84	126	84	86	37.0	.
214	3	124	82	84	124	82	86	36.8	.
214	6	120	80	84	124	82	84	36.8	.
214	7	.	.	.	.	.	.	.	61.00
214	9	120	82	84	120	84	84	36.9	.
214	12	120	80	84	120	80	84	36.8	.
214	14	120	80	82	120	82	84	36.8	60.50
214	21	120	80	84	120	80	84	36.8	60.50
214	28	124	82	84	124	82	84	36.9	60.00
216	0	110	76	88	110	80	90	36.8	78.00
216	1	110	76	88	110	76	90	36.8	.
216	3	110	70	88	110	76	90	36.8	.
216	6	110	78	90	110	78	90	36.9	.
216	7	.	.	.	.	.	.	.	78.50
216	9	110	80	90	110	80	90	36.9	.
216	12	110	76	88	110	80	90	36.9	.
216	14	110	76	88	110	76	90	36.9	79.00
216	21	110	80	88	110	80	90	36.9	30.00
216	28	110	76	86	110	76	88	36.9	80.00
218	0	110	70	84	110	80	100	37.4	46.00
218	1	110	70	82	110	80	99	37.4	.
218	3	100	60	96	100	75	92	36.8	.
218	6	110	80	88	100	80	112	36.8	.
218	7	.	.	.	.	.	.	.	45.50
218	12	110	70	108	110	70	112	37.5	.
218	14	100	60	96	100	60	112	37.2	46.00
218	21	110	60	100	100	60	100	36.9	45.00
218	28	120	80	92	110	60	108	36.8	44.00
219	0	110	70	92	110	80	112	37.2	53.50
219	1	110	70	90	110	75	110	37.1	.
219	3	100	60	104	100	70	120	36.7	.

FCE 20124/702 1

34

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
219	6	120	80	96	110	80	120	36.8	.
219	7	.	.	.	.	.	.	.	55.00
219	12	120	70	120	100	70	120	36.7	.
219	14	120	80	112	110	80	120	37.2	55.50
219	21	110	70	104	110	70	116	37.0	54.50
219	28	110	80	108	105	80	120	36.9	55.00
226	0	130	80	74	130	80	82	36.6	74.50
226	1	130	80	76	120	80	82	36.5	.
226	3	120	80	80	90	70	130	36.8	.
226	6	140	90	96	100	70	120	36.3	.
226	7	.	.	.	.	.	.	.	75.00
226	12	150	100	100	110	80	120	36.8	.
226	14	150	100	100	100	60	130	36.7	74.00
226	21	130	90	100	110	80	120	36.4	74.00
226	28	120	90	80	110	80	104	36.0	74.20
227	0	110	70	74	100	70	82	36.7	51.00
227	1	110	70	72	100	70	84	36.7	.
227	3	100	70	96	80	60	120	37.0	.
227	6	110	70	88	90	70	108	36.8	.
227	7	.	.	.	.	.	.	.	51.50
227	12	100	70	94	90	60	100	36.9	.
227	14	100	70	96	90	60	108	37.0	51.00
227	21	100	60	88	80	40	108	36.8	51.00
227	28	100	60	92	90	50	112	36.6	50.50
230	0	120	80	106	110	70	120	36.0	48.00
230	1	100	70	68	100	70	68	35.9	.
230	3	90	70	60	90	70	64	35.6	.
230	6	120	80	112	90	60	120	36.6	.
230	7	.	.	.	.	.	.	.	49.00
233	0	180	110	88	180	110	88	37.6	66.00
233	1	180	110	92	180	110	92	37.6	.
233	3	160	80	96	140	90	100	37.0	.
233	6	155	90	104	145	90	116	36.9	.
233	7	.	.	.	.	.	.	.	67.00
233	12	140	80	110	140	80	112	36.8	.
233	14	150	90	112	130	80	116	36.9	64.70
237	0	130	90	74	120	90	76	36.5	73.00
237	1	130	90	72	130	90	80	36.6	.
237	3	130	90	72	110	90	112	36.4	.
237	6	130	90	80	100	80	120	36.5	.
237	7	.	.	.	.	.	.	.	72.00
237	12	120	80	78	100	80	120	36.2	.
237	14	120	90	88	110	80	124	37.2	72.00
237	21	130	90	80	100	80	128	36.5	70.50
237	28	120	80	100	100	80	120	36.8	70.50

FCE 20124/702 i

35

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
238	0	120	70	72	120	60	80	36.8	53.00
238	1	110	60	72	120	60	76	36.8	.
238	3	110	60	84	80	50	108	36.7	.
238	6	120	70	84	80	50	100	36.5	.
238	7	.	.	.	.	.	.	.	53.00
238	12	100	70	92	70	50	120	37.0	.
238	14	110	60	84	90	60	100	36.5	53.00
238	21	120	70	84	100	60	100	36.4	54.00
238	28	110	60	82	90	60	100	36.5	53.50
243	0	130	80	82	130	80	86	36.6	70.00
243	1	130	75	86	130	80	88	36.6	.
243	3	130	75	86	130	75	88	36.6	.
243	6	130	75	82	130	80	86	36.7	.
243	7	.	.	.	.	.	.	.	70.00
243	9	130	75	86	130	75	88	36.6	.
243	12	130	70	82	130	75	84	36.6	.
243	14	130	70	82	130	75	84	36.6	70.10
243	21	130	70	86	130	70	86	36.7	70.80
243	28	130	70	82	130	70	82	36.6	71.00
245	0	130	70	86	130	70	88	36.6	59.10
245	1	130	70	86	130	75	86	36.7	.
245	3	130	70	82	130	70	84	36.6	.
245	6	130	70	86	130	70	88	36.6	.
245	7	.	.	.	.	.	.	.	59.00
245	9	130	70	88	130	70	90	36.6	.
245	12	130	70	82	130	70	86	36.6	.
245	14	130	70	86	130	70	88	36.6	60.10
245	21	130	70	86	130	70	88	36.7	60.70
245	28	130	70	86	130	70	88	36.6	61.10
249	0	130	60	82	130	60	84	36.6	58.00
249	1	130	65	86	130	60	86	36.6	.
249	3	130	60	82	130	60	84	36.7	.
249	6	130	60	86	130	60	88	36.6	.
249	7	.	.	.	.	.	.	.	57.80
249	9	130	60	88	130	65	90	36.6	.
249	12	130	65	86	130	60	88	36.7	.
249	14	130	70	82	130	70	86	36.6	58.00
249	21	130	70	88	125	70	86	36.6	58.40
249	28	125	70	86	130	70	88	36.6	58.80
251	0	110	80	86	110	80	88	36.7	62.50
251	1	110	80	86	110	80	88	36.7	.
251	3	110	80	86	110	80	88	36.8	.
251	6	110	82	86	110	82	86	36.8	.
251	7	.	.	.	.	.	.	.	63.00
251	9	110	80	86	110	82	86	36.8	.

485

FCE 20124/702 i

36

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
251	12	110	80	86	110	82	86	36.8	.
251	14	110	80	86	110	80	86	36.7	63.50
251	21	110	80	86	110	80	88	36.8	63.50
251	28	110	80	86	110	80	86	36.8	63.50
254	0	140	90	86	140	90	86	36.8	64.00
254	1	140	90	86	140	90	86	36.9	.
254	3	140	90	86	140	90	86	36.9	.
254	6	140	92	88	140	94	90	36.9	.
254	7	.	.	.	.	.	.	.	63.50
254	9	140	92	88	140	94	90	36.9	.
254	12	140	90	86	140	90	88	36.8	.
254	14	140	90	86	140	90	88	36.8	63.00
254	21	140	90	88	140	90	88	36.8	62.00
254	28	140	90	86	140	90	88	37.8	61.00
255	0	120	76	88	120	78	90	37.0	67.00
255	1	120	78	88	120	80	90	37.0	.
255	3	120	76	88	120	78	88	37.0	.
255	6	120	76	88	120	78	88	37.1	.
255	7	.	.	.	.	.	.	.	66.50
255	9	120	76	.	120	78	.	37.1	.
255	12	120	78	88	120	80	90	37.1	.
255	14	120	76	88	120	78	90	37.0	66.00
255	21	120	76	88	120	78	90	37.0	65.00
255	28	120	78	88	120	78	90	37.0	63.50
260	0	125	65	78	125	70	80	36.6	60.10
260	1	125	65	80	125	70	80	36.6	.
260	3	125	70	78	125	70	82	36.6	.
260	6	125	65	78	120	70	82	36.6	.
260	7	.	.	.	.	.	.	.	59.60
260	9	125	65	78	125	70	80	36.6	.
260	12	125	70	78	125	65	82	36.6	.
260	14	125	70	78	125	65	78	36.6	59.60
260	21	125	65	80	125	70	82	36.5	60.00
260	28	125	60	78	125	65	82	36.6	61.20
262	0	125	65	78	125	60	82	36.6	78.00
262	1	130	65	80	130	60	82	36.6	.
262	3	130	65	82	130	70	86	36.6	.
262	6	130	60	80	130	65	82	36.5	.
262	7	.	.	.	.	.	.	.	77.20
262	9	130	60	82	130	60	84	36.5	.
262	12	130	70	82	130	65	86	36.6	.
262	14	130	65	80	130	70	82	36.6	77.00
262	21	130	70	82	130	65	86	36.6	77.40
262	28	130	65	82	130	70	86	36.6	77.80
268	0	100	70	88	100	70	88	37.6	57.00

FCE 20124/702 i

37

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
268	1	100	70	88	100	70	90	37.7	.
268	3	100	70	88	100	70	88	37.6	.
268	6	100	70	88	100	70	88	37.6	.
268	7	.	.	.	.	.	.	.	56.80
268	9	100	70	86	100	70	88	37.0	.
268	12	100	70	88	100	70	90	37.7	.
268	14	100	70	88	100	70	90	37.7	57.00
268	21	100	70	90	100	70	90	37.8	57.20
268	28	100	70	90	100	72	90	37.7	57.30
269	0	100	70	88	100	72	88	36.8	79.50
269	1	100	72	88	100	72	90	36.9	.
269	3	100	72	90	100	74	90	36.9	.
269	6	105	72	90	105	72	92	36.9	.
269	7	.	.	.	.	.	.	.	79.00
269	9	105	70	90	105	70	92	36.6	.
269	12	105	70	90	105	70	92	36.9	.
269	14	105	70	90	105	70	90	36.9	79.00
269	21	105	72	90	105	72	90	36.8	79.00
269	28	105	72	90	105	72	90	36.8	79.40
273	0	110	70	88	110	70	90	36.8	56.50
273	1	110	70	90	110	72	90	36.8	.
273	3	110	70	90	110	72	92	36.9	.
273	6	110	70	90	110	70	92	36.9	.
273	7	.	.	.	.	.	.	.	56.70
273	9	110	70	90	110	70	92	36.8	.
273	12	110	72	90	110	72	90	36.9	.
273	14	110	72	90	112	72	90	36.8	56.90
273	21	110	72	90	112	72	92	36.9	57.20
273	28	110	70	90	110	72	90	36.8	57.30
929	0	150	90	90	150	90	90	36.6	61.00
929	1	140	80	82	145	80	84	36.6	.
929	3	150	80	88	145	80	90	36.4	.
929	6	150	90	88	150	90	90	36.6	.
929	7	.	.	.	.	.	.	.	64.00
931	0	150	80	84	145	80	84	36.3	58.00
931	1	135	80	82	140	80	84	36.2	.
931	3	130	80	76	130	80	78	36.5	.
931	6	130	80	82	135	80	82	36.6	.
931	7	.	.	.	.	.	.	.	59.50
931	12	140	80	78	140	80	80	36.2	.
931	14	135	80	80	130	75	80	36.4	61.00
931	21	120	80	76	125	80	78	36.2	63.00
931	28	130	80	78	135	80	80	36.4	62.50
932	0	130	80	76	130	80	82	36.4	74.00
932	1	135	80	82	140	80	80	36.2	.

FCE 20124/702 i

38

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
932	3	140	80	82	140	80	80	36.6	.
932	6	140	80	78	140	85	82	36.4	.
932	7	.	.	.	.	.	.	.	75.00
932	12	150	80	82	145	80	84	36.6	.
932	14	150	95	84	150	90	82	36.4	74.00
932	21	120	80	82	125	80	84	36.2	75.00
932	28	140	80	82	145	80	84	36.2	75.50
941	0	120	80	88	120	85	86	36.4	68.00
941	1	125	80	82	130	80	84	36.2	.
941	3	120	80	86	125	80	88	36.3	.
941	6	130	80	78	135	80	78	36.3	.
941	7	.	.	.	.	.	.	.	71.00
941	12	140	80	82	135	85	80	36.4	.
941	14	130	80	76	125	80	78	36.6	72.00
941	21	140	80	78	145	80	80	36.4	73.00
941	28	130	80	76	135	80	80	36.2	73.50
944	0	150	90	88	155	90	90	36.6	61.00
944	1	155	90	88	150	90	90	36.4	.
944	3	145	90	86	145	90	88	36.5	.
944	6	140	90	88	140	90	90	36.3	.
944	7	.	.	.	.	.	.	.	62.00
944	12	150	90	86	145	90	86	36.4	.
944	14	150	90	84	155	95	86	36.4	64.00
944	21	140	90	84	140	85	84	36.4	64.00
944	28	150	90	84	145	90	84	36.4	64.00
947	0	150	80	82	145	80	84	36.2	54.50
947	1	145	80	86	140	80	88	36.4	.
947	3	150	90	82	150	90	84	36.2	.
947	6	150	80	84	145	80	86	36.4	.
947	7	.	.	.	.	.	.	.	56.00
947	12	145	80	86	140	80	84	36.2	.
947	14	140	80	82	145	80	84	36.4	55.00
947	21	140	80	82	140	85	80	36.2	56.00
947	28	130	80	78	140	80	84	36.2	56.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

488



FCE 20124/702 i

39

REBOXETINE, Protocol ADE 08  
Table 5e - Vital Signs  
Treatment Group "C"

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
3	0	120	70	88	115	70	88	37.2	52.00
3	1	120	80	88	100	75	92	37.0	.
3	3	130	90	92	120	80	92	37.0	.
3	6	120	80	80	110	75	84	37.0	.
3	7	.	.	.	.	.	.	.	52.00
3	12	130	70	88	120	70	92	37.0	.
3	14	110	70	88	110	70	88	37.0	52.00
3	28	120	80	80	110	60	92	37.0	53.00
6	0	110	70	84	90	55	88	37.2	53.00
6	1	140	80	84	130	90	100	37.0	.
6	3	130	90	84	100	80	96	37.0	.
6	6	105	60	100	85	55	108	37.0	.
6	7	.	.	.	.	.	.	.	51.00
6	12	125	80	88	125	100	88	37.0	.
6	14	100	80	92	80	60	92	37.0	51.00
6	21	100	70	92	105	70	92	37.2	51.00
6	28	150	110	72	160	80	72	37.0	51.00
7	0	140	90	92	120	82	96	37.0	63.00
7	1	90	80	96	90	55	96	37.0	.
7	3	90	60	80	85	60	72	37.0	.
8	0	130	90	80	120	80	80	37.0	77.00
8	1	140	100	80	130	90	80	37.1	.
8	3	130	90	84	130	100	88	37.1	.
8	6	130	90	92	110	80	92	36.6	.
8	7	.	.	.	.	.	.	.	77.00
8	12	140	100	96	140	100	96	37.1	.
8	14	90	70	76	110	70	80	37.0	77.00
8	21	130	100	84	120	90	88	36.8	77.00
8	28	110	80	94	110	80	94	37.1	77.00
16	0	130	70	76	120	70	76	36.9	66.00
16	1	120	70	76	130	70	76	36.8	.
16	3	130	70	76	130	70	76	37.0	.
16	6	120	70	80	130	70	80	36.8	.
16	7	.	.	.	.	.	.	.	66.00
16	9	.	.	.	.	.	.	.	.
16	12	130	70	76	140	70	76	36.7	.
16	14	130	70	76	130	70	80	36.9	67.00
16	21	120	70	80	120	80	76	36.9	67.00
16	28	130	70	76	130	70	76	36.3	67.00
18	0	120	70	76	130	70	76	36.9	65.00
18	1	130	70	76	130	70	76	36.7	.
18	3	120	70	76	130	70	80	36.5	.
18	6	130	70	76	130	80	80	36.8	.
18	7	.	.	.	.	.	.	.	65.00
18	12	130	70	76	130	70	80	36.5	.

489

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

40

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
18	14	120	70	76	120	70	76	36.6	65.00
18	21	130	70	76	120	70	76	36.3	65.00
18	28	130	70	76	130	70	76	36.5	65.00
26	0	140	80	76	145	80	82	36.4	72.50
26	1	135	80	78	140	80	80	36.4	.
26	3	130	80	.	135	80	.	36.3	.
26	6	140	80	78	145	80	80	36.5	.
26	7	.	.	.	.	.	.	.	73.50
26	12	140	80	76	145	90	80	36.2	.
26	14	140	80	88	160	90	86	36.6	75.00
26	21	140	80	86	145	80	84	36.5	74.00
26	28	130	80	82	135	80	80	36.4	74.50
27	0	130	80	84	135	80	84	36.4	63.50
27	1	125	80	76	130	80	78	36.4	.
27	3	140	90	84	140	85	86	36.3	.
27	6	135	80	82	130	80	82	36.4	.
27	7	.	.	.	.	.	.	.	64.00
27	9	135	80	82	140	80	84	36.3	.
27	12	140	80	80	130	85	84	36.6	.
27	14	130	80	78	130	80	82	36.4	65.00
27	21	140	80	78	140	80	82	36.4	64.00
27	28	140	90	82	140	90	82	36.4	64.00
33	0	130	80	90	120	70	92	36.2	53.00
33	1	140	80	90	140	80	92	36.4	.
33	3	120	70	88	120	70	90	36.4	.
33	6	130	80	82	125	80	82	36.2	.
33	7	.	.	.	.	.	.	.	56.00
33	12	140	80	72	140	80	74	36.2	.
33	14	140	80	80	135	70	82	36.4	56.00
33	21	150	80	80	145	100	82	36.4	58.00
33	28	140	80	78	130	80	80	36.6	58.00
36	0	140	90	86	135	90	88	36.4	69.00
36	1	140	80	88	140	75	90	36.6	.
36	3	130	80	84	120	80	86	36.5	.
36	6	150	90	88	145	90	90	36.6	.
36	7	.	.	.	.	.	.	.	71.00
36	12	145	90	84	140	90	86	36.4	.
36	14	150	80	86	145	80	88	36.4	72.00
36	21	130	80	82	130	80	84	36.4	72.00
36	28	140	80	82	140	75	84	36.6	72.00
39	0	145	80	90	140	85	90	36.2	52.50
39	1	150	80	82	145	80	80	36.4	.
39	3	130	80	78	130	80	80	36.6	.
39	6	130	80	82	140	85	80	36.4	.
39	7	.	.	.	.	.	.	.	53.00

490

FCE 20124/702 i

41

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
39	12	140	85	80	140	80	82	36.5	.
39	14	140	80	78	145	80	80	36.4	55.00
39	21	140	80	80	140	75	82	36.5	56.00
39	28	140	70	80	135	70	82	36.4	56.00
40	0	130	80	80	125	80	82	36.2	66.50
40	1	130	80	82	120	75	84	36.6	.
40	3	140	80	78	135	80	80	36.2	.
40	6	130	80	78	135	80	82	36.4	.
40	7	.	.	.	.	.	.	.	76.00
40	9	140	80	80	140	85	82	36.4	.
40	12	130	80	78	135	80	80	36.4	.
40	14	120	70	80	120	70	82	36.4	76.00
40	21	145	85	78	140	80	80	36.4	78.00
40	28	140	80	78	140	85	80	36.4	76.00
43	0	140	80	84	135	80	86	36.4	64.00
43	1	140	80	84	135	80	86	36.4	.
43	3	120	70	80	125	70	82	36.3	.
43	6	135	80	78	130	80	80	36.4	.
43	7	.	.	.	.	.	.	.	66.00
43	9	125	80	82	120	80	84	36.4	.
43	12	130	80	78	125	80	80	36.4	.
43	14	125	80	80	130	80	82	36.4	67.00
43	21	140	80	76	135	80	78	36.2	66.00
43	28	140	80	82	140	75	84	36.2	67.00
46	0	110	80	86	105	80	88	36.4	75.00
46	1	120	80	80	120	75	82	36.4	.
46	3	130	80	80	130	80	82	36.4	.
46	6	120	80	82	125	80	84	36.5	.
46	7	.	.	.	.	.	.	.	78.00
46	12	130	80	84	135	80	86	36.4	.
46	14	140	80	82	145	80	84	36.4	78.00
46	21	140	80	84	145	80	86	36.6	79.00
46	28	140	80	80	140	85	82	36.6	77.00
52	0	140	90	78	130	85	76	36.2	65.50
52	1	140	80	84	135	80	82	36.3	.
52	3	130	80	78	130	80	77	36.2	.
52	6	135	80	78	130	80	77	36.1	.
52	7	.	.	.	.	.	.	.	65.00
52	9	140	80	82	130	80	84	36.2	.
52	12	135	85	81	135	85	84	36.2	.
52	14	130	80	76	120	80	80	36.4	65.00
52	21	140	90	76	135	85	78	36.2	65.00
52	28	140	90	80	140	90	82	36.1	65.50
53	0	145	90	82	140	90	84	36.8	84.50
53	1	140	80	82	135	80	84	36.8	.

491

FCE 20124/702 i

42

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
53	3	145	90	82	140	90	80	36.7	.
53	6	150	90	78	140	90	81	37.0	.
53	7	.	.	.	.	.	.	.	84.00
53	9	140	90	78	135	85	80	36.2	.
53	12	150	90	76	145	90	77	36.7	.
53	14	155	95	78	150	90	80	36.8	84.00
53	21	145	90	76	140	90	77	36.9	84.00
53	28	140	90	78	140	85	80	36.7	84.00
58	0	130	80	80	120	80	82	36.2	53.50
58	1	130	90	76	120	80	79	36.3	.
58	3	130	80	80	130	80	78	36.3	.
58	6	135	90	78	125	80	79	36.2	.
58	7	.	.	.	.	.	.	.	53.50
58	9	130	90	76	120	80	77	36.3	.
58	12	135	90	75	125	80	72	36.3	.
58	14	130	80	76	120	75	78	36.5	53.50
58	21	130	80	76	120	80	78	36.3	54.00
58	28	130	80	76	125	80	77	36.2	54.00
59	0	150	90	79	140	90	84	36.4	71.00
59	1	150	90	79	130	80	86	36.2	.
59	3	155	90	82	140	80	80	36.4	.
59	6	150	90	74	130	80	76	36.2	.
59	7	.	.	.	.	.	.	.	71.00
59	9	140	90	74	140	85	72	36.2	.
59	12	150	90	76	140	90	78	36.4	.
59	14	140	80	76	130	80	74	36.2	71.50
59	21	140	90	76	140	90	75	36.2	71.00
59	28	140	90	76	140	85	76	36.1	71.00
62	0	130	80	76	120	75	84	36.2	71.50
62	1	130	80	74	120	80	80	36.2	.
62	3	135	80	76	120	70	81	36.2	.
62	6	130	80	80	120	70	82	36.2	.
62	7	.	.	.	.	.	.	.	71.50
62	9	130	80	76	120	70	81	36.2	.
62	12	130	80	74	120	70	77	36.3	.
62	14	140	85	72	125	80	74	36.3	71.00
62	21	130	80	72	120	70	75	36.2	71.50
62	28	140	85	72	130	80	74	36.2	72.00
63	0	140	80	76	130	80	84	36.2	61.00
63	1	140	80	76	130	70	81	36.1	.
63	3	140	70	74	120	70	76	36.2	.
63	6	140	80	76	125	70	81	36.2	.
63	7	.	.	.	.	.	.	.	61.00
63	9	140	80	72	125	75	75	36.4	.
63	12	140	80	76	130	80	79	36.3	.

492

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

43

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
63	14	150	85	73	135	75	77	36.3	61.50
63	21	140	80	72	130	80	75	36.3	62.00
63	28	130	80	72	125	80	74	36.2	62.00
69	0	140	90	76	130	80	82	36.3	47.50
69	1	140	80	80	130	80	84	36.2	.
69	3	140	80	76	130	70	82	36.2	.
69	6	140	80	72	130	70	76	36.3	.
69	7	.	.	.	.	.	.	.	48.00
69	9	130	80	74	120	70	77	36.3	.
69	12	130	80	76	120	70	81	36.1	.
69	14	140	90	72	125	80	76	36.2	48.00
69	21	140	80	72	130	70	75	36.3	48.00
69	28	130	80	72	120	70	75	36.3	48.00
71	0	150	95	82	140	90	85	36.4	89.00
71	1	150	90	78	140	85	84	36.5	.
71	3	150	90	79	140	80	84	36.2	.
71	6	155	90	84	140	80	88	36.2	.
71	7	.	.	.	.	.	.	.	89.00
71	9	140	90	76	130	80	79	36.3	.
71	12	150	90	76	140	80	79	36.2	.
71	14	155	90	72	140	80	75	36.3	89.00
71	21	140	85	70	130	80	75	36.2	89.50
71	28	140	80	70	130	80	74	36.3	90.00
74	0	150	80	76	140	80	80	36.4	53.00
74	1	150	80	80	140	80	85	36.4	.
74	3	140	85	76	130	80	80	36.4	.
74	6	140	85	88	130	85	80	36.6	.
74	7	.	.	.	.	.	.	.	53.50
74	12	115	80	82	115	80	86	36.6	.
74	14	130	80	85	120	80	90	36.4	54.00
74	21	130	80	68	130	85	78	36.6	54.00
76	0	140	85	104	130	85	108	36.6	65.00
76	1	130	85	100	130	85	100	36.4	.
76	3	140	95	100	130	95	104	36.6	.
76	6	130	90	100	110	95	100	36.4	.
76	7	.	.	.	.	.	.	.	64.50
76	12	140	90	104	120	90	104	36.4	.
76	14	130	90	96	120	90	96	36.6	65.00
76	21	140	95	100	110	90	100	36.4	66.50
76	28	135	90	104	120	90	104	36.6	68.00
81	0	120	85	75	130	80	80	36.4	72.00
81	1	130	85	88	130	80	78	36.6	.
81	3	155	95	100	130	90	100	36.6	.
81	6	150	90	90	130	90	90	36.2	.
81	7	.	.	.	.	.	.	.	73.00

493

FCE 20124/702 i

44

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
81	9	140	90	84	13	90	88	36.5	.
81	12	100	70	90	110	70	90	36.6	.
81	14	100	70	80	110	70	80	36.8	74.50
81	21	100	65	80	110	70	76	36.5	64.60
81	28	110	70	72	105	70	76	36.6	65.00
82	0	150	100	90	145	110	96	36.6	92.50
82	1	170	105	96	150	100	86	36.5	.
82	3	130	80	68	130	80	82	36.5	.
82	6	140	95	90	130	105	80	36.4	.
82	7	.	.	.	.	.	.	.	93.00
82	9	140	90	72	140	95	72	36.6	.
82	12	150	100	72	160	100	76	36.6	.
82	14	160	105	76	150	110	72	36.8	93.50
82	21	120	80	80	110	85	80	36.6	94.00
82	28	140	90	78	140	90	78	36.6	94.00
86	0	125	85	88	110	80	92	36.4	74.50
86	1	110	80	80	110	80	92	36.6	.
86	3	145	95	78	140	95	82	36.2	.
86	6	120	90	72	120	95	80	36.4	.
86	7	.	.	.	.	.	.	.	74.50
86	9	120	90	68	120	90	72	36.4	.
86	12	125	90	64	120	90	68	36.4	.
86	14	130	90	68	130	95	72	36.4	75.00
86	21	140	90	76	120	95	84	36.2	74.00
86	28	140	90	72	140	90	72	36.4	75.30
89	0	130	80	100	150	90	100	36.6	62.70
89	1	130	80	80	120	80	84	36.4	.
89	3	105	70	84	115	80	80	36.6	.
89	6	115	80	76	120	80	80	36.6	.
89	7	.	.	.	.	.	.	.	62.70
89	9	120	80	72	115	80	80	36.6	.
89	12	120	75	92	115	80	88	36.4	.
89	14	120	70	88	115	70	92	36.6	62.50
89	21	110	80	80	115	75	84	36.4	62.00
89	28	120	70	76	110	70	84	36.4	62.50
92	0	120	80	76	125	80	86	36.4	63.00
92	1	120	80	76	130	90	86	36.4	.
92	3	130	90	72	120	85	80	36.6	.
92	6	140	85	92	140	95	100	36.8	.
92	7	.	.	.	.	.	.	.	63.00
92	9	135	80	88	140	90	92	36.5	.
92	12	140	90	76	130	90	80	36.5	.
92	14	130	85	80	130	90	84	36.6	63.00
92	21	120	85	86	130	90	90	36.5	63.50
92	28	120	80	72	120	80	76	36.4	63.50

494

FCE 20124/702 i

45

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
93	0	130	80	72	120	80	76	36.6	65.00
93	1	130	80	72	125	80	78	36.4	.
93	3	115	80	72	110	80	76	36.6	.
93	6	110	70	80	105	70	84	36.6	.
93	7	.	.	.	.	.	.	.	65.00
93	9	140	95	80	140	100	80	36.6	.
93	12	140	90	80	130	95	84	36.6	.
93	14	120	80	76	130	85	80	36.5	66.00
93	21	120	90	80	120	95	80	36.6	66.00
93	28	.	.	.	.	.	.	.	.
97	0	120	80	64	110	85	72	36.0	69.00
97	1	115	75	84	115	80	100	36.1	.
97	3	120	75	83	105	80	96	36.4	.
97	6	120	70	94	110	70	98	36.8	.
97	7	.	.	.	.	.	.	.	69.00
97	12	115	80	84	105	85	88	37.1	.
97	14	115	85	88	105	88	92	36.8	68.00
97	21	110	70	88	108	80	98	36.6	69.00
97	28	120	80	94	108	82	98	36.8	69.00
100	0	132	80	78	130	80	78	36.5	59.00
100	1	132	86	76	130	82	76	36.5	.
100	3	126	76	82	122	78	84	36.4	.
100	6	126	78	82	122	78	86	36.3	.
100	7	.	.	.	.	.	.	.	59.00
100	9	128	78	80	122	76	82	36.3	.
100	12	136	82	86	134	82	86	36.4	.
100	14	120	84	88	118	84	88	36.4	60.00
100	21	110	76	88	110	72	88	36.4	61.00
100	28	138	82	86	142	92	84	36.6	62.00
104	0	104	70	100	100	74	98	36.3	61.00
104	1	110	76	80	116	84	84	36.5	.
104	3	112	76	80	114	80	82	36.6	.
104	6	106	80	88	106	78	96	36.3	.
104	7	.	.	.	.	.	.	.	65.00
104	9	102	74	84	112	82	90	36.5	.
104	12	104	74	82	110	80	88	36.6	.
104	14	104	72	84	110	82	96	36.5	64.50
104	21	112	76	80	110	82	82	37.0	63.00
104	28	120	82	80	122	86	98	36.9	64.00
105	0	130	80	88	130	80	92	36.7	67.00
105	1	130	75	72	135	80	84	36.9	.
105	3	130	70	92	125	70	88	36.5	.
105	6	130	80	76	120	75	84	36.2	.
105	7	.	.	.	.	.	.	.	66.50
105	9	125	80	72	125	75	80	36.6	.

495

FCE 20124/702 i

46

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
105	12	130	80	72	130	75	72	36.6	.
105	14	130	80	78	125	80	86	36.2	66.30
111	0	115	70	62	110	70	76	36.2	68.50
111	1	115	80	66	115	75	68	35.9	.
111	3	110	80	72	100	75	72	35.6	.
111	6	110	80	72	105	75	80	35.2	.
111	7	.	.	.	.	.	.	.	68.00
111	9	110	80	64	110	75	68	36.1	.
111	12	110	75	62	105	75	68	35.7	.
111	14	90	60	60	90	60	68	35.0	68.00
111	21	100	75	66	95	70	74	35.6	68.00
111	28	90	60	68	90	60	72	35.8	68.00
112	0	125	80	72	115	75	80	35.7	79.50
112	1	110	80	80	110	75	84	35.0	.
112	3	110	75	76	110	70	82	35.3	.
112	6	110	70	80	105	70	84	36.0	.
112	7	.	.	.	.	.	.	.	79.00
112	9	110	75	72	105	70	78	36.0	.
112	12	110	75	72	105	70	78	35.8	.
112	14	110	75	76	100	70	84	35.8	78.60
112	21	120	80	68	110	70	72	36.9	78.00
112	28	110	75	72	105	70	76	36.1	75.00
116	0	125	75	72	120	75	76	36.5	56.00
116	1	130	85	80	120	80	80	36.4	.
116	3	135	80	72	130	80	76	36.3	.
116	6	130	80	68	120	75	72	36.4	.
116	7	.	.	.	.	.	.	.	56.00
116	9	122	75	72	115	78	76	36.3	.
116	12	125	75	72	120	75	76	36.2	.
116	14	115	70	72	115	70	76	36.5	56.00
116	21	120	80	72	120	75	76	36.4	58.00
116	28	120	80	70	120	75	74	36.4	58.00
117	0	120	90	76	115	85	80	36.4	46.50
117	1	130	85	72	120	80	76	36.6	.
117	3	125	80	76	120	70	80	36.6	.
117	6	120	75	80	115	70	84	36.7	.
117	7	.	.	.	.	.	.	.	46.50
117	9	115	80	72	110	75	76	36.3	.
117	12	125	80	72	120	75	76	36.4	.
117	14	100	70	84	95	65	88	36.5	47.00
117	21	100	70	84	95	70	88	36.4	48.00
117	28	100	70	80	95	65	88	36.7	48.00
121	0	160	90	74	150	90	74	36.5	69.00
121	1	160	90	72	170	90	80	36.7	.
121	3	140	90	78	130	90	86	36.7	.

496



FCE 20124/702 i

47

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
121	6	150	90	80	130	90	94	36.5	.
121	7	.	.	.	.	.	.	.	69.50
121	9	150	100	90	140	90	100	36.4	.
121	12	150	90	82	140	90	108	36.5	.
121	14	160	90	92	140	90	112	36.5	68.30
121	21	140	80	88	130	80	100	36.4	69.20
121	28	150	90	94	140	80	84	36.3	69.40
125	0	110	70	78	120	90	84	36.0	60.50
125	1	130	80	80	140	80	88	36.0	.
125	3	120	80	80	110	70	74	36.6	.
125	6	130	90	84	120	80	104	36.8	.
125	7	.	.	.	.	.	.	.	60.00
125	9	.	.	.	.	.	.	.	.
125	12	130	80	80	120	80	84	36.4	.
125	14	120	80	80	130	80	80	36.3	62.00
125	21	130	80	84	140	90	86	36.4	63.00
125	28	.	.	.	.	.	.	.	.
128	0	120	90	82	120	90	78	36.0	63.50
128	1	120	70	70	110	70	84	36.0	.
128	3	120	80	70	130	90	80	36.5	.
128	6	120	70	84	130	80	88	36.0	.
128	7	.	.	.	.	.	.	.	61.00
128	9	120	70	90	130	80	88	36.6	.
128	12	120	80	76	130	90	84	36.5	.
128	14	110	80	80	110	80	90	37.0	61.40
128	21	140	90	85	140	100	94	36.0	60.70
128	28	110	80	92	120	90	84	36.4	61.00
129	0	110	70	72	110	70	76	36.5	54.00
129	1	120	80	84	110	70	84	36.6	.
129	3	130	90	84	110	70	92	36.2	.
129	6	110	70	98	120	90	104	36.0	.
129	7	.	.	.	.	.	.	.	54.50
129	9	90	60	88	110	70	92	36.5	.
129	12	110	70	104	120	80	88	36.3	.
129	14	110	70	100	110	80	88	36.5	54.50
129	21	110	80	88	130	80	88	36.7	54.50
129	28	110	80	78	120	80	86	36.5	54.50
137	0	110	70	90	110	70	86	37.0	55.10
137	1	110	60	88	110	80	60	36.6	.
137	3	110	80	84	110	80	84	37.2	.
137	6	110	80	90	90	60	84	36.7	.
137	7	.	.	.	.	.	.	.	55.50
137	9	100	60	84	110	70	80	36.3	.
137	12	120	90	94	120	80	88	37.0	.
137	14	120	95	88	110	80	78	36.5	55.80

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

497

FCE 20124/702 i

48

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
137	21	120	80	92	110	80	80	36.2	55.30
137	28	120	80	84	130	90	78	36.5	54.50
138	0	130	90	84	120	100	88	36.0	62.50
138	1	160	90	93	140	110	102	36.0	.
138	3	140	90	92	130	100	96	36.6	.
138	6	130	80	92	110	90	100	36.0	.
138	7	.	.	.	.	.	.	.	63.00
138	9	110	70	92	110	70	96	36.0	.
138	12	130	90	90	120	90	106	36.8	.
138	14	140	90	100	130	90	96	36.5	63.30
138	21	140	95	100	130	90	96	36.5	63.30
141	0	110	70	70	100	70	70	36.5	62.50
141	1	110	70	66	100	70	74	36.5	.
141	3	120	70	80	120	70	82	36.3	.
141	6	130	90	76	120	80	80	36.5	.
141	7	.	.	.	.	.	.	.	61.80
141	9	120	80	80	110	70	80	36.4	.
141	12	130	90	84	120	80	88	36.6	.
141	14	120	80	76	110	70	78	36.1	62.30
141	21	110	70	80	100	60	98	36.0	63.10
141	28	110	80	80	130	100	88	35.0	63.20
145	0	110	70	69	140	100	76	35.0	67.00
145	1	110	70	68	120	80	68	35.4	.
145	3	100	50	76	110	60	80	36.0	.
145	6	90	60	60	90	70	59	36.0	.
145	7	.	.	.	.	.	.	.	67.00
145	9	110	80	70	110	70	70	36.5	.
145	12	110	70	80	100	70	80	35.9	.
145	14	100	80	70	100	80	70	35.7	68.00
145	21	120	80	70	120	70	80	36.5	67.00
145	28	120	90	80	120	90	84	36.5	67.00
173	0	130	80	86	130	80	92	36.5	77.10
173	1	130	80	88	125	80	90	36.5	.
173	3	130	80	88	125	80	92	36.6	.
173	6	125	80	86	125	80	90	36.6	.
173	7	.	.	.	.	.	.	.	77.40
173	9	125	75	88	125	80	90	36.6	.
173	12	125	80	86	125	80	90	36.6	.
173	14	125	80	88	125	80	92	36.7	77.80
173	21	125	80	88	125	80	88	36.6	78.10
173	28	125	75	88	125	75	90	36.6	78.90
174	0	125	75	88	125	75	90	36.5	71.80
174	1	125	75	88	125	70	90	36.6	.
174	3	125	75	86	125	70	88	36.6	.
174	6	125	60	88	125	60	92	36.6	.

498

FCE 20124/702 i

49

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
174	7	.	.	.	.	.	.	.	70.90
174	9	125	60	88	125	60	90	36.6	.
174	12	125	70	88	125	70	90	36.6	.
174	14	125	70	88	125	70	90	36.6	70.80
174	21	125	75	88	125	75	90	36.6	70.90
174	28	125	75	86	125	70	88	36.7	71.40
175	0	130	75	88	130	75	92	36.6	63.60
175	1	135	75	88	130	70	92	36.6	.
175	3	135	75	88	130	70	92	36.6	.
175	6	130	75	86	130	70	90	36.7	.
175	7	.	.	.	.	.	.	.	63.20
175	9	130	75	88	130	70	90	36.6	.
175	12	130	70	88	125	70	92	36.6	.
175	14	125	70	86	125	70	88	36.6	64.00
175	21	125	70	86	125	70	88	36.6	65.00
175	28	125	75	86	125	75	88	36.6	66.60
178	0	130	75	88	125	75	90	36.6	70.50
178	1	125	70	86	125	70	88	36.6	.
178	3	125	75	86	125	70	88	36.6	.
178	6	125	70	88	125	70	90	36.6	.
178	7	.	.	.	.	.	.	.	70.70
178	9	125	70	86	120	70	88	36.7	.
178	12	125	70	86	125	70	88	36.7	.
178	14	125	70	86	120	70	88	36.7	71.40
178	21	125	70	86	120	70	90	36.6	72.10
178	28	125	70	88	120	70	90	36.6	72.40
182	0	125	70	88	125	70	90	36.6	70.10
182	1	125	75	88	125	70	90	36.6	.
182	3	125	75	88	125	70	90	36.6	.
182	9	125	70	86	125	70	90	36.6	.
182	6	125	70	88	125	70	92	36.6	.
182	7	.	.	.	.	.	.	.	70.20
182	12	125	70	88	125	70	90	36.6	.
182	14	125	70	86	125	70	88	36.6	71.80
182	21	125	70	86	125	70	90	36.7	73.60
182	28	125	70	88	125	70	90	36.6	72.40
183	0	130	70	86	130	70	88	36.6	64.20
183	1	130	70	88	125	70	90	36.6	.
183	3	130	70	86	130	70	88	36.7	.
183	6	130	70	88	130	70	88	36.6	.
183	7	.	.	.	.	.	.	.	64.10
183	9	130	70	86	130	70	90	36.6	.
183	12	130	70	86	125	70	90	36.6	.
183	14	125	70	88	125	70	90	36.6	65.10
183	21	125	70	86	125	70	88	36.6	66.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

50

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
183	28	125	70	88	125	70	90	36.7	67.80
190	0	130	80	82	130	75	88	36.6	69.20
190	1	130	70	82	130	70	90	36.7	.
190	3	130	70	88	130	70	90	36.6	.
190	6	130	70	88	130	70	90	36.6	.
190	7	.	.	.	.	.	.	.	68.20
190	9	130	70	86	130	70	88	36.6	.
190	12	130	70	88	130	70	90	36.6	.
190	14	130	70	82	125	70	88	36.6	69.60
190	21	130	70	82	130	70	86	36.6	69.80
190	28	130	70	86	125	70	88	36.6	70.20
191	0	125	75	88	125	70	88	36.6	54.10
191	1	125	75	88	125	70	90	36.6	.
191	3	125	70	86	125	75	88	36.6	.
191	6	125	70	86	125	70	88	36.6	.
191	7	.	.	.	.	.	.	.	54.20
191	9	125	70	88	125	70	90	36.6	.
191	12	125	75	88	125	75	90	36.6	.
191	14	125	70	86	125	75	88	36.6	55.90
191	21	125	80	86	125	75	88	36.7	56.90
191	28	125	70	86	125	70	90	36.6	57.60
195	0	120	76	78	122	78	80	36.6	65.00
195	1	120	78	78	122	80	82	36.7	.
195	3	122	78	80	122	80	82	36.7	.
195	6	122	80	82	124	82	84	36.7	.
195	7	.	.	.	.	.	.	.	64.50
195	9	122	80	82	120	84	84	36.6	.
195	12	120	78	78	122	80	80	36.7	.
195	14	120	80	78	122	82	80	36.7	64.60
195	21	120	78	78	122	78	78	36.6	64.80
195	28	122	80	80	124	82	82	36.7	65.00
196	0	110	70	78	112	70	78	36.8	58.50
196	1	110	72	78	114	74	80	36.7	.
196	3	112	78	78	114	78	78	36.7	.
196	6	110	70	76	112	72	78	36.7	.
196	7	.	.	.	.	.	.	.	58.50
196	9	110	70	76	110	72	78	36.7	.
196	12	110	70	78	112	72	78	36.6	.
196	14	110	70	78	112	72	78	36.7	58.00
196	21	112	72	76	112	72	76	36.5	58.00
196	28	110	70	74	114	72	76	36.7	58.00
201	0	140	88	88	150	90	90	36.9	78.50
201	1	145	88	88	150	90	90	36.9	.
201	3	145	88	88	150	92	90	36.9	.
201	6	145	90	90	150	90	92	37.0	.

500

FCE 20124/702 i

51

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
201	7	.	.	.	145	.	.	.	78.00
201	9	145	90	90	145	90	92	36.9	.
201	12	145	85	88	150	88	90	36.9	.
201	14	145	86	86	148	86	88	36.8	77.50
201	21	145	85	86	150	85	88	36.9	77.50
201	28	140	85	86	145	88	88	36.9	77.50
204	0	120	70	82	120	72	84	37.0	80.00
204	1	120	70	84	125	72	84	37.1	.
204	3	120	70	82	120	72	84	37.0	.
204	6	120	70	82	120	72	84	37.0	.
204	7	.	.	.	.	.	.	.	80.50
204	9	120	70	82	120	72	82	37.0	.
204	12	120	72	84	120	72	84	37.0	.
204	14	120	70	82	120	72	84	37.0	80.50
204	21	120	70	80	120	70	82	37.0	80.50
204	28	120	70	80	120	72	82	37.0	80.50
205	0	110	80	82	110	80	82	36.5	79.50
205	1	110	80	82	110	80	82	36.6	.
205	3	110	80	82	110	80	84	36.7	.
205	6	110	80	82	110	82	84	36.9	.
205	7	.	.	.	.	.	.	.	79.00
205	9	110	80	82	110	80	82	36.8	.
205	12	110	80	82	110	80	84	36.9	.
205	14	110	80	82	110	82	82	36.7	78.00
205	21	110	80	82	110	82	84	36.6	78.00
205	28	110	80	82	110	80	82	36.6	78.00
207	0	140	90	88	140	90	88	37.0	65.50
207	1	140	90	88	140	90	88	37.0	.
207	3	140	90	88	140	92	90	36.9	.
207	6	140	90	88	140	90	88	36.9	.
207	7	.	.	.	.	.	.	.	65.50
207	9	140	90	80	140	90	80	37.0	.
207	12	140	90	88	140	90	88	37.0	.
207	14	140	90	86	140	90	86	36.9	63.00
207	21	140	90	88	140	92	90	37.0	63.50
207	28	140	90	88	140	90	88	37.0	64.00
212	0	120	80	80	124	82	82	37.0	63.50
212	1	120	80	82	120	82	82	36.9	.
212	3	124	82	84	126	84	84	37.0	.
212	6	120	80	82	124	82	84	36.9	.
212	7	.	.	.	.	.	.	.	60.00
212	9	120	80	84	124	82	84	37.0	.
212	12	120	80	82	120	82	84	36.9	.
212	14	120	82	82	122	84	84	37.0	60.00
212	21	120	80	80	120	80	82	36.9	60.00

501

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 1

52

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
212	28	120	80	82	120	80	82	36.9	60.00
213	0	100	70	86	100	72	88	36.7	79.50
213	1	100	70	86	100	70	88	36.7	.
213	3	100	70	86	100	70	88	37.7	.
213	6	100	68	86	100	70	88	36.7	.
213	7	.	.	.	.	.	.	.	79.50
213	9	100	70	86	100	70	86	36.7	.
213	12	105	72	88	105	74	90	36.9	.
213	14	106	72	88	106	72	88	36.7	79.00
213	21	100	70	84	100	70	84	36.8	79.00
213	28	100	70	84	104	72	84	36.8	79.00
220	0	120	80	72	120	80	88	36.7	63.00
220	1	120	80	72	120	80	80	36.6	.
220	3	130	80	80	120	90	108	36.8	.
220	6	140	90	88	130	90	116	36.6	.
220	7	.	.	.	.	.	.	.	62.00
220	12	160	90	80	120	90	112	36.5	.
220	14	120	80	88	110	80	104	36.8	63.00
220	21	160	100	120	130	100	126	36.5	61.00
220	28	140	90	100	140	100	120	36.8	62.00
221	0	100	70	64	90	65	68	36.4	48.50
221	1	100	70	66	95	70	68	36.5	.
221	3	110	80	76	90	60	88	37.0	.
221	6	90	70	88	90	60	108	36.4	.
221	7	.	.	.	.	.	.	.	47.50
221	12	90	60	92	.	.	116	36.5	.
221	14	90	60	88	90	60	108	37.0	46.00
221	21	90	60	100	90	60	100	36.5	49.00
221	28	90	70	100	90	65	120	36.0	49.00
225	0	110	60	64	110	60	72	36.2	52.00
225	1	110	60	60	100	50	72	36.0	.
225	3	120	80	80	100	60	120	36.6	.
225	6	120	70	96	90	50	120	36.5	.
225	7	.	.	.	.	.	.	.	52.00
225	12	120	80	80	110	80	120	36.7	.
225	14	120	80	76	100	60	120	36.8	53.00
225	21	120	80	88	110	70	96	36.5	54.00
228	0	120	70	96	110	60	110	37.0	48.00
228	1	120	70	92	100	45	116	37.2	.
228	3	.	.	.	120	60	130	36.6	.
228	6	120	60	80	100	60	100	36.0	.
228	7	.	.	.	.	.	.	.	47.50
228	12	120	60	80	110	60	92	36.2	47.00
229	0	100	60	72	90	60	80	36.6	50.00
229	1	100	70	80	100	70	84	36.8	.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

502

FCE 20124/702 i

53

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
229	3	110	80	96	110	80	110	36.8	.
229	6	110	70	98	105	75	118	37.0	.
229	7	.	.	.	.	.	.	.	50.00
229	14	110	70	104	105	70	118	37.1	49.50
229	21	110	80	100	110	80	120	36.8	50.00
229	28	115	85	96	110	85	108	36.8	51.00
234	0	140	70	100	140	70	120	37.0	51.50
234	1	140	85	82	135	85	112	36.5	.
234	3	145	85	96	125	90	136	36.8	.
234	6	120	70	108	100	80	140	37.2	.
234	7	.	.	.	.	.	.	.	51.60
234	12	115	70	80	110	80	110	37.5	.
234	14	115	70	120	115	70	128	37.0	53.00
234	21	110	80	112	110	60	130	36.6	53.50
234	28	120	80	88	100	80	108	36.6	53.00
236	0	120	80	85	120	80	100	37.1	63.00
236	3	100	70	100	100	80	120	37.2	.
236	1	120	80	80	110	80	90	37.1	.
236	6	110	70	86	100	70	120	37.0	.
236	7	.	.	.	.	.	.	.	63.40
236	12	110	80	84	100	80	124	36.5	.
236	14	120	80	88	90	80	124	36.7	63.50
236	21	100	70	96	100	70	120	36.6	63.50
236	28	110	70	88	100	80	120	37.0	63.50
239	0	100	60	70	80	60	82	36.7	52.00
239	1	100	60	70	80	60	82	36.7	.
239	3	100	60	100	80	60	120	37.0	.
239	6	100	70	100	90	70	120	36.9	.
239	7	.	.	.	.	.	.	.	52.50
239	12	100	75	90	90	60	100	36.8	.
239	14	100	80	88	80	60	96	36.8	52.50
239	21	100	60	96	90	60	112	36.5	52.50
239	28	100	70	100	90	60	100	36.5	52.50
241	0	130	80	88	125	30	90	36.6	63.10
241	1	130	75	88	130	75	88	36.6	.
241	3	130	80	86	130	75	88	36.6	.
241	6	130	75	88	130	75	90	36.7	.
241	7	.	.	.	.	.	.	.	62.00
241	9	130	75	90	130	70	88	36.6	.
241	12	130	75	86	130	70	90	36.6	.
241	14	130	70	88	130	70	90	36.6	63.10
241	21	130	70	86	130	70	88	36.6	63.80
241	28	130	70	88	130	70	90	36.6	64.00
242	0	125	70	82	125	70	86	36.6	63.20
242	1	125	70	82	125	70	86	36.6	.

503

FCE 20124/702 i

54

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
242	3	125	70	82	125	70	86	36.6	.
242	6	125	70	86	125	70	88	36.6	.
242	7	.	.	.	.	.	.	.	63.00
242	9	125	70	88	125	70	88	36.6	.
242	12	125	70	82	125	70	86	36.6	.
242	14	125	75	86	125	70	88	36.6	63.70
242	21	125	70	86	125	70	88	36.7	64.00
242	28	125	70	88	120	70	86	36.6	64.20
250	0	100	70	86	100	70	86	36.9	80.00
250	1	100	70	86	100	70	86	36.9	.
250	3	100	70	86	100	70	88	36.8	.
250	6	100	70	86	100	70	88	36.8	.
250	7	.	.	.	.	.	.	.	80.00
250	9	100	70	86	100	70	88	36.7	.
250	12	100	70	86	100	70	88	36.9	.
250	14	100	70	86	100	70	88	36.9	80.00
250	21	100	70	88	100	72	90	36.9	80.10
250	28	100	70	86	100	70	86	36.8	81.00
252	0	110	70	86	110	70	86	36.8	78.50
252	1	110	70	86	110	70	86	36.8	.
252	3	110	72	86	110	72	88	36.9	.
252	6	110	70	86	110	70	88	36.8	.
252	7	.	.	.	.	.	.	.	78.50
252	9	110	70	86	110	70	88	36.7	.
252	12	110	70	86	110	72	88	36.9	.
252	14	110	70	88	110	70	88	36.8	78.50
252	21	110	70	86	110	70	86	36.9	79.00
252	28	110	70	86	110	70	86	36.8	79.00
253	0	100	80	88	130	80	90	37.0	66.50
253	1	130	80	90	130	80	92	37.0	.
253	3	130	80	92	130	80	90	37.0	.
253	6	130	80	90	130	80	90	37.1	.
253	7	.	.	.	.	.	.	.	66.50
253	9	130	80	90	130	80	90	37.1	.
253	12	130	82	88	130	82	90	37.0	.
253	14	130	80	88	130	80	88	37.1	66.80
253	21	130	80	.	130	80	.	37.0	67.00
253	28	130	80	90	130	80	90	37.0	67.50
256	0	110	70	88	110	70	90	36.7	65.00
256	1	110	70	88	110	70	88	36.8	.
256	3	110	70	86	110	72	88	36.8	.
256	6	110	70	88	110	72	90	36.8	.
256	7	.	.	.	.	.	.	.	64.00
256	9	110	70	88	110	72	90	36.7	.
256	12	110	70	86	110	70	88	36.7	.

504



FCE 20124/702 i

55

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
256	14	110	70	88	110	72	90	36.9	63.50
256	21	110	70	88	110	72	90	36.9	63.00
256	28	110	70	88	110	72	88	36.9	63.00
261	0	130	70	82	130	75	84	36.6	75.90
261	1	130	65	80	130	65	82	36.6	.
261	3	130	70	82	130	65	84	36.6	.
261	6	130	65	82	130	65	84	36.6	.
261	7	.	.	.	.	.	.	.	75.20
261	9	130	65	86	130	65	88	36.6	.
261	12	130	70	82	130	65	86	36.6	.
261	14	130	75	80	125	165	84	36.6	75.40
261	21	130	70	78	130	65	82	36.6	75.60
261	28	160	70	80	130	70	84	36.6	75.80
264	0	130	70	80	130	65	86	36.6	78.20
264	1	130	65	80	130	60	84	36.6	.
264	3	130	70	82	130	65	86	36.6	.
264	6	130	65	82	130	70	84	36.5	.
264	7	.	.	.	.	.	.	.	78.20
264	9	130	65	86	130	65	86	36.6	.
264	12	130	65	84	130	65	82	36.6	.
264	14	130	70	80	130	65	86	36.6	78.00
264	21	130	70	82	130	65	84	36.6	77.60
264	28	130	65	82	130	60	86	36.6	77.20
265	0	125	70	80	125	70	84	36.6	80.00
265	1	125	65	80	125	65	84	36.5	.
265	3	125	70	82	125	65	82	36.6	.
265	6	125	70	82	125	65	86	36.6	.
265	7	.	.	.	.	.	.	.	79.40
265	9	125	70	86	125	70	84	36.6	.
265	12	125	70	84	125	70	86	36.6	.
265	14	125	70	82	125	65	86	36.5	78.60
265	21	125	65	82	120	65	86	36.5	79.20
265	28	125	60	82	125	65	86	36.6	79.80
266	0	120	60	82	120	60	84	36.6	59.40
266	1	120	60	82	120	60	86	36.6	.
266	3	120	60	78	120	65	84	36.5	.
266	6	120	60	80	120	60	82	36.6	.
266	7	.	.	.	.	.	.	.	59.00
266	9	120	60	82	120	60	84	36.6	.
266	12	120	65	80	120	60	84	36.6	.
266	14	125	65	80	120	60	84	36.5	59.80
266	21	120	60	82	120	60	86	36.5	60.20
266	28	120	60	80	120	65	86	36.6	60.80
272	0	140	90	92	140	92	94	37.0	61.30
272	1	140	92	110	142	94	110	.	.

505

FCE 20124/702 i

56

Pat. No.	Per. (dy)	Lying Sys.	Lying Dia.	Lying Heart Rate	Stand. Sys.	Stand. Dia.	Stand. Heart Rate	Temp.	Weight
272	3	140	92	96	145	96	98	37.1	.
272	6	140	90	92	140	90	92	36.9	.
272	7	.	.	.	.	.	.	.	60.80
272	9	140	90	90	140	90	92	36.8	.
272	12	140	90	92	140	92	92	37.0	.
272	14	140	90	90	142	90	92	37.0	60.00
272	21	140	90	90	140	90	92	36.9	59.70
272	28	140	90	90	142	90	92	36.8	59.30
927	0	140	85	80	145	80	82	36.6	56.00
927	1	140	80	84	145	80	86	36.4	.
927	3	140	80	82	145	80	80	36.4	.
927	6	135	80	76	140	80	80	36.4	.
927	7	.	.	.	.	.	.	.	57.50
927	12	150	90	80	150	90	82	36.5	.
927	14	145	80	78	140	80	80	36.5	58.00
927	21	130	80	78	125	80	84	36.6	57.00
927	28	145	80	76	140	80	82	36.4	61.00
940	0	130	80	86	130	70	88	36.2	59.00
940	1	140	85	88	140	80	88	36.4	.
940	3	150	85	84	145	80	86	36.6	.
940	6	130	80	82	120	80	86	36.6	.
940	7	.	.	.	.	.	.	.	60.00
940	12	140	70	84	140	75	88	36.6	.
940	14	135	80	76	130	80	80	36.4	62.00
940	21	140	80	78	140	82	80	36.2	61.00
940	28	130	80	82	130	70	84	36.4	62.50
943	0	145	90	88	150	90	90	36.6	69.00
943	1	140	80	86	145	80	90	36.5	.
943	3	130	85	86	130	80	92	36.5	.
943	6	140	85	84	135	80	86	36.8	.
943	7	.	.	.	.	.	.	.	70.00
943	12	140	90	86	135	80	88	36.5	.
943	14	135	80	82	130	80	84	36.6	71.00
943	21	140	85	78	140	80	80	36.6	72.00
943	28	140	90	84	140	85	86	36.6	72.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

506

FCE 20124/702 i

1

REBOXETINE Protocol ADE 08

Treatment Group "A"

Table 5f - Laboratory Data

\* = Value out-of-range

Screening (Period -01)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
1	-01	15.00	43.60	4.69	6.30	55.00	38.00	1.00	5.00
5	-01	13.80	40.90	4.58	6.40	56.00	34.00	1.00	8.00
9	-01	13.00	39.10	4.43	8.30	77.00*	12.00*	1.00	10.00*
12	-01	12.50*	37.10*	4.10	9.00*	63.00	25.00	3.00	8.00
13	-01	15.30	44.70	4.89	7.10	50.00	39.00	3.00	7.00
14	-01	16.20	48.10	5.14*	9.40*	52.00	39.00	2.00	7.00
25	-01	13.50	41.00	4.80	6.20	70.00	26.00	3.00	1.00
30	-01	13.90	36.60*	4.30*	5.30	51.00*	40.00*	3.00	6.00
34	-01	15.00	39.00	4.70	5.20	70.00	25.00	3.00	2.00
35	-01	14.80	39.00	5.00	5.20	66.00	28.00	2.00	4.00
37	-01	13.90	40.20	4.50	6.00	57.00*	32.00*	1.00	9.00*
38	-01	14.60	47.00	4.99	5.20	60.00	30.00*	4.00	4.00
45	-01	13.00	42.00	4.60	7.20	70.00	28.00	1.00	1.00
48	-01	13.90	39.00	4.60	5.90	68.00	26.00	2.00	4.00
49	-01	9.10	.45	4.60	6.70	70.00	27.00	2.00	1.00
50	-01	9.10	.45	4.70	6.70	73.00	25.00	1.00	1.00
56	-01	8.70	.45	5.30	6.00	65.00	31.00	1.00	2.00
57	-01	7.90	.41	4.01	5.90	68.00	27.00	2.00	2.00
64	-01	7.30*	.36	3.60*	5.40	55.00*	40.00	2.00	4.00
65	-01	8.20	.41	4.50	5.60	71.00	24.00*	1.00	3.00
68	-01	8.50	.48	5.60*	6.40	67.00	30.00	1.00	2.00
72	-01	8.90	.47	5.60*	6.70	70.00	26.00	1.00	3.00
73	-01	15.00	48.00	5.10	7.80	75.00*	18.00*	4.00	2.00*
75	-01	15.50	45.50	4.90	8.40	65.30	24.40	1.30	6.00
79	-01	15.50	46.20	5.13	6.27	53.30	34.90	1.90	7.30
80	-01	15.50	44.80	4.60	6.30	52.50	37.80	2.60	3.30*
85	-01	15.30	48.80*	4.92	9.28	57.60	27.60	4.70	7.50
87	-01	13.00	40.40	4.28	7.33	61.90	27.80	1.40	6.00
94	-01	16.50	50.90	5.08	7.36	56.20	32.50	1.50	7.10
96	-01	16.00	46.80	5.22	7.80	.	.	.	.
99	-01	12.10	33.50	3.90*	5.60	54.00	40.00	3.00	3.00
101	-01	14.70	40.90	4.63	4.80	46.00	51.00*	1.00	2.00
107	-01	14.30	38.10	4.67	7.40	50.00	48.00*	1.00	1.00*
108	-01	14.50	40.70	4.41	9.60	89.00*	10.00*	.00*	1.00*
109	-01	12.60	36.20*	4.37	5.60	56.00	44.00	.00*	.00*
114	-01	14.00	37.30	4.12*	4.90	46.00	46.00*	5.00	3.00
115	-01	17.60	44.40	5.11	6.70	78.00*	22.00	.00*	.00*
120	-01	12.00	33.90*	3.91*	5.70	68.00	32.00	.00*	.00*
122	-01	14.20	43.00	4.20	4.60*	49.00*	50.00*	1.00	.00*
123	-01	13.30	41.00	4.30	6.90	69.00	29.00	1.00	.00*
130	-01	12.80	40.00	4.20	5.30	61.00	38.00	1.00	.00*
131	-01	14.40	45.00	5.00	6.10	66.00	34.00	.00	.00*
134	-01	11.90*	37.00	4.07	6.40	60.00	40.00*	.00	.00*
135	-01	13.80	43.00	4.73	5.80	40.00*	60.00*	.00	.00*

FCE 20124/702 i

2

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMFS	EOSIN	MONOS
142	-01	14.70	46.00	5.06	6.80	70.00	26.00	4.00*	.00*
146	-01	15.00	48.00*	5.10	9.30	70.00	26.00	4.00*	.00*
169	-01	15.60	42.00	5.80*	6.10	60.00	30.00	3.00	6.00
171	-01	15.80	44.00	6.10	6.80	59.00	30.00	4.00*	6.00
176	-01	16.00	46.00	6.00*	5.90	61.00	30.00	2.00	6.00
177	-01	15.90	44.00	6.10	6.80	58.00	32.00	3.00	6.00
184	-01	16.00	44.00	6.20*	7.70	58.00	33.00	3.00	6.00
185	-01	16.00	44.00	6.10	7.10	60.00	30.00	3.00	7.00
189	-01	16.00	45.00	6.20*	7.10	59.00	32.00	2.00	6.00
192	-01	16.10	46.00	6.00*	7.20	59.00	32.00	2.00	6.00
194	-01	15.60	43.00	5.80	6.30	58.00	32.00	4.00*	6.00
198	-01	17.00	47.00	6.20*	6.10	56.00	34.00*	3.00	3.00
199	-01	16.00	41.00	6.40*	5.10	60.00	38.00*	6.00*	4.00
200	-01	15.80	45.00	7.00*	8.00	56.00	34.00*	3.00	4.00
208	-01	12.80*	41.00*	4.80	5.10	53.00*	37.00*	4.00*	3.00
209	-01	12.50	44.00	5.40	6.00	60.00	38.00*	6.00*	3.00
211	-01	15.30	42.00	5.40	4.80	58.00	32.00	4.00*	6.00
215	-01	13.00	39.00	5.40	6.20	56.00	34.00*	3.00	7.00
217	-01	12.80	40.00	.	5.50	57.00	36.00	2.00	5.00
222	-01	13.15	41.00	4.45	6.20	60.00	34.00	.00	5.00
223	-01	13.90	41.00	5.00	6.40	68.00	30.00	2.00	2.00
224	-01	12.65	38.00	4.44	6.05	78.00*	20.00	1.00	1.00
231	-01	16.85*	49.00	5.65*	7.50	68.00	26.00	6.00*	.00
232	-01	15.84*	46.00*	5.15*	6.60	59.00	36.00	2.00	3.00
235	-01	14.30	41.00	4.93	6.00	64.00	27.00	4.00	5.00
240	-01	13.15	43.00	4.65	6.60	55.00	37.00	5.00	2.00
244	-01	15.80	42.00	5.80*	6.00	59.00	30.00	4.00*	6.00
246	-01	16.00	44.00	6.20*	5.90	60.00	29.00	4.00*	6.00
247	-01	15.90	44.00	6.20*	5.90	60.00	29.00	4.00*	6.00
248	-01	16.00	44.00	6.30*	5.90	60.00	30.00	4.00*	6.00
257	-01	12.50	40.00	5.20	8.00	53.00*	37.00*	7.00*	3.00
258	-01	15.00	46.00	5.40	5.50	57.00	33.00	4.00*	3.00
259	-01	15.80	42.00	5.70*	6.20	57.00	33.00	6.00*	3.00
263	-01	15.80	42.00	5.80*	6.10	55.00	35.00*	3.00	4.00
267	-01	12.00	41.00*	4.60*	7.80	56.00	34.00*	6.00*	3.00
270	-01	12.50*	39.00	5.40	6.20	50.00*	40.00*	3.00	4.00
271	-01	14.20	47.00	5.20	8.10	55.00	35.00*	6.00*	2.00*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
1	-01	1.00	302.00	141.00	4.10	103.00	2.30	11.00	16.00	26.00
5	-01	1.00	261.00	143.00*	4.00	98.00	2.29	10.00	12.00	13.00
9	-01	.00	505.00*	139.00	4.50	98.00	2.39	20.00*	12.00	10.00
12	-01	1.00	480.00*	142.00	4.50	103.00	2.30	6.00	11.00	11.00
13	-01	1.00	193.00	142.00	4.10	103.00	2.43	9.00	8.00	13.00
14	-01	.00	286.00	142.00	4.30	99.00	2.48	8.00	9.00	19.00
25	-01	.00	230.00	146.00	4.60	98.00	2.30	12.00	14.00	14.00
30	-01	.00	225.00	141.00	4.50	102.00	2.48	8.00	11.00	34.00*
34	-01	.00	235.00	144.00	4.20	98.00	2.30	14.00	10.00	10.00
35	-01	.00	225.00	146.00	4.00	106.00	2.20	10.00	10.00	12.00
37	-01	1.00	250.00	140.00	4.40	98.00	2.30	14.00	16.00	16.00
38	-01	2.00*	220.00	140.00	4.00	104.00	2.30	18.00	22.00	30.00
45	-01	.00	220.00	142.00	4.90	104.00	2.40	16.00	18.00	20.00
48	-01	.00	250.00	142.00	4.30	102.00	2.30	14.00	14.00	12.00
49	-01	.00	174.00	141.00	4.00	101.00	2.30	11.00	13.00	9.00
50	-01	.00	191.00	141.00	4.30	102.00	2.20	11.00	9.00	8.00
56	-01	1.00	194.00	141.00	3.80	100.00	2.50	14.00	15.00	31.00*
57	-01	1.00	190.00	138.00	3.90	101.00	2.90*	10.00	12.00	30.00*
64	-01	.00	270.00	144.00	4.00	101.00	2.40	15.00	24.00*	36.00*
65	-01	1.00	156.00	141.00	4.10	101.00	2.50	12.00	10.00	31.00*
68	-01	.00	205.00	136.00*	3.80	103.00	2.60	12.00	14.00	31.00*
72	-01	1.00	204.00	137.00*	3.90	101.00	2.50	12.00	14.00	28.00
73	-01	1.00	280.00	148.00	4.00	102.00	9.40	17.00	14.00	14.00
75	-01	1.40	258.00	146.00	4.80	98.00	8.10	15.00	16.00	10.00
79	-01	.90	210.00	141.00	4.00	110.00	9.40	13.00	16.00	13.00
80	-01	1.40	259.00	145.00	4.40	110.00	9.70	21.00	48.00*	27.00
85	-01	1.30	293.00	136.00	3.60	108.00	9.90	27.00	23.00	55.00*
87	-01	1.00	283.00	143.00	4.00	106.00	9.30	21.00	20.00	9.00
94	-01	1.10	276.00	141.00	4.40	101.00	9.00	10.00	20.00	51.00*
96	-01	.	.	145.00	4.70	104.00	9.10	19.00	32.00	25.00
99	-01	.00	160.00	138.00	3.70	100.00	7.10*	20.00	21.00	27.00
101	-01	.00	356.00*	142.00	4.20	102.00	8.80	25.00	28.00	61.00*
107	-01	.00	360.00	137.00	4.60	115.90*	8.20	35.00*	37.00	28.00
108	-01	.00	170.00	143.20	4.39	108.20	8.60	20.00	17.00	22.00
109	-01	.00	341.00	140.00	4.60	112.80*	8.70	32.00	45.00	14.00
114	-01	.00	177.00	171.00	4.10	103.00	8.20	23.00	36.00	15.00
115	-01	.00	269.00	146.00	5.10	110.20*	9.50	25.00	29.00	26.00
120	-01	.00	238.00	135.00	3.70	104.00	9.00	10.00	13.00	7.40
122	-01	.00	271.00	137.00	3.90	340.00	9.50	15.00	15.00	7.00
123	-01	1.00	294.00	138.00	4.00	358.00	9.80	26.00	24.00	15.00
130	-01	.00	255.00	137.00	3.90	352.00	9.40	17.00	7.00	7.00
131	-01	.00	225.00	136.00	4.20	359.00	9.80	23.00	26.00	17.00
134	-01	.00	187.00	135.00	3.60*	351.00	9.80	15.00	12.00	9.00
135	-01	.00	224.00	137.00	3.50*	343.00	9.40	27.00	30.00	21.00
142	-01	.00	278.00	136.00	3.70	352.00	10.40	13.00	14.00	17.00
146	-01	.00	155.00	131.00*	3.90	124.00*	8.90	19.00	20.00*	16.00
169	-01	1.00	255.00	139.00	4.90	98.00	8.90	39.00	9.80	8.10
171	-01	1.00	275.00	141.00	5.20	97.00	9.10	38.00	9.70	8.00*
176	-01	1.00	270.00	138.00	5.10	97.00	9.00	38.00	9.90	8.00
177	-01	1.00	270.00	138.00	4.70	98.00	9.10	37.00	9.20	8.20*
184	-01	.00	280.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20*
185	-01	.00	270.00	138.00	4.90	100.00	9.20	38.00	10.00	8.10*
189	-01	1.00	270.00	140.00	5.10	98.00	9.00	38.00	9.70	8.10*
192	-01	1.00	275.00	138.00	5.10	98.00	9.20	37.00	9.80	8.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

4

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
194	-01	.00	270.00	145.00	4.80	98.00	9.20	31.00	18.00	30.00
198	-01	3.00*	276.00	142.00	5.10	108.00*	8.30*	15.00	25.00	25.00
199	-01	2.00*	295.00	132.00*	4.90	97.00	9.10	30.00	18.00	32.00
200	-01	3.00*	280.00	145.00	3.80	100.00	8.80	32.00	28.00	34.00
208	-01	3.00*	150.00	142.00	5.30	104.00	9.90	44.00	32.00	26.00
209	-01	2.00*	180.00	138.00	5.10	104.00	10.00	50.00	38.00*	25.00
211	-01	.00	270.00	145.00	4.70	97.00	9.10	30.00	18.00	30.00
215	-01	.00	300.00	144.00	5.10	100.00	10.00	25.00	28.00	40.00
217	-01	.00	.	142.00	4.60	99.00	9.90	15.00	11.20	13.00
222	-01	1.00	260.00	144.00	4.60	97.00	9.30	21.00*	16.00	46.00*
223	-01	.00	260.00	141.00	3.70	99.00	9.25	18.00	35.00*	53.00*
224	-01	.00	350.00	141.00	4.10	104.00	9.80	12.00	5.00	37.00*
231	-01	.00	380.00	141.00	4.60	96.00	9.10	18.00	11.00	22.00
232	-01	.00	450.00*	141.00	4.20	96.00	8.90	18.00	7.00	35.00*
235	-01	.00	290.00	138.00	4.00	94.00*	9.91	10.00	4.00	8.00
240	-01	1.00	315.00	132.00*	3.70	98.00	8.90	17.00	6.00	12.00
244	-01	1.00	285.00	139.00	4.80	99.00	8.80	39.00	9.80	8.10
246	-01	1.00	275.00	138.00	4.90	97.00	8.80	38.00	9.70	8.10*
247	-01	1.00	270.00	138.00	4.80	97.00	8.70	39.00	9.70	8.00
248	-01	.00	275.00	139.00	4.90	96.00	8.80	39.00	9.80	8.00*
257	-01	.00	185.00	142.00	5.30	105.00	9.60	26.00	29.00	42.00
258	-01	3.00*	275.00	140.00	5.00	105.00	8.20*	16.00	22.00	23.00
259	-01	1.00	250.00	148.00	5.10	103.00	8.60	36.00	26.00	32.00
263	-01	3.00*	300.00	140.00	5.20	103.00	9.10	27.00	36.00*	34.00
267	-01	1.00	250.00	138.00	5.20	118.00*	8.90	35.00	39.00*	26.00
270	-01	3.00*	300.00	142.00	5.40*	102.00	9.10	27.00	29.00	38.00
271	-01	.00	320.00	142.00	4.00	104.00	8.50*	30.00	32.00*	35.00

FCE 20124/702 i

5

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
1	-01	4.85	.97	121.00	2.90*	82.00	.34	8.00	2.60
5	-01	5.06	1.34	210.00*	4.10	93.00	.10*	10.00	2.40
9	-01	5.36	1.47*	92.00	3.20	88.00	.30	16.00	4.80*
12	-01	4.68	1.54*	74.00	3.00	72.00	.19	15.00	4.00
13	-01	4.18	1.16	98.00	4.10	95.00	.20	7.00	1.40
14	-01	4.73	1.28	89.00	2.90*	96.00	.39	6.00	1.90
25	-01	3.60	1.20	88.00	4.00	70.00	280.00	10.00	.00
30	-01	5.20	1.40	207.00	6.20	75.00	380.00	12.00	.00
34	-01	3.90	.90	108.00	4.60	70.00	230.00	8.00	.00
35	-01	4.00	1.50	108.00	5.00	70.00	200.00	12.00	.00
37	-01	5.30	1.40	170.00	3.60	70.00	260.00	8.00	.00
38	-01	4.20	1.30	200.00	1.90*	60.00	200.00	14.00	.00
45	-01	5.40	1.40	188.00	7.00	80.00	300.00	12.00	.00
48	-01	4.00	1.20	102.00	4.60	68.00	280.00	10.00	.00
49	-01	4.10	.90	27.00	9.00*	101.00*	83.00*	12.00	.00
50	-01	4.70	1.07	23.00	6.00	86.00	124.00*	12.00	.00
56	-01	4.10	1.10	27.00	8.00	80.00	146.00	14.00	.00
57	-01	4.10	1.00	24.00	8.00	91.00	157.00	11.00	.00
64	-01	5.10	.90	25.00	4.00	105.00*	141.00*	10.00	.00
65	-01	4.40	1.10	25.00	5.00	82.00	150.00	15.00	.00
68	-01	4.80	1.10	30.00	4.00	81.00	160.00	12.00	.00
72	-01	4.60	.90	27.00	5.00	62.00	154.00	11.00	.00
73	-01	68.00*	3.30	116.00	14.00	1.10	3.50	.54	.14
75	-01	84.00	5.40*	94.00	17.70	.90	3.90	.40	.10
79	-01	75.00	3.30	84.00	11.30	1.10	5.50	.70	.20
80	-01	81.00	3.70	82.00	15.10	1.00	4.50	.60	.30
85	-01	74.00	3.60	79.00	18.80	1.00	4.10	.80	.30
87	-01	79.00	2.70	87.00	21.00	.90	2.10*	.70	.10
94	-01	118.00*	3.00	112.00	10.40	1.20	8.00*	.60	.20
96	-01	86.00	4.10	76.00	18.60	1.10	4.00	1.10*	.10
99	-01	97.00	1.70*	181.00	25.00	.50	3.60	.30	.04
101	-01	75.00	3.00	161.00	36.00	.70	1.70*	.44	.08
107	-01	87.00	3.40	142.00	30.00	.70	3.50	.74	.10
108	-01	97.00	3.00	151.00	37.00	.90	2.40	.53	.07
109	-01	110.00	3.10	243.00	46.00	.50	2.40	.53	.06
114	-01	89.00	2.90	259.00	51.00*	.70	4.00	.47	.05
115	-01	76.00	4.20	143.00	27.00	.80	2.30*	.70	.08
120	-01	71.00	3.70	78.00*	29.00	.50	1.20*	.40	.03
122	-01	83.00	3.50	84.00	27.00	.90	3.80	.50*	.20*
123	-01	79.00	3.60	94.00*	25.00	.70*	4.90	.90	.40*
130	-01	90.00	3.60	68.00	28.00	.80	4.10	.60	.20*
131	-01	95.00	3.60	89.00	37.00	1.10	6.60	1.10	.50*
134	-01	101.00	3.30	55.00	27.00	.70*	5.30	.60	.30*
135	-01	99.00	2.90	113.00*	18.00*	.60*	4.40	.50*	.20*
142	-01	89.00	3.50	65.00	23.00	.50*	5.30	1.00	.50*
146	-01	86.00	3.30	20.00	23.00	1.20	4.20	.10*	.10
169	-01	97.00	3.80	170.00	11.20	1.00	4.20	.70	.40
171	-01	97.00	3.80	172.00	11.10	1.10	4.40	.80	.40
176	-01	92.00	4.00	172.00	11.10	1.00	4.70	.70	.40
177	-01	95.00	4.20	180.00	11.00	.99	4.80	.70	.40
184	-01	95.00	4.00	179.00	11.00	1.00	5.30	.70	.40
185	-01	96.00	3.90	170.00	11.10	1.10	5.60	.80	.50
189	-01	98.00	4.00	177.00	11.20	.98	5.20	.70	.40
192	-01	97.00	4.00	170.00	11.20	.99	5.70	.70	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

6

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
194	-01	95.00	3.70	130.00	11.30	.77	4.80	.90	.30
198	-01	110.00	4.10	128.00	11.50	.90	5.30	1.00	.40
199	-01	102.00	3.80	128.00	10.40	.65	5.20	1.20*	.30
200	-01	80.00	4.20	120.00	9.50	.78	5.00	.85	.10
208	-01	92.00	3.90	80.00	18.00	.87	5.20	.90	.40
209	-01	90.00	3.80	128.00	42.00*	1.30	5.30	.80	.50
211	-01	95.00	3.60	130.00	11.20	.76	4.70	.80	.20
215	-01	80.00	3.80	120.00	18.00	.80	4.60	.60	.40
217	-01	4.40	4.09	22.54	22.00	57.46	3.90	8.89	4.27*
222	-01	5.66	3.17	42.25	16.00*	68.06	3.50	9.40	3.42
223	-01	7.15*	3.08	49.59	29.00	101.66	4.60	11.11	3.42
224	-01	4.53	3.60	21.71	24.00	66.30	3.80	9.06	3.42
231	-01	5.50	2.70	24.91	21.00	119.34	6.80	12.48	2.73
232	-01	4.40	2.70	29.22	21.50	97.24	3.20	15.39	6.84*
235	-01	5.06	3.63	24.11	18.00*	97.24	3.30	11.62	5.13*
240	-01	4.67	3.83	34.24	19.00*	88.40	5.10	6.84	3.42
244	-01	90.00	3.70	170.00	11.20	1.10	5.40	.70	.40
246	-01	88.00	3.70	178.00	11.00	1.10	5.70	.60	.40
247	-01	90.00	3.70	170.00	11.10	1.00	5.20	.70	.40
248	-01	95.00	3.70	170.00	11.20	1.00	4.70	.70	.40
257	-01	90.00	3.60	125.00	19.00	.70	4.10	.70	.40
258	-01	105.00	4.00	127.00	10.00	.80	5.20	.20	.30
259	-01	110.00	3.70	126.00	13.00	.81	5.30	.80	.20
263	-01	112.00*	3.80	118.00	20.00	.80	4.80	.80	.20
267	-01	95.00	3.60	128.00	14.00	.82	5.20	1.20*	.80*
270	-01	85.00	3.80	118.00	18.00	.80	4.60	.80	.40
271	-01	100.00	3.70	120.00	16.00	.80	4.30	.90	.10

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

7

Pat. No.	Per. (dy)	TOTPROT	HLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
1	-01	60.00	35.80*	4.90	1.56	2.20	5.80*	7.40*	8.80*
5	-01	72.00	40.50*	4.50	1.30	2.70	6.80	9.10	12.90
9	-01	68.00	38.80*	3.90	.80	3.30	6.50	8.90	10.50*
12	-01	59.00*	35.90*	4.80	.99	2.20	5.00*	7.80*	8.10*
13	-01	68.00	41.80*	4.20	.42	2.30	6.00	8.20	9.70*
14	-01	70.00	42.60*	6.20	1.83	2.60	6.10	9.70	9.00*
25	-01	66.00	38.00	3.90	.80*	3.00	8.00	9.20	14.00
30	-01	70.00	40.00	6.20	1.30	4.60*	3.00	13.00*	16.00
34	-01	70.00	40.00	4.00	1.00	2.80	7.00	9.00	13.80
35	-01	78.00	36.00	4.40	1.50	3.40	8.00	10.00	14.00
37	-01	70.00	42.00	5.50	1.10	3.00	8.80	8.90	14.00
38	-01	70.00	40.00	5.50	1.20	3.40	8.00	9.20	14.00
45	-01	64.00	40.00	4.90	1.30	4.00*	8.80	11.60	17.00
48	-01	72.00	38.00	4.80	1.10	2.80	8.00	9.00	14.00
49	-01	68.00	50.00*	4.30	1.30	1.30*	5.10*	5.30*	8.00*
50	-01	69.00	46.00	4.90	1.30	1.90*	5.00*	5.30*	8.70*
56	-01	74.00	39.00	4.70	1.30	2.50	7.50	9.10	15.90
57	-01	71.00	41.00	4.10	1.10	1.30*	8.70	8.20	12.80
64	-01	64.00	39.00	7.40*	1.70	1.70*	6.80	7.00*	10.00*
65	-01	77.00	46.00	4.50	1.20	1.50*	5.90*	9.10	14.50
68	-01	70.00	41.00	4.70	1.80*	2.70	6.30*	8.00*	12.00*
72	-01	72.00	47.00	4.30	1.70	2.90	8.10	9.20	14.10
73	-01	7.00	3.43*	237.00*	195.00*	3.00	11.00	11.00	18.00
75	-01	6.70	4.40	227.00*	103.00	3.31	11.76	14.70	13.20
79	-01	6.50	4.60	291.00*	135.00	.	.	.	.
80	-01	7.00	4.40	274.00*	222.00*	2.14*	8.64	13.93	12.52
85	-01	7.10	4.50	196.00	109.00	2.32*	10.26	13.48	14.11
87	-01	7.60	4.70	217.00	126.00	1.90*	10.39	12.65	17.90
94	-01	7.50	4.60	360.00*	.	.	.	.	.
96	-01	7.70	4.60	222.00*	194.00*	.	.	.	.
99	-01	6.00*	55.70*	121.00*	185.00*	4.20	15.50*	12.50	15.10
101	-01	7.20	57.80	270.00*	69.00	4.30	10.80	11.90	15.20
107	-01	7.50	60.60	195.00	257.00*	3.20	8.50	14.50*	13.20
108	-01	7.20	63.80	270.00*	108.00	4.00	9.70	10.40	12.10
109	-01	7.50	53.30*	330.00*	104.00	3.30	13.00*	13.10	17.30
114	-01	7.00	53.30*	197.00	225.00*	2.60	8.20	16.70*	19.20
115	-01	6.90	58.50	182.00	160.00	2.70	10.90	13.50	14.40
120	-01	7.20	61.60	201.00	60.00	3.20	8.20	12.40	14.40
122	-01	7.10	4.40	206.00	221.00*	4.00	9.90	15.60*	13.80
123	-01	7.80	4.00	138.00	180.00	3.60	4.40*	15.20*	12.10
130	-01	7.70	3.90	147.00	84.00	1.70*	8.80*	9.70	16.00
131	-01	7.20	4.60	253.00	173.00	2.10*	9.40	10.70	11.20
134	-01	8.00	4.40	167.00	79.00	2.30*	7.30*	11.20	16.00
135	-01	6.60	3.70*	229.00	215.00*	1.70*	6.10*	12.10*	16.40
142	-01	8.40	5.40*	150.00	134.00	1.20*	8.80*	8.50	9.10*
146	-01	7.00	5.50	218.00	25.00	10.00*	12.00	16.00	19.00
169	-01	9.80*	4.20	210.00	95.00	.30	.70	.90	1.20
171	-01	8.70*	4.20	192.00	88.00	.32	.72	.91	1.10
176	-01	8.80*	4.70	190.00	88.00	.40	.70	.90	1.40
177	-01	8.70*	4.30	195.00	88.00	.34	.81	.98	1.10
184	-01	8.80*	4.60	195.00	90.00	.35	.75	.92	1.30
185	-01	6.70	5.00	200.00	90.00	.35	.75	.96	1.30
189	-01	8.70*	4.50	190.00	88.00	.41*	.72	.90	1.40
192	-01	6.70	5.10	190.00	92.00	.41*	.72	.99	1.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

8

Pat. No.	Per. (dy)	TOTPROT	HLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
194	-01	6.80	4.30	180.00	98.00	.30	.70	.80	1.40
198	-01	7.00	6.50*	205.00	130.00	.40	.70	.90	1.10
199	-01	7.40	4.80	150.00	120.00	.20	.80	.90	1.40
200	-01	6.30*	4.30	195.00	110.00	.40	.80	.70	1.40
208	-01	6.90	5.30	180.00	98.00	.30	.60	.80	1.30
209	-01	8.40*	5.40	220.00	160.00*	.20	.60	.80	.80
211	-01	6.70	4.20	180.00	96.00	.30	.70	.70	1.40
215	-01	7.00	5.00	160.00	100.00	.40	.90	.90	1.30
217	-01	6.55	4.20	5.98	210.00*	.	.	.	.
222	-01	6.85	4.60	5.95	58.00	.15*	.63	1.04	1.02
223	-01	7.90	4.53	6.76	86.00	.17*	.67	1.03	1.50*
224	-01	6.90	4.50	4.42	108.00	.21	.65	.85	1.31*
231	-01	7.10	4.28	4.94	189.00*	.18*	.43*	.98	1.23
232	-01	6.80	3.58	5.46	174.00	.41*	.53*	1.05	1.23
235	-01	7.50	4.28	4.81	98.00	.20	.59*	1.06	1.37*
240	-01	7.40	3.89	4.55	98.00	.17*	.56*	1.00	1.78*
244	-01	7.30	4.40	172.00	89.00	.34	.72	1.00	1.30
246	-01	7.20	4.40	200.00	80.00	.32	.75	1.10	1.40
247	-01	7.70	4.20	180.00	80.00	.33	.72	.99	1.20
248	-01	7.50	4.40	190.00	92.00	.33	.74	1.10	1.40
257	-01	7.00	5.10	180.00	104.00	.40	.70	.70	1.00
258	-01	6.80	6.40*	200.00	130.00	.30	.87	.80	1.10
259	-01	7.00	4.20	200.00	130.00	.30	.60	.90	1.10
263	-01	7.20	4.60	160.00	104.00	.30	.70	1.20*	1.10
267	-01	5.20*	4.10	210.00	130.00	.40	.60	.80	1.10
270	-01	7.30	4.30	162.00	105.00	.40	.80	1.20*	1.10
271	-01	8.00	5.10	164.00	110.00	.20	.60	.80	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

9

Pat. No.	Per. (dy)	T3	T4	SPBGRV	URALB	URSUG	URRBC	URWBC
1	-01	6.40	13.00	.	.	.	.	.
5	-01	7.80	17.00	.	.	.	.	.
9	-01	6.00	16.00	.	.	.	.	.
12	-01	5.30	18.00	.	.	.	.	.
13	-01	4.20	14.00	.	.	.	.	.
14	-01	5.70	14.00	.	.	.	.	.
25	-01	.90	96.00	1.022	0	0	0	0
30	-01	1.10	151.00	.	0	0	0	0
34	-01	1.00	110.00	1.022	0	0	0	0
35	-01	.90	80.00	1.024	0	0	0	0
37	-01	.90	70.00	1.022	0	0	0	0
38	-01	1.00	110.00	1.024	0	0	0	0
45	-01	.90	76.00	1.024	0	0	0	0
48	-01	.92	74.00	1.024	0	0	0	0
49	-01	1.01	83.00	1.020	0	0	0	0
50	-01	1.01	84.00	1.032*	0	0	0	0
56	-01	1.02	84.00	1.019	0	0	0	0
57	-01	.91	102.00	1.026	0	0	0	0
64	-01	1.03	73.00	1.018	0	0	0	0
65	-01	1.02	101.00	1.026	0	0	0	0
68	-01	.91	87.00	1.029	0	0	0	0
72	-01	.97	69.00	1.021	0	0	0	0
73	-01	87.00	7.00	1.015	0	0	0	0
75	-01	88.00	7.10	1.022*	0	0	0	0
79	-01	.	.	1.023*	0	0	0	0
80	-01	91.00	8.00	1.021*	1*	0	0	10*
85	-01	151.00	9.80	1.028*	0	0	0	0
87	-01	121.00	9.70	1.026*	0	0	0	0
94	-01	108.00	7.90	1.015	0	0	0	0
96	-01	102.00	10.10	1.030*	0	0	0	0
99	-01	126.00	7.00	1.019	0	0	0	0
101	-01	143.00	9.20	1.018	0	0	0	0
107	-01	132.00	7.30	1.015	0	0	0	0
108	-01	118.00*	12.20	1.012	0	0	0	0
109	-01	151.00	7.00	1.024	0	0	0	0
114	-01	124.00	5.80	1.016	0	0	0	0
115	-01	198.00	10.00	1.018	0	0	0	0
120	-01	149.00	6.80	1.004	0	0	0	0
122	-01	94.00	6.50	1.020	0	0	0	1
123	-01	105.00	11.60	1.015	0	0	0	1
130	-01	112.00	12.00	1.025	0	0	1	3
131	-01	133.00	12.50*	1.070	0	0	0	1
134	-01	102.00	5.40*	1.025	0	3*	0	8*
135	-01	142.00	12.90*	.	.	.	.	.
142	-01	.	.	1.028	0	0	2	5
146	-01	127.00	12.40	1.020	0	0	0	3
169	-01	110.00	7.60	1.010	0	0	0	4
171	-01	109.00	7.70	1.015	0	0	0	2
176	-01	110.00	7.70	1.020	0	0	0	4
177	-01	115.00	7.80	1.020	0	0	0	2
184	-01	110.00	7.50	1.020	0	0	0	4
185	-01	110.00	7.50	1.012	0	0	0	4
189	-01	110.00	7.30	1.015	0	0	0	4
192	-01	110.00	7.50	1.015	0	0	0	2

FCE 20124/702 i

10

Pat. No.	Per. (dy)	T3	T4	SPEGRAV	URALB	URSUG	URRBC	URWBC
194	-01	120.00	8.40	1.018	0	0	3	0
198	-01	130.00	5.10	1.020	0	0	2	4
199	-01	118.00	8.60	1.018	0	0	2	1
200	-01	120.00	8.40	1.016	0	0	3	4
208	-01	118.00	8.60	1.016	0	0	1	5
209	-01	120.00	10.20	1.020	0	0	1	5
211	-01	120.00	8.20	1.016	0	0	.	2
215	-01	150.00	9.20	1.018	0	0	1	3
217	-01	1.28	10.20	1.016	0	0	2	5
222	-01	1.60	6.30	1.018	0	0	0	3
223	-01	.93	7.70	1.027	0	0	0	5
224	-01	1.45	6.60	1.010*	0	0	2	2
231	-01	1.36	3.36*	1.018	0	0	0	3
232	-01	1.02	6.25	1.013*	0	0	1	2
235	-01	.99	6.90	1.015	0	0	1	3
240	-01	1.05	5.30	1.015	0	0	0	2
244	-01	110.00	7.70	1.015	0	0	0	2
246	-01	114.00	7.70	1.010	0	0	0	2
247	-01	110.00	7.60	1.012	0	0	0	2
248	-01	112.00	7.70	1.020	0	0	0	0
257	-01	153.00	9.30	1.020	0	0	1	2
258	-01	127.00	5.30	1.016	0	0	1	3
259	-01	116.00	5.10	1.005	0	0	2	2
263	-01	150.00	4.40*	1.020	0	0	2	4
267	-01	120.00	3.20*	1.018	0	0	2	3
270	-01	150.00	4.40*	1.018	0	0	1	4
271	-01	150.00	9.10	1.022	0	0	2	3

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

11

Treatment Group "A"  
Screening (Period -01)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	81	7
Hematocrit (HCT)	81	9
Red Blood Cells (RBC)	80	25
White Blood Cells (WBC)	81	3
Neutrophils (NEUTS)	80	13
Lymphocytes (LYMPS)	80	24
Eosinophils (EOSIN)	80	22
Monocytes (MONOS)	80	18
Basophils (BASOS)	80	9
Platelets (PLATES)	79	4
Sodium (NA+)	81	6
Phosphorous (K+)	81	3
Chlorine (CL-)	81	7
Calcium (CA++)	81	5
Aspartate Aminotransferase (SGOT)	81	3
Alanine Aminotransferase (SGPT)	81	8
γ-GT (YGT)	81	20
Blood Sugar (BLSUG)	81	4
Phosphorous (PO4)	81	4
Alkaline Phosphatase (ALKPHOS)	81	4
Urea Nitrogen (BUN)	81	10
Creatinine (CREAT)	81	6
Uric Acid (URACID)	81	9
Total Bilirubin (TOTBILI)	81	6
Direct Bilirubin (DIRBILI)	81	12
Total Protein (TOTPROT)	81	11
Albumin (BLALB)	81	15
Cholesterol (CHOLE)	81	11
Triglycerides (TRIGLY)	80	12
Globulins - α1 (GLOBAL)	77	23
Globulins - α2 (GLOBA2)	77	17
Globulins - β (GLOBETA)	77	14
Globulins - γ (GLOGAMA)	77	14
Thyroxine T3 (T3)	79	1
Thyroxine T4 (T4)	79	7
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	73	9
Albumin (URALB)	74	1
Sugar (URSUG)	74	1
Red Blood Cells (URRBC)	74	0
White Blood Cells (URWBC)	74	2

517

FCE 20124/702 i

\* = Value out-of-range

12

Day 7 (Period 072)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
1	072	16.30	48.90	4.98	6.60	53.00	33.00	2.00	11.00*
5	072	12.90*	37.20*	4.24	6.60	59.00	34.00	2.00	4.00
9	072	13.30	41.10	4.57	5.20	47.00*	38.00	8.00*	6.00
12	072	11.90*	35.40*	3.98*	8.60*	71.00*	20.00	2.00	7.00
13	072	15.10	45.80	4.90	7.00	53.00	31.00	2.00	13.00*
14	072	15.80	46.70	5.09*	8.40*	60.00	30.00	4.00*	5.00
25	072	14.00	42.00	4.90	5.00	66.00	28.00	4.00	1.00
30	072	14.00	36.80*	4.40*	5.50	50.00*	41.00*	2.00	7.00
34	072	14.80	41.00	4.90	5.80	68.00	28.00	2.00	2.00
35	072	14.60	40.00	5.10	5.00	66.00	29.00*	1.00	5.00
37	072	14.20	40.40	4.60	6.20	60.00	32.00*	1.00	1.00
38	072	14.40	46.00	4.80	5.30	62.00	28.00	5.00*	4.00
45	072	13.20	43.00	4.20*	7.20	72.00	26.00	2.00	.00*
48	072	14.00	41.00	4.70	5.80	66.00	28.00	3.00	4.00
49	072	8.90	.45	4.70	6.30	59.00*	39.00	1.00	1.00
50	072	9.30	.43	4.10	7.90	72.00	26.00	1.00	1.00
56	072	9.10	.49	5.10	6.30	65.00	29.00	2.00	4.00
57	072	8.00	.41	4.08	5.80	70.00	27.00	2.00	1.00
64	072	7.50	.32*	3.80*	5.30	57.00*	39.00	2.00	1.00
65	072	8.60	.42	4.70	5.20	69.00	24.00*	2.00	4.00
68	072	8.30	.46	5.50	6.00	66.00	29.00	1.00	4.00
72	072	8.70	.47	5.40	6.30	71.00	25.00	1.00	3.00
99	072	13.30	38.90	4.53	7.60	52.00	44.00	1.00	3.00
101	072	11.70*	32.90*	3.76*	5.20	54.00	45.00	1.00	.00*
107	072	12.50	33.30*	3.94*	7.00	63.00	36.00	1.00	.00*
108	072	14.30	37.40	4.32	4.80	65.00	35.00	.00*	.00*
109	072	12.60	36.30*	4.32	5.60	57.00	42.00	.00*	1.00*
114	072	14.30	37.00	4.30	5.00	50.00	47.00*	.00*	3.00
115	072	14.10	42.80	4.92	7.00	77.00*	20.00	1.00	2.00
120	072	12.80	33.30*	3.98*	5.90	61.00	39.00	.00*	.00*
122	072	15.40	47.00	5.10	5.00	50.00*	47.00*	3.00*	.00*
123	072	13.60	42.00	4.10	7.90	68.00	30.00	2.00	.00*
131	072	14.70	46.00	5.06	5.00	62.00	36.00	1.00	1.00*
134	072	11.50*	36.00*	3.96*	5.60	40.00*	60.00*	.00	.00*
135	072	13.10	41.00	4.51	5.20	40.00*	52.00*	6.00*	2.00*
142	072	14.40	45.00	4.95	6.70	77.00*	23.00	.00	.00*
146	072	14.70	44.00	5.20	7.20	58.00*	35.00	6.00*	1.00*
169	072	15.50	42.00	5.80*	6.30	59.00	30.00	4.00*	6.00
171	072	15.80	44.00	6.20*	6.70	60.00	30.00	4.00*	6.00
176	072	15.90	44.00	6.00*	7.10	60.00	31.00	3.00	6.00
177	072	16.00	45.00	6.10	6.70	59.00	31.00	3.00	6.00
184	072	16.00	44.00	6.10	7.20	61.00	30.00	3.00	7.00
185	072	16.00	46.00	6.10	7.00	59.00	32.00	2.00	6.00
189	072	16.00	46.00	6.00	5.90	60.00	32.00	2.00	6.00
192	072	15.90	44.00	6.00*	5.80	60.00	30.00	3.00	7.00
194	072	15.50	43.00	5.80	6.20	58.00	32.00	4.00*	6.00
198	072	17.50	48.00	6.20*	6.20	57.00	33.00	3.00	2.00*
199	072	16.50*	42.00	6.50*	5.40	60.00	29.00	4.00*	4.00
200	072	15.80	45.00	7.10*	8.10	56.00	35.00*	3.00	4.00
208	072	12.80*	40.00*	4.70	5.00	52.00*	38.00*	5.00*	4.00

FCE 20124/702 i

13

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
209	072	12.50	44.00	5.40	6.00	58.00	32.00	5.00*	4.00
211	072	15.20	41.00	5.40	4.90	57.00	33.00	3.00	6.00
215	072	13.00	40.00	5.30	6.40	55.00	35.00*	3.00	5.00
217	072	13.30	43.00	4.35	7.00	61.00	27.00	8.00*	4.00
222	072	12.81	38.50	4.25	5.30	67.00	28.00	1.00	4.00
223	072	14.06	42.00	4.85	6.50	69.00	28.00	1.00	1.00
224	072	13.10	39.50	4.65	5.95	73.00*	20.00	3.00	3.00
231	072	16.85*	49.00	5.45	7.20	64.00	30.00	4.00	2.00
232	072	14.30	45.00	5.13*	6.00	61.00	36.00	2.00	1.00
235	072	13.36	41.00	4.80	6.20	64.00	30.00	2.00	4.00
240	072	14.28	41.50	4.60	6.30	56.00	32.00	10.00*	2.00
244	072	15.60	42.00	5.80*	5.70	60.00	30.00	3.00	6.00
246	072	16.00	44.00	6.10	5.90	60.00	30.00	4.00*	6.00
247	072	16.00	44.00	6.00*	5.80	60.00	30.00	3.00	6.00
248	072	15.90	44.00	6.00	5.90	59.00	30.00	4.00*	6.00
257	072	12.50	39.00	5.10	8.00	52.00*	38.00*	8.00*	2.00*
258	072	15.00	43.90	5.30	5.50	56.00	34.00*	4.00*	3.00
259	072	15.80	42.00	5.80*	6.10	57.00	33.00	6.00*	3.00
263	072	15.80	42.00	5.90*	6.10	54.00	36.00*	4.00*	4.00
267	072	12.00*	42.00	4.60*	7.80	57.00	33.00	5.00*	3.00
270	072	12.50	39.00	5.40	6.20	52.00*	33.00	3.00	4.00
271	072	14.20	46.00	5.20	8.20	56.00	34.00*	6.00*	3.00

FCE 20124/702 i

14

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
1	072	1.00	371.00*	144.00*	4.50	102.00	2.41	12.00	21.00	25.00
5	072	1.00	293.00	142.00	3.90*	100.00	2.25	7.00	10.00	13.00
9	072	1.00	329.00	142.00	4.20	97.00	2.34	9.00	14.00	11.00
12	072	.00	417.00*	143.00*	4.40	104.00	2.21	6.00	6.00	8.00
13	072	1.00	237.00	144.00*	4.50	106.00	3.37*	8.00	13.00	11.00
14	072	1.00	343.00	142.00	4.20	102.00	2.46	10.00	11.00	19.00
25	072	1.00	236.00	139.00	4.00	96.00	2.20	14.00	14.00	12.00
30	072	.00	220.00	140.00	4.60	100.00	2.46	8.00	8.00	30.00*
34	072	.00	240.00	148.00*	4.00	102.00	2.20	12.00	10.00	14.00
35	072	.00	218.00	144.00	4.20	108.00	2.10	10.00	8.00	10.00
37	072	.00	245.00	142.00	4.30	102.00	2.20	6.00	8.00	10.00
38	072	1.00	225.00	144.00	4.20	106.00	2.30	16.00	20.00	28.00
45	072	.00	235.00	146.00	4.40	108.00	2.30	14.00	16.00	10.00
48	072	1.00	245.00	146.00	4.10	101.00	2.20	10.00	12.00	12.00
49	072	.00	201.00	141.00	4.20	103.00	2.20	12.00	13.00	12.00
50	072	.00	194.00	143.00	3.90	102.00	2.10	13.00	10.00	12.00
56	072	.00	205.00	136.00*	4.30	105.00	2.70	12.00	14.00	31.00*
57	072	.00	164.00	141.00	3.90	102.00	2.50	12.00	10.00	30.00*
64	072	1.00	174.00	140.00	3.90	104.00	2.60	12.00	11.00	24.00
65	072	1.00	162.00	139.00	3.80	103.00	2.40	10.00	8.00	30.00*
68	072	.00	215.00	137.00*	3.80	102.00	2.50	14.00	15.00	29.00*
72	072	.00	197.00	141.00	3.90	102.00	2.70	12.00	15.00	31.00*
99	072	.00	217.00	140.00	3.80	101.00	8.20	15.00	27.00	23.00
101	072	.00	283.00	143.00	4.70	101.00	7.80*	39.00*	66.00*	56.00*
107	072	.00	268.00	146.00	4.70	112.60*	8.20	30.00	36.00	19.00
108	072	.00	158.00	148.00	5.00	116.00*	8.20	14.00	22.00	19.00
109	072	.00	338.00	142.00	4.40	111.00*	8.60	33.00	42.00	14.00
114	072	.00	200.00	148.00	4.20	101.00	8.40	25.00	28.00	23.00
115	072	.00	260.00	147.10	5.43	110.00*	9.00	18.00	26.00	24.00
120	072	.00	241.00	134.00*	3.70	103.00	9.30	11.00	16.00	7.30
122	072	.00	321.00	138.00	3.90	342.00	9.40	42.00*	53.00*	10.00
123	072	.00	329.00	135.00	5.00	366.00	10.10	29.00	42.00*	20.00
131	072	.00	289.00	138.00	4.30	365.00	10.00	15.00	23.00	15.00
134	072	.00	115.00*	135.00	3.60*	365.00	9.90	15.00	16.00	12.00
135	072	.00	196.00	137.00	4.20	343.00	10.10	44.00*	56.00*	24.00
142	072	.00	281.00	133.00	8.50*	356.00	10.10	16.00	10.00	15.00
146	072	.00	175.00	136.00*	4.40	117.00*	8.40	28.00	16.00	18.00
169	072	1.00	230.00	138.00	4.90	97.00	8.80	38.00	9.60	8.50
171	072	.00	270.00	140.00	5.20	98.00	9.20	39.00	9.60	8.00*
176	072	.00	280.00	140.00	4.90	99.00	9.20	38.00	10.00	8.10
177	072	1.00	275.00	139.00	4.90	99.00	9.00	37.00	9.90	8.20*
184	072	.00	270.00	138.00	5.10	97.00	9.00	38.00	9.90	8.00*
185	072	1.00	285.00	149.00	4.90	100.00	9.00	37.00	9.90	8.20*
189	072	.00	280.00	137.00	5.10	99.00	9.10	39.00	10.00	8.10*
192	072	.00	275.00	142.00	4.80	97.00	9.20	39.00	10.00	8.10
194	072	.00	270.00	147.00	4.90	99.00	9.00	30.00	18.00	30.00
198	072	5.00*	290.00	145.00	5.20	110.00*	9.10	16.00	26.00	27.00
199	072	3.00*	296.00	133.00*	5.00	98.00	9.00	32.00	20.00	31.00
200	072	2.00*	281.00	146.00	4.00	102.00	8.90	31.00	29.00	32.00
208	072	1.00	152.00	144.00	5.40*	105.00	10.00	45.00	34.00	25.00
209	072	1.00	180.00	135.00	5.00	105.00	9.90	50.00	36.00	26.00
211	072	1.00	268.00	143.00	4.50	97.00	8.80	32.00	19.00	29.00
215	072	2.00*	280.00	140.00	5.00	105.00	9.70	26.00	30.00	38.00
217	072	.00	280.00	139.00	4.00	.	9.80	8.65	2.88	.



FCE 20124/702 i

15

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
222	072	.00	300.00	143.00	4.30	102.00	8.63	9.00	15.00	32.00*
223	072	1.00	240.00	142.00	4.00	105.10	9.40	15.00	28.50*	34.00*
224	072	1.00	320.00	135.00	4.00	90.00*	8.90	14.00	4.00	8.00
231	072	.00	340.00	133.00*	4.20	97.00	9.00	18.00	9.00	37.00
232	072	.00	400.00	144.00	4.60	94.00*	9.44	16.00	5.00	21.00
235	072	.00	320.00	147.00	4.30	94.00*	8.56	15.00	7.00	13.00
240	072	.00	300.00	141.00	4.40	98.00	8.63	15.00	7.00	17.00
244	072	1.00	270.00	139.00	4.90	97.00	8.90	39.00	9.90	8.00
246	072	.00	270.50	138.00	4.90	99.00	8.90	39.00	9.70	8.00*
247	072	1.00	275.50	137.00	4.70	98.00	8.80	38.00	9.70	8.10
248	072	1.00	280.00	137.00	4.90	97.00	8.80	37.00	9.70	8.10*
257	072	.00	185.00	144.00	5.20	105.00	9.50	26.00	29.00	41.00
258	072	3.00*	276.00	142.00	4.90	106.00*	8.10*	17.00	21.00	23.00
259	072	2.00	250.00	146.00	5.20	104.00	8.80	35.00	27.00	33.00
263	072	2.00*	300.00	138.00	5.20	104.00	9.10	28.00	32.00*	34.00
267	072	2.00*	251.00	139.00	5.10	120.00*	8.80	36.00	38.00*	27.00
270	072	3.00*	300.00	140.00	5.20	102.00	9.10	28.00	30.00*	36.00
271	072	1.00	320.00	142.00	4.30	104.00	8.50*	28.00	28.00	31.00

FCE 20124/702 i

16

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
1	072	4.67	1.15	116.00	4.20	95.00	.30	7.00	3.30
5	072	4.83	1.42	214.00*	3.70	83.00	.08*	6.00	1.40
9	072	4.29	1.47*	83.00	3.40	83.00	.28	6.00	1.40
12	072	4.75	1.36	70.00	4.40	71.00	.16	9.00	1.90
13	072	5.26	1.58*	119.00	2.30*	86.00	.23	4.00	1.90
14	072	5.57*	1.38	129.00	3.00	85.00	.40	6.00	1.90
25	072	4.00	1.30	86.00	4.20	74.00	278.00	10.00	.00
30	072	4.80	1.40	200.00	6.00	75.00	368.00	10.00	.00
34	072	3.80	1.00	110.00	5.00	72.00	220.00	10.00	.00
35	072	4.00	1.40	112.00	5.20	68.00	190.00*	8.00	.00
37	072	5.00	1.50	160.00	3.80	72.00	268.00	8.00	.00
38	072	4.40	1.40	188.00	2.20	62.00	198.00*	12.00	.00
45	072	4.60	1.50	192.00	6.60	76.00	280.00	10.00	.00
48	072	3.90	1.10	102.00	4.70	70.00	276.00	12.00	.00
49	072	4.10	1.10	25.00	6.00	93.00	124.00*	12.00	.00
50	072	4.00	.90	31.00	6.00	79.00	130.00*	14.00	.00
56	072	4.20	1.20	28.00	6.00	72.00	154.00	12.00	.00
57	072	4.10	1.30	31.00	7.00	92.00	154.00	15.00	.00
64	072	3.90	.80*	27.00	7.00	82.00	140.00*	12.00	.00
65	072	4.10	1.20	31.00	5.00	104.00*	141.00*	12.00	.00
68	072	4.90	1.00	32.00	4.00	76.00	154.00	10.00	.00
72	072	4.60	.90	27.00	3.00	75.00	154.00	14.00	.00
99	072	91.00	2.00*	208.00	43.00	.50	4.60	.78	.04
101	072	65.00	2.80	125.00	42.00	.70	2.40	.24	.04
107	072	69.00	3.40	107.00	28.00	.60	3.00	.26	.10
108	072	62.00	2.80	124.00	30.00	1.00	3.20	.46	.08
109	072	106.00	3.20	243.00	48.00	.50	2.60	.51	.06
114	072	86.00	3.10	270.00	39.00	.70	4.50	.50	.06
115	072	71.00	4.10	146.00	28.00	.70	2.20*	.65	.07
120	072	74.00	3.30	80.00*	33.00	.50	1.30*	.41	.03
122	072	81.00	3.60	87.00	23.00	.80	4.00	.50*	.20*
123	072	85.00	4.00	86.00	25.00	.80	5.20	.90	.30*
131	072	94.00	3.80	69.00	34.00	.70*	6.10	1.40	.40*
134	072	80.00	3.80	54.00	30.00	.80	4.50	.90	.40*
135	072	84.00	3.50	123.00*	18.00*	.70*	5.00	.80	.30*
142	072	83.00	3.10	30.00*	24.00	.60*	4.90	1.10	.50*
146	072	90.00	1.00*	74.00*	20.00	.70	4.00	.50*	.30*
169	072	98.00	3.90	169.00	11.10	1.00	4.80	.70	.40
171	072	98.00	3.80	170.00	11.00	1.10	4.70	.70	.40
176	072	97.00	3.90	170.00	11.00	1.10	5.20	.70	.40
177	072	97.00	4.00	175.00	11.10	1.00	4.40	.70	.40
184	072	95.00	4.00	178.00	11.10	1.00	5.60	.70	.40
185	072	96.00	4.00	172.00	11.10	1.00	5.60	.70	.40
189	072	97.00	4.00	170.00	11.10	1.00	4.90	.80	.40
192	072	99.00	3.80	171.00	11.00	1.00	5.60	.70	.40
194	072	98.00	3.80	130.00	11.20	.78	3.80	.40	.30
198	072	108.00	4.30	126.00	10.60	.80	5.40	.90	.20
199	072	100.00	3.90	125.00	10.20	.70	5.30	1.00	.20
200	072	85.00	4.20	121.00	9.20	.78	5.10	.88	.10
208	072	92.00	4.00	80.00	19.00	.88	5.30	.90	.30
209	072	90.00	3.90	127.00	40.00*	1.20	5.20	.80	.50
211	072	100.00	3.80	128.00	11.00	.75	4.80	.90	.40
215	072	90.00	3.90	118.00	16.00	.90	4.90	.90	.40
217	072	4.55	3.14	25.05	.	66.30	.	6.84	3.42

522

FCE 20124/702 i

17

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPPOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
222	072	5.50	3.30	40.91	13.00*	66.30	2.60	9.40	6.84*
223	072	7.31*	2.75	28.39	29.00	88.40	5.10	9.06	2.22
224	072	4.95	3.50	19.21	20.00	70.72	4.20	8.55	5.13*
231	072	4.95	3.30	28.89	21.00	123.76	6.80	12.82	4.27*
232	072	4.40	3.27	18.00	33.00	79.56	4.00	6.80	3.42
235	072	4.95	3.57	25.35	14.00*	83.98	4.00	11.11	3.42
240	072	4.40	3.53	38.41	23.00	79.56	5.40	5.98	2.56
244	072	87.00	3.70	175.00	11.20	1.10	5.40	.70	.40
246	072	87.00	3.70	180.00	11.10	1.00	5.40	.60	.40
247	072	87.00	3.70	170.00	11.10	1.00	5.20	.70	.40
248	072	85.00	3.80	175.00	11.00	1.10	5.30	.70	.40
257	072	95.00	3.50	125.00	19.00	.70	4.20	.80	.40
258	072	103.00	4.10	125.00	9.00	.80	5.10	.60	.20
259	072	108.00	3.80	127.00	12.00	.81	5.30	.80	.20
263	072	98.00	3.90	115.00	20.00	.80	4.80	.80	.20
267	072	90.00	3.70	130.00	16.00	.82	5.40	1.10*	.60*
270	072	95.00	3.90	120.00	17.00	.80	4.80	.90	.20
271	072	95.00	3.60	118.00	18.00	.90	4.30	.90	.20

FCE 20124/702 i

18

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
1	072	68.00	41.20*	5.50	1.60	2.30	6.30	6.70*	10.50*
5	072	70.00	39.80*	4.50	1.19	2.70	6.90	9.50	11.10*
9	072	71.00	43.70*	5.60	2.33*	2.10	5.00*	9.00	11.20*
12	072	61.00	37.50*	4.30	.72	2.20	5.10*	7.80*	8.40*
13	072	70.00	41.90*	5.10	1.42	2.40	7.10	8.50	10.10*
14	072	69.00	42.90*	6.40	2.01*	2.30	5.70*	9.00	9.10*
25	072	72.00	38.00	4.10	.90	3.20	9.00	9.40	14.20
30	072	72.00	42.00	6.00	1.20	5.00*	3.10	14.00*	14.00
34	072	71.00	39.00	3.80*	1.00	3.00	7.10	10.00	14.00
35	072	72.00	36.00	4.30	1.40	3.60	8.20	10.20	13.00
37	072	72.00	44.00	5.30	1.00	2.90	8.60	8.80	13.60
38	072	68.00	41.00	5.30	1.30	3.60	8.20	9.00	19.10*
45	072	66.00	42.00	4.80	1.40	4.20*	8.80	12.00	16.80
48	072	71.00	39.00	4.70	1.20	2.90	8.10	9.10	13.80
49	072	63.00	44.00	5.10	1.30	1.20*	4.10*	5.10*	9.10*
50	072	68.00	47.00	5.10	1.20	2.00*	5.10*	5.30*	8.70*
56	072	72.00	42.00	5.10	1.40	2.10*	6.50*	8.50	12.90
57	072	78.00	48.00	4.70	1.30	2.30*	7.70	8.00	12.00*
64	072	74.00	49.00	7.20*	1.80	1.90*	5.10*	8.30	9.10*
65	072	71.00	44.00	4.50	1.30	1.10*	6.40*	8.10	11.20*
68	072	74.00	43.00	5.10	1.80	2.90	7.10	8.40	12.60
72	072	69.00	44.00	4.90	1.80	2.70	8.10	8.80	15.10
99	072	6.90	57.70	161.00	458.00*	3.20	14.50*	13.50	11.10
101	072	5.90*	59.90	215.00	84.00	4.50	10.40	11.60	13.50
107	072	6.60	59.70	149.00	237.00*	3.50	11.00	14.00	11.80
108	072	6.50	61.20	177.00	112.00	4.00	10.20	11.00	13.60
109	072	7.50	53.80*	312.00*	106.00	3.40	13.00*	13.20	17.80
114	072	7.50	52.40*	180.00	255.00*	2.40*	9.00	17.00*	19.20*
115	072	7.20	58.10	147.00	224.00*	2.70	11.00	13.40	14.70
120	072	7.00	61.80	208.00	58.00	3.30	8.70	13.70	14.90
122	072	7.30	4.00	207.00	102.00	2.40*	8.20*	12.10*	11.80
123	072	8.30	4.30	194.00	141.00*	3.70	7.00*	10.00	9.30*
131	072	7.70	5.00	280.00	120.00	1.70*	9.20	10.50	11.60
134	072	6.90	4.70	135.00	75.00	2.10*	10.70	10.30	16.20
135	072	7.50	4.60	209.00	299.00*	1.60*	9.80	11.10	16.80
142	072	8.60*	5.30*	142.00	201.00	2.00*	10.00	7.40*	10.60
146	072	7.00	5.10	215.00	21.00	6.00	9.00	18.00*	19.00
169	072	6.80	4.10	208.00	93.00	.30	.72	1.00	1.40
171	072	6.80	4.30	190.00	80.00	.33	.75	.93	1.00
176	072	6.80	4.50	192.00	95.00	.39	.72	.95	1.30
177	072	6.80	4.70	196.00	87.00	.41*	.72	.96	1.20
184	072	6.80	4.70	199.00	87.00	.39	.75	.96	1.30
185	072	6.80	4.80	195.00	90.00	.36	.75	.92	1.20
189	072	6.70	4.50	195.00	90.00	.33	.82	1.10	1.30
192	072	8.80*	4.20	190.00	87.00	.42*	.71	.92	1.30
194	072	6.90	4.30	178.00	96.00	.30	.80	.90	1.30
198	072	7.20	6.20*	206.00	128.00	.40	.80	1.00	1.20
199	072	7.50	4.90	148.00	121.00	.30	.70	.80	1.30
200	072	6.30*	4.50	197.00	112.00	.30	.90	1.20*	1.30
208	072	6.70	5.40	180.00	98.00	.30	.70	.80	1.10
209	072	8.30*	5.30	222.00	160.00*	.30	.80	.70	.80
211	072	7.00	4.10	178.00	98.00	.20	.70	.80	1.00
215	072	7.00	5.20	165.00	115.00	.30	.90	.80	1.10
217	072	6.00	4.80	3.90*	.	.	.	.	.

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

19

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
222	072	7.50	4.55	5.90	64.00	.13*	.90	.93	.99
223	072	7.50	4.42	6.50	142.00	.26	.74	.91	1.17
224	072	6.50	4.50	4.29	100.00	.20	.69	.94	1.33*
231	072	7.00	4.08	4.81	188.00*	.25	.53*	.97	1.17
232	072	7.20	3.80	5.20	103.00	.19*	.63	1.00	1.50*
235	072	6.80	3.97	5.20	97.00	.24	.48*	1.13	1.06
240	072	7.70	3.99	4.94	106.00	.28	.68	1.03	1.72*
244	072	7.30	4.30	197.00	87.00	.33	.72	1.00	1.30
246	072	7.20	4.40	195.00	85.00	.32	.75	1.10	1.40
247	072	7.20	4.40	175.00	80.00	.34	.73	1.00	1.30
248	072	7.20	4.40	192.00	80.00	.32	.72	1.00	1.30
257	072	7.00	5.10	178.00	103.00	.40	.70	.70	1.20
258	072	6.80	6.10*	200.00	132.00	.30	.80	.70	1.00
259	072	7.00	4.20	200.00	130.00	.40	.70	.90	1.20
263	072	7.10	4.70	158.00	103.00	.30	.70	1.20*	1.10
267	072	5.40*	4.00	210.00	130.00	.30	.60	.70	1.00
270	072	7.20	4.20	160.00	106.00	.40	.70	1.10	1.00
271	072	8.10	5.20	162.00	112.00	.30	.70	.90	1.10

FCE 20124/702 i

20

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
25	072	1.020	0	0	0	0
30	072	.	0	0	0	0
34	072	1.026	0	0	0	0
35	072	1.020	0	0	0	0
37	072	1.020	0	0	0	0
38	072	1.020	0	0	0	0
45	072	1.024	0	0	0	0
48	072	1.024	0	0	0	0
49	072	1.021	0	0	0	0
50	072	1.025	0	0	0	0
56	072	1.028	0	0	0	0
57	072	1.025	0	0	0	0
64	072	1.021	0	0	0	0
65	072	1.028	0	0	0	0
68	072	1.019	0	0	0	0
72	072	1.024	0	0	0	0
99	072	1.020	0	0	0	0
101	072	1.020	0	0	0	0
107	072	1.022	0	0	0	0
108	072	1.002	0	0	0	0
109	072	1.016	0	0	0	0
114	072	1.015	0	0	0	0
115	072	1.012	0	0	0	0
120	072	1.009	0	0	0	0
122	072	1.020	0	0	0	3
123	072	1.025	0	0	0	25*
131	072	1.015	0	0	1	1
134	072	1.035*	0	0	10*	1
135	072	1.028	0	0	0	14*
142	072	1.030	0	0	1	2
146	072	1.018	0	0	0	3
169	072	1.015	0	0	2	2
171	072	1.020	0	0	0	4
176	072	1.010	0	0	0	2
177	072	1.010	0	0	0	4
184	072	1.009	0	0	0	4
185	072	1.012	0	0	0	4
189	072	1.010	0	0	0	4
192	072	1.010	0	0	0	4
194	072	1.020	0	0	4	0
199	072	1.016	0	0	3	1
200	072	1.016	0	0	3	1
208	072	1.016	0	0	2	3
209	072	1.016	0	0	1	4
211	072	1.020	0	0	1	2
215	072	1.020	0	0	1	1
217	072	1.010*	0	0	0	1
222	072	1.014*	0	0	0	1
223	072	1.013*	0	0	0	4
224	072	1.008*	0	0	1	3
231	072	1.018	0	0	0	1
232	072	1.013*	0	0	0	2
235	072	1.010*	0	0	1	3
240	072	1.011*	0	0	0	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

21

Pat. No.	Per. (dy)	SPECRAV	URALB	URSUG	URRBC	URWBC
244	072	1.012	0	0	0	2
246	072	1.015	0	0	0	4
247	072	1.020	0	0	0	2
248	072	1.015	0	0	0	2
257	072	1.016	0	0	1	1
258	072	1.020	0	0	1	2
259	072	1.010	0	0	2	4
263	072	1.006	0	0	2	4
267	072	1.016	0	0	1	3
270	072	1.016	0	0	1	3
271	072	1.020	0	0	1	2

FCE 20124/702 i

22

Treatment Group "A"

Day 7 (Period 072)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	72	8
Hematocrit (HCT)	72	10
Red Blood Cells (RBC)	72	22
White Blood Cells (WBC)	72	2
Neutrophils (NEUTS)	72	15
Lymphocytes (LYMPS)	72	15
Eosinophils (EOSIN)	72	26
Monocytes (MONOS)	72	17
Basophils (BASOS)	72	8
Platelets (PLATES)	72	3
Sodium (NA+)	72	10
Phosphorous (K+)	72	4
Chlorine (CL-)	71	11
Calcium (CA++)	72	4
Aspartate		
Aminotransferase (SGOT)	72	3
Alanine		
Aminotransferase (SGPT)	72	8
$\gamma$ -GT (GGT)	71	16
Blood Sugar (BLSUG)	72	2
Phosphorous (PO4)	72	5
Alkaline		
Phosphatase (ALPPOS)	72	5
Urea Nitrogen (BUN)	71	5
Creatinine (CREAT)	72	4
Uric Acid (URACID)	71	9
Total Bilirubin (TOTBILI)	72	3
Direct Bilirubin (DIRBILI)	72	11
Total Protein (TOTPROT)	72	6
Albumin (ALB)	72	11
Cholesterol (CHOLE)	72	4
Triglycerides (TRIGLY)	71	10
Globulins - $\alpha$ 1 (GLOB1)	71	18
Globulins - $\alpha$ 2 (GLOB2)	71	14
Globulins - $\beta$ (GLOBETA)	71	11
Globulins - $\gamma$ (GLOBGAMA)	71	17
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	64	8
Albumin (URALB)	65	0
Sugar (URSUG)	65	0
Red Blood Cells (URRBC)	65	1
White Blood Cells (URWBC)	65	21 282



FCE 20124/702 i

\* = Value out-of-range

23

Day 14 (Period 142)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
1	142	15.30	48.10	4.82	7.60	61.00	29.00	4.00*	5.00
5	142	13.00	38.80	4.41	7.10	68.00	26.00	2.00	4.00
9	142	13.20	40.60	4.56	5.30	47.00*	38.00	7.00*	7.00
12	142	11.90*	34.90*	3.99*	6.90	50.00	37.00	2.00	10.00*
13	142	16.00	47.50	4.79	9.20	63.00	33.00	.00*	4.00
14	142	16.80	50.50	5.11*	9.20*	51.00	34.00	3.00	11.00*
25	142	14.20	43.00	5.10*	5.20	70.00	24.00	3.00	2.00
30	142	14.00	36.80*	4.50	5.20	50.00*	38.00*	6.00*	4.00
35	142	14.60	38.00	5.10	4.90*	65.00	29.00*	3.00	3.00
37	142	14.40	40.60	4.40*	6.00	62.00	30.00*	.00*	8.00
38	142	14.30	45.00	4.70	5.20	63.00	27.00	5.00*	3.00
45	142	14.80	40.00	4.60	8.80	70.00	30.00*	.00*	.00*
48	142	14.10	40.00	4.60	5.90	70.00	26.00	2.00	2.00
49	142	9.10	.43	4.70	6.10	64.00	34.00	2.00	2.00
50	142	9.50	.45	4.70	7.20	70.00	26.00	2.00	2.00
56	142	8.90	.48	5.10	6.10	63.00	32.00	1.00	4.00
57	142	8.20	.46	4.20	6.10	67.00	25.00	3.00	4.00
64	142	7.90	.37	4.50	6.30	68.00	27.00	2.00	2.00
65	142	8.30	.45	4.60	5.90	67.00	26.00	3.00	3.00
68	142	8.10	.46	5.10	7.30	66.00	28.00	2.00	4.00
72	142	8.10	.47	5.30	6.70	69.00	27.00	1.00	3.00
73	142	14.80	48.00	5.00	7.50	76.00*	20.00	2.00	1.00*
75	142	15.00	43.20	5.03	11.10*	66.30	23.80	1.60	5.70
79	142	14.60	42.80	4.95	4.43*	57.60	30.30	2.20	6.50
80	142	16.40*	46.90	4.86	7.00	53.30	36.20	2.40	4.20
85	142	13.90	43.90	4.76	9.11	56.10	30.20	4.30	5.90
87	142	12.80	36.40	4.04	6.05	58.60	32.00	1.40	5.30
94	142	15.60	49.60	4.94	10.26	68.60	23.90	.80	5.10
96	142	15.10	46.00	5.13	7.77	59.30	31.50	1.40	5.20
99	142	13.30	38.80	4.54	7.60	53.00	43.00	1.00	3.00
101	142	12.60	41.50	4.57	5.30	48.00	48.00*	2.00	2.00
107	142	12.30	33.30*	3.79*	6.30	64.00	36.00	.00*	.00*
108	142	14.30	37.40	4.18*	4.40*	66.00	34.00	.00*	.00*
109	142	12.70	37.10	4.18*	5.90	62.00	38.00	.00*	.00*
114	142	14.50	39.10	4.46	5.50	54.00	43.00	1.00	2.00
115	142	16.40	42.70	4.89	7.90	74.00	24.00	.00*	2.00
120	142	12.60	32.90*	4.20	6.20	67.00	32.00	.00*	1.00*
122	142	13.70	43.00	4.30	4.90	48.00*	47.00*	2.00	3.00
123	142	14.40	45.00	4.80	5.70	62.00	35.00	3.00*	.00*
131	142	13.10	41.00	4.70	5.50	72.00*	26.00	.00	2.00*
134	142	12.00	37.00	4.07*	4.50*	68.00	30.00	.00	.00*
135	142	13.90	43.00	4.50	6.70	48.00*	50.00*	1.00	1.00*
142	142	14.50	43.00	4.73	6.50	75.00*	25.00	.00	.00*
146	142	15.40	51.30*	5.16	8.30	50.00*	31.00	8.00*	9.00
169	142	15.40	42.00	5.90*	6.10	58.00	32.00	3.00	6.00
171	142	15.90	44.00	6.20*	6.80	60.00	29.00	3.00	7.00
176	142	16.00	46.00	6.00*	5.90	61.00	30.00	3.00	5.00
177	142	15.90	44.00	5.90	6.70	58.00	32.00	4.00*	6.00
184	142	16.00	44.00	6.10	7.20	60.00	30.00	3.00	7.00
185	142	15.90	44.00	6.00	7.20	59.00	32.00	3.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

24

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
189	142	16.10	46.00	6.80*	7.10	59.00	32.00	2.00	6.00
192	142	15.80	44.00	5.90*	6.20	59.00	32.00	3.00	6.00
194	142	15.60	45.00	5.70	6.10	56.00	33.00	4.00*	5.00
198	142	17.60	48.00	6.30*	6.40	54.00	36.00*	3.00	2.00*
199	142	16.20*	40.00	6.60*	5.60	58.00	32.00	4.00*	4.00
200	142	15.80	45.00	7.20*	8.00	58.00	32.00	3.00	3.00
208	142	12.50*	40.00*	4.60*	5.10	53.00*	37.00*	4.00*	4.00
209	142	12.00	43.00	5.30	5.80	58.00	32.00	5.00*	3.00
211	142	15.10	40.00	5.10	4.80	53.00*	36.00*	3.00	6.00
215	142	13.00	40.00	5.20	6.30	54.00	36.00*	3.00	5.00
217	142	13.07	43.00	4.45	9.35*	63.00	28.00	6.00*	2.00
222	142	12.28	37.00	4.00	4.20	57.00	38.00	.00	5.00
224	142	13.20	39.00	4.55	6.10	75.00*	20.00	1.00	4.00
231	142	16.50*	46.00	5.54*	7.10	52.00	38.00	4.00	6.00
232	142	14.80	45.00	5.20*	5.60	64.00	32.00	.00	3.00
235	142	13.36	40.00	4.89	6.00	66.00	28.00	4.00	2.00
240	142	14.60	43.00	4.55	6.50	50.00	40.00	8.00*	2.00
244	142	15.60	42.00	5.90*	6.00	58.00	30.00	4.00*	7.00
246	142	16.00	44.00	6.20*	5.90	59.00	30.00	4.00*	6.00
247	142	15.60	44.00	5.90*	6.00	60.00	29.00	3.00	7.00
248	142	16.00	44.00	6.00	5.80	58.00	32.00	3.00	6.00
257	142	12.30	38.00	5.10	8.00	50.00*	38.00*	7.00*	3.00
258	142	14.50	45.00	5.00	5.10	56.00	34.00*	4.00*	3.00
259	142	15.90	42.00	5.90*	6.10	56.00	34.00*	4.00*	4.00
263	142	15.80	44.00	5.90*	5.60	54.00	36.00*	5.00*	3.00
267	142	12.00*	41.00*	4.50*	7.60	58.00	32.00	4.00*	3.00
270	142	12.40	39.00	5.30	6.20	53.00*	37.00*	4.00*	3.00
271	142	14.10	45.00	5.20	8.30	57.00	33.00	6.00*	3.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

25

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
1	142	1.00	385.00*	144.00*	4.40	99.00	2.32	12.00	14.00	27.00
5	142	.00	267.00	143.00*	4.10	98.00	2.25	14.00	10.00	15.00
9	142	1.00	253.00	142.00	4.30	99.00	2.33	9.00	12.00	10.00
12	142	1.00	378.00*	140.00	4.50	102.00	2.07*	7.00	7.00	9.00
13	142	.00	210.00	141.00	3.90*	98.00	2.41	11.00	13.00	14.00
14	142	1.00	.	142.00	4.00	100.00	2.43	9.00	8.00	18.00
25	142	1.00	280.00	146.00	4.00	100.00	2.10	10.00	8.00	10.00
30	142	2.00*	230.00	140.00	4.20	98.00	2.90*	10.00	10.00	28.00*
35	142	.00	220.00	146.00	4.00	104.00	2.10	10.00	8.00	12.00
37	142	.00	250.00	146.00	4.00	104.00	2.00	8.00	8.00	10.00
38	142	2.00*	226.00	146.00	4.20	104.00	2.10	14.00	18.00	18.00
45	142	.00	225.00	146.00	4.20	100.00	2.30	10.00	10.00	20.00
48	142	.00	225.00	144.00	4.30	102.00	2.10	12.00	10.00	14.00
49	142	.00	179.00	141.00	3.90	103.00	2.10	14.00	12.00	15.00
50	142	.00	197.00	140.00	3.90	103.00	2.10	12.00	14.00	20.00
56	142	.00	191.00	143.00	4.00	101.00	2.60	12.00	13.00	31.00*
57	142	1.00	161.00	138.00	4.10	101.00	2.60	10.00	12.00	28.00
64	142	1.00	193.00	136.00*	4.10	103.00	2.30	14.00	10.00	26.00
65	142	1.00	162.00	140.00	4.10	101.00	2.50	11.00	12.00	27.00
68	142	.00	198.00	136.00*	3.90	102.00	2.50	12.00	13.00	29.00*
72	142	.00	197.00	137.00*	4.10	101.00	2.50	12.00	14.00	31.00*
73	142	1.00	250.00	146.00	4.10	101.00	9.20	15.00	13.00	12.00
75	142	.50	280.00	140.00	4.70	109.00	9.40	22.00	32.00	12.00
79	142	1.20	211.00	142.00	4.30	110.00	9.00	16.00	30.00	14.00
80	142	2.40*	302.00	144.00	4.10	111.00*	9.50	16.00	39.00	28.00
85	142	1.40	285.00	143.00	3.80	109.00	9.00	17.00	21.00	39.00*
87	142	1.00	296.00	144.00	5.10	101.00	7.90	44.00	66.00*	10.00
94	142	.70	315.00	144.00	4.50	102.00	9.20	21.00	26.00	45.00*
96	142	.50	352.00	142.00	4.50	106.00	8.30	14.00	23.00	14.00
99	142	.00	228.00	142.00	3.80	101.00	8.30	21.00	25.00	23.00
101	142	.00	254.00	143.00	3.70	101.00	8.00*	50.00*	61.00*	45.00*
107	142	.00	200.00	147.00	5.10	113.20*	9.00	36.00*	29.00	18.00
108	142	.00	150.00	149.00	5.10	115.20*	9.80	39.00*	36.00	26.00
109	142	.00	322.00	135.00	4.50	117.00*	8.80	34.00	41.00	13.80
114	142	.00	247.00	151.70	4.09	110.00*	8.00*	24.00	32.00	13.00
115	142	.00	238.00	149.50	4.42	111.00*	9.20	54.00*	96.00*	23.00
120	142	.00	261.00	141.00	3.80	112.00*	8.90	12.00	14.00	7.90
122	142	.00	173.00	140.00	3.80	342.00	10.20	15.00	18.00	12.00
123	142	.00	348.00	138.00	4.90	352.00	10.10	23.00	22.00	16.00
131	142	.00	232.00	140.00	4.30	351.00	9.70	13.00	17.00	9.00
134	142	1.00	245.00	135.00	3.70	360.00	10.00	11.00	10.00	7.00
135	142	.00	215.00	137.00	4.30	342.00	9.70	47.00*	71.00*	24.00
142	142	.00	280.00	135.00	4.20	347.00	10.20	13.00	12.00	12.00
146	142	2.00*	214.00	140.00	3.80	108.00	9.00	30.00	12.00	15.00
169	142	1.00	.	137.00	4.70	98.00	8.70	39.00	9.50	8.60
171	142	1.00	270.00	145.00	5.10	97.00	9.10	38.00	9.50	7.90*
176	142	1.00	270.00	138.00	5.10	97.00	9.10	37.00	9.60	8.20
177	142	.00	285.00	140.00	4.90	97.00	9.10	40.00	9.80	8.10*
184	142	.00	280.00	140.00	4.80	99.00	9.20	37.00	9.90	8.20*
185	142	.00	270.00	139.00	4.90	97.00	9.00	37.00	9.90	8.20*
189	142	1.00	270.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20*
192	142	.00	275.00	140.00	5.10	98.00	9.00	38.00	9.80	8.10
194	142	2.00*	271.00	148.00	4.80	98.00	8.00	31.00	19.00	30.00
198	142	5.00*	288.00	143.00	5.20	108.00*	9.00	16.00	27.00	28.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

26

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
199	142	2.00*	298.00	135.00	5.20	99.00	9.30	33.00	22.00	31.00
200	142	4.00*	281.00	145.00	4.20	105.00	8.80	32.00	29.00	35.00
208	142	2.00*	150.00	144.00	5.30	105.00	10.00	46.00	35.00	25.00
209	142	2.00*	181.00	138.00	5.10	106.00*	9.80	49.00	36.00	27.00
211	142	1.00	265.00	140.00	4.30	96.00	8.90	34.00	22.00	30.00
215	142	2.00*	278.00	138.00	5.00	105.00	9.60	27.00	30.00	36.00
217	142	1.00	290.00	141.00	4.10	98.00	8.57	12.00	4.08	32.00*
222	142	.00	260.00	137.00	4.50	100.80	8.30	10.00	15.00	24.00
224	142	.00	390.00	141.00	4.50	102.00	9.70	12.00	5.00	14.00
231	142	.00	350.00	134.00*	4.10	96.00	9.30	20.00	8.00	36.00
232	142	1.00	460.00*	140.00	3.90	96.00	8.80	19.00	7.00	7.00
235	142	.00	300.00	137.00	4.30	94.00*	8.56	18.00	7.00	8.00
240	142	.00	310.00	138.00	4.40	105.00	8.72	15.00	6.00	10.00
244	142	1.00	250.00	138.00	4.90	98.00	8.80	39.00	9.70	8.10
246	142	1.00	270.00	139.00	4.90	98.00	8.70	38.00	9.70	8.10*
247	142	1.00	280.00	139.00	4.90	97.00	8.60	39.00	9.80	8.10
248	142	1.00	270.00	139.00	4.90	98.00	8.80	39.00	9.70	8.10*
257	142	2.00*	184.00	140.00	5.20	105.00	9.50	28.00	30.00	38.00
258	142	3.00*	270.00	140.00	4.80	106.00*	8.20*	17.00	22.00	24.00
259	142	2.00	250.00	145.00	5.10	105.00	8.70	36.00	27.00	33.00
263	142	2.00*	300.00	139.00	5.10	105.00	9.10	29.00	33.00*	34.00
267	142	3.00*	250.00	138.00	5.00	122.00*	8.10*	35.00	37.00*	26.00
270	142	3.00*	301.00	140.00	5.10	105.00	9.20	30.00	30.00*	35.00
271	142	1.00	318.00	140.00	4.30	105.00	8.60	29.00	30.00*	32.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

27

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
1	142	4.67	1.13	119.00	2.90*	92.00	.30	4.00	1.20
5	142	5.40	1.43	175.00	4.50	77.00	.13*	6.00	1.60
9	142	4.36	1.55*	69.00	3.70	90.00	.30	5.00	.90
12	142	4.77	1.32	71.00	4.00	68.00	.17	5.00	.90
13	142	5.24	1.31	138.00	3.50	92.00	.34	4.00	.90
14	142	5.69*	1.12	91.00	3.20	100.00*	.38	9.00	1.90
25	142	3.80	1.40	90.00	5.00	72.00	276.00	10.00	.00
30	142	4.60	1.20	206.00	5.80	62.00	360.00	10.00	.00
35	142	4.20	1.40	110.00	5.20	70.00	210.00	12.00	.00
37	142	4.80	1.40	164.00	4.60	72.00	270.00	8.00	.00
38	142	4.20	1.30	190.00	5.00	62.00	190.00*	12.00	.00
45	142	4.10	1.20	200.00	5.60	80.00	288.00	10.00	.00
48	142	3.80	1.10	102.00	4.60	72.00	270.00	14.00	.00
49	142	4.10	1.00	27.00	8.00	101.00*	124.00*	9.00	.00
50	142	3.90	1.00	31.00	6.00	81.00	130.00*	10.00	.00
56	142	4.30	1.00	39.00	5.00	71.00	149.00	12.00	.00
57	142	4.70	1.00	28.00	5.00	86.00	161.00	10.00	.00
64	142	5.10	.80*	30.00	6.00	87.00	139.00*	9.00	.00
65	142	4.80	.90	22.00	6.00	89.00	151.00	10.00	.00
68	142	5.10	.90	27.00	6.00	72.00	154.00	12.00	.00
72	142	5.00	1.10	27.00	4.00	71.00	154.00	13.00	.00
73	142	70.00	3.50	110.00	14.00	1.10	3.90	.50	.20
75	142	87.00	3.80	99.00	17.90	.90	4.60	.70	.30
79	142	79.00	3.10	85.00	10.20	1.00	4.60	.40	.20
80	142	76.00	3.40	105.00	8.80	.90	4.30	.20	.70*
85	142	65.00	4.00	65.00	11.60	.90	4.00	.60	.30
87	142	72.00	2.50	83.00	16.70	.80	7.20*	.60	.20
94	142	103.00	3.30	115.00	9.00	1.10	6.80	.60	.00
96	142	73.00	3.30	70.00	19.50	1.00	3.60	.70	.20
99	142	91.00	2.10*	184.00	42.00	.60	4.20	.39	.14
101	142	75.00	3.30	130.00	38.00	.70	2.00*	.28	.05
107	142	73.00	4.50	141.00	25.00	.70	3.70	.70	.10
108	142	71.00	4.30	142.00	31.00	.80	2.50	.50	.05
109	142	107.00	1.70*	241.00	50.00	.60	2.60	.52	.05
114	142	93.00	3.00	274.00	35.00	.70	4.80	.59	.04
115	142	74.00	4.00	144.00	33.00	.90	4.40	.22	.06
120	142	79.00	2.90	82.00*	39.00	.50	1.40*	.44	.04
122	142	76.00	3.60	82.00	24.00	.80	3.80	.60	.20*
123	142	75.00*	4.00	86.00	24.00	.70*	5.50	1.00	.50*
131	142	95.00	3.60	70.00	36.00	1.00	6.10	1.10	.50*
134	142	86.00	4.10	56.00	24.00	.90	5.00	.70	.30*
135	142	91.00	3.50	116.00*	23.00	.80	5.10	.90	.40*
142	142	79.00	3.40	71.00	23.00	.70*	5.20	.50*	.20*
146	142	95.00	3.50	30.00	30.00	1.00	4.00	.30*	.10
169	142	97.00	3.80	165.00	11.10	1.00	4.60	.80	.40
171	142	97.00	3.70	178.00	11.00	1.00	5.00	.60	.40
176	142	92.00	4.00	171.00	11.00	1.00	5.20	.70	.40
177	142	97.00	3.90	172.00	11.10	1.00	4.20	.80	.40
184	142	95.00	3.90	170.00	11.00	1.10	5.60	.80	.40
185	142	96.00	4.00	178.00	11.00	1.10	5.20	.70	.40
189	142	98.00	4.00	172.00	11.00	1.00	5.40	.70	.40
192	142	98.00	4.00	170.00	11.00	1.10	5.20	.70	.40
194	142	95.00	3.90	134.00	11.50	.80	3.60*	.50	.30
198	142	110.00	4.40	126.00	10.80	.90	5.50	1.00	.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

28

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
199	142	96.00	4.00	120.00	10.00	.80	5.40	1.20*	.30
200	142	125.00*	4.30	122.00	9.00	.79	5.20	.80	.20
208	142	95.00	3.90	82.00	19.00	.88	5.40	.90	.30
209	142	95.00	3.80	125.00	38.00*	1.20	5.10	.80	.40
211	142	110.00	3.90	125.00	10.50	.80	5.00	1.00	.50
215	142	95.00	3.80	118.00	16.00	.80	4.80	.80	.40
217	142	4.40	3.01	30.06	22.00	75.14	4.00	8.55	3.93*
222	142	5.39	3.10	36.74	16.50*	44.20	3.60	8.20	3.59*
224	142	4.95	3.10	21.70	21.00	8.40*	4.60	5.13	2.05
231	142	4.95	2.50	19.20	24.00	88.40	6.90	6.84	1.71
232	142	4.40	3.90	18.21	20.00	85.74	4.00	17.10	5.98*
235	142	5.22	3.73	21.00	20.00	66.30	5.10	11.97	5.13*
240	142	4.40	2.52	42.25	23.00	82.21	5.50	9.40	1.71
244	142	90.00	3.80	175.00	11.00	1.00	5.20	.70	.40
246	142	85.00	3.70	178.00	11.20	1.10	5.60	.60	.40
247	142	90.00	3.70	172.00	11.10	1.10	5.20	.70	.40
248	142	90.00	3.70	172.00	11.20	1.10	5.20	.70	.40
257	142	90.00	3.50	127.00	19.00	.70	4.30	.70	.30
258	142	100.00	4.30	125.00	9.00	.90	5.10	.70	.20
259	142	108.00	3.90	126.00	12.00	.70	5.20	.90	.10
263	142	95.00	3.90	115.00	20.00	.90	4.90	.70	.20
267	142	95.00	3.60	131.00	15.00	.80	5.20	1.00	.60*
270	142	100.00	3.90	121.00	16.00	.80	4.70	.80	.20
271	142	100.00	3.70	118.00	18.00	.80	4.40	.90	.20

FCE 20124/702 i

29

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRICLY	GLOBA1	GLOBA2	GLOBETA	GLOGAMA
1	142	66.00	40.00*	5.00	2.16*	2.10	6.00	7.70*	10.20*
5	142	78.00	47.50*	5.10	1.43	3.10	6.30	10.40	10.70*
9	142	69.00	40.20*	5.80	1.33	2.40	5.30*	9.30	11.80
12	142	56.00*	35.10*	4.50	.88	2.10	4.30*	7.10*	7.40*
13	142	74.00	43.50*	5.40	1.29	2.60	7.00	9.60	11.30*
14	142	70.00	43.50*	6.30	2.28*	2.70	5.70*	9.30	8.80*
25	142	73.00	39.00	4.20	1.00	3.40	9.80	10.00	14.60
30	142	72.00	40.00	6.00	1.20	4.80*	3.20	12.40*	14.80
35	142	70.00	34.00*	4.30	1.50	3.40	8.20	11.00	12.30*
37	142	70.00	44.00	5.00	1.10	3.00	8.80	9.00	13.80
38	142	69.00	40.00	5.20	1.40	3.80*	8.80	9.10	14.00
45	142	80.00	46.00	1.40*	1.10	3.60	9.00	12.00	16.00
48	142	68.00	38.00	4.60	1.20	2.80	8.20	9.00	13.60
49	142	69.00	49.00*	5.30	1.40	1.70*	5.10*	5.30*	8.10*
50	142	71.00	50.00*	5.30	1.10	2.00*	5.50*	5.10*	8.90*
56	142	73.00	44.00	4.80	1.50	2.00*	6.50*	8.50	12.00*
57	142	73.00	43.00	4.60	1.40	2.40	6.60	8.00	13.00
64	142	75.00	50.00*	7.30*	1.60	1.10*	4.20*	6.90*	10.10*
65	142	74.00	45.00	4.30	1.40	1.30*	8.10	8.60	12.00*
68	142	71.00	40.00	5.00	1.70	2.10*	7.90	8.90	12.10*
72	142	75.00	47.00	4.90	1.80	2.70	8.10	8.90	15.20
73	142	7.20	4.00	225.00*	170.00	.	.	.	.
75	142	7.00	4.50	229.00*	133.00	3.51	11.32	14.20	13.80
79	142	6.50	4.20	289.00*	234.00*	3.92	9.82	14.37	13.15
80	142	7.80	5.10	263.00*	243.00*	1.85*	10.02	14.84*	13.25
85	142	6.50	4.20	238.00*	131.00	2.41	10.50	13.28	16.99
87	142	7.70	4.60	270.00*	207.00*	1.84*	10.21	13.10	17.20
94	142	7.70	4.60	303.00*	139.00	3.40	12.37	16.83*	11.18
96	142	7.30	4.40	188.00	249.00*	2.31*	10.05	15.00*	17.01
99	142	6.50	66.00	160.00	354.00*	3.10	9.40	9.80	11.80
101	142	6.30	61.50	189.00	100.00	4.20	10.60	11.20	12.40
107	142	6.00	62.60	161.00	288.00*	3.00	9.00	14.20*	11.20
108	142	7.30	62.40	195.00	125.00	3.90	9.20	12.30	12.20
109	142	7.60	54.20*	302.00*	102.00	3.50	12.90*	13.10	16.80
114	142	7.80	50.90*	186.00	188.00*	2.60	8.90	17.80*	19.80*
115	142	7.00	57.90	200.00	219.00*	2.90	10.90	14.70*	13.80
120	142	7.40	58.90	203.00	56.00	3.60	8.60	13.90	15.10
122	142	7.60	4.20	183.00	221.00*	4.10	10.30	16.10*	14.70
123	142	8.70*	4.60	188.00	139.00*	3.70	6.90*	10.10	9.30*
131	142	7.10	4.40	267.00	168.00	1.60*	8.60*	9.60	12.60
134	142	8.10	4.40	143.00	54.00	1.80*	8.70*	10.30	14.70
135	142	7.40	4.40	211.00	181.00	1.30*	6.30*	10.70	19.90*
142	142	7.70	4.80	140.00	274.00*	3.00	8.00*	9.20	10.60
146	142	6.80	5.10	125.00	22.00	8.00	13.00	14.00	13.00*
169	142	8.70*	4.10	195.00	90.00	.32	.70	1.10	1.30
171	142	8.70*	4.30	188.00	79.00	.34	.73	.91	1.10
176	142	8.80*	4.80	199.00	87.00	.32	.75	.95	1.20
177	142	6.70	4.30	199.00	89.00	.38	.72	.89	1.30
184	142	6.80	4.80	195.00	85.00	.36	.75	.92	1.30
185	142	8.80*	4.70	200.00	89.00	.39	.75	.92	1.20
189	142	6.80	4.60	198.00	90.00	.35	.72	.91	1.10
192	142	8.70*	4.50	190.00	88.00	.38	.75	1.00	1.30
194	142	6.80	4.40	177.00	95.00	.30	.90	.80	1.40
198	142	7.10	6.30*	206.00	128.00	.30	.80	.90	1.30

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

30

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
199	142	7.60	5.00	150.00	125.00	.40	.70	.80	1.50
200	142	6.10*	4.50	195.00	110.00	.40	.90	1.10	1.40
208	142	6.70	5.40	182.00	94.00	.40	.70	.70	1.00
209	142	8.20	5.20	212.00	158.00*	.40	.80	.80	1.10
211	142	8.00	4.20	180.00	97.00	.30	.70	.80	1.10
215	142	7.00	5.10	165.00	118.00	.30	.80	.90	1.00
217	142	6.65	4.10	3.90*	120.00	.30	.60	.90	1.70*
222	142	6.30	4.05	5.46	117.00	.23	.45*	.78	.79
224	142	6.80	4.55	4.42	112.00	.16*	.48*	.75	.86
231	142	7.40	4.39	4.42	173.00*	.15*	.56*	1.07	1.23
232	142	7.50	4.29	5.98	100.00	.28	.61	1.09	1.23
235	142	7.30	4.28	4.68	103.00	.19*	.57*	1.25*	1.01
240	142	7.80	4.15	4.55	110.00	.14*	.65	1.25*	1.61*
244	142	7.20	4.50	200.00	90.00	.32	.75	1.00	1.30
246	142	7.20	4.40	192.00	82.00	.32	.77	1.00	1.30
247	142	7.20	4.40	190.00	92.00	.35	.72	1.10	1.40
248	142	7.20	4.40	192.00	88.00	.32	.72	1.10	1.30
257	142	8.00	5.10	178.00	103.00	.30	.80	.80	1.10
258	142	6.90	6.10*	205.00	135.00	.30	.90	.70	.90
259	142	7.10	4.40	202.00	131.00	.40	.70	.90	1.10
263	142	7.20	4.70	156.00	103.00	.30	.80	1.20*	1.10
267	142	5.20*	4.00	210.00	130.00	.30	.60	.70	1.00
270	142	7.10	4.10	158.00	105.00	.40	.60	1.00	.90
271	142	8.20	5.10	163.00	110.00	.40	.70	.90	1.10

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

31

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
25	142	1.020	0	0	0	0
30	142	.	0	0	0	0
35	142	1.022	0	0	0	0
37	142	1.022	0	0	0	0
38	142	1.020	0	0	0	0
45	142	1.020	0	0	0	0
48	142	1.024	0	0	0	0
49	142	1.020	0	0	0	0
50	142	1.027	0	0	0	0
56	142	1.009	0	0	0	0
57	142	1.028	0	0	0	0
64	142	1.017	0	0	0	0
65	142	1.028	0	0	0	0
68	142	1.028	0	0	0	0
72	142	1.024	0	0	0	0
73	142	1.020	0	0	0	0
75	142	1.029*	0	0	0	0
80	142	1.006	0	0	0	0
85	142	1.017	0	0	0	0
87	142	1.014	0	0	0	0
94	142	1.006	0	0	0	0
96	142	1.028*	0	0	0	0
99	142	1.021	0	0	0	0
101	142	1.022	0	0	0	0
107	142	1.015	0	0	0	0
108	142	1.015	0	0	0	0
109	142	1.020	0	0	0	0
114	142	.	0	0	0	0
115	142	1.016	0	0	0	0
120	142	1.012	0	0	0	0
122	142	1.020	0	0	0	9*
123	142	1.035	0	0	0	0
131	142	1.025	0	0	1	1
134	142	1.020	0	0	4*	1
135	142	1.030	0	0	0	4
142	142	1.025	0	0	0	2
146	142	1.017	0	0	0	2
169	142	1.010	0	0	4	2
171	142	1.010	0	0	0	4
176	142	1.012	0	0	0	4
177	142	1.010	0	0	0	2
184	142	1.012	0	0	0	2
185	142	1.015	0	0	0	4
189	142	1.012	0	0	0	4
192	142	1.010	0	0	2	4
194	142	1.020	0	0	2	1
199	142	1.016	0	0	2	1
200	142	1.020	0	0	3	1
208	142	1.016	0	0	2	3
209	142	1.016	0	0	1	5
215	142	1.016	0	0	1	2
217	142	1.026	0	0	3	4
222	142	1.016	0	0	0	2
224	142	1.011*	0	0	2	3

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

32

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
231	142	1.011*	0	0	0	2
232	142	1.020	0	0	0	0
235	142	1.023	0	0	2	2
240	142	1.013*	0	0	0	1
244	142	1.012	0	0	0	4
246	142	1.020	0	0	0	4
247	142	1.015	0	0	0	0
248	142	1.015	0	0	0	4
257	142	1.018	0	0	1	3
259	142	1.008	0	0	0	4
263	142	1.008	0	0	2	2
270	142	1.016	0	0	1	2
271	142	1.020	0	0	2	3

FCE 20124/702 i

33

Treatment Group "A"

Day 14 (Period 142)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	78	6
Hematocrit (HCT)	78	7
Red Blood Cells (RBC)	78	24
White Blood Cells (WBC)	78	8
Neutrophils (NEUTS)	78	13
Lymphocytes (LYMPS)	78	16
Eosinophils (EOSIN)	78	30
Monocytes (MONOS)	78	13
Basophils (BASOS)	78	16
Platelets (PLATES)	76	3
Sodium (NA+)	78	6
Phosphorous (K+)	78	1
Chlorine (CL-)	78	12
Calcium (CA++)	78	6
Aspartate		
Aminotransferase (SGOT)	78	5
Alanine		
Aminotransferase (SGPT)	78	8
γ-GT (YGT)	78	15
Blood Sugar (BLSUG)	78	3
Phosphorous (PO4)	78	4
Alkaline		
Phosphatase (ALPHOS)	78	2
Urea Nitrogen (BUN)	78	3
Creatinine (CREAT)	78	5
Uric Acid (URACID)	78	9
Total Bilirubin (TOTBILI)	78	3
Direct Bilirubin (DIRBILI)	78	12
Total Protein (TOTPROT)	78	9
Albumin (BLALB)	78	14
Cholesterol (CHOLE)	78	11
Triglycerides (TRIGLY)	78	16
Globulins - α1 (GLOBA1)	77	18
Globulins - α2 (GLOBA2)	77	17
Globulins - β (GLOBETA)	77	16
Globulins - γ (GLOGAMA)	77	18
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	65	5
Albumin (URALB)	67	0
Sugar (URSUG)	67	0
Red Blood Cells (URRBC)	67	1
White Blood Cells (URWBC)	67	1

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

34

\* = Value out-of-range

Day 28 (Period 282)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
1	282	17.50	52.50	5.37*	7.50	60.00	36.00	1.00	3.00
5	282	13.40	38.80	4.39	6.20	62.00	29.00	1.00	7.00
9	282	13.20	40.60	4.55	5.00	51.00	35.00	5.00*	8.00
12	282	11.40*	34.40*	3.76*	7.10	65.00	24.00	3.00	6.00
13	282	16.10	48.60	5.23*	10.50*	62.00	25.00	1.00	12.00*
14	282	14.70	43.20	4.68	9.90*	59.00	34.00	1.00	6.00
25	282	14.30	42.00	5.20*	5.10	69.00	25.00	3.00	3.00
30	282	14.00	39.00	4.60	5.40	55.00*	40.00*	3.00	2.00
35	282	14.60	38.00	5.10	4.80*	65.00	29.00*	3.00	3.00
37	282	14.20	40.40	4.80	5.80	72.00	26.00	1.00	1.00
38	282	14.20	44.00	4.70	5.50	62.00	30.00*	6.00*	2.00
45	282	14.80	40.00	4.20*	7.80	70.00	30.00*	.00*	.00*
48	282	14.20	42.00	4.80	5.60	68.00	26.00	2.00	3.00
49	282	9.10	.45	4.60	7.10	72.00	26.00	1.00	1.00
50	282	9.20	.43	4.10	6.70	69.00	30.00	1.00	.00*
56	282	8.90	.47	5.00	6.40	63.00	30.00	2.00	4.00
57	282	8.10	.47	4.60	7.10	73.00	20.00*	2.00	4.00
64	282	8.10	.39	4.60	6.20	67.00	28.00	2.00	2.00
65	282	8.60	.42	4.30	5.90	69.00	26.00	2.00	2.00
68	282	8.40	.47	5.10	6.90	65.00	29.00	1.00	4.00
72	282	8.40	.47	5.10	6.30	72.00	28.00	1.00	3.00
75	282	15.00	46.50	4.86	5.01	57.10	42.40	1.80	4.50
79	282	14.50	42.80	4.88	4.20*	52.30	34.80	3.10	6.90
80	282	16.30*	47.00	4.93	6.73	52.20	38.20	2.70	4.30
85	282	14.90	44.80	4.88	8.38	56.00	31.10	2.40	6.60
87	282	12.70	38.00	4.04	7.78	60.90	38.70	1.50	5.50
94	282	14.90	45.10	4.61*	9.06	57.70	33.70	1.00	5.20
96	282	15.80	50.70	5.35	8.18	57.80	34.00	1.20	4.50
99	282	12.90	36.40*	4.14*	9.00	64.00	32.00	3.00	1.00*
101	282	13.00	42.10	4.32	5.75	50.00	35.00	6.00	9.00
107	282	13.30	35.40*	4.19*	7.60	58.00	41.00	.00*	1.00*
108	282	15.20	38.90	4.40	4.70*	60.00	38.00	.00*	2.00
109	282	12.80	36.40*	4.20	6.20	58.00	40.00	.00*	2.00
114	282	14.50	37.40	4.22	5.10	60.00	37.00	1.00	2.00
115	282	17.10	43.20	4.98	6.40	71.00	27.00	.00*	2.00
120	282	12.80	33.70*	4.21	6.20	69.00	31.00	.00*	.00*
123	282	14.40	45.00	4.40	5.00	78.00*	20.00	2.00	.00*
131	282	14.00	43.00	4.60	6.40	68.00	31.00	.00	1.00*
135	282	13.60	42.00	4.62	5.70	58.00*	41.00*	1.00	.00*
142	282	14.60	45.00	4.45	7.70	70.00	30.00	.00	.00*
146	282	14.90	59.60*	5.16	10.10	62.00	28.00	6.00*	4.00*
169	282	15.50	42.00	5.90*	6.10	60.00	30.00	4.00*	6.00
171	282	15.90	44.00	6.20*	6.80	59.00	29.00	4.00*	6.00
176	282	15.90	44.00	5.90*	7.10	60.00	30.00	3.00	6.00
177	282	15.90	44.00	5.90	6.20	59.00	32.00	2.00	6.00
184	282	16.10	46.00	6.20*	7.20	59.00	32.00	2.00	6.00
185	282	16.00	46.00	6.10	7.20	60.00	30.00	3.00	7.00
189	282	16.00	46.00	6.20*	7.70	60.00	30.00	3.00	7.00
192	282	15.90	44.00	5.90*	6.20	58.00	33.00	3.00	6.00
194	282	15.70	44.00	5.80	6.40	57.00	33.00	5.00*	5.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

35

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
198	282	17.60	47.00	6.20*	6.30	55.00	35.00*	4.00*	1.00*
199	282	17.00*	44.00	6.80*	6.00	60.00	28.00	5.00*	4.00
200	282	15.80	46.00	7.30*	8.10	56.00	39.00	2.00	3.00
208	282	12.80*	41.00*	4.60*	5.00	53.00*	37.00*	5.00*	4.00
209	282	12.00	43.00	5.20	5.70	56.00	34.00*	5.00*	2.00*
211	282	15.00	41.00	5.20	4.90	56.00	34.00*	2.00	7.00
215	282	13.00	40.00	5.20	6.40	56.00	34.00*	3.00	7.00
217	282	13.04	42.00	4.98	9.30*	68.00	26.00	2.00	4.00
222	282	13.80	40.00	4.45	6.60	69.00	28.00	.00	3.00
224	282	12.99	40.00	4.54	5.95	71.00	23.00	2.00	3.00
231	282	16.20*	45.00	5.45	7.20	57.00	38.00	3.00	2.00
235	282	12.81	38.00	4.45	6.20	61.00	35.00	2.00	2.00
240	282	13.26	41.00	4.53	6.50	56.00	37.00	6.00*	1.00
244	282	15.80	44.00	6.00*	5.80	60.00	30.00	4.00*	6.00
246	282	16.00	44.00	6.20*	5.80	60.00	30.00	3.00	7.00
247	282	15.90	44.00	5.80*	6.00	60.00	30.00	3.00	6.00
248	282	15.90	42.00	5.90	6.00	60.00	30.00	3.00	6.00
257	282	12.00	37.00	5.00	8.00	52.00*	38.00*	6.00*	3.00
258	282	14.90	45.30	5.00	5.20	52.00*	38.00*	3.00	4.00
259	282	15.80	42.00	5.90*	6.00	57.00	33.00	5.00*	4.00
263	282	15.90	44.00	5.90*	6.00	54.00	36.00*	6.00*	3.00
267	282	11.90*	40.00*	4.50*	7.60	56.00	34.00*	6.00*	4.00
270	282	12.30	39.00	5.40	6.10	52.00*	38.00*	5.00*	3.00
271	282	14.10	45.00	5.20	8.20	58.00	32.00	5.00*	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

36

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
1	282	.00	324.00	141.00	4.40	101.00	2.45	15.00	26.00*	30.00*
5	282	1.00	322.00	143.00*	4.30	98.00	2.38	13.00	17.00	23.00*
9	282	1.00	312.00	141.00	4.70	98.00	2.20	8.00	10.00	12.00
12	282	2.00	355.00*	141.00	4.60	104.00	2.21	7.00	14.00	10.00
13	282	.00	237.00	139.00	4.10	99.00	2.40	9.00	11.00	11.00
14	282	.00	267.00	144.00*	4.30	101.00	2.55	7.00	9.00	18.00
25	282	.00	276.00	144.00	4.10	102.00	2.00*	12.00	10.00	10.00
30	282	.00	230.00	140.00	4.30	98.00	2.10	10.00	12.00	18.00*
35	282	.00	220.00	146.00	4.20	104.00	2.10	8.00	10.00	10.00
37	282	.00	250.00	142.00	4.00	104.00	2.20	10.00	8.00	12.00
38	282	.00	222.00	146.00	4.40	105.00	2.00*	14.00	16.00	18.00
45	282	.00	225.00	148.00*	4.00	108.00	2.00*	10.00	10.00	20.00
48	282	.00	235.00	142.00	4.00	102.00	2.10	14.00	14.00	16.00
49	282	.00	191.00	140.00	4.00	102.00	2.20	14.00	12.00	15.00
50	282	.00	202.00	141.00	3.80	101.00	2.00*	14.00	12.00	8.00
56	282	1.00	174.00	141.00	3.80	101.00	2.70	14.00	14.00	36.00*
57	282	1.00	161.00	139.00	4.10	100.00	2.70	14.00	11.00	27.00
64	282	1.00	168.00	140.00	4.10	104.00	2.10	16.00	10.00	21.00
65	282	1.00	169.00	139.00	4.00	101.00	2.60	12.00	10.00	21.00
68	282	1.00	201.00	141.00	3.90	101.00	2.40	15.00	12.00	30.00*
72	282	.00	199.00	139.00	4.00	102.00	2.30	12.00	13.00	31.00*
75	282	1.10	169.00	140.00	4.20	121.00*	8.50	28.00	41.00*	17.00
79	282	.90	237.00	142.00	4.40	108.00	9.30	14.00	22.00	9.00
80	282	1.00	302.00	150.00	.	105.00	9.60	17.00	28.00	21.00
85	282	2.00*	302.00	142.00	4.10	106.00	9.50	20.00	24.00	50.00*
87	282	1.00	324.00	143.00	4.40	104.00	9.60	61.00	114.00*	8.00
94	282	.90	273.00	141.00	4.70	104.00	9.30	13.00	11.00	31.00*
96	282	.70	375.00	139.00	4.70	103.00	9.10	12.00	18.00	18.00
99	282	.00	216.00	145.00	4.10	102.00	8.10	19.00	16.00	18.70
101	282	.00	263.00	148.00	3.70	102.00	8.50	27.00	42.00	41.00*
107	282	.00	281.00	147.00	4.20	115.00*	9.60	38.00*	39.00	22.00
108	282	.00	190.00	140.00	4.95	116.00*	10.20	40.00*	34.00	27.00
109	282	.00	320.00	137.00	4.50	112.00*	8.80	32.00	34.00	13.30
114	282	.00	191.00	148.10	4.22	111.00*	8.10	29.00	30.00	13.00
115	282	.00	261.00	142.30	4.39	107.00	9.00	84.00*	146.00*	31.00
120	282	.00	265.00	136.00	3.60	110.00*	9.00	12.00	15.00	7.90
123	282	.00	196.00	136.00	4.90	358.00	9.80	22.00	26.00	12.00
131	282	.00	225.00	141.00	4.40	340.00	9.30	10.00	19.00	7.00
135	282	.00	106.00*	138.00	3.80	348.00	9.80	47.00*	70.00*	20.00
142	282	.00	301.00	140.00	3.60*	353.00	9.90	18.00	14.00	12.00
146	282	.00	217.00	136.00*	4.00	95.00	10.00	30.00	15.00	15.00
169	282	.00	255.00	135.00	4.60	95.00	8.80	40.00	9.40	8.50
171	282	1.00	270.00	142.00	5.10	97.00	9.10	38.00	9.50	8.10*
176	282	1.00	275.00	140.00	5.10	98.00	9.00	38.00	9.70	8.10
177	282	1.00	280.00	138.00	4.80	99.00	8.90	37.00	9.90	8.10*
184	282	1.00	275.00	139.00	4.90	100.00	9.00	37.00	9.80	8.20*
185	282	.00	280.00	140.00	5.10	99.00	9.20	38.00	10.00	8.10*
189	282	.00	280.00	140.00	4.90	99.00	9.90	40.00	8.80	8.90*
192	282	.00	280.00	139.00	4.90	100.00	9.10	37.00	9.80	8.10
194	282	.00	271.00	147.00	4.70	97.00	9.40	32.00	20.00	28.00
198	282	5.00*	287.00	144.00	5.10	109.00*	9.10	17.00	28.00	27.00
199	282	3.00*	298.00	135.00	5.40*	105.00	9.50	32.00	22.00	32.00
200	282	.00	288.00	140.00	4.40	107.00*	9.00	32.00	28.00	34.00
208	282	1.00	153.00	143.00	5.40*	105.00	10.00	45.00	34.00	25.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

37

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
209	282	3.00*	182.00	140.00	5.20	107.00*	9.90	48.00	36.00	28.00
211	282	1.00	265.00	140.00	4.60	98.00	8.80	34.00	32.00	20.00
215	282	.00	230.00	138.00	5.10	108.00*	9.80	28.00	32.00	40.00
217	282	.00	290.00	147.00*	6.60*	103.00	9.10	12.00	6.00	36.00*
222	282	.00	320.00	143.00	4.20	102.20	9.00	10.00	14.00	21.00
224	282	1.00	330.00	140.00	3.90	101.00	9.80	12.00	5.00	10.00
231	282	.00	345.00	129.00*	4.10	92.00*	8.80	16.00	6.00	33.00
235	282	.00	320.00	136.00	4.70	93.00*	8.48*	16.00	8.00	4.00
240	282	.00	315.00	134.00*	4.20	100.00	8.90	16.00	6.00	8.00
244	282	.00	280.00	138.00	4.80	97.00	8.90	38.00	9.70	8.00
246	282	.00	270.00	139.00	4.90	98.00	8.80	37.00	9.70	8.00*
247	282	1.00	280.00	138.00	4.90	97.00	8.90	37.00	9.70	8.10
248	282	1.00	270.00	139.00	4.80	98.00	8.80	39.00	9.70	8.10*
257	282	1.00	186.00	140.00	5.10	105.00	9.50	29.00	30.00	38.00
258	282	3.00*	275.00	149.00	5.00	104.00	8.70	17.00	23.00	24.00
259	282	1.00	251.00	145.00	5.20	107.00*	8.60	36.00	28.00	34.00
263	282	1.00	301.00	136.00	5.00	108.00*	9.00	29.00	33.00*	34.00
267	282	.00	250.00	140.00	5.10	122.00*	8.10*	35.00	37.00*	26.00
270	282	2.00*	301.00	140.00	5.10	105.00	9.10	29.00	30.00*	33.00
271	282	1.00	318.00	140.00	4.20	105.00	8.70	28.00	28.00	32.00

FCE 20124/702 i

38

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
1	282	5.38	1.02	119.00	3.10	91.00	.19	8.00	1.90
5	282	5.01	1.76*	153.00	4.60	77.00	.13*	5.00	1.40
9	282	5.25	1.35	69.00	3.80	75.00	.22	3.50	.50
12	282	5.04	1.59*	67.00	3.70	75.00	.19	4.00	.90
13	282	5.30	1.09	122.00	3.80	78.00	.21	8.00	2.10
14	282	4.94	1.26	85.00	3.50	109.00*	.35	6.00	1.40
25	282	3.90	1.30	94.00	4.60	70.00	260.00	10.00	.00
30	282	4.00	1.40	200.00	5.20	84.00	340.00	14.00	.00
35	282	4.00	1.30	112.00	5.30	68.00	220.00	10.00	.00
37	282	4.80	1.20	164.00	6.20	72.00	270.00	8.00	.00
38	282	4.40	1.20	188.00	5.00	80.00	190.00*	14.00	.00
45	282	4.40	1.40	188.00	4.20	60.00	80.00*	10.00	.00
48	282	4.00	1.30	106.00	4.60	70.00	268.00	12.00	.00
49	282	4.30	1.20	27.00	6.00	89.00	131.00*	12.00	.00
50	282	3.90	1.10	31.00	6.00	90.00	131.00*	11.00	.00
56	282	4.10	1.00	29.00	6.00	68.00	154.00	14.00	.00
57	282	3.90	1.30	21.00	6.00	89.00	154.00	14.00	.00
64	282	4.60	.90	29.00	6.00	76.00	128.00*	12.00	.00
65	282	4.10	1.30	27.00	8.00	91.00	152.00	11.00	.00
68	282	5.00	.90	27.00	4.00	65.00	154.00	13.00	.00
72	282	4.70	1.10	29.00	5.00	71.00	154.00	12.00	.00
75	282	86.00	3.30	90.00	16.90	.90	3.50	.30	.20
79	282	79.00	3.50	83.00	11.30	1.10	6.70	1.20*	.50*
80	282	51.00*	4.20	98.00	.	.80	5.00	.50	.30
85	282	83.00	2.70	76.00	10.80	.90	5.00	.40	.10
87	282	74.00	3.90	74.00	13.40	.90	7.00	.70	.20
94	282	103.00	3.00	108.00	11.30	.90	7.30*	.60	.10
96	282	83.00	3.10	73.00	11.50	1.00	4.10	.80	.20
99	282	98.00	2.90	201.00	29.00	.60	4.50	.22	.04
101	282	76.00	3.40	115.00	28.00	.70	2.60	.34	.05
107	282	81.00	3.20	128.00	38.00	.70	3.30	.54	.05
108	282	78.00	3.00	155.00	33.00	.80	3.30	.72	.07
109	282	108.00	1.80	245.00	50.00	.70	2.70	.50	.05
114	282	82.00	3.50	227.00	32.00	.80	3.90	.50	.06
115	282	70.00	4.30	166.00	33.00	.70	3.70	.30	.08
120	282	73.00	2.90	81.00*	40.00	.50	1.50*	.45	.04
123	282	81.00	4.00	72.00	19.00*	.70*	4.70	.90	.40*
131	282	96.00	3.50	143.00*	36.00	.80	5.80	1.10	.50*
135	282	101.00	3.40	109.00*	19.00*	.60*	7.00	.80	.30*
142	282	74.00*	3.40	84.00	24.00	.80	5.80	.70	.30*
146	282	101.00	4.00	50.00	25.00	1.20	3.00	.40*	.20*
169	282	98.00	4.10	160.00	11.10	1.10	4.50	.70	.40
171	282	97.00	3.80	172.00	11.10	1.00	4.80	.70	.40
176	282	92.00	4.00	170.00	11.99	1.10	5.20	.70	.40
177	282	97.00	4.10	177.00	11.00	1.00	5.20	.70	.40
184	282	95.00	4.00	172.00	11.10	1.00	5.50	.80	.40
185	282	95.00	3.90	170.00	11.00	1.10	5.60	.80	.50
189	282	97.00	3.90	170.00	11.10	1.00	5.50	.70	.40
192	282	97.00	4.00	171.00	11.00	1.00	5.60	.70	.40
194	282	98.00	3.60	128.00	11.10	.76	4.90	.80	.40
198	282	109.00	4.50	125.00	10.60	.80	5.40	.90	.20
199	282	98.00	4.00	125.00	9.60	.90	5.40	1.10*	.30
200	282	108.00	4.10	120.00	9.10	.78	5.40	.80	.20
208	282	82.00	3.90	80.00	19.00	.88	5.20	.80	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

39

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
209	282	96.00	3.90	130.00	40.00*	1.30	5.40	.90	.40
211	282	102.00	3.80	127.00	11.00	.80	4.90	.80	.40
215	282	100.00	3.80	120.00	18.00	.90	5.00	.70	.40
217	282	5.22	7.24*	22.54	24.00	72.48	4.70	5.30	2.22
222	282	5.39	2.60	37.07	22.00	70.72	3.80	9.40	2.56
224	282	5.39	2.90	16.70	28.00	88.40	5.00	5.13	1.71
231	282	4.56	2.50	19.00	23.00	92.82	4.80	8.55	3.42
235	282	5.06	4.07	27.83	14.00*	85.74	4.90	11.11	4.27*
240	282	4.56	2.95	38.40	26.00	83.98	5.40	8.55	3.42
244	282	85.00	3.80	172.00	11.10	1.00	5.20	.60	.40
246	282	85.00	3.80	175.00	11.20	1.10	5.20	.60	.40
247	282	88.00	3.80	177.00	11.00	1.00	5.20	.70	.40
248	282	87.00	3.70	170.00	11.10	1.00	5.40	.70	.40
257	282	90.00	3.50	127.00	18.50	.80	4.80	.70	.30
258	282	102.00	4.00	128.00	10.00	.80	5.10	.60	.20
259	282	96.00	3.90	127.00	13.00	.80	5.50	.90	.10
263	282	96.00	3.90	116.00	20.00	.88	4.90	.70	.20
267	282	98.00	3.60	130.00	15.00	.80	5.10	1.00	.60*
270	282	105.00	3.80	120.00	16.00	.80	4.60	.90	.20
271	282	90.00	3.60	120.00	17.00	.70	4.20	.90	.20

FCE 20124/702 i

40

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
1	282	77.00	44.20*	5.90	1.68	2.70	8.10	9.90	12.10
5	282	75.00	42.30*	5.90	1.11	4.10	8.70	15.30	15.50
9	282	63.00	42.40*	4.63	.62	1.90	3.30*	7.30*	8.10*
12	282	60.00	37.80*	5.25	1.06	2.30	4.60*	7.80*	7.50*
13	282	77.00	49.80*	5.50	1.59	2.50	6.20	8.60	9.90*
14	282	64.00	40.20*	6.50	2.91*	2.40	5.40*	8.10	7.90*
25	282	72.00	40.00	4.10	1.00	3.60	9.60	10.20	14.00
30	282	82.00	46.00	5.80	1.20	5.00*	3.40	12.40*	14.60
35	282	78.00	30.00*	4.30	1.50	3.60	8.40	12.00	13.00
37	282	70.00	46.00	4.80	1.20	2.80	8.60	8.80	13.20
38	282	69.00	39.00	5.10	1.60	3.60	8.70	9.00	14.10
45	282	70.00	39.00	6.00	1.10	3.60	6.20*	8.20	16.00
48	282	70.00	40.00	4.40	1.30	2.90	8.40	10.00	13.80
49	282	73.00	52.00*	5.00	1.40	2.10*	5.00*	5.30*	9.10*
50	282	71.00	40.00	4.70	1.30	2.20*	4.90*	5.60*	9.10*
56	282	73.00	41.00	4.70	1.60	2.10*	7.10	8.80	14.00
57	282	75.00	43.00	4.90	1.70	2.40	6.60	9.10	13.90
64	282	72.00	50.00*	7.10*	1.80	1.20*	4.10*	5.90*	11.00*
65	282	73.00	44.00	4.30	1.70	1.10*	8.20	8.40	12.30*
68	282	74.00	44.00	5.30	1.40	2.10*	7.90	8.00*	12.00*
72	282	71.00	45.00	4.90	1.70	2.90	8.70	8.80	15.10
75	282	7.10	4.10	178.00	141.00	4.10	11.70	13.00	13.90
79	282	6.60	4.60	289.00*	218.00*	2.62	9.85	13.30	12.00
80	282	7.00	4.50	237.00*	316.00*	2.35*	8.32	14.24	13.26
85	282	7.10	4.30	233.00*	140.00	.	.	.	.
87	282	7.40	4.50	299.00*	231.00*	1.79*	9.11	13.50	17.05
94	282	7.10	4.50	312.00*	136.00	3.55	13.60	16.31*	11.06
96	282	7.40	4.70	233.00*	227.00*	2.57	9.88	14.75*	16.91
99	282	6.70	52.90*	191.00	250.00*	3.90	15.80*	14.00	13.40
101	282	7.00	61.50	245.00*	90.00	4.00	10.20	12.10	12.30
107	282	7.60	61.00	178.00	196.00*	2.70	8.90	14.70*	12.60
108	282	7.70	67.50	207.00	111.00	3.00	8.10	11.30	10.10
109	282	7.50	54.70*	278.00*	97.00	3.40	13.40*	13.30	15.20
114	282	7.50	50.20*	183.00	225.00*	2.90	8.90	18.10*	19.80*
115	282	7.20	58.90	223.00*	297.00*	2.80	10.80	13.70	14.60
120	282	7.40	58.60	210.00	45.00	3.40	8.60	14.00	15.40
123	282	7.50	4.30	189.00	136.00*	3.60	7.40*	10.60	9.70*
131	282	7.10	4.10	174.00	262.00*	1.80*	9.90	10.50	12.50
135	282	7.90	4.20	212.00	200.00	1.10*	8.60*	9.80	15.30
142	282	8.40	5.50*	157.00	166.00	2.20*	9.20	8.50	10.30
146	282	6.80	4.90	125.00	27.00	8.00	8.00	12.00	19.00
169	282	6.70	4.10	190.00	90.00	.31	.72	1.00	1.40
171	282	8.70*	4.20	189.00	78.00	.31	.72	.91	1.10
176	282	6.80	4.70	195.00	88.00	.39	.77	.95	1.30
177	282	8.80*	4.70	190.00	89.00	.32	.77	.96	1.20
184	282	8.70*	4.70	195.00	89.00	.39	.72	.92	1.20
185	282	6.80	4.80	195.00	92.00	.35	.79	.99	1.30
189	282	6.80	4.70	195.00	88.00	.41*	.72	1.00	1.30
192	282	6.80	4.70	190.00	87.00	.42*	.77	1.00	1.40
194	282	6.90	4.50	178.00	96.00	.20	.90	.60	1.60
198	282	7.20	6.20*	205.00	127.00	.40	.90	1.00	1.40
199	282	7.30	5.10	150.00	130.00	.40	.80	.80	1.50
200	282	6.20*	4.60	190.00	110.00	.40	.80	1.20*	1.30
208	282	6.80	5.30	179.00	96.00	.30	.70	.80	.90

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

41

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
209	282	8.30*	5.30	214.00	155.00	.40	.80	.90	1.10
211	282	8.00	4.30	175.00	100.00	.40	.60	.90	.90
215	282	8.00	5.50	160.00	120.00	.40	.90	.60	1.10
217	282	7.30	4.40	3.82*	88.00	.17*	.59*	1.02	1.08
222	282	6.50	4.41	5.79	67.00	.28	.54*	.71	.56*
224	282	7.00	4.11	4.55	132.00	.20	.63	.94	1.12
231	282	6.20	3.80	4.68	180.00*	.17*	.40*	.86	.97
235	282	6.80	3.97	5.33	105.00	.24	.48*	.84	1.27
240	282	7.40	3.80	4.62	106.00	.14*	.70	1.11	1.65*
244	282	7.20	5.20	195.00	90.00	.37	.72	1.00	1.30
246	282	7.40	4.40	192.00	90.00	.32	.75	1.00	1.30
247	282	7.30	4.50	192.00	88.00	.34	.75	1.00	1.30
248	282	7.20	4.40	192.00	90.00	.35	.72	1.10	1.40
257	282	8.00	5.10	178.00	103.00	.30	.80	.80	1.10
258	282	6.40*	6.40	200.00	130.00	.80*	.80	1.10	.90
259	282	7.20	4.30	202.00	132.00	.40	.70	.90	1.00
263	282	7.10	4.70	152.00	105.00	.30	.80	1.20*	1.00
267	282	5.20*	4.10	209.00	128.00	.30	.60	.70	1.00
270	282	7.10	4.10	156.00	105.00	.40	.70	1.00	.90
271	282	8.20	5.20	160.00	110.00	.40	.80	1.00	1.10

FCE 20124/702 i

42

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
25	282	1.024	0	0	0	0
30	282	.	0	0	0	0
35	282	1.022	0	0	0	0
37	282	1.020	0	0	0	0
38	282	1.020	0	0	0	0
45	282	1.020	0	0	0	0
48	282	1.024	0	0	0	0
49	282	1.019	0	0	0	0
50	282	1.025	0	0	0	0
56	282	1.018	0	0	0	0
57	282	1.027	0	0	0	0
64	282	1.024	0	0	0	0
65	282	1.027	0	0	0	0
68	282	1.021	0	0	0	0
72	282	1.018	0	0	0	0
75	282	1.022*	0	0	0	0
79	282	1.015	0	0	0	0
80	282	1.008	0	0	0	0
87	282	1.011	0	0	0	0
94	282	1.009	0	0	0	0
96	282	1.025*	0	0	0	0
99	282	1.013	0	0	0	0
101	282	1.014	0	0	0	0
107	282	1.013	0	0	0	0
108	282	1.016	0	0	0	0
109	282	1.018	0	0	0	0
114	282	1.018	0	0	0	0
115	282	1.013	0	0	0	0
120	282	1.007	0	0	0	0
123	282	1.020	0	0	0	20*
131	282	1.025	0	0	0	1
135	282	1.028	0	0	0	3
142	282	1.030	0	0	0	3
146	282	1.021	0	0	0	2
169	282	1.010	0	0	0	2
171	282	1.020	0	0	0	4
176	282	1.015	0	0	0	4
177	282	1.015	0	0	0	4
184	282	1.012	0	0	0	4
185	282	1.012	0	0	0	4
189	282	1.020	0	0	0	4
192	282	1.015	0	0	2	2
194	282	1.018	0	0	2	1
199	282	1.020	0	0	2	0
200	282	1.020	0	0	3	0
208	282	1.016	0	0	1	4
211	282	1.018	0	0	1	1
215	282	1.020	0	0	2	4
217	282	1.026	0	0	2	3
222	282	1.015	0	0	0	3
224	282	1.017	0	0	0	3
231	282	1.010*	0	0	0	1
235	282	1.015	0	0	0	2
240	282	1.012*	0	0	0	1

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

43

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
244	282	1.020	0	0	0	2
246	282	1.010	0	0	0	2
247	282	1.010	0	0	0	4
248	282	1.010	0	0	0	2
257	282	1.016	0	0	1	2
258	282	1.018	0	0	1	3
259	282	1.010	0	0	2	2
263	282	1.012	0	0	2	4
267	282	1.020	0	0	3	1
270	282	1.020	0	0	1	2

FCE 20124/702 i

Treatment Group "A"

44

Day 28 (Period 282)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	74	6
Hematocrit (HCT)	74	8
Red Blood Cells (RBC)	74	24
White Blood Cells (WBC)	74	6
Neutrophils (NEUTS)	74	7
Lymphocytes (LYMPS)	74	16
Eosinophils (EOSIN)	74	24
Monocytes (MONOS)	74	13
Basophils (BASOS)	74	6
Platelets (PLATES)	74	2
Sodium (NA+)	74	7
Phosphorous (K+)	73	4
Chlorine (CL-)	74	15
Calcium (CA++)	74	6
Aspartate		
Aminotransferase (SGOT)	74	4
Alanine		
Aminotransferase (SGPT)	74	8
$\tau$ -GT (YGT)	74	17
Blood Sugar (BLSUG)	74	2
Phosphorous (PO4)	74	3
Alkaline		
Phosphatase (ALKPHOS)	74	3
Urea Nitrogen (BUN)	73	4
Creatinine (CREAT)	74	3
Uric Acid (URACID)	74	8
Total Bilirubin (TOTBILI)	74	3
Direct Bilirubin (DIRBILI)	74	8
Total Protein (TOTPROT)	74	6
Albumin (BLALB)	74	15
Cholesterol (CHOLE)	74	11
Triglycerides (TRIGLY)	74	12
Globulins - $\alpha$ 1 (GLOBA1)	73	18
Globulins - $\alpha$ 2 (GLOBA2)	73	15
Globulins - $\beta$ (GLOBETA)	73	13
Globulins - $\tau$ (GLOGAMA)	73	13
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	63	4
Albumin (URALB)	64	0
Sugar (URSUG)	64	0
Red Blood Cells (URRBC)	64	0
White Blood Cells (URWBC)	64	1

FCE 20124/702 i

45

REBOXETINE Protocol ADE 08

Treatment Group "B"

Table 5 f- Laboratory Data

\* = Value out-of-range

Screening (Period -01)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
2	-01	13.20	38.90	4.27	8.10*	58.00	29.00	5.00*	7.00
4	-01	13.60	42.40	4.53	6.90	65.00	28.00	1.00	6.00
10	-01	12.10*	36.50*	4.00	8.00	67.00	27.00	1.00	4.00
11	-01	13.40	40.00	4.33	9.40*	61.00	27.00	4.00*	7.00
15	-01	13.70	40.30	4.64	5.30	*8.00*	40.00	4.00*	7.00
17	-01	13.30	40.80	4.02	4.70	50.00	40.00	2.00	7.00
28	-01	12.70	37.20	4.17*	8.10	52.00*	39.00*	4.00	5.00
29	-01	15.00	42.00	4.60	5.80	72.00	24.00	1.00	3.00
31	-01	15.00	40.00	5.20	5.40	70.00	26.00	3.00	1.00
32	-01	12.30	40.00	4.90	6.20	70.00	26.00	1.00	3.00
41	-01	14.80	40.00	4.90	6.80	70.00	26.00	1.00	3.00
42	-01	14.00	42.00	4.80	6.20	70.00	26.00	2.00	1.00
44	-01	15.00	39.00	4.60	5.80	70.00	26.00	1.00	3.00
47	-01	14.00*	40.00	4.60	5.80	72.00	24.00	.00*	4.00
51	-01	8.30	.42	4.10	5.00	74.00	21.00	1.00	4.00
54	-01	9.10	.50	5.10	6.10	63.00	31.00	2.00	3.00
55	-01	9.20	.47	5.20	6.10	67.00	26.00	2.00	4.00
60	-01	8.70	.45	4.90	6.10	65.00	28.00	2.00	4.00
61	-01	7.90	.43	4.90	6.20	75.00	20.00	1.00	3.00
66	-01	8.70	.43	4.71	5.90	64.00	30.00	2.00	4.00
67	-01	8.90	.46	4.90	5.80	63.00	31.00	1.00	3.00
70	-01	8.70	.47	5.20	6.10	78.00*	17.00	2.00	3.00
77	-01	12.90	39.30	4.60	6.00	.	.	.	.
78	-01	17.20	50.70	5.06	8.50	47.00	34.80	1.80	10.40*
83	-01	15.30	46.20	5.03	6.91	64.60	22.70	3.10	7.20
84	-01	14.30	42.80	4.68	5.25	46.60	41.40	2.20	6.70
88	-01	13.60	42.40	4.40	10.96*	53.90	33.20	3.30	6.80
90	-01	14.70	44.80	4.93	6.92	67.40	24.30	2.60	3.40
91	-01	17.00	52.00	5.48	8.26	51.40	40.70	1.60	3.90
95	-01	14.60	44.50	4.96	4.29*	53.90	34.40	3.20	5.70
98	-01	12.20	34.60*	3.87*	4.90	63.00	34.00	.00*	3.00
102	-01	15.10	42.60	4.79	3.20*	52.00	44.00	3.00	1.00*
103	-01	13.50*	37.40*	4.08*	5.70	52.00	44.00	3.00	1.00*
106	-01	14.10	38.30	4.31	7.30	58.00	38.00	2.00	2.00
110	-01	12.50	32.80*	3.67*	5.70	70.00	29.00	.00*	1.00*
113	-01	15.00	39.10	4.70	5.60	60.00	39.00	.00*	1.00*
118	-01	16.70	43.70	5.49	8.90	73.00	24.00	.00*	3.00
119	-01	15.30	42.80	4.77	6.30	38.00*	56.00*	3.00	3.00
124	-01	16.00	48.00*	5.20	5.60	71.00*	37.00*	.00	2.00*
126	-01	14.70	47.00	4.85	5.90	52.00*	45.00*	1.00	3.00*
127	-01	13.50	42.00	4.73	4.50*	66.00	49.00*	3.00*	1.00*
132	-01	14.00	44.00	4.84	4.00*	68.00	28.00	2.00	2.00*
133	-01	13.10	41.00	4.41	13.20*	80.00*	18.00*	2.00	.00*
136	-01	15.00	45.00	4.95	5.80	58.00*	40.00*	.00	.00*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

46

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
139	-01	13.90	43.00	4.73	6.30	64.00	34.00	2.00	.00*
140	-01	16.60*	52.00*	5.11	8.00	55.00*	44.00*	1.00	.00*
147	-01	13.50	41.20	4.33	9.90	58.00*	38.00*	3.00*	1.00*
148	-01	12.10	40.00	4.40	5.20	49.00*	41.00*	3.00*	7.00
170	-01	15.70	44.00	5.90	6.20	59.00	31.00	4.00*	6.00
172	-01	16.00	44.00	6.20*	6.00	58.00	30.00	4.00*	7.00
179	-01	16.00	44.00	6.80*	6.60	59.00	32.00	2.00	6.00
180	-01	15.90	44.00	6.10*	6.80	60.00	31.00	2.00	6.00
181	-01	15.90	44.00	6.00	5.90	60.00	30.00	3.00	7.00
186	-01	16.10	46.00	6.20*	7.70	58.00	33.00	2.00	6.00
187	-01	16.10	45.00	6.10	6.70	61.00	30.00	2.00	6.00
188	-01	15.90	44.00	6.00	5.90	60.00	30.00	3.00	7.00
193	-01	16.10*	46.00	5.10	6.00	59.00	31.00	5.00*	3.00
197	-01	17.00	46.00	6.20*	5.40	58.00	32.00	3.00	4.00
202	-01	16.00	45.00	5.80*	8.00	51.00*	39.00*	6.00*	2.00*
203	-01	14.00	46.00	5.80	5.00	56.00	34.00*	3.00	7.00
206	-01	13.10	42.00	5.10	4.90	52.00*	38.00*	4.00*	4.00
210	-01	16.00	47.00	5.20	8.00	52.00*	38.00*	6.00*	4.00
214	-01	14.00	44.00	5.10	8.20	58.00	32.00	2.00	7.00
216	-01	16.00	47.00	5.10	6.00	57.00	33.00	4.00*	3.00
218	-01	13.30	40.00	4.79	7.00	55.00	36.00	3.00	5.00
219	-01	14.70	43.00	5.16*	11.50*	82.00*	15.00*	.00	3.00
226	-01	12.90	40.00	4.30	6.80	66.00	27.00	3.00	3.00
227	-01	9.14*	39.00	3.85*	7.80	54.00	45.00*	1.00	.00
230	-01	14.89	42.00	5.00	8.20*	80.00*	17.00*	.00	3.00
233	-01	13.50	40.50	5.30	5.65	75.00*	20.00	1.00	4.00
237	-01	15.96	47.00	5.85*	6.50	68.00	27.00	2.00	3.00
238	-01	13.72	40.00	4.46	5.30	69.00	28.00	.00	2.00
243	-01	15.80	44.00	6.00	6.20	60.00	30.00	4.00*	6.00
245	-01	16.20	44.00	6.20*	5.90	59.00	30.00	4.00*	6.00
249	-01	15.60	42.00	5.90*	6.10	60.00	32.00	2.00	6.00
251	-01	13.00	45.00	4.80	6.00	56.00	34.00	6.00*	3.00
254	-01	12.50	39.00	5.00	4.80	53.00*	37.00*	3.00	3.00
255	-01	14.80	43.00	5.10	6.20	52.00*	38.00*	2.00	4.00
260	-01	15.80	42.00	5.90*	6.20	58.00	32.00	5.00*	4.00
262	-01	15.90	44.00	5.90	6.30	59.00	31.00	6.00*	3.00
268	-01	12.00	42.00	4.10*	7.40	52.00*	38.00*	4.00*	4.00
269	-01	13.20*	40.00*	5.10	4.80	51.00*	39.00*	4.00*	3.00
273	-01	13.50	44.00	4.80	7.50	53.00*	37.00*	6.00*	2.00*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

47

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
2	-01	1.00	242.00	141.00	4.00	100.00	2.22	6.00	5.00	9.00
4	-01	.00	329.00	142.00	4.60	103.00	.	15.00	29.00*	17.00
10	-01	1.00	265.00	140.00	4.60	101.00	2.24	6.00	5.00	6.00
11	-01	1.00	229.00	140.00	4.40	100.00	2.24	5.00	4.00*	5.00
15	-01	1.00	276.00	143.00*	4.40	103.00	2.29	8.00	10.00	14.00
17	-01	1.00	251.00	144.00*	4.50	102.00	2.31	8.00	15.00	14.00
28	-01	.00	275.00	141.00	4.30	100.20	2.10	6.00	5.00	21.00
29	-01	.00	232.00	146.00	4.90	100.00	2.40	14.00	16.00	14.00
31	-01	.00	238.00	148.00*	4.20	102.00	2.30	14.00	16.00	16.00
32	-01	.00	225.00	140.00	4.40	102.00	2.30	10.00	12.00	8.00
41	-01	.00	206.00	142.00	4.40	106.00	2.30	8.00	10.00	10.00
42	-01	1.00	188.00	146.00	4.00	104.00	2.00*	10.00	10.00	12.00
44	-01	.00	220.00	138.00	4.70	100.00	2.30	10.00	12.00	10.00
47	-01	.00	222.00	145.00	4.30	102.00	2.20	12.00	14.00	14.00
51	-01	.00	172.00	141.00	4.40	104.00	2.10	13.00	16.00	8.00
54	-01	1.00	184.00	137.00*	4.10	101.00	2.50	12.00	13.00	29.00*
55	-01	1.00	192.00	141.00	3.90	99.00	2.40	14.00	12.00	31.00*
60	-01	1.00	182.00	142.00	4.10	103.00	2.50	12.00	14.00	32.00*
61	-01	1.00	182.00	139.00	4.30	104.00	2.40	14.00	12.00	30.00*
66	-01	.00	184.00	139.00	4.20	99.00	2.70	12.00	14.00	32.00*
67	-01	.00	159.00	141.00	4.30	102.00	2.50	12.00	14.00	31.00*
70	-01	.00	192.00	141.00	4.00	103.00	2.40	14.00	12.00	31.00*
77	-01	.	.	136.00	3.10*	101.00	8.90	25.00	36.00	18.00
78	-01	1.20	275.00	140.00	4.60	102.00	10.20	29.00	35.00	96.00*
83	-01	.60	239.00	140.00	4.00	102.00	9.40	18.00	28.00	17.00
84	-01	.90	207.00	139.00	4.00	108.00	9.30	8.00	15.00	8.00
88	-01	.90	252.00	138.00	5.30	105.00	6.70*	10.00	6.00	8.00
90	-01	.70	196.00	146.00	4.50	110.00	9.00	11.00	10.00	8.00
91	-01	.90	229.00	141.00	4.30	104.00	9.50	9.00	8.00	7.00
95	-01	.50	157.00	142.00	3.80*	106.00	8.90	18.00	31.00	17.00
98	-01	.00	148.00*	140.00	3.80	101.00	8.40	20.00	27.00	35.00*
102	-01	.00	148.00*	138.00	4.20	100.00	8.50	30.00	26.00	19.90
103	-01	.00	226.00	140.00	4.10	99.00	10.50*	26.00	18.00	19.00
106	-01	.00	231.00	139.00	4.20	103.00	8.80	19.00	17.00	18.00
110	-01	.00	264.00	144.80	3.92	115.80*	8.70	13.00	15.00	16.00
113	-01	.00	189.00	137.00	4.80	113.00*	7.80*	16.00	22.00	21.00
118	-01	.00	183.00	138.00	3.80	110.00*	9.30	32.00	78.00*	61.00*
119	-01	.00	272.00	146.60	4.40	111.00*	8.80	18.00	16.00	9.30*
124	-01	.00	217.00	141.00	3.50*	358.00	9.70	15.00	15.00	14.00
126	-01	.00	309.00	138.00	5.10	340.00	9.30	14.00	7.00	6.00
127	-01	1.00	218.00	141.00	5.10	347.00	9.30	17.00	16.00	8.00
132	-01	.00	268.00	138.00	3.60*	360.00	9.70	20.00	13.00	15.00
133	-01	.00	277.00	135.00	4.00	360.00	9.70	20.00	24.00	10.00
136	-01	2.00	157.00	139.00	4.10	351.00	9.40	13.00	14.00	8.00
139	-01	.00	239.00	139.00	3.80	344.00	10.20	24.00	22.00	12.50
140	-01	.00	193.00	138.00	3.40*	346.00	9.80	28.00	18.00	10.50
147	-01	.00	220.00	139.00	4.00	95.00	8.00	3.00*	3.00	6.00
148	-01	.00	120.00*	138.00	3.80	100.00	6.80*	7.00	3.00	8.00
170	-01	.00	280.00	151.00	4.70	99.00	9.10	37.00	12.10	20.00
172	-01	1.00	277.00	138.00	5.10	97.00	9.20	38.00	9.70	8.10*
179	-01	1.00	285.00	140.00	5.10	98.00	9.00	38.00	9.70	8.10*
180	-01	1.00	270.00	140.00	5.10	97.00	9.10	37.00	9.80	8.10
181	-01	.00	280.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20*
186	-01	1.00	275.00	148.00	4.90	100.00	9.20	42.10	22.00	16.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

48

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
187	-01	1.00	280.00	138.00	5.10	98.00	9.00	39.00	9.80	8.10*
188	-01	.00	285.00	140.00	4.90	99.00	9.10	37.00	10.00	8.10*
193	-01	2.00*	268.00	138.00	5.00	100.00	9.10	31.00	18.00	30.00
197	-01	3.00*	266.00	138.00	4.60	100.00	9.50	29.00	18.00	28.00
202	-01	2.00*	300.00	145.00	4.10	105.00	9.10	28.00	24.00	28.00
203	-01	.00	370.00	145.00	4.90	99.00	10.00	40.00	32.00	52.00
206	-01	2.00*	180.00	150.00	5.20	102.00	10.20	31.00	24.00	22.00
210	-01	.00	230.00	135.00	5.20	99.00	9.60	40.00	34.00	24.00
214	-01	1.00	340.00	148.00	5.30	102.00	9.60	26.00	29.00	42.00
216	-01	3.00*	280.00	140.00	5.00	105.00	8.20*	16.00	22.00	23.00
218	-01	1.00	280.00	140.00	4.20	.	9.09	9.60	3.84	38.00*
219	-01	.00	300.00	142.00	4.10	.	8.40*	9.12	3.36	23.00
226	-01	1.00	300.00	139.00	4.20	103.00	10.00	8.00	5.00	16.00
227	-01	.00	290.00	134.00*	4.40	100.00	8.50	10.00	7.00	16.00
230	-01	.00	300.00	137.00	4.30	97.00	8.50	16.00	7.00	28.00
233	-01	.00	380.00	136.00	3.60	97.00	8.90	13.00	18.00	36.00
237	-01	.00	290.00	139.00	4.60	96.00	9.45	13.00	6.00	17.00
238	-01	1.00	310.00	139.00	4.00	106.00	8.69	18.00	4.00	13.00
243	-01	.00	275.00	151.00	4.70	97.00	9.10	36.00	12.10	18.00
245	-01	1.00	280.00	139.00	4.90	99.00	9.80	38.00	9.70	8.00*
249	-01	.00	275.00	135.00	4.90	95.00	8.80	38.00	9.70	8.10
251	-01	1.00	180.00	136.00	4.90	100.00	8.90	41.00	32.00	30.00
254	-01	4.00*	310.00	135.00	4.20	104.00	8.80	30.00	32.00	35.00
255	-01	4.00*	248.00	138.00	5.10	104.00	7.90*	43.00	36.00	26.00
260	-01	1.00	280.00	136.00	5.20	109.00*	4.60*	35.00	28.00	33.00
262	-01	1.00	318.00	140.00	4.80	105.00	8.60	30.00	31.00*	34.00
268	-01	1.00	180.00	150.00	5.10	96.00	9.20	43.00	32.00*	24.00
269	-01	3.00*	230.00	145.00	4.70	97.00	8.20*	30.00	16.00	32.00
273	-01	2.00*	230.00	138.00	5.20	112.00*	9.10	36.00	38.00*	27.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

49

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPPOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
2	-01	4.34	1.23	94.00	6.50	84.00	.15	6.00	1.40
4	-01	4.30	.	142.00	3.30	83.00	.34	7.00	1.90
10	-01	5.50	1.21	85.00	5.10	76.00	.60*	4.00	.70
11	-01	4.57	1.26	105.00	3.30	76.00	.08*	5.00	.70
15	-01	4.84	1.43	123.00	3.00	74.00	.19	8.00	7.20*
17	-01	5.49	1.30	148.00	3.30	83.00	.20	4.00	.90
28	-01	5.30	1.00	188.00	5.00	90.00	300.00	8.00	.00
29	-01	4.20	1.40	180.00	5.20	75.00	260.00	12.00	.00
31	-01	3.80	1.30	180.00	5.60	72.00	300.00	16.00	.00
32	-01	3.90	.90	102.00	4.00	68.00	250.00	8.00	.00
41	-01	3.20	1.00	96.00	6.00	72.00	240.00	8.00	.00
42	-01	4.60	1.30	86.00	5.20	64.00	188.00*	14.00	.00
44	-01	4.20	1.40	106.00	6.00	72.00	280.00	8.00	.00
47	-01	3.80	1.30	110.00	4.60	70.00	260.00	10.00	.00
51	-01	5.40	.90	29.00	8.00	74.00	121.00*	14.00	.00
54	-01	4.60	1.30	30.00	3.00	69.00	161.00	13.00	.00
55	-01	5.00	.90	27.00	5.00	91.00	158.00	11.00	.00
60	-01	4.70	1.00	27.00	8.00	76.00	161.00	14.00	.00
61	-01	3.90	.90	29.00	4.00	69.00	154.00	11.00	.00
66	-01	4.50	1.00	30.00	8.00	88.00	151.00	14.00	.00
67	-01	4.10	1.10	27.00	4.00	67.00	161.00	14.00	.00
70	-01	4.70	1.00	28.00	8.00	72.00	151.00	17.00	.00
77	-01	66.00*	3.80	64.00	9.70	1.00	7.60*	.50	.10
78	-01	99.00	2.80	117.00	23.40*	1.30*	6.30	1.50*	.40*
83	-01	91.00	3.40	85.00	11.20	.80	4.70	.50	.30
84	-01	88.00	3.80	83.00	13.30	.80	3.00*	.40	.30
88	-01	75.00	4.00	111.00	8.20	.90	2.80*	.40	.10
90	-01	76.00	3.70	74.00	11.80	1.00	2.70*	.60	.10
91	-01	81.00	4.40	76.00	16.50	1.10	5.40	1.30*	.10
95	-01	88.00	3.60	50.00	12.10	1.10	4.80	.90	.10
98	-01	111.00*	2.60	127.00	42.00	.70	3.50	.24	.05
102	-01	72.00	2.20*	151.00	31.00	.90	2.50	.40	.10
103	-01	72.00	2.90	120.00	38.00	.70	3.10	.52	.10
106	-01	97.00	2.70	175.00	36.00	.80	2.30*	.53	.10
110	-01	91.00	3.70	159.00	31.00	.40*	1.30*	.30	.02
113	-01	127.00*	3.50	138.00	39.00	.70	4.30	.75	.07
118	-01	79.00	2.50	214.00	54.00*	1.20	3.70	.60	.07
119	-01	76.00	3.50	203.00	32.00	.80	3.70	.27	.05
124	-01	78.00	3.80	95.00*	22.00	.50*	3.70	.90	.30*
126	-01	97.00	3.40	57.00	31.00	.90	2.60	.70	.30*
127	-01	89.00	3.70	69.00	26.00	.90	3.80	1.70	.70*
132	-01	123.00*	3.90	101.00*	36.00	.90	3.50	1.40	.60*
133	-01	86.00	3.80	69.00	29.00	.80	5.10	.90	.40*
136	-01	100.00	3.60	81.00	23.00	.80	4.90	.60	.30*
139	-01	77.00	3.10	67.00	21.00	.70*	3.20	.60	.20*
140	-01	79.00	3.40	77.00	28.00	.90	7.20	3.20*	1.30*
147	-01	82.00	2.60	12.00	16.00*	.70	2.30*	.70	.40*
148	-01	95.00	2.70	30.00	17.00*	.60	2.40*	.80	.60*
170	-01	92.00	3.80	132.00	12.10	1.10	4.60	.90	.40
172	-01	97.00	3.90	171.00	11.20	1.00	4.60	.70	.40
179	-01	98.00	4.10	170.00	11.10	1.00	5.20	.70	.40
180	-01	97.00	3.90	172.00	11.00	1.00	4.70	.70	.40
181	-01	92.00	4.00	172.00	11.10	1.00	5.70	.70	.40
186	-01	97.00	4.10	180.00	12.10	1.20	6.10	.80	.50

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

50

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
187	-01	97.00	4.00	170.00	11.10	1.10	5.20	.70	.40
188	-01	78.00	3.90	170.00	11.10	1.10	5.60	.70	.40
193	-01	100.00	3.90	131.00	11.50	.79	4.90	.70	.10
197	-01	108.00	3.80	135.00	22.50	.79	4.60	.70	.30
202	-01	102.00	3.50	80.00	14.00	1.20	4.90	.60	.50
203	-01	90.00	3.80	134.00	13.00	.75	4.80	.90	.30
206	-01	90.00	3.90	130.00	11.00	1.20	5.40	.90	.40
210	-01	90.00	3.60	130.00	26.00*	.76	4.70	.90	.40
214	-01	90.00	3.60	125.00	19.00	.70	4.20	.80	.50
216	-01	105.00	4.00	127.00	11.00	.80	5.20	.80	.30
218	-01	4.95	3.75	55.11*	24.00	88.40	3.30	5.13	3.42
219	-01	4.40	3.99	56.78*	27.00	66.30	3.60	5.13	1.71
226	-01	5.22	2.60	38.41	32.00	70.72	5.30	5.98	1.71
227	-01	4.29	2.80	28.39	21.50	110.25*	4.20	8.55	4.10*
230	-01	5.06	2.70	39.24	24.00	97.24	5.00	8.55	1.71
233	-01	6.49	2.70	28.00	17.00*	79.56	4.90	11.97	1.71
237	-01	5.33	4.39	2.70*	16.00*	110.50	6.00	17.95*	5.98*
238	-01	4.95	4.07	29.00	22.00	66.30	5.98	5.98	2.56
243	-01	86.00	3.80	134.00	12.10	1.10	5.40	.90	.40
245	-01	88.00	3.90	175.00	11.20	1.10	5.20	.60	.40
249	-01	90.00	3.70	170.00	11.20	1.00	4.90	.70	.40
251	-01	98.00	3.90	127.00	10.50	.70	5.20	.80	.10
254	-01	105.00	3.90	118.00	18.00	.80	4.40	.80	.20
255	-01	95.00	3.80	80.00	18.00	.87	5.00	.90	.30
260	-01	100.00	3.60	118.00	11.00	.80	5.30	.80	.20
262	-01	96.00	3.80	120.00	16.00	.80	4.30	.90	.20
268	-01	98.00	3.80	126.00	16.00	.77	4.70	.80	.20
269	-01	90.00	3.50	130.00	11.20	.75	4.70	1.00	.20
273	-01	104.00	3.80	132.00	16.00	.75	5.20	.80	.30

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

51

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
2	-01	65.00	38.70*	7.90*	1.08	1.80	5.90*	7.70*	10.90*
4	-01	66.00	38.00*	7.50*	.	2.30	7.10	10.20	8.40*
10	-01	68.00	39.60*	5.00	1.00	2.90	6.70	9.20	9.60*
11	-01	71.00	43.60*	4.60	.80	3.90	9.00	11.80	13.90
15	-01	59.00*	34.00*	5.10	.46	2.20	4.60*	7.40*	10.80*
17	-01	62.00	39.90*	6.00	1.40	2.50	6.30	7.70*	5.60*
28	-01	72.00	43.00	6.00	1.30	3.10	7.80	8.20	17.00
29	-01	74.00	38.00	5.00	1.20	3.00	8.10	10.00	14.00
31	-01	72.00	40.00	5.00	1.20	3.00	7.40	10.00	13.00
32	-01	70.00	39.00	4.10	.90	2.60	7.00	8.40	14.00
41	-01	76.00	40.00	6.00	1.30	2.60	6.90	9.00	14.00
42	-01	70.00	40.00	4.90	.90	3.20	8.00	8.80	14.00
44	-01	70.00	42.00	4.60	1.20	3.60	8.20	8.40	14.00
47	-01	70.00	38.00	4.40	1.20	2.80	7.00	10.00	14.00
51	-01	76.00	50.00*	6.30	1.40	1.80*	5.30*	8.00*	11.00*
54	-01	73.00	43.00	5.40	1.10	2.40	6.60	8.40	12.60
55	-01	73.00	41.00	5.10	1.30	2.40	6.10*	8.70	14.60
60	-01	71.00	40.00	4.60	1.50	2.50	6.50*	9.10	12.90
61	-01	72.00	45.00	4.70	1.90	2.70	8.10	9.20	14.30
66	-01	80.00	50.00*	5.30	1.40	2.60	6.40*	8.20	12.80
67	-01	77.00	45.00	4.60	1.60	2.20*	6.80	9.10	13.90
70	-01	73.00	41.00	5.10	1.70	2.10*	6.90	8.10	14.90
77	-01	7.10	4.30	263.00*	172.00*	.	.	.	.
78	-01	7.90	5.00*	333.00*	282.00*	3.15	13.35	16.35*	16.15
83	-01	7.70	4.30	183.00	147.00	2.29*	13.79*	16.63*	15.18
84	-01	7.00	4.10	191.00	134.00	.	.	.	.
88	-01	6.80	4.30	292.00*	344.00*	.	.	.	.
90	-01	6.80	4.30	258.00*	83.00	2.73	9.97	13.96	14.22
91	-01	7.10	4.80	164.00*	101.00	3.21	9.82	14.83*	13.90
95	-01	6.80	4.20	187.00	.	.	.	.	.
98	-01	6.60	65.90	172.00	178.00*	3.10	9.50	9.80	11.70
102	-01	6.80	63.40	189.00	87.00	2.70	8.00	10.80	14.60
103	-01	8.30	58.40	203.00	143.00	3.40	9.40	11.70	17.10
106	-01	7.50	58.50	186.00	115.00	2.90	10.10	11.40	17.10
110	-01	6.80	58.80	139.00	185.00*	2.50	9.10	12.00	17.50
113	-01	7.30	54.50*	205.00	131.00	2.80	9.80	15.50*	17.40
118	-01	8.10	53.60*	180.00	93.00	4.30	10.90	13.20	18.10*
119	-01	7.30	61.70	148.00	141.00	3.20	8.30	12.40	14.50
124	-01	6.90	4.10	189.00	190.00	2.70	6.90*	11.30	10.60
126	-01	6.70	3.60*	166.00	188.00	4.00	9.70	8.80	10.60
127	-01	6.80	4.00	119.00*	50.00	1.90*	8.10*	7.40*	13.50
132	-01	7.50	5.60*	234.00	207.00	1.80*	10.00	8.10	14.20
133	-01	7.90	4.80	159.00	195.00	2.00*	10.00	8.40	12.90
136	-01	7.10	4.40	187.00	110.00	2.20*	10.10	9.40	7.90*
139	-01	7.60	5.00	202.00	133.00	3.30	4.60*	11.70	10.20
140	-01	8.30	5.40*	163.00	80.00	1.70*	7.70*	7.90*	10.50
147	-01	7.50	5.50	175.00	30.00	6.00	10.00	11.00	15.00
148	-01	7.50	5.40	150.00	35.00	6.00	7.00*	10.00*	23.00
170	-01	7.70	4.10	175.00	92.00	.30	.80	.90	1.30
172	-01	6.80	4.10	195.00	90.00	.32	.71	.96	1.30
179	-01	6.70	4.40	197.00	88.00	.31	.72	.91	1.20
180	-01	8.70*	4.20	190.00	88.00	.32	.72	.93	1.20
181	-01	8.80*	4.70	175.00	72.00	.33	.72	.95	1.30
186	-01	8.10	4.30	194.00	87.00	.35	.75	.92	1.50

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
187	-01	6.70	4.50	190.00	88.00	.40	.70	.90	1.30
188	-01	8.80*	4.60	205.00	89.00	.32	.81	1.10	1.30
193	-01	7.00	4.50	130.00*	98.00	.30	.60	.80	1.40
197	-01	6.90	4.80	182.00	96.00	.30	.80	.70	1.30
202	-01	8.10	5.20	250.00	150.00	.40	.80	1.00	1.50
203	-01	6.90	4.40	150.00	130.00	.30	.60	.80	1.40
206	-01	6.80	4.30	180.00	99.00	.40	.80	1.10	1.00
210	-01	8.20	4.20	210.00	130.00	.40	.60	.80	1.10
214	-01	7.00	5.10	180.00	105.00	.40	.80	.80	1.20
216	-01	6.80	6.40*	210.00	132.00	.30	.80	.80	1.20
218	-01	6.30	5.00	6.24	59.00	.20	.60	1.00	2.00*
219	-01	6.00	4.00	5.98	80.00	.25	.90	1.14	1.31*
226	-01	7.50	4.47	4.42	140.00	.14*	.67	.97	1.25
227	-01	7.60	4.01	5.20	116.00	.16*	.68	1.24*	1.51*
230	-01	6.70	3.54	4.68	180.00*	.12*	.62	1.13	1.29
233	-01	7.20	4.00	5.72	90.00	.16*	.62	1.18	1.24
237	-01	7.90	4.93	5.66	102.00	.30	.58*	.93	1.16
238	-01	6.60	3.30	4.29	126.00	.18*	.48*	.88	1.76*
243	-01	7.60	4.50	175.00	82.00	.34	.72	1.10	1.40
245	-01	7.10	4.20	198.00	88.00	.32	.72	1.10	1.40
249	-01	7.20	4.20	195.00	85.00	.33	.75	1.10	1.30
251	-01	6.90	5.40	200.00	132.00	.30	.80	.80	1.21
254	-01	8.00	5.10	164.00	105.00	.20	.60	.80	1.20
255	-01	8.90*	5.30	180.00	99.00	.20	.70	.30*	1.30
260	-01	6.90	4.10	176.00	95.00	.40	.60	.80	1.10
262	-01	4.90*	3.60	162.00	110.00	.20	.60	.80	1.20
268	-01	8.20	5.10	245.00	145.00	.40	.80	.90	1.20
269	-01	6.70	4.10	182.00	97.00	.30	.70	.60	1.40
273	-01	6.10	3.80	230.00	130.00	.40	.60	.90	1.20

52

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

53

Pat. No.	Per. (dy)	T3	T4	SPEGRAV	URALE	URSUG	URRBC	URWBC
2	-01	4.80	14.00	.	.	.	.	.
4	-01	6.90	15.00	.	.	.	.	.
10	-01	6.00	14.00	.	.	.	.	.
11	-01	5.30	13.00	.	.	.	.	.
15	-01	6.40	12.80	.	.	.	.	.
17	-01	4.20	15.00	.	.	.	.	.
28	-01	1.00	104.00	1.022	0	0	0	0
29	-01	.90	78.00	1.024	0	0	0	0
31	-01	.90	90.00	1.020	0	0	0	0
32	-01	.90	80.00	1.018	0	0	0	0
41	-01	.96	102.00	1.020	0	0	0	0
42	-01	.88	80.00	1.020	0	0	0	0
44	-01	.90	100.00	1.026	0	0	0	0
47	-01	.90	90.00	1.024	0	0	0	0
51	-01	1.02	74.00	1.021	0	0	0	0
54	-01	.96	86.00	1.031*	0	0	0	0
55	-01	1.01	150.00	1.029	0	0	0	0
60	-01	1.00	76.00	1.025	0	0	0	0
61	-01	.97	69.00	1.017	0	0	0	0
66	-01	.97	87.00	1.021	0	0	0	0
67	-01	.95	69.00	1.011	0	0	0	0
70	-01	.97	86.00	1.018	0	0	0	0
77	-01	140.00	10.50	1.022*	0	0	0	0
78	-01	.	.	1.033*	3*	0	0	0
83	-01	94.00	9.70	1.014*	0	0	0	0
84	-01	80.00*	4.40*	1.016	0	0	0	0
88	-01	127.00	7.30	1.011*	0	0	0	0
90	-01	98.00	8.00	1.015	0	0	0	0
91	-01	126.00	9.70	1.031*	3*	0	0	10*
95	-01	78.00	5.90	.	.	.	.	.
98	-01	176.00	8.50	1.016	0	0	0	0
102	-01	178.00	9.00	1.012	0	0	0	0
103	-01	138.00	6.20	1.007	0	0	0	0
106	-01	137.00	7.10	1.030	0	0	0	0
110	-01	152.00	7.90	1.015	0	0	0	0
113	-01	153.00	8.20	1.015	0	0	0	0
118	-01	128.00	6.00	1.021	0	0	0	0
119	-01	189.00	12.50	1.018	0	0	0	0
124	-01	103.00	8.10	1.020	0	0	0	1
126	-01	134.00	10.20	1.020	0	0	1	3
127	-01	133.00	8.70	1.030	0	0	1	1
132	-01	125.00	12.70*	1.030	0	0	0	2
133	-01	152.00	12.00	1.030	0	0	3	45*
136	-01	116.00	12.70*	1.030	0	0	0	1
139	-01	139.00	12.50*	1.025	0	0	3*	3
140	-01	134.00	14.10*	1.020	0	0	0	1
147	-01	193.00*	12.70*	1.020	0	0	0	2
148	-01	98.00	5.30	1.020	0	0	0	8*
170	-01	115.00	8.60	1.020	0	0	0	4
172	-01	110.00	7.60	1.015	0	0	0	2
179	-01	110.00	7.60	1.010	0	0	0	2
180	-01	120.00	7.40	1.015	0	0	0	0
181	-01	115.00	7.70	1.012	0	0	0	2
186	-01	110.00	8.60	1.012	0	0	0	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

54

Pat. No.	Per. (dy)	T3	T4	SPEGRAV	URALB	URSUG	URRBC	URWBC
187	-01	112.00	7.70	1.020	0	0	0	4
188	-01	111.00	7.50	1.015	0	0	0	4
193	-01	118.00	8.20	1.020	0	0	3	0
197	-01	118.00	8.10	1.016	0	0	1	30*
202	-01	115.00	6.00	1.016	0	0	1	4
203	-01	120.00	8.20	1.020	0	0	1	2
206	-01	110.00	8.40	1.014	0	0	2	4
210	-01	150.00	10.50	1.018	0	0	2	3
214	-01	153.00	9.40	1.020	0	0	1	2
216	-01	128.00	5.30	1.018	0	0	1	3
218	-01	1.13	7.40	1.018	0	0	0	1
219	-01	1.10	6.10	1.015	0	0	0	2
226	-01	1.07	3.60*	1.018	0	0	0	1
227	-01	1.14	4.80	1.022	0	0	1	2
230	-01	1.74	9.10	1.011*	0	0	0	3
233	-01	.90	6.40	.	0	0	8*	3
237	-01	.98	7.30	1.015	0	0	0	1
238	-01	1.30	8.50	1.008*	0	0	2	1
243	-01	110.00	7.80	1.012	0	0	0	2
245	-01	112.00	7.60	1.015	0	0	0	2
249	-01	110.00	7.80	1.015	0	0	0	2
251	-01	128.00	5.80	1.020	0	0	1	4
254	-01	94.00	9.10	1.016	0	0	1	3
255	-01	98.00	8.60	1.020	0	0	2	2
260	-01	126.00	5.30	1.012	0	0	2	4
262	-01	150.00	9.10	1.012	0	0	0	2
268	-01	120.00	4.10*	1.016	0	0	2	4
269	-01	120.00	3.10*	1.018	0	0	1	3
273	-01	120.00	8.20	1.022	0	0	2	4

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

55

Treatment Group "B"

Screening (Period -01)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	83	7
Hematocrit (HCT)	83	7
Red Blood Cells (RBC)	83	17
White Blood Cells (WBC)	83	10
Neutrophils (NEUTS)	82	22
Lymphocytes (LYMPS)	82	22
Eosinophils (EOSIN)	82	26
Monocytes (MONOS)	82	16
Basophils (BASOS)	82	9
Platelets (PLATES)	82	3
Sodium (NA+)	83	5
Phosphorous (K+)	83	5
Chlorine (CL-)	81	6
Calcium (CA++)	82	10
Aspartate		
Aminotransferase (SGOT)	83	1
Alanine		
Aminotransferase (SGPT)	83	6
$\gamma$ -GT (GGT)	83	18
Blood Sugar (BLSUG)	83	4
Phosphorous (PO4)	82	1
Alkaline		
Phosphatase (ALPKPHOS)	83	5
Urea Nitrogen (BUN)	83	7
Creatinine (CREAT)	83	5
Uric Acid (URACID)	83	12
Total Bilirubin (TOTBILI)	83	4
Direct Bilirubin (DIRBILI)	83	14
Total Protein (TOTPROT)	83	6
Albumin (BLALB)	83	15
Cholesterol (CHOLE)	83	9
Triglycerides (TRIGLY)	81	6
Globulins - $\alpha$ 1 (GLOBAL1)	79	14
Globulins - $\alpha$ 2 (GLOBAL2)	79	14
Globulins - $\beta$ (GLOBETA)	79	13
Globulins - $\gamma$ (GLOBAMA)	79	12
Thyroxine T3 (T3)	82	2
Thyroxine T4 (T4)	82	9
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	75	8
Albumin (URALB)	76	2
Sugar (URSUG)	76	0
Red Blood Cells (URRBC)	76	2
White Blood Cells (URWBC)	76	4

FCE 20124/702 i

56

\* = Value out-of-range

Day 7 (Period 072)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
2	072	12.70*	35.50*	3.99*	5.40	57.00	29.00	3.00	10.00*
4	072	12.80*	38.10	4.07	7.50	59.00	31.00	2.00	7.00
10	072	12.60*	37.80*	4.30	8.90*	67.00	23.00	1.00	9.00
11	072	13.20	39.70	4.44	9.00*	67.00	26.00	1.00	5.00
15	072	12.90*	37.70	4.28	5.20	57.00	32.00	2.00	8.00
17	072	13.00	39.70	3.97*	4.40	52.00	36.00	3.00	8.00
28	072	12.60	37.40	4.87	8.40	60.00	34.00*	4.00	2.00
29	072	15.20*	42.00	4.80	5.60	70.00	22.00	4.00	3.00
31	072	14.60*	42.00	5.80*	6.00	66.00	28.00	3.00	1.00
32	072	13.50	41.00	5.00	6.00	68.00	28.00	2.00	2.00
41	072	14.60	40.00	4.80	6.70	71.00	25.00	2.00	2.00
42	072	14.20	40.00	4.60	5.80	68.00	28.00	3.00	1.00
44	072	14.60	38.00	4.80	5.90	68.00	24.00	5.00*	2.00
47	072	14.20*	40.00	4.40	5.60	70.00	24.00	3.00	3.00
51	072	8.40	.43	4.50	5.20	73.00	22.00	2.00	3.00
54	072	8.90	.46	5.10	6.30	64.00	30.00	2.00	3.00
55	072	8.90	.46	5.30	6.40	65.00	31.00	1.00	3.00
60	072	8.40	.45	5.00	5.90	61.00	33.00	1.00	4.00
61	072	7.80	.43	5.00	6.00	75.00	21.00	1.00	3.00
66	072	8.70	.44	5.10	6.70	65.00	29.00	2.00	3.00
67	072	8.70	.46	5.10	6.30	72.00	21.00	2.00	4.00
70	072	8.90	.48	5.40	6.00	75.00	21.00	1.00	3.00
77	072	12.80	40.80	4.40	5.11	55.00	29.40	1.30	9.50*
98	072	12.30	33.70*	3.83*	6.00	70.00	28.00	.00	2.00
102	072	16.00	44.60	5.08	4.30*	57.00	38.00	3.00	2.00
103	072	14.20	40.50*	4.49*	7.00	66.00	21.00	9.00*	4.00
106	072	13.70	37.40	4.22	7.20	89.00*	14.00*	4.00	3.00
110	072	14.10	37.00	4.29	4.80	63.00	34.00	1.00	2.00
113	072	16.10*	40.80	4.68	5.40	59.00	38.00	2.00	1.00*
118	072	16.30	42.90	3.98*	8.70	70.00	29.00	.00*	1.00*
119	072	16.60	44.50	4.95	6.20	44.00	48.00*	3.00	5.00
124	072	14.80	45.00	4.80	4.50*	50.00*	50.00*	.00	4.00*
126	072	13.10	41.00	4.51	5.00	59.00*	35.00	3.00*	3.00*
127	072	13.40	42.00	4.62	4.10*	70.00	30.00	.00	.00*
132	072	13.10	41.00	4.00*	4.40*	68.00	30.00	1.00	1.00*
133	072	13.50	42.00	4.42	6.80	51.00*	48.00*	1.00	.00*
136	072	17.10*	52.00*	5.02	5.40	72.00*	26.00	2.00	.00*
139	072	15.50	48.00*	5.28	6.50	63.00	36.00*	1.00	.00*
140	072	17.20*	53.00*	5.30	5.90	62.00	34.00	4.00*	.00*
147	072	13.00	40.00	4.50	7.10	60.00	35.00	2.00	1.00*
148	072	12.00	36.00*	4.90	6.00	65.00	30.00	3.00*	2.00*
170	072	15.80	44.00	6.10	7.20	60.00	30.00	3.00	6.00
172	072	15.90	44.00	6.00	5.90	60.00	30.00	3.00	7.00
179	072	16.10	45.00	6.10	6.80	61.00	30.00	2.00	6.00
180	072	15.90	44.00	6.00*	6.80	59.00	32.00	2.00	6.00
181	072	15.90	44.00	6.00	5.90	60.00	31.00	3.00	6.00
186	072	16.00	46.00	6.00	7.10	61.00	30.00	2.00	6.00
187	072	16.10	45.00	6.20*	7.30	60.00	30.00	3.00	7.00
188	072	15.90	45.00	5.90	6.20	59.00	32.00	2.00	6.00
193	072	16.20*	45.00	5.10	6.00	58.00	32.00	5.00*	3.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

57

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
197	072	17.10	47.00	6.30*	5.50	57.00	33.00	6.00*	2.00*
202	072	16.00	45.00	5.80*	8.10	52.00*	38.00*	6.00*	3.00
203	072	14.00	47.00	5.70	5.10	58.00	32.00	2.00	7.00
206	072	13.10	42.00	5.20	4.80	53.00*	37.00*	4.00*	4.00
210	072	16.00	47.00	5.20	8.10	54.00	36.00*	5.00*	3.00
214	072	14.00	44.00	5.10	8.30	58.00	32.00	2.00	7.00
216	072	16.00	46.00	5.10	6.10	54.00	36.00*	3.00	6.00
218	072	13.50	41.00	4.35	7.90	69.00	25.00	3.00	3.00
219	072	14.27	44.00	5.10*	8.32*	80.00*	17.00*	2.00	1.00
226	072	12.42	37.00	4.55	6.70	63.00	35.00	1.00	1.00
227	072	12.55	38.00	3.70*	6.00	57.00	36.00	3.00	4.00
230	072	13.90	43.00	4.90	7.90	77.00*	16.00*	2.00	4.00
233	072	13.90	41.00	5.25	5.95	75.00*	20.00	1.00	4.00
237	072	15.50	44.00	5.25	6.05	68.00	29.00	1.00	2.00
238	072	13.90	43.00	4.55	5.50	64.00	32.00	2.00	2.00
243	072	15.90	44.00	6.20*	5.90	59.00	31.00	4.00*	6.00
245	072	16.00	44.00	6.10	5.90	60.00	30.00	3.00	6.00
249	072	15.60	42.00	5.80*	6.10	60.00	30.00	4.00*	6.00
251	072	13.00	45.00	4.80	6.00	56.00	34.00	7.00*	3.00
254	072	12.50	38.00	5.00	4.80	52.00*	38.00*	3.00	4.00
255	072	14.70	43.00	5.10	6.00	54.00	36.00*	3.00	3.00
260	072	15.80	42.00	5.60*	6.20	57.00	33.00	5.00*	4.00
262	072	15.90	42.00	5.90	6.20	59.00	31.00	5.00*	4.00
268	072	12.20	42.00	4.20	7.30	53.00*	37.00*	5.00*	4.00
269	072	13.10*	40.00*	5.10	4.70*	52.00*	38.00*	4.00*	3.00
273	072	13.50	43.00	4.80	7.50	54.00	36.00*	6.00*	1.00*

FCE 20124/702 i

58

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
2	072	1.00	267.00	141.00	4.30	102.00	2.28	8.00	7.00	15.00
4	072	1.00	342.00	143.00*	5.00*	104.00	2.45	10.00	28.00*	14.00
10	072	.00	348.00	141.00	4.50	107.00	2.45	8.00	7.00	9.00
11	072	1.00	317.00	142.00	4.20	105.00	2.29	7.00	5.00	6.00
15	072	1.00	241.00	143.00*	4.30	100.00	2.29	8.00	9.00	15.00
17	072	1.00	243.00	143.00*	4.30	99.00	2.20	7.00	12.00	13.00
28	072	.00	270.00	140.00	4.40	100.00	2.00*	6.00	6.00	20.00
29	072	1.00	220.00	146.00	4.30	102.00	2.30	10.00	12.00	10.00
31	072	2.00*	296.00	148.00*	4.60	101.00	2.30	16.00	18.00	19.00
32	072	.00	230.00	142.00	4.30	102.00	2.10	12.00	12.00	14.00
41	072	.00	230.00	144.00	4.50	105.00	2.10	10.00	12.00	12.00
42	072	.00	210.00	142.00	3.90	106.00	1.90*	8.00	12.00	14.00
44	072	1.00	236.00	145.00	4.90	102.00	2.20	12.00	10.00	14.00
47	072	.00	230.00	142.00	4.30	102.00	2.10	14.00	12.00	14.00
51	072	.00	184.00	139.00	4.20	104.00	2.30	13.00	15.00	10.00
54	072	1.00	189.00	142.00	3.90	98.00	2.40	12.00	14.00	29.00*
55	072	.00	192.00	139.00	4.10	100.00	2.40	13.00	15.00	24.00
60	072	.00	187.00	141.00	3.90	100.00	2.70	12.00	13.00	27.00
61	072	.00	187.00	140.00	3.80	101.00	2.40	15.00	12.00	32.00*
66	072	1.00	189.00	138.00	3.90	101.00	2.60	14.00	15.00	30.00*
67	072	1.00	154.00	141.20	4.10	102.00	2.40	10.00	8.00	26.00
70	072	.00	173.00	138.00	3.90	101.00	2.60	12.00	13.00	29.00*
77	072	.80	255.00	.	.	.	.	.	.	.
98	072	.00	123.00*	140.00	3.80	101.00	9.40	21.00	31.00	29.00
102	072	.00	164.00	138.00	4.10	102.00	9.10	30.00	43.00	26.00
103	072	.00	257.00	156.00*	5.00	112.00*	8.90	25.00	25.00	16.00
106	072	.00	228.00	148.00	5.00	114.00*	8.60	25.00	17.00	21.00
110	072	.00	265.00	152.40	5.22	115.90*	8.90	25.00	23.00	12.90
113	072	.00	203.00	135.60	4.30	112.80*	8.20	17.00	22.00	15.00
118	072	.00	176.00	137.00	3.70	113.00*	9.40	33.00	74.00*	60.00*
119	072	.00	294.00	148.00	4.40	112.00*	9.00	11.00	19.00	15.00
124	072	.00	191.00	138.00	4.90	370.00	9.60	13.00	10.00	7.00
126	072	.00	239.00	141.00	4.70	347.00	9.30	15.00	10.00	8.00
127	072	.00	197.00	136.00	4.10	343.00	9.40	18.00	9.00	9.00
132	072	.00	282.00	131.00*	3.60*	355.00	9.90	17.00	22.00	12.00
133	072	.00	185.00	136.00	4.10	359.00	10.10	20.00	25.00	14.00
136	072	.00	224.00	139.00	4.10	347.00	9.40	13.00	14.00	10.00
139	072	.00	269.00	135.00	4.00	340.00	9.70	25.00	18.00	10.00
140	072	.00	190.00	137.00	4.40	346.00	10.00	18.00	17.00	14.00
147	072	2.00*	220.00	136.00*	4.10	100.00	8.90	8.00	4.00	5.00
148	072	.00	160.00	138.00	4.00	100.00	9.00	8.00	4.00	6.00
170	072	1.00	270.00	155.00*	4.80	97.00	9.10	38.00	11.80	18.00
172	072	.00	280.00	140.00	4.90	98.00	9.20	38.00	10.00	8.10*
179	072	1.00	275.00	137.00	5.20	98.00	9.10	38.00	9.70	8.00*
180	072	1.00	270.00	138.00	5.10	97.00	9.10	38.00	9.70	8.00
181	072	.00	280.00	137.00	5.10	97.00	9.20	38.00	9.70	8.20*
186	072	1.00	280.00	140.00	5.70*	99.00	9.20	38.00	10.00	8.20*
187	072	.00	280.00	139.00	4.90	100.00	9.00	37.00	9.90	8.10*
188	072	1.00	270.00	140.00	5.10	98.00	9.00	38.00	9.80	8.00*
193	072	2.00*	268.50	139.00	5.00	100.00	9.20	30.00	18.00	31.00
197	072	2.00*	270.00	140.00	4.80	102.00	9.80	30.00	18.00	32.00
202	072	1.00	300.00	143.00	4.00	103.00	9.20	26.00	24.00	26.00
203	072	1.00	321.00	144.00	4.90	100.00	10.00	41.00	32.00	52.00
206	072	2.00*	150.00	151.00	5.20	102.00	10.10	30.00	24.00	21.00

FCE 20124/702 i

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT	59
210	072	2.00*	230.00	134.00*	5.10	100.00	9.70	41.00	35.00	26.00	
214	072	1.00	320.00	146.00	5.20	105.00	9.40	28.00	30.00	40.00	
216	072	1.00	280.00	138.00	4.90	105.00	8.10*	15.00	22.00	24.00	
218	072	.00	250.00	137.00	3.70	96.00	8.59	7.68	6.24	50.00*	
219	072	.00	280.00	147.00	5.40	100.00	9.01	8.64	7.20	39.00*	
226	072	.00	380.00	137.00	4.20	100.00	9.50	8.00	5.00	19.00	
227	072	.00	280.00	139.00	4.30	100.00	8.50	10.00	5.00	18.00	
230	072	1.00	280.00	148.00*	4.90	105.00	8.70	16.00	5.00	27.00	
233	072	.00	320.00	149.00*	3.90	103.00	9.63	18.00	7.00	36.00	
237	072	.00	310.00	128.00*	3.90	99.00	9.63	18.00	5.00	10.00	
238	072	.00	315.00	140.00	4.60	93.00*	9.47	18.00	8.00	21.00	
243	072	.00	275.00	150.00	4.60	97.00	9.10	35.00	11.90	18.00	
245	072	1.00	255.00	138.00	4.90	98.00	8.90	38.00	9.70	8.10*	
249	072	.00	270.00	139.00	4.90	98.00	8.90	39.00	9.80	8.00	
251	072	.00	180.00	148.00	4.80	109.00*	8.90	32.00	30.00	30.00	
254	072	3.00*	310.00	135.00	4.10	106.00*	8.70	30.00	31.00	36.00	
255	072	4.00*	250.00	137.00	5.00	105.00	7.60*	44.00	35.00	25.00	
260	072	1.00	281.00	139.00	5.30	110.00*	4.70*	36.00	29.00*	32.00	
262	072	1.00	318.00	140.00	5.00	106.00*	8.60	31.00	30.00*	33.00	
268	072	1.00	180.00	150.00	5.20	97.00	9.20	43.00	32.00*	25.00	
269	072	3.00*	230.00	144.00	4.80	98.00	8.30*	31.00	16.00	32.00	
273	072	3.00*	230.00	137.00	5.10	112.00*	9.20	36.00	37.00*	28.00	

FCE 20124/702 i

60

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
2	072	4.80	1.23	69.00	5.90	91.00	.19	6.00	1.60
4	072	5.48	1.54*	130.00	2.00*	83.00	.30	3.00	.90
10	072	5.09	1.31	120.00	5.20	85.00	.26	5.00	1.20
11	072	5.23	1.17	97.00	6.50	84.00	.07*	7.00	1.60
15	072	4.24	1.30	118.00	3.40	67.00	.18	8.00	2.10
17	072	5.12	1.43	130.00	4.60	75.00	.19	8.00	1.60
28	072	5.00	1.00	180.00	4.60	88.00	302.00	10.00	.00
29	072	3.90	1.30	130.00	5.00	68.00	240.00	10.00	.00
31	072	3.80	1.20	178.00	6.20	80.00	280.00	14.00	.00
32	072	4.10	1.00	110.00	4.20	66.00	245.00	10.00	.00
41	072	3.60	1.20	98.00	6.40	74.00	242.00	10.00	.00
42	072	4.00	1.40	88.00	5.00	60.00	160.00*	12.00	.00
44	072	4.10	1.30	110.00	6.20	78.00	290.00	12.00	.00
47	072	3.90	1.20	118.00	4.40	72.00	255.00	12.00	.00
51	072	5.00	.80*	24.00	7.00	78.00	130.00*	11.00	.00
54	072	4.10	1.00	31.00	8.00	63.00	160.00	11.00	.00
55	072	4.70	1.10	30.00	4.00	76.00	154.00	12.00	.00
60	072	4.10	1.00	31.00	8.00	71.00	154.00	15.00	.00
61	072	4.70	.90	27.00	5.00	74.00	161.00	13.00	.00
66	072	4.70	1.10	27.00	8.00	97.00	155.00	12.00	.00
67	072	4.00	1.10	24.00	4.00	78.00	162.00	15.00	.00
70	072	4.10	1.00	29.00	4.00	76.00	157.00	11.00	.00
98	072	87.00	3.20	154.00	39.00	.70	3.30	.26	.07
102	072	86.00	3.00	145.00	31.00	.90	3.20	1.67*	.36*
103	072	80.00	3.00	120.00	30.00	.70	3.60	.64	.10
106	072	83.00	2.40*	173.00	30.00	.80	2.40	.60	.10
110	072	77.00	3.60	195.00	30.00	.50	1.20*	.50	.04
113	072	105.00	3.00	143.00	33.00	.60	3.70	.70	.06
118	072	78.00	2.80	201.00	53.00*	1.10	3.70	.63	.05
119	072	76.00	3.70	239.00	36.00	.90	3.60	.47	.07
124	072	70.00*	3.70	53.00	53.00*	1.00	3.40	.60	.20*
126	072	89.00	3.40	66.00	28.00	1.00	3.20	.90	.30*
127	072	96.00	3.60	71.00	28.00	.80	3.10	1.40	.60*
132	072	103.00	3.50	65.00	29.00	.90	3.00	1.00	.40*
133	072	90.00	3.90	87.00	31.00	.80	5.00	1.20	.60*
136	072	82.00	3.50	78.00	25.00	.80	5.10	.90	.40*
139	072	78.00	3.20	82.00	23.00	.70*	3.10	.90	.40*
140	072	78.00	3.40	120.00	19.00*	.90	5.00	2.40*	.90*
147	072	95.00	3.10	30.00	30.00	.70	3.50	.70	.50*
148	072	90.00	2.60	40.00	22.00	.70	3.20	.80	.60*
170	072	90.00	3.70	134.00	12.20	1.00	4.80	.80	.40
172	072	97.00	3.90	170.00	11.20	1.10	4.60	.70	.40
179	072	98.00	4.10	175.00	11.10	1.00	5.20	.70	.40
180	072	97.00	4.00	175.00	11.10	1.00	5.60	.70	.40
181	072	95.00	4.10	172.00	11.10	.98	5.60	.70	.40
186	072	97.00	4.00	177.00	11.30	1.20	5.20	.70	.40
187	072	97.00	4.00	172.00	11.10	1.00	4.70	.80	.40
188	072	98.00	4.00	170.00	11.20	.99	4.50	.70	.40
193	072	105.00	3.60	136.00	11.50	.78	5.00	.80	.10
197	072	110.00	3.90	138.00	11.60	.79	4.80	.80	.30
202	072	100.00	3.40	78.00*	15.00	1.10	4.70	.50	.40
203	072	100.00	3.80	135.00	16.00	.70	4.70	.80	.20
206	072	91.00	3.80	130.00	10.90	1.10	5.30	.90	.40
210	072	95.00	3.80	135.00	18.00	.76	4.70	.90	.40

FCE 20124/702 i

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
214	072	100.00	3.80	124.00	18.00	.80	4.30	.90	.50
216	072	110.00	4.20	126.00	10.00	.70	5.10	.40	.40
218	072	4.73	3.17	18.03	25.00	88.40	2.90	7.69	3.42
219	072	4.73	6.20*	38.02	20.00	68.06	4.40	6.84	1.71
226	072	5.66	3.00	33.40	20.50	88.40	5.70	9.06	4.10*
227	072	4.95	2.80	26.72	18.00*	63.64	3.20	4.27	1.71
230	072	5.00	2.60	37.07	26.50	101.66	5.20	6.84	3.42
233	072	5.83	3.27	37.00	29.00	106.08	4.20	5.13	1.71
237	072	5.50	3.53	48.43	15.00*	106.08	5.80	.85	.35*
238	072	4.84	5.19*	49.26	22.00	70.72	6.20	5.13	2.56
243	072	86.00	3.70	135.00	12.00	1.00	5.40	.80	.40
245	072	87.00	3.70	175.00	11.20	1.10	5.20	.60	.40
249	072	89.00	3.70	175.00	11.20	1.10	5.20	.70	.40
251	072	126.00*	4.10	125.00	10.50	.70	5.10	.80	.10
254	072	108.00	3.90	118.00	18.00	.80	4.60	.90	.20
255	072	90.00	3.90	85.00	20.00	.86	4.90	.70	.20
260	072	104.00	3.70	116.00	11.00	.90	5.20	.90	.10
262	072	100.00	3.90	118.00	18.00	.80	4.40	.90	.20
268	072	100.00	3.90	128.00	16.00	.78	4.80	.80	.20
269	072	95.00	3.60	131.00	11.40	.75	4.80	1.10*	.30
273	072	110.00	3.90	132.00	18.00	.76	5.30	.80	.20

61

FCE 20124/702 i

62

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
2	072	70.00	40.80*	7.60*	1.41	2.00	5.40*	8.00	13.80
4	072	62.00	35.50*	6.80*	.	2.70	7.90	9.30	6.60*
10	072	75.00	38.80*	5.70	1.11	3.50	9.00	11.50	12.20
11	072	68.00	41.30*	3.90	.66	2.40	6.20	8.10	9.00*
15	072	61.00	34.90*	5.60	.98	2.00	4.50*	8.10	11.50
17	072	60.00	38.60*	5.80	1.12	2.50	5.80*	7.40*	5.70*
28	072	74.00	42.00	5.90	1.40	3.00	7.60	8.00	16.00
29	072	72.00	36.00	5.10	1.30	3.10	8.00	10.60	13.80
31	072	74.00	38.00	4.80	1.30	3.20	7.80	11.00	14.20
32	072	71.00	40.00	4.00	3.80*	2.80	7.20	8.20	14.10
41	072	78.00	42.00	5.60	1.40	2.80	7.00	9.80	15.00
42	072	72.00	38.00	4.70	.80	3.60	8.00	12.40*	16.00
44	072	72.00	41.00	4.40	1.10	3.80*	9.00	8.60	15.00
47	072	72.00	36.00	4.30	1.20	2.90	7.20	10.00	13.80
51	072	73.00	49.00*	6.20	1.30	1.40*	5.20*	8.10	10.10*
54	072	70.00	40.00	5.00	1.40	2.30*	6.70	8.80	12.20*
55	072	72.00	43.00	4.70	1.50	2.10*	6.70	8.40	12.00*
60	072	73.00	43.00	4.90	1.80	2.20*	6.80	8.90	14.10
61	072	70.00	43.00	4.70	1.60	2.80	6.90	8.90	13.70
66	072	79.00	48.00	5.70	1.80	2.40	7.60	8.10	12.90
67	072	78.00	47.00	.	.	2.10*	6.90	8.10	12.90
70	072	75.00	44.00	5.10	1.80	2.40	7.60	8.40	12.60
98	072	7.10	65.70	128.00	217.00*	2.90	10.10	10.40	10.90
102	072	7.40	63.00	190.00	137.00	2.80	8.00	11.60	14.50
103	072	7.40	56.40	188.00	110.00	3.50	10.20	12.50	17.40
106	072	7.10	58.30	136.00	74.00	2.90	9.70	11.20	17.70
110	072	8.10	55.10*	156.00	180.00*	3.10	9.90	13.60	17.70
113	072	7.40	55.10*	180.00	161.00	2.70	10.10	14.90*	17.70
118	072	8.00	52.70*	183.00	91.00	4.60*	11.10	13.10	17.90
119	072	7.30	61.80	226.00*	132.00	3.30	8.80	13.70	14.90
124	072	7.80	4.60	182.00	74.00	1.80*	8.70*	13.00*	19.00*
126	072	7.20	3.90	201.00	216.00*	3.60	10.00	9.30	13.80
127	072	7.00	3.70*	116.00*	46.00	2.00*	7.90*	7.10*	14.20
132	072	8.00	4.90	193.00	285.00*	1.60*	10.80	8.40	14.40
133	072	7.50	4.50	174.00	196.00	2.30*	7.40*	14.10*	15.10
136	072	6.60	4.60	225.00	105.00	2.10*	6.90*	12.90*	7.20*
139	072	8.60*	5.40*	221.00	147.00	3.20	7.90*	10.20	12.80
140	072	8.10	5.20*	172.00	124.00	1.80*	8.20*	8.20	12.20
147	072	7.50	5.50	200.00	80.00	6.00	9.00	12.00	16.00
148	072	7.00	5.30	175.00	50.00	6.00	9.00	11.00	15.00
170	072	7.60	4.20	190.00	95.00	.30	.80	1.00	1.50
172	072	6.80	4.20	197.00	89.00	.40	.71	1.00	1.20
179	072	6.70	4.40	190.00	89.00	.31	.71	.92	1.40
180	072	8.70*	4.50	188.00	87.00	.31	.71	.92	1.40
181	072	6.80	4.70	197.00	88.00	.40	.70	.90	1.40
186	072	6.80	4.70	195.00	92.00	.38	.72	.95	1.30
187	072	6.70	4.50	200.00	90.00	.31	.82	1.20*	1.40
188	072	8.70*	4.20	190.00	92.00	.41*	.72	.93	1.40
193	072	7.10	4.40	178.00	99.00	.40	.70	1.50*	1.50
197	072	7.00	4.90	180.00	97.00	.40	.70	1.80*	1.30
202	072	8.20	5.10	148.00	148.00	.40	.80	1.00	1.50
203	072	6.80	4.30	150.00	132.00	.20	.50	.80	1.30
206	072	6.90	4.20	181.00	99.00	.40	.70	1.10	.90
210	072	8.10	4.10	210.00	130.00	.40	.60	.70	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

63

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
214	072	8.00	5.20	185.00	108.00	.30	.80	.90	1.30
216	072	6.60	6.10*	200.00	135.00	.30	.70	.70	1.00
218	072	7.00	4.70	6.11	64.00	.10*	.61	.76	1.26
219	072	6.70	4.50	6.05	130.00	.15*	.65	.92	.96
226	072	.	.	4.78	169.00*	.	.	.	.
227	072	7.70	4.24	4.94	169.00*	.20	.57*	1.26*	1.43*
230	072	6.40	3.62	5.25	184.00*	.18*	.52*	.99	1.09
233	072	7.40	4.11	5.46	100.00	.21	.67	1.03	1.38*
237	072	7.10	3.70	5.20	108.00	.23	.65	1.02	1.44
238	072	7.55	4.10	5.20	118.00	.22	.51*	1.00	1.72*
243	072	7.50	4.20	170.00	91.00	.34	.72	1.00	1.40
245	072	7.20	4.40	192.00	82.00	.36	.75	1.00	1.40
249	072	7.30	4.40	192.00	85.00	.30	.70	1.10	1.30
251	072	6.80	5.40	200.00	132.00	.30	.80	.80	1.20
254	072	8.10	5.10	165.00	105.00	.20	.60	.80	1.10
255	072	8.60*	5.20	183.00	102.00	.20	.70	.20*	1.10
260	072	6.90	4.10	177.00	96.00	.40	.60	.80	1.10
262	072	4.90*	3.60	160.00	112.00	.30	.70	.90	1.10
268	072	8.20	5.20	246.00	145.00	.50*	.80	.90	1.00
269	072	6.70	4.10	181.00	98.00	.30	.70	.60	1.30
273	072	6.00	3.90	230.00	130.00	.40	.50	.90	1.10

FCE 20124/702 i

64

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
28	072	1.020	0	0	0	0
29	072	1.020	0	0	0	0
31	072	1.026	0	0	0	0
32	072	1.020	0	0	0	0
41	072	1.026	0	0	0	0
42	072	1.024	0	0	0	0
44	072	1.024	0	0	0	0
47	072	1.020	0	0	0	0
51	072	1.020	0	0	0	0
54	072	1.028	0	0	0	0
55	072	1.026	0	0	0	0
60	072	1.024	0	0	0	0
61	072	1.027	0	0	0	0
66	072	1.027	0	0	0	0
67	072	1.021	0	0	0	0
70	072	1.029	0	0	0	0
98	072	1.005	0	0	0	0
102	072	1.010	0	0	0	0
103	072	1.012	0	0	0	0
106	072	.	0	0	0	0
110	072	1.018	0	0	0	0
113	072	1.013	0	0	0	0
118	072	1.019	0	0	0	0
119	072	1.013	0	0	0	0
124	072	1.030	0	0	0	5
126	072	1.030	0	0	0	2
127	072	1.020	0	0	0	3
132	072	1.020	0	0	0	2
133	072	1.025	0	0	1	1
136	072	1.020	0	0	0	1
139	072	1.025	0	0	0	1
140	072	1.028	0	0	0	1
147	072	1.020	0	0	0	1
148	072	1.020	0	0	0	2
170	072	1.015	0	0	0	2
172	072	1.015	0	0	0	4
179	072	1.015	0	0	0	2
180	072	1.020	0	0	0	4
181	072	1.010	0	0	2	4
186	072	1.012	0	0	0	4
187	072	1.020	0	0	0	2
188	072	1.010	0	0	0	2
193	072	1.016	0	0	4	0
197	072	1.016	0	0	2	5
202	072	1.018	0	0	1	3
203	072	1.018	0	0	1	2
206	072	1.016	0	0	1	4
210	072	1.018	0	0	2	3
214	072	1.018	0	0	2	3
216	072	1.016	0	0	2	3
218	072	1.016	0	0	0	1
219	072	1.021	0	0	0	2
226	072	1.009*	0	0	1	2
227	072	1.021	0	0	2	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

570

FCE 20124/702 i

65

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
230	072	1.022	0	0	3	25*
233	072	1.007*	0	0	3	2
237	072	1.015	0	0	0	5
238	072	1.010*	0	0	0	2
243	072	1.015	0	0	0	2
245	072	1.020	0	0	0	0
249	072	1.012	0	0	0	4
251	072	1.018	0	0	1	4
254	072	1.018	0	0	2	2
255	072	1.020	0	0	2	2
260	072	1.005	0	0	2	2
262	072	1.006	0	0	0	2
268	072	1.018	0	0	2	3
269	072	1.020	0	0	1	3
273	072	1.022	0	0	2	4

FCE 20124/702 i

66

Treatment Group "B"

Day 7 (Period 072)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	76	12
Hematocrit (HCT)	76	9
Red Blood Cells (RBC)	76	16
White Blood Cells (WBC)	76	8
Neutrophils (NEUTS)	76	13
Lymphocytes (LYMPS)	76	17
Eosinophils (EOSIN)	76	19
Monocytes (MONOS)	76	16
Basophils (BASOS)	76	10
Platelets (PLATES)	76	1
Sodium (NA+)	75	12
Phosphorous (K+)	75	3
Chlorine (CL-)	75	12
Calcium (CA++)	75	6
Aspartate Aminotransferase (SGOT)	75	0
Alanine Aminotransferase (SGPT)	75	6
γ-GT (YGT)	75	18
Blood Sugar (BLSUG)	75	2
Phosphorous (PO4)	75	5
Alkaline Phosphatase (ALPKHOS)	75	1
Urea Nitrogen (BUN)	75	6
Creatinine (CREAT)	75	1
Uric Acid (URACID)	75	4
Total Bilirubin (TOTBILI)	75	3
Direct Bilirubin (DIRBILI)	75	13
Total Protein (TOTPROT)	74	5
Albumin (BLALB)	74	14
Cholesterol (CHOLE)	74	4
Triglycerides (TRIGLY)	74	8
Globulins - α1 (GLOBAL1)	74	18
Globulins - α2 (GLOBAL2)	74	13
Globulins - β (GLOBETA)	74	12
Globulins - γ (GLOGAMA)	74	11
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	68	3
Albumin (URALB)	69	0
Sugar (URSUG)	69	0
Red Blood Cells (URRBC)	69	0
White Blood Cells (URWBC)	69	1

572

FCE 20124/702 i

67

\* = Value out-of-range

Day 14 (Period 142)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
2	142	13.00	39.70	4.17	5.40	62.00	23.00	5.00*	9.00
10	142	12.30*	36.00*	4.11	7.70	61.00	31.00	2.00	6.00
11	142	12.90*	38.90	4.08	10.30*	60.00	27.00	2.00	11.00*
15	142	12.20*	36.30*	4.00	4.80	67.00	23.00	1.00	7.00
17	142	13.10	39.70	4.10	4.30	64.00	28.00	1.00	7.00
28	142	12.60	37.60	4.22*	8.00	60.00	36.00*	2.00	1.00
31	142	14.80	44.00	5.90*	6.20	70.00	25.00	3.00	.00*
32	142	13.80	40.00	5.10*	5.80	69.00	27.00	2.00	2.00
41	142	14.50	41.00	4.60	6.00	69.00	25.00	4.00	2.00
42	142	14.20	41.00	4.50	5.90	69.00	29.00*	2.00	.00*
44	142	14.50	39.00	4.80	5.60	69.00	25.00	4.00	1.00
47	142	14.00*	42.00	4.60	5.80	68.00	26.00	4.00	2.00
51	142	8.00	.41	3.90*	5.30	72.00	24.00	1.00	2.00
54	142	9.20	.47	5.30	6.00	65.00	29.00	2.00	3.00
55	142	8.80	.46	5.10	7.20	67.00	29.00	1.00	2.00
60	142	8.30	.44	5.10	6.40	62.00	31.00	2.00	4.00
61	142	7.80	.42	5.10	7.00	75.00	24.00	.00*	1.00
66	142	9.40	.46	5.30	6.10	64.00	31.00	2.00	3.00
67	142	8.90	.45	4.90	6.30	72.00	24.00	1.00	3.00
70	142	9.10	.49	5.40	7.00	73.00	24.00	1.00	2.00
77	142	13.50	40.00	4.98	5.73	58.90	26.20	1.60	7.90
78	142	17.90	51.70	5.18	8.73	49.20	34.20	2.60	9.00
83	142	15.30	44.30	4.90	4.97	69.60	17.20*	3.20	7.30
84	142	13.10	39.80	4.25	4.08*	49.00	39.80	2.40	6.80
88	142	14.50	43.10	4.63	10.86*	53.10	34.20	2.80	5.90
90	142	12.60	37.80	4.16	5.67	65.00	24.50	4.00	3.50
91	142	16.80	50.60	5.44	8.31	49.90	42.50	1.90	3.10*
95	142	14.60	44.50	4.96	4.29*	53.90	34.40	3.20	5.70
98	142	12.70	34.70*	3.96*	5.80	60.00	36.00	1.00	3.00
102	142	15.00	41.20*	4.85	4.30*	56.00	38.00	5.00	1.00*
103	142	14.20	39.30*	4.34*	7.60	61.00	22.00	1.00	16.00*
106	142	13.80	37.20	4.24	5.20	70.00	24.00	6.00	.00*
110	142	12.40	33.20*	3.79*	5.90	68.00	30.00	1.00	1.00*
113	142	15.30	40.20	4.65	5.70	65.00	30.00	2.00	3.00
118	142	15.90	43.10	4.38*	8.60	69.00	31.00	.00*	.00*
119	142	15.30	40.70	4.59*	5.70	37.00*	54.00*	8.00*	1.00*
124	142	14.10	43.00	4.00	5.60	54.00*	42.00*	1.00	3.00*
126	142	12.10	38.00	4.18*	6.40	60.00	40.00*	.00	.00*
127	142	11.80*	37.00	4.07*	5.10	70.00	28.00	2.00	.00*
132	142	11.50*	36.00*	3.60*	3.80*	68.00	30.00	2.00	.00*
133	142	12.90	40.00	4.40	9.90	50.00*	50.00*	.00	.00*
136	142	16.00	49.00*	5.30	6.90	74.00*	22.00	4.00*	.00*
139	142	13.60	42.00	4.97	5.20	65.00	31.00	1.00	3.00*
140	142	16.50*	51.00*	5.01	5.90	73.00*	23.00	1.00	3.00*
147	142	14.00	42.00	4.30	6.90	65.00	30.00	3.00*	2.00*
148	142	12.50	37.50	4.20	6.30	64.00	30.00	2.00	2.00*
170	142	15.70	44.00	6.00	6.30	60.00	30.00	4.00*	6.00
172	142	15.90	44.00	6.10	6.70	60.00	30.00	3.00	6.00
179	142	16.10	44.00	6.10	6.70	61.00	30.00	2.00	6.00

FCE 20124/702 i

68

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
180	142	16.10*	45.00	6.20*	6.90	60.00	31.00	2.00	6.00
181	142	15.80	44.00	5.90	6.20	59.00	32.00	2.00	6.00
186	142	15.90	44.00	6.00	7.10	59.00	32.00	3.00	6.00
187	142	16.00	45.00	6.10	7.20	58.00	33.00	2.00	6.00
188	142	16.00	46.00	6.00	5.90	61.00	30.00	2.00	6.00
193	142	16.30*	46.00	5.20	6.10	59.00	31.00	4.00*	3.00
197	142	17.20	47.00	6.30*	5.40	58.00	32.00	5.00*	4.00
202	142	16.10*	47.00	5.90*	8.10	53.00*	37.00*	4.00*	3.00
203	142	13.50*	45.00	5.50	5.10	56.00	34.00*	5.00*	3.00
206	142	13.10	41.00	5.10	4.70*	51.00*	39.00*	5.00*	4.00
210	142	16.20	40.00*	5.30	8.00	53.00*	37.00*	4.00*	4.00
214	142	13.50	43.00	5.00	8.20	56.00	34.00*	4.00*	6.00
216	142	15.80	45.00	5.00	6.20	52.00*	38.00*	3.00	6.00
218	142	13.35	39.00	4.42	11.30*	75.00*	16.00*	2.00	7.00*
219	142	14.50	43.00	5.02*	9.00*	69.00	26.00	2.00	3.00
226	142	14.69	41.50	4.40	7.30	64.00	31.00	3.00	2.00
227	142	12.23	37.00	3.94*	5.95	59.00	34.00	3.00	3.00
233	142	15.50	50.00*	5.45	8.50*	77.00*	21.00	1.00	1.00
237	142	15.09	45.00	5.50	6.60	69.00	24.00	2.00	5.00
238	142	13.53	42.00	4.45	5.40	56.00	37.00	5.00	2.00
243	142	15.60	42.00	5.90	6.00	60.00	30.00	3.00	6.00
245	142	16.00	44.00	6.00	5.70	60.00	30.00	3.00	6.00
249	142	15.80	44.00	6.00*	6.10	60.00	30.00	3.00	6.00
251	142	13.10	45.00	4.90	6.00	55.00	35.00*	6.00*	4.00
254	142	12.00	37.00	5.00	4.70*	52.00*	38.00*	3.00	4.00
255	142	14.70	44.00	5.10	6.00	53.00*	37.00*	4.00*	3.00
260	142	15.90	44.00	6.00*	6.40	54.00	36.00*	5.00*	3.00
262	142	16.00	44.00	6.10	5.80	57.00	33.00	6.00*	4.00
268	142	12.10	41.00	4.20	7.30	51.00*	39.00*	6.00*	3.00
269	142	13.00*	40.00*	5.00	4.70*	53.00*	37.00*	6.00*	3.00
273	142	13.40	43.00	4.70	7.60	56.00	34.00*	6.00*	2.00*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

69

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
2	142	1.00	298.00	141.00	4.40	100.00	2.20	7.00	5.00	15.00
10	142	.00	382.00*	140.00	4.90*	97.00	2.49	7.00	7.00	10.00
11	142	.00	290.00	141.00	4.10	105.00	2.35	7.00	6.00	8.00
15	142	2.00*	331.00	143.00*	4.60	104.00	2.33	10.00	11.00	18.00
17	142	.00	248.00	143.00*	4.70	98.00	2.18	9.00	9.00	12.00
28	142	1.00	216.00	142.00	4.30	100.60	2.10	8.00	8.00	16.00
31	142	2.00*	236.00	148.00*	4.70	102.00	2.20	14.00	16.00	16.00
32	142	.00	220.00	141.00	3.90	102.00	2.00*	12.00	10.00	12.00
41	142	.00	235.00	142.00	3.90	106.00	2.00*	12.00	14.00	14.00
42	142	.00	225.00	142.00	4.00	108.00	1.90*	8.00	12.00	10.00
44	142	1.00	198.00	146.00	4.20	101.00	2.10	10.00	10.00	12.00
47	142	.00	230.00	143.00	4.40	104.00	2.00*	10.00	12.00	12.00
51	142	1.00	174.00	139.00	4.00	101.00	2.40	15.00	15.00	12.00
54	142	1.00	189.00	137.00*	4.00	101.00	2.30	14.00	13.00	29.00*
55	142	1.00	176.00	145.00	4.30	104.00	2.60	14.00	15.00	31.00*
60	142	1.00	181.00	140.00	3.80	101.00	2.70	14.00	13.00	27.00
61	142	.00	187.00	136.00*	4.10	102.00	2.60	12.00	10.00	31.00*
66	142	.00	172.00	138.00	3.80	102.00	2.60	14.00	15.00	27.00
67	142	.00	201.00	137.00*	3.90	102.00	2.50	14.00	12.00	26.00
70	142	.00	187.00	142.00	4.00	101.00	2.50	12.00	12.00	31.00*
77	142	1.30	235.00	136.00	3.10*	101.00	.	26.00	35.00	18.00
78	142	2.00*	297.00	144.00	5.10	101.00	10.50*	21.00	31.00	29.00
83	142	1.40	191.00	147.00	4.60	108.00	7.80*	18.00	23.00	18.00
84	142	.80	207.00	142.00	4.10	109.00	8.00	10.00	22.00	14.00
88	142	.70	503.00*	139.00	5.00	98.00	8.60	8.00	10.00	8.00
90	142	.80	182.00	140.00	4.30	103.00	8.50	11.00	13.00	8.00
91	142	1.10	239.00	140.00	4.20	101.00	9.20	9.00	9.00	6.00
95	142	.50	157.00	141.00	3.80*	107.00	9.30	13.00	15.00	12.00
98	142	.00	122.00*	141.00	3.80	102.00	9.50	22.00	27.00	20.00
102	142	.00	144.00*	140.00	4.30	101.00	9.60	26.00	31.00	23.00
103	142	.00	245.00	148.00	5.00	114.00*	9.40	24.00	25.00	21.00
106	142	.00	239.00	148.00	4.20	115.20*	8.70	20.00	18.00	19.00
110	142	.00	248.00	148.80	3.94	114.00*	8.20	18.00	19.00	8.00
113	142	.00	200.00	141.00	4.50	107.00	8.30	15.00	21.00	17.00
118	142	.00	179.00	137.00	3.80	110.00*	9.40	31.00	67.00*	59.00*
119	142	.00	248.00	145.00	4.40	110.00*	8.90	15.00	13.00	9.00*
124	142	.00	127.00*	139.00	5.00	377.00	10.00	13.00	13.00	8.00
126	142	.00	238.00	136.00	4.50	342.00	9.40	19.00	7.00	7.00
127	142	.00	247.00	135.00	4.30	352.00	9.40	16.00	11.00	9.00
132	142	.00	217.00	139.00	4.20	353.00	9.80	16.00	26.00	9.00
133	142	.00	147.00*	132.00*	4.00	370.00	9.90	18.00	23.00	15.00
136	142	.00	246.00	138.00	3.90	343.00	9.70	12.00	16.00	15.00
139	142	.00	187.00	136.00	3.80	347.00	10.20	17.00	16.00	12.00
140	142	1.00	192.00	137.00	4.40	346.00	10.20	20.00	18.00	11.00
147	142	.00	199.00	141.00	4.40	100.00	9.00	12.00	8.00	8.00
148	142	2.00*	165.00	129.00*	3.60	98.00	9.00	8.00	8.00	6.00
170	142	.00	275.00	150.00	4.70	96.00	9.20	39.00	11.70	17.00
172	142	1.00	275.00	140.00	5.10	97.00	9.10	38.00	9.90	8.10*
179	142	1.00	270.00	140.00	5.10	98.00	9.00	38.00	9.70	8.00*
180	142	1.00	270.00	138.00	5.20	96.00	9.10	38.00	9.70	8.00
181	142	1.00	285.00	138.00	4.90	100.00	9.00	37.00	9.90	8.20*
186	142	.00	275.00	138.00	5.10	97.00	9.10	37.00	9.80	8.30*
187	142	1.00	270.50	138.00	5.10	97.00	9.10	38.00	9.90	8.00*
188	142	1.00	280.00	138.00	5.10	97.00	9.10	38.00	9.80	8.10*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

70

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
193	142	3.00*	268.00	138.00	5.10	99.00	9.00	30.00	19.00	31.00
197	142	1.00	270.00	139.00	4.90	105.00	9.90	31.00	19.00	31.00
202	142	2.00*	300.00	144.00	4.20	100.00	9.30	27.00	27.00	38.00
203	142	2.00*	318.00	140.00	4.50	100.00	9.20	40.00	32.00	50.00
206	142	1.00	151.00	150.00	5.00	100.00	10.00	31.00	24.00	20.00
210	142	2.00*	231.00	132.00*	5.30	102.00	9.60	41.00	34.00	26.00
214	142	.00	320.00	144.00	5.10	100.00	9.40	30.00	30.00	40.00
216	142	1.00	285.00	138.00	4.90	105.00	8.10*	18.00	24.00	24.00
218	142	.00	266.00	146.00*	5.40	96.00	9.01	17.00	14.00	45.00*
219	142	.00	306.00	142.00	4.30	100.00	9.30	8.00	14.00	37.00*
226	142	.00	320.00	139.00	4.20	102.00	9.00	7.00	5.00	14.00
227	142	1.00	290.00	139.00	4.20	100.00	9.50	9.00	6.00	7.00
233	142	.00	450.00*	135.00	4.60	89.00*	9.20	15.00	11.00	5.00
237	142	.00	350.00	140.00	4.50	92.00*	8.45*	10.00	5.00	11.00
238	142	.00	320.00	136.00	4.00	97.00	8.62	20.00	9.00	13.00
243	142	1.00	255.00	139.00	4.70	97.00	8.80	38.00	9.80	8.10*
245	142	1.00	270.00	138.00	4.70	95.00	8.70	38.00	9.70	8.10*
249	142	1.00	270.00	138.00	4.80	97.00	8.80	38.00	9.70	8.00
251	142	.00	178.00	149.00	4.90	108.00*	8.90	34.00	30.00	30.00
254	142	3.00*	308.00	136.00	4.10	106.00*	8.70	32.00	30.00	37.00
255	142	3.00*	251.00	137.00	4.90	106.00*	7.60*	45.00	36.00	26.00
260	142	2.00*	280.00	139.00	5.20	108.00*	4.80*	38.00	30.00*	32.00
262	142	.00	316.00	138.00	5.00	107.00*	8.80	32.00	30.00*	33.00
268	142	1.00	180.00	149.00	5.20	98.00	9.30	42.00	32.00*	26.00
269	142	2.00*	231.00	143.00	4.70	98.00	8.20*	31.00	16.00	32.00
273	142	2.00*	230.00	136.00	5.20	112.00*	9.10	34.00	36.00*	29.00



FCE 20124/702 i

71

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
2	142	5.13	1.30	83.00	5.50	83.00	.18	5.00	.90
10	142	5.19	1.35	106.00	5.50	86.00	.20	5.00	1.20
11	142	4.61	1.13	113.00	3.50	79.00	.11*	5.00	1.20
15	142	5.42	1.11	143.00	3.20	70.00	.20	7.00	1.90
17	142	5.01	1.31	135.00	3.90	70.00	.18	6.00	1.40
28	142	4.40	1.10	176.00	4.80	80.00	300.00	8.00	.00
31	142	3.90	1.30	180.00	6.00	78.00	270.00	10.00	.00
32	142	4.20	1.10	112.00	4.40	68.00	240.00	14.00	.00
41	142	4.00	1.10	96.00	6.20	68.00	240.00	12.00	.00
42	142	4.40	1.50	90.00	6.20	58.00*	170.00*	14.00	.00
44	142	3.90	1.20	121.00	6.00	76.00	288.00	10.00	.00
47	142	3.90	1.30	130.00	5.00	74.00	250.00	10.00	.00
51	142	4.90	.90	27.00	8.00	83.00	131.00*	14.00	.00
54	142	4.30	1.10	31.00	7.00	76.00	154.00	11.00	.00
55	142	4.70	1.30	27.00	4.00	74.00	152.00	11.00	.00
60	142	4.70	.90	32.00	4.00	72.00	156.00	16.00	.00
61	142	5.10	.90	27.00	6.00	72.00	164.00	13.00	.00
66	142	4.90	1.10	32.00	7.00	54.00	161.00	13.00	.00
67	142	4.30	1.00	27.00	4.00	69.00	159.00	8.00	.00
70	142	3.90	.90	28.00	5.00	72.00	161.00	10.00	.00
77	142	66.00*	3.80	.	9.70	1.00	7.60*	.30	.10
78	142	64.00*	3.10	101.00	17.90	1.30*	4.90	.70	.30
83	142	91.00	3.10	87.00	17.60	1.00	5.90	.30	.20
84	142	94.00	3.90	78.00	12.70	.80	4.40	.40	.40*
88	142	73.00	4.40	137.00*	14.00	1.00	3.00*	.50	.
90	142	73.00	3.90	80.00	16.30	1.00	1.70*	.50	.10
91	142	79.00	4.30	83.00	19.50	1.20	5.90	1.20*	.20
95	142	78.00	3.50	48.00	16.00	1.10	2.70*	.50	.10
98	142	84.00	3.70	202.00	25.00	.90	4.80	.32	.08
102	142	90.00	3.00	74.00*	37.00	1.10	2.90	1.58*	.30*
103	142	83.00	3.00	115.00	43.00	.70	2.10*	.53	.10
106	142	75.00	2.50	170.00	32.00	.90	2.50	.50	.10
110	142	73.00	3.00	157.00	36.00	.40*	2.50	.49	.04
113	142	115.00*	3.90	141.00	36.00	.70	4.10	.65	.09
118	142	80.00	2.70	207.00	56.00*	1.20	3.80	.70	.07
119	142	53.00*	3.70	194.00	23.00	.70	3.00	.37	.06
124	142	79.00	4.00	50.00	23.00	.90	4.20	.60	.20*
126	142	99.00	3.60	66.00	26.00	.90	2.70	.90	.30*
127	142	88.00	3.90	69.00	24.00	.80	3.20	1.30	.60*
132	142	121.00*	3.60	72.00	31.00	1.00	3.60	1.20	.50*
133	142	94.00	3.80	80.00	25.00	.80	5.30	.80	.30*
136	142	102.00	3.60	87.00	25.00	.90	5.50	1.00	.40*
139	142	77.00	3.00	69.00	20.00	.70*	3.30	1.00	.40*
140	142	77.00	2.90	85.00*	14.00*	.90	5.30	3.00*	1.30*
147	142	95.00	2.10*	30.00	25.00	.90	3.50	.70	.40*
148	142	90.00	2.40	30.00	21.00	.70	3.00	.90	.30*
170	142	90.00	3.60	130.00	11.80	1.10	4.80	.80	.30
172	142	97.00	3.90	170.00	11.10	1.00	4.70	.80	.40
179	142	98.00	4.00	170.00	11.10	1.00	5.20	.70	.40
180	142	97.00	3.90	170.00	11.00	1.10	5.60	.70	.40
181	142	95.00	4.00	177.00	11.00	1.00	5.70	.70	.40
186	142	95.00	4.20	176.00	11.10	.99	4.80	.80	.40
187	142	98.00	4.00	172.00	11.00	1.00	4.80	.70	.40
188	142	97.00	4.10	172.00	11.10	1.00	4.80	.70	.40

FCE 20124/702 i

72

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
193	142	105.00	3.80	138.00	11.60	.79	4.90	.80	.20
197	142	115.00*	3.90	140.00	11.80	.79	4.80	.90	.20
202	142	105.00	3.40	79.00	15.00	1.10	4.70	.50	.30
203	142	90.00	3.80	130.00	16.00	.70	4.50	.80	.20
206	142	95.00	3.80	130.00	11.20	1.10	5.40	.80	.30
210	142	98.00	3.70	135.00	28.00*	.76	4.60	.80	.40
214	142	110.00	3.90	124.00	18.00	.70	4.20	.80	.50
216	142	105.00	4.20	124.00	14.00	1.00	5.40	.80	.40
218	142	5.55	7.60*	19.20	24.00	79.56	3.30	8.89	3.42
219	142	5.06	2.58	43.42	20.00	57.46	4.80	6.84	2.22
226	142	5.77	3.00	34.23	24.00	57.46	5.80	3.42	1.71
227	142	5.50	3.30	30.06	22.00	88.40	3.20	4.27	3.24
233	142	5.83	3.00	31.85	21.50	103.40	4.50	8.55	2.56
237	142	5.06	3.16	47.59	22.00	97.24	3.70	10.26	2.56
238	142	4.40	2.66	39.24	24.00	75.14	5.60	8.55	1.71
243	142	88.00	3.70	170.00	11.20	1.00	4.70	.70	.40
245	142	87.00	3.70	172.00	11.00	1.10	5.20	.70	.40
249	142	87.00	3.70	172.00	11.20	1.00	5.20	.70	.40
251	142	120.00*	4.10	125.00	10.00	.80	5.10	.80	.20
254	142	110.00	3.90	118.00	18.00	.80	4.80	.90	.20
255	142	95.00	3.90	86.00	20.00	.87	5.00	.80	.20
260	142	95.00	3.90	118.00	11.00	.90	5.30	.90	.10
262	142	102.00	3.90	118.00	18.00	.90	4.30	.90	.20
268	142	95.00	3.70	127.00	15.00	.78	4.80	.90	.20
269	142	97.00	3.60	131.00	11.40	.76	4.90	1.10	.30
273	142	100.00	3.90	130.00	18.00	.76	5.30	.80	.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

73

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
2	142	73.00	43.30*	7.60*	1.09	2.00	5.10*	8.50	14.10
10	142	71.00	40.10*	5.40	1.96*	3.40	6.90	10.20	10.40*
11	142	70.00	41.40*	4.08	1.03	2.70	6.60	9.30	10.00*
15	142	62.00	34.30*	5.20	.58	2.00	4.60*	8.60	12.50
17	142	60.00	39.10*	5.70	1.25	2.10	6.10	7.10*	5.60*
28	142	76.00	44.00	5.80	1.60	3.20	7.00	8.20	15.80
31	142	70.00	36.00	4.40	1.40	3.60	8.00	11.60	14.40
32	142	70.00	38.00	4.10	3.90*	3.00	7.40	8.40	14.00
41	142	74.00	40.00	5.40	1.30	3.00	8.00	10.00	14.60
42	142	68.00	30.00*	4.50	1.00	3.80*	8.00	11.00	16.20
44	142	70.00	42.00	4.10	1.30	3.90*	10.00*	8.80	14.00
47	142	74.00	38.00	4.20	1.30	3.00	7.80	11.00	13.60
51	142	74.00	40.00	6.00	1.20	1.80*	5.20*	8.10	9.90*
54	142	74.00	41.00	4.30	1.20	2.70	6.90	8.50	15.00
55	142	73.00	41.00	5.30	1.40	2.00*	6.90	8.70	14.50
60	142	73.00	43.00	4.90	1.80	2.20*	6.80	9.10	13.90
61	142	71.00	46.00	5.10	1.90	2.70	8.90	8.70	14.20
66	142	73.00	41.00	5.10	1.10	2.20*	6.40*	9.40	14.00
67	142	73.00	40.00	4.10	1.80	2.40	7.60	8.90	14.10
70	142	75.00	45.00	5.10	1.70	2.70	7.30	8.00*	12.00*
77	142	7.90	4.30	263.00*	172.00*	.	.	.	.
78	142	7.80	4.90	187.00	205.00*	3.11	13.35	16.32*	16.18
83	142	6.70	4.20	260.00*	138.00	3.33	12.30	15.50*	18.77
84	142	6.70	4.10	204.00*	326.00*	.	.	.	.
88	142	7.60	4.60	263.00*	413.00*	.	.	.	.
90	142	6.80	4.30	215.00	.	.	.	.	.
91	142	7.60	5.00*	180.00	.	.	.	.	.
95	142	7.00	4.30	173.00	73.00	2.44	8.11	13.28	15.41
98	142	7.10	64.40	200.00	164.00	2.80	10.30	10.40	10.90
102	142	7.50	63.70	191.00	110.00	2.40*	8.20	11.30	14.40
103	142	7.30	56.80	190.00	106.00	3.40	10.10	12.10	17.30
106	142	7.20	54.10*	154.00	100.00	3.10	10.60	12.80	19.40*
110	142	7.40	61.20	200.00	162.00	2.30*	8.10	12.80	15.60
113	142	7.40	53.20*	201.00	127.00	3.10	9.70	14.10*	17.70
118	142	8.10	53.00*	173.00	86.00	4.50	12.30*	13.40	17.60
119	142	7.40	62.30	188.00	119.00	3.90	8.70	13.70	15.20
124	142	7.90	4.70	187.00	85.00	2.10*	8.80*	8.40	17.20
126	142	7.90	4.60	171.00	200.00	4.00	11.30	9.70	14.00
127	142	6.60	3.80	96.00*	38.00	1.20*	8.40*	6.20*	13.10
132	142	7.70	4.90	230.00	257.00*	1.70*	10.80	9.90	13.90
133	142	8.00	4.40	167.00	136.00	1.90*	8.50*	8.40	14.10
136	142	6.40	4.60	198.00	151.00	2.20*	7.60*	14.20*	9.30*
139	142	8.00	5.00	210.00	128.00	1.50*	6.80*	9.30	14.30
140	142	8.00	5.00	176.00	114.00	2.10*	9.80	8.00	11.00
147	142	7.50	5.30	200.00	90.00	6.00	8.00	13.00	18.00
148	142	7.20	5.30	146.00	40.00	6.00	9.00	11.00	21.00
170	142	7.50	4.30	192.00	88.00	.31	.85	1.10	1.40
172	142	6.70	4.10	190.00	92.00	.32	.71	.92	1.10
179	142	6.80	4.50	192.00	90.00	.40	.70	.90	1.40
180	142	8.70*	4.50	192.00	89.00	.39	.72	.91	1.30
181	142	6.80	4.70	192.00	95.00	.34	.75	.92	1.30
186	142	6.80	4.70	200.00	92.00	.40	.72	.94	1.30
187	142	7.70	4.20	197.00	95.00	.34	.82	1.00	1.30
188	142	6.70	4.80	199.00	92.00	.33	.71	.92	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

74

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
193	142	7.00	4.50	180.00	98.00	.30	.80	.60	1.40
197	142	7.30	4.90	178.00	96.00	.30	.60	.80	1.50
202	142	8.10	5.20	246.00	148.00	.40	.70	1.00	1.40
203	142	6.70	4.20	145.00	130.00	.20	.50	.80	1.20
206	142	6.80	4.10	182.00	98.00	.30	.80	.90	1.00
210	142	8.10	4.20	210.00	130.00	.40	.60	.70	1.20
214	142	8.10	5.10	180.00	112.00	.20	.70	.80	1.40
216	142	6.20*	6.00*	205.00	130.00	.30	.80	.60	1.10
218	142	7.60	3.84	5.90	65.00	.24	.81	.79	1.32*
219	142	7.80	4.76	6.24	89.00	.15*	.70	1.11	1.08
226	142	7.50	4.26	4.81	179.00*	.23	.68	1.19	1.14
227	142	7.20	3.60	5.20	178.00*	.19*	.66	1.14	1.57*
233	142	8.40*	4.42	5.33	100.00	.34	.82	1.26*	1.50*
237	142	7.60	4.79	5.46	112.00	.22	.52*	.97	1.10
238	142	7.40	3.82	4.88	106.00	.22	.65	.95	1.76*
243	142	7.50	4.20	190.00	85.00	.30	.70	.90	1.20
245	142	7.20	4.20	187.00	90.00	.33	.75	1.10	1.30
249	142	7.20	4.40	192.00	85.00	.32	.71	1.00	1.30
251	142	6.90	5.40	200.00	132.00	.30	.80	.80	1.20
254	142	8.10	5.10	160.00	110.00	.30	.80	.80	1.00
255	142	8.70*	5.10	187.00	102.00	.30	.70	.20*	1.20
260	142	6.80	4.20	178.00	97.00	.40	.80	.80	1.20
262	142	4.90*	3.70	160.00	112.00	.30	.70	.90	1.10
268	142	8.10	5.20	243.00	146.00	.50*	.80	.90	1.10
269	142	6.70	4.10	181.00	98.00	.30	.70	.60	1.30
273	142	6.00	3.80	231.00	132.00	.40	.60	1.10	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

75

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
28	142	1.026	0	0	0	0
31	142	1.024	0	0	0	0
32	142	1.022	0	0	0	0
41	142	1.026	0	0	0	0
42	142	1.020	0	0	0	0
44	142	1.024	0	0	0	0
47	142	1.020	0	0	0	0
51	142	1.021	0	0	0	0
54	142	1.026	0	0	0	0
55	142	1.028	0	0	0	0
60	142	1.024	0	0	0	0
61	142	1.021	0	0	0	0
66	142	1.027	0	0	0	0
67	142	1.019	0	0	0	0
70	142	1.019	0	0	0	0
77	142	1.015	1*	0	0	0
78	142	1.030*	0	0	0	0
83	142	1.013*	0	0	0	0
84	142	1.012*	0	0	0	0
88	142	1.011*	0	0	0	0
90	142	1.012*	0	0	0	0
91	142	1.032*	0	0	0	0
95	142	1.029*	0	0	0	0
98	142	1.015	0	0	0	0
102	142	1.018	0	0	0	0
103	142	1.023	0	0	0	0
106	142	.	0	0	0	0
110	142	1.017	0	0	0	0
113	142	1.016	0	0	0	0
118	142	1.020	0	0	0	0
119	142	1.012	0	0	0	0
124	142	1.010	0	0	0	1
126	142	1.030	0	0	0	1
127	142	1.030	0	0	0	2
132	142	1.030	0	0	0	2
133	142	1.025	0	0	1	24*
136	142	1.025	0	0	1	2
139	142	1.033*	0	0	6*	1
140	142	1.015	0	0	0	1
147	142	1.020	0	0	0	1
148	142	1.020	0	0	0	2
170	142	1.010	0	0	0	4
172	142	1.020	0	0	0	2
179	142	1.020	0	0	0	4
180	142	1.020	0	0	0	4
181	142	1.010	0	0	0	0
186	142	1.015	0	0	0	4
187	142	1.010	0	0	0	4
188	142	1.010	0	0	0	4
193	142	1.020	0	0	4	0
197	142	1.016	0	0	1	4
202	142	1.016	0	0	1	4
203	142	1.016	0	0	2	2
206	142	1.016	0	0	1	4

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
210	142	1.020	0	0	2	3
214	142	1.016	0	0	2	2
216	142	1.016	0	0	2	2
218	142	1.015	0	0	3	1
219	142	1.016	0	0	0	2
226	142	1.010*	0	0	2	1
227	142	1.018	0	0	1	2
233	142	1.025	0	0	3	3
237	142	1.009*	0	0	0	1
238	142	1.011*	0	0	0	5
243	142	1.020	0	0	0	4
245	142	1.010	0	0	0	2
249	142	1.015	0	0	0	0
251	142	1.018	0	0	1	3
254	142	1.018	0	0	2	1
255	142	1.018	0	0	0	2
260	142	1.005	0	0	2	4
262	142	1.012	0	0	0	4
268	142	1.020	0	0	1	4
269	142	1.018	0	0	1	3
273	142	1.020	0	0	1	3

76

FCE 20124/702 i

Treatment Group "B"

77

Day 14 (Period 142)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	80	12
Hematocrit (HCT)	80	12
Red Blood Cells (RBC)	80	19
White Blood Cells (WBC)	80	12
Neutrophils (NEUTS)	80	15
Lymphocytes (LYMPS)	80	21
Eosinophils (EOSIN)	80	21
Monocytes (MONOS)	80	22
Basophils (BASOS)	80	13
Platelets (PLATES)	80	7
Sodium (NA+)	80	10
Phosphorous (K+)	80	3
Chlorine (CL-)	80	13
Calcium (CA++)	79	11
Aspartate		
Aminotransferase (SGOT)	80	0
Alanine		
Aminotransferase (SGPT)	80	5
γ-GT (GGT)	80	16
Blood Sugar (BLSUG)	80	7
Phosphorous (PO4)	80	2
Alkaline		
Phosphatase (ALPKHOS)	79	3
Urea Nitrogen (BUN)	80	3
Creatinine (CREAT)	80	4
Uric Acid (URACID)	80	8
Total Bilirubin (TOTBILI)	80	3
Direct Bilirubin (DIRBILI)	79	12
Total Protein (TOTPROT)	80	5
Albumin (BLALB)	80	11
Cholesterol (CHOLE)	80	6
Triglycerides (TRIGLY)	78	9
Globulins - α1 (GLOBAL)	75	18
Globulins - α2 (GLOBA2)	75	12
Globulins - β (GLOBETA)	75	9
Globulins - γ (GLOGAMA)	75	11

URNALYSIS

Specific Gravity (SPECGRAV)	74	11
Albumin (URALB)	75	1
Sugar (URSUG)	75	0
Red Blood Cells (URRBC)	75	1
White Blood Cells (URWBC)	75	1

FCE 20124/702 i

\* = Value out-of-range

78

Day 28 (Period 282)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
2	282	13.60	41.20	4.30	5.50	56.00	37.00	2.00	5.00
10	282	13.90	40.40	4.63	6.70	62.00	28.00	2.00	7.00
11	282	12.90*	39.80	4.60	8.30*	51.00	38.00	2.00	8.00
15	282	13.80	41.70	4.76	5.20	44.00*	48.00*	2.00	6.00
17	282	14.00	37.70	3.94*	4.80	48.00*	42.00*	3.00	6.00
31	282	14.60*	45.00	6.00*	6.20	68.00	25.00	3.00	2.00
32	282	14.00	41.00	5.20*	6.00	70.00	26.00	3.00	1.00
41	282	14.30	41.00	4.50	6.00	66.00	26.00	4.00	4.00
42	282	14.40	42.00	5.00	5.20	70.00	28.00	1.00	1.00
44	282	14.40	40.00	4.90	5.20	70.00	25.00	3.00	1.00
47	282	14.20*	41.00	4.80	5.60	67.00	26.00	4.00	3.00
51	282	7.60	.37	3.80*	4.30	74.00	21.00	1.00	4.00
54	282	8.90	.45	4.90	6.10	64.00	31.00	2.00	3.00
55	282	9.20	.50	5.30	6.70	65.00	28.00	2.00	4.00
60	282	8.70	.46	5.30	6.70	66.00	27.00	2.00	4.00
61	282	7.80	.43	4.90	6.30	69.00	25.00	2.00	3.00
66	282	8.80	.43	5.10	6.20	65.00	29.00	2.00	3.00
67	282	8.80	.46	4.90	6.30	67.00	29.00	1.00	3.00
70	282	8.70	.47	5.00	6.70	69.00	27.00	2.00	2.00
78	282	17.90	52.20	5.15	8.63	53.80	30.70	3.80	8.70
83	282	14.40	44.90	4.76	5.18	65.20	23.20	2.40	6.90
84	282	13.40	40.90	4.32	4.39*	53.70	31.30	5.20	6.30
88	282	13.90	40.60	4.41	9.43	53.70	34.30	2.60	5.60
90	282	12.60	39.20	4.22	6.20	65.60	25.00	2.80	3.70
91	282	16.30	45.10	4.95	7.54	49.40	40.80	2.20	4.20
95	282	14.30	43.50	4.93	7.10	.	.	.	.
98	282	12.40	34.80*	3.91*	5.60	78.00*	21.00	.00*	1.00*
102	282	15.40	41.50*	4.79	5.10	79.00*	17.00*	3.00	1.00*
103	282	14.30	39.70*	4.42*	6.60	65.00	32.00	1.00	2.00
106	282	13.60	37.30	4.22	6.40	72.00	20.00	5.00	2.00
110	282	13.20	34.40*	3.91*	6.90	65.00	30.00	2.00	3.00
113	282	15.90	40.10	4.75	5.80	68.00	30.00	1.00	1.00*
118	282	16.80	42.80	4.54*	8.70	71.00	29.00	.00*	.00*
119	282	15.70	41.90	4.75	6.70	40.00	57.00*	3.00	.00*
124	282	14.90	45.00	4.80	5.60	56.00*	42.00*	.00	2.00*
126	282	14.00	44.00	5.20	5.40	56.00*	44.00*	.00	.00*
127	282	14.00	44.00	4.84	5.10	54.00*	58.00*	.00	.00*
132	282	13.80	43.00	4.24	4.00*	38.00*	58.00*	.00	4.00*
133	282	14.00	43.00	4.40	5.30	60.00	34.00	6.00*	.00*
136	282	15.50	47.00	5.17	6.50	73.00*	27.00	.00	.00*
139	282	14.70	43.00	4.86	4.60*	62.00	38.00*	.00	.00*
140	282	15.10	47.00	4.94	4.30*	62.00	38.00*	.00	.00*
148	282	12.40	37.20	5.00	7.00	60.00	30.00	3.00*	5.00
170	282	15.80	42.00	6.10	6.70	59.00	31.00	3.00	6.00
172	282	16.00	45.00	6.10	6.70	59.00	32.00	2.00	6.00
179	282	15.90	44.00	6.00	6.70	59.00	32.00	2.00	7.00
180	282	16.00	45.00	6.00*	6.70	59.00	31.00	3.00	6.00
181	282	16.00	45.00	5.90	6.10	59.00	32.00	2.00	6.00
186	282	16.00	45.00	6.00	7.10	59.00	32.00	2.00	6.00
187	282	15.90	44.00	6.00	7.20	60.00	32.00	2.00	6.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

79

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
188	282	16.00	45.00	6.10	6.70	59.00	33.00	2.00	6.00
193	282	16.20*	46.00	5.10	6.20	58.00	32.00	5.00*	3.00
197	282	17.30	47.00	6.30*	5.50	56.00	34.00*	6.00*	3.00
202	282	16.20*	47.00	5.90*	8.10	52.00*	38.00*	4.00*	3.00
203	282	13.50*	45.00	5.50	5.10	55.00	35.00*	5.00*	3.00
206	282	13.00	41.00	5.10	4.60*	52.00*	38.00*	5.00*	4.00
210	282	16.20	48.00	5.30	8.00	55.00	35.00*	4.00*	3.00
214	282	16.50	44.00	5.00	8.00	55.00	35.00*	4.00*	5.00
216	282	15.80	45.00	5.00	6.20	52.00*	38.00*	4.00*	5.00
218	282	12.20	38.00	4.97	5.50	58.00	33.00	4.00	5.00
219	282	13.30	40.00	4.26	7.90	76.00*	22.00	.00	2.00
226	282	13.80	43.00	4.65	6.60	49.00*	49.00*	2.00	.00
227	282	11.32*	32.50*	3.57*	4.60	53.00	39.00	4.00	4.00
237	282	15.50	42.00	5.35	6.75	70.00	26.00	2.00	2.00
238	282	13.99	40.00	4.40	5.30	64.00	33.00	1.00	2.00
243	282	15.80	44.00	6.00	5.90	58.00	30.00	4.00*	7.00
245	282	16.00	44.00	6.10	5.80	59.00	30.00	4.00*	6.00
249	282	15.80	44.00	5.90*	6.00	60.00	30.00	3.00	6.00
251	282	13.20	46.00	4.90	6.00	54.00	36.00*	6.00*	4.00
254	282	12.00	37.00	5.00	4.60*	52.00*	38.00*	6.00*	3.00
255	282	14.80	44.00	5.10	6.00	51.00*	39.00*	4.00*	4.00
260	282	15.90	44.00	6.00*	5.70	58.00	32.00	6.00*	3.00
262	282	16.00	44.00	6.00	5.60	58.00	32.00	5.00*	4.00
268	282	12.00	40.00	4.10*	7.20	51.00*	39.00*	6.00*	3.00
269	282	13.00*	40.00*	5.00	4.60*	52.00*	38.00*	5.00*	4.00
273	282	13.30	42.00	4.80	7.60	58.00	32.00	6.00*	3.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

80

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
2	282	.00	258.00	142.00	4.10	103.00	2.27	10.00	9.00	12.00
10	282	1.00	354.00*	140.00	4.50	95.00	2.53	9.00	6.00	10.00
11	282	1.00	258.00	139.00	4.10	94.00	2.31	8.00	4.00*	7.00
15	282	.00	235.00	142.00	4.20	101.00	2.56	8.00	10.00	12.00
17	282	1.00	228.00	144.00*	4.30	104.00	2.25	9.00	12.00	14.00
31	282	2.00*	240.00	146.00	4.00	101.00	2.10	14.00	14.00	16.00
32	282	.00	228.00	146.00	4.10	103.00	2.10	14.00	14.00	16.00
41	282	2.00*	226.00	144.00	4.10	108.00	2.10	14.00	14.00	14.00
42	282	.00	215.00	143.00	4.20	108.00	1.90*	10.00	8.00	14.00
44	282	1.00	210.00	146.00	4.00	102.00	2.00*	8.00	10.00	10.00
47	282	.00	210.00	142.00	3.90	102.00	1.90*	12.00	12.00	12.00
51	282	.00	178.00	139.00	4.50	104.00	2.10	8.00	13.00	17.00
54	282	.00	192.00	141.00	3.90	99.00	2.70	12.00	14.00	29.00*
55	282	1.00	172.00	143.00	4.20	102.00	2.40	14.00	14.00	31.00*
60	282	1.00	172.00	143.00	3.90	102.00	2.50	14.00	12.00	31.00*
61	282	1.00	189.00	137.00*	4.10	101.00	2.40	13.00	12.00	33.00*
66	282	1.00	189.00	137.00*	4.10	104.00	2.50	12.00	15.00	31.00*
67	282	.00	171.00	138.00	3.90	101.00	2.70	10.00	8.00	25.00
70	282	.00	188.00	137.00*	4.10	102.00	2.60	14.00	14.00	33.00*
77	282	.	.	132.00	.	93.00	10.30	25.00	25.00	11.00
78	282	1.20	294.00	142.00	5.10	104.00	10.30	21.00	33.00	17.00
83	282	1.40	181.00	135.00	3.80*	100.00	9.10	19.00	29.00	16.00
84	282	.80	207.00	139.00	3.80*	107.00	9.10	10.00	13.00	12.00
88	282	.70	463.00*	138.00	4.60	102.00	9.40	10.00	7.00	7.00
90	282	.80	178.00	137.00	4.20	99.00	8.30	11.00	7.00	5.00*
91	282	.80	203.00	139.00	4.60	97.00	9.20	12.00	8.00	5.00*
95	282	.	.	140.00	4.20	106.00	9.10	11.00	11.00	11.00
98	282	.00	141.00*	136.00	3.50	101.00	9.30	26.00	31.00	24.00
102	282	.00	142.00*	141.00	4.50	99.00	8.90	61.00*	79.00*	39.00*
103	282	.00	246.00	150.00	5.10	117.00*	8.50	38.00*	36.00	28.00
106	282	.00	229.00	139.00	4.60	111.60*	7.10*	18.00	38.00	29.00
110	282	.00	307.00	149.80	3.86	114.70*	8.70	25.00	21.00	16.00
113	282	.00	210.00	142.00	4.50	105.00	9.20	17.00	23.00	20.00
118	282	.00	182.00	138.00	3.70	112.00*	9.40	24.00	60.00*	55.00*
119	282	.00	237.00	147.00	4.30	112.00*	9.00	17.00	14.00	11.00
124	282	.00	161.00	140.00	5.00	358.00	10.10	48.00*	50.00*	25.00
126	282	.00	301.00	145.00	4.90	363.00	9.70	15.00	10.00	8.00
127	282	.00	180.00	143.00	4.30	341.00	9.70	11.00	11.00	7.00
132	282	.00	136.00*	130.00	3.80	381.00	10.30	17.00	21.00	14.00
133	282	.00	390.00	139.00	4.10	368.00	9.80	23.00	35.00	18.00
136	282	.00	262.00	138.00	3.90	353.00	9.90	12.00	19.00	9.00
139	282	.00	241.00	129.00*	3.90	347.00	10.20	17.00	19.00	15.00
140	282	.00	196.00	131.00*	4.10	348.00	10.30	27.00	18.00	14.00
148	282	2.00*	170.00	138.00	3.60	110.00	8.00	8.00	10.00	6.00
170	282	1.00	270.00	157.00*	4.70	96.00	9.20	37.00	11.50	17.00
172	282	1.00	280.00	139.00	4.90	100.00	9.10	37.00	9.60	8.20*
179	282	.00	270.00	142.00	5.20	97.00	9.10	37.00	9.50	8.10*
180	282	1.00	270.00	142.00	4.80	99.00	9.10	38.00	10.00	8.10
181	282	1.00	270.00	140.00	5.10	98.00	9.00	38.00	9.80	8.00*
186	282	1.00	270.00	140.00	5.10	98.00	9.00	38.00	9.80	8.00*
187	282	.00	275.00	140.00	5.10	98.00	9.10	39.00	9.70	8.10*
188	282	.00	275.00	135.00	5.10	97.00	9.20	37.00	9.80	8.10*
193	282	2.00*	269.00	140.00	5.00	98.00	9.20	29.00	18.00	31.00
197	282	1.00	271.00	140.00	4.90	104.00	9.80	32.00	18.00	31.00

FCE 20124/702 i

81

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
202	282	2.00*	300.00	145.00	4.10	98.00	9.30	28.00	27.00	30.00
203	282	2.00*	320.00	142.00	4.60	105.00	9.10	42.00	34.00	50.00
206	282	1.00	152.00	149.00	5.10	100.00	10.00	30.00	25.00	23.00
210	282	3.00*	231.00	134.00*	5.20	103.00	9.70	43.00	35.00	25.00
214	282	1.00	338.00	140.00	5.20	105.00	9.50	29.00	30.00	40.00
216	282	1.00	285.00	136.00	4.30	100.00	7.20*	18.00	22.00	24.00
218	282	.00	295.00	138.00	4.40	103.00	9.60	14.00	12.00	30.00
219	282	.00	317.00	139.00	3.90	100.00	9.05	8.00	11.00	39.00*
226	282	.00	420.00*	143.00	4.10	101.00	9.10	13.00	12.00	16.00
227	282	.00	320.00	139.00	4.20	99.00	8.50	8.00	4.00	8.00
237	282	.00	320.00	124.00*	3.70	103.00	9.35	16.00	7.00	12.00
238	282	.00	330.00	131.00*	4.00	91.00*	9.07	18.00	7.00	13.00
243	282	1.00	270.00	139.00	4.90	98.00	8.70	39.00	9.70	8.10*
245	282	1.00	275.50	139.00	4.90	98.00	8.90	38.00	9.60	8.10*
249	282	1.00	275.00	139.00	4.70	98.00	8.80	38.00	9.80	8.10
251	282	.00	178.00	148.00	4.80	108.00*	8.90	38.00	30.00	30.00
254	282	1.00	308.00	136.00	4.10	105.00	8.70	32.00	30.00	36.00
255	282	2.00*	252.00	136.00	5.10	106.00*	8.10*	45.00	38.00*	26.00
260	282	1.00	281.00	140.00	5.30	109.00*	4.90*	39.00	30.00*	33.00
262	282	1.00	315.00	139.00	5.00	106.00*	8.80	32.00	30.00*	34.00
268	282	1.00	180.00	150.00	5.20	99.00	9.40	42.00	31.00*	27.00
269	282	1.00	230.00	140.00	4.50	100.00	8.40*	33.00	16.00	32.00
273	282	1.00	231.00	134.00*	5.20	114.00*	9.00	35.00	35.00*	30.00

FCE 20124/702 i

82

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
2	282	5.43	1.13	59.00	3.90	82.00	.13*	7.00	1.40
10	282	5.02	1.19	112.00	5.20	81.00	.19	6.00	1.40
11	282	4.67	1.19	99.00	4.30	72.00	.10*	8.00	4.00
15	282	4.75	1.08	148.00	3.10	74.00	.10*	8.00	1.40
17	282	5.21	1.24	126.00	4.80	77.00	.22	8.00	1.40
31	282	4.10	1.20	190.00	5.80	76.00	268.00	12.00	.00
32	282	4.10	1.00	115.00	4.50	66.00	238.00	16.00	.00
41	282	4.10	1.20	98.00	6.10	66.00	218.00	14.00	.00
42	282	4.20	1.50	88.00	6.00	50.00*	162.00*	12.00	.00
44	282	4.10	1.10	136.00	5.00	78.00	280.00	8.00	.00
47	282	4.10	1.20	138.00	4.80	70.00	248.00	12.00	.00
51	282	4.70	1.00	28.00	6.00	90.00	131.00*	7.00	.00
54	282	4.70	.90	32.00	4.00	72.00	154.00	12.00	.00
55	282	4.60	1.30	31.00	4.00	76.00	154.00	13.00	.00
60	282	4.70	1.10	28.00	7.00	68.00	159.00	12.00	.00
61	282	4.10	1.10	27.00	6.00	74.00	153.00	12.00	.00
66	282	5.10	1.00	29.00	8.00	76.00	161.00	11.00	.00
67	282	4.00	1.00	27.00	4.00	74.00	161.00	8.00	.00
70	282	4.70	1.10	29.00	5.50	58.00	161.00	12.00	.00
77	282	97.00	3.10	84.00	19.40	1.40*	10.50*	1.10*	.50*
78	282	86.00	3.60	99.00	13.60	1.30*	4.40	.50	.20
83	282	132.00*	.	79.00	15.00	.80	5.10	.70	.30
84	282	80.00	2.90	76.00	14.20	.70	4.40	.60	.30
88	282	83.00	4.40	143.00*	14.10	1.00	3.20*	.50	.30
90	282	75.00	3.40	76.00	15.70	.90	2.50	.90	.30
91	282	81.00	4.00	73.00	14.50	1.20	5.70	.80	.20
95	282	78.00	3.20	48.00	18.40	1.10	2.10*	.70	.20
98	282	92.00	3.20	194.00	41.00	.80	4.20	.29	.07
102	282	67.00	2.90	170.00	38.00	.90	2.60	1.10*	.20
103	282	71.00	3.40	179.00	38.00	.60	3.60	.57	.09
106	282	76.00	3.00	181.00	33.00	.70	4.30	.40	.10
110	282	77.00	2.80	186.00	30.00	.40*	2.30*	.54	.08
113	282	100.00	3.90	152.00	41.00	.80	4.40	.80	.10
118	282	82.00	2.00*	200.00	57.00*	1.20	3.80	.70	.06
119	282	72.00	3.60	166.00	35.00	.80	3.80	.39	.05
124	282	73.00*	3.90	71.00	29.00	.90	6.80	.70	.30*
126	282	98.00	3.80	86.00	21.00	.90	3.10	.80	.30*
127	282	89.00	3.60	89.00	22.00	.90	3.70	.80	.30*
132	282	125.00*	3.80	89.00	34.00	.90	4.80	.70	.30*
133	282	96.00	4.20	81.00	34.00	.80	5.20	.70	.30*
136	282	85.00	3.80	122.00*	28.00	1.00	4.00	.80	.30*
139	282	81.00	3.30	35.00	21.00	.70*	3.50	1.00	.40*
140	282	83.00	3.40	69.00	26.00	.90	5.60	1.60	.70*
148	282	90.00	2.60	40.00	30.00	.70	3.40	.80	.60*
170	282	89.00	3.80	138.00	12.10	1.10	5.10	.70	.40
172	282	96.00	4.00	172.00	11.10	1.00	4.50	.80	.40
179	282	97.00	4.10	180.00	11.00	1.00	5.60	.70	.40
180	282	95.00	3.80	180.00	11.00	1.10	5.70	.70	.40
181	282	92.00	4.00	178.00	11.20	1.00	5.60	.70	.50
186	282	92.00	4.00	170.00	11.20	1.00	4.70	.70	.40
187	282	92.00	4.20	177.00	11.90	1.99	5.20	.70	.40
188	282	97.00	4.20	170.00	11.10	1.00	6.10	.70	.40
193	282	108.00	3.80	140.00	11.80	.76	5.00	.80	.20
197	282	116.00*	3.80	141.00	11.80	.78	4.90	.90	.30

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

83

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
202	282	105.00	3.40	78.00*	15.00	1.00	4.70	.50	.30
203	282	100.00	3.70	128.00	16.00	.60	4.50	.70	.20
206	282	98.00	3.90	130.00	11.30	1.20	5.40	.90	.30
210	282	99.00	3.80	134.00	30.00*	.80	4.50	.90	.40
214	282	105.00	3.50	125.00	17.00	.80	4.10	.80	.52
216	282	100.00	4.10	124.00	8.00	.80	5.00	.60	.50
218	282	4.95	3.69	22.54	15.00*	88.40	3.60	7.69	3.42
219	282	4.95	2.52	45.59	19.00*	68.06	4.20	6.84	2.56
226	282	4.62	3.60	34.23	20.50	66.30	5.90	8.89	3.42
227	282	4.56	2.80	23.70	19.00*	66.30	3.60	9.40	5.98*
237	282	5.22	3.68	45.09	24.00	103.40	4.20	11.97	3.42
238	282	4.67	3.68	40.84	27.00	70.72	5.00	10.26	1.71
243	282	90.00	3.80	172.00	11.10	1.10	5.20	.70	.40
245	282	85.00	3.70	177.00	11.10	1.00	5.20	.60	.40
249	282	88.00	3.70	177.00	11.10	1.10	5.40	.70	.40
251	282	110.00	4.00	124.00	10.00	.80	5.10	.80	.20
254	282	110.00	3.90	116.00	18.00	.80	4.90	.80	.20
255	282	110.00	4.10	80.00	21.00	.86	5.10	.80	.20
260	282	98.00	3.80	119.00	12.00	.90	5.40	.90	.10
262	282	105.00	3.90	118.00	18.00	.90	4.20	.90	.30
268	282	95.00	3.70	128.00	15.00	.78	4.80	.90	.20
269	282	100.00	3.80	132.00	11.40	.77	5.00	1.20*	.30
273	282	100.00	3.70	132.00	19.00	.78	5.40	.90	.20

FCE 20124/702 i

84

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
2	282	73.00	42.10*	6.60*	1.15	2.40	5.60*	8.30	14.60
10	282	74.00	41.40*	6.40	1.19	3.00	7.20	10.50	11.90
11	282	71.00	43.30*	4.70	.70	2.50	6.20	8.60	9.40*
15	282	71.00	41.30*	5.60	.66	2.20	4.90*	9.30	13.30
17	282	62.00	42.50*	6.10	1.71	1.80	5.80*	7.50*	4.40*
31	282	72.00	34.00*	4.30	1.50	3.80	8.10	11.40	14.00
32	282	71.00	39.00	4.10	3.80*	3.10	7.30	9.00	13.80
41	282	72.00	39.00	5.30	1.20	3.10	8.60	11.00	13.90
42	282	66.00	30.00*	4.40	1.10	3.90*	7.80	8.90	14.80
44	282	71.00	40.00	4.00	1.20	3.80*	10.80*	9.00	13.60
47	282	72.00	36.00	4.10	1.20	3.10	7.60	11.20	13.80
51	282	66.00	42.00	5.90	1.20	1.70*	5.30*	7.90*	9.40*
54	282	74.00	40.00	5.40	1.70	2.20*	7.30	8.10	15.40
55	282	73.00	43.00	4.60	1.20	2.10*	6.90	8.40	12.60
60	282	75.00	43.00	4.60	1.60	2.40	6.60	9.00	14.00
61	282	74.00	46.00	4.90	1.70	2.90	7.80	8.90	14.70
66	282	74.00	42.00	5.40	1.40	2.10*	6.90	8.50	14.50
67	282	78.00	45.00	4.70	1.30	2.70	7.30	9.00	14.00
70	282	72.00	40.00	4.90	1.60	2.70	8.30	8.00*	13.00
77	282	8.80*	5.10*	302.00*	146.00	.	.	.	.
78	282	7.70	4.80	224.00*	246.00*	2.65	14.20*	11.91	13.40
83	282	7.80	4.40	218.00	134.00	2.92	12.90	13.36	17.84
84	282	6.90	3.90	239.00*	112.00	2.22*	8.69	12.81	16.03
88	282	7.10	4.30	255.00*	411.00*	2.42	12.56	13.91	13.07
90	282	6.40	4.20	220.00	149.00	3.04	8.43	12.26	14.47
91	282	7.20	4.80	164.00*	130.00	2.64	7.09	11.85	12.39
95	282	7.40	4.70	162.00*	89.00	2.74	9.21	14.12	15.56
98	282	6.60	65.10	191.00	138.00	3.10	9.80	10.10	11.80
102	282	7.00	59.30	196.00	133.00	3.10	9.40	13.40	14.80
103	282	7.40	56.40	216.00	119.00	3.50	10.20	12.50	17.40
106	282	6.60	59.00	161.00	69.00	2.70	9.50	11.20	17.60
110	282	7.40	58.50	132.00	166.00	2.70	9.60	12.50	16.80
113	282	8.10	56.10	193.00	129.00	3.10	9.50	13.90	17.10
118	282	8.00	51.20*	165.00	78.00	4.70*	12.80*	13.50	17.80
119	282	7.50	58.50	212.00	156.00	3.40	8.70	14.20*	15.40
124	282	8.20	5.20*	190.00	81.00	2.20*	8.90*	7.90*	12.10
126	282	7.60	4.70	187.00	208.00	2.10*	9.60	8.90	13.10
127	282	7.20	4.00	114.00*	39.00	1.60*	8.30*	6.00*	10.80
132	282	8.80*	4.70	257.00	256.00*	1.80*	12.10	9.00	16.20
133	282	8.00	5.10*	172.00	150.00	2.20*	11.10	10.20	17.10
136	282	7.00	4.70	199.00	151.00	2.30*	11.30	12.40*	12.60
139	282	7.80	4.80	208.00	160.00	1.50*	6.90*	9.30	16.70
140	282	7.50	4.70	149.00	131.00	2.10*	10.20	7.90*	11.70
148	282	7.00	5.00	175.00	50.00	5.00	10.00	15.00	20.00
170	282	7.50	4.30	195.00	92.00	.33	.85	1.20	1.50
172	282	6.80	4.40	290.00	89.00	.35	.82	1.00	1.20
179	282	6.70	4.60	192.00	90.00	.32	.71	.91	1.30
180	282	8.80*	4.70	189.00	90.00	.31	.72	.90	1.40
181	282	8.80*	4.70	196.00	87.00	.32	.75	.95	1.20
186	282	8.80	4.60	195.00	89.00	.35	.76	.98	1.20
187	282	6.70	4.60	190.00	89.00	.41*	.77	.92	1.20
188	282	8.80*	4.60	200.00	92.00	.41*	.72	.99	1.30
193	282	7.10	4.60	180.00	99.00	.30	.70	.60	1.50
197	282	7.00	4.80	179.00	97.00	.20	.70	.80	1.50

FCE 20124/702 i

85

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
202	282	8.10	5.20	245.00	147.00	.30	.70	1.00	1.30
203	282	6.50	4.10	143.00	130.00	.20	.50	.80	1.10
206	282	6.90	4.20	180.00	99.00	.40	.70	.90	1.10
210	282	8.00	4.10	210.00	130.00	.40	.50	.70	1.20
214	282	7.00	5.20	178.00	105.00	.30	.70	.90	1.30
216	282	6.20*	6.00*	188.00	140.00	.20	.60	.80	.90
218	282	7.40	4.68	5.98	58.00	.08*	.53*	.87	1.24
219	282	7.10	4.46	6.11	78.00	.13*	.60	.97	.94
226	282	6.90	4.10	4.94	164.00	.19*	.53*	.97	1.11
227	282	6.80	4.10	4.68	159.00	.13*	.49*	.85	1.16
237	282	7.90	4.49	5.20	100.00	.20	.64	1.14	1.43*
238	282	7.40	3.93	4.94	98.00	.27	.63	.84	1.73*
243	282	7.20	4.10	190.00	92.00	.30	.70	.90	1.30
245	282	7.50	4.40	198.00	85.00	.37	.72	1.00	1.30
249	282	7.30	4.20	190.00	85.00	.32	.75	1.10	1.40
251	282	6.90	5.30	200.00	130.00	.20	.70	.70	1.00
254	282	8.20	5.10	160.00	110.00	.30	.80	.70	1.10
255	282	8.80*	5.20	182.00	101.00	.30	.70	.21*	1.00
260	282	6.90	4.30	178.00	99.00	.30	.60	.90	1.20
262	282	4.80*	3.60	158.00	116.00	.40	.60	.90	1.10
268	282	8.10	5.30	243.00	146.00	.50*	.70	.90	1.20
269	282	6.70	4.10	180.00	98.00	.30	.60	.60	1.10
273	282	6.10	3.90	231.00	133.00	.40	.70	1.10	1.00

FCE 20124/702 i

86

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
31	282	1.024	0	0	0	0
32	282	1.022	0	0	0	0
41	282	1.022	0	0	0	0
42	282	1.024	0	0	0	0
44	282	1.022	0	0	0	0
47	282	1.022	0	0	0	0
51	282	1.020	0	0	0	0
54	282	1.029	0	0	0	0
55	282	1.029	0	0	0	0
60	282	1.012	0	0	0	0
61	282	1.026	0	0	0	0
66	282	1.027	0	0	0	0
67	282	1.020	0	0	0	0
70	282	1.021	0	0	0	0
78	282	1.026*	1	0	0	0
83	282	1.010*	0	0	0	0
84	282	1.004*	0	0	0	0
90	282	1.014*	0	0	0	0
91	282	1.024*	0	0	0	0
95	282	1.031*	0	0	0	0
98	282	1.007	0	0	0	0
102	282	1.020	0	0	0	0
103	282	1.017	0	0	0	0
106	282	.	0	0	0	0
110	282	1.018	0	0	0	0
113	282	1.018	0	0	0	0
118	282	1.024	0	0	0	0
119	282	1.015	0	0	0	0
124	282	1.015	0	0	0	1
126	282	1.020	0	0	0	0
127	282	1.025	0	0	3*	14*
132	282	1.032*	0	0	0	2
133	282	1.025	0	0	1	32*
136	282	1.020	0	0	0	2
139	282	1.025	0	0	1	2
140	282	1.025	0	0	1	2
148	282	1.022	0	0	0	2
170	282	1.012	0	0	0	2
172	282	1.020	0	0	0	2
179	282	1.010	0	0	0	4
180	282	1.020	0	0	0	4
181	282	1.015	0	0	2	4
186	282	1.020	0	0	0	2
187	282	1.015	0	0	0	2
188	282	1.015	0	0	0	4
193	282	1.020	0	0	3	0
197	282	1.016	0	0	1	5
202	282	1.018	0	0	1	4
203	282	1.018	0	0	1	2
206	282	1.020	0	0	2	5
210	282	1.020	0	0	1	2
214	282	1.020	0	0	2	3
216	282	1.018	0	0	1	2
218	282	1.011*	0	0	0	3

592



FCE 20124/702 i

87

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
219	282	1.015	0	0	1	3
226	282	1.010*	0	0	2	2
227	282	1.015	0	0	0	10*
237	282	1.014*	0	0	0	2
238	282	1.011*	0	0	1	1
243	282	1.015	0	0	0	2
245	282	1.015	0	0	0	2
249	282	1.010	0	0	0	0
251	282	1.020	0	0	1	2
254	282	1.018	0	0	1	2
255	282	1.018	0	0	1	2
260	282	1.015	0	0	2	4
262	282	1.015	0	0	0	4
268	282	1.018	0	0	1	5
269	282	1.016	0	0	2	3
273	282	1.020	0	0	1	4

FCE 20124/702 i

Treatment Group "B"

88

Day 28 (Period 282)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	76	8
Hematocrit (HCT)	76	6
Red Blood Cells (RBC)	76	15
White Blood Cells (WBC)	76	8
Neutrophils (NEUTS)	75	18
Lymphocytes (LYMPS)	75	23
Eosinophils (EOSIN)	75	22
Monocytes (MONOS)	75	13
Basophils (BASOS)	75	8
Platelets (PLATES)	75	6
Sodium (NA+)	77	11
Phosphorous (K+)	77	2
Chlorine (CL-)	77	11
Calcium (CA++)	77	8
Aspartate		
Aminotransferase (SGOT)	77	3
Alanine		
Aminotransferase (SGPT)	77	9
γ-GT (YGT)	77	19
Blood Sugar (BLSUG)	77	4
Phosphorous (PO4)	76	1
Alkaline		
Phosphatase (ALKPHOS)	77	3
Urea Nitrogen (BUN)	77	5
Creatinine (CREAT)	77	5
Uric Acid (URACID)	77	9
Total Bilirubin (TOTBILI)	77	3
Direct Bilirubin (DIRBILI)	77	11
Total Protein (TOTPROT)	77	8
Albumin (BLALB)	77	12
Cholesterol (CHOLE)	77	8
Triglycerides (TRIGLY)	77	4
Globulins - α1 (GLOBAL)	76	23
Globulins - α2 (GLOBA2)	76	13
Globulins - β (GLOBETA)	76	9
Globulins - γ (GLOGAMA)	76	5
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	69	11
Albumin (URALB)	70	0
Sugar (URSUG)	70	0
Red Blood Cells (URRBC)	70	1
White Blood Cells (URWBC)	70	3

FCE 20124/702 i

REBOXETINE Protocol ADE 08

89

Treatment Group "C"

Table 5e - Laboratory Data

\* = Value out-of-range

Screening (Period -01)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
3	-01	13.90	41.10	4.70	7.80	53.00	40.00	1.00	6.00
6	-01	12.30*	36.40*	3.95*	7.60	51.00	44.00*	.00*	5.00
7	-01	14.60	42.20	4.75	7.10	49.00*	41.00*	2.00	7.00
8	-01	15.00	44.40	4.10	5.50	42.00*	37.00	11.00*	9.00
16	-01	14.20	42.00	4.56	5.40	55.00	26.00	10.00*	7.00
18	-01	14.50	41.00	4.50	6.90	41.00*	39.00	5.00*	10.00*
26	-01	15.20	42.00	5.00	7.00	70.00	26.00	1.00	3.00
27	-01	14.00	39.00	4.60	5.90	70.00	25.00	3.00	2.00
33	-01	13.30	38.20	4.44	8.10	70.00	28.00	1.00	1.00
36	-01	14.70	44.30	4.63	7.40	66.00	20.00	1.00	10.00*
39	-01	13.60	40.00	4.20	6.60	70.00	26.00	3.00	1.00
40	-01	14.90	40.00	5.00	6.00	72.00	26.00	2.00	.00*
43	-01	14.00	40.00	4.60	5.40	72.00	26.00	1.00	1.00
46	-01	16.00	44.00	4.90	7.00	70.00	26.00	2.00	2.00
52	-01	8.10	.40	4.30	6.60	82.00*	15.00	1.00	2.00
53	-01	9.60	.48	4.70	8.40	78.00*	17.00	2.00	4.00
58	-01	9.10	.49	4.50	6.00	71.00	21.00	3.00	4.00
59	-01	9.20	.49	5.10	6.30	58.00*	37.00	2.00	3.00
62	-01	8.20	.47	5.30	8.00	71.00	25.00	1.00	3.00
63	-01	8.90	.49	5.60*	6.10	70.00	25.00	2.00	3.00
69	-01	9.10	.50	5.60*	7.10	68.00	27.00	2.00	3.00
71	-01	8.60	.47	5.30	7.10	76.00*	17.00	2.00	4.00
74	-01	13.00	40.70	4.33	4.17*	48.30	41.40	1.50	5.60
76	-01	16.00	57.40*	5.90	12.46*	62.60	22.80	3.00	10.00*
81	-01	14.00	41.80	4.28	8.30	57.80	31.50	1.30	6.80
82	-01	16.10	48.20	4.97	10.70	50.00	37.20	5.70	4.80
86	-01	16.10	47.50	5.16	5.07	51.70	34.40	2.30	6.60
89	-01	13.60	44.60	4.51	13.42*	.	.	.	.
92	-01	14.50	44.10	4.71	4.81	55.30	35.20	2.30	4.30
93	-01	13.30	40.50	4.35	5.02	64.30	25.50	1.50	6.20
97	-01	17.90	47.80	4.68	5.80	72.00	24.00	1.00	3.00
100	-01	13.60	38.30	4.56	6.60	56.00	38.00	4.00	2.00
104	-01	13.70	38.00	4.41	8.30	62.00	37.00	1.00	.00*
105	-01	15.50	41.20*	4.64	9.00	61.00	35.00	1.00	3.00
111	-01	15.50	42.80	4.77	6.20	38.00*	56.00*	4.00	2.00
112	-01	13.00*	38.90*	4.16*	5.00	58.00	42.00	.00*	.00*
116	-01	15.80	41.20	4.51	6.70	77.00*	20.00	.00*	3.00
117	-01	13.10*	38.80*	4.15*	5.10	58.00	41.00	.00*	1.00*
121	-01	12.20	38.00	3.20*	4.70*	68.00	29.00	.00	.00*
125	-01	17.20*	54.00*	6.00*	4.50*	48.00*	44.00*	4.00*	4.00*
128	-01	13.40	42.00	4.62	5.60	68.00	32.00	.00	.00*
129	-01	12.40	39.00	4.29	5.00	50.00*	50.00*	.00	.00*
137	-01	12.80	40.00	4.40	6.50	72.00	28.00	.00	.00*
138	-01	13.20	41.00	4.51	6.10	70.00	30.00	.00	.00*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

90

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
141	-01	15.00	45.00	4.95	6.40	64.00	32.00	4.00*	.00*
145	-01	11.90*	35.60*	3.68	6.00	58.00*	32.00	8.00*	2.00*
173	-01	15.90	44.00	6.20*	6.40	59.00	30.00	4.00*	6.00
174	-01	16.00	45.00	6.10	6.80	59.00	32.00	2.00	6.00
175	-01	15.90	44.00	6.00*	7.20	60.00	30.00	3.00	6.00
178	-01	16.00	45.00	6.10	6.20	59.00	32.00	2.00	6.00
182	-01	16.00	46.00	6.10	7.30	58.00	33.00	3.00	6.00
183	-01	15.90	44.00	6.00*	5.90	60.00	30.00	3.00	7.00
190	-01	16.00	46.00	6.10*	7.20	59.00	32.00	2.00	6.00
191	-01	16.00	46.00	6.00	7.70	61.00	30.00	2.00	6.00
195	-01	15.20	42.00	5.20	3.40*	56.00	34.00*	3.00	5.00
196	-01	14.80	40.00	4.20	3.80*	55.00	35.00*	3.00	2.00*
201	-01	13.00	43.00	4.80	5.00	54.00	36.00*	2.00	6.00
204	-01	14.00	45.00	4.90	7.00	54.00	36.00*	4.00*	4.00
205	-01	12.50	42.00	4.30	7.50	53.00*	37.00*	6.00*	2.00*
207	-01	15.10	45.00	5.80	8.20	53.00*	38.00*	4.00*	4.00
212	-01	14.00	45.00	5.10	5.10	54.00	36.00*	3.00	6.00
213	-01	14.10	47.00	5.50	8.10	53.00*	37.00*	3.00	7.00
220	-01	15.50*	46.00*	4.15	8.50*	36.00*	61.00*	3.00	.00
221	-01	13.10	41.00	4.54	4.50	54.00	43.00*	3.00	.00
225	-01	14.98	43.50	4.78	8.60*	59.00	32.00	4.00	5.00
228	-01	8.88*	35.00*	3.58*	8.90*	89.00*	10.00*	.00	1.00
229	-01	12.98	37.00	4.95	5.50	57.00	39.00	2.00	2.00
234	-01	15.10	46.00	5.00	8.50*	77.00	16.00*	.00	4.00
236	-01	16.85*	50.00*	5.75*	8.75*	70.00	22.00	4.00	3.00
239	-01	12.81	40.00	4.35	7.70	54.00	40.00	2.00	4.00
241	-01	15.90	44.00	6.10	7.20	59.00	31.00	4.00*	6.00
242	-01	15.90	44.00	5.80	6.10	60.00	30.00	3.00	6.00
250	-01	14.00	43.00	5.20	7.00	50.00*	39.00*	7.00*	3.00
252	-01	14.50	44.00	6.10	7.00	54.00	36.00*	7.00*	3.00
253	-01	13.00*	38.00*	5.40	6.10	56.00	34.00*	4.00*	3.00
256	-01	15.20	42.00	5.30	4.80	58.00	32.00	4.00*	6.00
261	-01	16.10	44.00	6.20*	7.10	55.00	35.00*	3.00	3.00
264	-01	16.00	44.00	6.30*	7.20	51.00*	39.00*	6.00*	3.00
265	-01	15.90	42.00	5.90	6.40	57.00	33.00	4.00	4.00
266	-01	15.70	42.00	5.90*	6.10	57.00	33.00	5.00*	3.00
272	-01	12.20	42.00	4.80	5.80	58.00	32.00	4.00*	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

91

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
3	-01	.00	200.00	141.00	4.20	99.00	2.21	12.00	9.00	9.00
6	-01	.00	383.00*	143.00*	4.00	101.00	.	8.00	7.00	12.00
7	-01	1.00	238.00	141.00	3.60*	99.00	2.33	11.00	9.00	20.00
8	-01	1.00	.	141.00	4.70	96.00	2.28	10.00	9.00	23.00
16	-01	2.00*	207.00	143.00*	3.90*	101.00	2.29	6.00	8.00	19.00
18	-01	.00	265.00	141.00	4.10	97.00	2.32	11.00	11.00	17.00
26	-01	.00	210.00	142.00	5.10	96.00	2.30	14.00	18.00	20.00
27	-01	.00	228.00	148.00*	4.10	101.00	2.30	14.00	16.00	16.00
33	-01	.00	290.00	140.00	4.40	100.00	2.20	11.00	6.00	28.00
36	-01	3.00*	180.00	145.00	3.90	98.00	2.20	8.00	7.00	34.00
39	-01	.00	160.00	142.00	4.00	101.00	2.30	8.00	10.00	12.00
40	-01	.00	180.00	148.00*	4.30	104.00	2.30	16.00	18.00	18.00
43	-01	.00	230.00	144.00	4.10	101.00	2.30	14.00	12.00	12.00
46	-01	.00	186.00	142.00	4.60	100.00	2.50	16.00	18.00	26.00
52	-01	.00	187.00	142.00	4.10	103.00	2.27	19.00*	11.00	7.00
53	-01	1.00	191.00	143.00	4.50	104.00	2.30	10.00	19.00	24.00
58	-01	1.00	181.00	139.00	3.90	98.00	2.90*	12.00	10.00	31.00*
59	-01	.00	167.00	141.00	3.90	103.00	2.40	14.00	12.00	31.00*
62	-01	.00	204.00	144.00	4.20	103.00	2.40	14.00	15.00	29.00*
63	-01	.00	187.00	137.00*	4.10	102.00	2.40	12.00	13.00	29.00*
69	-01	.00	186.00	141.00	3.90	102.00	2.30	12.00	14.00	25.00
71	-01	1.00	220.00	139.00	4.20	102.00	2.40	10.00	8.00	27.00
74	-01	1.20	125.00*	142.00	4.00	111.00*	8.00*	22.00	18.00	9.00
76	-01	.40	272.00	144.00	4.90	108.00	10.10	17.00	28.00	14.00
81	-01	.70	370.00	134.00	4.10	101.00	9.00	15.00	18.00	8.00
82	-01	1.00	256.00	146.00	4.80	110.00	9.70	20.00	28.00	22.00
86	-01	1.80*	222.00	138.00	3.40*	101.00	9.60	22.00	21.00	13.00
89	-01	.	160.70	145.00	5.60	105.00	9.10	15.00	16.00	10.00
92	-01	1.00	317.00	140.00	4.50	102.00	8.80	20.00	30.00	12.00
93	-01	.30	223.00	138.00	4.40	98.00	9.20	10.00	10.00	10.00
97	-01	.00	145.00*	136.00	3.50	99.00	9.60	25.00	42.00	32.00
100	-01	.00	265.00	136.00	3.70	100.00	8.50	21.00	12.00	8.80
104	-01	.00	396.00	149.80	3.80	101.00	8.30	18.00	26.00	30.00
105	-01	.00	387.00*	143.00	4.20	102.00	9.60	40.00*	49.00*	38.00*
111	-01	.00	268.00	146.50	4.45	111.20*	8.80	18.00	15.00	9.20*
112	-01	.00	206.00	147.90	5.00	113.40*	9.10	35.00*	51.00*	75.00*
116	-01	.00	229.00	130.40*	3.80	109.00	8.60	21.00	25.00	19.00
117	-01	.00	207.00	147.80	6.00*	113.50*	9.20	35.00*	51.00*	76.00*
121	-01	3.00	171.00	133.00	3.90	.	.	.	.	.
125	-01	.00	292.00	147.00*	4.10	353.00	10.10	16.00	17.00	13.00
128	-01	.00	199.00	144.00	4.20	353.00	9.70	16.00	12.00	14.00
129	-01	.00	218.00	141.00	4.90	340.00	9.20	16.00	6.00	7.00
137	-01	.00	257.00	140.00	3.50*	344.00	9.70	13.00	17.00	8.00
138	-01	.00	257.00	137.00	3.60*	340.00	9.60	20.00	23.00	10.00
141	-01	.00	131.22*	141.00	3.60*	366.00	10.20	21.00	22.00	16.00
145	-01	.00	220.00	150.00	5.00	116.00*	8.00	1.80*	18.00	.
173	-01	1.00	285.00	138.00	4.80	98.00	8.70	38.00	9.70	8.20*
174	-01	1.00	275.00	140.00	4.90	99.00	9.30	38.00	10.00	8.10*
175	-01	1.00	270.00	140.00	5.00	98.00	9.10	39.00	9.90	8.10
178	-01	1.00	275.00	140.00	5.10	98.00	9.00	38.00	9.80	8.00*
182	-01	.00	270.00	138.00	5.10	97.00	9.00	38.00	9.90	8.00*
183	-01	.00	280.00	140.00	4.90	99.00	9.20	38.00	10.00	8.10
190	-01	1.00	270.00	139.00	4.90	97.00	9.20	37.00	9.80	8.10
191	-01	1.00	275.50	139.00	4.80	97.00	9.10	37.00	9.90	8.20*

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

92

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
195	-01	2.00*	268.00	142.00	5.00	96.00	9.00	30.00	16.00	31.00
196	-01	1.00	266.00	140.00	4.50	92.00*	9.10	28.00	16.00	28.00
201	-01	2.00*	250.00	138.00	4.90	102.00	9.90	35.00	26.00	39.00
204	-01	2.00*	280.00	140.00	4.60	100.00	9.80	35.00	30.00	26.00
205	-01	2.00*	230.00	140.00	5.10	112.00*	9.00	36.00	30.00	26.00
207	-01	1.00	160.00	150.00	5.20	98.00	9.80	45.00	34.00	22.00
212	-01	1.00	300.00	136.00	4.30	97.00	10.00	27.00	28.00	39.00
213	-01	.00	320.00	140.00	4.20	104.00	8.80	30.00	32.00	35.00
220	-01	.00	580.00*	143.00	3.90	104.00	8.73	13.29	4.56	14.00
221	-01	.00	240.00	142.00	3.90	104.00	9.19	12.00	3.36	21.00
225	-01	.00	280.00	140.00	4.90	99.00	9.00	9.00	5.00	16.00
228	-01	.00	580.00*	139.00	4.00	103.00	9.90	9.00	6.00	16.00
229	-01	.00	290.00	138.00	4.10	94.00*	8.20*	18.00	4.00	8.00
234	-01	.00	290.00	137.00	4.60	90.00*	8.45*	18.00	4.00	20.00
236	-01	1.00	330.00	142.00	4.40	90.00*	10.30	19.00	7.00	7.00
239	-01	.00	290.00	146.00*	3.90	103.00	8.75	15.00	5.00	13.00
241	-01	.00	275.00	150.00	4.70	98.00	9.20	37.00	12.10	20.00
242	-01	1.00	270.50	140.00	5.10	98.00	9.00	38.00	9.70	8.10*
250	-01	.00	270.00	140.00	5.30	106.00*	8.20*	44.00	32.00	26.00
252	-01	.00	290.00	138.00	5.00	105.00	8.70	38.00	27.00	30.00
253	-01	3.00*	300.00	144.00	5.35*	100.00	10.00	27.00	28.00	29.00
256	-01	.00	275.00	145.00	4.70	97.00	9.10	30.00	18.00	30.00
261	-01	4.00*	180.00	150.00	5.30	109.00*	3.80*	25.00	23.00	30.00
264	-01	1.00	232.00	145.00	4.80	102.00	8.20*	28.00	18.00	32.00
265	-01	2.00*	178.00	150.00	5.20	96.00	9.20	42.00	31.00*	24.00
266	-01	2.00*	250.00	136.00	5.40*	108.00*	3.80*	35.00	38.00*	36.00
272	-01	2.00*	180.00	150.00	5.20	102.00	3.50*	25.00	22.00	30.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

93

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
3	-01	4.62	1.49*	99.00	3.70	69.00	.14*	5.00	.70
6	-01	5.00	.	.	2.80*	68.00	.18	4.00	1.20
7	-01	4.49	.98	104.00	5.50	83.00	.34	13.00	2.40
8	-01	4.01	1.31	78.00	5.50	96.00	.40	10.00	2.40
16	-01	4.74	1.17	107.00	4.30	96.00	.26	7.00	1.90
18	-01	4.84	1.25	106.00	4.20	87.00	.31	11.00	2.08
26	-01	4.10	1.20	130.00	3.00	78.00	180.00*	8.00	.00
27	-01	4.10	1.30	118.00	5.00	64.00	286.00	12.00	.00
33	-01	4.80	1.10	112.00	4.00	85.00	280.00	10.00	.00
36	-01	5.40	1.10	92.00	3.50	95.00	260.00	8.00	.00
39	-01	4.00	.90	88.00	4.20	62.00	210.00	8.00	.00
40	-01	4.00	1.30	150.00	6.20	80.00	300.00	10.00	.00
43	-01	3.90	1.30	104.00	5.20	70.00	260.00	10.00	.00
46	-01	4.20	1.30	170.00	4.80	56.00*	300.00	12.00	.00
52	-01	5.40	1.17	24.00	6.00	90.00	124.00*	14.00	.00
53	-01	3.90	.90	25.00	4.00	90.00	131.00*	11.00	.00
58	-01	4.70	1.10	28.00	8.00	90.00	161.00	12.00	.00
59	-01	5.10	1.10	29.00	8.00	89.00	161.00	12.00	.00
62	-01	4.10	.90	31.00	5.00	81.00	161.00	9.00	.00
63	-01	4.70	.90	32.00	7.00	68.00	159.00	14.00	.00
69	-01	4.00	.90	21.00	6.00	69.00	158.00	14.00	.00
71	-01	4.60	1.10	29.00	4.00	61.00	159.00	9.00	.00
74	-01	70.00	4.10	58.00	15.20	.90	2.70*	.80	.30
76	-01	85.00	3.80	90.00	16.10	1.00	4.30	.70	.50*
81	-01	72.00	2.80	70.00	12.50	.80	4.60	.30	.20
82	-01	79.00	3.50	127.00*	18.30	1.30*	6.60	.60	.30
86	-01	72.00	2.90	63.00	16.80	1.10	5.00	1.80*	.30
89	-01	84.00	4.00	79.00	21.60*	.90	4.50	.40	.
92	-01	79.00	3.70	69.00	19.40	.80	2.80*	.50	.10
93	-01	91.00	4.30	103.00	14.60	1.00	4.40	.70	.10
97	-01	83.00	2.10*	246.00	25.00	1.00	3.70	1.00	.04
100	-01	111.00*	2.70	217.00	37.00	.80	5.10	.53	.10
104	-01	80.00	2.30*	160.00	28.00	.50	3.60	.60	.08
105	-01	100.00	3.80	130.00	37.00	.80	3.70	.40	.04
111	-01	75.00	3.40	203.00	31.00	.80	3.70	.27	.05
112	-01	90.00	2.30*	200.00	38.00	.80	4.80	.63	.10
116	-01	83.00	2.90	186.00	55.00*	.80	2.90	.60	.08
117	-01	90.00	2.40*	201.00	38.00	.80	4.90	.64	.11
121	-01	.	.	.	.	.	1.90*	.60	.20*
125	-01	83.00	3.70	100.00*	27.00	.90	4.20	.40*	.10
128	-01	92.00	3.80	64.00	21.00	.90	4.30	.70	.30*
129	-01	84.00	3.40	54.00	26.00	.80	2.90	.50*	.20*
137	-01	78.00	3.40	57.00	40.00	.90	5.80	.80	.30*
138	-01	97.00	3.10	74.00	24.00	.90	6.20	.80	.30*
141	-01	87.00	3.40	73.00	27.00	.90	6.10	1.20	.60*
145	-01	78.00*	3.00	40.00	32.50	1.00	2.70	.50*	.40*
173	-01	95.00	3.70	170.00	11.10	1.10	5.20	.70	.40
174	-01	97.00	3.90	170.00	11.10	1.10	5.60	.80	.40
175	-01	92.00	3.80	170.00	11.10	1.00	5.40	.80	.40
178	-01	92.00	4.00	170.00	11.20	.90	5.40	.70	.40
182	-01	100.00	4.00	172.00	11.10	1.00	5.20	.70	.40
183	-01	96.00	3.90	170.00	11.10	1.00	5.20	.70	.40
190	-01	97.00	4.10	172.00	11.10	1.00	4.40	.80	.40
191	-01	97.00	4.00	172.00	11.10	1.00	5.20	.70	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

94

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
195	-01	96.00	3.50	130.00	11.00	.75	4.70	.80	.30
196	-01	98.00	3.80	128.00	11.00	.74	4.20	.70	.20
201	-01	95.00	3.80	130.00	14.00	1.00	5.10	.80	.40
204	-01	100.00	3.50	128.00	15.00	.90	6.00	.80	.40
205	-01	103.00	3.70	130.00	16.00	.75	5.40	.80	.30
207	-01	100.00	3.60	128.00	16.00	.79	4.80	.80	.40
212	-01	85.00	3.90	118.00	16.00	.90	4.50	.80	.50
213	-01	105.00	3.90	118.00	18.00	.80	4.40	.80	.20
220	-01	4.40	3.25	46.76	21.00	75.14	4.30	12.31	3.42
221	-01	4.57	3.06	40.91	21.00	72.48	2.50	6.84	3.42
225	-01	4.84	2.90	44.25	32.50	88.40	5.60	43.60*	12.82*
228	-01	5.66	2.30	28.39	19.00	106.08	4.00	8.55	2.73
229	-01	5.39	2.50	30.39	18.00	88.40	4.40	5.13	3.42
234	-01	4.67	6.95	27.00	25.00	79.56	4.00	8.55	3.42
236	-01	5.39	4.07	34.92	30.00	106.00	4.80	14.53	5.13*
239	-01	4.56	4.60	34.92	23.00	82.21	5.50	14.53	10.26*
241	-01	88.00	3.80	135.00	12.10	1.10	5.20	.90	.40
242	-01	87.00	3.90	170.00	11.10	1.00	4.50	.70	.40
250	-01	95.00	3.90	95.00	18.00	.87	5.20	.90	.30
252	-01	90.00	3.90	125.00	11.00	.80	5.20	.50	.20
253	-01	105.00	3.80	120.00	17.00	.80	5.40	.70	.20
256	-01	95.00	3.60	130.00	11.20	.76	4.70	.80	.20
261	-01	90.00	3.90	130.00	11.00	1.10	5.40	.80	.40
264	-01	93.00	3.50	128.00	11.40	.76	4.70	1.00	.10
265	-01	100.00	5.30*	126.00	15.00	.77	4.70	.80	.20
266	-01	91.00	3.70	128.00	15.00	.80	4.10	.70	.20
272	-01	90.00	3.90	130.00	11.00	1.10	5.40	.80	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

95

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
3	-01	64.00	38.90*	5.30	.88	2.40	5.30*	7.60*	9.80*
6	-01	67.00	35.50*	5.40	.83	3.30	11.30*	9.20	7.70*
7	-01	65.00	42.40*	5.20	1.33	2.20	5.50*	7.00*	7.90*
8	-01	63.00	40.60*	5.90	1.56	2.20	5.00*	7.60*	7.60*
16	-01	66.00	43.80*	6.50	1.08	2.00	4.70*	7.60*	7.90*
18	-01	62.00	41.40*	4.30	.18*	1.50	5.00*	6.10*	8.00*
26	-01	72.00	39.00	3.90	.80	3.00	9.00	14.00*	13.00
27	-01	78.00	40.00	4.90	1.30	3.00	7.80	9.80	14.00
33	-01	67.00	42.00	4.20	1.10	2.60	8.00	9.20	14.00
36	-01	70.00	34.00*	4.80	1.00	3.00	6.60	11.00	16.00
39	-01	66.00	32.00*	3.80	.90	2.60	6.80	8.40	12.60
40	-01	72.00	40.00	5.00	1.20	3.00	8.00	11.00	14.00
43	-01	78.00	40.00	4.60	1.00	3.00	7.80	9.00	14.00
46	-01	76.00	40.00	5.80	1.40	3.00	8.00	10.00	16.00
52	-01	65.90	40.70	4.70	1.40	2.80	5.70*	8.90	8.90*
53	-01	81.00*	56.00*	7.50*	1.90	2.30*	5.40*	6.70*	10.20*
58	-01	77.00	48.00	4.90	1.10	2.30*	6.20*	8.00*	12.60
59	-01	72.00	41.00	5.10	1.30	2.00*	6.00*	8.70	14.30
62	-01	75.00	47.00	5.20	1.80	2.70	6.90	8.70	15.10
63	-01	68.00	42.00	5.10	1.90	2.70	8.30	8.90	15.00
69	-01	68.00	46.00	4.90	1.80	2.70	8.30	9.10	14.20
71	-01	70.00	47.00	5.00	1.50	2.70	7.10	8.90	12.90
74	-01	7.20	4.70	167.00*	66.00	2.35*	10.43	14.75*	16.40
76	-01	7.10	4.30	251.00*	126.00	1.80*	11.20	15.00*	19.70
81	-01	6.30	4.20	174.00	88.00	2.78	13.65*	13.94	12.31
82	-01	7.70	4.20	239.00*	235.00*	2.65	8.80	14.22	18.77
86	-01	7.30	4.90	215.00	211.00*	.	.	.	.
89	-01	6.90	4.40	241.00*	97.00	2.77	12.63	12.53	12.53
92	-01	7.00	4.50	288.00*	.	.	.	.	.
93	-01	8.60*	4.20	163.00*	47.00	.	.	.	.
97	-01	7.80	65.30	194.00	73.00	2.50	7.70	13.30	10.80
100	-01	6.90	55.10*	208.00	211.00*	2.30*	8.30	13.90	20.40*
104	-01	7.50	58.50	218.00	197.00*	2.90	10.10	11.40	17.10
105	-01	7.50	54.30*	211.00	784.00*	3.40	12.40*	16.00*	14.00
111	-01	5.80*	62.60	147.00	140.00	4.10	9.10	13.60	10.70
112	-01	6.70	62.70	180.00	165.00	2.50	9.40	14.00	11.40
116	-01	7.20	59.70	194.00	123.00	3.40	9.00	15.30*	12.80
117	-01	8.10	52.70*	180.00	166.00	4.50	12.80*	13.40	17.90
121	-01	8.10	4.10	253.00	48.00	2.13*	13.80	13.00*	12.50
125	-01	7.50	4.40	146.00	139.00	2.40*	6.80*	7.00*	11.10
128	-01	8.70*	5.20*	218.00	412.00*	2.30*	9.40	8.00	8.90*
129	-01	8.30	5.10*	186.00	186.00	2.10*	9.60	8.90	13.10
137	-01	6.70	4.50	171.00	102.00	2.40*	9.10	11.60	10.90
138	-01	8.50*	5.00	235.00	73.00	1.70*	9.00	14.00*	12.00
141	-01	8.30	5.00	149.00	178.00	1.80*	7.50*	8.80	16.50
145	-01	6.00	3.50	131.00	20.00	6.00	8.00	12.00	16.00
173	-01	8.70*	4.10	195.00	90.00	.31	.72	.91	1.30
174	-01	6.70	4.10	192.00	89.00	.40	.70	1.00	1.30
175	-01	8.70*	4.70	190.00	89.00	.34	.75	.92	1.20
178	-01	6.80	4.50	185.00	82.00	.37	.75	.92	1.20
182	-01	6.80	4.70	195.00	88.00	.39	.72	.95	1.40
183	-01	8.80*	4.80	195.00	90.00	.40	.75	.98	1.20
190	-01	7.70	4.20	200.00	90.00	.32	.82	1.10	1.20
191	-01	6.70	5.60*	202.00	90.00	.31	.81	1.10	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

96

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
195	-01	6.70	4.30	178.00	96.00	.30	.60	.70	1.30
196	-01	7.00	4.80	178.00	96.00	.20	.50	.60	1.80*
201	-01	6.80	5.00	260.00	150.00	.40	.60	1.00	1.50
204	-01	8.00	5.00	200.00	150.00	.30	.70	.80	.90
205	-01	6.40	5.20	230.00	130.00	.40	.70	.80	1.10
207	-01	8.30*	5.10	200.00	145.00	.30	.80	.90	1.80*
212	-01	8.00	4.80	160.00	120.00	.30	.80	1.40*	1.50
213	-01	8.00	5.10	164.00	105.00	.20	.60	.80	1.20
220	-01	6.90	4.40	5.72	130.00	.08*	.50*	1.10	1.42*
221	-01	6.30	4.00	4.81	95.00	.14*	.68	.96	.96
225	-01	7.70	5.02*	5.20	112.00	.25	.49*	.83	1.11
228	-01	7.70	4.40	6.24	141.00	.23	.51*	1.21*	1.35*
229	-01	7.20	4.00	4.42	136.00	.16*	.53*	1.18	1.33*
234	-01	7.50	4.06	5.20	108.00	.23	.92	.89	1.40*
236	-01	7.90	5.00	5.40	108.00	.18*	.62	1.11	.99
239	-01	7.70	3.30	5.48	100.00	.18*	.75	1.13	2.34*
241	-01	7.70	4.20	170.00	90.00	.30	.70	.90	1.40
242	-01	7.10	4.20	170.00	85.00	.32	.71	.91	1.30
250	-01	6.90	5.30	180.00	98.00	.30	.60	.80	1.30
252	-01	6.90	6.40*	200.00	132.00	.20	.70	.70	1.00
253	-01	7.00	5.00	160.00	100.00	.40	.90	1.30*	1.10
256	-01	6.70	4.10	180.00	96.00	.30	.70	.70	1.40
261	-01	6.80	4.30	180.00	98.00	.40	.60	1.10	.90
264	-01	6.70	4.20	130.00*	96.00	.40	.60	.60	1.40
265	-01	6.80	3.90	243.00	142.00	.40	.80	.90	.20
266	-01	6.30	4.20	210.00	128.00	.30	.60	.70	1.00
272	-01	6.80	4.30	180.00	99.00	.40	.70	1.10	.90

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

97

Pat. No.	Per. (dy)	T3	T4	SPBGRV	URALB	URSUG	URRBC	URWBC
3	-01	5.10	12.00	.	.	.	.	.
6	-01	3.70*	13.00	.	.	.	.	.
7	-01	4.60	19.00	.	.	.	.	.
8	-01	6.90	18.00	.	.	.	.	.
16	-01	4.20	15.00	.	.	.	.	.
18	-01	6.40	20.00	.	.	.	.	.
26	-01	.86	140.00	1.024	0	0	0	0
27	-01	.92	90.00	1.026	0	0	0	0
33	-01	.96	120.00	1.016	0	0	0	0
36	-01	.90	80.00	1.020	0	0	0	0
39	-01	.90	72.00	1.020	0	0	0	0
40	-01	.88	80.00	1.026	0	0	0	0
43	-01	1.00	110.00	1.026	0	0	0	0
46	-01	.92	110.00	1.020	0	0	0	0
52	-01	.89	84.00	1.019	0	0	0	0
53	-01	1.05	87.00	1.031*	0	0	0	0
58	-01	.91	94.00	1.029	0	0	0	0
59	-01	.91	141.00	1.027	0	0	0	0
62	-01	1.03	84.00	1.025	0	0	0	0
63	-01	1.02	92.00	1.027	0	0	0	0
69	-01	1.02	74.00	1.018	0	0	0	0
71	-01	.95	87.00	1.026	0	0	0	0
74	-01	54.00*	6.50	1.018	0	0	0	0
76	-01	110.00	15.00*	1.021*	0	0	0	0
81	-01	139.00	10.00	1.010	0	0	0	0
82	-01	121.00	11.20	1.019	0	0	0	0
86	-01	76.00	6.60	1.036*	0	0	0	0
89	-01	117.00	9.80	1.020	0	0	0	0
92	-01	137.00	9.20	1.012	0	0	0	0
93	-01	87.00	9.20	1.016	0	0	0	0
97	-01	142.00	8.00	1.017	0	0	0	0
100	-01	172.00	8.00	1.016	0	0	0	0
104	-01	182.00	11.60	1.019	0	0	0	0
105	-01	142.00	7.00	1.020	0	0	0	0
111	-01	122.00	5.40	.	.	.	.	.
112	-01	145.00	7.30	1.020	0	0	0	0
116	-01	137.00	7.20	1.016	0	0	0	0
117	-01	123.00	5.70	1.020	0	0	0	0
121	-01	104.00	9.60	1.014	0	1	15*	40*
125	-01	143.00	8.10	1.025	0	0	1	1
128	-01	88.00	13.60*	1.010	0	0	0	2
129	-01	101.00	11.70	1.020	0	0	0	1
137	-01	138.00	7.50	1.030	0	0	3*	5
138	-01	145.00	13.60*	1.030	0	0	0	2
141	-01	157.00	14.50*	1.029	0	0	2	2
145	-01	92.00	5.70	1.020	0	0	0	2
173	-01	112.00	7.70	1.020	0	0	0	4
174	-01	112.00	7.80	1.010	0	0	0	2
175	-01	110.00	7.50	1.012	0	0	0	4
178	-01	115.00	7.60	1.010	0	0	2	4
182	-01	110.00	8.10	1.010	0	0	0	4
183	-01	112.00	7.70	1.020	0	0	2	2
190	-01	110.00	7.70	1.010	0	0	0	0
191	-01	114.00	7.70	1.010	0	0	0	4

FCE 20124/702 i

98

Pat. No.	Per. (dy)	T3	T4	SPEGRAV	URALB	URSUG	URRBC	URWBC
195	-01	118.00	8.30	1.018	0	0	2	1
196	-01	115.00	7.80	1.018	0	0	2	1
201	-01	105.00	8.20	1.014	0	0	2	4
204	-01	60.00	6.20	1.016	0	0	1	4
205	-01	120.00	8.30	1.022	0	0	2	4
207	-01	120.00	8.90	1.018	0	0	2	4
212	-01	150.00	10.20	1.016	0	0	1	2
213	-01	150.00	9.10	1.020	0	0	1	3
220	-01	1.60	8.20	1.016	0	0	2	25*
221	-01	1.45	6.90	1.008*	0	0	2	35*
225	-01	.91	7.10	1.025	0	0	0	1
228	-01	1.34	7.35	1.007*	0	0	0	3
229	-01	1.34	2.18*	1.010*	0	0	1	2
234	-01	1.10	11.10	1.017	0	0	0	2
236	-01	1.36	4.70	1.025	0	0	0	2
239	-01	1.90	9.25	1.015	0	0	0	3
241	-01	112.00	7.90	1.010	0	0	0	2
242	-01	115.00	7.80	1.015	0	0	0	2
250	-01	120.00	8.60	1.018	0	0	1	4
252	-01	128.00	5.30	1.018	0	0	1	3
253	-01	150.00	9.20	1.018	0	0	1	3
256	-01	120.00	8.20	1.016	0	0	1	2
261	-01	114.00	8.10	1.005	0	0	0	4
264	-01	118.00	3.10*	1.015	0	0	0	4
265	-01	116.00	4.10*	1.012	0	0	0	2
266	-01	118.00	3.30*	1.010	0	0	2	4
272	-01	110.00	8.30	1.016	0	0	2	4

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

99

Treatment Group "C"

Screening (Period -01)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	81	9
Hematocrit (HCT)	81	11
Red Blood Cells (RBC)	81	16
White Blood Cells (WBC)	81	12
Neutrophils (NEUTS)	80	19
Lymphocytes (LYMPS)	80	22
Eosinophils (EOSIN)	80	22
Monocytes (MONOS)	80	17
Basophils (BASOS)	80	12
Platelets (PLATES)	80	7
Sodium (NA+)	81	8
Phosphorous (K+)	81	9
Chlorine (CL-)	80	13
Calcium (CA++)	79	9
Aspartate Aminotransferase (SGOT)	80	5
Alanine Aminotransferase (SGPT)	80	5
γ-GT (GGT)	79	14
Blood Sugar (BLSUG)	80	2
Phosphorous (PO4)	79	6
Alkaline Phosphatase (ALPKHOS)	79	2
Urea Nitrogen (BUN)	80	3
Creatinine (CREAT)	80	2
Uric Acid (URACID)	81	7
Total Bilirubin (TOTBILI)	81	5
Direct Bilirubin (DIRBILI)	80	11
Total Protein (TOTPROT)	81	9
Albumin (ALALB)	81	17
Cholesterol (CHOLE)	81	8
Triglycerides (TRIGLY)	80	7
Globulins - α1 (GLOBAL)	78	18
Globulins - α2 (GLOBA2)	78	19
Globulins - β (GLOBETA)	78	18
Globulins - γ (GLOGAMA)	78	17
Thyroxine T3 (T3)	81	2
Thyroxine T4 (T4)	81	8
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	74	6
Albumin (URALB)	74	0
Sugar (URSUG)	74	0
Red Blood Cells (URRBC)	74	2
White Blood Cells (URWBC)	74	3

FCE 20124/702 i

100

\* = Value out-of-range

Day 7 (Period 072)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
3	072	13.50	41.60	4.56	5.50	46.00*	37.00	4.00*	12.00*
6	072	13.00	38.60	4.07	5.80	53.00	39.00	1.00	7.00
8	072	14.10	42.10	3.90*	4.60	40.00*	35.00	15.00*	9.00
16	072	14.30	44.70	4.84	6.20	50.00	33.00	7.00*	8.00
18	072	14.70	43.20	4.67	6.40	56.00	33.00	1.00	9.00
26	072	15.00	43.00	4.90	7.10	66.00	28.00	4.00	2.00
27	072	14.10	39.00	4.70	6.00	68.00	25.00	3.00	3.00
33	072	14.00	39.00	4.50	8.00	69.00	28.00	2.00	1.00
36	072	14.60*	42.00	4.60	7.20	68.00	22.00	2.00	6.00
39	072	13.80	41.00	4.30	6.00	68.00	28.00	2.00	1.00
40	072	14.80	41.00	5.00	6.20	70.00	26.00	2.00	2.00
43	072	14.10	42.00	4.80	5.60	70.00	25.00	2.00	3.00
46	072	15.80	43.80	4.60	7.20	68.00	28.00	2.00	1.00
52	072	8.00	.41	4.20	6.00	79.00*	17.00	1.00	2.00
53	072	9.20	.46	4.70	8.10	72.00	24.00	2.00	3.00
58	072	9.10	.49	5.10	6.70	69.00	25.00	2.00	3.00
59	072	8.90	.46	5.40	6.30	62.00	31.00	2.00	4.00
62	072	8.70	.49	5.20	7.40	72.00	26.00	.00*	2.00
63	072	9.10	.50	5.40	6.70	71.00	26.00	1.00	2.00
69	072	8.90	.49	5.10	6.80	70.00	26.00	1.00	3.00
71	072	8.80	.47	5.60*	7.10	75.00	18.00	2.00	4.00
74	072	14.00	41.00	4.40	5.10	50.10	39.40	1.50	5.00
76	072	15.70	46.20	5.01	10.50	63.10	24.60	2.70	9.10*
89	072	13.70	44.40	4.62	12.13*	69.40	20.60	1.40	4.80
97	072	15.30	48.30	4.65	6.30	58.00	32.00	2.00	8.00
100	072	14.50	38.80	4.65	5.30	47.00	50.00*	2.00	1.00*
104	072	14.50	39.30	4.49	9.70	60.00	39.00	1.00	.00*
105	072	14.70	39.60*	4.47*	6.30	54.00	43.00	.00*	3.00
111	072	16.60	44.40	4.97	6.20	44.00	48.00*	3.00	5.00
112	072	17.00	42.80	4.52*	6.60	60.00	38.00	.00*	2.00
116	072	14.20	37.20	4.04*	5.90	68.00	31.00	.00*	1.00*
117	072	17.60	47.90	4.52*	6.50	61.00	39.00	.00*	.00*
121	072	12.40	38.00	4.70	5.40	54.00*	45.00*	.00	1.00*
125	072	17.00*	53.00*	6.00*	5.00	57.00*	41.00*	1.00	1.00*
128	072	13.10	41.00	4.51	5.40	63.00	36.00*	1.00	.00*
129	072	11.80*	37.00	4.07*	4.00*	50.00*	48.00*	.00	2.00*
137	072	13.40	41.00	4.51	7.70	64.00	34.00	2.00	.00*
138	072	13.50	42.00	4.62	7.80	63.00	34.00	3.00*	.00*
141	072	15.90	49.00	5.29	5.80	48.00*	49.00*	3.00*	.00*
145	072	11.40*	37.00	3.80	7.60	45.00*	52.00*	3.00*	.00*
173	072	15.80	44.00	6.20*	6.40	60.00	30.00	4.00*	6.00
174	072	15.80	44.00	5.90	6.10	59.00	32.00	2.00	6.00
175	072	15.90	44.00	6.00*	7.10	60.00	30.00	3.00	7.00
178	072	15.90	44.00	6.00	5.90	60.00	30.00	3.00	7.00
182	072	16.20	46.00	6.30*	7.10	58.00	31.00	3.00	7.00
183	072	15.90	44.00	5.80*	5.60	60.00	30.00	3.00	6.00
190	072	15.90	44.00	6.00*	5.90	60.00	30.00	3.00	7.00
191	072	16.20	46.00	6.50*	7.10	59.00	32.00	2.00	6.00
195	072	15.50	43.00	5.10	3.50*	57.00	33.00	4.00*	4.00
196	072	14.50	40.00	4.10*	3.70*	57.00	33.00	4.00*	5.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

101

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPHS	EOSIN	MONOS
201	072	13.00	43.00	4.80	5.10	52.00*	38.00*	2.00	6.00
204	072	14.00	45.00	4.90	6.50	53.00*	37.00*	4.00	4.00
205	072	12.50	42.00	4.20	7.50	54.00	36.00*	6.00*	3.00
207	072	15.10	45.00	5.80	6.20	53.00*	37.00*	5.00*	3.00
212	072	14.00	45.00	5.00	5.10	53.00*	36.00*	2.00	7.00
213	072	14.00	46.00	5.20	8.10	52.00*	38.00*	3.00	7.00
220	072	15.49*	45.00	5.25*	6.35	40.00*	49.00*	9.00*	2.00
221	072	13.15	39.00	4.35	5.10	59.00	36.00	1.00	4.00
225	072	14.89	45.00	4.67	7.60	52.00	40.00	5.00	2.00
228	072	10.56*	31.50*	4.00	6.00	67.00	29.00	1.00	3.00
229	072	13.17	38.00	4.60	5.80	59.00	34.00	3.00	3.00
234	072	15.53	47.00	5.15	8.20*	71.00	25.00	2.00	2.00
236	072	16.85*	50.00*	5.64*	8.95*	69.00	23.00	5.00	3.00
239	072	13.90	40.00	4.50	7.20	51.00	43.00*	3.00	3.00
241	072	15.80	44.00	6.00	7.10	58.00	30.00	5.00*	6.00
242	072	16.00	46.00	6.10	6.20	59.00	32.00	2.00	6.00
250	072	14.00	43.00	5.20	7.10	52.00*	38.00*	7.00*	3.00
252	072	14.50	44.00	6.00	7.00	54.00	36.00*	5.00*	3.00
253	072	13.00*	37.00*	5.40	6.10	55.00	35.00*	4.00*	3.00
256	072	15.20	41.00*	5.40	4.80	57.00	33.00*	3.00	6.00
261	072	16.00	44.00	6.10	7.20	55.00	35.00*	3.00	4.00
264	072	16.00	44.00	6.10	7.30	51.00*	39.00*	6.00*	4.00
265	072	15.90	44.00	6.10	5.70	53.00*	37.00*	2.00	4.00
266	072	15.80	42.00	5.90*	6.20	57.00	33.00	6.00*	4.00
272	072	12.10	41.00	4.80	5.90	56.00	34.00*	5.00*	3.00

FCE 20124/702 i

102

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
3	072	1.00	177.00	142.00	4.60	103.00	2.23	10.00	7.00	5.00
6	072	.00	317.00	139.00	4.30	96.00	2.29	10.00	10.00	9.00
8	072	1.00	267.00	141.00	4.70	100.00	2.24	11.00	10.00	28.00
16	072	2.00*	229.00	144.00*	3.20*	100.00	2.33	8.00	10.00	19.00
18	072	1.00	267.00	142.00	4.40	99.00	2.36	9.00	14.00	15.00
26	072	.00	188.00	146.00	4.10	98.00	2.20	12.00	12.00	10.00
27	072	1.00	230.00	146.00	4.20	102.00	2.20	16.00	14.00	14.00
33	072	.00	220.00	142.00	4.10	102.00	2.00*	8.00	6.00	22.00
36	072	2.00*	168.00	144.00	4.00	102.00	2.10	6.00	6.00	32.00
39	072	1.00	224.00	144.00	4.10	102.00	2.20	6.00	10.00	10.00
40	072	.00	200.00	146.00	4.20	103.00	2.20	14.00	14.00	16.00
43	072	1.00	240.00	145.00	4.20	102.00	2.30	14.00	14.00	12.00
46	072	1.00	192.00	138.00	4.00	102.00	2.40	16.00	18.00	14.00
52	072	.00	174.00	140.00	4.20	104.00	2.10	11.00	15.00	12.00
53	072	1.00	190.00	142.00	4.40	103.00	2.40	14.00	12.00	20.00
58	072	1.00	191.00	142.00	3.90	101.00	2.90*	13.00	12.00	29.00*
59	072	1.00	173.00	139.00	4.10	101.00	2.70	16.00	14.00	34.00*
62	072	.00	208.00	142.00	4.00	103.00	2.50	14.00	8.00	31.00*
63	072	.00	189.00	143.00	3.90	103.00	2.40	14.00	12.00	27.00
69	072	.00	193.00	139.00	4.10	102.00	2.40	14.00	12.00	26.00
71	072	1.00	214.00	141.00	3.90	102.00	2.50	10.00	8.00	34.00*
74	072	1.90*	127.00*	140.00	4.00	111.00*	8.80	13.00	14.00	8.00
76	072	.40	285.00	142.00	4.20	110.00	9.90	16.00	30.00	11.00
89	072	.90	153.80	.	.	.	.	.	.	.
97	072	.00	159.00	136.00	3.50	98.00	8.60	18.00	37.00	37.00
100	072	.00	254.00	135.00	3.60	99.00	8.30	21.00	10.00	10.00
104	072	.00	420.00*	149.00	5.70*	111.00*	9.00	24.00	30.00	40.00*
105	072	.00	233.00	141.00	4.00	100.00	10.10	30.00	33.00	34.00
111	072	.00	294.00	148.00	4.40	112.00*	9.00	11.00	18.00	14.00
112	072	.00	242.00	148.00	4.45	110.40*	10.20	30.00	46.00	59.00*
116	072	.00	188.00	132.80*	3.96	109.80*	8.90	22.00	26.00	9.00
117	072	.00	243.00	148.10	4.50	111.00*	10.30	31.00	47.00*	60.00*
121	072	.00	203.00	139.00	4.60	350.00	10.00	47.00*	49.00*	14.00
125	072	.00	227.00	140.00	4.10	352.00	9.70	24.00	22.00	15.00
128	072	.00	206.00	142.00	4.70	348.00	9.50	12.00	10.00	9.00
129	072	.00	274.00	144.00	4.80	346.00	9.40	14.00	22.00	8.00
137	072	.00	379.00	139.00	3.60*	360.00	10.20	10.00	14.00	11.00
138	072	.00	257.00	137.00	5.30	342.00	9.60	12.00	13.00	9.50
141	072	.00	313.00	136.00	3.60*	357.00	10.00	21.00	24.00	12.00
145	072	.00	205.00	139.00	3.60	117.00*	9.00	7.00	4.00	5.00
173	072	.00	275.00	135.00	4.70	97.00	8.60	39.00	9.60	8.10*
174	072	1.00	275.00	138.00	5.20	97.00	9.00	38.00	9.70	8.00*
175	072	.00	270.00	140.00	4.90	99.00	9.20	38.00	10.00	8.10
178	072	.00	280.00	140.00	4.90	99.00	9.20	38.00	10.00	8.10*
182	072	1.00	280.50	137.00	5.10	92.00*	9.00	39.00	9.90	8.20*
183	072	1.00	275.00	140.00	5.00	98.00	9.10	39.00	9.80	8.10
190	072	.00	280.00	140.00	4.90	99.00	9.20	39.00	10.00	8.10
191	072	1.00	285.00	139.00	4.90	100.00	9.10	38.00	9.50	8.20*
195	072	2.00*	268.00	142.00	4.80	97.00	9.00	32.00	18.00	30.00
196	072	1.00	265.00	138.00	4.40	90.00*	9.00	26.00	15.00	26.00
201	072	2.00*	251.00	137.00	4.70	103.00	9.50	36.00	28.00	29.00
204	072	2.00*	280.00	140.00	4.70	102.00	9.70	36.00	31.00	27.00
205	072	1.00	230.00	140.00	5.10	115.00*	9.10	38.00	34.00	31.00
207	072	2.00*	161.00	150.00	5.10	100.00	10.00	46.00	34.00	21.00

608



FCE 20124/702 i

103

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
212	072	1.00	300.00	135.00	4.20	96.00	9.00	27.00	28.00	38.00
213	072	.00	318.00	138.00	4.10	100.00	8.60	32.00	30.00	35.00
220	072	.00	270.00	140.00	4.50	102.00	9.30	9.00	7.00	36.00*
221	072	.00	250.00	140.00	3.90	104.00	9.18	12.00	5.00	29.00
225	072	1.00	290.00	140.00	4.80	102.00	10.20	7.00	6.00	7.00
228	072	.00	500.00*	135.00	4.00	100.00	8.50	13.00	7.00	8.00
229	072	1.00	300.00	139.00	4.30	100.00	8.60	15.00	3.00	14.00
234	072	.00	520.00*	129.00*	4.60	86.00*	9.80	13.00	6.00	15.00
236	072	.00	310.00	139.00	5.70*	98.00	10.09	16.00	6.00	19.00
239	072	.00	320.00	137.00	3.90	93.00*	8.96	16.00	3.00	17.00
241	072	1.00	275.00	152.00	4.60	97.00	9.10	38.00	12.20	20.00
242	072	1.00	270.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20*
250	072	.00	270.00	138.00	5.20	105.00	8.20*	42.00	32.00	27.00
252	072	2.00*	290.00	138.00	5.00	105.00	8.60	39.00	27.00	30.00
253	072	3.00*	300.00	143.00	5.80*	100.00	9.80	27.00	28.00	28.00
256	072	1.00	268.00	144.00	4.70	97.00	8.80	32.00	19.00	29.00
261	072	3.00*	180.00	148.00	5.20	108.00*	3.80*	25.00	23.00	30.00
264	072	.00	232.00	144.00	4.90	103.00	8.30*	29.00	18.00	32.00
265	072	4.00*	178.00	150.00	5.20	96.00	9.30	40.00	30.00*	24.00
266	072	.00	250.00	137.00	5.40*	108.00*	3.90*	35.00	36.00*	35.00
272	072	2.00*	180.00	150.00	5.20	102.00	3.60*	25.00	22.00	30.00

FCE 20124/702 i

104

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
3	072	4.58	1.42	117.00	3.40	87.00	.13*	5.00	1.60
6	072	4.01	1.62*	46.00	2.10*	81.00	.	6.00	1.20
8	072	4.83	1.29	79.00	3.60	87.00	.29	8.00	1.90
16	072	4.96	1.12	102.00	5.00	94.00	.25	6.00	.90
18	072	4.63	4.00*	87.00	5.10	95.00	.31	5.00	1.60
26	072	4.10	1.10	132.00	3.40	70.00	278.00	8.00	.00
27	072	4.10	1.30	120.00	5.20	66.00	290.00	14.00	.00
33	072	5.10	1.20	115.00	4.10	88.00	268.00	10.00	.00
36	072	5.00	1.00	90.00	3.40	80.00	246.00	6.00	.00
39	072	4.00	1.00	90.00	4.40	64.00	212.00	8.00	.00
40	072	3.90	1.20	155.00	6.00	78.00	288.00	12.00	.00
43	072	4.10	1.20	106.00	5.40	68.00	266.00	12.00	.00
46	072	4.80	1.40	150.00	4.90	70.00	320.00	10.00	.00
52	072	4.10	1.00	27.00	9.00*	89.00	121.00*	8.00	.00
53	072	4.10	1.00	26.00	6.00	86.00	131.00*	12.00	.00
58	072	4.80	1.30	29.00	8.00	81.00	161.00	10.00	.00
59	072	4.70	1.30	27.00	8.00	87.00	151.00	12.00	.00
62	072	4.70	.90	27.00	7.00	71.00	159.00	8.00	.00
63	072	5.10	1.10	29.00	4.00	69.00	154.00	11.00	.00
69	072	4.70	1.00	25.00	5.00	67.00	159.00	13.00	.00
71	072	4.70	1.00	29.00	4.00	76.00	154.00	11.00	.00
74	072	74.00	5.40*	50.00	20.20	1.00	3.00*	.60	.20
76	072	76.00	3.80	85.00	15.00	1.10	4.20	.50	.30
97	072	71.00	2.30*	112.00	24.00	.80	4.30	.59	.05
100	072	72.00	2.40*	255.00	35.00	.60	4.40	.46	.08
104	072	105.00	3.40	140.00	18.00	.40*	3.30	.33	.05
105	072	79.00	4.00	137.00	42.00	.90	4.30	.50	.07
111	072	75.00	3.70	238.00	36.00	.90	3.60	.47	.07
112	072	73.00	2.00*	237.00	24.00	.80	4.00	.70	.08
116	072	78.00	3.60	172.00	26.00	.70	2.40	.70	.09
117	072	73.00	2.10*	238.00	24.00	.70	4.30	.71	.09
121	072	83.00	3.40	143.00*	41.00*	.90	2.70	.80	.40*
125	072	71.00*	3.50	87.00	25.00	.70*	6.30	.60	.20*
128	072	95.00	3.60	81.00	31.00	.90	4.50	.70	.30*
129	072	101.00	3.50	97.00*	25.00	1.00	6.60	.70	.30*
137	072	97.00	3.90	72.00	27.00	.90	4.50	.90	.40*
138	072	99.00	3.20	84.00	20.00	.90	2.80	.70	.30*
141	072	82.00	3.30	75.00	26.00	1.00	5.70	1.10	.50*
145	072	75.00*	3.80	20.00	23.00	1.05	3.50	.30*	.10
173	072	97.00	3.70	165.00	11.00	1.10	4.80	.70	.40
174	072	97.00	4.10	172.00	11.10	1.10	4.70	.70	.40
175	072	92.00	3.90	177.00	11.10	1.10	5.30	.70	.50
178	072	97.00	3.90	170.00	11.10	1.00	5.20	.80	.40
182	072	97.00	4.10	178.00	11.10	1.00	5.20	.70	.40
183	072	96.00	3.90	172.00	11.10	1.00	5.40	.70	.40
190	072	98.00	3.90	170.00	11.10	.99	4.20	.80	.40
191	072	97.00	4.10	172.00	11.00	1.10	5.50	.70	.40
195	072	98.00	4.00	132.00	11.20	.78	4.80	.80	.30
196	072	96.00	3.60	124.00	10.80	.68	4.00	.80	.20
201	072	100.00	3.70	126.00	16.00	.90	5.20	.90	.30
204	072	105.00	3.60	129.00	16.00	.90	6.10	.80	.40
205	072	105.00	3.90	132.00	18.00	.80	5.40	.90	.80
207	072	105.00	3.80	125.00	15.00	.80	4.80	.90	.50
212	072	85.00	3.80	118.00	17.00	.80	4.40	.80	.50

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

105

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
213	072	120.00*	4.00	118.00	17.00	.80	4.20	.90	.30
220	072	4.73	2.39	47.26	22.00	70.72	4.80	12.52	1.71
221	072	4.67	1.78	39.57	28.00	75.14	3.00	5.98	3.42
225	072	4.95	3.50	35.07	20.00	92.82	4.80	30.78*	6.84*
228	072	5.50	2.80	33.40	22.00	66.30	3.40	4.27	3.42
229	072	5.11	2.90	29.22	15.00	92.82	4.80	9.40	5.13*
234	072	4.56	4.26	26.01	23.50	88.40	4.20	9.40	4.27*
236	072	5.61	4.28	26.00	34.00	97.24	5.00	12.48	2.56
239	072	4.67	3.06	38.07	25.00	88.40	4.80	8.55	3.42
241	072	85.00	3.60	135.00	12.00	1.00	5.20	.90	.40
242	072	87.00	4.00	170.00	11.10	1.00	4.50	.70	.40
250	072	98.00	3.90	98.00	18.00	.87	5.10	.90	.20
252	072	95.00	3.80	120.00	11.50	.80	5.10	.70	.20
253	072	110.00	3.70	120.00	17.00	.70	5.30	.80	.20
256	072	102.00	3.90	130.00	11.00	.75	4.80	.90	.40
261	072	96.00	3.90	128.00	11.00	1.10	5.40	.80	.40
264	072	94.00	3.50	127.00	11.40	.77	4.90	1.00	.10
265	072	98.00	5.40*	124.00	15.00	.77	4.70	.70	.20
266	072	95.00	3.70	128.00	15.00	.80	5.20	.80	.20
272	072	90.00	3.90	130.00	12.00	1.00	5.40	.90	.30

FCE 20124/702 i

106

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLES	TRIGLY	GLOBAL	GLOB2	GLOBETA	GLOGAMA
3	072	63.00	38.40*	4.70	1.27	2.10	5.70*	7.20*	9.60*
6	072	73.00	44.20*	7.10*	.	2.20	7.50	10.10	9.00*
8	072	65.00	41.00*	5.80	1.68	2.30	5.20*	8.00	8.50*
16	072	65.00	41.90*	6.40	.77	2.00	4.90*	7.40*	8.80*
18	072	63.00	36.60*	4.00	1.12	1.50	5.40*	6.90*	9.60*
26	072	74.00	36.00	3.60*	.80	3.20	8.80	14.20*	13.60
27	072	76.00	40.00	4.90	1.40	3.00	7.90	9.60	14.10
33	072	68.00	43.00	4.20	1.00	2.60	7.80	9.00	14.00
36	072	74.00	38.00	4.60	1.10	4.00*	6.70	11.20	16.00
39	072	71.00	39.00	.80*	2.70*	2.80	6.90	8.80	12.00*
40	072	70.00	38.00	5.10	1.30	3.20	8.20	11.40	14.00
43	072	76.00	41.00	4.40	1.10	3.10	7.80	10.00	13.80
46	072	79.00	42.00	5.40	1.30	3.20	7.80	10.00	15.80
52	072	84.00*	50.00*	4.60	1.20	2.40	8.30	11.10	15.20
53	072	80.00	53.00*	5.00	1.40	2.40	5.60*	6.70*	12.10*
58	072	72.00	43.00	5.10	1.40	2.30*	6.70	8.00*	12.00*
59	072	76.00	45.00	5.10	1.30	2.40	6.60	8.00*	14.00
62	072	71.00	46.00	4.80	1.70	2.70	8.30	8.90	14.70
63	072	68.00	42.00	5.10	1.90	2.70	6.70	8.90	14.30
69	072	78.00	49.00*	5.10	1.80	2.60	8.70	9.10	14.20
71	072	68.00	45.00	5.10	1.80	2.90	8.10	8.90	14.10
74	072	6.60	4.30	187.00	72.00	2.30*	9.78	14.42	15.40
76	072	7.10	4.20	282.00*	138.00	2.80	14.20*	14.00	18.80
97	072	7.30	62.40	200.00	247.00*	2.90	8.90	14.70*	11.20
100	072	7.60	49.80*	230.00*	421.00*	2.50	8.80	16.10*	22.90*
104	072	7.00	59.10	200.00	200.00*	3.90	9.00	11.00	16.80
105	072	8.20	60.70	194.00	623.00*	2.60	8.50	15.10*	13.00
111	072	6.60	58.50	226.00*	132.00	4.50	10.30	14.20*	12.60
112	072	8.00	65.70	126.00*	71.00	2.40*	9.30	12.90	9.70*
116	072	6.00	56.00	167.00	172.00	3.60	10.40	17.70*	12.40
117	072	8.00	53.10*	127.00*	92.00	4.70*	12.30*	13.10	18.10*
121	072	7.80	4.20	243.00	87.00	3.00	12.20	10.20	19.10*
125	072	7.60	4.50	131.00	126.00	2.00*	6.40*	6.90*	9.70*
128	072	7.20	3.40*	199.00	350.00*	2.00*	10.10	9.60	8.40*
129	072	7.40	4.30	154.00	158.00	3.00	8.70*	9.40	14.00
137	072	7.10	4.70	198.00	124.00	2.50	12.60	9.60	11.70
138	072	9.10*	4.50	225.00	115.00	2.20*	11.80	13.40*	11.70
141	072	8.50*	4.80	123.00*	196.00	2.10*	8.00*	9.80	18.40*
145	072	6.50	3.50	175.00	12.00	6.00	9.00	11.00	15.00
173	072	8.80*	4.00	192.00	89.00	.30	.71	.92	1.20
174	072	6.70	4.40	192.00	87.00	.40	.70	.90	1.30
175	072	6.80	4.70	192.00	89.00	.40	.70	.90	1.40
178	072	6.80	4.70	200.00	89.00	.34	.75	.92	1.30
182	072	6.80	5.10	200.00	92.00	.37	.75	.91	1.20
183	072	6.80	4.70	200.00	88.00	.35	.72	.92	1.20
190	072	8.80*	4.50	200.00	98.00	.42*	.75	1.10	1.40
191	072	8.80*	4.70	190.00	88.00	.41*	.82	1.00	1.30
195	072	6.80	4.40	178.00	97.00	.40	.70	1.80*	1.20
196	072	6.00*	4.60	169.00	96.00	.40	.60	.50*	1.60
201	072	6.70	4.90	258.00	148.00	.30	.80	1.30*	1.20
204	072	7.90	4.90	198.00	148.00	.40	.70	.60	.90
205	072	6.00*	5.10	232.00	132.00	.40	.60	.80	1.10
207	072	8.20	5.00	252.00	144.00	.30	.80	.80	1.70
212	072	8.00	4.70	159.00	118.00	.30	.80	1.10	1.60

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

107

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
213	072	7.00	5.00	160.00	100.00	.20	.60	.80	1.20
220	072	6.85	4.85	5.64	120.00	.15*	.56*	1.09	1.48*
221	072	7.00	4.02	5.20	122.00	.14*	.81	1.04	.90
225	072	7.30	4.20	4.81	124.00	.28	.65	1.02	1.15
228	072	7.60	4.34	6.50	173.00*	.18*	.60	1.03	1.45*
229	072	7.20	4.05	4.42	134.00	.20	.56*	1.02	1.37*
234	072	7.90	4.63	4.86	.	.26	.88	.94	1.19
236	072	8.00	5.34*	4.96	120.00	.24	.54*	.91	.97
239	072	8.20*	4.17	5.20	116.00	.27	.67	1.01	2.08*
241	072	7.60	4.20	180.00	87.00	.30	.70	1.00	1.30
242	072	7.20	4.20	179.00	80.00	.33	.71	1.10	1.40
250	072	6.90	5.20	180.00	100.00	.30	.70	.80	1.10
252	072	6.60	4.60	201.00	133.00	.20	.80	.70	.90
253	072	7.00	5.00	160.00	102.00	.40	.80	1.00	.80
256	072	7.00	4.70	98.00*	98.00	.70*	.80	.80	1.00
261	072	6.90	4.20	180.00	97.00	.30	.80	.80	1.10
264	072	6.80	4.20	131.00*	96.00	.40	.60	.70	1.30
265	072	6.90	3.80	242.00	140.00	.40	.90	.90	.80
266	072*	6.20	4.20	210.00	126.00	.30	.60	.70	1.00
272	072	6.70	4.20	178.00	100.00	.40	.70	.90	1.00

FCE 20124/702 i

108

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
26	072	1.020	0	0	0	0
27	072	1.022	0	0	0	0
33	072	1.022	0	0	0	0
36	072	1.022	0	0	0	0
39	072	1.020	0	0	0	0
40	072	1.024	0	0	0	0
43	072	1.024	0	0	0	0
46	072	1.024	0	0	0	0
52	072	1.021	0	0	0	0
53	072	1.028	0	0	0	0
58	072	1.026	0	0	0	0
59	072	1.026	0	0	0	0
62	072	1.019	0	0	0	0
63	072	1.027	0	0	0	0
69	072	1.027	0	0	0	0
71	072	1.018	0	0	0	0
74	072	1.019	0	0	0	0
76	072	1.020	0	0	0	0
97	072	1.015	0	0	0	0
100	072	1.014	0	0	0	0
104	072	1.007	0	0	0	0
105	072	1.028	0	0	0	0
111	072	1.013	0	0	0	0
112	072	1.017	0	0	0	0
116	072	1.009	0	0	0	0
117	072	1.017	0	0	0	0
121	072	1.026	0	0	0	2
125	072	1.030	0	0	1	2
129	072	1.020	0	0	0	3
137	072	1.025	0	0	0	1
138	072	1.025	0	0	40*	11*
141	072	1.012	0	0	0	1
145	072	1.015	0	0	0	0
173	072	1.015	0	0	0	2
174	072	1.012	0	0	0	4
175	072	1.020	0	0	0	4
178	072	1.010	0	0	0	4
182	072	1.015	0	0	2	4
183	072	1.020	0	0	2	4
190	072	1.020	0	0	2	4
191	072	1.015	0	0	2	4
195	072	1.020	0	0	2	1
196	072	1.020	0	0	2	0
201	072	1.016	0	0	2	3
204	072	1.018	0	0	1	3
205	072	1.020	0	0	1	4
207	072	1.016	0	0	2	4
212	072	1.018	0	0	2	3
213	072	1.018	0	0	0	2
220	072	1.022	0	0	1	2
221	072	1.016	0	0	0	40*
225	072	1.012*	0	0	0	1
229	072	1.016	0	0	0	2
234	072	1.016	0	0	0	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

109

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
236	072	1.014*	0	0	2	3
239	072	1.008*	0	0	0	2
241	072	1.010	0	0	0	2
242	072	1.015	0	0	0	4
250	072	1.022	0	0	1	4
252	072	1.016	0	0	1	3
253	072	1.020	0	0	1	2
256	072	1.018	0	0	1	2
261	072	1.020	0	0	0	4
264	072	1.010	0	0	0	2
265	072	1.012	0	0	0	4
266	072	1.012	0	0	2	2
272	072	1.018	0	0	1	5

FCE 20124/702 i

110

Treatment Group "C"

Day 7 (Period 072)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	75	8
Hematocrit (HCT)	75	6
Red Blood Cells (RBC)	75	18
White Blood Cells (WBC)	75	6
Neutrophils (NEUTS)	75	17
Lymphocytes (LYMPS)	75	24
Eosinophils (EOSIN)	75	24
Monocytes (MONOS)	75	14
Basophils (BASOS)	75	12
Platelets (PLATES)	75	4
Sodium (NA+)	74	3
Phosphorous (K+)	74	7
Chlorine (CL-)	74	14
Calcium (CA++)	74	7
Aspartate		
Aminotransferase (SGOT)	74	1
Alanine		
Aminotransferase (SGPT)	74	4
γ-GT (YGT)	74	14
Blood Sugar (BLSUG)	74	3
Phosphorous (PO4)	74	8
Alkaline		
Phosphatase (ALPKHOS)	74	2
Urea Nitrogen (BUN)	74	3
Creatinine (CREAT)	74	2
Uric Acid (URACID)	73	4
Total Bilirubin (TOTBILI)	74	2
Direct Bilirubin (DIRBILI)	74	10
Total Protein (TOTPROT)	74	10
Albumin (BLALB)	74	12
Cholesterol (CHOLE)	74	11
Triglycerides (TRIGLY)	72	7
Globulins - α1 (GLOBAL)	74	15
Globulins - α2 (GLOBAL2)	74	13
Globulins - β (GLOBETA)	74	17
Globulins - γ (GLOGAMA)	74	19
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	67	3
Albumin (URALB)	67	0
Sugar (URSUG)	67	0
Red Blood Cells (URRBC)	67	1
White Blood Cells (URWBC)	67	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

111

\* = Value out-of-range

Day 14 (Period 142)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
3	142	13.70	40.50	4.41	7.00	57.00	36.00	2.00	5.00
6	142	14.50	43.10	4.60	5.50	34.00*	55.00*	1.00	9.00
8	142	13.90	41.60	3.88*	4.60	42.00*	38.00	13.00*	7.00
16	142	14.80	43.50	4.75	6.00	53.00	27.00	10.00*	9.00
18	142	15.00	43.80	4.71	6.30	48.00*	37.00	1.00	14.00*
26	142	14.60*	42.00	4.80	7.00	68.00	28.00	2.00	1.00
27	142	13.90	40.00	4.80	5.90	68.00	26.00	2.00	4.00
33	142	13.80	39.00	4.60	8.00	70.00	28.00	1.00	1.00
36	142	14.40*	44.10	4.50	6.80	70.00	26.00	1.00	3.00
39	142	14.10	42.00	4.40	5.80	67.00	29.00*	2.00	2.00
40	142	14.80	42.00	5.30	6.10	68.00	28.00	1.00	2.00
43	142	14.30	44.00	4.60	5.40	69.00	24.00	3.00	3.00
46	142	15.60	43.40	4.50	7.00	68.00	26.00	4.00	1.00
52	142	9.20	.45	4.70	4.60	68.00	27.00	1.00	4.00
53	142	9.20	.45	4.70	8.70	71.00	26.00	1.00	2.00
58	142	8.90	.46	5.10	7.00	71.00	24.00	2.00	3.00
59	142	9.00	.46	5.10	6.40	60.00	33.00	3.00	3.00
62	142	8.90	.49	5.70*	6.90	71.00	24.00	2.00	3.00
63	142	8.90	.47	5.30	6.70	68.00	25.00	2.00	4.00
69	142	9.10	.48	5.10	6.90	65.00	30.00	1.00	3.00
71	142	9.10	.48	5.60*	6.70	72.00	22.00	2.00	4.00
74	142	14.00	42.10	4.46	5.38	54.30	36.30	1.60	4.90
76	142	15.10	48.80	5.08	15.42*	66.20	20.10	3.00	8.80
81	142	15.10	45.70	4.60	6.84	56.00	30.30	1.90	7.90
82	142	16.00	49.50	5.11	13.02*	50.00	37.20	4.80	5.70
86	142	16.30	46.30	5.15	5.45	41.20	45.40	2.30	7.30
89	142	13.40	42.60	4.53	11.38*	64.40	25.40	1.60	5.10
92	142	14.50	43.20	4.63	5.39	40.60	48.80*	3.20	4.20
93	142	12.70	38.90	4.16	4.86	63.70	26.40	1.50	5.80
97	142	16.20	44.20	5.60	6.50	63.00	31.00	3.00	3.00
100	142	14.60	38.80	4.62	5.40	49.00	48.00*	2.00	1.00*
104	142	14.10	39.00	4.44	9.10	74.00	26.00	.00*	.00*
105	142	13.90	38.00*	4.27*	4.90	60.00	38.00	.00*	2.00
111	142	15.20	40.70*	4.59*	5.50	37.00*	54.00*	8.00*	1.00*
112	142	16.70	40.90*	4.27*	6.80	65.00	35.00	.00*	.00*
116	142	12.80	34.00*	3.69*	5.10	62.00	36.00	.00*	2.00
117	142	16.30	40.70*	4.28*	6.90	65.00	35.00	.00*	.00*
121	142	12.50	39.00	4.37	5.00	44.00*	56.00*	.00	.00*
125	142	16.90*	53.00*	5.83*	5.00	60.00	37.00*	3.00*	.00*
128	142	13.40	42.00	4.62	4.90	76.00*	24.00	2.00	.00*
129	142	13.40	42.00	4.62	5.50	58.00*	38.00*	2.00	.00*
137	142	14.80	45.00	4.95	5.80	59.00*	39.00*	1.00	1.00*
138	142	14.40	45.00	4.95	8.20	61.00	39.00*	.00	.00*
141	142	15.90	49.00	5.12	5.80	70.00	28.00	1.00	1.00*
145	142	10.80*	36.00*	3.40	8.80	44.00*	50.00*	6.00*	.00*
173	142	15.90	44.00	6.10	6.30	58.00	30.00	5.00*	6.00
174	142	16.00	45.00	6.10	6.70	60.00	30.00	3.00	6.00
175	142	16.00	46.00	6.10*	7.20	59.00	32.00	2.00	6.00
178	142	16.00	46.00	6.00	7.10	60.00	30.00	3.00	6.00
182	142	16.00	44.00	6.00	7.70	61.00	30.00	2.00	6.00

FCE 20124/702 i

112

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
183	142	16.00	46.00	6.10*	7.20	59.00	31.00	3.00	6.00
190	142	16.00	46.00	6.10*	6.20	59.00	32.00	2.00	6.00
191	142	16.00	44.00	6.00	5.90	59.00	32.00	2.00	6.00
195	142	15.40	44.00	5.20	3.80*	58.00	30.00	6.00*	2.00*
196	142	14.20	39.00	4.30	3.60*	54.00	36.00*	4.00*	4.00
201	142	12.50	43.00	4.80	5.00	53.00*	37.00*	4.00*	3.00
204	142	14.10	46.00	5.00	6.50	54.00	36.00*	5.00*	3.00
205	142	12.00	41.00	4.10*	7.00	56.00	34.00*	5.00*	4.00
207	142	15.20	46.00	5.90	8.20	52.00*	38.00*	4.00*	6.00
212	142	14.10	44.00	5.00	5.00	53.00*	36.00*	3.00	7.00
213	142	14.00	45.00	5.10	8.00	53.00*	37.00*	2.00	7.00
220	142	15.50*	44.00	5.19*	5.40	49.00*	44.00*	2.00	5.00
221	142	12.58	37.00	4.10	6.40	52.00	44.00*	.00	3.00
225	142	14.21	44.00	4.95	6.90	33.00*	58.00*	7.00*	2.00
228	142	10.34*	31.50*	3.85*	6.20	68.00	30.00	1.00	1.00
229	142	12.90	37.00	4.50	5.45	61.00	32.00	2.00	4.00
234	142	15.96	48.00	5.10	8.50*	68.00	26.00	3.00	2.00
236	142	16.83*	50.00*	5.70*	8.50*	67.00	27.00	5.00	1.00
239	142	14.60	43.00	4.55	6.50	50.00	40.00	2.00	2.00
241	142	15.90	44.00	6.20*	7.00	59.00	30.00	5.00*	6.00
242	142	16.00	46.00	6.00	5.90	61.00	30.00	2.00	6.00
250	142	14.20	44.00	5.20	7.20	53.00*	37.00*	6.00*	3.00
252	142	14.60	45.00	5.90	7.00	54.00	36.00*	6.00*	3.00
253	142	13.10*	39.00*	5.40	6.20	56.00	34.00*	4.00*	3.00
256	142	15.00	40.00*	5.10	4.80	52.00*	38.00*	3.00	6.00
261	142	16.00	44.00	6.10	5.60	53.00*	37.00*	6.00*	3.00
264	142	16.00	44.00	6.20*	7.00	50.00*	40.00*	6.00*	4.00
265	142	16.00	44.00	6.10	5.80	52.00*	38.00*	4.00	3.00
266	142	15.90	44.00	5.90*	6.20	58.00	32.00	5.00*	3.00
272	142	12.10	40.00	4.90	5.90	56.00	34.00*	4.00*	4.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

113

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
3	142	.00	206.00	141.00	4.10	103.00	2.19	8.00	7.00	7.00
6	142	1.00	337.00	140.00	4.30	95.00	2.45	8.00	6.00	9.00
8	142	.00	239.00	139.00	5.00*	103.00	2.23	12.00	9.00	29.00*
16	142	1.00	241.00	142.00	4.00	100.00	2.38	11.00	14.00	18.00
18	142	.00	269.00	143.00*	4.10	101.00	2.28	10.00	13.00	16.00
26	142	1.00	190.00	142.00	4.00	96.00	2.40	10.00	12.00	10.00
27	142	.00	240.00	146.00	4.10	102.00	2.10	14.00	12.00	16.00
33	142	.00	200.00	140.00	4.10	105.00	2.10	7.00	6.00	18.00
36	142	.00	186.00	140.00	4.00	101.00	2.00*	8.00	10.00	10.00
39	142	.00	230.00	144.00	4.00	101.00	2.10	8.00	8.00	10.00
40	142	1.00	216.00	146.00	4.10	102.00	2.10	12.00	14.00	16.00
43	142	1.00	228.00	144.00	4.00	101.00	2.20	14.00	14.00	12.00
46	142	1.00	205.00	145.00	4.30	104.00	2.20	8.00	10.00	10.00
52	142	.00	184.00	142.00	4.30	101.00	2.20	5.00	7.00	5.00
53	142	.00	191.00	142.00	4.10	103.00	2.30	11.00	15.00	20.00
58	142	.00	184.00	139.00	3.80	99.00	2.90*	14.00	12.00	27.00
59	142	1.00	173.00	141.00	3.80	103.00	2.70	15.00	16.00	31.00*
62	142	.00	188.00	137.00*	4.10	101.00	2.70	12.00	13.00	34.00*
63	142	1.00	176.00	141.00	3.90	101.00	2.30	14.00	10.00	27.00
69	142	1.00	189.00	136.00*	3.90	101.00	2.40	12.00	14.00	26.00
71	142	.00	199.00	139.00	4.10	101.00	2.30	10.00	11.00	30.00*
74	142	.80	132.00	140.00	4.20	109.00	9.00	14.00	14.00	9.00
76	142	.80	321.00	135.00	4.90	99.00	10.70*	18.00	46.00*	20.00
81	142	1.20	342.00	132.00	4.80	115.00*	9.00	11.00	17.00	8.00
82	142	1.00	255.00	140.00	5.20	111.00*	11.10*	24.00	37.00	25.00
86	142	1.30	204.00	144.00	4.40	104.00	9.90	21.00	24.00	13.00
89	142	1.10	155.00	142.00	6.00	106.00	9.80	18.00	16.00	11.00
92	142	1.40	328.00	141.00	4.60	103.00	10.00	14.00	20.00	13.00
93	142	.40	172.00	139.00	4.20	97.00	8.80	14.00	18.00	18.00
97	142	.00	146.00*	137.00	3.80	99.00	9.20	28.00	69.00*	49.00
100	142	.00	262.00	139.00	3.70	101.00	8.30	22.00	10.00	11.00
104	142	.00	395.00*	151.00	5.00	112.00*	8.70	21.00	31.00	41.00*
105	142	.00	212.00	150.00	4.30	100.00	9.00	29.00	30.00	35.00
111	142	.00	245.00	145.60	4.44	111.10*	8.90	15.00	13.00	9.00*
112	142	.00	235.00	147.80	4.90	111.30*	10.50*	35.00*	50.00*	39.00
116	142	.00	182.00	130.00*	3.70	110.00*	8.50	18.00	19.00	14.00
117	142	.00	236.00	147.00	4.90	110.00*	10.60*	36.00*	51.00*	39.00
121	142	.00	173.00	139.00	4.90	380.00	10.20	29.00	50.00*	12.00
125	142	.00	213.00	140.00	4.30	348.00	9.60	34.00	48.00*	25.00
128	142	.00	182.00	138.00	4.90	346.00	9.40	10.00	11.00	13.00
129	142	.00	234.00	136.00	4.30	343.00	9.70	10.00	10.00	12.00
137	142	.00	367.00	142.00	4.20	363.00	9.70	12.00	13.00	10.00
138	142	.00	263.00	138.00	4.20	341.00	9.60	21.00	19.00	14.00
141	142	.00	253.00	135.00	3.40*	347.00	10.10	21.00	23.00	14.00
145	142	.00	221.00	140.00	4.00	100.00*	9.00	10.00	4.50	5.00
173	142	1.00	280.00	137.00	4.80	95.00	8.70	38.00	9.50	8.20*
174	142	1.00	270.00	140.00	5.00	98.00	9.10	38.00	9.90	8.10*
175	142	1.00	275.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20
178	142	1.00	270.00	140.00	4.90	99.00	9.20	39.00	10.00	8.10*
182	142	1.00	270.80	138.00	5.10	98.00	9.00	38.00	9.90	8.00*
183	142	1.00	280.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20
190	142	1.00	270.00	139.00	4.90	101.00	9.20	37.00	9.80	8.30
191	142	1.00	280.00	140.00	4.90	97.00	9.10	38.00	9.70	8.20*
195	142	.00	270.00	143.00	4.90	98.00	9.20	32.00	18.00	32.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

114

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
196	142	2.00*	265.00	136.00	4.30	92.00*	9.30	27.00	16.00	27.00
201	142	3.00*	249.00	135.00	4.70	105.00	9.50	34.00	24.00	34.00
204	142	2.00*	278.00	138.00	4.80	102.00	9.30	35.00	30.00	28.00
205	142	1.00	229.00	140.00	5.00	112.00*	8.90	40.00	34.00	28.00
207	142	.00	162.00	148.00	5.20	102.00	10.10	45.00	36.00	22.00
212	142	1.00	300.00	136.00	4.10	97.00	9.00	28.00	29.00	39.00
213	142	1.00	315.00	135.00	4.00	98.00	8.40*	32.00	32.00	35.00
220	142	.00	305.00	140.00	4.10	103.00	10.38	16.00	12.00	37.00*
221	142	1.00	320.00	140.00	3.70	98.00	8.91	12.00	8.00	40.00*
225	142	.00	360.00	136.00	3.90	100.00	8.90	10.00	6.00	15.00
228	142	.00	490.00*	139.00	4.30	100.00	9.30	15.00	5.00	8.00
229	142	1.00	310.00	140.00	4.50	102.00	9.60	18.00	3.00	13.00
234	142	1.00	495.00*	141.00	4.80	95.00*	9.36	16.00	9.00	19.00
236	142	.00	315.00	135.00	5.30	94.00*	9.63	16.00	7.00	12.00
239	142	.00	310.00	138.00	4.00	99.00	10.47	20.00	8.00	23.00
241	142	.00	280.00	152.00	4.50	96.00	9.10	37.00	12.10	20.00
242	142	1.00	280.00	137.00	5.10	97.00	9.00	38.00	9.80	8.00*
250	142	1.00	271.00	138.00	5.10	105.00	8.20*	42.00	32.00	27.00
252	142	1.00	290.00	137.00	5.00	105.00	8.60	38.00	27.00	30.00
253	142	3.00*	300.00	143.00	5.70*	98.00	9.70	29.00	29.00	30.00
256	142	1.00	264.00	139.00	4.20	95.00	8.80	34.00	22.00	30.00
261	142	1.00	182.00	147.00	5.30	108.00*	3.80*	26.00	24.00	32.00
264	142	.00	231.00	142.00	4.80	103.00	8.40*	28.00	18.00	32.00
265	142	3.00*	176.00	148.00	5.10	98.00	9.20	41.00	31.00*	24.00
266	142	2.00*	250.00	136.00	5.30	109.00*	3.90*	36.00	34.00*	35.00
272	142	2.00*	179.00	148.00	5.20	102.00	3.60*	27.00	23.00	32.00

FCE 20124/702 i

115

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
3	142	4.73	1.44	107.00	3.70	87.00	.13*	8.00	2.40
6	142	4.31	1.61*	53.00	2.00*	100.00*	.16	9.00	1.60
8	142	4.62	1.25	.	3.40	82.00	.26	8.00	1.90
16	142	4.78	1.14	93.00	4.30	99.00	.20	11.00	2.40
18	142	4.98	1.56*	114.00	4.00	93.00	.29	8.00	1.36
26	142	4.00	1.40	160.00	5.00	64.00	280.00	10.00	.00
27	142	3.80	1.10	136.00	5.40	68.00	280.00	12.00	.00
33	142	4.80	1.20	120.00	4.20	72.00	276.00	8.00	.00
36	142	4.60	1.20	98.00	4.60	76.00	224.00	5.00	.00
39	142	4.20	1.10	100.00	4.80	64.00	216.00	8.00	.00
40	142	4.00	1.10	160.00	5.80	72.00	270.00	12.00	.00
43	142	4.00	1.20	118.00	5.20	66.00	264.00	14.00	.00
46	142	4.60	1.20	148.00	5.10	74.00	310.00	8.00	.00
52	142	4.90	.90	22.00	7.00	90.00	132.00*	11.00	.00
53	142	4.10	.90	29.00	6.50	90.00	129.00*	12.00	.00
58	142	5.00	1.00	24.00	7.00	89.00	151.00	11.00	.00
59	142	5.00	1.10	29.00	6.00	89.00	161.00	14.00	.00
62	142	4.30	1.10	29.00	7.00	72.00	159.00	12.00	.00
63	142	4.30	1.00	33.00	7.00	69.00	154.00	8.00	.00
69	142	4.10	1.00	25.00	3.00	61.00	162.00	10.00	.00
71	142	4.10	1.00	28.00	3.00	65.00	159.00	9.00	.00
74	142	74.00	4.30	53.00	15.50	.80	2.30*	.50	.20
76	142	70.00	4.40	93.00	10.10	1.00	4.60	.40	.30
81	142	76.00	3.30	71.00	12.50	.80	4.00	.40	.20
82	142	77.00	4.00	136.00*	14.90	1.50*	8.80*	.60	.30
86	142	59.00*	4.00	64.00	11.30	1.00	8.00*	.80	.20
89	142	82.00	4.30	79.00	17.00	.90	2.40*	.50	.10
92	142	80.00	4.20	75.00	14.80	.90	3.00*	.40	.10
93	142	130.00*	3.60	114.00	13.90	1.00	5.20	.70	.30
97	142	80.00	2.30*	241.00	22.00	.70	6.30*	.46	.01
100	142	74.00	2.60	258.00	34.00	.60	4.40	.48	.08
104	142	72.00	3.10	121.00	23.00	.50	4.00	.60	.10
105	142	81.00	3.00	140.00	41.00	.90	4.00	.50	.10
111	142	53.00*	3.60	193.00	22.00	.60	3.00	.37	.05
112	142	70.00	3.50	275.00	31.00	.80	3.60	.65	.10
116	142	70.00	3.00	183.00	44.00	.70	2.50	.52	.07
117	142	71.00	3.60	276.00	32.00	.80	3.60	.66	.09
121	142	85.00	3.60	160.00*	56.00*	1.00	2.50	.80	.30*
125	142	87.00	3.40	91.00	25.00	.10*	7.00	.50*	.20*
128	142	94.00	3.70	83.00	22.00	.80	5.10	.70	.30*
129	142	81.00	3.80	62.00	15.00*	.70*	2.40	.60	.30*
137	142	79.00	3.70	78.00	40.00	.80	5.80	.70	.40*
138	142	106.00	3.50	21.00*	17.00*	.90	5.00	.70	.30*
141	142	92.00	2.90	78.00	28.00	1.00	5.80	1.40	.60*
145	142	86.00	3.40	30.00	18.00*	.70	2.10*	.70	.40*
173	142	99.00	3.60	170.00	11.00	1.00	4.90	.70	.40
174	142	98.00	3.90	170.00	11.00	1.10	5.20	.80	.40
175	142	92.00	4.00	171.00	11.00	1.00	5.20	.70	.50
178	142	92.00	3.90	170.00	11.00	.99	5.20	.70	.40
182	142	94.00	4.00	177.00	11.00	1.10	5.20	.70	.40
183	142	97.00	4.00	178.00	11.10	1.00	5.20	.70	.40
190	142	97.00	4.10	177.00	11.10	1.10	5.70	.70	.40
191	142	98.00	4.20	177.00	11.00	1.00	5.60	.70	.40
195	142	96.00	4.00	130.00	11.30	.76	4.90	.90	.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

116

Pat. No.	Per. (dy)	ELSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
196	142	94.00	3.50	122.00	11.00	.65	4.60	.70	.20
201	142	95.00	3.70	120.00	18.00	.90	5.10	.80	.30
204	142	100.00	3.70	130.00	16.00	.80	6.00	.70	.30
205	142	100.00	3.90	128.00	20.00	.70	5.20	1.00	.50
207	142	100.00	4.10	120.00	14.00	.90	4.90	.90	.40
212	142	85.00	3.90	118.00	18.00	.90	4.20	.80	.40
213	142	100.00	4.00	115.00	16.00	.70	4.40	.80	.20
220	142	5.00	3.28	43.42	21.00	97.24	2.80	12.31	5.13*
221	142	4.56	2.97	37.57	25.00	70.72	4.40	5.98	2.56
225	142	5.39	2.90	46.76	20.00	112.26	5.00	22.23*	4.61*
228	142	5.20	2.30	31.67	18.00	81.32	3.60	4.27	1.71
229	142	5.22	2.70	21.71	14.00	88.40	4.90	12.82	6.84*
234	142	5.22	5.30	29.66	25.00	88.40	4.20	8.89	3.42
236	142	5.39	3.53	31.37	30.00	106.08	5.00	12.82	5.13*
239	142	4.40	3.64	42.25	23.00	82.21	5.60	16.24	4.27*
241	142	88.00	3.70	137.00	12.00	1.10	5.10	.90	.40
242	142	87.00	4.00	172.00	11.10	.99	4.80	.70	.40
250	142	100.00	3.90	110.00	16.00	.86	5.00	.90	.20
252	142	95.00	3.80	120.00	11.30	.80	5.00	.80	.20
253	142	100.00	3.80	115.00	17.00	.80	5.30	.70	.20
256	142	90.00	3.90	125.00	10.50	.80	5.00	1.00	.50
261	142	98.00	3.90	130.00	13.00	1.10	5.40	.90	.30
264	142	94.00	3.60	127.00	11.20	.70	4.90	1.00	.10
265	142	105.00	5.40*	124.00	16.00	.77	4.80	.70	.20
266	142	98.00	3.70	129.00	16.00	.75	5.30	.90	.10
272	142	100.00	3.90	135.00	14.00	1.10	5.50	.90	.30

FCE 20124/702 i

117

Pat. No.	Per. (dy)	TOTPROT	HLALB	CHOLE	TRIGLY	GLOBA1	GLOBA2	GLOBETA	GLOGAMA
3	142	64.00	39.80*	5.20	1.01	2.10	5.10*	7.60*	9.40*
6	142	77.00	44.60*	8.00*	1.08	2.50	8.80	10.60	10.90*
8	142	62.00	40.30*	5.20	1.86	2.10	4.70*	7.40*	7.50*
16	142	69.00	47.00*	6.10	.64	1.90	4.60*	7.20*	8.50*
18	142	66.00	44.00*	4.10	.56	1.70	5.30*	6.90*	8.10*
26	142	70.00	32.00*	3.90	.90	3.40	8.60	14.00*	14.40
27	142	70.00	36.00	4.80	1.30	3.00	7.60	10.00	12.10*
33	142	68.00	41.00	4.10	1.00	2.80	8.00	9.10	15.00
36	142	76.00	38.00	4.40	1.20	4.20*	6.80	12.00	15.80
39	142	67.00	29.00*	.90*	2.60*	2.90	6.90	9.00	14.00
40	142	68.00	37.00	5.10	1.40	3.40	8.20	12.00	14.20
43	142	74.00	40.00	4.20	1.20	3.20	7.90	11.00	12.80
46	142	80.00	43.00	5.20	1.20	3.30	7.60	9.80	14.80
52	142	75.00	49.00*	5.80	1.50	2.40	5.70*	5.90*	12.70
53	142	76.00	50.00*	4.10	1.40	2.30*	5.10*	6.70*	12.10*
58	142	80.00	50.00*	4.30	1.10	2.00*	6.00*	8.30	12.70
59	142	74.00	40.00	5.10	1.40	3.10	7.90	8.70	14.30
62	142	70.00	50.00*	5.10	1.70	2.70	8.10	9.40	14.20
63	142	71.00	45.00	5.00	1.90	2.90	7.80	8.90	16.10
69	142	78.00	50.00*	4.90	1.60	2.70	6.90	8.10	14.10
71	142	71.00	47.00	5.60	1.70	2.70	8.10	8.80	12.90
74	142	6.70	4.40	199.00	81.00	3.71	11.40	14.71*	16.30
76	142	6.90	4.10	249.00*	258.00*	2.40	11.00	15.32*	19.20
81	142	6.70	4.10	185.00	87.00	2.94	13.50	12.35	12.35
82	142	8.60*	4.80	256.00*	408.00*	2.81	8.62	14.74*	16.29
86	142	6.90	4.60	212.00	275.00*	2.73	8.47	12.01	15.76
89	142	7.10	4.50	258.00*	194.00*	2.69	11.01	12.70	13.62
92	142	6.80	4.40	250.00*	.	2.79	14.21*	12.98	12.81
93	142	8.20	4.00	139.00*	64.00	3.41	10.89	13.55	13.55
97	142	7.50	64.20	178.00	210.00*	2.90	8.50	14.20*	10.20
100	142	7.80	49.60*	241.00*	412.00*	2.40*	8.70	15.80*	21.40*
104	142	7.40	60.80	207.00	157.00	2.90	8.30	10.70	17.20
105	142	6.90	59.20	134.00	218.00*	2.80	8.90	15.10*	13.70
111	142	6.40	62.00	186.00	118.00	3.70	9.10	14.40*	10.50
112	142	8.70*	60.50	172.00	85.00	3.70	10.60	15.20*	10.70
116	142	6.90	57.20	178.00	138.00	3.10	9.90	16.70	13.80
117	142	8.10	51.20*	173.00	86.00	4.70*	11.10	13.20	18.10*
121	142	7.20	3.60*	220.00	220.00	3.00	12.20	12.90*	16.40
125	142	7.70	4.30	187.00	201.00	2.30*	6.70*	7.90*	11.80
128	142	7.70	4.50	190.00	381.00*	1.90*	9.60	8.30	9.10*
129	142	7.40	4.70	168.00	174.00	2.60	10.20	9.40	14.00
137	142	8.00	5.00	202.00	110.00	1.90*	9.50	12.60*	10.70
138	142	7.20	4.20	220.00	121.00	2.20*	9.70	16.90*	13.40
141	142	8.60*	5.20*	145.00	209.00	2.00*	7.70*	8.80	16.00
145	142	6.00	3.80	130.00	15.00	5.00	8.00	11.00	15.00
173	142	6.80	4.10	190.00	90.00	.32	.72	.92	1.30
174	142	7.70	4.20	195.00	92.00	.31	.72	.91	1.20
175	142	7.70	4.50	198.00	85.00	.35	.72	.91	1.20
178	142	6.80	4.70	195.00	85.00	.37	.75	.92	1.30
182	142	8.80*	4.70	200.00	88.00	.40	.72	.95	1.40
183	142	8.80*	4.70	195.00	89.00	.35	.72	.95	1.20
190	142	6.70	4.80	197.00	95.00	.35	.77	.91	1.20
191	142	8.70*	4.70	195.00	87.00	.41*	.72	1.00	1.20
195	142	6.90	4.50	180.00	98.00	.30	.70	.80	1.20

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

118

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOB1	GLOB2	GLOBETA	GLOGAMA
196	142	6.40	4.50	162.00	95.00	.30	.50	.60	1.50
201	142	6.60	4.80	255.00	145.00	.20	.80	1.00	1.20
204	142	7.80	4.70	198.00	148.00	.30	.60	.70	.80
205	142	6.51	5.10	230.00	132.00	.60*	.40	.80	1.10
207	142	8.10	5.10	250.00	143.00	.40	.70	.80	1.70
212	142	6.00*	4.60	150.00	120.00	.30	.90	1.40*	1.70
213	142	7.00	5.00	160.00	105.00	.30	.70	.80	1.10
220	142	7.90	4.42	5.85	193.00*	.17*	.66	1.10	1.55*
221	142	7.60	3.84	5.53	124.00	.18*	.83	1.11	1.04
225	142	6.70	4.03	4.60	145.00	.13*	.54*	.83	1.17
228	142	7.00	3.95	6.11	180.00*	.23	.46*	1.04	1.32*
229	142	7.60	4.05	4.68	154.00	.18*	.68	1.07	1.62*
234	142	7.50	4.87	5.72	103.00	.20	.66	.77	1.00
236	142	7.05	4.01	5.14	111.00	.25	.61	.97	1.21
239	142	8.30*	3.68	5.64	102.00	.25	.80	1.20	2.37*
241	142	7.70	4.30	180.00	85.00	.33	.71	1.10	1.40
242	142	7.50	4.20	180.00	78.00	.32	.71	1.00	1.30
250	142	6.90	5.10	178.00	100.00	.30	.70	.80	1.10
252	142	6.90	6.50*	200.00	135.00	.20	.80	.70	.60*
253	142	8.00	5.00	150.00	103.00	.40	.90	1.00	1.10
256	142	8.00	4.40	180.00	95.00	.30	.70	.80	1.00
261	142	6.90	4.20	180.00	96.00	.30	.80	.80	1.20
264	142	6.90	4.20	130.00*	97.00	.30	.60	.70	1.30
265	142	6.70	3.90	242.00	138.00	.40	.70	.80	.80
266	142	6.80	4.00	212.00	124.00	.30	.70	.70	.90
272	142	6.70	4.30	176.00	100.00	.40	.80	.90	1.10



FCE 20124/702 i

119

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URREC	URWBC
26	142	1.023	0	0	0	0
27	142	1.026	0	0	0	0
33	142	1.020	0	0	0	0
36	142	1.022	0	0	0	0
39	142	1.020	0	0	0	0
40	142	1.024	0	0	0	0
43	142	1.022	0	0	0	0
46	142	1.020	0	0	0	0
52	142	1.021	0	0	0	0
53	142	1.029	0	0	0	0
58	142	1.019	0	0	0	0
59	142	1.019	0	0	0	0
62	142	1.026	0	0	0	0
63	142	1.019	0	0	0	0
69	142	1.019	0	0	0	0
71	142	1.024	0	0	0	0
74	142	1.019	0	0	0	0
76	142	1.018	0	0	0	0
81	142	1.017	0	0	0	0
82	142	1.021*	0	0	0	0
86	142	1.019	0	0	0	0
89	142	1.011	0	0	0	0
92	142	1.021*	0	0	0	0
93	142	1.020	0	0	0	0
97	142	1.012	0	0	0	0
100	142	1.013	0	0	0	0
104	142	1.007	0	0	0	0
105	142	1.023	0	0	0	0
111	142	1.012	0	0	0	0
112	142	1.013	0	0	0	0
116	142	1.010	0	0	0	0
117	142	1.013	0	0	0	0
121	142	1.030	0	0	0	0
125	142	1.010	0	0	0	1
128	142	1.020	0	0	0	3
129	142	1.010	0	0	0	3
137	142	1.005	0	0	0	9*
138	142	1.010	0	0	1	2
141	142	1.020	0	0	6*	8*
145	142	1.015	0	0	0	3
173	142	1.015	0	0	0	4
174	142	1.015	0	0	0	2
175	142	1.012	0	0	2	4
178	142	1.010	0	0	0	4
182	142	1.012	0	0	2	2
183	142	1.012	0	0	2	4
190	142	1.015	0	0	2	4
191	142	1.010	0	0	0	4
195	142	1.016	0	0	2	0
201	142	1.016	0	0	2	3
204	142	1.020	0	0	1	3
205	142	1.018	0	0	2	3
207	142	1.016	0	0	2	4
212	142	1.018	0	0	1	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

120

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
213	142	1.018	0	0	1	2
220	142	1.014*	0	0	1	9*
221	142	1.015	0	0	0	45*
225	142	1.009*	0	0	0	1
228	142	1.013*	0	0	30	3
229	142	1.008*	0	0	1	2
234	142	1.015	0	0	0	1
236	142	1.018	0	0	0	3
239	142	1.013*	0	0	0	1
241	142	1.015	0	0	0	2
242	142	1.010	0	0	0	2
250	142	1.020	0	0	1	4
252	142	1.020	0	0	1	3
253	142	1.016	0	0	1	3
256	142	1.018	0	0	1	2
261	142	1.015	0	0	0	2
264	142	1.005	0	0	0	4
265	142	1.020	0	0	4	0
266	142	1.005	0	0	2	2
272	142	1.016	0	0	1	4

FCE 20124/702 i

121

Treatment Group "C"

Day 14 (Period 142)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	80	8
Hematocrit (HCT)	80	11
Red Blood Cells (RBC)	80	19
White Blood Cells (WBC)	80	7
Neutrophils (NEUTS)	80	20
Lymphocytes (LYMPS)	80	29
Eosinophils (EOSIN)	80	26
Monocytes (MONOS)	80	15
Basophils (BASOS)	80	7
Platelets (PLATES)	80	4
Sodium (NA+)	80	4
Phosphorous (K+)	80	3
Chlorine (CL-)	80	14
Calcium (CA++)	80	12
Aspartate Aminotransferase (SGOT)	80	2
Alanine Aminotransferase (SGPT)	80	8
γ-GT (YGT)	80	14
Blood Sugar (BLSUG)	80	3
Phosphorous (PO4)	80	4
Alkaline Phosphatase (ALKPHOS)	79	3
Urea Nitrogen (BUN)	80	5
Creatinine (CREAT)	80	4
Uric Acid (URACID)	80	10
Total Bilirubin (TOTBILI)	80	2
Direct Bilirubin (DIRBILI)	80	13
Total Protein (TOTPROT)	80	8
Albumin (BLALB)	80	17
Cholesterol (CHOLE)	80	9
Triglycerides (TRIGLY)	79	11
Globulins - α1 (GLOBα1)	80	15
Globulins - α2 (GLOBα2)	80	12
Globulins - β (GLOBβ)	80	21
Globulins - γ (GLOBγ)	80	15
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	77	7
Albumin (URALB)	77	0
Sugar (URSUG)	77	0
Red Blood Cells (URRBC)	77	1
White Blood Cells (URWBC)	77	4

FCE 20124/702 i

122

\* = Value out-of-range

Day 28 (Period 282)

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
3	282	13.60	41.10	4.61	6.70	55.00	35.00	2.00	8.00
6	282	13.00	39.20	4.12	8.80*	57.00	39.00	.00*	3.00
8	282	15.00	44.30	4.21	6.60	48.00*	38.00	7.00*	6.00
16	282	15.30	45.60	5.03*	5.40	50.00	29.00	12.00*	8.00
18	282	14.80	42.80	4.74	7.30	47.00*	44.00*	1.00	8.00
26	282	14.40*	43.00	4.90	6.80	69.00	27.00	3.00	1.00
27	282	14.10	40.00	4.60	5.50	66.00	26.00	4.00	3.00
33	282	14.00	39.00	4.80	7.80	68.00	28.00	2.00	2.00
36	282	14.60*	44.20	4.60	6.60	68.00	30.00*	1.00	.00*
39	282	14.00	41.00	4.60	5.80	68.00	28.00	1.00	3.00
40	282	14.60	43.00	5.30	6.00	69.00	27.00	2.00	2.00
43	282	14.10	43.00	4.50	5.20	68.00	26.00	3.00	3.00
46	282	15.50	43.80	4.90	6.80	68.00	28.00	2.00	1.00
52	282	8.60	.42	4.30	3.60*	58.00*	37.00	1.00	2.00
53	282	9.70	.46	4.80	7.60	71.00	26.00	1.00	2.00
58	282	8.90	.46	5.00	6.10	70.00	24.00	2.00	3.00
59	282	9.10	.47	5.30	6.10	56.00*	38.00	2.00	3.00
62	282	8.50	.47	5.10	6.90	65.00	30.00	1.00	3.00
63	282	8.80	.49	4.90	6.10	70.00	26.00	1.00	3.00
69	282	8.70	.47	5.20	6.80	71.00	24.00	1.00	3.00
71	282	8.90	.48	5.70*	6.80	70.00	26.00	1.00	3.00
76	282	16.90	52.00	5.40	11.90*	59.90	23.00	3.40	9.30*
81	282	15.00	46.20	4.60	12.10*	66.60	22.80	1.80	5.90
82	282	16.00	49.20	5.20	11.40*	51.00	36.20	5.50	5.30
86	282	16.30	44.90	5.06	5.19	43.40	44.60	2.30	6.20
89	282	13.00	41.40	4.35	7.96	64.80	25.60	1.50	4.10
92	282	14.40	41.00	4.62	6.90	64.00	30.00	1.00	5.00
97	282	16.30	43.10	5.02	6.70	63.00	32.00	3.00	2.00
100	282	12.90	35.60*	4.32	6.00	42.00	54.00*	4.00	.00*
104	282	14.90	40.70	4.60	8.70	38.00*	58.00*	2.00	2.00
111	282	15.80	41.90*	4.75	6.70	40.00	57.00*	3.00	.00*
112	282	17.30	43.30	4.56*	8.10	62.00	30.00	3.00	5.00
116	282	12.90	35.00*	3.75	5.50	66.00	34.00	.00*	.00*
117	282	17.20	43.20	4.56*	7.90	62.00	37.00	.00*	1.00*
121	282	11.50*	36.00*	4.30	5.00	58.00*	52.00*	.00	.00*
125	282	16.60*	52.00*	5.72*	6.40	62.00	37.00*	1.00	.00*
128	282	14.00	44.00	4.80	5.00	53.00*	40.00*	.00	.00*
129	282	15.30	48.00	5.28	5.00	50.00*	30.00	2.00	.00*
137	282	13.60	42.00	4.62	6.60	60.00	40.00*	.00	.00*
138	282	13.70	42.00	4.62	6.10	54.00*	44.00*	.00	2.00*
141	282	16.70*	49.00	5.39	6.00	62.00	38.00*	.00	.00*
173	282	15.80	44.00	6.20*	6.40	60.00	30.00	4.00*	6.00
174	282	16.00	45.00	6.20	6.70	59.00	32.00	2.00	6.00
175	282	15.90	45.00	6.00*	7.20	59.00	32.00	2.00	6.00
178	282	16.10	46.00	6.10	7.20	61.00	30.00	2.00	6.00
182	282	16.00	44.00	5.90	6.10	60.00	30.00	3.00	6.00
183	282	16.10*	46.00	6.10*	7.10	60.00	30.00	3.00	7.00
190	282	15.90	44.00	6.00*	5.90	60.00	31.00	3.00	6.00
191	282	16.00	45.00	5.90	6.20	59.00	32.00	3.00	5.00
195	282	15.20	43.00	5.30	3.50*	56.00	33.00	3.00	3.00

FCE 20124/702 i

123

Pat. No.	Per. (dy)	HGB	HCT	RBC	WBC	NEUTS	LYMPS	EOSIN	MONOS
196	282	14.30	40.00	4.60	3.80*	56.00	34.00*	5.00*	3.00
201	282	12.50	42.00	4.70	4.90	54.00	36.00*	4.00*	3.00
204	282	14.10	46.00	5.10	6.80	52.00*	38.00*	6.00*	3.00
205	282	12.00	41.00	4.00*	7.00	55.00	36.00*	4.00*	4.00
207	282	15.30	48.00	5.90	8.40	52.00*	37.00*	6.00*	3.00
212	282	14.00	44.00	5.00	5.10	54.00	36.00*	3.00	7.00
213	282	13.20	43.00	5.00	8.00	51.00*	39.00*	3.00	7.00
220	282	15.00	45.00	4.35	4.95	44.00*	47.00*	3.00	6.00
221	282	12.38	38.50	4.48	6.00	52.00	37.00	1.00	10.00*
225	282	15.51	46.00	5.25	5.80	51.00	39.00	9.00*	1.00
229	282	12.15	37.00	4.75	5.80	66.00	30.00	2.00	2.00
234	282	15.32	47.00	5.25	8.10*	65.00	29.00	3.00	2.00
236	282	16.38*	50.00*	5.65*	8.70*	67.00	25.00	7.00*	1.00
239	282	12.56	38.00	4.49	7.30	53.00	40.00	5.00	2.00
241	282	15.90	44.00	7.00*	6.80	58.00	30.00	5.00*	6.00
242	282	15.90	44.00	6.00	5.90	60.00	30.00	3.00	7.00
250	282	14.50	45.00	5.20	7.20	54.00	36.00*	6.00*	3.00
252	282	14.50	45.00	5.80	7.10	52.00*	38.00*	6.00*	2.00*
253	282	13.10*	39.00*	5.40	6.10	56.00	34.00*	4.00*	3.00
256	282	14.50	39.00*	5.00	4.70*	56.00	34.00*	2.00	7.00
261	282	16.00	44.00	6.10	5.60	54.00	36.00*	5.00*	3.00
264	282	16.10	44.00	5.90	6.20	53.00*	37.00*	5.00*	4.00
265	282	16.00	44.00	6.10	5.70	51.00*	39.00*	5.00*	3.00
266	282	15.80	44.00	5.90*	6.40	58.00	32.00	5.00*	3.00
272	282	12.00	40.00	4.80	5.80	56.00	34.00*	4.00*	4.00

Anhang: Dokumentation der Stellungnahmen zum Vorbericht A05-20C. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

FCE 20124/702 i

124

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
3	282	.00	198.00	141.00	4.40	104.00	2.20	9.00	6.00	5.00
6	282	1.00	404.00*	142.00	4.30	104.00	2.38	10.00	10.00	7.00
8	282	1.00	246.00	138.00	1.19*	98.00	2.22	8.00	6.00	22.00
16	282	1.00	242.00	143.00*	4.00	102.00	2.36	12.00	19.00	24.00
18	282	.00	272.00	143.00*	4.20	103.00	2.36	7.00	9.00	16.00
26	282	.00	210.00	146.00	4.00	100.20	2.10	10.00	12.00	10.00
27	282	1.00	230.00	140.00	3.90	101.00	2.00*	12.00	14.00	14.00
33	282	.00	225.00	144.00	4.00	106.00	2.20	8.00	8.00	10.00
36	282	1.00	186.00	146.00	4.20	102.00	1.80*	6.00	8.00	12.00
39	282	.00	142.00*	143.00	4.00	102.00	2.00*	10.00	10.00	12.00
40	282	.00	218.00	144.00	4.20	101.00	2.00*	10.00	12.00	16.00
43	282	.00	230.00	142.00	3.90	101.00	2.10	12.00	14.00	14.00
46	282	1.00	210.00	146.00	4.60	104.00	2.30	8.00	10.00	15.00
52	282	2.00*	191.00	142.00	3.90	101.00	2.30	10.00	9.00	8.00
53	282	.00	199.00	143.00	3.90	101.00	2.10	14.00	12.00	21.00
58	282	1.00	164.00	141.00	3.90	98.00	3.10*	13.00	12.00	34.00*
59	282	1.00	167.00	141.00	4.00	99.00	2.60	14.00	15.00	30.00*
62	282	1.00	215.00	138.00	3.90	102.00	2.60	14.00	12.00	32.00*
63	282	.00	181.00	141.00	4.00	101.00	2.40	12.00	9.00	31.00*
69	282	1.00	213.00	139.00	4.10	103.00	2.30	10.00	8.00	26.00
71	282	.00	215.00	141.00	3.90	103.00	2.40	10.00	8.00	28.00
76	282	1.30	312.00	150.00	5.10	106.00	10.50*	24.00	75.00*	28.00
81	282	1.00	334.00	137.00	4.30	101.00	11.30*	13.00	14.00	7.00
82	282	.00	250.00	139.00	4.30	107.00	9.50	26.00	39.00	25.00
86	282	1.70*	232.00	143.00	4.50	101.00	8.00*	17.00	21.00	16.00
89	282	.90	139.80	142.00	5.10	107.00	9.20	14.00	14.00	10.00
92	282	.00	.	144.00	4.30	.	.	18.00	23.00	21.00
97	282	.00	134.00*	138.00	3.90	98.00	9.80	20.00	38.00	36.00
100	282	.00	265.00	136.00	3.70	101.00	8.10	18.00	14.00	10.00
104	282	.00	410.00*	150.00	4.99	114.70*	9.20	32.00	42.00	37.00*
111	282	.00	236.00	147.80	4.30	111.20*	9.00	17.00	14.00	11.00
112	282	.00	250.00	162.70*	5.50	113.60*	9.90	42.00*	78.00*	38.00
116	282	.00	176.00	131.50*	3.80	110.90*	8.60	34.00	39.00	15.00
117	282	.00	253.00	162.00*	5.50*	113.00*	9.90	43.00*	56.00*	39.00
121	282	.00	204.00	142.00	4.00	335.00	10.00	32.00*	37.00	12.00
125	282	.00	252.00	143.00	3.70	367.00	9.30	43.00*	93.00*	22.00
128	282	.00	285.00	143.00	4.20	348.00	9.70	10.00	10.00	11.00
129	282	.00	332.00	136.00	4.20	347.00	9.80	16.00	10.00	11.00
137	282	.00	332.00	141.00	4.00	358.00	10.10	10.00	12.00	14.00
138	282	.00	206.00	133.00*	3.50*	360.00	10.20	22.00	22.00	.
141	282	.00	250.00	132.00*	3.80	352.00	10.30	20.00	25.00	16.00
173	282	.00	275.00	138.00	4.70	96.00	8.50*	39.00	9.30	8.10*
174	282	1.00	275.00	138.00	5.10	97.00	9.00	38.00	9.70	8.10*
175	282	1.00	280.00	139.00	4.90	100.00	9.00	37.00	9.90	8.20
178	282	1.00	275.00	139.00	5.20	97.00	9.10	37.00	9.70	8.20*
182	282	1.00	270.00	140.00	5.00	98.00	9.10	38.00	9.90	8.10*
183	282	.00	280.00	138.00	5.10	97.00	9.00	38.00	9.90	8.00
190	282	.00	275.00	138.00	5.10	97.00	9.00	38.00	9.90	8.00
191	282	1.00	275.00	142.00	5.00	98.00	9.10	38.00	9.90	8.10*
195	282	4.00*	268.00	143.00	5.00	98.00	9.10	28.00	19.00	29.00
196	282	2.00*	268.00	138.00	4.50	95.00	8.80	18.00	28.00	98.00
201	282	3.00*	245.00	130.00*	4.80	105.00	9.50	33.00	26.00	36.00
204	282	1.00	281.00	138.00	4.90	100.00	9.90	37.00	32.00	30.00
205	282	2.00*	229.00	140.00	4.00	110.00*	8.80	40.00	35.00	28.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

125

Pat. No.	Per. (dy)	BASOS	PLATES	NA+	K	CL-	CA++	SGOT	SGPT	YGT
207	282	2.00*	162.00	148.00	5.10	100.00	10.00	48.00	36.00	22.00
212	282	.00	301.00	138.00	4.20	99.00	10.10	29.00	26.00	28.00
213	282	.00	310.00	130.00*	4.00	97.00	8.10*	30.00	32.00	30.00
220	282	.00	466.00*	141.00	4.10	101.70	8.40*	8.00	15.00	34.00*
221	282	.00	380.00	149.00*	4.40	104.80	9.10	8.00	6.00	21.00
225	282	.00	300.00	136.00	3.90	100.00	8.90	21.00*	5.00	15.00
229	282	.00	290.00	134.00*	4.30	91.00*	9.90	18.00	6.00	27.00
234	282	1.00	385.00	138.00	4.50	92.00*	10.18	15.00	9.00	26.00
236	282	.00	310.00	150.00*	4.20	95.00*	8.94	20.00	8.00	4.00
239	282	.00	310.00	136.00	4.20	98.00	9.16	19.00	9.00	15.00
241	282	1.00	275.50	150.00	4.50	95.00	9.00	38.00	12.10	21.00
242	282	.00	275.00	140.00	4.90	99.00	9.20	39.00	10.00	8.10*
250	282	1.00	272.00	139.00	5.20	106.00*	8.20*	42.00	32.00	28.00
252	282	2.00*	290.00	137.00	5.00	105.00	8.60	38.00	28.00	28.00
253	282	3.00*	301.00	141.00	5.70*	99.00	9.50	30.00	31.00	29.00
256	282	1.00	260.00	140.00	4.60	98.00	8.80	34.00	32.00	20.00
261	282	2.00*	181.00	144.00	5.20	110.00*	3.90*	29.00	25.00	32.00
264	282	1.00	231.00	143.00	4.90	105.00	8.30*	29.00	20.00	32.00
265	282	2.00*	174.00	146.00	5.10	97.00	8.70	42.00	30.00*	25.00
266	282	2.00*	251.00	138.00	5.40*	105.00	4.00*	36.00	33.00*	36.00
272	282	2.00*	180.00	146.00	5.10	102.00	3.60*	27.00	23.00	31.00

FCE 20124/702 i

126

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
3	282	4.62	.90	106.00	4.90	86.00	.14*	7.00	1.40
6	282	4.83	1.99*	62.00	7.00*	76.00	.17	5.00	1.20
8	282	3.95	1.19	83.00	4.10	75.00	.27	5.00	1.00
16	282	5.04	1.03	97.00	4.20	105.00*	.24	7.00	1.90
18	282	4.72	1.31	115.00	5.30	94.00	.27	9.00	1.90
26	282	4.00	1.50	180.00	5.20	80.00	288.00	10.00	.00
27	282	3.90	1.00	137.00	5.30	66.00	276.00	12.00	.00
33	282	4.60	1.10	118.00	4.60	76.00	270.00	10.00	.00
36	282	4.60	1.00	102.00	5.00	60.00	220.00	10.00	.00
39	282	4.60	1.20	104.00	5.60	60.00	210.00	10.00	.00
40	282	4.10	1.20	164.00	5.60	70.00	271.00	12.00	.00
43	282	3.80	1.10	120.00	5.10	65.00	260.00	12.00	.00
46	282	4.80	1.30	150.00	4.80	60.00	280.00	10.00	.00
52	282	4.10	1.06	25.00	6.00	100.00*	124.00*	18.00*	.00
53	282	4.00	.80*	31.00	5.00	82.00	124.00*	14.00	.00
58	282	5.10	1.00	27.00	6.00	87.00	161.00	13.00	.00
59	282	5.10	1.00	31.00	8.00	89.00	150.00	14.00	.00
62	282	4.00	.90	24.00	4.00	70.00	157.00	10.00	.00
63	282	4.10	1.10	27.00	3.00	67.00	161.00	7.00	.00
69	282	4.10	1.10	22.00	4.00	69.00	161.00	8.00	.00
71	282	4.10	1.10	27.00	5.00	71.00	161.00	8.00	.00
76	282	69.00*	4.80*	96.00	10.90	1.10	4.60	.50	.30
81	282	81.00	4.50	71.00	16.80	.90	5.70	.30	.20
82	282	74.00	3.90	119.00*	20.10	1.20	8.50*	.50	.30
86	282	54.00*	3.10	57.00	14.00	1.00	9.40*	.60	.30
89	282	76.00	3.90	72.00	14.10	.90	2.80*	.60	.10
92	282	94.00	.	142.00*	46.00*	.82	.	.45	.14
97	282	87.00	2.70	170.00	14.00	.70	4.10	.71	.20
100	282	80.00	3.30	220.00	39.00	.60	4.80	.59	.10
104	282	73.00	3.40	189.00	27.00	.50	4.10	.55	.10
111	282	71.00	3.50	166.00	35.00	.80	3.80	.38	.04
112	282	91.00	3.60	275.00	34.00	.90	4.00	.68	.07
116	282	70.00	3.10	170.00	43.00	.70	2.90	.60	.07
117	282	91.00	3.70	274.00	34.00	.80	4.10	.69	.07
121	282	84.00	3.60	170.00*	39.00	1.00	2.80	.70	.30*
125	282	78.00	4.00	116.00*	23.00	.90	7.20	.60	.20*
128	282	90.00	3.60	80.00	26.00	.90	3.90	.70	.30*
129	282	80.00	3.60	54.00	26.00	.80	2.20	.50*	.30*
137	282	92.00	3.90	67.00	29.00	.80	4.60	.70	.40
138	282	93.00	3.00	.	23.00	1.10	4.60	.80	.30*
141	282	93.00	3.30	103.00*	19.00*	.70*	5.40	.80	.30*
173	282	97.00	3.60	175.00	11.00	1.10	5.10	.70	.40
174	282	97.00	4.10	172.00	11.10	1.10	5.20	.70	.40
175	282	96.00	4.00	172.00	11.10	1.10	5.40	.80	.50
178	282	96.00	4.00	170.00	11.00	.90	5.20	.70	.40
182	282	99.00	3.90	170.00	11.10	1.00	5.40	.80	.40
183	282	96.00	4.00	177.00	11.10	1.10	5.60	.70	.40
190	282	97.00	4.00	172.00	11.10	.99	5.50	.70	.40
191	282	99.00	3.90	170.00	11.10	1.10	5.60	.70	.40
195	282	97.00	3.70	133.00	11.20	.78	4.80	.80	.40
196	282	100.00	2.80	124.00	11.20	.68	4.80	.90	.20
201	282	100.00	3.70	120.00	18.00	.70	4.90	.40	.40
204	282	105.00	3.80	128.00	18.00	.70	5.90	.70	.30
205	282	90.00	3.90	130.00	20.00	.75	5.20	.80	.40

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

127

Pat. No.	Per. (dy)	BLSUG	PO4	ALKPHOS	BUN	CREAT	URACID	TOTBILI	DIRBILI
207	282	110.00	4.20	125.00	15.00	.90	4.80	.90	.40
212	282	95.00	3.60	120.00	19.00	.70	4.30	.60	.40
213	282	100.00	4.00	115.00	15.00	.80	4.30	.60	.50
220	282	5.88	3.20	45.09	25.00	49.50	6.50	8.89	3.59*
221	282	5.11	3.90	29.22	38.00	72.48	6.30	5.47	2.05
225	282	4.84	2.90	47.92	20.00	97.24	5.80	21.37*	4.27*
229	282	5.00	2.90	28.00	18.00	92.82	4.60	11.60	5.13*
234	282	4.62	4.10	25.82	22.50	92.82	4.50	9.40	4.27*
236	282	4.73	2.66	40.91	27.00	88.40	5.10	12.82	4.27*
239	282	4.67	4.43	40.08	26.00	92.82	5.30	15.39	3.42
241	282	87.00	3.60	135.00	12.10	1.10	4.80	.80	.40
242	282	87.00	3.90	170.00	11.10	1.00	5.20	.70	.40
250	282	110.00	3.90	108.00	15.00	.86	5.00	.90	.20
252	282	98.00	3.90	120.00	11.20	.80	5.00	.80	.20
253	282	100.00	3.90	115.00	19.00	.80	5.10	.70	.20
256	282	102.00	3.80	127.00	11.00	.80	4.90	.80	.30
261	282	98.00	2.70	131.00	12.00	1.10	5.20	.80	.20
264	282	100.00	3.60	127.00	11.20	.77	4.90	.90	.10
265	282	98.00	5.30*	123.00	18.00	.77	4.80	.80	.20
266	282	95.00	3.70	128.00	16.00	.75	5.40	.90	.10
272	282	105.00	3.80	134.00	16.00	1.10	5.40	.80	.20

FCE 20124/702 i

128

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLE	TRIGLY	GLOBAL1	GLOBAL2	GLOBETA	GLOGAMA
3	282	60.00	37.60*	4.50	.94	1.90	4.50*	6.60*	9.40*
6	282	63.00	39.20*	5.90	3.82*	2.20	6.90	7.30*	7.40*
8	282	62.00	39.40*	5.00	1.35	2.10	5.60*	7.60*	7.30*
16	282	73.00	45.50*	6.50	.72	2.20	5.40*	9.00	10.90*
18	282	65.00	40.90*	4.00	1.01	1.80	6.20	7.10*	9.00*
26	282	71.00	39.00	4.00	.80	3.50	8.60	13.80*	14.80
27	282	71.00	37.00	4.70	1.20	3.00	7.00	10.00	11.80*
33	282	70.00	42.00	3.90	.90	1.20*	8.10	9.00	14.80
36	282	74.00	37.00	4.30	1.10	4.30*	7.00	12.20*	14.80
39	282	72.00	38.00	.80*	2.40*	3.00	6.80	9.20	14.20
40	282	71.00	38.00	5.00	1.30	3.00	7.80	11.00	14.00
43	282	72.00	38.00	4.10	1.00	3.30	8.00	11.20	14.00
46	282	78.00	42.00	5.00	1.10	3.60	7.80	9.80	14.00
52	282	68.00	44.00	5.00	.70*	1.90*	5.10*	5.70*	11.20*
53	282	77.00	52.00*	4.90	1.40	2.90	5.40*	4.90*	12.10*
58	282	72.00	41.00	5.20	1.20	2.30*	6.80	8.70	13.00
59	282	79.00	45.00	5.30	1.10	3.30	7.70	8.90	14.00
62	282	68.00	45.00	4.80	1.50	2.70	8.10	8.70	14.50
63	282	71.00	46.00	5.00	1.80	3.00	8.70	8.90	14.10
69	282	72.00	48.00	5.00	1.80	2.90	6.90	8.70	14.20
71	282	75.00	47.00	5.10	1.70	2.90	6.90	8.40	14.60
76	282	7.70	4.80	328.00*	266.00*	2.70	11.40	16.43*	15.50
81	282	7.60	4.80	269.00*	114.00	3.49	13.49	14.61	13.84
82	282	7.70	4.50	245.00*	183.00*	3.38	9.39	13.90	18.30
86	282	6.80	4.40	244.00*	326.00*	2.29*	8.25	11.56	14.92
89	282	6.90	4.40	251.00*	108.00	2.63	9.76	12.37	15.07
92	282	7.23	4.74	.	.	3.50	8.50	8.60	13.80
97	282	7.80	67.70	165.00	208.00*	2.30*	7.80	12.40	9.60*
100	282	7.50	51.60*	270.00*	172.00	2.50	9.00	13.50	23.40*
104	282	8.40	60.60	184.00	147.00	2.90	8.60	10.50	17.50
111	282	6.39	59.80	210.00	156.00	3.60	9.20	14.50*	12.80
112	282	8.20	61.70	193.00	125.00	3.40	11.20	13.60	10.20
116	282	6.30	58.70	193.00	115.00	2.90	10.20	15.00*	13.30
117	282	8.00	53.60*	164.00	126.00	4.60*	12.30*	13.50	17.60
121	282	7.10	4.10	245.00	127.00	2.40*	8.20*	12.00	15.10
125	282	8.30	5.20*	186.00	151.00	2.30*	6.80*	8.00	12.10
128	282	8.30	4.50	280.00	700.00*	1.80*	9.80	8.70	8.30*
129	282	8.00	5.10*	201.00	224.00*	1.60*	8.40*	6.50*	10.30
137	282	6.80	4.20	196.00	118.00	.80*	10.90	8.80	7.90*
138	282	8.60*	4.60	239.00	150.00	2.60	12.70	13.40*	12.80
141	282	8.70*	5.10*	131.00	146.00	1.60*	7.00*	9.60	17.10
173	282	6.80	4.10	190.00	89.00	.31	.72	.91	1.30
174	282	6.80	4.70	190.00	92.00	.41*	.71	.91	1.20
175	282	8.70*	4.70	192.00	88.00	.35	.72	.96	1.30
178	282	8.80*	4.70	195.00	85.00	.40	.70	.90	1.40
182	282	8.80*	4.70	195.00	90.00	.41*	.72	.98	1.20
183	282	6.80	4.60	190.00	89.00	.40	.70	.90	1.30
190	282	8.80*	4.50	190.00	87.00	.41*	.72	.98	1.20
191	282	8.70*	4.70	190.00	87.00	.35	.72	.98	1.30
195	282	6.90	4.50	180.00	98.00	.40	.80	.80	1.60
196	282	6.10*	4.80	160.00	100.00	.30	.70	.80	1.20
201	282	6.80	4.80	250.00	145.00	.30	.90	.80	1.30
204	282	7.80	4.60	198.00	148.00	.20	.60	.70	.90
205	282	6.50	5.20	230.00	132.00	.60*	.40	.90	1.00

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

129

Pat. No.	Per. (dy)	TOTPROT	BLALB	CHOLES	TRIGLY	GLOBAL	GLOBA2	GLOBETA	GLOGAMA
207	282	8.20	5.20	251.00	145.00	.40	.80	.90	1.60
212	282	7.00	4.60	155.00	125.00	.40	.80	1.10	1.30
213	282	6.00*	5.00	150.00	105.00	.30	.60	.80	1.00
220	282	7.80	4.43	6.03	230.00*	.21	.63	1.05	1.48*
221	282	6.90	4.24	6.50	93.00	.17*	.79	.90	.80
225	282	6.70	4.03	4.04	130.00	.13*	.54*	.83	1.17
229	282	7.00	3.84	4.55	146.00	.19*	.61	.99	1.37*
234	282	7.60	4.54	5.66	108.00	.23	.76	1.01	1.06
236	282	8.00	4.84	4.75	114.00	.19*	.70	1.05	1.22
239	282	8.00	3.97	5.59	120.00	.18*	.72	1.08	2.05*
241	282	7.60	4.20	175.00	80.00	.31	.72	1.10	1.40
242	282	7.20	4.20	178.00	79.00	.35	.71	1.00	1.40
250	282	6.90	5.10	178.00	105.00	.30	.80	.80	1.10
252	282	6.90	6.40*	200.00	135.00	.20	.80	.70	.60*
253	282	8.00	6.00*	156.00	105.00	.30	.80	.90	1.00
256	282	8.00	4.30	175.00	100.00	.40	.60	.90	.90
261	282	6.80	4.30	178.00	98.00	.30	.80	.90	1.00
264	282	6.70	4.10	130.00*	98.00	.40	.60	.70	1.20
265	282	6.70	3.90	242.00	136.00	.39	.70	.80	1.10
266	282	6.70	4.00	212.00	124.00	.30	.70	.70	1.00
272	282	6.70	4.20	175.00	100.00	.40	.80	.80	1.10

FCE 20124/702 i

130

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
26	282	1.022	0	0	0	0
27	282	1.025	0	0	0	0
33	282	1.022	0	0	0	0
36	282	1.020	0	0	0	0
39	282	1.024	0	0	0	0
40	282	1.024	0	0	0	0
43	282	1.022	0	0	0	0
46	282	1.024	0	0	0	0
52	282	1.021	0	0	0	0
53	282	1.030	0	0	0	0
58	282	1.027	0	0	0	0
59	282	1.029	0	0	0	0
62	282	1.021	0	0	0	0
63	282	1.021	0	0	0	0
69	282	1.018	0	0	0	0
71	282	1.024	0	0	0	0
76	282	1.025*	3*	0	0	0
81	282	1.015	0	0	0	0
82	282	1.023*	0	0	0	0
86	282	1.015	0	0	0	0
92	282	1.023*	0	0	0	0
97	282	1.010	0	0	0	0
100	282	1.008	0	0	0	0
104	282	1.012	0	0	0	0
111	282	1.020	0	0	0	0
112	282	1.027	0	0	0	0
116	282	1.016	0	0	0	0
117	282	1.027	0	0	0	0
121	282	1.020	0	0	0	3
125	282	1.020	0	0	0	2
128	282	1.020	0	0	0	1
129	282	1.010	0	0	1	8*
137	282	1.020	0	0	5*	2
138	282	1.028	0	0	13*	4
141	282	1.026	0	0	1	2
173	282	1.020	0	0	0	4
174	282	1.020	0	0	0	4
175	282	1.010	0	0	2	2
178	282	1.015	0	0	0	2
182	282	1.015	0	0	0	2
183	282	1.012	0	0	2	2
190	282	1.015	0	0	2	4
191	282	1.020	0	0	0	2
195	282	1.016	0	0	2	0
201	282	1.018	0	0	2	4
204	282	1.018	0	0	1	3
205	282	1.018	0	0	1	4
207	282	1.018	0	0	1	5
212	282	1.016	0	0	1	2
213	282	1.020	0	0	1	3
220	282	1.015	0	0	2	3
221	282	1.010*	0	0	0	30*
225	282	1.016	0	0	0	3
229	282	1.008*	0	0	1	2

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

131

Pat. No.	Per. (dy)	SPEGRAV	URALB	URSUG	URRBC	URWBC
234	282	1.009*	0	0	0	1
236	282	1.014*	0	0	0	3
239	282	1.012*	0	0	0	1
241	282	1.010	0	0	0	4
242	282	1.015	0	0	0	2
250	282	1.020	0	0	1	4
252	282	1.020	0	0	1	3
253	282	1.016	0	0	1	2
256	282	1.018	0	0	0	1
261	282	1.012	0	0	0	4
264	282	1.012	0	0	0	4
265	282	1.005	0	0	0	2
266	282	1.012	0	0	2	4
272	282	1.018	0	0	1	5

FCE 20124/702 i

132

Treatment Group "C"

Day 28 (Period 282)

<u>Test</u>	<u>Total No. of Observations</u>	<u>Total No. of Out of Range Observations</u>
<u>BLOOD TESTS</u>		
Hemoglobin (HGB)	75	8
Hematocrit (HCT)	75	8
Red Blood Cells (RBC)	75	13
White Blood Cells (WBC)	75	10
Neutrophils (NEUTS)	75	16
Lymphocytes (LYMPS)	75	27
Eosinophils (EOSIN)	75	22
Monocytes (MONOS)	75	15
Basophils (BASOS)	75	13
Platelets (PLATES)	74	5
Sodium (NA+)	75	12
Phosphorous (K+)	75	5
Chlorine (CL-)	74	11
Calcium (CA++)	74	16
Aspartate		
Aminotransferase (SGOT)	75	5
Alanine		
Aminotransferase (SGPT)	75	6
γ-GT (YGT)	74	12
Blood Sugar (ELSUG)	75	2
Phosphorous (PO4)	74	4
Alkaline		
Phosphatase (ALKPHOS)	74	5
Urea Nitrogen (BUN)	75	3
Creatinine (CREAT)	75	3
Uric Acid (URACID)	74	6
Total Bilirubin (TOTBILI)	75	3
Direct Bilirubin (DIRBILI)	75	11
Total Protein (TOTPROT)	75	9
Albumin (BLALB)	75	13
Cholesterol (CHOLE)	74	8
Triglycerides (TRIGLY)	74	10
Globulins - α1 (GLOBAL)	75	22
Globulins - α2 (GLOBA2)	75	11
Globulins - β (GLOBETA)	75	13
Globulins - γ (GLOGAMA)	75	16
<u>URNALYSIS</u>		
Specific Gravity (SPECGRAV)	72	8
Albumin (URALB)	72	1
Sugar (URSUG)	72	0
Red Blood Cells (URRBC)	72	2
White Blood Cells (URWBC)	72	2

638

FCE 20124/702 i

table 5f - cont.

REBOXETINE, Protocol ADE 08

CENTER N. 1 - FRANCE

RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	13 - 17	g/dl
HCT	38 - 52	%
RBC	4.0 - 5.5	x 10 <sup>6</sup> /ml
WBC	4 - 8	x 10 <sup>3</sup> /ml
NEUTROPHILS	50 - 70	%
LYMPHOCYTES	20 - 40	%
EOSINOPHILS	1 - 3	%
MONOCYTES	3 - 9	%
BASOPHILS	< 1	%
PLATELETS	150 - 350	x 10 <sup>3</sup> /ml
NA +	136 - 142	m mol/l
K +	4.0 - 4.5	m mol/l
CL -	90 - 111	m mol/l
CA ++	2.1 - 2.65	mEq/l
PO4	0.8 - 1.45	m mol/l
SGOT	5 - 17	U/l
SGPT	5 - 23	U/l
γ GT	4 - 18 females 6 - 28 males	U/l
BLOOD SUGAR	2.8 - 5.5	m mol/l
ALKALINE PHOSPHATASE	40 - 190	U/l
BUN	3.0 - 6.7	m mol/l
CREATININE	44 - 97	micro mol/l
URIC ACID	0.15 - 0.42	m mol/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

CENTER N. 1

RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
TOTAL BILIRUBIN	..... < 17	micro mol/l
DIRECT BILIRUBIN	..... < 4.3	micro mol/l
TOTAL PROTEIN	..... 60 - 80	g/l
BLOOD ALBUMIN	..... 58 - 66	%
GLOBULINS $\alpha$ 1	.....0.5 - 4.5	%
$\alpha$ 2	..... 6 - 10	%
$\beta$	..... 8 - 12	%
$\gamma$	.....11.5-18.5	%
T 3	..... 4 - 8	p mol/l
T 4	..... 10 - 25	p mol/l
CHOLESTEROL	.....3.9 - 6.5	m mol/l
TRIGLYCERIDES	.....0.41-1.88	m mol/l



FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 2 - HUNGARY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 15 females 14.7 - 17 males	g/dl
HCT	0.37 - 0.48	
RBC	4.5 - 5.0 females 4.5 - 5.5 males	$\times 10^6/\text{ml}$
WBC	5 - 10	$\times 10^3/\text{ml}$
NEUTROPHILS	60 - 75	%
LYMPHOCYTES	20 - 28	%
EOSINOPHILS	1 - 4	%
MONOCYTES	1 - 8	%
BASOPHILS	> 1	%
PLATELETS	150 - 300	$\times 10^3/\text{ml}$
NA +	135 - 146	m mol/l
K +	3.8 - 5.2	m mol/l
CL -	95 - 108	m mol/l
CA ++	2.1 - 2.6	m Eq/l
PO4	0.8 - 1.6	m mol/l
SGOT	> 21 females > 25 males	U/l
SGPT	> 22 females > 29 males	U/l
$\gamma$ GT	5 - 25 females 8 - 38 males	U/l
BLOOD SUGAR	2.8 - 5.6	m mol/l
ALKALINE PHOSPHATASE	73 - 207	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 2 - HUNGARY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
BUN	2 - 9	m mol/l
CREATININE	60 - 100	micro mol/l
URIC ACID	200 - 420	micro mol/l
TOTAL BILIRUBIN	< 17	micro mol/l
DIRECT BILIRUBIN	0	micro mol/l
TOTAL PROTEIN	60 - 85	g/l
BLOOD ALBUMIN	35 - 48	g/l
GLOBULINS $\alpha$ 1	2.4 - 3.6	%
$\alpha$ 2	6.6 - 9.8	%
$\beta$	8.1 - 12.1	%
$\gamma$	12.6 - 18.8	%
T 3	0.85 - 1.2	(uptake)
T 4	80 - 160	m mol/l
CHOLESTEROL	3.9 - 6.5	m mol/l
TRIGLYCERIDES	0.81-7.0	m mol/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 3 - HUNGARY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	7.5 - 11.2	m mol/l
HCT	0.35 - 0.50	
RBC	4.0 - 5.5	$\times 10^6/\text{ml}$
WBC	4 - 9	$\times 10^3/\text{ml}$
NEUTROPHILS	60 - 75	%
LYMPHOCYTES	25 - 40	%
EOSINOPHILS	1 - 4	%
MONOCYTES	1 - 8	%
BASOPHILS	0 - 1	%
PLATELETS	150 - 300	$\times 10^3/\text{ml}$
NA +	138 - 148	m mol/l
K +	3.5 - 5.0	m mol/l
CL -	95 - 108	m mol/l
CA ++	2.1 - 2.7	m Eq/l
PO4	0.9 - 1.6	m mol/l
SGOT	< 18	U/l
SGPT	< 22	U/l
$\gamma$ GT	4 - 28	U/l
BLOOD SUGAR	3.89 - 5.55	m mol/l
ALKALINE PHOSPHATASE	20 - 48	U/l

FCE 20124/702 1

REBOXETINE, Protocol ADE 08  
 CENTER N. 3 - HUNGARY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
BUN	1.7 - 8.3	m mol/l
CREATININE	44 - 97	micro mol/l
URIC ACID	142 - 416	micro mol/l
TOTAL BILIRUBIN	< 17	micro mol/l
DIRECT BILIRUBIN	< 4.3	micro mol/l
TOTAL PROTEIN	60 - 80	g/l
BLOOD ALBUMIN	35 - 48	g/l
GLOBULINS $\alpha$ 1	2.4 - 3.6	%
$\alpha$ 2	6.6 - 8.8	%
$\beta$	8.1 - 12.1	%
$\gamma$	12.6 - 18.8	%
T 3	0.8 - 1.2	(uptake)
T 4	50 - 160	m mol/l
CHOLESTEROL	3.9 - 6.5	m mol/l
TRIGLYCERIDES	0.8 - 1.9	m mol/l

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

REBOXETINE, Protocol ADE 08  
 CENTER N. 4 - ITALY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 16 females 14 - 18 males	g/dl
HCT	37 - 47 females 42 - 52 males	%
RBC	4.2 - 5.4 females 4.7 - 6.1 males	$\times 10^6/\text{ml}$
WBC	4.8 - 10.8	$\times 10^3/\text{ml}$
NEUTROPHILS	40 - 74	%
LYMPHOCYTES	19 - 48	%
EOSINOPHILS	< 7	%
MONOCYTES	3.4 - 9.0	%
BASOPHILS	< 1.5	%
PLATELETS	130 - 400	$\times 10^3/\text{ml}$
NA +	130 - 150	m mol/l
K +	4 - 6	m mol/l
CL -	90 - 110	m mol/l
CA ++	8.1 - 10.4	mg/dl
PO4	2.7 - 4.5	mg/dl
SGOT	< 37	U/l
SGPT	< 40	U/l
$\gamma$ GT	8 - 28	U/l
BLOOD SUGAR	70 - 110	mg/dl
ALKALINE PHOSPHATASE	39 - 117	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
CENTER N. 4 - ITALY  
RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
BUN	5 - 21	mg/dl
CREATININE	0.6 - 1.2	mg/dl
URIC ACID	3.4 - 7.0	mg/dl
TOTAL BILIRUBIN	< 1	mg/dl
DIRECT BILIRUBIN	< 0.3	mg/dl
TOTAL PROTEIN	6.0 - 8.5	g/dl
BLOOD ALBUMIN	3.8 - 4.9	g/dl
GLOBULINS $\alpha$ 1	2.4 - 4.6	%
$\alpha$ 2	6.6 - 13.6	%
$\beta$	9.1 - 14.7	%
$\gamma$	9.0 - 20.6	%
T 3	86 - 187	ng/dl
T 4	4.5 - 12.5	micro g/dl
CHOLESTEROL	170 - 220	mg/dl
TRIGLYCERIDES	60 - 170	mg/dl

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 5 - ITALY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 16 females 14 - 18 males	g/dl
HCT	37 - 47 females 42 - 52 males	%
RBC	4.2 - 5.4 females 4.6 - 6.2 males	x 10 <sup>6</sup> /ml
WBC	4.8 - 10.8	x 10 <sup>3</sup> /ml
NEUTROPHILS	40 - 75	%
LYMPHOCYTES	20 - 45	%
EOSINOPHILS	1 - 6	%
MONOCYTES	2 - 10	%
BASOPHILS	< 1	%
PLATELETS	150 - 350	x 10 <sup>3</sup> /ml
NA +	135 - 153	m mol/l
K +	3.5 - 5.3	m mol/l
CL -	98 - 109	m mol/l
CA ++	8.1 - 10.4	mg/dl
PO4	2.5 - 5.0	mg/dl
SGOT	11 - 34	U/l
SGPT	8 - 45	U/l
γ GT	7 - 32 females 11 - 50 males	U/l
BLOOD SUGAR	60 - 110	mg/dl
ALKALINE PHOSPHATASE	98 - 279	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 5 - ITALY  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
UREA	10 - 50	mg/dl
CREATININE	0.5 - 1.0 females	mg/dl
	0.6 - 1.2 males	
URIC ACID	2.4 - 5.7	mg/dl
TOTAL BILIRUBIN	< 1	mg/dl
DIRECT BILIRUBIN	< 0.25	mg/dl
TOTAL PROTEIN	6.2 - 8.5	g/dl
BLOOD ALBUMIN	56 - 68	%
GLOBULINS $\alpha$ 1	2.4 - 4.5	%
	$\alpha$ 2 6.5 - 12.0	%
	$\beta$ 9 - 14	%
	$\gamma$ 10 - 18	%
T 3	120 - 220	ng/dl
T 4	5 - 13	micro g/dl
CHOLESTEROL	130 - 220	mg/dl
TRIGLYCERIDES	< 175	mg/dl

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

**REBOXETINE, Protocol ADE 08**  
**CENTER N. 6/7 - MEXICO**  
**RANGE OF NORMAL LABORATORY VALUES**

<b>TEST</b>		<b>UNITS</b>
HGB .....	12 - 16	g/dl
HCT .....	37 - 47	%
RBC .....	4.2 - 5.4	x 10 <sup>6</sup> /ml
WBC .....	4.8 - 10.8	x 10 <sup>3</sup> /ml
NEUTROPHILS .....	60 - 70	%
LYMPHOCYTES .....	20 - 35	%
EOSINOPHILS .....	< 2	%
MONOCYTES .....	< 3	%
BASOPHILS .....	< 0	%
PLATELETS .....	150 - 450	x 10 <sup>3</sup> /ml
NA + .....	135 - 145	mEq/l
K + .....	3.7 - 5.5	mEq/l
CL - .....	334 - 395	mg/dl
CA ++ .....	9.0 - 10.6	mg/dl
PO4 .....	2.0 - 4.7	mg/dl
SGOT .....	10 - 30	U/l
SGPT .....	6 - 37	U/l
γ GT .....	5 - 27	U/l
BLOOD SUGAR .....	76 - 115	mg/dl
ALKALINE PHOSPHATASE .....	36 - 92	U/l

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

CENTER N. 6/7 - MEXICO

RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
UREA	..... 20 - 40	mg/dl
CREATININE	..... 0.8 - 1.5	mg/dl
URIC ACID	..... 2.1 - 7.4	mg/dl
TOTAL BILIRUBIN	.....0.6 - 1.7	mg/dl
DIRECT BILIRUBIN	.....0.1 - 0.8	mg/dl
TOTAL PROTEIN	..... 6.4 - 8.4	g/dl
BLOOD ALBUMIN	.....3.8 - 5.0	g/dl
GLOBULINS $\alpha$ 1	.....2.5 - 4.5	%
$\alpha$ 2	..... 9 - 14	%
$\beta$	.....8 - 12	%
$\gamma$	.....10 - 18	%
T 3	..... 75 - 250	ng/dl
T 4	..... 6 - 12	micro g/dl
CHOLESTEROL	.....131 - 300	mg/dl
TRIGLYCERIDES	..... < 210	mg/dl

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 8 - PANAMA  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 16 females	g/dl
	14 - 18 males	
HCT	37 - 47 females	%
	42 - 52 males	
RBC	4.2 - 5.4 females	x 10 <sup>6</sup> /ml
	4.7 - 6.1 males	
WBC	4.8 - 10.8	x 10 <sup>3</sup> /ml
NEUTROPHILS	54 - 62	%
LYMPHOCYTES	25 - 33	%
EOSINOPHILS	1 - 3	%
MONOCYTES	3 - 7	%
BASOPHILS	< 1	%
PLATELETS	130 - 400	x 10 <sup>3</sup> /ml
NA +	135 - 153	mEq/l
K +	3.5 - 5.3	mEq/l
CL -	95 - 105	mEq/l
CA ++	8.8 - 10.3	mg/dl
PO <sub>4</sub>	2.5 - 4.9	mg/dl
SGOT	12 - 52	U/l
SGPT	3.7 - 29.4	U/l
γ GT	5 - 55 females	U/l
	15 - 65 males	
BLOOD SUGAR	70 - 110	mg/dl
ALKALINE PHOSPHATASE	79 - 258	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 8 - PANAMA  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
BUN	5 - 25	mg/dl
CREATININE	0.5 - 1.4	mg/dl
URIC ACID	2.4 - 6.0 females	mg/dl
	3.7 - 8.6 males	
TOTAL BILIRUBIN	0.1 - 1.0	mg/dl
DIRECT BILIRUBIN	< 0.5	mg/dl
TOTAL PROTEIN	6.3 - 8.5	g/dl
BLOOD ALBUMIN	3.5 - 5.5	g/dl
GLOBULINS $\alpha$ 1	0.2 - 0.4	g/dl
	$\alpha$ 2	g/dl
	0.5 - 0.9	
	$\beta$	g/dl
	0.6 - 1.1	
	$\gamma$	g/dl
	0.7 - 1.1	
T 3	44 - 194	ng/dl
T 4	4.5 - 11.5	micro g/dl
CHOLESTEROL	140.1 - 300.1	mg/dl
TRIGLYCERIDES	47 - 155	mg/dl

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 9 - PANAMA  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 16 females	g/dl
	14 - 18 males	
HCT	37 - 47 females	%
	42 - 52 males	
RBC	4.2 - 5.4 females	x 10 <sup>6</sup> /ml
	4.7 - 6.1 males	
WBC	4.8 - 10.8	x 10 <sup>3</sup> /ml
NEUTROPHILS	54 - 62	%
LYMPHOCYTES	25 - 33	%
EOSINOPHILS	1 - 3	%
MONOCYTES	3 - 7	%
BASOPHILS	< 1	%
PLATELETS	130 - 400	x 10 <sup>3</sup> /ml
NA +	135 - 153	m Eq/l
K +	3.5 - 5.3	m Eq/l
CL -	95 - 105	m Eq/l
CA ++	8.6 - 10.3	mg/dl
PO4	2.5 - 4.9	mg/dl
SGOT	12 - 52	U/l
SGPT	3 - 36	U/l
γ GT	5 - 55	U/l
BLOOD SUGAR	70 - 110	mg/dl
ALKALINE PHOSPHATASE	79 - 258	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

CENTER N. 9 - PANAMA

RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
BUN	5 - 25	mg/dl
CREATININE	0.5 - 1.4	mg/dl
URIC ACID	2.4 - 6.0 females	mg/dl
	3.7 - 8.6 males	
TOTAL BILIRUBIN	0.1 - 1.0	mg/dl
DIRECT BILIRUBIN	< 0.5	mg/dl
TOTAL PROTEIN	6.4 - 8.2	g/dl
BLOOD ALBUMIN	3.5 - 5.5	g/dl
GLOBULINS $\alpha$ 1	0.2 - 0.4	g/dl
	$\alpha$ 2	0.5 - 0.9
	$\beta$	0.6 - 1.1
	$\gamma$	0.7 - 1.7
T 3	44 - 194	ng/dl
T 4	4.5 - 11.5	micro g/dl
CHOLESTEROL	140.1 - 300.1	mg/dl
TRIGLYCERIDES	47 - 155	mg/dl

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

REBOXETINE, Protocol ADE 08

CENTER N. 10 - PERU

RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
HGB	12 - 15 females	g/dl
	13 - 16 males	
HCT	36 - 45 females	%
	39 - 49 males	
RBC	4.0 - 5.0 females	$\times 10^6/\text{ml}$
	4.5 - 5.5 males	
WBC	4 - 8	$\times 10^3/\text{ml}$
NEUTROPHILS	50 - 70	%
LYMPHOCYTES	20 - 40	%
EOSINOPHILS	< 5	%
MONOCYTES	< 6	%
BASOPHILS	< 1	%
PLATELETS	150 - 400	$\times 10^3/\text{ml}$
NA +	135 - 145	mEq/l
K +	3.5 - 5.6	mEq/l
CL -	96 - 106	mEq/l
CA ++	8.6 - 10.3	mg/dl
PO4	2.5 - 4.5	mg/dl
SGOT	4 - 20	U/l
SGPT	2 - 18	U/l
$\gamma$ GT	0 - 30 females	U/l
	0 - 45 males	
BLOOD SUGAR	4.4 - 8.05	m mol/l
ALKALINE PHOSPHATASE	13.36 - 50.1	U/l

FCE 20124/702 i

REBOXETINE, Protocol ADE 08  
 CENTER N. 10 - PERU  
 RANGE OF NORMAL LABORATORY VALUES

TEST		UNITS
UREA	20 - 45	mg/dl
CREATININE	44.2 - 106.08 females	micromol/l
	61.8 - 132.60 males	
URIC ACID	2.0 - 7.0 females	mg/dl
	2.6 - 8.0 males	
TOTAL BILIRUBIN	< 17.1	micromol/l
DIRECT BILIRUBIN	< 3.42	micromol/l
TOTAL PROTEIN	6 - 8	g/dl
BLOOD ALBUMIN	3.3 - 5.0	g/dl
GLOBULINS $\alpha$ 1	0.2 - 0.4	g/dl
	$\alpha$ 2	0.6 - 1.0
	$\beta$	0.6 - 1.2
	$\gamma$	0.7 - 1.3
T 3	0.25 - 2.1	ng/ml
T 4	4.2 - 12.1	micro g/dl
CHOLESTEROL	4.16 - 6.76	m mol/l
TRIGLYCERIDES	36 - 165	mg/dl



FCE 20124/702 1

REBOXETINE PROTOCOL 008

LABORATORY RANGE OF NORMAL VALUES

URINALYSIS ALL CENTERS

Spec.	1.010	-	1.030
Albumin			NEG.
Sugar			NEG.
RBC	0	-	5
WBC	0	-	5

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 6 - List of Signs and Symptoms

Treatment Group "A"

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
1	TACHYCARDIA	0	1	6	1 hr	Moderate	2	1	2
5	HYPOTENSION	0	1	9	4 hr	Moderate	0	1	0
50	HYPOTENSION	0	0	4	4 dy	Moderate	1	1	0
56	SKIN RASH	0	1	4	7 dy	Mild	1	1	0
73	METALLIC TASTE	0	0	12	4 dy	Moderate	1	1	0
79	CONSTIPATION	0	0	9	12 dy	Moderate	0	0	0
87	LASSITUDE	0	1	9	2 dy	Moderate	1	1	0
87	ELEVATED SGOT/SGPT	.	1	15	14 dy	Moderate	1	1	1
94	HYPOTENSION	1	1	14	15 dy	Moderate	1	1	1
99	DRY MOUTH	0	1	13	9 dy	Moderate	1	1	0
99	NAUSEA	0	1	14	8 dy	Mild	0	1	0
99	DULL MIND	0	1	20	8 dy	Severe	0	1	1
101	EXCITEMENT	0	1	20	1 dy	Mild	1	1	0
108	URINARY HESITANCY	0	1	4	5 min	Moderate	1	1	0
108	DRY MOUTH	0	1	7	22 dy	Severe	1	1	1
108	DIZZINESS	1	1	9	4 dy	Mild	0	1	0
108	HEADACHE	1	1	20	3 dy	Moderate	0	1	0
115	EXCITEMENT	1	1	22	7 dy	Mild	0	1	1
122	DRY MOUTH	1	2	3	20 min	Mild	1	1	0
122	CONSTIPATION	1	1	6	8 dy	Mild	1	1	0
122	VOMITING	0	1	6	.	Mild	0	1	0
122	BLURRED VISION	1	1	7	5 min	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry

<sup>2</sup> 0=Yes 1=No

<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain

<sup>4</sup> 0=Yes 1=No

<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
 2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
 4=Not tolerated

FCE 20124/702 i

2

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
123	INSOMNIA	0	1	2	12 dy	Mild	1	0	1
131	DRY MOUTH	1	1	1	26 dy	Mild	1	1	1
131	DIZZINESS	1	1	4	3 dy	Mild	1	1	1
134	EXCITEMENT	1	1	11	3 dy	Moderate	0	1	1
134	TACHYCARDIA	1	1	12	2 dy	Severe	1	1	1
135	HEADACHE	.	0	8	4 dy	Mild	.	.	.
142	DROWSINESS	1	1	22	6 dy	Mild	0	1	1
142	TACHYCARDIA	1	1	23	5 dy	Mild	0	1	1
146	DRY MOUTH	1	1	6	1 dy	Mild	1	1	0
146	CONSTIPATION	1	1	6	1 dy	Mild	1	1	0
146	CONSTIPATION	1	1	17	3 dy	Mild	1	1	0
169	DECREASED APPETITE	1	0	1	6 dy	Mild	1	1	0
169	INCREASED SALIVATION	0	0	2	3 dy	Mild	1	1	0
169	HEADACHE	0	2	6	7 dy	Mild	1	1	0
169	DROWSINESS	0	1	12	2 dy	Mild	1	1	0
169	CONSTIPATION	0	0	19	2 dy	Mild	1	1	0
169	NASAL CONGESTION	0	2	25	3 dy	Mild	1	1	0
171	CONSTIPATION	0	0	1	3 dy	Mild	1	0	0
171	HEADACHE	0	2	1	2 dy	Mild	1	1	0
171	SWEATING	0	1	2	5 dy	Mild	1	1	0
171	DIARRHEA	0	1	2	5 dy	Mild	1	1	0
171	LISSITUDE	0	2	8	2 dy	Mild	1	1	0
171	DECREASED APPETITE	1	0	8	9 dy	Mild	1	1	0
176	INSOMNIA	1	0	1	4 dy	Mild	1	1	0
176	INCREASED SALIVATION	0	2	2	3 dy	Mild	1	1	0
176	DROWSINESS	0	2	4	3 dy	Mild	1	1	0
176	DECREASED APPETITE	1	0	4	3 dy	Mild	1	1	0
176	LISSITUDE	0	2	7	3 dy	Mild	1	1	0
176	VOMITING	0	2	11	2 dy	Mild	1	1	0
176	HEADACHE	0	2	17	2 dy	Mild	1	1	0
176	DIARRHEA	0	0	25	3 dy	Mild	1	1	0
176	SWEATING	0	2	25	2 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

3

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
177	INCREASED SALIVATION	0	0	2	4 dy	Mild	1	1	0
177	INSOMNIA	0	0	2	11 dy	Mild	1	1	0
177	SWEATING	1	2	5	3 dy	Mild	1	1	0
177	LASSITUDE	0	1	5	4 dy	Mild	1	1	0
177	DIARRHEA	0	2	11	4 dy	Mild	1	1	0
177	HEADACHE	0	2	17	3 dy	Mild	1	1	0
184	SWEATING	0	1	3	8 dy	Mild	1	1	0
184	NASAL CONGESTION	0	2	6	4 dy	Mild	1	1	0
184	DROWSINESS	1	1	7	2 dy	Mild	1	1	0
184	INCREASED SALIVATION	0	1	11	3 dy	Mild	1	1	0
184	DECR. MOTOR ACTIVITY	0	1	24	3 dy	Mild	1	1	0
184	HEADACHE	0	2	24	3 dy	Mild	1	1	0
185	DIZZINESS	0	1	4	4 dy	Mild	1	1	0
185	DROWSINESS	0	1	7	7 dy	Mild	1	1	0
185	TACHYCARDIA	0	1	8	6 dy	Mild	1	1	0
185	NASAL CONGESTION	0	1	10	4 dy	Mild	1	1	0
185	HEADACHE	0	1	11	5 dy	Mild	1	1	0
185	INCR. MOTOR ACTIVITY	1	1	19	3 dy	Mild	1	1	0
185	SWEATING	0	0	19	3 dy	Mild	1	1	0
189	TACHYCARDIA	0	2	1	6 dy	Mild	1	1	0
189	NASAL CONGESTION	0	2	2	3 dy	Mild	1	1	0
189	SWEATING	0	0	5	4 dy	Mild	1	1	0
189	INCR. MOTOR ACTIVITY	0	1	7	3 dy	Mild	1	1	0
189	DECREASED APPETITE	0	0	7	8 dy	Mild	1	1	0
189	EXCITEMENT	0	1	18	3 dy	Mild	1	1	0
189	HEADACHE	0	1	19	4 dy	Mild	1	1	0
189	DECR. MOTOR ACTIVITY	1	0	25	3 dy	Mild	1	1	0
192	DECR. MOTOR ACTIVITY	1	0	2	8 dy	Mild	1	1	0
192	LASSITUDE	0	1	5	3 dy	Mild	1	1	0
192	DIARRHEA	0	1	10	4 dy	Mild	1	1	0
192	DROWSINESS	0	1	11	3 dy	Mild	1	1	0
192	DECREASED APPETITE	0	1	19	10 dy	Mild	1	1	0
192	INSOMNIA	0	1	25	3 dy	Mild	1	1	0
194	DRY MOUTH	0	0	4	3 dy	Mild	1	1	0
194	CONSTIPATION	0	0	4	2 dy	Mild	1	1	0
199	SWEATING	0	1	4	14 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry

<sup>2</sup> 0=Yes 1=No

<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain

<sup>4</sup> 0=Yes 1=No

<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued

2=Disappeared after dosage reduction 3=Persisted after dosage reduction

4=Not tolerated

FCE 20124/702 i

4

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
200	DIARRHEA	0	1	9	3 dy	Mild	1	1	0
208	DRY MOUTH	0	1	4	4 hr	Mild	1	1	1
208	SWEATING	0	1	4	4 hr	Mild	1	1	1
209	NASAL CONGESTION	0	1	21	3 hr	Mild	1	1	0
209	HEADACHE	0	1	21	3 hr	Mild	1	1	0
211	CONSTIPATION	0	1	6	4 dy	Mild	1	1	0
211	INCREASED SALIVATION	0	1	14	15 dy	Mild	1	1	1
211	SWEATING	0	1	14	15 dy	Mild	1	1	1
215	VOMITING	0	1	7	10 hr	Mild	1	.	0
215	SWEATING	0	1	7	13 hr	Moderate	1	.	0
217	BITTER TASTE	0	1	9	1 dy	Mild	1	1	0
217	NAUSEA	0	1	14	3 hr	Mild	1	1	0
217	VOMITING	0	1	14	3 hr	Mild	1	1	0
217	POSTURAL HYPOTENSION	1	0	14	7 dy	Mild	1	1	0
217	BLURRED VISION	0	0	17	5 dy	Mild	0	1	0
217	DIZZINESS	0	1	26	3 dy	Mild	1	1	1
222	HEADACHE	0	1	13	2 dy	Moderate	0	1	0
222	SKIN RASH	0	1	18	3 dy	Moderate	2	0	4
222	VOMITING	1	1	19	10 min	Mild	1	1	0
224	FACE BURNING	1	1	6	.	Mild	1	1	0
224	PALPITATIONS	1	1	11	2 hr	Mild	0	1	0
231	DRY MOUTH	0	1	2	2 dy	Mild	1	1	0
231	DIZZINESS	0	1	16	11 dy	Mild	0	1	1
231	PARESTHESIAS	0	1	24	3 dy	Mild	0	1	1
231	HYPOTENSION	0	1	27	1 hr	Mild	1	1	1
232	DRY MOUTH	0	2	16	6 dy	Mild	0	1	1
232	AKATHISIA	0	1	16	6 dy	Moderate	1	1	1
232	DECREASED APPETITE	0	0	18	4 dy	Severe	0	1	1

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

5

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
235	PARESTHESIAS	0	1	2	5 dy	Mild	0	1	0
235	DRY MOUTH	1	1	5	3 dy	Mild	0	1	0
235	COUGH	0	1	6	2 dy	Mild	0	0	0
235	THROAT PAIN	0	1	6	4 dy	Mild	0	0	0
235	DEPERSONALIZATION	1	1	12	6 dy	Moderate	1	1	0
235	ECG:ST FLATTENING	.	1	26	.	.	.	1	0
240	INCREASED APPETITE	0	1	1	6 dy	Mild	0	1	0
240	INSOMNIA	0	1	9	2 dy	Mild	0	1	0
240	CONSTIPATION	1	0	10	11 dy	Mild	1	0	0
240	SWEATING	1	0	11	3 dy	Mild	0	1	0
240	HYPOTENSION	1	0	21	7 dy	Mild	1	1	1
244	SWEATING	0	2	2	3 dy	Mild	1	1	0
244	HEADACHE	0	2	2	2 dy	Mild	1	1	0
244	DIARRHEA	0	1	4	4 dy	Mild	1	0	0
244	NASAL CONGESTION	0	0	7	3 dy	Mild	1	1	0
244	HEADACHE	0	0	7	3 dy	Mild	1	1	0
244	DIZZINESS	0	1	8	2 dy	Mild	1	1	0
244	INCR.MOTOR ACTIVITY	1	1	11	2 dy	Mild	1	1	0
244	CONSTIPATION	0	0	19	3 dy	Mild	1	1	0
244	BLURRED VISION	0	1	26	2 dy	Mild	1	1	0
246	SWEATING	0	1	5	3 dy	Mild	1	1	0
246	HEADACHE	0	1	5	3 dy	Mild	1	1	0
246	LISSITUDE	0	1	6	3 dy	Mild	1	1	0
246	DIARRHEA	0	0	11	3 dy	Mild	1	1	0
246	DRY MOUTH	0	0	18	4 dy	Mild	1	1	0
246	NASAL CONGESTION	0	2	19	3 dy	Mild	1	1	0
246	CONSTIPATION	0	0	26	3 dy	Mild	1	1	0
246	DROWSINESS	1	0	27	2 dy	Mild	1	1	0
247	DROWSINESS	1	1	2	3 dy	Mild	1	1	0
247	HEADACHE	0	0	2	2 dy	Mild	1	1	0
247	NASAL CONGESTION	0	1	4	3 dy	Mild	1	1	0
247	SWEATING	0	0	7	2 dy	Mild	1	1	0
247	DIZZINESS	0	1	10	2 dy	Mild	1	1	0
247	LISSITUDE	1	1	10	2 dy	Mild	1	1	0
247	DRY MOUTH	0	1	19	4 dy	Mild	1	1	0
247	CONSTIPATION	0	0	23	4 dy	Mild	1	1	0
247	INCR.MOTOR ACTIVITY	1	1	24	2 dy	Mild	1	1	0

1 0=Spontaneously 1=Open inquiry  
 2 0=Yes 1=No  
 3 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
 4 0=Yes 1=No  
 5 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
 2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
 4=Not tolerated

FCE 20124/702 i

6

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
248	SWEATING	0	0	4	4 dy	Mild	1	1	0
248	HEADACHE	0	0	6	2 dy	Mild	1	1	0
248	LASSITUDE	0	2	8	2 dy	Mild	1	1	0
248	DIARRHEA	0	1	10	4 dy	Mild	1	1	0
248	INCR.MOTOR ACTIVITY	1	1	19	2 dy	Mild	1	1	0
248	DRY MOUTH	0	0	24	3 dy	Mild	1	1	0
248	CONSTIPATION	0	1	24	2 dy	Mild	1	1	0
257	HEADACHE	0	1	21	2 hr	Moderate	1	1	0
257	DRY MOUTH	0	1	27	2 hr	Moderate	1	1	0
257	SWEATING	0	1	27	4 hr	Moderate	1	1	0
258	HEADACHE	0	1	10	7 hr	Moderate	1	1	0
259	SWEATING	0	0	5	2 dy	Mild	1	1	0
259	DIARRHEA	0	1	9	3 dy	Mild	1	1	0
259	DIZZINESS	0	1	9	2 dy	Mild	1	1	0
259	NASAL CONGESTION	0	1	12	3 dy	Mild	1	1	0
259	LASSITUDE	0	1	20	3 dy	Mild	1	1	0
259	CONSTIPATION	0	1	24	4 dy	Mild	1	1	0
263	LASSITUDE	1	1	2	3 dy	Mild	1	1	0
263	DECREASED APPETITE	0	0	2	2 dy	Mild	1	1	0
263	HEADACHE	0	2	2	4 dy	Mild	1	1	0
263	DIZZINESS	0	2	5	2 dy	Mild	1	1	0
263	NASAL CONGESTION	0	1	12	3 dy	Mild	1	1	0
263	DIARRHEA	0	1	13	2 dy	Mild	1	1	0
263	DRY MOUTH	0	1	18	4 dy	Mild	1	1	0
263	CONSTIPATION	0	0	25	3 dy	Mild	1	1	0
267	DRY MOUTH	0	1	28	2 hr	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Open inquiry

<sup>2</sup> 0=Yes 1=No

<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain

<sup>4</sup> 0=Yes 1=No

<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued

2=Disappeared after dosage reduction 3=Persisted after dosage reduction

4=Not tolerated

FCE 20124/702 1

7

Table 6 - List of Signs and Symptoms

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel.to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
2	TACHYCARDIA	0	1	6	4 hr	Moderate	2	1	2
10	HYPOTENSION	1	2	10	2 dy	Moderate	1	1	0
10	TACHYCARDIA	0	1	14	2 dy	Moderate	1	1	0
10	DRY MOUTH	0	1	14	4 hr	Moderate	1	1	0
15	TREMOR	0	1	5	3 dy	Mild	1	1	0
15	TACHYCARDIA	0	1	6	9 dy	Mild	1	1	0
17	TACHYCARDIA	0	1	13	17 dy	Mild	1	1	1
44	ECG: INCOMP. RBBB	.	1	14	.	.	1	1	1
51	DRY MOUTH	0	0	4	4 dy	Moderate	2	1	0
51	DROWSINESS	0	0	4	4 dy	Moderate	2	1	0
51	HYPOTENSION	0	0	4	10 dy	Moderate	2	1	0
78	DRY MOUTH	0	1	5	24 dy	Severe	2	1	1
78	DESQUAMATION OF HANDS	1	1	7	8 dy	Moderate	0	1	0
83	INSOMNIA	0	0	11	4 dy	Moderate	0	0	0
84	HYPERTENSION	0	1	2	3 hr	Moderate	0	0	0
84	INSOMNIA	0	0	3	5 dy	Moderate	0	0	0
84	DRY MOUTH	1	1	4	17 dy	Mild	1	1	0
84	CONSTIPATION	0	0	5	4 dy	Moderate	0	0	0
84	HYPOTENSION	0	1	10	12 hr	Mild	0	0	0
88	HYPOTENSION	1	1	4	13 dy	Moderate	1	1	0
88	VOMITING	0	1	9	1 dy	Moderate	0	1	0
90	SWEATING	0	1	3	4 dy	Moderate	1	1	0
90	DRY MOUTH	1	1	4	15 dy	Mild	1	1	0
90	CONSTIPATION	0	1	4	7 dy	Moderate	1	1	0
90	BLURRED VISION	0	1	9	13 dy	Moderate	2	1	2

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated



FCE 20124/702 i

8

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
98	DRY MOUTH	1	1	3	26 dy	Severe	1	1	1
98	CONSTIPATION	0	1	4	7 dy	Moderate	1	0	0
98	DIZZINESS	1	1	7	8 dy	Mild	1	1	0
98	HYPOTENSION	0	1	18	30 min	Moderate	0	1	0
102	DRY MOUTH	0	1	2	26 dy	Very Sev.	1	1	1
102	INSOMNIA	1	1	12	6 dy	Moderate	0	1	0
102	ANXIETY	0	0	20	2 hr	Very Sev.	0	0	0
103	CONSTIPATION	0	1	1	2 dy	Moderate	1	1	0
103	URINARY HESITANCY	0	1	1	1 dy	Moderate	1	1	0
106	DRY MOUTH	0	1	3	1 dy	Moderate	1	1	0
106	DECR.MOTOR ACTIVITY	0	1	6	8 dy	Moderate	0	1	0
106	CONSTIPATION	1	1	8	9 dy	Severe	1	1	0
106	HYPOTENSION	0	1	22	6 hr	Moderate	0	0	0
110	HYPOTENSION	0	1	12	3 dy	Mild	1	0	1
110	NAUSEA	0	1	13	2 dy	Mild	0	1	0
118	DRY MOUTH	0	1	6	23 dy	Moderate	1	1	1
118	CONSTIPATION	0	1	6	23 dy	Moderate	1	1	1
124	DRY MOUTH	1	1	1	20 dy	Severe	1	1	0
124	SWEATING	1	1	1	28 dy	Mild	1	1	1
124	BLURRED VISION	1	1	3	11 dy	Mild	1	1	0
124	DROWSINESS	1	1	3	18 dy	Mild	1	1	0
124	PARESTHESIAS	0	1	9	1 dy	Mild	1	1	0
124	HYPERTENSION	1	1	20	1 dy	Mild	1	1	0
126	CONSTIPATION	1	1	1	27 dy	Moderate	1	1	1
126	DRY MOUTH	1	1	2	26 dy	Moderate	1	1	1
127	DIZZINESS	1	1	1	9 dy	Moderate	1	1	1
127	CONSTIPATION	1	1	2	20 dy	Moderate	1	1	0
127	DRY MOUTH	1	1	3	25 dy	Severe	1	1	1
127	VOMITING	1	1	3	2 dy	Mild	1	1	.
127	DROWSINESS	1	1	5	23 dy	Mild	1	1	1
127	BLURRED VISION	1	1	11	3 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Open inquiry

<sup>2</sup> 0=Yes 1=No

<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain

<sup>4</sup> 0=Yes 1=No

<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued

2=Disappeared after dosage reduction 3=Persisted after dosage reduction

4=Not tolerated

FCE 20124/702 i

9

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
132	CONSTIPATION	0	1	1	26 dy	Moderate	1	0	1
132	DRY MOUTH	0	1	3	24 dy	Moderate	1	1	1
132	BLURRED VISION	0	1	4	23 dy	Moderate	1	1	1
132	DIARRHEA	0	1	7	3 dy	Moderate	1	1	0
133	DRY MOUTH	1	1	1	26 dy	Mild	1	1	1
133	HYPERTENSION	0	1	1	6 dy	Moderate	1	0	1
133	TACHYCARDIA	1	1	2	5 min	Moderate	1	1	0
133	SWEATING	0	1	5	23 dy	Mild	1	1	1
139	CONSTIPATION	1	1	2	6 dy	Moderate	1	1	0
139	BLURRED VISION	1	1	3	2 dy	Mild	1	1	0
139	DIZZINESS	0	1	3	5 dy	Moderate	1	1	0
139	DRY MOUTH	1	1	4	16 dy	Moderate	1	1	0
139	DROWINESS	1	1	16	13 dy	Mild	1	1	1
140	DRY MOUTH	1	1	1	26 dy	Moderate	1	1	1
140	LASSITUDE	1	1	2	3 dy	Moderate	1	1	0
140	HEADACHE	0	1	2	3 dy	Moderate	1	1	0
140	BLURRED VISION	1	1	4	3 dy	Moderate	1	1	0
140	CONSTIPATION	1	1	9	11 dy	Moderate	1	1	0
140	TREMOR	0	1	11	3 dy	Moderate	1	1	0
140	HYPERTENSION	1	1	14	3 hr	Moderate	1	1	0
147	DRY MOUTH	1	1	1	14 dy	Mild	1	1	1
148	DRY MOUTH	1	1	10	19 dy	Moderate	1	1	0
148	SWEATING	0	1	22	6 dy	Mild	1	1	0
170	NASAL CONGESTION	0	1	3	7 dy	Mild	1	1	0
170	SWEATING	0	2	5	4 dy	Mild	1	1	0
170	LASSITUDE	0	1	5	3 dy	Mild	1	1	0
170	DRY MOUTH	0	0	10	9 dy	Mild	1	1	1
170	CONSTIPATION	0	0	16	5 dy	Moderate	1	0	0
170	DIZZINESS	0	2	18	2 dy	Mild	1	1	0
170	HEADACHE	0	2	18	3 dy	Mild	1	1	0
170	BLURRED VISION	0	1	23	3 dy	Mild	1	1	0
170	DIZZINESS	0	2	23	2 dy	Mild	1	1	0
170	INCR.MOTOR ACTIVITY	1	1	24	4 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

10

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
172	NASAL CONGESTION	0	2	2	3 dy	Mild	1	1	0
172	LASSITUDE	0	1	4	3 dy	Mild	1	1	0
172	DIZZINESS	0	1	4	5 dy	Mild	1	1	0
172	SWEATING	0	2	6	2 dy	Mild	1	1	0
172	DECREASED APPETITE	1	0	8	4 dy	Mild	1	1	0
172	CONSTIPATION	0	0	10	6 dy	Mild	1	1	0
172	HEADACHE	0	2	10	6 dy	Mild	1	1	0
172	DRY MOUTH	0	0	16	7 dy	Mild	1	1	1
172	DROWSINESS	1	1	16	3 dy	Mild	1	1	0
172	BLURRED VISION	0	1	24	3 dy	Mild	1	1	0
179	NASAL CONGESTION	0	1	1	14 dy	Mild	1	1	0
179	INSOMNIA	0	1	1	6 dy	Mild	1	1	0
179	HEADACHE	0	2	1	15 dy	Mild	1	1	0
179	DECREASED APPETITE	0	0	3	3 dy	Mild	0	1	0
179	SWEATING	0	1	5	7 dy	Mild	1	1	0
179	LASSITUDE	0	1	6	6 dy	Mild	1	1	0
179	DROWSINESS	0	1	11	4 dy	Mild	2	1	2
179	BLURRED VISION	0	1	11	4 dy	Mild	1	1	1
179	HYPOTENSION	1	1	16	6 dy	Mild	2	1	0
179	TACHYCARDIA	0	1	16	6 dy	Mild	1	1	0
179	CONSTIPATION	0	0	22	4 dy	Moderate	1	0	0
179	DRY MOUTH	0	0	24	7 dy	Mild	1	1	0
180	SWEATING	0	0	2	6 dy	Mild	1	1	0
180	DRY MOUTH	0	0	3	7 dy	Mild	1	1	0
180	INSOMNIA	0	0	3	9 dy	Mild	1	1	0
180	HEADACHE	0	0	5	6 dy	Mild	1	1	0
180	DIARRHEA	0	0	10	7 dy	Mild	1	1	0
180	NASAL CONGESTION	0	2	10	4 dy	Mild	1	1	0
180	BLURRED VISION	0	0	16	3 dy	Mild	1	1	0
180	INCR.MOTOR ACTIVITY	1	1	24	3 dy	Mild	1	1	0
180	CONSTIPATION	0	0	25	4 dy	Moderate	1	0	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

667

FCE 20124/702 i

11

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
181	NASAL CONGESTION	0	1	1	4 dy	Mild	1	1	0
181	HEADACHE	0	0	1	7 dy	Mild	1	1	0
181	DRY MOUTH	0	0	5	3 dy	Mild	1	1	0
181	CONSTIPATION	0	0	5	4 dy	Mild	1	1	0
181	DROWSINESS	0	0	7	3 dy	Mild	1	1	0
181	SWEATING	0	0	7	5 dy	Mild	1	1	0
181	BLURRED VISION	0	0	11	2 dy	Mild	1	1	0
181	DIZZINESS	0	0	12	3 dy	Mild	1	1	0
181	INCREASED SALIVATION	0	0	18	4 dy	Mild	1	1	0
181	DIARRHEA	0	0	25	4 dy	Mild	1	0	0
181	LASSITUDE	0	0	26	3 dy	Mild	1	1	0
186	INSOMNIA	0	0	1	6 dy	Mild	1	1	0
186	HEADACHE	0	0	2	9 dy	Mild	1	1	0
186	DRY MOUTH	0	0	3	7 dy	Mild	1	1	0
186	CONSTIPATION	0	0	3	8 dy	Moderate	1	0	0
186	NASAL CONGESTION	0	0	6	3 dy	Mild	1	1	0
186	TACHYCARDIA	1	2	7	3 dy	Mild	1	1	0
186	SWEATING	0	0	10	3 dy	Mild	1	1	0
186	LASSITUDE	0	0	10	6 dy	Mild	1	1	0
186	DIZZINESS	0	0	11	2 dy	Mild	1	1	0
186	DROWSINESS	0	0	19	3 dy	Mild	1	1	0
186	BLURRED VISION	0	0	19	3 dy	Mild	1	1	0
187	SWEATING	0	0	1	6 dy	Mild	1	1	0
187	NASAL CONGESTION	0	0	2	4 dy	Mild	1	1	0
187	CONSTIPATION	0	2	3	4 dy	Mild	1	0	0
187	INSOMNIA	0	0	4	2 dy	Mild	1	1	0
187	LASSITUDE	0	0	13	3 dy	Mild	1	1	0
187	DRY MOUTH	0	0	19	4 dy	Mild	1	1	0
187	DIARRHEA	0	0	24	3 dy	Mild	1	1	0
187	INCREASED SALIVATION	0	0	24	3 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

12

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
188	SWEATING	0	0	1	4 dy	Mild	1	1	0
188	INSOMNIA	0	0	1	6 dy	Mild	1	1	1
188	DECREASED APPETITE	0	0	2	9 dy	Mild	1	1	1
188	CONSTIPATION	0	0	2	4 dy	Mild	1	1	0
188	HEADACHE	0	2	6	8 dy	Mild	1	1	0
188	NASAL CONGESTION	0	0	7	4 dy	Mild	1	1	0
188	LASSITUDE	0	0	7	3 dy	Mild	1	1	0
188	DIARRHEA	0	1	11	3 dy	Mild	1	1	0
188	DROWSINESS	0	1	17	3 dy	Mild	1	1	0
188	DRY MOUTH	0	0	17	4 dy	Mild	1	1	0
188	BLURRED VISION	0	1	26	3 dy	Mild	1	1	0
188	TACHYCARDIA	1	1	26	3 dy	Mild	1	1	0
193	VOMITING	0	2	12	2 dy	Mild	1	1	0
193	DIARRHEA	0	1	26	3 dy	Mild	1	1	0
193	SWEATING	0	1	27	2 dy	Mild	1	1	0
197	SWEATING	0	1	11	19 dy	Mild	1	1	1
197	DRY MOUTH	0	1	13	17 dy	Mild	1	1	1
202	DRY MOUTH	0	1	5	16 dy	Mild	1	1	1
202	SWEATING	0	1	5	16 dy	Mild	1	1	0
203	DIARRHEA	1	1	13	1 dy	Mild	1	0	0
206	HEADACHE	0	1	9	7 dy	Mild	1	1	0
210	NASAL CONGESTION	0	1	28	3 hr	Moderate	1	1	0
214	DRY MOUTH	0	1	3	1 dy	Mild	1	1	0
214	CONSTIPATION	0	1	3	1 dy	Mild	1	1	0
214	SWEATING	0	1	7	4 dy	Mild	1	1	0
214	DIARRHEA	0	1	28	6 hr	Mild	1	1	0
216	DIARRHEA	0	1	7	8 hr	Mild	1	1	0
216	NASAL CONGESTION	0	1	14	15 dy	Mild	1	1	1
216	SWEATING	0	1	16	8 hr	Mild	1	1	0

- <sup>1</sup> 0=Spontaneously 1=Upon inquiry
- <sup>2</sup> 0=Yes 1=No
- <sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain
- <sup>4</sup> 0=Yes 1=No
- <sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

13

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
218	PALPITATIONS	0	0	1	3 dy	Mild	1	1	0
218	PARESTHESIAS	1	1	1	6 dy	Mild	1	1	0
218	DROWSINESS	1	1	1	6 dy	Mild	1	1	0
218	FLUSHING OF FACE	0	1	1	3 dy	Mild	1	1	0
218	BITTER TASTE	0	1	6	19 dy	Mild	1	1	0
218	DIZZINESS	0	1	8	10 dy	Mild	1	1	0
218	NAUSEA	0	1	9	4 dy	Mild	0	1	0
218	VOMITING	0	1	9	5 min	Mild	0	1	0
218	RASH	0	1	9	2 dy	Moderate	1	1	0
218	PRURITUS	0	1	9	2 dy	Mild	1	1	0
218	DRY MOUTH	1	1	10	15 dy	Mild	1	1	0
218	ECG:ST FLATTENING	.	1	11	12 dy	.	1	1	1
218	FEVER	0	1	12	1 dy	Mild	0	0	0
218	TACHYCARDIA	.	1	23	.	.	1	1	1
219	LASSITUDE	0	1	2	2 dy	Mild	1	1	0
219	DIZZINESS	0	1	3	1 dy	Mild	1	1	0
219	NAUSEA	1	1	15	4 dy	Mild	0	1	0
219	ECG:T,ST FLATTENING	.	1	26	.	.	1	1	1
226	DRY MOUTH	0	0	3	25 dy	Mild	0	1	0
226	INSOMNIA	0	0	3	1 dy	Severe	1	0	0
226	DIZZINESS	0	0	3	11 dy	Moderate	1	1	0
226	TACHYCARDIA	.	.	7	6 dy	Mild	1	1	0
226	POSTURAL HYPOTENSION	1	2	12	9 dy	Moderate	1	1	0
226	BITTER TASTE	0	1	15	6 dy	Moderate	1	1	0
226	BLURRED VISION	0	0	18	.	Mild	1	1	0
226	SWEATING	0	1	18	10 dy	Mild	0	1	0
226	NERVOUSNESS	0	1	19	2 dy	Moderate	1	1	0
227	TACHYCARDIA	.	1	4	17 dy	Mild	1	1	0
227	DRY MOUTH	0	1	5	9 dy	Moderate	1	1	0
227	CONSTIPATION	1	0	11	3 dy	Mild	0	1	0
230	HYPOTENSION	.	1	3	5 dy	Mild	1	1	0
230	TACHYCARDIA	.	1	7	4 dy	Moderate	1	1	0
230	AGITATION	0	0	9	2 dy	Very Sev.	0	0	4
233	HEADACHE	0	0	7	7 dy	Moderate	0	1	1
233	TACHYCARDIA	1	2	7	8 dy	Mild	0	1	0
233	SWEATING	0	1	9	6 dy	Mild	1	1	1
233	COLDNESS	0	1	10	5 dy	Moderate	0	1	1

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

670

FCE 20124/702 i

14

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
237	DRY MOUTH	0	0	1	20 dy	Mild	1	1	1
237	HYPOTENSION	1	1	7	1 hr	Mild	1	1	0
237	TACHYCARDIA	1	1	7	22 dy	Mild	1	1	1
237	INCREASED DREAMING	0	0	15	6 dy	Mild	1	1	0
238	HYPOTENSION	1	1	2	19 dy	Mild	1	1	0
238	TACHYCARDIA	1	1	2	4 dy	Mild	1	1	0
238	TREMOR	0	1	8	12 dy	Mild	1	1	0
238	DIZZINESS	1	1	13	6 dy	Mild	1	1	0
238	SKIN REACTION	0	1	17	9 dy	Mild	0	1	1
243	SWEATING	0	2	5	3 dy	Mild	1	1	0
243	HEADACHE	0	1	6	3 dy	Mild	1	1	0
243	LASSITUDE	0	1	7	4 dy	Mild	1	1	0
243	NASAL CONGESTION	0	1	7	6 dy	Mild	1	1	0
243	DIARRHEA	0	1	8	3 dy	Mild	1	1	0
243	DROWSINESS	0	1	19	2 dy	Mild	1	1	0
245	INSOMNIA	0	0	2	3 dy	Mild	1	1	0
245	INCREASED SALIVATION	0	1	4	2 dy	Mild	1	1	0
245	SEXUAL DISTURBANCE	0	0	6	3 dy	Mild	1	1	0
245	NASAL CONGESTION	0	0	11	2 dy	Mild	1	1	0
245	DIZZINESS	0	2	11	2 dy	Mild	1	1	0
245	CONSTIPATION	0	0	18	4 dy	Mild	1	0	0
245	LASSITUDE	1	2	19	2 dy	Mild	1	1	0
245	DROWSINESS	1	1	26	2 dy	Mild	1	1	0
249	SWEATING	0	1	1	7 dy	Mild	1	1	0
249	HEADACHE	0	1	1	4 dy	Mild	1	1	0
249	NASAL CONGESTION	0	0	3	6 dy	Mild	1	1	0
249	LASSITUDE	1	1	4	4 dy	Mild	1	1	0
249	DECR. MOTOR ACTIVITY	1	1	8	2 dy	Mild	1	1	0
249	INCREASED SALIVATION	0	1	19	3 dy	Mild	1	1	0
249	CONSTIPATION	0	0	23	4 dy	Mild	1	0	0
251	HEADACHE	0	1	4	5 hr	Moderate	1	0	0
251	TACHYCARDIA	0	1	6	4 min	Mild	1	1	0
251	SWEATING	0	1	6	4 dy	Moderate	1	1	0
251	DRY MOUTH	0	1	14	1 dy	Moderate	1	1	0
254	CONSTIPATION	0	1	6	4 dy	Moderate	1	1	0
254	DRY MOUTH	0	1	6	4 dy	Moderate	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

15

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
255	DRY MOUTH	0	1	20	2 dy	Moderate	1	1	0
255	HEADACHE	0	1	20	4 dy	Mild	1	0	0
260	HEADACHE	0	1	2	3 dy	Mild	1	1	0
260	URINARY HESITANCY	0	2	6	2 dy	Mild	1	1	0
260	LAISSITUDE	1	1	8	4 dy	Mild	1	1	0
260	NASAL CONGESTION	0	1	11	3 dy	Mild	1	1	0
260	SWEATING	0	2	23	3 dy	Mild	1	1	0
260	DROWSINESS	1	1	24	2 dy	Mild	1	1	0
262	DROWSINESS	1	2	2	2 dy	Mild	0	1	0
262	HEADACHE	0	1	2	5 dy	Mild	1	1	0
262	DECR. MOTOR ACTIVITY	1	0	5	3 dy	Mild	1	1	0
262	LAISSITUDE	0	1	9	2 dy	Mild	1	1	0
262	URINARY HESITANCY	0	1	11	3 dy	Mild	1	1	0
262	NASAL CONGESTION	0	2	17	3 dy	Mild	1	1	0
262	DIARRHEA	0	1	17	4 dy	Moderate	1	0	0
262	BLURRED VISION	0	1	25	4 dy	Mild	1	1	0
269	DIARRHEA	0	1	4	1½ hr	Mild	1	1	0
269	SWEATING	0	1	10	1 dy	Moderate	1	1	0
273	DRY MOUTH	0	1	19	2 dy	Mild	1	1	0
273	CONSTIPATION	0	1	19	2 dy	Mild	1	1	0

- <sup>1</sup> 0=Spontaneously 1=Upon inquiry
- <sup>2</sup> 0=Yes 1=No
- <sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain
- <sup>4</sup> 0=Yes 1=No
- <sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued
- 2=Disappeared after dosage reduction 3=Persisted after dosage reduction
- 4=Not tolerated

672



FCE 20124/702 i

16

Table 6 - List of Signs and Symptoms

Treatment Group "C"									
Pat. No.	Symptom	Pre- Rpt. <sup>1</sup>	Pre- Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel.to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
3	TACHYCARDIA	0	1	13	6 dy	Severe	2	1	2
3	WEIGHT LOSS	0	1	21	1 dy	Moderate	1	0	0
8	BLURRED VISION	0	1	20	7 dy	Mild	1	1	1
8	DIZZINESS	0	1	20	7 dy	Mild	1	1	1
53	DRY MOUTH	0	0	3	7 dy	Moderate	1	1	0
53	INSOMNIA	0	0	3	1 dy	Moderate	1	1	0
53	HYPERTENSION	0	0	3	11 dy	Moderate	1	1	0
53	DROWSINESS	0	0	5	4 dy	Moderate	1	1	0
59	SWEATING	0	1	4	4 dy	Moderate	1	1	0
62	HEADACHE	0	1	1	12 dy	Moderate	1	1	0
63	DROWSINESS	0	1	1	10 dy	Moderate	1	1	0
69	URTICARIA	0	1	2	7 dy	Moderate	1	1	0
71	CONSTIPATION	0	1	1	7 dy	Moderate	1	1	0
74	CONSTIPATION	0	0	1	8 dy	Mild	0	1	0
74	FREQ.VENT.EXTRA SYSTOL.	1	0	12	6 dy	Severe	1	1	4
76	AGITATION	0	1	3	3 dy	Moderate	0	1	0
76	INSOMNIA	1	0	3	1 dy	Moderate	0	1	0
76	DRY MOUTH	0	1	5	19 dy	Moderate	1	1	1
81	INSOMNIA	0	0	1	1 dy	Severe	1	0	0
81	AGITATION	0	1	4	10 dy	Moderate	1	1	0
81	LAISSITUDE	1	1	4	19 dy	Mild	1	1	1
81	SWEATING	1	1	4	9 dy	Mild	1	1	0
82	INSOMNIA	1	1	5	2 dy	Moderate	1	0	0
86	INSOMNIA	0	1	7	22 dy	Moderate	1	0	3
92	DRY MOUTH	1	1	6	22 dy	Moderate	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
 2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
 4=Not tolerated

673

FCE 20124/702 i

17

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
97	CONSTIPATION	0	1	17	12 dy	Moderate	1	1	1
104	HEADACHE	1	1	13	3 hr	Moderate	0	1	0
105	DIARRHEA	0	1	9	6 dy	Severe	0	0	0
111	CONSTIPATION	0	0	2	3 dy	Severe	0	0	0
111	URINARY HESITANCY	0	1	8	7 dy	Moderate	1	1	0
111	URINARY RETENTION	0	1	19	8 hr	Severe	3	1	2
112	CONSTIPATION	0	1	9	4 dy	Moderate	0	1	0
117	CONSTIPATION	1	1	6	7 dy	Mild	1	1	0
117	DRY MOUTH	1	1	6	23 dy	Moderate	1	1	1
117	HYPOTENSION	1	1	14	13 dy	Mild	1	1	1
121	DRY MOUTH	1	1	2	26 dy	Moderate	1	1	1
121	CONSTIPATION	1	1	2	10 dy	Moderate	1	1	0
121	URINARY RETENTION	1	1	2	13 dy	Moderate	1	1	0
121	DIARRHEA	0	1	12	3 dy	Moderate	0	0	0
125	URINARY HESITANCY	1	1	5	6 dy	Moderate	1	1	1
128	CONSTIPATION	0	1	16	11 dy	Moderate	1	1	1
128	TREMOR	0	1	16	5 dy	Mild	1	1	1
129	DRY MOUTH	0	1	1	26 dy	Severe	1	1	1
129	BLURRED VISION	0	1	3	4 dy	Moderate	1	1	0
129	HEADACHE	0	1	6	21 dy	Severe	1	0	1
129	PARESTHESIAS	1	1	13	1 dy	Mild	1	1	0
137	DROWSINESS	1	1	1	12 dy	Mild	1	1	0
137	CONSTIPATION	1	1	2	2 dy	Moderate	1	1	0
137	DIZZINESS	1	1	4	1 dy	Mild	1	1	0
137	TREMOR	1	1	5	5 dy	Mild	1	1	1
137	SWEATING	1	0	18	3 dy	Moderate	1	1	0
137	DRY MOUTH	1	0	25	2 dy	Moderate	1	1	0
138	CONSTIPATION	0	1	3	17 dy	Moderate	1	1	1
138	HYPERTENSION	1	1	4	16 dy	Moderate	0	0	4
138	DROWSINESS	1	1	7	14 dy	Moderate	1	1	1

- <sup>1</sup> 0=Spontaneously 1=Upon inquiry
- <sup>2</sup> 0=Yes 1=No
- <sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain
- <sup>4</sup> 0=Yes 1=No
- <sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued
- 2=Disappeared after dosage reduction 3=Persisted after dosage reduction
- 4=Not tolerated

674

FCE 20124/702 i

18

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
141	CONSTIPATION	1	1	1	26 dy	Severe	1	0	1
141	HEADACHE	1	1	1	6 dy	Mild	1	1	0
141	BLURRED VISION	0	1	4	23 dy	Moderate	1	1	1
141	DRY MOUTH	1	1	12	15 dy	Severe	1	1	1
145	DRY MOUTH	0	1	1	10 dy	Severe	1	1	0
145	CONSTIPATION	1	1	3	4 dy	Moderate	0	1	0
173	LASSITUDE	0	1	1	4 dy	Mild	1	1	0
173	DIARRHEA	0	2	12	3 dy	Moderate	1	0	0
173	SWEATING	0	2	13	4 dy	Mild	1	1	0
173	DRY MOUTH	0	0	18	6 dy	Mild	1	1	0
173	NASAL CONGESTION	0	2	18	3 dy	Mild	1	1	0
173	CONSTIPATION	0	1	19	4 dy	Moderate	1	0	0
173	HEADACHE	0	0	24	2 dy	Mild	1	1	0
174	NASAL CONGESTION	0	1	1	5 dy	Mild	1	1	0
174	HEADACHE	0	1	1	6 dy	Mild	1	1	0
174	DIZZINESS	0	0	1	2 dy	Mild	1	1	0
174	DRY MOUTH	0	0	2	3 dy	Mild	1	1	0
174	INSOMNIA	0	0	4	3 dy	Mild	1	1	0
174	LASSITUDE	1	1	11	2 dy	Mild	1	1	0
174	SWEATING	0	2	11	2 dy	Mild	1	1	0
174	DROWSINESS	1	1	17	1 dy	Mild	1	1	0
175	NASAL CONGESTION	0	2	2	6 dy	Mild	1	1	0
175	DECREASED APPETITE	0	0	2	6 dy	Moderate	0	1	0
175	DIARRHEA	0	2	7	3 dy	Mild	0	0	0
175	DRY MOUTH	0	0	10	4 dy	Moderate	1	1	0
175	HEADACHE	0	2	10	4 dy	Mild	1	1	0
175	INCR.MOTOR ACTIVITY	1	1	17	2 dy	Mild	1	1	0
175	DECREASED SALIVATION	0	1	25	4 dy	Moderate	1	1	0
178	DRY MOUTH	0	0	6	7 dy	Mild	1	1	0
178	LASSITUDE	0	1	7	3 dy	Mild	1	1	0
178	DIARRHEA	0	1	10	4 dy	Mild	1	1	0
178	HEADACHE	0	1	11	6 dy	Mild	1	1	0
178	DROWSINESS	1	1	19	3 dy	Mild	1	1	0

- <sup>1</sup> 0=Spontaneously 1=Upon inquiry
- <sup>2</sup> 0=Yes 1=No
- <sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain
- <sup>4</sup> 0=Yes 1=No
- <sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

675

FCE 20124/702 1

19

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
182	DECREASED APPETITE	0	0	3	5 dy	Mild	1	1	0
182	CONSTIPATION	0	1	4	3 dy	Mild	1	1	0
182	SWEATING	0	2	6	3 dy	Mild	1	1	0
182	LASSITUDE	0	1	7	2 dy	Mild	1	1	0
182	DIZZINESS	0	1	12	2 dy	Mild	1	1	0
182	DIARRHEA	0	2	19	4 dy	Mild	1	0	0
182	NASAL CONGESTION	0	2	25	3 dy	Mild	1	1	0
182	HEADACHE	0	2	25	4 dy	Mild	1	1	0
183	DRY MOUTH	0	0	3	3 dy	Mild	1	1	0
183	NASAL CONGESTION	0	1	3	7 dy	Mild	1	1	0
183	CONSTIPATION	0	1	5	4 dy	Moderate	1	0	0
183	HEADACHE	0	2	6	3 dy	Mild	1	1	0
183	INSOMNIA	0	0	11	4 dy	Mild	1	1	0
183	SWEATING	0	1	11	3 dy	Mild	1	1	0
183	LASSITUDE	0	1	18	4 dy	Mild	1	1	0
183	INCR. MOTOR ACTIVITY	0	1	25	2 dy	Mild	1	1	0
190	NASAL CONGESTION	0	1	3	4 dy	Mild	1	1	0
190	INSOMNIA	0	0	3	13 dy	Moderate	0	1	1
190	DECREASED APPETITE	0	0	3	12 dy	Moderate	0	1	1
190	SWEATING	0	0	6	4 dy	Mild	1	1	0
190	DRY MOUTH	0	1	13	8 dy	Mild	1	1	0
190	TACHYCARDIA	0	1	14	3 dy	Mild	1	1	0
190	LASSITUDE	0	1	20	3 dy	Mild	1	1	0
190	HEADACHE	0	1	27	2 dy	Mild	1	1	0
190	URINARY HESITANCY	0	1	27	3 dy	Mild	1	1	0
191	DIARRHEA	0	1	2	4 dy	Moderate	1	0	0
191	NASAL CONGESTION	0	1	3	6 dy	Mild	1	1	0
191	HEADACHE	0	1	4	5 dy	Mild	1	1	0
191	DRY MOUTH	0	1	8	4 dy	Mild	1	1	0
191	CONSTIPATION	0	1	16	3 dy	Mild	1	1	0
191	INCREASED SALIVATION	0	1	26	2 dy	Mild	1	1	0
196	DECREASED APPETITE	0	0	3	8 dy	Mild	1	1	1
201	DRY MOUTH	0	1	11	10 dy	Mild	1	1	1
201	SWEATING	0	1	11	17 dy	Mild	1	1	1
201	URINARY HESITANCY	0	1	12	16 dy	Mild	1	1	1

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

20

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
205	HEADACHE	0	1	4	5 hr	Moderate	1	0	0
205	DIARRHEA	0	1	14	1 hr	Mild	1	1	0
205	VOMITING	0	1	14	1 hr	Mild	1	1	0
207	HEADACHE	0	1	7	8 hr	Mild	1	1	0
207	NASAL CONGESTION	0	1	21	6 hr	Mild	1	1	0
212	CONSTIPATION	0	1	9	20 dy	Mild	1	1	1
213	HEADACHE	0	1	10	5 hr	Moderate	1	0	1
220	SWEATING	0	1	5	9 dy	Mild	1	1	0
220	PALPITATIONS	0	2	7	7 dy	Mild	1	1	1
220	TACHYCARDIA	0	1	7	14 dy	Moderate	1	1	0
220	TINNITUS	0	1	8	20 dy	Mild	0	1	0
220	ORTHOSTATIC DIZZINESS	0	1	20	8 dy	Mild	1	1	1
221	DECR. MOTOR ACTIVITY	1	0	10	4 dy	Moderate	1	1	0
221	LASSITUDE	1	1	10	4 dy	Moderate	1	1	0
221	TACHYCARDIA	0	1	14	7 dy	Moderate	1	1	0
221	ECG: INVERTED T WAVE	.	.	15	13 dy	.	1	1	1
221	SUFFOCATION	0	1	16	2 dy	Mild	2	1	0
221	CHEST OPPRESSION	0	1	16	7 dy	Mild	2	1	2
221	NAUSEA	0	1	23	5 dy	Mild	0	1	1
225	TACHYCARDIA	.	1	3	11 dy	Moderate	1	.	0
225	NAUSEA	1	1	4	3 dy	Mild	0	1	0
225	DIZZINESS	0	1	4	3 dy	Mild	1	1	0
225	DRY MOUTH	1	1	5	17 dy	Mild	0	1	1
225	HYPOTENSION	.	1	7	7 dy	Mild	1	1	0
228	EXCITEMENT	0	0	3	1 dy	Severe	1	1	0
229	TACHYCARDIA	.	1	7	15 dy	Mild	1	1	0
229	SKIN RASH	.	1	22	8 dy	Mild	0	1	1
234	TACHYCARDIA	1	1	7	7 dy	Moderate	0	1	0
234	URINARY HESITANCY	0	0	12	3 dy	Mild	1	1	0
234	CONSTIPATION	0	2	12	10 dy	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
 2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
 4=Not tolerated

677

FCE 20124/702 i

21

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment at 1st Episode	Total Duration	Maximum Severity	Max. Rel.to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
236	"COLDNESS-FEET"	0	1	1	6 dy	Moderate	0	1	0
236	"BURNING" (FACE)	0	1	1	3 dy	Moderate	0	1	0
236	TACHYCARDIA	1	1	3	25 dy	Moderate	1	1	1
236	HYPOTENSION	1	1	14	1 hr	Mild	1	1	0
239	TACHYCARDIA	1	1	3	20 dy	Mild	1	1	0
239	HYPOTENSION	1	1	4	26 dy	Mild	1	1	1
239	DIZZINESS	0	1	4	2 dy	Moderate	1	1	0
239	BITTER TASTE	1	1	7	3 dy	Mild	1	1	0
241	INSOMNIA	0	0	2	3 dy	Mild	1	1	0
241	HEADACHE	0	0	2	6 dy	Mild	1	1	0
241	LASSITUDE	0	1	5	2 dy	Mild	1	1	0
241	SWEATING	0	1	6	5 dy	Mild	1	1	0
241	DRY MOUTH	0	1	11	4 dy	Mild	1	1	0
241	DROWSINESS	0	1	12	3 dy	Mild	1	1	0
241	CONSTIPATION	0	0	25	3 dy	Mild	1	1	0
241	NASAL CONGESTION	0	1	25	3 dy	Mild	1	1	0
242	NASAL CONGESTION	0	0	3	7 dy	Mild	1	1	0
242	DIZZINESS	0	1	5	2 dy	Mild	1	1	0
242	HEADACHE	0	0	5	5 dy	Mild	1	1	0
242	LASSITUDE	0	1	11	2 dy	Mild	1	1	0
242	INCREASED SALIVATION	0	1	11	3 dy	Mild	1	1	0
242	DIARRHEA	0	1	18	3 dy	Mild	1	1	0
250	HEADACHE	0	1	3	5 hr	Moderate	1	1	0
252	HEADACHE	0	1	4	4 hr	Moderate	1	0	0
252	VOMITING	0	1	7	3 min	Moderate	1	1	0
252	CONSTIPATION	0	1	12	2 dy	Moderate	1	1	0
252	DRY MOUTH	0	1	13	12 hr	Moderate	1	1	0
253	NASAL CONGESTION	0	1	6	12 hr	Mild	1	1	0
253	SWEATING	0	1	6	30 min	Moderate	1	1	0
253	HEADACHE	0	1	7	.	Moderate	1	1	0
256	HEADACHE	0	1	13	12 hr	Mild	1	1	0

<sup>1</sup> 0=Spontaneously 1=Upon inquiry  
<sup>2</sup> 0=Yes 1=No  
<sup>3</sup> 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
<sup>4</sup> 0=Yes 1=No  
<sup>5</sup> 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
4=Not tolerated

FCE 20124/702 i

22

Pat. No.	Symptom	Rpt. <sup>1</sup>	Pre-Study <sup>2</sup>	Days of Treatment		Maximum Severity	Max. Rel. to Study Meds. <sup>3</sup>	Tx. Req. <sup>4</sup>	Course <sup>5</sup>
				at 1st Episode	Total Duration				
261	INSOMNIA	0	0	3	6 dy	Mild	1	1	0
261	DECREASED APPETITE	0	0	3	6 dy	Mild	1	1	0
261	NASAL CONGESTION	0	2	12	3 dy	Mild	1	1	0
261	DECR. MOTOR ACTIVITY	1	0	13	2 dy	Mild	1	1	0
261	INCREASED SALIVATION	0	1	16	4 dy	Mild	1	1	0
261	DIZZINESS	0	2	26	2 dy	Mild	1	1	0
261	HEADACHE	0	0	26	3 dy	Mild	1	1	0
264	HEADACHE	0	1	2	3 dy	Mild	1	1	0
264	SWEATING	0	1	6	2 dy	Mild	1	1	0
264	DROWSINESS	0	1	10	2 dy	Mild	1	1	0
264	DIARRHEA	0	0	13	3 dy	Mild	1	1	0
264	DECREASED APPETITE	0	0	18	4 dy	Mild	1	1	0
264	DECR. MOTOR ACTIVITY	0	0	19	3 dy	Mild	1	1	0
264	URINARY HESITANCY	0	1	26	2 dy	Mild	1	1	0
265	HEADACHE	0	1	3	2 dy	Mild	1	1	0
265	SWEATING	0	0	5	3 dy	Mild	1	1	0
265	DIZZINESS	0	1	5	2 dy	Mild	1	1	0
265	DIARRHEA	0	1	8	2 dy	Mild	1	1	0
265	DROWSINESS	0	1	12	3 dy	Mild	1	1	0
265	DRY MOUTH	0	0	18	3 dy	Mild	1	1	0
265	URINARY HESITANCY	0	1	25	2 dy	Mild	1	1	0
265	INCR. MOTOR ACTIVITY	0	1	25	3 dy	Mild	1	1	0
266	DIARRHEA	0	1	1	2 dy	Mild	1	1	0
266	HEADACHE	0	1	1	2 dy	Mild	1	1	0
266	DECREASED APPETITE	0	0	5	3 dy	Mild	1	1	0
266	SWEATING	1	1	8	3 dy	Mild	1	1	0
266	NASAL CONGESTION	0	1	12	3 dy	Mild	1	1	0
266	CONSTIPATION	0	1	12	3 dy	Mild	1	1	0
266	URINARY HESITANCY	0	1	18	3 dy	Mild	1	1	0
266	DRY MOUTH	0	0	25	4 dy	Mild	1	1	0
266	INCR. MOTOR ACTIVITY	0	1	26	3 dy	Mild	1	1	0
272	TACHYCARDIA	0	1	4	6 hr	Mild	1	1	0
272	HEADACHE	0	1	21	2 hr	Mild	1	1	0

1 0=Spontaneously 1=Open Inquiry  
 2 0=Yes 1=No  
 3 0=Unknown 1=Possible/Doubtful 2=Probable 3=Certain  
 4 0=Yes 1=No  
 5 0=Disappeared, trial drug continued 1=Persisted, trial drug continued  
 2=Disappeared after dosage reduction 3=Persisted after dosage reduction  
 4=Not tolerated

679

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7 - Summary by Sign/Symptom

Total No. Reported (First Episode)

Treatment Group "A"

First Episode Sign/Symptom	Total No. Reported:		Unknown
	Spontaneously	Upon Inquiry	
Headache	17	1	1
Sweating	15	2	
Constipation	13	3	
Dry Mouth	12	4	
Diarrhea	11		
Nasal Congestion	10		
Lassitude	8	2	
Dizziness	7	2	
Drowsiness	4	4	
Decreased Appetite	4	3	
Hypotension	4	3	
Insomnia	5	1	
Increased Salivation	5		
Vomiting	4	1	
Tachycardia	2	3	
Increased Motor Activity	1	4	
Excitement	2	2	
Blurred Vision	2	1	
Decreased Motor Activity	1	2	
Skin Rash	2		
Nausea	2		
Paresthesias	2		
Taste Disturbance	2		
Akathisia	1		
Cough	1		
Throat Pain	1		
Increased appetite	1		
Dull Mind	1		
Urinary Hesitancy	1		
Face Burning		1	
Palpitations		1	
Depersonalization		1	
ECG Abnormality			2
<b>TOTALS:</b>	<b>141</b>	<b>42</b>	<b>3</b>

680



FCE 20124/702 i

2

First Episode Sign/Symptom	Treatment Group "B"		
	Total No. Reported: Spontaneously	Upon Inquiry	Unknown
Dry Mouth	25	12	
Sweating	23	1	
Constipation	19	6	
Headache	16		
Nasal Congestion	15		
Tachycardia	6	6	4
Blurred Vision	11	4	
Drowsiness	6	8	
Lassitude	10	4	
Dizziness	9	3	
Hypotension	5	6	1
Diarrhea	11		
Insomnia	9	1	
Hypertension	2	2	
Increased Salivation	4		
Vomiting	3	1	
Nausea	3		
Tremor	3		
Urinary Hesitancy	3		
Decreased Appetite	2	1	
Decreased Motor Activity	1	2	
Taste Disturbance	2		
Increased Motor Activity		2	
Desquamation of hands		1	
Rash	1		
Skin Reaction	1		
Anxiety	1		
Paresthesias	1	1	
Sexual Disturbance	1		
Palpitations	1		
Flushing of Face	1		
Pruritus	1		
Fever	1		
Nervousness	1		
Agitation	1		
Coldness	1		
Increased Dreaming	1		
ECG Abnormality			3
<b>TOTALS:</b>	<b>201</b>	<b>61</b>	<b>8</b>

681

FCE 20124/702 i

3

First Episode Sign/Symptom	Treatment Group "C"		
	Total No. Reported: Spontaneously	Upon Inquiry	Unknown
Headache	24	2	
Dry Mouth	16	6	
Constipation	16	5	
Sweating	11	3	
Nasal Congestion	13		
Diarrhea	12		
Insomnia	8	2	
Dizziness	9	1	
Lassitude	7	3	
Drowsiness	5	4	
Tachycardia	5	3	2
Urinary Hesitancy	7	1	
Decreased Appetite	7		
Hypotension		4	1
Increased Motor Activity	3	1	
Increased Salivation	3		
Blurred Vision	3		
Decreased Motor Activity	1	2	
Agitation	2		
Vomiting	2		
Nausea	1	1	
Decreased Salivation	1		
Tremor	1	1	
Urinary Retention	1	1	
Hypertension	1	1	
ECG Abnormality	2		
Excitement	1		
Skin Rash	1		
Coldness - Feet	1		
Burning - Face	1		
Taste Disturbance	1		
Weight Loss	1		
Palpitations	1		
Tinnitus	1		
Suffocation	1		
Chest Oppression	1		
Paresthesias	1		
Urticaria	1		
<b>TOTALS:</b>	<b>173</b>	<b>41</b>	<b>3</b>

682

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7a - Summary by Sign/Symptom

Total No. Onset Week (First Episode)

Treatment Group "A"

WEEK 1

Sign/Symptom	Total Reported
Sweating	12
Dry Mouth	8
Headache	7
Constipation	6
Lassitude	5
Insomnia	4
Drowsiness	4
Nasal Congestion	4
Decreased Appetite	4
Increased Salivation	3
Dizziness	3
Diarrhea	3
Tachycardia	2
Vomiting	2
Hypotension	1
Skin Rash	1
Blurred Vision	1
Urinary Hesitancy	1
Decreased Motor Activity	1
Increased Motor Activity	1
Facial Burning	1
Palpitations	1
Paresthesias	1
Cough	1
Throat Pain	1
Increased Appetite	1
Total:	79

683

FCE 20124/702 i

2

Treatment Group "A"

WEEK 2

Sign/Symptom	Total Reported
Diarrhea	7
Lassitude	4
Dizziness	4
Headache	4
Nasal Congestion	3
Hypotension	3
Taste Disturbance	2
Tachycardia	2
Nausea	2
Drowsiness	2
Vomiting	2
Increased Salivation	2
Sweating	2
Constipation	1
Insomnia	1
Dry Mouth	1
Excitement	1
Decreased Appetite	1
Elevated SGOT/SGPT	1
Increased Motor Activity	1
Paresthesias	1
Depersonalization	1
Total:	48

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

3

Treatment Group "A"

WEEK 3

Sign/Symptom	Total Reported
Headache	6
Dry Mouth	5
Constipation	2
Excitement	2
Decreased Appetite	2
Nasal Congestion	2
Sweating	2
Increased Motor Activity	2
Skin Rash	1
Lassitude	1
Vomiting	1
Blurred Vision	1
Dizziness	1
Dull Mind	1
Akathisia	1
Total:	30

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

685

FCE 20124/702 i

4

**Treatment Group "A"**

**WEEK 4**

Sign/Symptom	Total Reported
Constipation	5
Dry Mouth	3
Drowsiness	2
Sweating	2
Diarrhea	2
Decreased Motor Activity	2
Tachycardia	1
Hypotension	1
Excitement	1
Blurred Vision	1
Insomnia	1
Dizziness	1
Headache	1
Nasal Congestion	1
Increased Motor Activity	1
ECG Abnormality	1
<b>Total:</b>	<b>26</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

5

Table 7a - Summary by Sign/Symptom

Total No. Onset Week (First Episode)

Treatment Group "B"

WEEK 1

Sign/Symptom	Total Reported
Dry Mouth	25
Constipation	15
Sweating	15
Headache	12
Tachycardia	11
Nasal Congestion	9
Insomnia	8
Lassitude	8
Drowsiness	6
Dizziness	6
Hypotension	5
Blurred Vision	4
Diarrhea	3
Hypertension	2
Urinary Hesitancy	2
Decreased Motor Activity	2
Decreased Appetite	2
Desquamation - Hands	1
Vomiting	1
Paresthesias	1
Increased Salivation	1
Sexual Disturbance	1
Palpitations	1
Facial Flushing	1
Total:	143

687

FCE 20124/702 i

6

Treatment Group "B"	
WEEK 2	
Sign/Symptom	Total Reported
Dry Mouth	8
Sweating	5
Dizziness	5
Constipation	4
Nasal Congestion	4
Hypotension	4
Blurred Vision	4
Lassitude	4
Insomnia	3
Diarrhea	3
Vomiting	3
Headache	2
Tachycardia	2
Nausea	2
ECG Abnormality	2
Drowsiness	1
Hypertension	1
Urinary Hesitancy	1
Decreased Motor Activity	1
Decreased Appetite	1
Tremor	1
Paresthesias	1
Skin Rash	1
Pruritus	1
Taste Disturbance	1
Agitation	1
Coldness	1
Fever	1
Total:	68

688



FCE 20124/702 i

7

Treatment Group "B"	
WEEK 3	
Sign/Symptom	Total Reported
Drowsiness	5
Dry Mouth	4
Constipation	3
Blurred Vision	3
Tachycardia	2
Hypotension	2
Sweating	2
Diarrhea	2
Headache	2
Increased Salivation	2
Hypertension	1
Dizziness	1
Anxiety	1
Nausea	1
Lassitude	1
Nasal Congestion	1
Taste Disturbance	1
Nervousness	1
Increased Dreaming	1
Skin Reaction	1
Total:	37

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

8

Treatment Group "B"

WEEK 4

Sign/Symptom	Total Reported
Blurred Vision	4
Diarrhea	4
Constipation	3
Sweating	3
Tachycardia	2
Drowsiness	2
Increased Motor Activity	2
Lassitude	1
Nasal Congestion	1
Increased Salivation	1
ECG Abnormality	1
Total:	24

FCE 20124/702 i

9

Table 7a - Summary by Sign/Symptom

Total No. Onset Week (First Episode)

Treatment Group "C"

WEEK 1

Sign/Symptom	Total Reported
Headache	17
Dry Mouth	11
Constipation	11
Sweating	9
Insomnia	9
Nasal Congestion	8
Tachycardia	7
Decreased Appetite	6
Dizziness	6
Lassitude	5
Drowsiness	4
Diarrhea	3
Hypotension	2
Hypertension	2
Blurred Vision	2
Agitation	2
Urinary Retention	1
Urinary Hesitancy	1
Tremor	1
Nausea	1
Vomiting	1
Palpitations	1
Excitement	1
Taste Disturbance	1
Urticaria	1
Coldness - Feet	1
Facial Burning	1
Total:	115

691

FCE 20124/702 i

10

Treatment Group "C"	
WEEK 2	
Sign/Symptom	Total Reported
Diarrhea	7
Dry Mouth	7
Headache	6
Constipation	5
Sweating	5
Lassitude	4
Tachycardia	3
Urinary Hesitancy	3
Drowsiness	3
Nasal Congestion	2
Hypotension	2
Decreased Motor Activity	2
Insomnia	1
Dizziness	1
Vomiting	1
Paresthesias	1
Increased Salivation	1
Tinnitus	1
ECG Abnormality	1
Total:	56

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

692

FCE 20124/702 i

11

Treatment Group "C"	
WEEK 3	
Sign/Symptom	Total Reported
Constipation	4
Dizziness	2
Lassitude	2
Drowsiness	2
Nasal Congestion	2
Sweating	1
Urinary Hesitancy	1
Urinary Retention	1
Decreased Motor Activity	1
Increased Motor Activity	1
Diarrhea	1
Dry Mouth	1
Headache	1
Increased Salivation	1
Blurred Vision	1
Tremor	1
Decreased Appetite	1
Suffocation	1
Chest Oppression	1
ECG Abnormality	1
Total:	26

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

693

FCE 20124/702 i

12

**Treatment Group "C"**

**WEEK 4**

Sign/Symptom	Total Reported
Nasal Congestion	3
Urinary Hesitancy	3
Increased Motor Activity	3
Headache	3
Dry Mouth	2
Sweating	1
Constipation	1
Dizziness	1
Drowsiness	1
Increased Salivation	1
Nausea	1
Skin Rash	1
Weight Loss	1
<b>Total:</b>	<b>22</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7b - Summary by Sign/Symptom

Total No. Present at End of Treatment

Treatment Group "A"

Sign/Symptom	Total
Dry Mouth	6
Constipation	5
Hypotension	4
Tachycardia	4
Headache	4
Drowsiness	3
Decreased Motor Activity	3
Decreased Appetite	3
Sweating	3
Excitement	2
Dull Mind	1
Taste Disturbance	1
Elevated SGOT/SGPT	1
Nasal Congestion	1
Diarrhea	1
Insomnia	1
Increased Salivation	1
Dizziness	1
Blurred Vision	1
Skin Rash	1
Vomiting	1
Paresthesias	1
Akathisia	1
Increased Motor Activity	1
ECG Abnormality	1
<b>TOTAL:</b>	<b>52</b>

FCE 20124/702 i

2

Treatment Group "B"

Sign/Symptom	Total
Dry Mouth	16
Sweating	9
Constipation	8
Tachycardia	5
Blurred Vision	5
Headache	4
Drowsiness	4
Diarrhea	4
Nasal Congestion	3
Lassitude	2
Increased Motor Activity	2
Hypotension	1
Agitation	1
Increased Salivation	1
Dizziness	1
Skin Reaction	1
Coldness	1
ECG Abnormality	1
<b>TOTAL:</b>	<b>69</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41



FCE 20124/702 i

3

Treatment Group "C"

Sign/Symptom	Total
Dry Mouth	10
Headache	10
Nasal Congestion	5
Constipation	4
Urinary Hesitancy	4
Increased Motor Activity	3
Dizziness	3
Blurred Vision	2
Hypotension	2
ECG Abnormality	2
Tachycardia	1
Sweating	1
Insomnia	1
Increased Salivation	1
Decreased Salivation	1
Skin Rash	1
Chest Oppression	1
Nausea	1
Tinnitus	1
<b>TOTAL:</b>	<b>54</b>

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

697

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7c - Summary by Sign/Symptom

Total No. by each Severity Degree for all Reports

Sign/Symptom	Treatment Group "A"				Missing Data
	Mild	Moderate	Severe	Very Severe	
HEADACHE	19	5			
SWEATING	20	2			
DRY MOUTH	15	2	1		
CONSTIPATION	14	1			
DIARRHEA	12	1			
NASAL CONGESTION	10				
DECREASED APPETITE	9		1		
DIZZINESS	9				
DROWSINESS	9				
LASSITUDE	9				
INSOMNIA	6	1			
TACHYCARDIA	5	1	1		
HYPOTENSION	4	3			
VOMITING	5				
INCREASED SALIVATION	5				
INCREASED MOTOR ACTIVITY	5				
DECREASED MOTOR ACTIVITY	4				
EXCITEMENT	3	1			
BLURRED VISION	3				
PARESTHESIAS	2	1			
NAUSEA	2				
SKIN RASH	1				
TASTE DISTURBANCE	1	1			
LASSITUDE		1			
ELEVATED SGOT/SGPT		1			
DULL MIND			1		
URINARY HESITANCY		1			
SKIN RASH		1			
FACIAL BURNING	1				
PALPITATIONS	1				
AKATHISIA		1			
COUGH	1				
THROAT PAIN	1				
DEPERSONALIZATION		1			
ECG ABNORMALITY					1
INCREASED APPETITE	1				
<b>TOTALS:</b>	<b>177</b>	<b>25</b>	<b>4</b>	<b>0</b>	<b>1</b>

FCE 20124/702 i

2

Table 7c - Summary by Sign/Symptom

Total No. by each Severity Degree for all Reports

Sign/Symptom	Treatment Group "B"				Missing Data
	Mild	Moderate	Severe	Very Severe	
DRY MOUTH	22	11	2		
SWEATING	26	4			
HEADACHE	26	3			
CONSTIPATION	12	16	1		
NASAL CONGESTION	19	1			
LASSITUDE	16	1			
TACHYCARDIA	12	4			1
BLURRED VISION	12	3			
DIZZINESS	12	3			
HYPOTENSION	9	6			
DROWSINESS	12	2			
DIARRHEA	11	3			
INSOMNIA	8	4	1		
DRY MOUTH	2	2	2	1	
DECREASED APPETITE	4				
INCREASED SALIVATION	4				
VOMITING	3	1			
NAUSEA	3				
TREMOR	2	1			
HYPERTENSION		3			
DECREASED MOTOR ACTIVITY	2	1			
ECG ABNORMALITY					3
INCREASED MOTOR ACTIVITY	2				
URINARY HESITANCY	2				
HANDS DESQUAMATION		1			
HYPERTENSION		1			
ANXIETY				1	
URINARY HESITANCY	1				
PARESTHESIAS	1				
SEXUAL DISTURBANCE	1				
PALPITATIONS	1				
PARESTHESIAS	1				
FLUSHING OF FACE	1				
RASH		1			
PRURITUS	1				
TASTE DISTURBANCE	1	1			
FEVER	1				
NERVOUSNESS		1			
AGITATION				1	
COLDNESS		1			
INCREASED DREAMING	1				
SKIN REACTION	1				
<b>TOTALS:</b>	<b>232</b>	<b>75</b>	<b>6</b>	<b>3</b>	<b>4</b>

699

FCE 20124/702 i

3

Table 7c - Summary by Sign/Symptom

Total No. by each Severity Degree for all Reports

Sign/Symptom	Treatment Group "C"				Missing Data
	Mild	Moderate	Severe	Very Severe	
HEADACHE	26	8	1		
DRY MOUTH	15	8	3		
CONSTIPATION	9	11	2		
NASAL CONGESTION	18				
SWEATING	14	3			
DIARRHEA	8	3	1		
LASSITUDE	10	1			
TACHYCARDIA	4	6	1		
DIZZINESS	9	1			
INSOMNIA	4	5	1		
DROWSINESS	7	3			
URINARY HESITANCY	6	2			
DECREASED APPETITE	5	2			
HYPOTENSION	4				
INCREASED MOTOR ACTIVITY	4				
INCREASED SALIVATION	3				
DECREASED MOTOR ACTIVITY	2	1			
BLURRED VISION	1	2			
HYPERTENSION		2			
AGITATION		2			
TREMOR	2				
CHEST OPPRESSION	2				
NALURIA	2				
URINARY RETENTION		1	1		
VOMITING	1	1			
ECG ABNORMALITY			1		1
URTICARIA		1			
WEIGHT LOSS		1			
PARESTHESIAS	1				
DECREASED SALIVATION		1			
PALPITATIONS	1				
TINNITUS	1				
SUFFOCATION	1				
EXCITEMENT			1		
SKIN RASH	1				
"COLDNESS- FEET"		1			
"BURNING" (FACE)		1			
TASTE DISTURBANCE	1				
<b>TOTALS:</b>	<b>162</b>	<b>67</b>	<b>12</b>	<b>0</b>	<b>1</b>

700

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7d - Summary by Sign/Symptom

Total No. by each Treatment Relationship - All Reports

Treatment Group "A"

Sign/Symptom	Possible/ Doubtful	Probable	Certain	Unknown	Missing Data
HEADACHE	21			2	1
SWEATING	21			1	
DRY MOUTH	16			2	
CONSTIPATION	14			1	
DIARRHEA	13				
LASSITUDE	10				
NASAL CONGESTION	10				
DECREASED APPETITE	9			1	
DROWSINESS	8			1	
DIZZINESS	7			2	
TACHYCARDIA	5	1		1	
HYPOTENSION	5			2	
INSOMNIA	6			1	
INCREASED SALIVATION	5				
INCREASED MOTOR ACTIVITY	5				
VOMITING	4			1	
DECREASED MOTOR ACTIVITY	3	1			
EXCITEMENT	2			2	
BLURRED VISION	2			1	
PARESTHESIAS				3	
TASTE DISTURBANCE	2				
SKIN RASH	1	1			
NAUSEA	1			1	
ELEVATED SGOT/SGPT	1				
DULL MIND				1	
URINARY HESITANCY	1				
FACE BURNING	1				
PALPITATIONS				1	
AKATHISIA	1				
COUGH				1	
THROAT PAIN				1	
DEPERSONALIZATION	1				
ECG ABNORMALITY					1
INCREASED APPETITE				1	
<b>TOTALS:</b>	<b>175</b>	<b>3</b>	<b>0</b>	<b>27</b>	<b>2</b>

701

FCE 20124/702 i

2

Table 7d - Summary by Sign/Symptom  
Total No. by each Treatment Relationship - All Reports

Sign/Symptom	Treatment Group "B"				Missing Data
	Possible/ Doubtful	Probable	Certain	Unknown	
DRY MOUTH	39	1		2	
SWEATING	29			1	
HEADACHE	27	1		1	
CONSTIPATION	27			2	
NASAL CONGESTION	20				
TACHYCARDIA	15	1		1	
LASSITUDE	17				
HYPOTENSION	11	2		3	
DIZZINESS	15				
BLURRED VISION	14	1			
DIARRHEA	14				
DROWSINESS	11	2		1	
INSOMNIA	9			4	
INCREASED SALIVATION	4				
HYPERTENSION	3			1	
DECREASED APPETITE	3			1	
VOMITING	2			2	
URINARY HESITANCY	3				
NAUSEA				3	
TREMOR	3				
ECG ABNORMALITY	3				
DECREASED MOTOR ACTIVITY	2			1	
PARESTHESIAS	2				
INCREASED MOTOR ACTIVITY	2				
TASTE DISTURBANCE	2				
HANDS DESQUAMATION				1	
ANXIETY				1	
SEXUAL DISTURBANCE	1				
PALPITATIONS	1				
FLUSHING OF FACE	1				
RASH	1				
PRURITUS	1				
FEVER				1	
NERVOUSNESS	1				
AGITATION				1	
COLDNESS				1	
INCREASED DREAMING	1				
SKIN REACTION				1	
TOTALS:	284	8	0	29	0

702

FCE 20124/702 i

3

Table 7d - Summary by Sign/Symptom  
Total No. by each Treatment Relationship - All Reports

Sign/Symptom	Treatment Group "C"				
	Possible/ Doubtful	Probable	Certain	Unknown	Missing Data
HEADACHE	34			1	
DRY MOUTH	25			1	
CONSTIPATION	18			4	
NASAL CONGESTION	18				
SWEATING	17				
DIARRHEA	9			3	
LASSITUDE	11				
TACHYCARDIA	9	1		1	
DIZZINESS	10				
DROWSINESS	10				
INSOMNIA	8			2	
URINARY HESITANCY	8				
DECREASED APPETITE	5			2	
HYPOTENSION	4				
INCREASED MOTOR ACTIVITY	4				
BLURRED VISION	3				
INCREASED SALIVATION	3				
DECREASED MOTOR ACTIVITY	3				
VOMITING	2				
TREMOR	2				
NAUSEA				2	
HYPERTENSION	1			1	
AGITATION	1			1	
URINARY RETENTION	1		1		
CHEST OPPRESSION		1	1		
WEIGHT LOSS	1				
URTICARIA	1				
ECG ABNORMALITY	1				
PARESTHESIAS	1				
DECREASED SALIVATION	1				
PALPITATIONS	1				
TINNITUS				1	
ECG ABNORMALITY	1				
SUFFOCATION		1			
EXCITEMENT	1				
SKIN RASH				1	
"COLDNESS- FEET"				1	
"BURNING"(FACE)				1	
TASTE DISTURBANCE	1				
TOTALS:	215	3	2	22	0

703

090177e1803f2368\Approved\Approved On: 11-Nov-2002 20:41

FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7e - Summary by Sign/Symptom

Total No. Requiring Treatment - All Reports

Treatment Group "A"

Sign/Symptom	Total Number
CONSTIPATION	3
DIARRHEA	2
INSOMNIA	1
SKIN RASH	1
COUGH	1
THROAT PAIN	1
TOTAL:	9

Treatment Group "B"

Sign/Symptom	Total Number
CONSTIPATION	11
DIARRHEA	5
INSOMNIA	4
HYPOTENSION	3
HYPERTENSION	2
HEADACHE	2
ANXIETY	1
FEVER	1
AGITATION	1
TOTAL:	30

Treatment Group "C"

Sign/Symptom	Total Number
DIARRHEA	6
CONSTIPATION	5
HEADACHE	4
INSOMNIA	3
HYPERTENSION	1
WEIGHT LOSS	1
TOTAL:	20

704



FCE 20124/702 i

1

REBOXETINE, Protocol ADE 08

Table 7f - Summary by Sign/Symptom

Total Number by Course - Last Episode

Treatment Group "A"

Sign/Symptom	Disappeared Trial Drug Continued (0)	Persisted Trial Drug Continued (1)	Disappeared After Dose Reduction (2)	Persisted After Dose Reduction (3)	Not Tolerated (4)
SWEATING	15	2			
HEADACHE	16				
DRY MOUTH	12	4			
CONSTIPATION	14				
DIARRHEA	11				
NASAL CONGESTION	10				
LASSITUDE	9				
DIZZINESS	6	3			
DROWSINESS	7	1			
DECREASED APPETITE	6	1			
INSOMNIA	5	1			
HYPOTENSION	2	4			
VOMITING	5				
INCREASED MOTOR ACTIVITY	5				
INCREASED SALIVATION	4	1			
TACHYCARDIA	2	2	1		
EXCITEMENT	2	2			
BLURRED VISION	3				
DECREASED MOTOR ACTIVITY	3				
TASTE DISTURBANCE	2				
NAUSEA	2				
LASSITUDE	1				
ELEVATED SGOT/SGPT		1			
SKIN RASH	1				
DULL MIND		1			
URINARY HESITANCY	1				
HEADACHE	1				
SKIN RASH					1
FACE BURNING	1				
PALPITATIONS	1				
PARESTHESIAS	1	1			
AKATHISIA		1			
COUGH	1				
THROAT PAIN	1				
DEPERSONALIZATION	1				
ECG ABNORMALITY	1				
INCREASED APPETITE	1				
<b>TOTALS:</b>	<b>153</b>	<b>25</b>	<b>1</b>	<b>0</b>	<b>1</b>

705

FCE 20124/702 i

2

Table 7f - Summary by Sign/Symptom

Total Number by Course - Last Episode

Treatment Group "B"

Sign/Symptom	Disappeared Trial Drug Continued (0)	Persisted Trial Drug Continued (1)	Disappeared After Dose Reduction (2)	Persisted After Dose Reduction (3)	Not Tolerated (4)
DRY MOUTH	24	13			
CONSTIPATION	21	4			
SWEATING	20	4			
TACHYCARDIA	12	3	1		
HEADACHE	15	1			
NASAL CONGESTION	14	1			
BLURRED VISION	12	2	1		
DROWSINESS	11	2	1		
LASSITUDE	14				
DIARRHEA	12				
DIZZINESS	11	1			
INSOMNIA	9	1			
HYPOTENSION	8	2			
INCREASED SALIVATION	4				
HYPERTENSION	3	1			
VOMITING	3				
URINARY HESITANCY	3				
DECREASED MOTOR ACTIVITY	3				
NAUSEA	3				
DECREASED APPETITE	3				
HYPOTENSION	2				
PARESTHESIAS	2				
TREMOR	2				
INCREASED MOTOR ACTIVITY	2				
TASTE DISTURBANCE	2				
ECG ABNORMALITY		2			
TREMOR	1				
ECG ABNORMALITY		1			
HANDS DESQUAMATION	1				
ANXIETY	1				
SEXUAL DISTURBANCE	1				
PALPITATIONS	1				
FLUSHING OF FACE	1				
RASH	1				
PRURITUS	1				
FEVER	1				
NERVOUSNESS	1				
AGITATION					1
COLDNESS		1			
INCREASED DREAMING	1				
SKIN REACTION		1			
TOTALS: 266		40	3	0	1

706

FCE 20124/702 i

3

Total Number by Course - Last Episode

Treatment Group "C"

Sign/Symptom	Disappeared Trial Drug Continued (0)	Persisted Trial Drug Continued (1)	Disappeared After Dose Reduction (2)	Persisted After Dose Reduction (3)	Not Tolerated (4)
HEADACHE	24	2			
DRY MOUTH	15	7			
CONSTIPATION	16	5			
SWEATING	14	1			
NASAL CONGESTION	13				
DIARRHEA	10				
INSOMNIA	9	1		1	
TACHYCARDIA	8	1	1		
DIZZINESS	8	2			
LASSITUDE	9	1			
DROWSINESS	8	1			
URINARY HESITANCY	6	2			
DECREASED APPETITE	5	2			
INCREASED MOTOR ACTIVITY	4				
HYPOTENSION	2	2			
INCREASED SALIVATION	3				
DECREASED MOTOR ACTIVITY	3				
BLURRED VISION	1	2			
AGITATION	2				
DIARRHEA	2				
TREMOR		2			
VOMITING	2				
NAUSEA	1	1			
WEIGHT LOSS	1				
HYPERTENSION	1				1
URTICARIA	1				1
ECG ABNORMALITY		1			
URINARY RETENTION	1		1		
PARESTHESIAS	1				
DECREASED SALIVATION	1				
PALPITATIONS		1			
TINNITUS	1				
SUFFOCATION	1				
CHEST OPPRESSION	1				
EXCITEMENT	1				
SKIN RASH		1			
"COLDNESS-FEET"	1				
"BURNING"(FACE)	1				
TASTE DISTURBANCE	1				
<b>TOTALS:</b>	<b>176</b>	<b>35</b>	<b>2</b>	<b>1</b>	<b>2</b>

707